id	sid	tid	token	lemma	pos
bptjm-17	1	1	circulating	circulate	VERB
bptjm-17	1	2	nucleic	nucleic	ADJ
bptjm-17	1	3	acids	acid	NOUN
bptjm-17	1	4	as	as	ADP
bptjm-17	1	5	promising	promise	VERB
bptjm-17	1	6	biomarkersa	biomarkersa	ADJ
bptjm-17	1	7	new	new	ADJ
bptjm-17	1	8	frontier	frontier	NOUN
bptjm-17	1	9	of	of	ADP
bptjm-17	1	10	personalized	personalized	ADJ
bptjm-17	1	11	medicine	medicine	NOUN
bptjm-17	1	12	berkeley	berkeley	PROPN
bptjm-17	1	13	pharma	pharma	PROPN
bptjm-17	1	14	tech	tech	NOUN
bptjm-17	1	15	journal	journal	NOUN
bptjm-17	1	16	of	of	ADP
bptjm-17	1	17	medicine	medicine	NOUN
bptjm-17	1	18	correspondence	correspondence	NOUN
bptjm-17	1	19	carolynskotz@gmail.com	carolynskotz@gmail.com	PUNCT
bptjm-17	2	1	keywords	keyword	NOUN
bptjm-17	2	2	biomarker	biomarker	VERB
bptjm-17	2	3	circulating	circulate	VERB
bptjm-17	2	4	dna	dna	PROPN
bptjm-17	2	5	liquid	liquid	ADJ
bptjm-17	2	6	biopsy	biopsy	NOUN
bptjm-17	2	7	microrna	microrna	PROPN
bptjm-17	2	8	nsclc	nsclc	PROPN
bptjm-17	2	9	personalized	personalize	VERB
bptjm-17	2	10	medicine	medicine	NOUN
bptjm-17	2	11	prognosis	prognosis	NOUN
bptjm-17	2	12	submitted	submit	VERB
bptjm-17	2	13	june	june	PROPN
bptjm-17	2	14	29	29	NUM
bptjm-17	2	15	,	,	PUNCT
bptjm-17	2	16	2021	2021	NUM
bptjm-17	2	17	accepted	accept	VERB
bptjm-17	2	18	july	july	PROPN
bptjm-17	2	19	6	6	NUM
bptjm-17	2	20	,	,	PUNCT
bptjm-17	2	21	2021	2021	NUM
bptjm-17	2	22	published	publish	VERB
bptjm-17	2	23	december	december	PROPN
bptjm-17	2	24	17	17	NUM
bptjm-17	2	25	,	,	PUNCT
bptjm-17	2	26	2021	2021	NUM
bptjm-17	2	27	full	full	ADJ
bptjm-17	2	28	open	open	ADJ
bptjm-17	2	29	access	access	NOUN
bptjm-17	2	30	creative	creative	ADJ
bptjm-17	2	31	commons	common	NOUN
bptjm-17	2	32	attribution	attribution	NOUN
bptjm-17	2	33	license	license	VERB
bptjm-17	2	34	4.0	4.0	NUM
bptjm-17	2	35	abstract	abstract	ADJ
bptjm-17	2	36	biomarkers	biomarker	NOUN
bptjm-17	2	37	are	be	AUX
bptjm-17	2	38	a	a	DET
bptjm-17	2	39	range	range	NOUN
bptjm-17	2	40	of	of	ADP
bptjm-17	2	41	biological	biological	ADJ
bptjm-17	2	42	signals	signal	NOUN
bptjm-17	2	43	that	that	PRON
bptjm-17	2	44	measure	measure	VERB
bptjm-17	2	45	the	the	DET
bptjm-17	2	46	presence	presence	NOUN
bptjm-17	2	47	and	and	CCONJ
bptjm-17	2	48	severity	severity	NOUN
bptjm-17	2	49	of	of	ADP
bptjm-17	2	50	the	the	DET
bptjm-17	2	51	disease	disease	NOUN
bptjm-17	2	52	.	.	PUNCT
bptjm-17	3	1	this	this	DET
bptjm-17	3	2	literature	literature	NOUN
bptjm-17	3	3	review	review	PROPN
bptjm-17	3	4	assesses	assesse	NOUN
bptjm-17	3	5	circulating	circulate	VERB
bptjm-17	3	6	dna	dna	NOUN
bptjm-17	3	7	(	(	PUNCT
bptjm-17	3	8	ctdna	ctdna	NOUN
bptjm-17	3	9	)	)	PUNCT
bptjm-17	3	10	and	and	CCONJ
bptjm-17	3	11	microrna	microrna	PROPN
bptjm-17	3	12	(	(	PUNCT
bptjm-17	3	13	mirna	mirna	PROPN
bptjm-17	3	14	)	)	PUNCT
bptjm-17	3	15	biomarkers	biomarker	NOUN
bptjm-17	3	16	detected	detect	VERB
bptjm-17	3	17	in	in	ADP
bptjm-17	3	18	liquid	liquid	ADJ
bptjm-17	3	19	and	and	CCONJ
bptjm-17	3	20	tissue	tissue	NOUN
bptjm-17	3	21	biopsies	biopsy	NOUN
bptjm-17	3	22	and	and	CCONJ
bptjm-17	3	23	their	their	PRON
bptjm-17	3	24	importance	importance	NOUN
bptjm-17	3	25	in	in	ADP
bptjm-17	3	26	the	the	DET
bptjm-17	3	27	prognosis	prognosis	NOUN
bptjm-17	3	28	,	,	PUNCT
bptjm-17	3	29	outcomes	outcome	NOUN
bptjm-17	3	30	,	,	PUNCT
bptjm-17	3	31	and	and	CCONJ
bptjm-17	3	32	treatments	treatment	NOUN
bptjm-17	3	33	for	for	ADP
bptjm-17	3	34	non	non	ADJ
bptjm-17	3	35	-	-	ADJ
bptjm-17	3	36	small	small	ADJ
bptjm-17	3	37	cell	cell	NOUN
bptjm-17	3	38	lung	lung	NOUN
bptjm-17	3	39	cancer	cancer	NOUN
bptjm-17	3	40	(	(	PUNCT
bptjm-17	3	41	nsclc	nsclc	NOUN
bptjm-17	3	42	)	)	PUNCT
bptjm-17	3	43	.	.	PUNCT
bptjm-17	4	1	these	these	DET
bptjm-17	4	2	biomarkers	biomarker	NOUN
bptjm-17	4	3	have	have	VERB
bptjm-17	4	4	the	the	DET
bptjm-17	4	5	potential	potential	NOUN
bptjm-17	4	6	for	for	ADP
bptjm-17	4	7	clinical	clinical	ADJ
bptjm-17	4	8	use	use	NOUN
bptjm-17	4	9	;	;	PUNCT
bptjm-17	4	10	however	however	ADV
bptjm-17	4	11	,	,	PUNCT
bptjm-17	4	12	further	further	ADJ
bptjm-17	4	13	studies	study	NOUN
bptjm-17	4	14	with	with	ADP
bptjm-17	4	15	requisite	requisite	ADJ
bptjm-17	4	16	data	datum	NOUN
bptjm-17	4	17	and	and	CCONJ
bptjm-17	4	18	sufficiently	sufficiently	ADV
bptjm-17	4	19	large	large	ADJ
bptjm-17	4	20	trials	trial	NOUN
bptjm-17	4	21	are	be	AUX
bptjm-17	4	22	required	require	VERB
bptjm-17	4	23	to	to	PART
bptjm-17	4	24	refine	refine	VERB
bptjm-17	4	25	our	our	PRON
bptjm-17	4	26	understanding	understanding	NOUN
bptjm-17	4	27	of	of	ADP
bptjm-17	4	28	their	their	PRON
bptjm-17	4	29	applicability	applicability	NOUN
bptjm-17	4	30	.	.	PUNCT
bptjm-17	5	1	the	the	DET
bptjm-17	5	2	prognostic	prognostic	ADJ
bptjm-17	5	3	significance	significance	NOUN
bptjm-17	5	4	of	of	ADP
bptjm-17	5	5	ctdna	ctdna	NOUN
bptjm-17	5	6	and	and	CCONJ
bptjm-17	5	7	mirna	mirna	PROPN
bptjm-17	5	8	biomarkers	biomarker	NOUN
bptjm-17	5	9	in	in	ADP
bptjm-17	5	10	nsclc	nsclc	NOUN
bptjm-17	5	11	care	care	NOUN
bptjm-17	5	12	has	have	AUX
bptjm-17	5	13	demonstrated	demonstrate	VERB
bptjm-17	5	14	that	that	SCONJ
bptjm-17	5	15	liquid	liquid	ADJ
bptjm-17	5	16	biopsy	biopsy	NOUN
bptjm-17	5	17	and	and	CCONJ
bptjm-17	5	18	molecular	molecular	ADJ
bptjm-17	5	19	diagnostic	diagnostic	ADJ
bptjm-17	5	20	testing	testing	NOUN
bptjm-17	5	21	may	may	AUX
bptjm-17	5	22	provide	provide	VERB
bptjm-17	5	23	a	a	DET
bptjm-17	5	24	feasible	feasible	ADJ
bptjm-17	5	25	and	and	CCONJ
bptjm-17	5	26	noninvasive	noninvasive	ADJ
bptjm-17	5	27	method	method	NOUN
bptjm-17	5	28	for	for	ADP
bptjm-17	5	29	tailoring	tailor	VERB
bptjm-17	5	30	treatment	treatment	NOUN
bptjm-17	5	31	plans	plan	NOUN
bptjm-17	5	32	to	to	ADP
bptjm-17	5	33	the	the	DET
bptjm-17	5	34	specific	specific	ADJ
bptjm-17	5	35	mutational	mutational	ADJ
bptjm-17	5	36	landscape	landscape	NOUN
bptjm-17	5	37	of	of	ADP
bptjm-17	5	38	diverse	diverse	ADJ
bptjm-17	5	39	nsclc	nsclc	NOUN
bptjm-17	5	40	patients	patient	NOUN
bptjm-17	5	41	.	.	PUNCT
bptjm-17	6	1	however	however	ADV
bptjm-17	6	2	,	,	PUNCT
bptjm-17	6	3	further	further	ADJ
bptjm-17	6	4	testing	testing	NOUN
bptjm-17	6	5	must	must	AUX
bptjm-17	6	6	be	be	AUX
bptjm-17	6	7	conducted	conduct	VERB
bptjm-17	6	8	to	to	PART
bptjm-17	6	9	analyze	analyze	VERB
bptjm-17	6	10	the	the	DET
bptjm-17	6	11	significance	significance	NOUN
bptjm-17	6	12	and	and	CCONJ
bptjm-17	6	13	benefit	benefit	NOUN
bptjm-17	6	14	of	of	ADP
bptjm-17	6	15	ctdna	ctdna	NOUN
bptjm-17	6	16	and	and	CCONJ
bptjm-17	6	17	mirna	mirna	PROPN
bptjm-17	6	18	biomarkers	biomarker	NOUN
bptjm-17	6	19	in	in	ADP
bptjm-17	6	20	larger	large	ADJ
bptjm-17	6	21	cohorts	cohort	NOUN
bptjm-17	6	22	and	and	CCONJ
bptjm-17	6	23	substantiate	substantiate	VERB
bptjm-17	6	24	the	the	DET
bptjm-17	6	25	standardization	standardization	NOUN
bptjm-17	6	26	of	of	ADP
bptjm-17	6	27	liquid	liquid	ADJ
bptjm-17	6	28	biopsy	biopsy	NOUN
bptjm-17	6	29	in	in	ADP
bptjm-17	6	30	clinical	clinical	ADJ
bptjm-17	6	31	practice	practice	NOUN
bptjm-17	6	32	.	.	PUNCT
bptjm-17	7	1	circulating	circulate	VERB
bptjm-17	7	2	nucleic	nucleic	ADJ
bptjm-17	7	3	acids	acid	NOUN
bptjm-17	7	4	as	as	ADP
bptjm-17	7	5	promising	promise	VERB
bptjm-17	7	6	biomarkers	biomarker	NOUN
bptjm-17	7	7	:	:	PUNCT
bptjm-17	7	8	a	a	DET
bptjm-17	7	9	new	new	ADJ
bptjm-17	7	10	frontier	frontier	NOUN
bptjm-17	7	11	of	of	ADP
bptjm-17	7	12	personalized	personalized	ADJ
bptjm-17	7	13	medicine	medicine	NOUN
bptjm-17	7	14	by	by	ADP
bptjm-17	7	15	:	:	PUNCT
bptjm-17	7	16	carolyn	carolyn	PROPN
bptjm-17	7	17	skotz	skotz	PROPN
bptjm-17	7	18	,	,	PUNCT
bptjm-17	7	19	samrat	samrat	PROPN
bptjm-17	7	20	thapa	thapa	PROPN
bptjm-17	7	21	,	,	PUNCT
bptjm-17	7	22	mary	mary	PROPN
bptjm-17	7	23	nowak	nowak	PROPN
bptjm-17	7	24	,	,	PUNCT
bptjm-17	7	25	hoc	hoc	PROPN
bptjm-17	7	26	lan	lan	PROPN
bptjm-17	7	27	phung	phung	PROPN
bptjm-17	7	28	,	,	PUNCT
bptjm-17	7	29	akshitha	akshitha	NOUN
bptjm-17	7	30	mamidi	mamidi	NOUN
bptjm-17	7	31	,	,	PUNCT
bptjm-17	7	32	hetu	hetu	NOUN
bptjm-17	7	33	patel	patel	NOUN
bptjm-17	7	34	and	and	CCONJ
bptjm-17	7	35	mabel	mabel	PROPN
bptjm-17	7	36	ho	ho	PROPN
bptjm-17	7	37	circulating	circulate	VERB
bptjm-17	7	38	dna	dna	PROPN
bptjm-17	7	39	and	and	CCONJ
bptjm-17	7	40	microrna	microrna	PROPN
bptjm-17	7	41	are	be	AUX
bptjm-17	7	42	useful	useful	ADJ
bptjm-17	7	43	biomarkers	biomarker	NOUN
bptjm-17	7	44	in	in	ADP
bptjm-17	7	45	non	non	ADJ
bptjm-17	7	46	-	-	ADJ
bptjm-17	7	47	small	small	ADJ
bptjm-17	7	48	cell	cell	NOUN
bptjm-17	7	49	lung	lung	NOUN
bptjm-17	7	50	cancer	cancer	NOUN
bptjm-17	7	51	prognosis	prognosis	NOUN
bptjm-17	7	52	and	and	CCONJ
bptjm-17	7	53	treatment	treatment	NOUN
bptjm-17	7	54	.	.	PUNCT
bptjm-17	8	1	image	image	NOUN
bptjm-17	8	2	credits	credit	NOUN
bptjm-17	8	3	:	:	PUNCT
bptjm-17	8	4	n	n	CCONJ
bptjm-17	8	5	/	/	SYM
bptjm-17	8	6	c	c	NOUN
bptjm-17	8	7	introduction	introduction	NOUN
bptjm-17	8	8	despite	despite	SCONJ
bptjm-17	8	9	representing	represent	VERB
bptjm-17	8	10	13	13	NUM
bptjm-17	8	11	%	%	NOUN
bptjm-17	8	12	of	of	ADP
bptjm-17	8	13	all	all	DET
bptjm-17	8	14	cancer	cancer	NOUN
bptjm-17	8	15	diagnoses	diagnosis	NOUN
bptjm-17	8	16	,	,	PUNCT
bptjm-17	8	17	lung	lung	NOUN
bptjm-17	8	18	cancer	cancer	NOUN
bptjm-17	8	19	accounts	account	VERB
bptjm-17	8	20	for	for	ADP
bptjm-17	8	21	24	24	NUM
bptjm-17	8	22	%	%	NOUN
bptjm-17	8	23	of	of	ADP
bptjm-17	8	24	all	all	DET
bptjm-17	8	25	cancer	cancer	NOUN
bptjm-17	8	26	deaths	death	NOUN
bptjm-17	8	27	in	in	ADP
bptjm-17	8	28	the	the	DET
bptjm-17	8	29	united	united	PROPN
bptjm-17	8	30	states	states	PROPN
bptjm-17	8	31	each	each	DET
bptjm-17	8	32	year	year	NOUN
bptjm-17	8	33	.	.	PUNCT
bptjm-17	9	1	among	among	ADP
bptjm-17	9	2	the	the	DET
bptjm-17	9	3	two	two	NUM
bptjm-17	9	4	subsets	subset	NOUN
bptjm-17	9	5	of	of	ADP
bptjm-17	9	6	lung	lung	NOUN
bptjm-17	9	7	cancer	cancer	NOUN
bptjm-17	9	8	(	(	PUNCT
bptjm-17	9	9	non	non	ADJ
bptjm-17	9	10	-	-	ADJ
bptjm-17	9	11	small	small	ADJ
bptjm-17	9	12	cell	cell	NOUN
bptjm-17	9	13	and	and	CCONJ
bptjm-17	9	14	small	small	ADJ
bptjm-17	9	15	cell	cell	NOUN
bptjm-17	9	16	)	)	PUNCT
bptjm-17	9	17	,	,	PUNCT
bptjm-17	9	18	nsclc	nsclc	NOUN
bptjm-17	9	19	accounts	account	VERB
bptjm-17	9	20	for	for	ADP
bptjm-17	9	21	80	80	NUM
bptjm-17	9	22	%	%	NOUN
bptjm-17	9	23	of	of	ADP
bptjm-17	9	24	all	all	DET
bptjm-17	9	25	lung	lung	NOUN
bptjm-17	9	26	cancers	cancer	NOUN
bptjm-17	9	27	.	.	PUNCT
bptjm-17	10	1	with	with	ADP
bptjm-17	10	2	only	only	ADV
bptjm-17	10	3	19	19	NUM
bptjm-17	10	4	%	%	NOUN
bptjm-17	10	5	of	of	ADP
bptjm-17	10	6	the	the	DET
bptjm-17	10	7	diagnosed	diagnose	VERB
bptjm-17	10	8	patients	patient	NOUN
bptjm-17	10	9	surpassing	surpass	VERB
bptjm-17	10	10	the	the	DET
bptjm-17	10	11	ve	ve	NOUN
bptjm-17	10	12	-	-	PUNCT
bptjm-17	10	13	year	year	NOUN
bptjm-17	10	14	survival	survival	NOUN
bptjm-17	10	15	rate	rate	NOUN
bptjm-17	10	16	,	,	PUNCT
bptjm-17	10	17	there	there	PRON
bptjm-17	10	18	is	be	VERB
bptjm-17	10	19	an	an	DET
bptjm-17	10	20	urgent	urgent	ADJ
bptjm-17	10	21	need	need	NOUN
bptjm-17	10	22	for	for	ADP
bptjm-17	10	23	early	early	ADJ
bptjm-17	10	24	detection	detection	NOUN
bptjm-17	10	25	,	,	PUNCT
bptjm-17	10	26	diagnosis	diagnosis	NOUN
bptjm-17	10	27	,	,	PUNCT
bptjm-17	10	28	and	and	CCONJ
bptjm-17	10	29	prognosis	prognosis	NOUN
bptjm-17	10	30	.	.	PUNCT
bptjm-17	11	1	recently	recently	ADV
bptjm-17	11	2	,	,	PUNCT
bptjm-17	11	3	studies	study	NOUN
bptjm-17	11	4	have	have	AUX
bptjm-17	11	5	shown	show	VERB
bptjm-17	11	6	that	that	SCONJ
bptjm-17	11	7	these	these	DET
bptjm-17	11	8	predictions	prediction	NOUN
bptjm-17	11	9	for	for	ADP
bptjm-17	11	10	nsclc	nsclc	NOUN
bptjm-17	11	11	can	can	AUX
bptjm-17	11	12	be	be	AUX
bptjm-17	11	13	assessed	assess	VERB
bptjm-17	11	14	via	via	ADP
bptjm-17	11	15	biomarkers	biomarker	NOUN
bptjm-17	11	16	(	(	PUNCT
bptjm-17	11	17	howlader	howlader	NOUN
bptjm-17	11	18	et	et	PROPN
bptjm-17	11	19	al	al	PROPN
bptjm-17	11	20	.	.	PROPN
bptjm-17	11	21	,	,	PUNCT
bptjm-17	11	22	2020	2020	NUM
bptjm-17	11	23	)	)	PUNCT
bptjm-17	11	24	.	.	PUNCT
bptjm-17	12	1	a	a	DET
bptjm-17	12	2	biomarker	biomarker	NOUN
bptjm-17	12	3	is	be	AUX
bptjm-17	12	4	broadly	broadly	ADV
bptjm-17	12	5	de	de	X
bptjm-17	12	6	ned	ned	NOUN
bptjm-17	12	7	as	as	ADP
bptjm-17	12	8	an	an	DET
bptjm-17	12	9	indicator	indicator	NOUN
bptjm-17	12	10	of	of	ADP
bptjm-17	12	11	the	the	DET
bptjm-17	12	12	presence	presence	NOUN
bptjm-17	12	13	and	and	CCONJ
bptjm-17	12	14	severity	severity	NOUN
bptjm-17	12	15	of	of	ADP
bptjm-17	12	16	a	a	DET
bptjm-17	12	17	disease	disease	NOUN
bptjm-17	12	18	state	state	NOUN
bptjm-17	12	19	.	.	PUNCT
bptjm-17	13	1	it	it	PRON
bptjm-17	13	2	can	can	AUX
bptjm-17	13	3	refer	refer	VERB
bptjm-17	13	4	to	to	ADP
bptjm-17	13	5	a	a	DET
bptjm-17	13	6	range	range	NOUN
bptjm-17	13	7	of	of	ADP
bptjm-17	13	8	biological	biological	ADJ
bptjm-17	13	9	signals	signal	NOUN
bptjm-17	13	10	,	,	PUNCT
bptjm-17	13	11	including	include	VERB
bptjm-17	13	12	pulse	pulse	NOUN
bptjm-17	13	13	,	,	PUNCT
bptjm-17	13	14	blood	blood	NOUN
bptjm-17	13	15	pressure	pressure	NOUN
bptjm-17	13	16	,	,	PUNCT
bptjm-17	13	17	blood	blood	NOUN
bptjm-17	13	18	tests	test	NOUN
bptjm-17	13	19	,	,	PUNCT
bptjm-17	13	20	and	and	CCONJ
bptjm-17	13	21	tissue	tissue	NOUN
bptjm-17	13	22	tests	test	NOUN
bptjm-17	13	23	.	.	PUNCT
bptjm-17	14	1	hundreds	hundred	NOUN
bptjm-17	14	2	of	of	ADP
bptjm-17	14	3	novel	novel	ADJ
bptjm-17	14	4	biomarker	biomarker	NOUN
bptjm-17	14	5	-	-	PUNCT
bptjm-17	14	6	related	relate	VERB
bptjm-17	14	7	articles	article	NOUN
bptjm-17	14	8	are	be	AUX
bptjm-17	14	9	published	publish	VERB
bptjm-17	14	10	each	each	DET
bptjm-17	14	11	year	year	NOUN
bptjm-17	14	12	,	,	PUNCT
bptjm-17	14	13	but	but	CCONJ
bptjm-17	14	14	only	only	ADV
bptjm-17	14	15	a	a	DET
bptjm-17	14	16	few	few	ADJ
bptjm-17	14	17	biomarkers	biomarker	NOUN
bptjm-17	14	18	are	be	AUX
bptjm-17	14	19	currently	currently	ADV
bptjm-17	14	20	used	use	VERB
bptjm-17	14	21	in	in	ADP
bptjm-17	14	22	practice	practice	NOUN
bptjm-17	14	23	(	(	PUNCT
bptjm-17	14	24	rinaldi	rinaldi	PROPN
bptjm-17	14	25	et	et	PROPN
bptjm-17	14	26	al	al	PROPN
bptjm-17	14	27	.	.	PROPN
bptjm-17	14	28	,	,	PUNCT
bptjm-17	14	29	2011	2011	NUM
bptjm-17	14	30	)	)	PUNCT
bptjm-17	14	31	.	.	PUNCT
bptjm-17	15	1	notably	notably	ADV
bptjm-17	15	2	,	,	PUNCT
bptjm-17	15	3	the	the	DET
bptjm-17	15	4	current	current	ADJ
bptjm-17	15	5	approach	approach	NOUN
bptjm-17	15	6	relies	rely	VERB
bptjm-17	15	7	primarily	primarily	ADV
bptjm-17	15	8	on	on	ADP
bptjm-17	15	9	the	the	DET
bptjm-17	15	10	use	use	NOUN
bptjm-17	15	11	of	of	ADP
bptjm-17	15	12	tissue	tissue	NOUN
bptjm-17	15	13	biopsy	biopsy	NOUN
bptjm-17	15	14	-	-	PUNCT
bptjm-17	15	15	based	base	VERB
bptjm-17	15	16	biomarker	biomarker	NOUN
bptjm-17	15	17	testing	testing	NOUN
bptjm-17	15	18	.	.	PUNCT
bptjm-17	16	1	tissue	tissue	NOUN
bptjm-17	16	2	biopsy	biopsy	NOUN
bptjm-17	16	3	refers	refer	VERB
bptjm-17	16	4	to	to	ADP
bptjm-17	16	5	an	an	DET
bptjm-17	16	6	invasive	invasive	ADJ
bptjm-17	16	7	procedure	procedure	NOUN
bptjm-17	16	8	in	in	ADP
bptjm-17	16	9	which	which	PRON
bptjm-17	16	10	solid	solid	ADJ
bptjm-17	16	11	matter	matter	NOUN
bptjm-17	16	12	from	from	ADP
bptjm-17	16	13	the	the	DET
bptjm-17	16	14	body	body	NOUN
bptjm-17	16	15	,	,	PUNCT
bptjm-17	16	16	usually	usually	ADV
bptjm-17	16	17	coming	come	VERB
bptjm-17	16	18	directly	directly	ADV
bptjm-17	16	19	from	from	ADP
bptjm-17	16	20	the	the	DET
bptjm-17	16	21	tumor	tumor	NOUN
bptjm-17	16	22	or	or	CCONJ
bptjm-17	16	23	bone	bone	NOUN
bptjm-17	16	24	marrow	marrow	NOUN
bptjm-17	16	25	,	,	PUNCT
bptjm-17	16	26	is	be	AUX
bptjm-17	16	27	sampled	sample	VERB
bptjm-17	16	28	and	and	CCONJ
bptjm-17	16	29	assessed	assess	VERB
bptjm-17	16	30	for	for	ADP
bptjm-17	16	31	the	the	DET
bptjm-17	16	32	presence	presence	NOUN
bptjm-17	16	33	of	of	ADP
bptjm-17	16	34	clinically	clinically	ADV
bptjm-17	16	35	actionable	actionable	ADJ
bptjm-17	16	36	biomarkers	biomarker	NOUN
bptjm-17	16	37	.	.	PUNCT
bptjm-17	17	1	although	although	SCONJ
bptjm-17	17	2	this	this	DET
bptjm-17	17	3	method	method	NOUN
bptjm-17	17	4	is	be	AUX
bptjm-17	17	5	deemed	deem	VERB
bptjm-17	17	6	the	the	DET
bptjm-17	17	7	gold	gold	ADJ
bptjm-17	17	8	standard	standard	NOUN
bptjm-17	17	9	for	for	ADP
bptjm-17	17	10	nsclc	nsclc	NOUN
bptjm-17	17	11	testing	testing	NOUN
bptjm-17	17	12	,	,	PUNCT
bptjm-17	17	13	it	it	PRON
bptjm-17	17	14	is	be	AUX
bptjm-17	17	15	time	time	NOUN
bptjm-17	17	16	-	-	PUNCT
bptjm-17	17	17	intensive	intensive	ADJ
bptjm-17	17	18	,	,	PUNCT
bptjm-17	17	19	invasive	invasive	ADJ
bptjm-17	17	20	,	,	PUNCT
bptjm-17	17	21	and	and	CCONJ
bptjm-17	17	22	often	often	ADV
bptjm-17	17	23	fails	fail	VERB
bptjm-17	17	24	to	to	PART
bptjm-17	17	25	capture	capture	VERB
bptjm-17	17	26	tumor	tumor	NOUN
bptjm-17	17	27	heterogeneity	heterogeneity	NOUN
bptjm-17	17	28	(	(	PUNCT
bptjm-17	17	29	rijavec	rijavec	VERB
bptjm-17	17	30	et	et	PROPN
bptjm-17	17	31	al	al	PROPN
bptjm-17	17	32	.	.	PROPN
bptjm-17	17	33	,	,	PUNCT
bptjm-17	17	34	2019	2019	NUM
bptjm-17	17	35	)	)	PUNCT
bptjm-17	17	36	.	.	PUNCT
bptjm-17	18	1	liquid	liquid	ADJ
bptjm-17	18	2	biopsy	biopsy	NOUN
bptjm-17	18	3	is	be	AUX
bptjm-17	18	4	an	an	DET
bptjm-17	18	5	emerging	emerge	VERB
bptjm-17	18	6	,	,	PUNCT
bptjm-17	18	7	minimally	minimally	ADV
bptjm-17	18	8	invasive	invasive	ADJ
bptjm-17	18	9	process	process	NOUN
bptjm-17	18	10	that	that	PRON
bptjm-17	18	11	can	can	AUX
bptjm-17	18	12	address	address	VERB
bptjm-17	18	13	this	this	DET
bptjm-17	18	14	demand	demand	NOUN
bptjm-17	18	15	for	for	ADP
bptjm-17	18	16	early	early	ADJ
bptjm-17	18	17	disease	disease	NOUN
bptjm-17	18	18	monitoring	monitoring	NOUN
bptjm-17	18	19	.	.	PUNCT
bptjm-17	19	1	via	via	ADP
bptjm-17	19	2	this	this	DET
bptjm-17	19	3	method	method	NOUN
bptjm-17	19	4	,	,	PUNCT
bptjm-17	19	5	clinicians	clinician	NOUN
bptjm-17	19	6	can	can	AUX
bptjm-17	19	7	quantify	quantify	VERB
bptjm-17	19	8	biological	biological	ADJ
bptjm-17	19	9	components	component	NOUN
bptjm-17	19	10	circulating	circulate	VERB
bptjm-17	19	11	in	in	ADP
bptjm-17	19	12	bodily	bodily	ADJ
bptjm-17	19	13	liquids	liquid	NOUN
bptjm-17	19	14	,	,	PUNCT
bptjm-17	19	15	such	such	ADJ
bptjm-17	19	16	as	as	ADP
bptjm-17	19	17	tumor	tumor	NOUN
bptjm-17	19	18	cells	cell	NOUN
bptjm-17	19	19	and	and	CCONJ
bptjm-17	19	20	nucleic	nucleic	ADJ
bptjm-17	19	21	acids	acid	NOUN
bptjm-17	19	22	,	,	PUNCT
bptjm-17	19	23	including	include	VERB
bptjm-17	19	24	dna	dna	NOUN
bptjm-17	19	25	and	and	CCONJ
bptjm-17	19	26	mirna	mirna	PROPN
bptjm-17	19	27	.	.	PUNCT
bptjm-17	20	1	circulating	circulate	VERB
bptjm-17	20	2	dna	dna	PROPN
bptjm-17	20	3	(	(	PUNCT
bptjm-17	20	4	ctdna	ctdna	NOUN
bptjm-17	20	5	)	)	PUNCT
bptjm-17	20	6	is	be	AUX
bptjm-17	20	7	derived	derive	VERB
bptjm-17	20	8	from	from	ADP
bptjm-17	20	9	dna	dna	NOUN
bptjm-17	20	10	and	and	CCONJ
bptjm-17	20	11	released	release	VERB
bptjm-17	20	12	by	by	ADP
bptjm-17	20	13	cancerous	cancerous	ADJ
bptjm-17	20	14	cells	cell	NOUN
bptjm-17	20	15	and	and	CCONJ
bptjm-17	20	16	tumors	tumor	NOUN
bptjm-17	20	17	into	into	ADP
bptjm-17	20	18	the	the	DET
bptjm-17	20	19	bloodstream	bloodstream	NOUN
bptjm-17	20	20	.	.	PUNCT
bptjm-17	21	1	as	as	SCONJ
bptjm-17	21	2	a	a	DET
bptjm-17	21	3	tumor	tumor	NOUN
bptjm-17	21	4	grows	grow	VERB
bptjm-17	21	5	,	,	PUNCT
bptjm-17	21	6	newer	new	ADJ
bptjm-17	21	7	cells	cell	NOUN
bptjm-17	21	8	replace	replace	VERB
bptjm-17	21	9	older	old	ADJ
bptjm-17	21	10	cells	cell	NOUN
bptjm-17	21	11	.	.	PUNCT
bptjm-17	22	1	the	the	DET
bptjm-17	22	2	dead	dead	ADJ
bptjm-17	22	3	cells	cell	NOUN
bptjm-17	22	4	are	be	AUX
bptjm-17	22	5	broken	break	VERB
bptjm-17	22	6	down	down	ADP
bptjm-17	22	7	into	into	ADP
bptjm-17	22	8	their	their	PRON
bptjm-17	22	9	main	main	ADJ
bptjm-17	22	10	components	component	NOUN
bptjm-17	22	11	,	,	PUNCT
bptjm-17	22	12	releasing	release	VERB
bptjm-17	22	13	dna	dna	NOUN
bptjm-17	22	14	into	into	ADP
bptjm-17	22	15	the	the	DET
bptjm-17	22	16	bloodstream	bloodstream	NOUN
bptjm-17	22	17	(	(	PUNCT
bptjm-17	22	18	mader	mader	NOUN
bptjm-17	22	19	et	et	PROPN
bptjm-17	22	20	al	al	PROPN
bptjm-17	22	21	.	.	PROPN
bptjm-17	22	22	,	,	PUNCT
bptjm-17	22	23	2017	2017	NUM
bptjm-17	22	24	)	)	PUNCT
bptjm-17	22	25	.	.	PUNCT
bptjm-17	23	1	microrna	microrna	PROPN
bptjm-17	23	2	(	(	PUNCT
bptjm-17	23	3	mirna	mirna	PROPN
bptjm-17	23	4	)	)	PUNCT
bptjm-17	23	5	are	be	AUX
bptjm-17	23	6	single	single	ADJ
bptjm-17	23	7	-	-	PUNCT
bptjm-17	23	8	stranded	strand	VERB
bptjm-17	23	9	,	,	PUNCT
bptjm-17	23	10	non	non	ADJ
bptjm-17	23	11	-	-	ADJ
bptjm-17	23	12	coding	coding	ADJ
bptjm-17	23	13	rnas	rna	NOUN
bptjm-17	23	14	in	in	ADP
bptjm-17	23	15	the	the	DET
bptjm-17	23	16	blood	blood	NOUN
bptjm-17	23	17	and	and	CCONJ
bptjm-17	23	18	function	function	NOUN
bptjm-17	23	19	as	as	ADP
bptjm-17	23	20	antisense	antisense	NOUN
bptjm-17	23	21	rna	rna	NOUN
bptjm-17	23	22	to	to	PART
bptjm-17	23	23	regulate	regulate	VERB
bptjm-17	23	24	the	the	DET
bptjm-17	23	25	target	target	NOUN
bptjm-17	23	26	genes	gene	NOUN
bptjm-17	23	27	.	.	PUNCT
bptjm-17	24	1	multiple	multiple	ADJ
bptjm-17	24	2	mirnas	mirna	NOUN
bptjm-17	24	3	can	can	AUX
bptjm-17	24	4	target	target	VERB
bptjm-17	24	5	the	the	DET
bptjm-17	24	6	same	same	ADJ
bptjm-17	24	7	gene	gene	NOUN
bptjm-17	24	8	(	(	PUNCT
bptjm-17	24	9	wang	wang	PROPN
bptjm-17	24	10	et	et	PROPN
bptjm-17	24	11	al	al	PROPN
bptjm-17	24	12	.	.	PROPN
bptjm-17	24	13	,	,	PUNCT
bptjm-17	24	14	2018	2018	NUM
bptjm-17	24	15	)	)	PUNCT
bptjm-17	24	16	.	.	PUNCT
bptjm-17	25	1	the	the	DET
bptjm-17	25	2	pathways	pathway	NOUN
bptjm-17	25	3	of	of	ADP
bptjm-17	25	4	ctdna	ctdna	NOUN
bptjm-17	25	5	and	and	CCONJ
bptjm-17	25	6	mirna	mirna	PROPN
bptjm-17	25	7	are	be	AUX
bptjm-17	25	8	depicted	depict	VERB
bptjm-17	25	9	in	in	ADP
bptjm-17	25	10	figure	figure	NOUN
bptjm-17	25	11	2	2	NUM
bptjm-17	25	12	and	and	CCONJ
bptjm-17	25	13	figure	figure	VERB
bptjm-17	25	14	3	3	NUM
bptjm-17	25	15	,	,	PUNCT
bptjm-17	25	16	respectively	respectively	ADV
bptjm-17	25	17	.	.	PUNCT
bptjm-17	26	1	there	there	PRON
bptjm-17	26	2	are	be	VERB
bptjm-17	26	3	three	three	NUM
bptjm-17	26	4	main	main	ADJ
bptjm-17	26	5	classes	class	NOUN
bptjm-17	26	6	of	of	ADP
bptjm-17	26	7	biomarkers	biomarker	NOUN
bptjm-17	26	8	.	.	PUNCT
bptjm-17	27	1	predictive	predictive	ADJ
bptjm-17	27	2	biomarkers	biomarker	NOUN
bptjm-17	27	3	interact	interact	VERB
bptjm-17	27	4	with	with	ADP
bptjm-17	27	5	speci	speci	PROPN
bptjm-17	27	6	c	c	PROPN
bptjm-17	27	7	treatments	treatment	NOUN
bptjm-17	27	8	to	to	ADP
bptjm-17	27	9	a	a	DET
bptjm-17	27	10	ect	ect	NOUN
bptjm-17	27	11	the	the	DET
bptjm-17	27	12	outcome	outcome	NOUN
bptjm-17	27	13	,	,	PUNCT
bptjm-17	27	14	prognostic	prognostic	ADJ
bptjm-17	27	15	biomarkers	biomarker	NOUN
bptjm-17	27	16	are	be	AUX
bptjm-17	27	17	berkeley	berkeley	PROPN
bptjm-17	27	18	pharma	pharma	PROPN
bptjm-17	27	19	tech	tech	NOUN
bptjm-17	27	20	journal	journal	NOUN
bptjm-17	27	21	of	of	ADP
bptjm-17	27	22	medicine	medicine	NOUN
bptjm-17	27	23	|	|	ADV
bptjm-17	27	24	117	117	NUM
bptjm-17	27	25	associated	associate	VERB
bptjm-17	27	26	with	with	ADP
bptjm-17	27	27	particular	particular	ADJ
bptjm-17	27	28	outcomes	outcome	NOUN
bptjm-17	27	29	regardless	regardless	ADV
bptjm-17	27	30	of	of	ADP
bptjm-17	27	31	the	the	DET
bptjm-17	27	32	course	course	NOUN
bptjm-17	27	33	of	of	ADP
bptjm-17	27	34	treatment	treatment	NOUN
bptjm-17	27	35	,	,	PUNCT
bptjm-17	27	36	and	and	CCONJ
bptjm-17	27	37	treatment	treatment	NOUN
bptjm-17	27	38	-	-	PUNCT
bptjm-17	27	39	focused	focus	VERB
bptjm-17	27	40	biomarkers	biomarker	NOUN
bptjm-17	27	41	are	be	AUX
bptjm-17	27	42	any	any	DET
bptjm-17	27	43	biomarkers	biomarker	NOUN
bptjm-17	27	44	that	that	SCONJ
bptjm-17	27	45	in	in	ADP
bptjm-17	27	46	uence	uence	NOUN
bptjm-17	27	47	the	the	DET
bptjm-17	27	48	selection	selection	NOUN
bptjm-17	27	49	of	of	ADP
bptjm-17	27	50	a	a	DET
bptjm-17	27	51	speci	speci	NOUN
bptjm-17	27	52	c	c	PROPN
bptjm-17	27	53	course	course	NOUN
bptjm-17	27	54	of	of	ADP
bptjm-17	27	55	treatment	treatment	NOUN
bptjm-17	27	56	(	(	PUNCT
bptjm-17	27	57	stein	stein	PROPN
bptjm-17	27	58	,	,	PUNCT
bptjm-17	27	59	n.d	n.d	PROPN
bptjm-17	27	60	.	.	PROPN
bptjm-17	27	61	)	)	PUNCT
bptjm-17	27	62	.	.	PUNCT
bptjm-17	28	1	this	this	DET
bptjm-17	28	2	paper	paper	NOUN
bptjm-17	28	3	outlines	outline	VERB
bptjm-17	28	4	several	several	ADJ
bptjm-17	28	5	ctdna	ctdna	NOUN
bptjm-17	28	6	and	and	CCONJ
bptjm-17	28	7	mirna	mirna	PROPN
bptjm-17	28	8	biomarkers	biomarker	NOUN
bptjm-17	28	9	detected	detect	VERB
bptjm-17	28	10	from	from	ADP
bptjm-17	28	11	liquid	liquid	ADJ
bptjm-17	28	12	biopsies	biopsy	NOUN
bptjm-17	28	13	and	and	CCONJ
bptjm-17	28	14	uses	use	VERB
bptjm-17	28	15	previous	previous	ADJ
bptjm-17	28	16	data	datum	NOUN
bptjm-17	28	17	to	to	PART
bptjm-17	28	18	assess	assess	VERB
bptjm-17	28	19	their	their	PRON
bptjm-17	28	20	value	value	NOUN
bptjm-17	28	21	in	in	ADP
bptjm-17	28	22	delineating	delineate	VERB
bptjm-17	28	23	nsclc	nsclc	NOUN
bptjm-17	28	24	prognosis	prognosis	NOUN
bptjm-17	28	25	,	,	PUNCT
bptjm-17	28	26	outcome	outcome	NOUN
bptjm-17	28	27	prediction	prediction	NOUN
bptjm-17	28	28	,	,	PUNCT
bptjm-17	28	29	or	or	CCONJ
bptjm-17	28	30	treatment	treatment	NOUN
bptjm-17	28	31	strategies	strategy	NOUN
bptjm-17	28	32	.	.	PUNCT
bptjm-17	29	1	studies	study	NOUN
bptjm-17	29	2	regarding	regard	VERB
bptjm-17	29	3	these	these	DET
bptjm-17	29	4	biomarkers	biomarker	NOUN
bptjm-17	29	5	were	be	AUX
bptjm-17	29	6	reviewed	review	VERB
bptjm-17	29	7	according	accord	VERB
bptjm-17	29	8	to	to	ADP
bptjm-17	29	9	sample	sample	NOUN
bptjm-17	29	10	size	size	NOUN
bptjm-17	29	11	,	,	PUNCT
bptjm-17	29	12	procedure	procedure	NOUN
bptjm-17	29	13	,	,	PUNCT
bptjm-17	29	14	and	and	CCONJ
bptjm-17	29	15	clinical	clinical	ADJ
bptjm-17	29	16	relevance	relevance	NOUN
bptjm-17	29	17	.	.	PUNCT
bptjm-17	30	1	the	the	DET
bptjm-17	30	2	speci	speci	PROPN
bptjm-17	30	3	c	c	PROPN
bptjm-17	30	4	ctdnas	ctdna	NOUN
bptjm-17	30	5	and	and	CCONJ
bptjm-17	30	6	mirnas	mirna	NOUN
bptjm-17	30	7	addressed	address	VERB
bptjm-17	30	8	in	in	ADP
bptjm-17	30	9	this	this	DET
bptjm-17	30	10	paper	paper	NOUN
bptjm-17	30	11	are	be	AUX
bptjm-17	30	12	summarized	summarize	VERB
bptjm-17	30	13	in	in	ADP
bptjm-17	30	14	figure	figure	NOUN
bptjm-17	30	15	1	1	NUM
bptjm-17	30	16	.	.	PUNCT
bptjm-17	31	1	figure	figure	NOUN
bptjm-17	31	2	1	1	NUM
bptjm-17	31	3	:	:	PUNCT
bptjm-17	31	4	list	list	NOUN
bptjm-17	31	5	of	of	ADP
bptjm-17	31	6	nsclc	nsclc	NOUN
bptjm-17	31	7	ctdna	ctdna	NOUN
bptjm-17	31	8	and	and	CCONJ
bptjm-17	31	9	mirna	mirna	PROPN
bptjm-17	31	10	biomarkers	biomarker	NOUN
bptjm-17	31	11	.	.	PUNCT
bptjm-17	32	1	this	this	DET
bptjm-17	32	2	list	list	NOUN
bptjm-17	32	3	is	be	AUX
bptjm-17	32	4	not	not	PART
bptjm-17	32	5	comprehensive	comprehensive	ADJ
bptjm-17	32	6	;	;	PUNCT
bptjm-17	32	7	it	it	PRON
bptjm-17	32	8	serves	serve	VERB
bptjm-17	32	9	as	as	ADP
bptjm-17	32	10	a	a	DET
bptjm-17	32	11	brief	brief	ADJ
bptjm-17	32	12	summary	summary	NOUN
bptjm-17	32	13	of	of	ADP
bptjm-17	32	14	the	the	DET
bptjm-17	32	15	ctdna	ctdna	NOUN
bptjm-17	32	16	and	and	CCONJ
bptjm-17	32	17	mirna	mirna	PROPN
bptjm-17	32	18	biomarkers	biomarker	NOUN
bptjm-17	32	19	discussed	discuss	VERB
bptjm-17	32	20	in	in	ADP
bptjm-17	32	21	this	this	DET
bptjm-17	32	22	paper	paper	NOUN
bptjm-17	32	23	.	.	PUNCT
bptjm-17	33	1	common	common	ADJ
bptjm-17	33	2	methods	method	NOUN
bptjm-17	33	3	utilized	utilize	VERB
bptjm-17	33	4	for	for	ADP
bptjm-17	33	5	circulating	circulate	VERB
bptjm-17	33	6	nucleic	nucleic	ADJ
bptjm-17	33	7	acid	acid	NOUN
bptjm-17	33	8	assessment	assessment	NOUN
bptjm-17	33	9	:	:	PUNCT
bptjm-17	33	10	several	several	ADJ
bptjm-17	33	11	primary	primary	ADJ
bptjm-17	33	12	technologies	technology	NOUN
bptjm-17	33	13	have	have	AUX
bptjm-17	33	14	been	be	AUX
bptjm-17	33	15	used	use	VERB
bptjm-17	33	16	to	to	PART
bptjm-17	33	17	assess	assess	VERB
bptjm-17	33	18	circulating	circulate	VERB
bptjm-17	33	19	nucleic	nucleic	ADJ
bptjm-17	33	20	acid	acid	NOUN
bptjm-17	33	21	biomarkers	biomarker	NOUN
bptjm-17	33	22	.	.	PUNCT
bptjm-17	34	1	1	1	X
bptjm-17	34	2	.	.	X
bptjm-17	34	3	fluorescence	fluorescence	NOUN
bptjm-17	34	4	in	in	ADP
bptjm-17	34	5	situ	situ	ADJ
bptjm-17	34	6	hybridization	hybridization	NOUN
bptjm-17	34	7	(	(	PUNCT
bptjm-17	34	8	fish	fish	NOUN
bptjm-17	34	9	):	):	PUNCT
bptjm-17	34	10	fish	fish	NOUN
bptjm-17	34	11	utilizes	utilize	VERB
bptjm-17	34	12	a	a	DET
bptjm-17	34	13	dna	dna	PROPN
bptjm-17	34	14	sequence	sequence	NOUN
bptjm-17	34	15	probe	probe	NOUN
bptjm-17	34	16	with	with	ADP
bptjm-17	34	17	a	a	DET
bptjm-17	34	18	uorescent	uorescent	ADJ
bptjm-17	34	19	dye	dye	NOUN
bptjm-17	34	20	attachment	attachment	NOUN
bptjm-17	34	21	to	to	PART
bptjm-17	34	22	locate	locate	VERB
bptjm-17	34	23	and	and	CCONJ
bptjm-17	34	24	label	label	VERB
bptjm-17	34	25	a	a	DET
bptjm-17	34	26	speci	speci	PROPN
bptjm-17	34	27	c	c	PROPN
bptjm-17	34	28	complementary	complementary	ADJ
bptjm-17	34	29	dna	dna	PROPN
bptjm-17	34	30	strand	strand	NOUN
bptjm-17	34	31	on	on	ADP
bptjm-17	34	32	a	a	DET
bptjm-17	34	33	chromosome	chromosome	NOUN
bptjm-17	34	34	.	.	PUNCT
bptjm-17	35	1	this	this	DET
bptjm-17	35	2	uorescent	uorescent	ADJ
bptjm-17	35	3	marker	marker	NOUN
bptjm-17	35	4	can	can	AUX
bptjm-17	35	5	be	be	AUX
bptjm-17	35	6	visualized	visualize	VERB
bptjm-17	35	7	through	through	ADP
bptjm-17	35	8	microscopy	microscopy	NOUN
bptjm-17	35	9	.	.	PUNCT
bptjm-17	36	1	this	this	DET
bptjm-17	36	2	method	method	NOUN
bptjm-17	36	3	is	be	AUX
bptjm-17	36	4	applicable	applicable	ADJ
bptjm-17	36	5	to	to	ADP
bptjm-17	36	6	blood	blood	NOUN
bptjm-17	36	7	,	,	PUNCT
bptjm-17	36	8	cytology	cytology	NOUN
bptjm-17	36	9	smears	smear	NOUN
bptjm-17	36	10	,	,	PUNCT
bptjm-17	36	11	and	and	CCONJ
bptjm-17	36	12	bone	bone	NOUN
bptjm-17	36	13	marrow	marrow	NOUN
bptjm-17	36	14	to	to	PART
bptjm-17	36	15	detect	detect	VERB
bptjm-17	36	16	duplications	duplication	NOUN
bptjm-17	36	17	,	,	PUNCT
bptjm-17	36	18	deletions	deletion	NOUN
bptjm-17	36	19	,	,	PUNCT
bptjm-17	36	20	and	and	CCONJ
bptjm-17	36	21	total	total	ADJ
bptjm-17	36	22	chromosomal	chromosomal	ADJ
bptjm-17	36	23	loss	loss	NOUN
bptjm-17	36	24	or	or	CCONJ
bptjm-17	36	25	gain	gain	NOUN
bptjm-17	36	26	(	(	PUNCT
bptjm-17	36	27	green	green	ADJ
bptjm-17	36	28	)	)	PUNCT
bptjm-17	36	29	.	.	PUNCT
bptjm-17	37	1	2	2	X
bptjm-17	37	2	.	.	X
bptjm-17	37	3	immunohistochemistry	immunohistochemistry	NOUN
bptjm-17	37	4	(	(	PUNCT
bptjm-17	37	5	ihc	ihc	PROPN
bptjm-17	37	6	):	):	PUNCT
bptjm-17	37	7	during	during	ADP
bptjm-17	37	8	ihc	ihc	PROPN
bptjm-17	37	9	,	,	PUNCT
bptjm-17	37	10	xed	xed	X
bptjm-17	37	11	tissue	tissue	NOUN
bptjm-17	37	12	is	be	AUX
bptjm-17	37	13	exposed	expose	VERB
bptjm-17	37	14	to	to	ADP
bptjm-17	37	15	antibodies	antibody	NOUN
bptjm-17	37	16	,	,	PUNCT
bptjm-17	37	17	which	which	PRON
bptjm-17	37	18	enter	enter	VERB
bptjm-17	37	19	and	and	CCONJ
bptjm-17	37	20	adhere	adhere	VERB
bptjm-17	37	21	to	to	ADP
bptjm-17	37	22	antigenic	antigenic	ADJ
bptjm-17	37	23	determinants	determinant	NOUN
bptjm-17	37	24	.	.	PUNCT
bptjm-17	38	1	once	once	ADV
bptjm-17	38	2	this	this	DET
bptjm-17	38	3	antibody	antibody	NOUN
bptjm-17	38	4	-	-	PUNCT
bptjm-17	38	5	antigen	antigen	NOUN
bptjm-17	38	6	substrate	substrate	NOUN
bptjm-17	38	7	is	be	AUX
bptjm-17	38	8	created	create	VERB
bptjm-17	38	9	,	,	PUNCT
bptjm-17	38	10	it	it	PRON
bptjm-17	38	11	catalyzes	catalyze	VERB
bptjm-17	38	12	an	an	DET
bptjm-17	38	13	oxidation	oxidation	NOUN
bptjm-17	38	14	reaction	reaction	NOUN
bptjm-17	38	15	to	to	PART
bptjm-17	38	16	form	form	VERB
bptjm-17	38	17	a	a	DET
bptjm-17	38	18	visible	visible	ADJ
bptjm-17	38	19	colorized	colorize	VERB
bptjm-17	38	20	marker	marker	NOUN
bptjm-17	38	21	.	.	PUNCT
bptjm-17	39	1	this	this	DET
bptjm-17	39	2	can	can	AUX
bptjm-17	39	3	berkeley	berkeley	PROPN
bptjm-17	39	4	pharma	pharma	PROPN
bptjm-17	39	5	tech	tech	NOUN
bptjm-17	39	6	journal	journal	NOUN
bptjm-17	39	7	of	of	ADP
bptjm-17	39	8	medicine	medicine	NOUN
bptjm-17	39	9	|	|	ADV
bptjm-17	39	10	118	118	NUM
bptjm-17	39	11	be	be	AUX
bptjm-17	39	12	used	use	VERB
bptjm-17	39	13	as	as	ADP
bptjm-17	39	14	a	a	DET
bptjm-17	39	15	tool	tool	NOUN
bptjm-17	39	16	for	for	ADP
bptjm-17	39	17	measuring	measure	VERB
bptjm-17	39	18	protein	protein	NOUN
bptjm-17	39	19	and	and	CCONJ
bptjm-17	39	20	nucleic	nucleic	ADJ
bptjm-17	39	21	acid	acid	NOUN
bptjm-17	39	22	expression	expression	NOUN
bptjm-17	39	23	(	(	PUNCT
bptjm-17	39	24	schildhaus	schildhaus	PROPN
bptjm-17	39	25	et	et	PROPN
bptjm-17	39	26	al	al	PROPN
bptjm-17	39	27	.	.	PROPN
bptjm-17	39	28	,	,	PUNCT
bptjm-17	39	29	2020	2020	NUM
bptjm-17	39	30	)	)	PUNCT
bptjm-17	39	31	.	.	PUNCT
bptjm-17	40	1	3	3	X
bptjm-17	40	2	.	.	X
bptjm-17	40	3	polymerase	polymerase	NOUN
bptjm-17	40	4	chain	chain	NOUN
bptjm-17	40	5	reaction	reaction	NOUN
bptjm-17	40	6	(	(	PUNCT
bptjm-17	40	7	pcr	pcr	PROPN
bptjm-17	40	8	):	):	PUNCT
bptjm-17	40	9	pcr	pcr	NOUN
bptjm-17	40	10	allows	allow	VERB
bptjm-17	40	11	for	for	ADP
bptjm-17	40	12	the	the	DET
bptjm-17	40	13	rapid	rapid	ADJ
bptjm-17	40	14	ampli	ampli	NOUN
bptjm-17	40	15	cation	cation	NOUN
bptjm-17	40	16	of	of	ADP
bptjm-17	40	17	small	small	ADJ
bptjm-17	40	18	dna	dna	PROPN
bptjm-17	40	19	fragments	fragment	NOUN
bptjm-17	40	20	.	.	PUNCT
bptjm-17	41	1	first	first	ADV
bptjm-17	41	2	,	,	PUNCT
bptjm-17	41	3	the	the	DET
bptjm-17	41	4	sample	sample	NOUN
bptjm-17	41	5	dna	dna	PROPN
bptjm-17	41	6	is	be	AUX
bptjm-17	41	7	denatured	denature	VERB
bptjm-17	41	8	at	at	ADP
bptjm-17	41	9	a	a	DET
bptjm-17	41	10	high	high	ADJ
bptjm-17	41	11	temperature	temperature	NOUN
bptjm-17	41	12	to	to	PART
bptjm-17	41	13	form	form	VERB
bptjm-17	41	14	two	two	NUM
bptjm-17	41	15	single	single	ADJ
bptjm-17	41	16	-	-	PUNCT
bptjm-17	41	17	stranded	strand	VERB
bptjm-17	41	18	dna	dna	NOUN
bptjm-17	41	19	fragments	fragment	NOUN
bptjm-17	41	20	.	.	PUNCT
bptjm-17	42	1	second	second	ADJ
bptjm-17	42	2	,	,	PUNCT
bptjm-17	42	3	taq	taq	NOUN
bptjm-17	42	4	polymerase	polymerase	NOUN
bptjm-17	42	5	,	,	PUNCT
bptjm-17	42	6	a	a	DET
bptjm-17	42	7	thermostable	thermostable	NOUN
bptjm-17	42	8	enzyme	enzyme	NOUN
bptjm-17	42	9	,	,	PUNCT
bptjm-17	42	10	attaches	attach	VERB
bptjm-17	42	11	complementary	complementary	ADJ
bptjm-17	42	12	dna	dna	PROPN
bptjm-17	42	13	strands	strand	NOUN
bptjm-17	42	14	(	(	PUNCT
bptjm-17	42	15	known	know	VERB
bptjm-17	42	16	as	as	ADP
bptjm-17	42	17	primers	primer	NOUN
bptjm-17	42	18	)	)	PUNCT
bptjm-17	42	19	to	to	ADP
bptjm-17	42	20	each	each	DET
bptjm-17	42	21	exposed	expose	VERB
bptjm-17	42	22	strand	strand	NOUN
bptjm-17	42	23	.	.	PUNCT
bptjm-17	43	1	this	this	DET
bptjm-17	43	2	process	process	NOUN
bptjm-17	43	3	results	result	VERB
bptjm-17	43	4	in	in	ADP
bptjm-17	43	5	the	the	DET
bptjm-17	43	6	duplication	duplication	NOUN
bptjm-17	43	7	of	of	ADP
bptjm-17	43	8	the	the	DET
bptjm-17	43	9	original	original	ADJ
bptjm-17	43	10	dna	dna	NOUN
bptjm-17	43	11	strand	strand	NOUN
bptjm-17	43	12	once	once	ADV
bptjm-17	43	13	elongation	elongation	NOUN
bptjm-17	43	14	has	have	AUX
bptjm-17	43	15	been	be	AUX
bptjm-17	43	16	completed	complete	VERB
bptjm-17	43	17	.	.	PUNCT
bptjm-17	44	1	millions	million	NOUN
bptjm-17	44	2	of	of	ADP
bptjm-17	44	3	copies	copy	NOUN
bptjm-17	44	4	of	of	ADP
bptjm-17	44	5	a	a	DET
bptjm-17	44	6	speci	speci	PROPN
bptjm-17	44	7	c	c	PROPN
bptjm-17	44	8	dna	dna	PROPN
bptjm-17	44	9	strand	strand	NOUN
bptjm-17	44	10	can	can	AUX
bptjm-17	44	11	be	be	AUX
bptjm-17	44	12	produced	produce	VERB
bptjm-17	44	13	after	after	ADP
bptjm-17	44	14	several	several	ADJ
bptjm-17	44	15	cycles	cycle	NOUN
bptjm-17	44	16	of	of	ADP
bptjm-17	44	17	this	this	DET
bptjm-17	44	18	process	process	NOUN
bptjm-17	44	19	(	(	PUNCT
bptjm-17	44	20	waters	water	NOUN
bptjm-17	44	21	&	&	CCONJ
bptjm-17	44	22	shapter	shapter	PROPN
bptjm-17	44	23	,	,	PUNCT
bptjm-17	44	24	2014	2014	NUM
bptjm-17	44	25	)	)	PUNCT
bptjm-17	44	26	.	.	PUNCT
bptjm-17	45	1	4	4	X
bptjm-17	45	2	.	.	X
bptjm-17	45	3	next	next	ADJ
bptjm-17	45	4	generation	generation	NOUN
bptjm-17	45	5	sequencing	sequence	VERB
bptjm-17	45	6	(	(	PUNCT
bptjm-17	45	7	ngs	ng	NOUN
bptjm-17	45	8	):	):	PUNCT
bptjm-17	45	9	ngs	ng	NOUN
bptjm-17	45	10	refers	refer	VERB
bptjm-17	45	11	to	to	ADP
bptjm-17	45	12	the	the	DET
bptjm-17	45	13	parallel	parallel	ADJ
bptjm-17	45	14	sequencing	sequencing	NOUN
bptjm-17	45	15	of	of	ADP
bptjm-17	45	16	genomic	genomic	ADJ
bptjm-17	45	17	segments	segment	NOUN
bptjm-17	45	18	.	.	PUNCT
bptjm-17	46	1	there	there	PRON
bptjm-17	46	2	are	be	VERB
bptjm-17	46	3	three	three	NUM
bptjm-17	46	4	main	main	ADJ
bptjm-17	46	5	kinds	kind	NOUN
bptjm-17	46	6	of	of	ADP
bptjm-17	46	7	ngs	ng	NOUN
bptjm-17	46	8	:	:	PUNCT
bptjm-17	46	9	a.	a.	NOUN
bptjm-17	46	10	illumina	illumina	PROPN
bptjm-17	46	11	sequencing	sequence	VERB
bptjm-17	46	12	:	:	PUNCT
bptjm-17	46	13	in	in	ADP
bptjm-17	46	14	illumina	illumina	PROPN
bptjm-17	46	15	sequencing	sequencing	NOUN
bptjm-17	46	16	,	,	PUNCT
bptjm-17	46	17	the	the	DET
bptjm-17	46	18	dna	dna	PROPN
bptjm-17	46	19	bases	basis	NOUN
bptjm-17	46	20	are	be	AUX
bptjm-17	46	21	identi	identi	ADJ
bptjm-17	46	22	ed	ed	NOUN
bptjm-17	46	23	by	by	ADP
bptjm-17	46	24	their	their	PRON
bptjm-17	46	25	unique	unique	ADJ
bptjm-17	46	26	uorescent	uorescent	ADJ
bptjm-17	46	27	signals	signal	NOUN
bptjm-17	46	28	.	.	PUNCT
bptjm-17	47	1	b.	b.	PROPN
bptjm-17	47	2	roche	roche	PROPN
bptjm-17	47	3	454	454	NUM
bptjm-17	47	4	:	:	PUNCT
bptjm-17	47	5	roche	roche	NOUN
bptjm-17	47	6	454	454	NUM
bptjm-17	47	7	sequencing	sequencing	NOUN
bptjm-17	47	8	relies	relie	NOUN
bptjm-17	47	9	on	on	ADP
bptjm-17	47	10	the	the	DET
bptjm-17	47	11	release	release	NOUN
bptjm-17	47	12	of	of	ADP
bptjm-17	47	13	visible	visible	ADJ
bptjm-17	47	14	uorescent	uorescent	ADJ
bptjm-17	47	15	pyrophosphate	pyrophosphate	NOUN
bptjm-17	47	16	that	that	PRON
bptjm-17	47	17	occurs	occur	VERB
bptjm-17	47	18	upon	upon	SCONJ
bptjm-17	47	19	nucleotide	nucleotide	ADJ
bptjm-17	47	20	addition	addition	NOUN
bptjm-17	47	21	to	to	ADP
bptjm-17	47	22	a	a	DET
bptjm-17	47	23	new	new	ADJ
bptjm-17	47	24	strand	strand	NOUN
bptjm-17	47	25	of	of	ADP
bptjm-17	47	26	dna	dna	PROPN
bptjm-17	47	27	.	.	PUNCT
bptjm-17	48	1	c.	c.	PROPN
bptjm-17	48	2	ion	ion	PROPN
bptjm-17	48	3	torrent	torrent	NOUN
bptjm-17	48	4	:	:	PUNCT
bptjm-17	48	5	ion	ion	NOUN
bptjm-17	48	6	torrent	torrent	NOUN
bptjm-17	48	7	sequencing	sequencing	NOUN
bptjm-17	48	8	measures	measure	NOUN
bptjm-17	48	9	the	the	DET
bptjm-17	48	10	release	release	NOUN
bptjm-17	48	11	of	of	ADP
bptjm-17	48	12	protons	proton	NOUN
bptjm-17	48	13	due	due	ADP
bptjm-17	48	14	to	to	ADP
bptjm-17	48	15	the	the	DET
bptjm-17	48	16	incorporation	incorporation	NOUN
bptjm-17	48	17	of	of	ADP
bptjm-17	48	18	nucleotide	nucleotide	ADJ
bptjm-17	48	19	bases	basis	NOUN
bptjm-17	48	20	in	in	ADP
bptjm-17	48	21	the	the	DET
bptjm-17	48	22	dna	dna	NOUN
bptjm-17	48	23	.	.	PUNCT
bptjm-17	49	1	circulating	circulate	VERB
bptjm-17	49	2	dna	dna	PROPN
bptjm-17	49	3	biomarkers	biomarker	NOUN
bptjm-17	49	4	figure	figure	VERB
bptjm-17	49	5	2	2	NUM
bptjm-17	49	6	:	:	PUNCT
bptjm-17	49	7	an	an	DET
bptjm-17	49	8	illustration	illustration	NOUN
bptjm-17	49	9	of	of	ADP
bptjm-17	49	10	the	the	DET
bptjm-17	49	11	ctdna	ctdna	NOUN
bptjm-17	49	12	pathway	pathway	NOUN
bptjm-17	49	13	.	.	PUNCT
bptjm-17	50	1	at	at	ADP
bptjm-17	50	2	the	the	DET
bptjm-17	50	3	top	top	NOUN
bptjm-17	50	4	,	,	PUNCT
bptjm-17	50	5	the	the	DET
bptjm-17	50	6	tissue	tissue	NOUN
bptjm-17	50	7	cells	cell	NOUN
bptjm-17	50	8	are	be	AUX
bptjm-17	50	9	shedding	shed	VERB
bptjm-17	50	10	into	into	ADP
bptjm-17	50	11	the	the	DET
bptjm-17	50	12	bloodstream	bloodstream	NOUN
bptjm-17	50	13	.	.	PUNCT
bptjm-17	51	1	an	an	DET
bptjm-17	51	2	immune	immune	ADJ
bptjm-17	51	3	response	response	NOUN
bptjm-17	51	4	occurs	occur	VERB
bptjm-17	51	5	in	in	ADP
bptjm-17	51	6	order	order	NOUN
bptjm-17	51	7	to	to	PART
bptjm-17	51	8	eliminate	eliminate	VERB
bptjm-17	51	9	the	the	DET
bptjm-17	51	10	tumor	tumor	NOUN
bptjm-17	51	11	cells	cell	NOUN
bptjm-17	51	12	entering	enter	VERB
bptjm-17	51	13	the	the	DET
bptjm-17	51	14	bloodstream	bloodstream	NOUN
bptjm-17	51	15	and	and	CCONJ
bptjm-17	51	16	to	to	PART
bptjm-17	51	17	eliminate	eliminate	VERB
bptjm-17	51	18	any	any	DET
bptjm-17	51	19	ctcs	ctcs	NOUN
bptjm-17	51	20	.	.	PUNCT
bptjm-17	52	1	as	as	ADP
bptjm-17	52	2	part	part	NOUN
bptjm-17	52	3	of	of	ADP
bptjm-17	52	4	this	this	DET
bptjm-17	52	5	elimination	elimination	NOUN
bptjm-17	52	6	,	,	PUNCT
bptjm-17	52	7	many	many	ADJ
bptjm-17	52	8	tumor	tumor	NOUN
bptjm-17	52	9	cells	cell	NOUN
bptjm-17	52	10	are	be	AUX
bptjm-17	52	11	berkeley	berkeley	PROPN
bptjm-17	52	12	pharma	pharma	PROPN
bptjm-17	52	13	tech	tech	NOUN
bptjm-17	52	14	journal	journal	NOUN
bptjm-17	52	15	of	of	ADP
bptjm-17	52	16	medicine	medicine	NOUN
bptjm-17	52	17	|	|	ADV
bptjm-17	52	18	119	119	NUM
bptjm-17	52	19	phagocytized	phagocytized	ADJ
bptjm-17	52	20	,	,	PUNCT
bptjm-17	52	21	thus	thus	ADV
bptjm-17	52	22	increasing	increase	VERB
bptjm-17	52	23	the	the	DET
bptjm-17	52	24	concentration	concentration	NOUN
bptjm-17	52	25	of	of	ADP
bptjm-17	52	26	ctdna	ctdna	NOUN
bptjm-17	52	27	in	in	ADP
bptjm-17	52	28	the	the	DET
bptjm-17	52	29	bloodstream	bloodstream	NOUN
bptjm-17	52	30	,	,	PUNCT
bptjm-17	52	31	which	which	PRON
bptjm-17	52	32	can	can	AUX
bptjm-17	52	33	be	be	AUX
bptjm-17	52	34	analyzed	analyze	VERB
bptjm-17	52	35	through	through	ADP
bptjm-17	52	36	liquid	liquid	ADJ
bptjm-17	52	37	biopsy	biopsy	NOUN
bptjm-17	52	38	(	(	PUNCT
bptjm-17	52	39	delmonico	delmonico	PROPN
bptjm-17	52	40	et	et	PROPN
bptjm-17	52	41	al	al	PROPN
bptjm-17	52	42	.	.	PROPN
bptjm-17	52	43	,	,	PUNCT
bptjm-17	52	44	2020	2020	NUM
bptjm-17	52	45	,	,	PUNCT
bptjm-17	52	46	bettegowda	bettegowda	NOUN
bptjm-17	52	47	et	et	PROPN
bptjm-17	52	48	al	al	PROPN
bptjm-17	52	49	.	.	PROPN
bptjm-17	52	50	,	,	PUNCT
bptjm-17	52	51	2014	2014	NUM
bptjm-17	52	52	)	)	PUNCT
bptjm-17	52	53	.	.	PUNCT
bptjm-17	53	1	ercc1	ercc1	PROPN
bptjm-17	53	2	excision	excision	PROPN
bptjm-17	53	3	repair	repair	PROPN
bptjm-17	53	4	cross	cross	ADJ
bptjm-17	53	5	-	-	ADJ
bptjm-17	53	6	complementation	complementation	ADJ
bptjm-17	53	7	group	group	NOUN
bptjm-17	53	8	1	1	NUM
bptjm-17	53	9	(	(	PUNCT
bptjm-17	53	10	ercc1	ercc1	PROPN
bptjm-17	53	11	)	)	PUNCT
bptjm-17	53	12	is	be	AUX
bptjm-17	53	13	a	a	DET
bptjm-17	53	14	part	part	NOUN
bptjm-17	53	15	of	of	ADP
bptjm-17	53	16	the	the	DET
bptjm-17	53	17	nucleotide	nucleotide	ADJ
bptjm-17	53	18	excision	excision	NOUN
bptjm-17	53	19	repair	repair	PROPN
bptjm-17	53	20	(	(	PUNCT
bptjm-17	53	21	ner	ner	NOUN
bptjm-17	53	22	)	)	PUNCT
bptjm-17	53	23	pathway	pathway	NOUN
bptjm-17	53	24	that	that	PRON
bptjm-17	53	25	acts	act	VERB
bptjm-17	53	26	as	as	ADP
bptjm-17	53	27	a	a	DET
bptjm-17	53	28	mechanism	mechanism	NOUN
bptjm-17	53	29	for	for	ADP
bptjm-17	53	30	dna	dna	PROPN
bptjm-17	53	31	repair	repair	NOUN
bptjm-17	53	32	,	,	PUNCT
bptjm-17	53	33	and	and	CCONJ
bptjm-17	53	34	also	also	ADV
bptjm-17	53	35	removes	remove	VERB
bptjm-17	53	36	the	the	DET
bptjm-17	53	37	cytotoxic	cytotoxic	ADJ
bptjm-17	53	38	elements	element	NOUN
bptjm-17	53	39	from	from	ADP
bptjm-17	53	40	genomic	genomic	ADJ
bptjm-17	53	41	dna	dna	PROPN
bptjm-17	53	42	.	.	PUNCT
bptjm-17	54	1	for	for	ADP
bptjm-17	54	2	example	example	NOUN
bptjm-17	54	3	,	,	PUNCT
bptjm-17	54	4	platinum	platinum	NOUN
bptjm-17	54	5	is	be	AUX
bptjm-17	54	6	a	a	DET
bptjm-17	54	7	cell	cell	NOUN
bptjm-17	54	8	-	-	PUNCT
bptjm-17	54	9	damaging	damage	VERB
bptjm-17	54	10	agent	agent	NOUN
bptjm-17	54	11	that	that	PRON
bptjm-17	54	12	causes	cause	VERB
bptjm-17	54	13	apoptosis	apoptosis	NOUN
bptjm-17	54	14	,	,	PUNCT
bptjm-17	54	15	therefore	therefore	ADV
bptjm-17	54	16	regulating	regulate	VERB
bptjm-17	54	17	cell	cell	NOUN
bptjm-17	54	18	growth	growth	NOUN
bptjm-17	54	19	and	and	CCONJ
bptjm-17	54	20	death	death	NOUN
bptjm-17	54	21	in	in	ADP
bptjm-17	54	22	the	the	DET
bptjm-17	54	23	body	body	NOUN
bptjm-17	54	24	.	.	PUNCT
bptjm-17	55	1	overexpression	overexpression	NOUN
bptjm-17	55	2	of	of	ADP
bptjm-17	55	3	ercc1	ercc1	NOUN
bptjm-17	55	4	can	can	AUX
bptjm-17	55	5	cause	cause	VERB
bptjm-17	55	6	lower	low	ADJ
bptjm-17	55	7	platinum	platinum	NOUN
bptjm-17	55	8	absorption	absorption	NOUN
bptjm-17	55	9	,	,	PUNCT
bptjm-17	55	10	resulting	result	VERB
bptjm-17	55	11	in	in	ADP
bptjm-17	55	12	decreased	decrease	VERB
bptjm-17	55	13	cell	cell	NOUN
bptjm-17	55	14	death	death	NOUN
bptjm-17	55	15	and	and	CCONJ
bptjm-17	55	16	subsequent	subsequent	ADJ
bptjm-17	55	17	increased	increase	VERB
bptjm-17	55	18	cell	cell	NOUN
bptjm-17	55	19	growth	growth	NOUN
bptjm-17	55	20	and	and	CCONJ
bptjm-17	55	21	carcinogenesis	carcinogenesis	NOUN
bptjm-17	55	22	.	.	PUNCT
bptjm-17	56	1	underexpression	underexpression	NOUN
bptjm-17	56	2	of	of	ADP
bptjm-17	56	3	ercc1	ercc1	NOUN
bptjm-17	56	4	can	can	AUX
bptjm-17	56	5	cause	cause	VERB
bptjm-17	56	6	carcinogenic	carcinogenic	ADJ
bptjm-17	56	7	factors	factor	NOUN
bptjm-17	56	8	to	to	PART
bptjm-17	56	9	enter	enter	VERB
bptjm-17	56	10	genomic	genomic	ADJ
bptjm-17	56	11	dna	dna	NOUN
bptjm-17	56	12	and	and	CCONJ
bptjm-17	56	13	hinder	hinder	VERB
bptjm-17	56	14	dna	dna	PROPN
bptjm-17	56	15	repair	repair	NOUN
bptjm-17	56	16	mechanisms	mechanism	NOUN
bptjm-17	56	17	because	because	SCONJ
bptjm-17	56	18	ercc1	ercc1	PROPN
bptjm-17	56	19	typically	typically	ADV
bptjm-17	56	20	repairs	repair	VERB
bptjm-17	56	21	any	any	DET
bptjm-17	56	22	dna	dna	PROPN
bptjm-17	56	23	damage	damage	NOUN
bptjm-17	56	24	done	do	VERB
bptjm-17	56	25	by	by	ADP
bptjm-17	56	26	platinum	platinum	NOUN
bptjm-17	56	27	(	(	PUNCT
bptjm-17	56	28	li	li	PROPN
bptjm-17	56	29	et	et	PROPN
bptjm-17	56	30	al	al	PROPN
bptjm-17	56	31	.	.	PROPN
bptjm-17	56	32	,	,	PUNCT
bptjm-17	56	33	2016	2016	NUM
bptjm-17	56	34	)	)	PUNCT
bptjm-17	56	35	.	.	PUNCT
bptjm-17	57	1	hence	hence	ADV
bptjm-17	57	2	,	,	PUNCT
bptjm-17	57	3	ercc1	ercc1	NOUN
bptjm-17	57	4	expression	expression	NOUN
bptjm-17	57	5	level	level	NOUN
bptjm-17	57	6	directly	directly	ADV
bptjm-17	57	7	correlates	correlate	VERB
bptjm-17	57	8	to	to	ADP
bptjm-17	57	9	platinum	platinum	NOUN
bptjm-17	57	10	sensitivity	sensitivity	NOUN
bptjm-17	57	11	(	(	PUNCT
bptjm-17	57	12	hamilton	hamilton	PROPN
bptjm-17	57	13	et	et	PROPN
bptjm-17	57	14	al	al	PROPN
bptjm-17	57	15	.	.	PROPN
bptjm-17	57	16	,	,	PUNCT
bptjm-17	57	17	2018	2018	NUM
bptjm-17	57	18	)	)	PUNCT
bptjm-17	57	19	.	.	PUNCT
bptjm-17	58	1	programmed	program	VERB
bptjm-17	58	2	death	death	NOUN
bptjm-17	58	3	receptor-1	receptor-1	NUM
bptjm-17	58	4	is	be	AUX
bptjm-17	58	5	an	an	DET
bptjm-17	58	6	immune	immune	ADJ
bptjm-17	58	7	-	-	PUNCT
bptjm-17	58	8	regulatory	regulatory	ADJ
bptjm-17	58	9	protein	protein	NOUN
bptjm-17	58	10	with	with	ADP
bptjm-17	58	11	two	two	NUM
bptjm-17	58	12	ligands	ligand	NOUN
bptjm-17	58	13	,	,	PUNCT
bptjm-17	58	14	pd	pd	PROPN
bptjm-17	58	15	-	-	PROPN
bptjm-17	58	16	l1	l1	PROPN
bptjm-17	58	17	and	and	CCONJ
bptjm-17	58	18	pd	pd	NOUN
bptjm-17	58	19	-	-	NOUN
bptjm-17	58	20	l2	l2	NOUN
bptjm-17	58	21	,	,	PUNCT
bptjm-17	58	22	that	that	PRON
bptjm-17	58	23	is	be	AUX
bptjm-17	58	24	expressed	express	VERB
bptjm-17	58	25	by	by	ADP
bptjm-17	58	26	immune	immune	ADJ
bptjm-17	58	27	cells	cell	NOUN
bptjm-17	58	28	and	and	CCONJ
bptjm-17	58	29	tumor	tumor	NOUN
bptjm-17	58	30	cells	cell	NOUN
bptjm-17	58	31	.	.	PUNCT
bptjm-17	59	1	in	in	ADP
bptjm-17	59	2	a	a	DET
bptjm-17	59	3	study	study	NOUN
bptjm-17	59	4	done	do	VERB
bptjm-17	59	5	by	by	ADP
bptjm-17	59	6	buderath	buderath	PROPN
bptjm-17	59	7	et	et	PROPN
bptjm-17	59	8	al	al	PROPN
bptjm-17	59	9	.	.	PROPN
bptjm-17	59	10	,	,	PUNCT
bptjm-17	59	11	pd	pd	PROPN
bptjm-17	59	12	-	-	PUNCT
bptjm-17	59	13	l1	l1	PROPN
bptjm-17	59	14	,	,	PUNCT
bptjm-17	59	15	pd	pd	NOUN
bptjm-17	59	16	-	-	NOUN
bptjm-17	59	17	l2	l2	NOUN
bptjm-17	59	18	,	,	PUNCT
bptjm-17	59	19	and	and	CCONJ
bptjm-17	59	20	ercc1	ercc1	NOUN
bptjm-17	59	21	levels	level	NOUN
bptjm-17	59	22	were	be	AUX
bptjm-17	59	23	measured	measure	VERB
bptjm-17	59	24	in	in	ADP
bptjm-17	59	25	83	83	NUM
bptjm-17	59	26	patients	patient	NOUN
bptjm-17	59	27	with	with	ADP
bptjm-17	59	28	epithelial	epithelial	ADJ
bptjm-17	59	29	ovarian	ovarian	ADJ
bptjm-17	59	30	cancer	cancer	NOUN
bptjm-17	59	31	through	through	ADP
bptjm-17	59	32	liquid	liquid	ADJ
bptjm-17	59	33	biopsy	biopsy	NOUN
bptjm-17	59	34	.	.	PUNCT
bptjm-17	60	1	results	result	NOUN
bptjm-17	60	2	showed	show	VERB
bptjm-17	60	3	that	that	SCONJ
bptjm-17	60	4	higher	high	ADJ
bptjm-17	60	5	ercc1	ercc1	NOUN
bptjm-17	60	6	expression	expression	NOUN
bptjm-17	60	7	was	be	AUX
bptjm-17	60	8	associated	associate	VERB
bptjm-17	60	9	with	with	ADP
bptjm-17	60	10	lower	low	ADJ
bptjm-17	60	11	pd	pd	ADJ
bptjm-17	60	12	-	-	PUNCT
bptjm-17	60	13	l2	l2	NOUN
bptjm-17	60	14	levels	level	NOUN
bptjm-17	60	15	.	.	PUNCT
bptjm-17	61	1	lower	low	ADJ
bptjm-17	61	2	sp	sp	NOUN
bptjm-17	61	3	-	-	PUNCT
bptjm-17	61	4	l2	l2	NOUN
bptjm-17	61	5	levels	level	NOUN
bptjm-17	61	6	were	be	AUX
bptjm-17	61	7	found	find	VERB
bptjm-17	61	8	to	to	PART
bptjm-17	61	9	be	be	AUX
bptjm-17	61	10	associated	associate	VERB
bptjm-17	61	11	with	with	ADP
bptjm-17	61	12	platinum	platinum	NOUN
bptjm-17	61	13	resistance	resistance	NOUN
bptjm-17	61	14	(	(	PUNCT
bptjm-17	61	15	p	p	X
bptjm-17	61	16	<	<	X
bptjm-17	61	17	0.0001	0.0001	NUM
bptjm-17	61	18	)	)	PUNCT
bptjm-17	61	19	,	,	PUNCT
bptjm-17	61	20	which	which	PRON
bptjm-17	61	21	supports	support	VERB
bptjm-17	61	22	the	the	DET
bptjm-17	61	23	results	result	NOUN
bptjm-17	61	24	from	from	ADP
bptjm-17	61	25	previous	previous	ADJ
bptjm-17	61	26	studies	study	NOUN
bptjm-17	61	27	(	(	PUNCT
bptjm-17	61	28	li	li	PROPN
bptjm-17	61	29	et	et	PROPN
bptjm-17	61	30	al	al	PROPN
bptjm-17	61	31	.	.	PROPN
bptjm-17	61	32	,	,	PUNCT
bptjm-17	61	33	2016	2016	NUM
bptjm-17	61	34	;	;	PUNCT
bptjm-17	61	35	hamilton	hamilton	PROPN
bptjm-17	61	36	et	et	PROPN
bptjm-17	61	37	al	al	PROPN
bptjm-17	61	38	.	.	PROPN
bptjm-17	61	39	,	,	PUNCT
bptjm-17	61	40	2018	2018	NUM
bptjm-17	61	41	)	)	PUNCT
bptjm-17	61	42	.	.	PUNCT
bptjm-17	62	1	higher	high	ADJ
bptjm-17	62	2	pd	pd	ADJ
bptjm-17	62	3	-	-	PUNCT
bptjm-17	62	4	l2	l2	NOUN
bptjm-17	62	5	levels	level	NOUN
bptjm-17	62	6	were	be	AUX
bptjm-17	62	7	associated	associate	VERB
bptjm-17	62	8	with	with	ADP
bptjm-17	62	9	lower	low	ADJ
bptjm-17	62	10	ercc1	ercc1	NOUN
bptjm-17	62	11	expression	expression	NOUN
bptjm-17	62	12	and	and	CCONJ
bptjm-17	62	13	reduced	reduced	ADJ
bptjm-17	62	14	progression	progression	NOUN
bptjm-17	62	15	free	free	ADJ
bptjm-17	62	16	survival	survival	NOUN
bptjm-17	62	17	(	(	PUNCT
bptjm-17	62	18	pfs	pfs	PROPN
bptjm-17	62	19	)	)	PUNCT
bptjm-17	62	20	and	and	CCONJ
bptjm-17	62	21	overall	overall	ADJ
bptjm-17	62	22	survival	survival	NOUN
bptjm-17	62	23	(	(	PUNCT
bptjm-17	62	24	os	os	NOUN
bptjm-17	62	25	)	)	PUNCT
bptjm-17	62	26	,	,	PUNCT
bptjm-17	62	27	while	while	SCONJ
bptjm-17	62	28	lower	low	ADJ
bptjm-17	62	29	pd	pd	ADJ
bptjm-17	62	30	-	-	PUNCT
bptjm-17	62	31	l2	l2	NOUN
bptjm-17	62	32	levels	level	NOUN
bptjm-17	62	33	were	be	AUX
bptjm-17	62	34	associated	associate	VERB
bptjm-17	62	35	with	with	ADP
bptjm-17	62	36	platinum	platinum	NOUN
bptjm-17	62	37	resistance	resistance	NOUN
bptjm-17	62	38	and	and	CCONJ
bptjm-17	62	39	higher	high	ADJ
bptjm-17	62	40	ercc1	ercc1	NOUN
bptjm-17	62	41	expression	expression	NOUN
bptjm-17	62	42	(	(	PUNCT
bptjm-17	62	43	buderath	buderath	NOUN
bptjm-17	62	44	et	et	PROPN
bptjm-17	62	45	al	al	PROPN
bptjm-17	62	46	.	.	PROPN
bptjm-17	62	47	,	,	PUNCT
bptjm-17	62	48	2019	2019	NUM
bptjm-17	62	49	)	)	PUNCT
bptjm-17	62	50	.	.	PUNCT
bptjm-17	63	1	this	this	PRON
bptjm-17	63	2	demonstrates	demonstrate	VERB
bptjm-17	63	3	that	that	SCONJ
bptjm-17	63	4	ercc1	ercc1	NOUN
bptjm-17	63	5	expression	expression	NOUN
bptjm-17	63	6	levels	level	NOUN
bptjm-17	63	7	detected	detect	VERB
bptjm-17	63	8	through	through	ADP
bptjm-17	63	9	liquid	liquid	ADJ
bptjm-17	63	10	biopsies	biopsy	NOUN
bptjm-17	63	11	can	can	AUX
bptjm-17	63	12	be	be	AUX
bptjm-17	63	13	used	use	VERB
bptjm-17	63	14	to	to	PART
bptjm-17	63	15	predict	predict	VERB
bptjm-17	63	16	the	the	DET
bptjm-17	63	17	outcomes	outcome	NOUN
bptjm-17	63	18	of	of	ADP
bptjm-17	63	19	multiple	multiple	ADJ
bptjm-17	63	20	cancers	cancer	NOUN
bptjm-17	63	21	,	,	PUNCT
bptjm-17	63	22	including	include	VERB
bptjm-17	63	23	nsclc	nsclc	NOUN
bptjm-17	63	24	and	and	CCONJ
bptjm-17	63	25	epithelial	epithelial	ADJ
bptjm-17	63	26	ovarian	ovarian	ADJ
bptjm-17	63	27	cancer	cancer	NOUN
bptjm-17	63	28	.	.	PUNCT
bptjm-17	64	1	met	meet	VERB
bptjm-17	64	2	met	meet	VERB
bptjm-17	64	3	is	be	AUX
bptjm-17	64	4	a	a	DET
bptjm-17	64	5	proto	proto	NOUN
bptjm-17	64	6	-	-	PUNCT
bptjm-17	64	7	oncogene	oncogene	NOUN
bptjm-17	64	8	involved	involve	VERB
bptjm-17	64	9	in	in	ADP
bptjm-17	64	10	cell	cell	NOUN
bptjm-17	64	11	growth	growth	NOUN
bptjm-17	64	12	,	,	PUNCT
bptjm-17	64	13	wound	wound	NOUN
bptjm-17	64	14	healing	healing	NOUN
bptjm-17	64	15	,	,	PUNCT
bptjm-17	64	16	and	and	CCONJ
bptjm-17	64	17	post	post	ADJ
bptjm-17	64	18	-	-	ADJ
bptjm-17	64	19	physical	physical	ADJ
bptjm-17	64	20	injury	injury	NOUN
bptjm-17	64	21	response	response	NOUN
bptjm-17	64	22	.	.	PUNCT
bptjm-17	65	1	it	it	PRON
bptjm-17	65	2	encodes	encode	VERB
bptjm-17	65	3	the	the	DET
bptjm-17	65	4	receptor	receptor	NOUN
bptjm-17	65	5	tyrosine	tyrosine	NOUN
bptjm-17	65	6	kinase	kinase	PROPN
bptjm-17	65	7	c	c	AUX
bptjm-17	65	8	-	-	PUNCT
bptjm-17	65	9	met	meet	VERB
bptjm-17	65	10	,	,	PUNCT
bptjm-17	65	11	for	for	ADP
bptjm-17	65	12	hepatocyte	hepatocyte	NOUN
bptjm-17	65	13	growth	growth	NOUN
bptjm-17	65	14	factor	factor	NOUN
bptjm-17	65	15	,	,	PUNCT
bptjm-17	65	16	which	which	PRON
bptjm-17	65	17	causes	cause	VERB
bptjm-17	65	18	c	c	NOUN
bptjm-17	65	19	-	-	PUNCT
bptjm-17	65	20	met	meet	VERB
bptjm-17	65	21	dimerization	dimerization	NOUN
bptjm-17	65	22	and	and	CCONJ
bptjm-17	65	23	autophosphorylation	autophosphorylation	NOUN
bptjm-17	65	24	.	.	PUNCT
bptjm-17	66	1	this	this	DET
bptjm-17	66	2	results	result	NOUN
bptjm-17	66	3	in	in	ADP
bptjm-17	66	4	the	the	DET
bptjm-17	66	5	activation	activation	NOUN
bptjm-17	66	6	of	of	ADP
bptjm-17	66	7	mitogen	mitogen	NOUN
bptjm-17	66	8	-	-	PUNCT
bptjm-17	66	9	activated	activate	VERB
bptjm-17	66	10	protein	protein	NOUN
bptjm-17	66	11	kinases	kinase	NOUN
bptjm-17	66	12	(	(	PUNCT
bptjm-17	66	13	mapk	mapk	NOUN
bptjm-17	66	14	)	)	PUNCT
bptjm-17	66	15	,	,	PUNCT
bptjm-17	66	16	phosphatidyl	phosphatidyl	NOUN
bptjm-17	66	17	-	-	PUNCT
bptjm-17	66	18	inositol-3	inositol-3	NOUN
bptjm-17	66	19	’	'	PUNCT
bptjm-17	66	20	phosphate	phosphate	NOUN
bptjm-17	66	21	kinases	kinase	NOUN
bptjm-17	66	22	(	(	PUNCT
bptjm-17	66	23	pi3k	pi3k	PROPN
bptjm-17	66	24	)	)	PUNCT
bptjm-17	66	25	,	,	PUNCT
bptjm-17	66	26	viral	viral	ADJ
bptjm-17	66	27	oncogene	oncogene	NOUN
bptjm-17	66	28	homologs	homolog	NOUN
bptjm-17	66	29	,	,	PUNCT
bptjm-17	66	30	and	and	CCONJ
bptjm-17	66	31	signal	signal	NOUN
bptjm-17	66	32	transducers	transducer	NOUN
bptjm-17	66	33	berkeley	berkeley	PROPN
bptjm-17	66	34	pharma	pharma	PROPN
bptjm-17	66	35	tech	tech	NOUN
bptjm-17	66	36	journal	journal	NOUN
bptjm-17	66	37	of	of	ADP
bptjm-17	66	38	medicine	medicine	NOUN
bptjm-17	66	39	|	|	ADV
bptjm-17	66	40	120	120	NUM
bptjm-17	66	41	and	and	CCONJ
bptjm-17	66	42	activators	activator	NOUN
bptjm-17	66	43	of	of	ADP
bptjm-17	66	44	transcriptional	transcriptional	ADJ
bptjm-17	66	45	signaling	signal	VERB
bptjm-17	66	46	pathways	pathway	NOUN
bptjm-17	66	47	.	.	PUNCT
bptjm-17	67	1	mutated	mutate	VERB
bptjm-17	67	2	met	meet	VERB
bptjm-17	67	3	initiates	initiate	VERB
bptjm-17	67	4	the	the	DET
bptjm-17	67	5	growth	growth	NOUN
bptjm-17	67	6	of	of	ADP
bptjm-17	67	7	cancer	cancer	NOUN
bptjm-17	67	8	cells	cell	NOUN
bptjm-17	67	9	.	.	PUNCT
bptjm-17	68	1	unusual	unusual	ADJ
bptjm-17	68	2	met	meet	VERB
bptjm-17	68	3	expression	expression	NOUN
bptjm-17	68	4	has	have	AUX
bptjm-17	68	5	been	be	AUX
bptjm-17	68	6	shown	show	VERB
bptjm-17	68	7	to	to	PART
bptjm-17	68	8	correspond	correspond	VERB
bptjm-17	68	9	with	with	ADP
bptjm-17	68	10	nsclc	nsclc	NOUN
bptjm-17	68	11	,	,	PUNCT
bptjm-17	68	12	as	as	ADV
bptjm-17	68	13	well	well	ADV
bptjm-17	68	14	as	as	ADP
bptjm-17	68	15	gastrointestinal	gastrointestinal	ADJ
bptjm-17	68	16	cancer	cancer	NOUN
bptjm-17	68	17	and	and	CCONJ
bptjm-17	68	18	hepatocellular	hepatocellular	ADJ
bptjm-17	68	19	carcinoma	carcinoma	NOUN
bptjm-17	68	20	.	.	PUNCT
bptjm-17	69	1	if	if	SCONJ
bptjm-17	69	2	the	the	DET
bptjm-17	69	3	met	meet	VERB
bptjm-17	69	4	receptor	receptor	NOUN
bptjm-17	69	5	is	be	AUX
bptjm-17	69	6	overexpressed	overexpresse	VERB
bptjm-17	69	7	via	via	ADP
bptjm-17	69	8	genomic	genomic	ADJ
bptjm-17	69	9	ampli	ampli	NOUN
bptjm-17	69	10	cation	cation	NOUN
bptjm-17	69	11	,	,	PUNCT
bptjm-17	69	12	mutation	mutation	NOUN
bptjm-17	69	13	,	,	PUNCT
bptjm-17	69	14	or	or	CCONJ
bptjm-17	69	15	alternative	alternative	ADJ
bptjm-17	69	16	splicing	splicing	NOUN
bptjm-17	69	17	,	,	PUNCT
bptjm-17	69	18	cellular	cellular	ADJ
bptjm-17	69	19	degradation	degradation	NOUN
bptjm-17	69	20	of	of	ADP
bptjm-17	69	21	met	meet	VERB
bptjm-17	69	22	can	can	AUX
bptjm-17	69	23	occur	occur	VERB
bptjm-17	69	24	(	(	PUNCT
bptjm-17	69	25	mo	mo	PROPN
bptjm-17	69	26	et	et	PROPN
bptjm-17	69	27	al	al	PROPN
bptjm-17	69	28	.	.	PROPN
bptjm-17	69	29	,	,	PUNCT
bptjm-17	69	30	2017	2017	NUM
bptjm-17	69	31	)	)	PUNCT
bptjm-17	69	32	.	.	PUNCT
bptjm-17	70	1	c	c	X
bptjm-17	70	2	-	-	PUNCT
bptjm-17	70	3	met	meet	VERB
bptjm-17	70	4	receptor	receptor	NOUN
bptjm-17	70	5	activation	activation	NOUN
bptjm-17	70	6	is	be	AUX
bptjm-17	70	7	associated	associate	VERB
bptjm-17	70	8	with	with	ADP
bptjm-17	70	9	egfr	egfr	ADJ
bptjm-17	70	10	-	-	PUNCT
bptjm-17	70	11	tki	tki	NOUN
bptjm-17	70	12	resistance	resistance	NOUN
bptjm-17	70	13	and	and	CCONJ
bptjm-17	70	14	has	have	VERB
bptjm-17	70	15	poor	poor	ADJ
bptjm-17	70	16	prognosis	prognosis	NOUN
bptjm-17	70	17	.	.	PUNCT
bptjm-17	71	1	a	a	DET
bptjm-17	71	2	trial	trial	NOUN
bptjm-17	71	3	consisting	consist	VERB
bptjm-17	71	4	of	of	ADP
bptjm-17	71	5	167	167	NUM
bptjm-17	71	6	patients	patient	NOUN
bptjm-17	71	7	examined	examine	VERB
bptjm-17	71	8	the	the	DET
bptjm-17	71	9	prognosis	prognosis	NOUN
bptjm-17	71	10	,	,	PUNCT
bptjm-17	71	11	determined	determine	VERB
bptjm-17	71	12	by	by	ADP
bptjm-17	71	13	pfs	pf	NOUN
bptjm-17	71	14	,	,	PUNCT
bptjm-17	71	15	after	after	ADP
bptjm-17	71	16	treatment	treatment	NOUN
bptjm-17	71	17	with	with	ADP
bptjm-17	71	18	met	meet	VERB
bptjm-17	71	19	inhibitors	inhibitor	NOUN
bptjm-17	71	20	,	,	PUNCT
bptjm-17	71	21	erlotinib	erlotinib	NOUN
bptjm-17	71	22	and	and	CCONJ
bptjm-17	71	23	tivantinib	tivantinib	NOUN
bptjm-17	71	24	.	.	PUNCT
bptjm-17	72	1	84	84	NUM
bptjm-17	72	2	patients	patient	NOUN
bptjm-17	72	3	were	be	AUX
bptjm-17	72	4	randomly	randomly	ADV
bptjm-17	72	5	assigned	assign	VERB
bptjm-17	72	6	to	to	PART
bptjm-17	72	7	receive	receive	VERB
bptjm-17	72	8	oral	oral	ADJ
bptjm-17	72	9	erlotinib	erlotinib	NOUN
bptjm-17	72	10	and	and	CCONJ
bptjm-17	72	11	tivantinib	tivantinib	NOUN
bptjm-17	72	12	(	(	PUNCT
bptjm-17	72	13	et	et	NOUN
bptjm-17	72	14	group	group	NOUN
bptjm-17	72	15	)	)	PUNCT
bptjm-17	72	16	,	,	PUNCT
bptjm-17	72	17	and	and	CCONJ
bptjm-17	72	18	83	83	NUM
bptjm-17	72	19	patients	patient	NOUN
bptjm-17	72	20	were	be	AUX
bptjm-17	72	21	randomly	randomly	ADV
bptjm-17	72	22	assigned	assign	VERB
bptjm-17	72	23	to	to	PART
bptjm-17	72	24	receive	receive	VERB
bptjm-17	72	25	erlotinib	erlotinib	NOUN
bptjm-17	72	26	plus	plus	CCONJ
bptjm-17	72	27	placebo	placebo	NOUN
bptjm-17	72	28	(	(	PUNCT
bptjm-17	72	29	ep	ep	PROPN
bptjm-17	72	30	group	group	NOUN
bptjm-17	72	31	)	)	PUNCT
bptjm-17	72	32	.	.	PUNCT
bptjm-17	73	1	the	the	DET
bptjm-17	73	2	average	average	ADJ
bptjm-17	73	3	pfs	pfs	PROPN
bptjm-17	73	4	was	be	AUX
bptjm-17	73	5	3.8	3.8	NUM
bptjm-17	73	6	months	month	NOUN
bptjm-17	73	7	for	for	ADP
bptjm-17	73	8	et	et	NOUN
bptjm-17	73	9	and	and	CCONJ
bptjm-17	73	10	2.3	2.3	NUM
bptjm-17	73	11	months	month	NOUN
bptjm-17	73	12	for	for	ADP
bptjm-17	73	13	ep	ep	PROPN
bptjm-17	73	14	,	,	PUNCT
bptjm-17	73	15	which	which	PRON
bptjm-17	73	16	is	be	AUX
bptjm-17	73	17	statistically	statistically	ADV
bptjm-17	73	18	signi	signi	ADJ
bptjm-17	73	19	ca	can	AUX
bptjm-17	73	20	nt	not	PART
bptjm-17	73	21	(	(	PUNCT
bptjm-17	73	22	p	p	NOUN
bptjm-17	73	23	=	=	NOUN
bptjm-17	73	24	.24	.24	NUM
bptjm-17	73	25	)	)	PUNCT
bptjm-17	73	26	(	(	PUNCT
bptjm-17	73	27	sequist	sequist	NOUN
bptjm-17	73	28	et	et	PROPN
bptjm-17	73	29	al	al	PROPN
bptjm-17	73	30	.	.	PROPN
bptjm-17	73	31	,	,	PUNCT
bptjm-17	73	32	2011	2011	NUM
bptjm-17	73	33	)	)	PUNCT
bptjm-17	73	34	.	.	PUNCT
bptjm-17	74	1	deng	deng	PROPN
bptjm-17	74	2	et	et	PROPN
bptjm-17	74	3	al	al	PROPN
bptjm-17	74	4	.	.	PROPN
bptjm-17	74	5	also	also	ADV
bptjm-17	74	6	studied	study	VERB
bptjm-17	74	7	nsclc	nsclc	NOUN
bptjm-17	74	8	patients	patient	NOUN
bptjm-17	74	9	with	with	ADP
bptjm-17	74	10	met	meet	VERB
bptjm-17	74	11	ampli	ampli	NOUN
bptjm-17	74	12	cation	cation	NOUN
bptjm-17	74	13	and	and	CCONJ
bptjm-17	74	14	egfr	egfr	ADJ
bptjm-17	74	15	mutation	mutation	NOUN
bptjm-17	74	16	.	.	PUNCT
bptjm-17	75	1	for	for	ADP
bptjm-17	75	2	one	one	NUM
bptjm-17	75	3	patient	patient	NOUN
bptjm-17	75	4	,	,	PUNCT
bptjm-17	75	5	a	a	DET
bptjm-17	75	6	combination	combination	NOUN
bptjm-17	75	7	of	of	ADP
bptjm-17	75	8	crizotinib	crizotinib	NOUN
bptjm-17	75	9	and	and	CCONJ
bptjm-17	75	10	osimertinib	osimertinib	NOUN
bptjm-17	75	11	was	be	AUX
bptjm-17	75	12	administered	administer	VERB
bptjm-17	75	13	,	,	PUNCT
bptjm-17	75	14	which	which	PRON
bptjm-17	75	15	greatly	greatly	ADV
bptjm-17	75	16	improved	improve	VERB
bptjm-17	75	17	his	his	PRON
bptjm-17	75	18	overall	overall	ADJ
bptjm-17	75	19	health	health	NOUN
bptjm-17	75	20	.	.	PUNCT
bptjm-17	76	1	results	result	NOUN
bptjm-17	76	2	showed	show	VERB
bptjm-17	76	3	a	a	DET
bptjm-17	76	4	20	20	NUM
bptjm-17	76	5	-	-	SYM
bptjm-17	76	6	40	40	NUM
bptjm-17	76	7	%	%	NOUN
bptjm-17	76	8	partial	partial	ADJ
bptjm-17	76	9	response	response	NOUN
bptjm-17	76	10	rate	rate	NOUN
bptjm-17	76	11	to	to	ADP
bptjm-17	76	12	dual	dual	ADJ
bptjm-17	76	13	therapy	therapy	NOUN
bptjm-17	76	14	with	with	ADP
bptjm-17	76	15	and	and	CCONJ
bptjm-17	76	16	without	without	ADP
bptjm-17	76	17	prior	prior	ADJ
bptjm-17	76	18	treatment	treatment	NOUN
bptjm-17	76	19	with	with	ADP
bptjm-17	76	20	tkis	tkis	NOUN
bptjm-17	76	21	.	.	PUNCT
bptjm-17	77	1	unfortunately	unfortunately	ADV
bptjm-17	77	2	,	,	PUNCT
bptjm-17	77	3	met	meet	VERB
bptjm-17	77	4	mutations	mutation	NOUN
bptjm-17	77	5	have	have	AUX
bptjm-17	77	6	occasionally	occasionally	ADV
bptjm-17	77	7	been	be	AUX
bptjm-17	77	8	shown	show	VERB
bptjm-17	77	9	to	to	PART
bptjm-17	77	10	cause	cause	VERB
bptjm-17	77	11	resistance	resistance	NOUN
bptjm-17	77	12	to	to	PART
bptjm-17	77	13	crizotinib	crizotinib	VERB
bptjm-17	77	14	treatment	treatment	NOUN
bptjm-17	77	15	(	(	PUNCT
bptjm-17	77	16	deng	deng	PROPN
bptjm-17	77	17	et	et	PROPN
bptjm-17	77	18	al	al	PROPN
bptjm-17	77	19	.	.	PROPN
bptjm-17	77	20	,	,	PUNCT
bptjm-17	77	21	2018	2018	NUM
bptjm-17	77	22	)	)	PUNCT
bptjm-17	77	23	.	.	PUNCT
bptjm-17	78	1	in	in	ADP
bptjm-17	78	2	a	a	DET
bptjm-17	78	3	study	study	NOUN
bptjm-17	78	4	done	do	VERB
bptjm-17	78	5	by	by	ADP
bptjm-17	78	6	bardelli	bardelli	NOUN
bptjm-17	78	7	et	et	PROPN
bptjm-17	78	8	al	al	PROPN
bptjm-17	78	9	.	.	PROPN
bptjm-17	78	10	,	,	PUNCT
bptjm-17	78	11	7	7	NUM
bptjm-17	78	12	patients	patient	NOUN
bptjm-17	78	13	with	with	ADP
bptjm-17	78	14	metastatic	metastatic	ADJ
bptjm-17	78	15	colorectal	colorectal	ADJ
bptjm-17	78	16	tumors	tumor	NOUN
bptjm-17	78	17	who	who	PRON
bptjm-17	78	18	had	have	AUX
bptjm-17	78	19	responded	respond	VERB
bptjm-17	78	20	to	to	PART
bptjm-17	78	21	panitumumab	panitumumab	VERB
bptjm-17	78	22	or	or	CCONJ
bptjm-17	78	23	cetuximab	cetuximab	NOUN
bptjm-17	78	24	-	-	PUNCT
bptjm-17	78	25	based	base	VERB
bptjm-17	78	26	treatment	treatment	NOUN
bptjm-17	78	27	and	and	CCONJ
bptjm-17	78	28	later	later	ADV
bptjm-17	78	29	relapsed	relapse	VERB
bptjm-17	78	30	were	be	AUX
bptjm-17	78	31	analyzed	analyze	VERB
bptjm-17	78	32	.	.	PUNCT
bptjm-17	78	33	met	meet	VERB
bptjm-17	78	34	expression	expression	NOUN
bptjm-17	78	35	was	be	AUX
bptjm-17	78	36	higher	high	ADJ
bptjm-17	78	37	in	in	ADP
bptjm-17	78	38	post	post	ADJ
bptjm-17	78	39	-	-	ADJ
bptjm-17	78	40	relapse	relapse	ADJ
bptjm-17	78	41	patients	patient	NOUN
bptjm-17	78	42	compared	compare	VERB
bptjm-17	78	43	to	to	ADP
bptjm-17	78	44	rst	rst	VERB
bptjm-17	78	45	-	-	PUNCT
bptjm-17	78	46	occurence	occurence	NOUN
bptjm-17	78	47	patients	patient	NOUN
bptjm-17	78	48	.	.	PUNCT
bptjm-17	79	1	in	in	ADP
bptjm-17	79	2	relapse	relapse	NOUN
bptjm-17	79	3	patients	patient	NOUN
bptjm-17	79	4	with	with	ADP
bptjm-17	79	5	kras	kras	PROPN
bptjm-17	79	6	mutations	mutation	NOUN
bptjm-17	79	7	,	,	PUNCT
bptjm-17	79	8	met	meet	VERB
bptjm-17	79	9	expression	expression	NOUN
bptjm-17	79	10	was	be	AUX
bptjm-17	79	11	low	low	ADJ
bptjm-17	79	12	or	or	CCONJ
bptjm-17	79	13	undetectable	undetectable	ADJ
bptjm-17	79	14	.	.	PUNCT
bptjm-17	80	1	met	meet	VERB
bptjm-17	80	2	ampli	ampli	NOUN
bptjm-17	80	3	cation	cation	NOUN
bptjm-17	80	4	was	be	AUX
bptjm-17	80	5	seen	see	VERB
bptjm-17	80	6	in	in	ADP
bptjm-17	80	7	the	the	DET
bptjm-17	80	8	blood	blood	NOUN
bptjm-17	80	9	before	before	ADP
bptjm-17	80	10	relapse	relapse	NOUN
bptjm-17	80	11	,	,	PUNCT
bptjm-17	80	12	indicating	indicate	VERB
bptjm-17	80	13	that	that	PRON
bptjm-17	80	14	met	meet	VERB
bptjm-17	80	15	monitoring	monitoring	NOUN
bptjm-17	80	16	could	could	AUX
bptjm-17	80	17	be	be	AUX
bptjm-17	80	18	used	use	VERB
bptjm-17	80	19	to	to	PART
bptjm-17	80	20	predict	predict	VERB
bptjm-17	80	21	relapse	relapse	NOUN
bptjm-17	80	22	.	.	PUNCT
bptjm-17	81	1	met	meet	VERB
bptjm-17	81	2	ampli	ampli	NOUN
bptjm-17	81	3	cation	cation	NOUN
bptjm-17	81	4	is	be	AUX
bptjm-17	81	5	detected	detect	VERB
bptjm-17	81	6	in	in	ADP
bptjm-17	81	7	5	5	NUM
bptjm-17	81	8	-	-	SYM
bptjm-17	81	9	20	20	NUM
bptjm-17	81	10	%	%	NOUN
bptjm-17	81	11	of	of	ADP
bptjm-17	81	12	egfr	egfr	NOUN
bptjm-17	81	13	-	-	PUNCT
bptjm-17	81	14	mutated	mutate	VERB
bptjm-17	81	15	lung	lung	NOUN
bptjm-17	81	16	cancers	cancer	NOUN
bptjm-17	81	17	(	(	PUNCT
bptjm-17	81	18	bardelli	bardelli	NOUN
bptjm-17	81	19	et	et	NOUN
bptjm-17	81	20	al	al	PROPN
bptjm-17	81	21	.	.	PROPN
bptjm-17	81	22	,	,	PUNCT
bptjm-17	81	23	2013	2013	NUM
bptjm-17	81	24	)	)	PUNCT
bptjm-17	81	25	.	.	PUNCT
bptjm-17	82	1	in	in	ADP
bptjm-17	82	2	metastatic	metastatic	ADJ
bptjm-17	82	3	colorectal	colorectal	ADJ
bptjm-17	82	4	tumors	tumor	NOUN
bptjm-17	82	5	and	and	CCONJ
bptjm-17	82	6	nsclc	nsclc	NOUN
bptjm-17	82	7	,	,	PUNCT
bptjm-17	82	8	met	meet	VERB
bptjm-17	82	9	can	can	AUX
bptjm-17	82	10	be	be	AUX
bptjm-17	82	11	used	use	VERB
bptjm-17	82	12	for	for	ADP
bptjm-17	82	13	predictive	predictive	ADJ
bptjm-17	82	14	outcomes	outcome	NOUN
bptjm-17	82	15	and	and	CCONJ
bptjm-17	82	16	may	may	AUX
bptjm-17	82	17	help	help	VERB
bptjm-17	82	18	direct	direct	VERB
bptjm-17	82	19	the	the	DET
bptjm-17	82	20	course	course	NOUN
bptjm-17	82	21	of	of	ADP
bptjm-17	82	22	treatment	treatment	NOUN
bptjm-17	82	23	.	.	PUNCT
bptjm-17	83	1	ntrk	ntrk	PROPN
bptjm-17	83	2	neurotrophic	neurotrophic	PROPN
bptjm-17	83	3	tyrosine	tyrosine	PROPN
bptjm-17	83	4	kinase	kinase	PROPN
bptjm-17	83	5	receptor	receptor	NOUN
bptjm-17	83	6	(	(	PUNCT
bptjm-17	83	7	ntrk	ntrk	NOUN
bptjm-17	83	8	)	)	PUNCT
bptjm-17	83	9	mutations	mutation	NOUN
bptjm-17	83	10	are	be	AUX
bptjm-17	83	11	found	find	VERB
bptjm-17	83	12	in	in	ADP
bptjm-17	83	13	many	many	ADJ
bptjm-17	83	14	solid	solid	ADJ
bptjm-17	83	15	malignancies	malignancy	NOUN
bptjm-17	83	16	,	,	PUNCT
bptjm-17	83	17	including	include	VERB
bptjm-17	83	18	nsclc	nsclc	NOUN
bptjm-17	83	19	.	.	PUNCT
bptjm-17	84	1	trk	trk	NOUN
bptjm-17	84	2	receptors	receptor	NOUN
bptjm-17	84	3	include	include	VERB
bptjm-17	84	4	three	three	NUM
bptjm-17	84	5	transmembrane	transmembrane	ADJ
bptjm-17	84	6	proteins	protein	NOUN
bptjm-17	84	7	:	:	PUNCT
bptjm-17	84	8	trka	trka	ADJ
bptjm-17	84	9	,	,	PUNCT
bptjm-17	84	10	trkb	trkb	NOUN
bptjm-17	84	11	,	,	PUNCT
bptjm-17	84	12	and	and	CCONJ
bptjm-17	84	13	trkc	trkc	NOUN
bptjm-17	84	14	,	,	PUNCT
bptjm-17	84	15	which	which	PRON
bptjm-17	84	16	are	be	AUX
bptjm-17	84	17	encoded	encode	VERB
bptjm-17	84	18	by	by	ADP
bptjm-17	84	19	ntrk1	ntrk1	PROPN
bptjm-17	84	20	,	,	PUNCT
bptjm-17	84	21	ntrk2	ntrk2	PROPN
bptjm-17	84	22	,	,	PUNCT
bptjm-17	84	23	and	and	CCONJ
bptjm-17	84	24	ntrk3	ntrk3	PROPN
bptjm-17	84	25	,	,	PUNCT
bptjm-17	84	26	respectively	respectively	ADV
bptjm-17	84	27	.	.	PUNCT
bptjm-17	85	1	in	in	ADP
bptjm-17	85	2	carcinogenesis	carcinogenesis	NOUN
bptjm-17	85	3	,	,	PUNCT
bptjm-17	85	4	trka	trka	NOUN
bptjm-17	85	5	,	,	PUNCT
bptjm-17	85	6	trkb	trkb	NOUN
bptjm-17	85	7	,	,	PUNCT
bptjm-17	85	8	and	and	CCONJ
bptjm-17	85	9	trkc	trkc	NOUN
bptjm-17	85	10	undergo	undergo	VERB
bptjm-17	85	11	changes	change	NOUN
bptjm-17	85	12	that	that	PRON
bptjm-17	85	13	lead	lead	VERB
bptjm-17	85	14	to	to	ADP
bptjm-17	85	15	activation	activation	NOUN
bptjm-17	85	16	of	of	ADP
bptjm-17	85	17	signaling	signal	VERB
bptjm-17	85	18	berkeley	berkeley	PROPN
bptjm-17	85	19	pharma	pharma	PROPN
bptjm-17	85	20	tech	tech	NOUN
bptjm-17	85	21	journal	journal	NOUN
bptjm-17	85	22	of	of	ADP
bptjm-17	85	23	medicine	medicine	NOUN
bptjm-17	85	24	|	|	ADV
bptjm-17	85	25	121	121	NUM
bptjm-17	85	26	pathways	pathway	NOUN
bptjm-17	85	27	involved	involve	VERB
bptjm-17	85	28	in	in	ADP
bptjm-17	85	29	cell	cell	NOUN
bptjm-17	85	30	growth	growth	NOUN
bptjm-17	85	31	and	and	CCONJ
bptjm-17	85	32	proliferation	proliferation	NOUN
bptjm-17	85	33	.	.	PUNCT
bptjm-17	86	1	mutations	mutation	NOUN
bptjm-17	86	2	to	to	ADP
bptjm-17	86	3	ntrk1	ntrk1	PROPN
bptjm-17	86	4	,	,	PUNCT
bptjm-17	86	5	ntrk2	ntrk2	PROPN
bptjm-17	86	6	,	,	PUNCT
bptjm-17	86	7	and	and	CCONJ
bptjm-17	86	8	ntrk3	ntrk3	PROPN
bptjm-17	86	9	have	have	AUX
bptjm-17	86	10	also	also	ADV
bptjm-17	86	11	been	be	AUX
bptjm-17	86	12	observed	observe	VERB
bptjm-17	86	13	in	in	ADP
bptjm-17	86	14	2	2	NUM
bptjm-17	86	15	-	-	SYM
bptjm-17	86	16	3	3	NUM
bptjm-17	86	17	%	%	NOUN
bptjm-17	86	18	of	of	ADP
bptjm-17	86	19	nsclc	nsclc	NOUN
bptjm-17	86	20	patients	patient	NOUN
bptjm-17	86	21	.	.	PUNCT
bptjm-17	87	1	for	for	ADP
bptjm-17	87	2	example	example	NOUN
bptjm-17	87	3	,	,	PUNCT
bptjm-17	87	4	overexpression	overexpression	NOUN
bptjm-17	87	5	,	,	PUNCT
bptjm-17	87	6	in	in	ADP
bptjm-17	87	7	-	-	PUNCT
bptjm-17	87	8	frame	frame	NOUN
bptjm-17	87	9	deletions	deletion	NOUN
bptjm-17	87	10	,	,	PUNCT
bptjm-17	87	11	and	and	CCONJ
bptjm-17	87	12	alternative	alternative	ADJ
bptjm-17	87	13	splicing	splicing	NOUN
bptjm-17	87	14	of	of	ADP
bptjm-17	87	15	ntrk1	ntrk1	NOUN
bptjm-17	87	16	have	have	AUX
bptjm-17	87	17	been	be	AUX
bptjm-17	87	18	demonstrated	demonstrate	VERB
bptjm-17	87	19	to	to	PART
bptjm-17	87	20	be	be	AUX
bptjm-17	87	21	potential	potential	ADJ
bptjm-17	87	22	oncogenic	oncogenic	ADJ
bptjm-17	87	23	mechanisms	mechanism	NOUN
bptjm-17	87	24	.	.	PUNCT
bptjm-17	88	1	several	several	ADJ
bptjm-17	88	2	ntrk	ntrk	NOUN
bptjm-17	88	3	inhibitors	inhibitor	NOUN
bptjm-17	88	4	have	have	AUX
bptjm-17	88	5	been	be	AUX
bptjm-17	88	6	developed	develop	VERB
bptjm-17	88	7	,	,	PUNCT
bptjm-17	88	8	but	but	CCONJ
bptjm-17	88	9	only	only	ADV
bptjm-17	88	10	loxo-101	loxo-101	NOUN
bptjm-17	88	11	and	and	CCONJ
bptjm-17	88	12	entrectinib	entrectinib	NOUN
bptjm-17	88	13	are	be	AUX
bptjm-17	88	14	under	under	ADP
bptjm-17	88	15	clinical	clinical	ADJ
bptjm-17	88	16	evaluation	evaluation	NOUN
bptjm-17	88	17	(	(	PUNCT
bptjm-17	88	18	ricciuti	ricciuti	NOUN
bptjm-17	88	19	et	et	NOUN
bptjm-17	88	20	al	al	PROPN
bptjm-17	88	21	.	.	PROPN
bptjm-17	88	22	,	,	PUNCT
bptjm-17	88	23	2017	2017	NUM
bptjm-17	88	24	)	)	PUNCT
bptjm-17	88	25	.	.	PUNCT
bptjm-17	89	1	of	of	ADP
bptjm-17	89	2	1,378	1,378	NUM
bptjm-17	89	3	patients	patient	NOUN
bptjm-17	89	4	with	with	ADP
bptjm-17	89	5	locally	locally	ADV
bptjm-17	89	6	advanced	advanced	ADJ
bptjm-17	89	7	or	or	CCONJ
bptjm-17	89	8	metastatic	metastatic	ADJ
bptjm-17	89	9	solid	solid	ADJ
bptjm-17	89	10	tumor	tumor	NOUN
bptjm-17	89	11	malignancies	malignancy	NOUN
bptjm-17	89	12	with	with	ADP
bptjm-17	89	13	ntrk1	ntrk1	PROPN
bptjm-17	89	14	,	,	PUNCT
bptjm-17	89	15	ntrk2	ntrk2	PROPN
bptjm-17	89	16	,	,	PUNCT
bptjm-17	89	17	ntrk3	ntrk3	PROPN
bptjm-17	89	18	,	,	PUNCT
bptjm-17	89	19	ros1	ros1	PROPN
bptjm-17	89	20	,	,	PUNCT
bptjm-17	89	21	or	or	CCONJ
bptjm-17	89	22	alkmutations	alkmutation	NOUN
bptjm-17	89	23	,	,	PUNCT
bptjm-17	89	24	two	two	NUM
bptjm-17	89	25	showed	show	VERB
bptjm-17	89	26	ntrk1	ntrk1	NOUN
bptjm-17	89	27	gene	gene	NOUN
bptjm-17	89	28	rearrangements	rearrangement	NOUN
bptjm-17	89	29	on	on	ADP
bptjm-17	89	30	anchored	anchor	VERB
bptjm-17	89	31	multiplex	multiplex	PROPN
bptjm-17	89	32	pcr	pcr	PROPN
bptjm-17	89	33	.	.	PUNCT
bptjm-17	90	1	one	one	NUM
bptjm-17	90	2	patient	patient	NOUN
bptjm-17	90	3	,	,	PUNCT
bptjm-17	90	4	a	a	DET
bptjm-17	90	5	45	45	NUM
bptjm-17	90	6	-	-	PUNCT
bptjm-17	90	7	year	year	NOUN
bptjm-17	90	8	-	-	PUNCT
bptjm-17	90	9	old	old	ADJ
bptjm-17	90	10	male	male	NOUN
bptjm-17	90	11	with	with	ADP
bptjm-17	90	12	a	a	DET
bptjm-17	90	13	history	history	NOUN
bptjm-17	90	14	of	of	ADP
bptjm-17	90	15	smoking	smoking	NOUN
bptjm-17	90	16	,	,	PUNCT
bptjm-17	90	17	was	be	AUX
bptjm-17	90	18	treated	treat	VERB
bptjm-17	90	19	with	with	ADP
bptjm-17	90	20	400	400	NUM
bptjm-17	90	21	mg	mg	NOUN
bptjm-17	90	22	/	/	SYM
bptjm-17	90	23	m2	m2	PROPN
bptjm-17	90	24	oral	oral	ADJ
bptjm-17	90	25	entrectinib	entrectinib	NOUN
bptjm-17	90	26	daily	daily	ADV
bptjm-17	90	27	.	.	PUNCT
bptjm-17	91	1	ct	ct	PROPN
bptjm-17	91	2	scans	scan	NOUN
bptjm-17	91	3	of	of	ADP
bptjm-17	91	4	his	his	PRON
bptjm-17	91	5	lungs	lung	NOUN
bptjm-17	91	6	26	26	NUM
bptjm-17	91	7	days	day	NOUN
bptjm-17	91	8	after	after	ADP
bptjm-17	91	9	beginning	begin	VERB
bptjm-17	91	10	the	the	DET
bptjm-17	91	11	treatment	treatment	NOUN
bptjm-17	91	12	showed	show	VERB
bptjm-17	91	13	no	no	DET
bptjm-17	91	14	tumor	tumor	NOUN
bptjm-17	91	15	growth	growth	NOUN
bptjm-17	91	16	.	.	PUNCT
bptjm-17	92	1	after	after	ADP
bptjm-17	92	2	155	155	NUM
bptjm-17	92	3	days	day	NOUN
bptjm-17	92	4	,	,	PUNCT
bptjm-17	92	5	ct	ct	NUM
bptjm-17	92	6	scans	scan	NOUN
bptjm-17	92	7	showed	show	VERB
bptjm-17	92	8	a	a	DET
bptjm-17	92	9	77	77	NUM
bptjm-17	92	10	%	%	NOUN
bptjm-17	92	11	overall	overall	ADJ
bptjm-17	92	12	tumor	tumor	NOUN
bptjm-17	92	13	reduction	reduction	NOUN
bptjm-17	92	14	(	(	PUNCT
bptjm-17	92	15	farago	farago	PROPN
bptjm-17	92	16	et	et	PROPN
bptjm-17	92	17	al	al	PROPN
bptjm-17	92	18	.	.	PROPN
bptjm-17	92	19	,	,	PUNCT
bptjm-17	92	20	2015	2015	NUM
bptjm-17	92	21	)	)	PUNCT
bptjm-17	92	22	.	.	PUNCT
bptjm-17	93	1	cdkn2a	cdkn2a	VERB
bptjm-17	93	2	the	the	DET
bptjm-17	93	3	cdkn2a	cdkn2a	PROPN
bptjm-17	93	4	mutation	mutation	NOUN
bptjm-17	93	5	is	be	AUX
bptjm-17	93	6	uniquely	uniquely	ADV
bptjm-17	93	7	present	present	ADJ
bptjm-17	93	8	in	in	ADP
bptjm-17	93	9	nsclc	nsclc	NOUN
bptjm-17	93	10	.	.	PUNCT
bptjm-17	94	1	studies	study	NOUN
bptjm-17	94	2	have	have	AUX
bptjm-17	94	3	suggested	suggest	VERB
bptjm-17	94	4	that	that	SCONJ
bptjm-17	94	5	the	the	DET
bptjm-17	94	6	cdkn2a	cdkn2a	PROPN
bptjm-17	94	7	mutation	mutation	NOUN
bptjm-17	94	8	is	be	AUX
bptjm-17	94	9	associated	associate	VERB
bptjm-17	94	10	with	with	ADP
bptjm-17	94	11	the	the	DET
bptjm-17	94	12	increased	increase	VERB
bptjm-17	94	13	expression	expression	NOUN
bptjm-17	94	14	of	of	ADP
bptjm-17	94	15	the	the	DET
bptjm-17	94	16	extracellular	extracellular	ADJ
bptjm-17	94	17	matrix	matrix	NOUN
bptjm-17	94	18	and	and	CCONJ
bptjm-17	94	19	metabolic	metabolic	NOUN
bptjm-17	94	20	gene	gene	NOUN
bptjm-17	94	21	sets	set	NOUN
bptjm-17	94	22	in	in	ADP
bptjm-17	94	23	nsclc	nsclc	NOUN
bptjm-17	94	24	cell	cell	NOUN
bptjm-17	94	25	lines	line	NOUN
bptjm-17	94	26	(	(	PUNCT
bptjm-17	94	27	kim	kim	PROPN
bptjm-17	94	28	et	et	PROPN
bptjm-17	94	29	al	al	PROPN
bptjm-17	94	30	.	.	PROPN
bptjm-17	94	31	,	,	PUNCT
bptjm-17	94	32	2015	2015	NUM
bptjm-17	94	33	)	)	PUNCT
bptjm-17	94	34	.	.	PUNCT
bptjm-17	95	1	this	this	DET
bptjm-17	95	2	heightened	heighten	VERB
bptjm-17	95	3	expression	expression	NOUN
bptjm-17	95	4	has	have	AUX
bptjm-17	95	5	been	be	AUX
bptjm-17	95	6	suggested	suggest	VERB
bptjm-17	95	7	as	as	ADP
bptjm-17	95	8	an	an	DET
bptjm-17	95	9	indicator	indicator	NOUN
bptjm-17	95	10	of	of	ADP
bptjm-17	95	11	increased	increase	VERB
bptjm-17	95	12	mortality	mortality	NOUN
bptjm-17	95	13	in	in	ADP
bptjm-17	95	14	lung	lung	NOUN
bptjm-17	95	15	,	,	PUNCT
bptjm-17	95	16	breast	breast	NOUN
bptjm-17	95	17	,	,	PUNCT
bptjm-17	95	18	and	and	CCONJ
bptjm-17	95	19	gastric	gastric	ADJ
bptjm-17	95	20	cancers	cancer	NOUN
bptjm-17	95	21	(	(	PUNCT
bptjm-17	95	22	gilkes	gilkes	PROPN
bptjm-17	95	23	,	,	PUNCT
bptjm-17	95	24	semenza	semenza	NOUN
bptjm-17	95	25	,	,	PUNCT
bptjm-17	95	26	and	and	CCONJ
bptjm-17	95	27	wirtz	wirtz	PROPN
bptjm-17	95	28	,	,	PUNCT
bptjm-17	95	29	2014	2014	NUM
bptjm-17	95	30	)	)	PUNCT
bptjm-17	95	31	.	.	PUNCT
bptjm-17	96	1	as	as	ADP
bptjm-17	96	2	a	a	DET
bptjm-17	96	3	result	result	NOUN
bptjm-17	96	4	,	,	PUNCT
bptjm-17	96	5	early	early	ADJ
bptjm-17	96	6	detection	detection	NOUN
bptjm-17	96	7	of	of	ADP
bptjm-17	96	8	cdkn2a	cdkn2a	PROPN
bptjm-17	96	9	mutations	mutation	NOUN
bptjm-17	96	10	is	be	AUX
bptjm-17	96	11	critical	critical	ADJ
bptjm-17	96	12	.	.	PUNCT
bptjm-17	97	1	the	the	DET
bptjm-17	97	2	e	e	PROPN
bptjm-17	97	3	cacy	cacy	NOUN
bptjm-17	97	4	of	of	ADP
bptjm-17	97	5	liquid	liquid	ADJ
bptjm-17	97	6	biopsy	biopsy	NOUN
bptjm-17	97	7	for	for	ADP
bptjm-17	97	8	mutation	mutation	NOUN
bptjm-17	97	9	detection	detection	NOUN
bptjm-17	97	10	has	have	AUX
bptjm-17	97	11	been	be	AUX
bptjm-17	97	12	suggested	suggest	VERB
bptjm-17	97	13	in	in	ADP
bptjm-17	97	14	breast	breast	NOUN
bptjm-17	97	15	cancer	cancer	NOUN
bptjm-17	97	16	studies	study	NOUN
bptjm-17	97	17	,	,	PUNCT
bptjm-17	97	18	but	but	CCONJ
bptjm-17	97	19	further	further	ADJ
bptjm-17	97	20	testing	testing	NOUN
bptjm-17	97	21	is	be	AUX
bptjm-17	97	22	needed	need	VERB
bptjm-17	97	23	to	to	PART
bptjm-17	97	24	determine	determine	VERB
bptjm-17	97	25	whether	whether	SCONJ
bptjm-17	97	26	the	the	DET
bptjm-17	97	27	detection	detection	NOUN
bptjm-17	97	28	of	of	ADP
bptjm-17	97	29	cdkn2a	cdkn2a	PROPN
bptjm-17	97	30	alterations	alteration	NOUN
bptjm-17	97	31	via	via	ADP
bptjm-17	97	32	liquid	liquid	ADJ
bptjm-17	97	33	biopsy	biopsy	NOUN
bptjm-17	97	34	would	would	AUX
bptjm-17	97	35	yield	yield	VERB
bptjm-17	97	36	signi	signi	ADJ
bptjm-17	97	37	ca	can	AUX
bptjm-17	97	38	nt	not	PART
bptjm-17	97	39	clinical	clinical	VERB
bptjm-17	97	40	bene	bene	NOUN
bptjm-17	97	41	t	t	PROPN
bptjm-17	97	42	for	for	ADP
bptjm-17	97	43	nsclc	nsclc	NOUN
bptjm-17	97	44	patients	patient	NOUN
bptjm-17	97	45	possessing	possess	VERB
bptjm-17	97	46	alterations	alteration	NOUN
bptjm-17	97	47	in	in	ADP
bptjm-17	97	48	this	this	DET
bptjm-17	97	49	gene	gene	NOUN
bptjm-17	97	50	(	(	PUNCT
bptjm-17	97	51	veldore	veldore	NOUN
bptjm-17	97	52	et	et	PROPN
bptjm-17	97	53	al	al	PROPN
bptjm-17	97	54	.	.	PROPN
bptjm-17	97	55	,	,	PUNCT
bptjm-17	97	56	2018	2018	NUM
bptjm-17	97	57	;	;	PUNCT
bptjm-17	97	58	delmonico	delmonico	PROPN
bptjm-17	97	59	et	et	PROPN
bptjm-17	97	60	al	al	PROPN
bptjm-17	97	61	.	.	PROPN
bptjm-17	97	62	,	,	PUNCT
bptjm-17	97	63	2019	2019	NUM
bptjm-17	97	64	)	)	PUNCT
bptjm-17	97	65	.	.	PUNCT
bptjm-17	98	1	cdkn2a	cdkn2a	PROPN
bptjm-17	98	2	alterations	alteration	NOUN
bptjm-17	98	3	in	in	ADP
bptjm-17	98	4	nsclc	nsclc	NOUN
bptjm-17	98	5	can	can	AUX
bptjm-17	98	6	be	be	AUX
bptjm-17	98	7	categorized	categorize	VERB
bptjm-17	98	8	into	into	ADP
bptjm-17	98	9	several	several	ADJ
bptjm-17	98	10	discrete	discrete	ADJ
bptjm-17	98	11	classes	class	NOUN
bptjm-17	98	12	,	,	PUNCT
bptjm-17	98	13	including	include	VERB
bptjm-17	98	14	copy	copy	NOUN
bptjm-17	98	15	number	number	NOUN
bptjm-17	98	16	changes	change	NOUN
bptjm-17	98	17	,	,	PUNCT
bptjm-17	98	18	hyperphosphorylation	hyperphosphorylation	NOUN
bptjm-17	98	19	,	,	PUNCT
bptjm-17	98	20	and	and	CCONJ
bptjm-17	98	21	deletion	deletion	NOUN
bptjm-17	98	22	(	(	PUNCT
bptjm-17	98	23	liu	liu	PROPN
bptjm-17	98	24	et	et	PROPN
bptjm-17	98	25	al	al	PROPN
bptjm-17	98	26	.	.	PROPN
bptjm-17	98	27	,	,	PUNCT
bptjm-17	98	28	2020	2020	NUM
bptjm-17	98	29	)	)	PUNCT
bptjm-17	98	30	.	.	PUNCT
bptjm-17	99	1	a	a	DET
bptjm-17	99	2	study	study	NOUN
bptjm-17	99	3	by	by	ADP
bptjm-17	99	4	wen	wen	PROPN
bptjm-17	99	5	et	et	PROPN
bptjm-17	99	6	al	al	PROPN
bptjm-17	99	7	.	.	PROPN
bptjm-17	99	8	suggests	suggest	VERB
bptjm-17	99	9	that	that	SCONJ
bptjm-17	99	10	the	the	DET
bptjm-17	99	11	relative	relative	ADJ
bptjm-17	99	12	frequency	frequency	NOUN
bptjm-17	99	13	of	of	ADP
bptjm-17	99	14	cdkn2a	cdkn2a	PROPN
bptjm-17	99	15	alterations	alteration	NOUN
bptjm-17	99	16	exhibits	exhibit	NOUN
bptjm-17	99	17	signi	signi	ADJ
bptjm-17	99	18	ca	can	AUX
bptjm-17	99	19	nt	not	PART
bptjm-17	99	20	variability	variability	VERB
bptjm-17	99	21	among	among	ADP
bptjm-17	99	22	di	di	NOUN
bptjm-17	99	23	erent	erent	NOUN
bptjm-17	99	24	racial	racial	ADJ
bptjm-17	99	25	groups	group	NOUN
bptjm-17	99	26	,	,	PUNCT
bptjm-17	99	27	with	with	ADP
bptjm-17	99	28	prevalence	prevalence	NOUN
bptjm-17	99	29	ranging	range	VERB
bptjm-17	99	30	from	from	ADP
bptjm-17	99	31	5.1	5.1	NUM
bptjm-17	99	32	to	to	PART
bptjm-17	99	33	21.5	21.5	NUM
bptjm-17	99	34	percent	percent	NOUN
bptjm-17	99	35	in	in	ADP
bptjm-17	99	36	lung	lung	NOUN
bptjm-17	99	37	adenocarcinomas	adenocarcinoma	NOUN
bptjm-17	99	38	and	and	CCONJ
bptjm-17	99	39	23.2	23.2	NUM
bptjm-17	99	40	to	to	PART
bptjm-17	99	41	43.6	43.6	NUM
bptjm-17	99	42	percent	percent	NOUN
bptjm-17	99	43	in	in	ADP
bptjm-17	99	44	squamous	squamous	ADJ
bptjm-17	99	45	cell	cell	NOUN
bptjm-17	99	46	lung	lung	NOUN
bptjm-17	99	47	carcinomas	carcinoma	NOUN
bptjm-17	99	48	.	.	PUNCT
bptjm-17	100	1	percentages	percentage	NOUN
bptjm-17	100	2	in	in	ADP
bptjm-17	100	3	this	this	DET
bptjm-17	100	4	study	study	NOUN
bptjm-17	100	5	were	be	AUX
bptjm-17	100	6	drawn	draw	VERB
bptjm-17	100	7	fromngs	fromng	NOUN
bptjm-17	100	8	assessment	assessment	NOUN
bptjm-17	100	9	of	of	ADP
bptjm-17	100	10	1200	1200	NUM
bptjm-17	100	11	chinese	chinese	ADJ
bptjm-17	100	12	nsclc	nsclc	NOUN
bptjm-17	100	13	patients	patient	NOUN
bptjm-17	100	14	and	and	CCONJ
bptjm-17	100	15	the	the	DET
bptjm-17	100	16	cancer	cancer	NOUN
bptjm-17	100	17	genome	genome	NOUN
bptjm-17	100	18	atlas	atlas	PROPN
bptjm-17	100	19	(	(	PUNCT
bptjm-17	100	20	tcga	tcga	PROPN
bptjm-17	100	21	)	)	PUNCT
bptjm-17	100	22	data	datum	NOUN
bptjm-17	100	23	for	for	ADP
bptjm-17	100	24	american	american	ADJ
bptjm-17	100	25	and	and	CCONJ
bptjm-17	100	26	european	european	ADJ
bptjm-17	100	27	cohorts	cohort	NOUN
bptjm-17	100	28	(	(	PUNCT
bptjm-17	100	29	wen	wen	PROPN
bptjm-17	100	30	et	et	PROPN
bptjm-17	100	31	al	al	PROPN
bptjm-17	100	32	.	.	PROPN
bptjm-17	100	33	,	,	PUNCT
bptjm-17	100	34	2019	2019	NUM
bptjm-17	100	35	)	)	PUNCT
bptjm-17	100	36	.	.	PUNCT
bptjm-17	101	1	liu	liu	PROPN
bptjm-17	101	2	et	et	PROPN
bptjm-17	101	3	al	al	PROPN
bptjm-17	101	4	.	.	PROPN
bptjm-17	101	5	,	,	PUNCT
bptjm-17	101	6	also	also	ADV
bptjm-17	101	7	assessed	assess	VERB
bptjm-17	101	8	data	datum	NOUN
bptjm-17	101	9	from	from	ADP
bptjm-17	101	10	tcga	tcga	PROPN
bptjm-17	101	11	to	to	PART
bptjm-17	101	12	pinpoint	pinpoint	VERB
bptjm-17	101	13	important	important	ADJ
bptjm-17	101	14	genes	gene	NOUN
bptjm-17	101	15	implicated	implicate	VERB
bptjm-17	101	16	in	in	ADP
bptjm-17	101	17	lung	lung	NOUN
bptjm-17	101	18	cancer	cancer	NOUN
bptjm-17	101	19	tumor	tumor	NOUN
bptjm-17	101	20	biology	biology	NOUN
bptjm-17	101	21	related	relate	VERB
bptjm-17	101	22	to	to	ADP
bptjm-17	101	23	cdkn2a	cdkn2a	PROPN
bptjm-17	101	24	.	.	PUNCT
bptjm-17	102	1	a549	a549	PROPN
bptjm-17	102	2	and	and	CCONJ
bptjm-17	102	3	h322	h322	PROPN
bptjm-17	102	4	cell	cell	NOUN
bptjm-17	102	5	lines	line	NOUN
bptjm-17	102	6	were	be	AUX
bptjm-17	102	7	berkeley	berkeley	PROPN
bptjm-17	102	8	pharma	pharma	PROPN
bptjm-17	102	9	tech	tech	NOUN
bptjm-17	102	10	journal	journal	NOUN
bptjm-17	102	11	of	of	ADP
bptjm-17	102	12	medicine	medicine	NOUN
bptjm-17	102	13	|	|	ADV
bptjm-17	102	14	122	122	NUM
bptjm-17	102	15	cultured	cultured	ADJ
bptjm-17	102	16	and	and	CCONJ
bptjm-17	102	17	evaluated	evaluate	VERB
bptjm-17	102	18	through	through	ADP
bptjm-17	102	19	real	real	ADJ
bptjm-17	102	20	-	-	PUNCT
bptjm-17	102	21	time	time	NOUN
bptjm-17	102	22	pcr	pcr	NOUN
bptjm-17	102	23	,	,	PUNCT
bptjm-17	102	24	western	western	ADJ
bptjm-17	102	25	blot	blot	NOUN
bptjm-17	102	26	analysis	analysis	NOUN
bptjm-17	102	27	,	,	PUNCT
bptjm-17	102	28	2,5	2,5	NUM
bptjm-17	102	29	-	-	PUNCT
bptjm-17	102	30	diphenyl	diphenyl	VERB
bptjm-17	102	31	tetrazolium	tetrazolium	NOUN
bptjm-17	102	32	bromide	bromide	NOUN
bptjm-17	102	33	(	(	PUNCT
bptjm-17	102	34	mtt	mtt	NOUN
bptjm-17	102	35	)	)	PUNCT
bptjm-17	102	36	assay	assay	NOUN
bptjm-17	102	37	,	,	PUNCT
bptjm-17	102	38	and	and	CCONJ
bptjm-17	102	39	cell	cell	NOUN
bptjm-17	102	40	counting	counting	NOUN
bptjm-17	102	41	,	,	PUNCT
bptjm-17	102	42	invasion	invasion	NOUN
bptjm-17	102	43	,	,	PUNCT
bptjm-17	102	44	wound	wound	NOUN
bptjm-17	102	45	healing	healing	NOUN
bptjm-17	102	46	,	,	PUNCT
bptjm-17	102	47	and	and	CCONJ
bptjm-17	102	48	migration	migration	NOUN
bptjm-17	102	49	assays	assay	NOUN
bptjm-17	102	50	.	.	PUNCT
bptjm-17	103	1	the	the	DET
bptjm-17	103	2	researchers	researcher	NOUN
bptjm-17	103	3	observed	observe	VERB
bptjm-17	103	4	a	a	DET
bptjm-17	103	5	marked	mark	VERB
bptjm-17	103	6	decrease	decrease	NOUN
bptjm-17	103	7	in	in	ADP
bptjm-17	103	8	survival	survival	NOUN
bptjm-17	103	9	among	among	ADP
bptjm-17	103	10	patients	patient	NOUN
bptjm-17	103	11	with	with	ADP
bptjm-17	103	12	cdkn2a	cdkn2a	PROPN
bptjm-17	103	13	depletions	depletion	NOUN
bptjm-17	103	14	and	and	CCONJ
bptjm-17	103	15	found	find	VERB
bptjm-17	103	16	a	a	DET
bptjm-17	103	17	direct	direct	ADJ
bptjm-17	103	18	correlation	correlation	NOUN
bptjm-17	103	19	between	between	ADP
bptjm-17	103	20	cdkn2a	cdkn2a	PROPN
bptjm-17	103	21	knockdown	knockdown	NOUN
bptjm-17	103	22	and	and	CCONJ
bptjm-17	103	23	increased	increase	VERB
bptjm-17	103	24	cell	cell	NOUN
bptjm-17	103	25	invasion	invasion	NOUN
bptjm-17	103	26	,	,	PUNCT
bptjm-17	103	27	migration	migration	NOUN
bptjm-17	103	28	,	,	PUNCT
bptjm-17	103	29	and	and	CCONJ
bptjm-17	103	30	proliferation	proliferation	NOUN
bptjm-17	103	31	in	in	ADP
bptjm-17	103	32	experiments	experiment	NOUN
bptjm-17	103	33	in	in	ADP
bptjm-17	103	34	a549	a549	PROPN
bptjm-17	103	35	and	and	CCONJ
bptjm-17	103	36	h322	h322	PROPN
bptjm-17	103	37	cell	cell	NOUN
bptjm-17	103	38	lines	line	NOUN
bptjm-17	103	39	.	.	PUNCT
bptjm-17	104	1	a	a	DET
bptjm-17	104	2	tcga	tcga	ADJ
bptjm-17	104	3	provisional	provisional	ADJ
bptjm-17	104	4	and	and	CCONJ
bptjm-17	104	5	pan	pan	NOUN
bptjm-17	104	6	-	-	ADJ
bptjm-17	104	7	cancer	cancer	ADJ
bptjm-17	104	8	atlas	atlas	PROPN
bptjm-17	104	9	survival	survival	PROPN
bptjm-17	104	10	analysis	analysis	NOUN
bptjm-17	104	11	and	and	CCONJ
bptjm-17	104	12	further	further	ADJ
bptjm-17	104	13	studies	study	NOUN
bptjm-17	104	14	on	on	ADP
bptjm-17	104	15	other	other	ADJ
bptjm-17	104	16	diseases	disease	NOUN
bptjm-17	104	17	have	have	AUX
bptjm-17	104	18	suggested	suggest	VERB
bptjm-17	104	19	decreased	decrease	VERB
bptjm-17	104	20	survival	survival	NOUN
bptjm-17	104	21	rates	rate	NOUN
bptjm-17	104	22	and	and	CCONJ
bptjm-17	104	23	other	other	ADJ
bptjm-17	104	24	adverse	adverse	ADJ
bptjm-17	104	25	e	e	NOUN
bptjm-17	104	26	ects	ect	VERB
bptjm-17	104	27	in	in	ADP
bptjm-17	104	28	patients	patient	NOUN
bptjm-17	104	29	with	with	ADP
bptjm-17	104	30	cdkn2a	cdkn2a	PROPN
bptjm-17	104	31	depletion	depletion	NOUN
bptjm-17	104	32	.	.	PUNCT
bptjm-17	105	1	(	(	PUNCT
bptjm-17	105	2	reis	reis	NOUN
bptjm-17	105	3	et	et	NOUN
bptjm-17	105	4	al	al	PROPN
bptjm-17	105	5	.	.	PROPN
bptjm-17	105	6	,	,	PUNCT
bptjm-17	105	7	2015	2015	NUM
bptjm-17	105	8	;	;	PUNCT
bptjm-17	105	9	zeng	zeng	PROPN
bptjm-17	105	10	et	et	PROPN
bptjm-17	105	11	al	al	PROPN
bptjm-17	105	12	.	.	PROPN
bptjm-17	105	13	,	,	PUNCT
bptjm-17	105	14	2018	2018	NUM
bptjm-17	105	15	;	;	PUNCT
bptjm-17	105	16	dacic	dacic	NOUN
bptjm-17	105	17	et	et	PROPN
bptjm-17	105	18	al	al	PROPN
bptjm-17	105	19	.	.	PROPN
bptjm-17	105	20	,	,	PUNCT
bptjm-17	105	21	2008	2008	NUM
bptjm-17	105	22	)	)	PUNCT
bptjm-17	105	23	.	.	PUNCT
bptjm-17	106	1	while	while	SCONJ
bptjm-17	106	2	cdkn2a	cdkn2a	PROPN
bptjm-17	106	3	loss	loss	NOUN
bptjm-17	106	4	is	be	AUX
bptjm-17	106	5	suggested	suggest	VERB
bptjm-17	106	6	to	to	PART
bptjm-17	106	7	have	have	VERB
bptjm-17	106	8	a	a	DET
bptjm-17	106	9	negative	negative	ADJ
bptjm-17	106	10	in	in	ADP
bptjm-17	106	11	uence	uence	NOUN
bptjm-17	106	12	on	on	ADP
bptjm-17	106	13	prognosis	prognosis	NOUN
bptjm-17	106	14	and	and	CCONJ
bptjm-17	106	15	survival	survival	NOUN
bptjm-17	106	16	outcomes	outcome	NOUN
bptjm-17	106	17	,	,	PUNCT
bptjm-17	106	18	more	more	ADJ
bptjm-17	106	19	research	research	NOUN
bptjm-17	106	20	is	be	AUX
bptjm-17	106	21	necessary	necessary	ADJ
bptjm-17	106	22	to	to	PART
bptjm-17	106	23	understand	understand	VERB
bptjm-17	106	24	cdkn2a	cdkn2a	PROPN
bptjm-17	106	25	’s	’s	PART
bptjm-17	106	26	speci	speci	NOUN
bptjm-17	106	27	c	c	PROPN
bptjm-17	106	28	implications	implication	NOUN
bptjm-17	106	29	in	in	ADP
bptjm-17	106	30	lung	lung	NOUN
bptjm-17	106	31	cancer	cancer	NOUN
bptjm-17	106	32	(	(	PUNCT
bptjm-17	106	33	liu	liu	PROPN
bptjm-17	106	34	et	et	PROPN
bptjm-17	106	35	al	al	PROPN
bptjm-17	106	36	.	.	PROPN
bptjm-17	106	37	,	,	PUNCT
bptjm-17	106	38	2020	2020	NUM
bptjm-17	106	39	)	)	PUNCT
bptjm-17	106	40	.	.	PUNCT
bptjm-17	107	1	with	with	ADP
bptjm-17	107	2	cdkn2a	cdkn2a	PROPN
bptjm-17	107	3	’s	’s	PART
bptjm-17	107	4	potential	potential	NOUN
bptjm-17	107	5	to	to	PART
bptjm-17	107	6	be	be	AUX
bptjm-17	107	7	a	a	DET
bptjm-17	107	8	clinically	clinically	ADV
bptjm-17	107	9	actionable	actionable	ADJ
bptjm-17	107	10	biomarker	biomarker	NOUN
bptjm-17	107	11	,	,	PUNCT
bptjm-17	107	12	testing	testing	NOUN
bptjm-17	107	13	and	and	CCONJ
bptjm-17	107	14	genomic	genomic	NOUN
bptjm-17	107	15	panels	panel	NOUN
bptjm-17	107	16	with	with	ADP
bptjm-17	107	17	this	this	DET
bptjm-17	107	18	gene	gene	NOUN
bptjm-17	107	19	have	have	AUX
bptjm-17	107	20	been	be	AUX
bptjm-17	107	21	bene	bene	NOUN
bptjm-17	107	22	cial	cial	NOUN
bptjm-17	107	23	and	and	CCONJ
bptjm-17	107	24	often	often	ADV
bptjm-17	107	25	included	include	VERB
bptjm-17	107	26	in	in	ADP
bptjm-17	107	27	biomarker	biomarker	NOUN
bptjm-17	107	28	testing	testing	NOUN
bptjm-17	107	29	.	.	PUNCT
bptjm-17	108	1	recent	recent	ADJ
bptjm-17	108	2	advances	advance	NOUN
bptjm-17	108	3	in	in	ADP
bptjm-17	108	4	assay	assay	NOUN
bptjm-17	108	5	techniques	technique	NOUN
bptjm-17	108	6	have	have	AUX
bptjm-17	108	7	established	establish	VERB
bptjm-17	108	8	ctdna	ctdna	NOUN
bptjm-17	108	9	as	as	ADP
bptjm-17	108	10	a	a	DET
bptjm-17	108	11	viable	viable	ADJ
bptjm-17	108	12	biomarker	biomarker	NOUN
bptjm-17	108	13	for	for	ADP
bptjm-17	108	14	detection	detection	NOUN
bptjm-17	108	15	.	.	PUNCT
bptjm-17	109	1	one	one	NUM
bptjm-17	109	2	study	study	NOUN
bptjm-17	109	3	suggests	suggest	VERB
bptjm-17	109	4	that	that	SCONJ
bptjm-17	109	5	cdkn2a	cdkn2a	PROPN
bptjm-17	109	6	ctdna	ctdna	NOUN
bptjm-17	109	7	,	,	PUNCT
bptjm-17	109	8	along	along	ADP
bptjm-17	109	9	with	with	ADP
bptjm-17	109	10	the	the	DET
bptjm-17	109	11	ctdna	ctdna	NOUN
bptjm-17	109	12	of	of	ADP
bptjm-17	109	13	several	several	ADJ
bptjm-17	109	14	other	other	ADJ
bptjm-17	109	15	cell	cell	NOUN
bptjm-17	109	16	-	-	PUNCT
bptjm-17	109	17	cycle	cycle	NOUN
bptjm-17	109	18	related	relate	VERB
bptjm-17	109	19	genes	gene	NOUN
bptjm-17	109	20	,	,	PUNCT
bptjm-17	109	21	exhibit	exhibit	VERB
bptjm-17	109	22	only	only	ADV
bptjm-17	109	23	an	an	DET
bptjm-17	109	24	81.6	81.6	NUM
bptjm-17	109	25	%	%	NOUN
bptjm-17	109	26	concordance	concordance	NOUN
bptjm-17	109	27	rate	rate	NOUN
bptjm-17	109	28	to	to	ADP
bptjm-17	109	29	their	their	PRON
bptjm-17	109	30	corresponding	corresponding	ADJ
bptjm-17	109	31	solid	solid	ADJ
bptjm-17	109	32	tumor	tumor	NOUN
bptjm-17	109	33	biopsies	biopsy	NOUN
bptjm-17	109	34	(	(	PUNCT
bptjm-17	109	35	mao	mao	X
bptjm-17	109	36	et	et	PROPN
bptjm-17	109	37	al	al	PROPN
bptjm-17	109	38	.	.	PROPN
bptjm-17	109	39	,	,	PUNCT
bptjm-17	109	40	2017	2017	NUM
bptjm-17	109	41	)	)	PUNCT
bptjm-17	109	42	.	.	PUNCT
bptjm-17	110	1	studies	study	NOUN
bptjm-17	110	2	analyzing	analyze	VERB
bptjm-17	110	3	the	the	DET
bptjm-17	110	4	concordance	concordance	NOUN
bptjm-17	110	5	of	of	ADP
bptjm-17	110	6	cdkn2a	cdkn2a	PROPN
bptjm-17	110	7	mutation	mutation	NOUN
bptjm-17	110	8	in	in	ADP
bptjm-17	110	9	both	both	CCONJ
bptjm-17	110	10	liquid	liquid	ADJ
bptjm-17	110	11	and	and	CCONJ
bptjm-17	110	12	tissue	tissue	NOUN
bptjm-17	110	13	biopsies	biopsy	NOUN
bptjm-17	110	14	from	from	ADP
bptjm-17	110	15	breast	breast	NOUN
bptjm-17	110	16	cancer	cancer	NOUN
bptjm-17	110	17	patients	patient	NOUN
bptjm-17	110	18	also	also	ADV
bptjm-17	110	19	revealed	reveal	VERB
bptjm-17	110	20	di	di	NOUN
bptjm-17	110	21	erences	erence	NOUN
bptjm-17	110	22	in	in	ADP
bptjm-17	110	23	mutations	mutation	NOUN
bptjm-17	110	24	detected	detect	VERB
bptjm-17	110	25	through	through	ADP
bptjm-17	110	26	cell	cell	NOUN
bptjm-17	110	27	-	-	PUNCT
bptjm-17	110	28	free	free	ADJ
bptjm-17	110	29	dna	dna	NOUN
bptjm-17	110	30	analysis	analysis	NOUN
bptjm-17	110	31	and	and	CCONJ
bptjm-17	110	32	tissue	tissue	NOUN
bptjm-17	110	33	biopsy	biopsy	NOUN
bptjm-17	110	34	,	,	PUNCT
bptjm-17	110	35	although	although	SCONJ
bptjm-17	110	36	overall	overall	ADJ
bptjm-17	110	37	mutational	mutational	ADJ
bptjm-17	110	38	prevalence	prevalence	NOUN
bptjm-17	110	39	was	be	AUX
bptjm-17	110	40	quite	quite	ADV
bptjm-17	110	41	similar	similar	ADJ
bptjm-17	110	42	to	to	ADP
bptjm-17	110	43	frequencies	frequency	NOUN
bptjm-17	110	44	observed	observe	VERB
bptjm-17	110	45	in	in	ADP
bptjm-17	110	46	tissue	tissue	NOUN
bptjm-17	110	47	samples	sample	NOUN
bptjm-17	110	48	(	(	PUNCT
bptjm-17	110	49	delmonico	delmonico	X
bptjm-17	110	50	et	et	PROPN
bptjm-17	110	51	al	al	PROPN
bptjm-17	110	52	.	.	PROPN
bptjm-17	110	53	,	,	PUNCT
bptjm-17	110	54	2020	2020	NUM
bptjm-17	110	55	)	)	PUNCT
bptjm-17	110	56	.	.	PUNCT
bptjm-17	111	1	hence	hence	ADV
bptjm-17	111	2	,	,	PUNCT
bptjm-17	111	3	the	the	DET
bptjm-17	111	4	impetus	impetus	NOUN
bptjm-17	111	5	for	for	ADP
bptjm-17	111	6	further	further	ADJ
bptjm-17	111	7	exploration	exploration	NOUN
bptjm-17	111	8	of	of	ADP
bptjm-17	111	9	ctdna	ctdna	NOUN
bptjm-17	111	10	’s	’s	PART
bptjm-17	111	11	clinical	clinical	ADJ
bptjm-17	111	12	value	value	NOUN
bptjm-17	111	13	is	be	AUX
bptjm-17	111	14	essential	essential	ADJ
bptjm-17	111	15	to	to	PART
bptjm-17	111	16	develop	develop	VERB
bptjm-17	111	17	increasingly	increasingly	ADV
bptjm-17	111	18	accurate	accurate	ADJ
bptjm-17	111	19	,	,	PUNCT
bptjm-17	111	20	noninvasive	noninvasive	ADJ
bptjm-17	111	21	,	,	PUNCT
bptjm-17	111	22	and	and	CCONJ
bptjm-17	111	23	timely	timely	ADJ
bptjm-17	111	24	methods	method	NOUN
bptjm-17	111	25	of	of	ADP
bptjm-17	111	26	detection	detection	NOUN
bptjm-17	111	27	to	to	PART
bptjm-17	111	28	ensure	ensure	VERB
bptjm-17	111	29	that	that	SCONJ
bptjm-17	111	30	cdkn2a	cdkn2a	PROPN
bptjm-17	111	31	mutations	mutation	NOUN
bptjm-17	111	32	are	be	AUX
bptjm-17	111	33	subject	subject	ADJ
bptjm-17	111	34	to	to	ADP
bptjm-17	111	35	earlier	early	ADJ
bptjm-17	111	36	interventions	intervention	NOUN
bptjm-17	111	37	,	,	PUNCT
bptjm-17	111	38	which	which	PRON
bptjm-17	111	39	may	may	AUX
bptjm-17	111	40	ultimately	ultimately	ADV
bptjm-17	111	41	lead	lead	VERB
bptjm-17	111	42	to	to	ADP
bptjm-17	111	43	a	a	DET
bptjm-17	111	44	better	well	ADJ
bptjm-17	111	45	prognosis	prognosis	NOUN
bptjm-17	111	46	for	for	ADP
bptjm-17	111	47	nsclc	nsclc	NOUN
bptjm-17	111	48	patients	patient	NOUN
bptjm-17	111	49	.	.	PUNCT
bptjm-17	112	1	ret	ret	PROPN
bptjm-17	112	2	rearranged	rearrange	VERB
bptjm-17	112	3	during	during	ADP
bptjm-17	112	4	transfection	transfection	NOUN
bptjm-17	112	5	(	(	PUNCT
bptjm-17	112	6	ret	ret	NOUN
bptjm-17	112	7	)	)	PUNCT
bptjm-17	112	8	activating	activate	VERB
bptjm-17	112	9	fusion	fusion	NOUN
bptjm-17	112	10	mutations	mutation	NOUN
bptjm-17	112	11	are	be	AUX
bptjm-17	112	12	found	find	VERB
bptjm-17	112	13	to	to	PART
bptjm-17	112	14	occur	occur	VERB
bptjm-17	112	15	in	in	ADP
bptjm-17	112	16	approximately	approximately	ADV
bptjm-17	112	17	1	1	NUM
bptjm-17	112	18	%	%	NOUN
bptjm-17	112	19	to	to	PART
bptjm-17	112	20	2	2	NUM
bptjm-17	112	21	%	%	NOUN
bptjm-17	112	22	of	of	ADP
bptjm-17	112	23	nsclc	nsclc	NOUN
bptjm-17	112	24	patients	patient	NOUN
bptjm-17	112	25	and	and	CCONJ
bptjm-17	112	26	have	have	AUX
bptjm-17	112	27	been	be	AUX
bptjm-17	112	28	suggested	suggest	VERB
bptjm-17	112	29	to	to	PART
bptjm-17	112	30	show	show	VERB
bptjm-17	112	31	heightened	heightened	ADJ
bptjm-17	112	32	prevalence	prevalence	NOUN
bptjm-17	112	33	in	in	ADP
bptjm-17	112	34	patients	patient	NOUN
bptjm-17	112	35	who	who	PRON
bptjm-17	112	36	never	never	ADV
bptjm-17	112	37	/	/	SYM
bptjm-17	112	38	lightly	lightly	ADV
bptjm-17	112	39	smoked	smoke	VERB
bptjm-17	112	40	and	and	CCONJ
bptjm-17	112	41	who	who	PRON
bptjm-17	112	42	are	be	AUX
bptjm-17	112	43	younger	young	ADJ
bptjm-17	112	44	(	(	PUNCT
bptjm-17	112	45	kohno	kohno	NOUN
bptjm-17	112	46	et	et	PROPN
bptjm-17	112	47	al	al	PROPN
bptjm-17	112	48	.	.	PROPN
bptjm-17	112	49	,	,	PUNCT
bptjm-17	112	50	2013	2013	NUM
bptjm-17	112	51	;	;	PUNCT
bptjm-17	112	52	kato	kato	PROPN
bptjm-17	112	53	et	et	PROPN
bptjm-17	112	54	al	al	PROPN
bptjm-17	112	55	.	.	PROPN
bptjm-17	112	56	,	,	PUNCT
bptjm-17	112	57	2017	2017	NUM
bptjm-17	112	58	)	)	PUNCT
bptjm-17	112	59	.	.	PUNCT
bptjm-17	113	1	ret	ret	PROPN
bptjm-17	113	2	codes	code	NOUN
bptjm-17	113	3	for	for	ADP
bptjm-17	113	4	a	a	DET
bptjm-17	113	5	receptor	receptor	NOUN
bptjm-17	113	6	tyrosine	tyrosine	NOUN
bptjm-17	113	7	kinase	kinase	NOUN
bptjm-17	113	8	that	that	PRON
bptjm-17	113	9	recognizes	recognize	VERB
bptjm-17	113	10	growth	growth	NOUN
bptjm-17	113	11	factors	factor	NOUN
bptjm-17	113	12	for	for	ADP
bptjm-17	113	13	the	the	DET
bptjm-17	113	14	neurotropic	neurotropic	ADJ
bptjm-17	113	15	factor	factor	NOUN
bptjm-17	113	16	family	family	NOUN
bptjm-17	113	17	,	,	PUNCT
bptjm-17	113	18	which	which	PRON
bptjm-17	113	19	is	be	AUX
bptjm-17	113	20	derived	derive	VERB
bptjm-17	113	21	from	from	ADP
bptjm-17	113	22	glial	glial	ADJ
bptjm-17	113	23	cell	cell	NOUN
bptjm-17	113	24	lines	line	NOUN
bptjm-17	113	25	.	.	PUNCT
bptjm-17	114	1	fusion	fusion	NOUN
bptjm-17	114	2	of	of	ADP
bptjm-17	114	3	the	the	DET
bptjm-17	114	4	ret	ret	PROPN
bptjm-17	114	5	proto	proto	PROPN
bptjm-17	114	6	oncogene	oncogene	NOUN
bptjm-17	114	7	can	can	AUX
bptjm-17	114	8	activate	activate	VERB
bptjm-17	114	9	the	the	DET
bptjm-17	114	10	receptor	receptor	NOUN
bptjm-17	114	11	tyrosine	tyrosine	NOUN
bptjm-17	114	12	kinase	kinase	PROPN
bptjm-17	114	13	in	in	ADP
bptjm-17	114	14	the	the	DET
bptjm-17	114	15	berkeley	berkeley	PROPN
bptjm-17	114	16	pharma	pharma	PROPN
bptjm-17	114	17	tech	tech	NOUN
bptjm-17	114	18	journal	journal	NOUN
bptjm-17	114	19	of	of	ADP
bptjm-17	114	20	medicine	medicine	NOUN
bptjm-17	114	21	|	|	ADV
bptjm-17	114	22	123	123	NUM
bptjm-17	114	23	absence	absence	NOUN
bptjm-17	114	24	of	of	ADP
bptjm-17	114	25	its	its	PRON
bptjm-17	114	26	ligand	ligand	NOUN
bptjm-17	114	27	.	.	PUNCT
bptjm-17	115	1	such	such	DET
bptjm-17	115	2	an	an	DET
bptjm-17	115	3	activation	activation	NOUN
bptjm-17	115	4	can	can	AUX
bptjm-17	115	5	have	have	VERB
bptjm-17	115	6	downstream	downstream	ADJ
bptjm-17	115	7	e	e	NOUN
bptjm-17	115	8	ects	ect	NOUN
bptjm-17	115	9	on	on	ADP
bptjm-17	115	10	other	other	ADJ
bptjm-17	115	11	pathways	pathway	NOUN
bptjm-17	115	12	such	such	ADJ
bptjm-17	115	13	as	as	ADP
bptjm-17	115	14	those	those	PRON
bptjm-17	115	15	including	include	VERB
bptjm-17	115	16	pi3k	pi3k	NOUN
bptjm-17	115	17	and	and	CCONJ
bptjm-17	115	18	mapk	mapk	NOUN
bptjm-17	115	19	(	(	PUNCT
bptjm-17	115	20	kato	kato	PROPN
bptjm-17	115	21	et	et	PROPN
bptjm-17	115	22	al	al	PROPN
bptjm-17	115	23	.	.	PROPN
bptjm-17	115	24	,	,	PUNCT
bptjm-17	115	25	2017	2017	NUM
bptjm-17	115	26	)	)	PUNCT
bptjm-17	115	27	.	.	PUNCT
bptjm-17	116	1	the	the	DET
bptjm-17	116	2	existence	existence	NOUN
bptjm-17	116	3	of	of	ADP
bptjm-17	116	4	fda	fda	PROPN
bptjm-17	116	5	-	-	PUNCT
bptjm-17	116	6	approved	approve	VERB
bptjm-17	116	7	therapies	therapy	NOUN
bptjm-17	116	8	for	for	ADP
bptjm-17	116	9	ret	ret	NOUN
bptjm-17	116	10	-	-	PUNCT
bptjm-17	116	11	altered	alter	VERB
bptjm-17	116	12	cancers	cancer	NOUN
bptjm-17	116	13	such	such	ADJ
bptjm-17	116	14	as	as	ADP
bptjm-17	116	15	vandetanib	vandetanib	NOUN
bptjm-17	116	16	and	and	CCONJ
bptjm-17	116	17	cabozantinib	cabozantinib	ADV
bptjm-17	116	18	underscores	underscore	VERB
bptjm-17	116	19	the	the	DET
bptjm-17	116	20	value	value	NOUN
bptjm-17	116	21	of	of	ADP
bptjm-17	116	22	early	early	ADJ
bptjm-17	116	23	ret	ret	PROPN
bptjm-17	116	24	detection	detection	NOUN
bptjm-17	116	25	to	to	PART
bptjm-17	116	26	improve	improve	VERB
bptjm-17	116	27	prognosis	prognosis	NOUN
bptjm-17	116	28	for	for	ADP
bptjm-17	116	29	patients	patient	NOUN
bptjm-17	116	30	with	with	ADP
bptjm-17	116	31	nsclc	nsclc	NOUN
bptjm-17	116	32	presenting	presenting	NOUN
bptjm-17	116	33	with	with	ADP
bptjm-17	116	34	ret	ret	NOUN
bptjm-17	116	35	-	-	PUNCT
bptjm-17	116	36	altered	alter	VERB
bptjm-17	116	37	cancers	cancer	NOUN
bptjm-17	116	38	.	.	PUNCT
bptjm-17	117	1	clinical	clinical	ADJ
bptjm-17	117	2	trials	trial	NOUN
bptjm-17	117	3	with	with	ADP
bptjm-17	117	4	vandetanib	vandetanib	NOUN
bptjm-17	117	5	and	and	CCONJ
bptjm-17	117	6	everolimus	everolimus	NOUN
bptjm-17	117	7	have	have	AUX
bptjm-17	117	8	demonstrated	demonstrate	VERB
bptjm-17	117	9	the	the	DET
bptjm-17	117	10	potential	potential	NOUN
bptjm-17	117	11	of	of	ADP
bptjm-17	117	12	these	these	DET
bptjm-17	117	13	drugs	drug	NOUN
bptjm-17	117	14	to	to	PART
bptjm-17	117	15	serve	serve	VERB
bptjm-17	117	16	viable	viable	ADJ
bptjm-17	117	17	treatments	treatment	NOUN
bptjm-17	117	18	for	for	ADP
bptjm-17	117	19	ret	ret	NOUN
bptjm-17	117	20	-	-	PUNCT
bptjm-17	117	21	altered	alter	VERB
bptjm-17	117	22	cancers	cancer	NOUN
bptjm-17	117	23	that	that	PRON
bptjm-17	117	24	have	have	AUX
bptjm-17	117	25	metastasized	metastasize	VERB
bptjm-17	117	26	to	to	ADP
bptjm-17	117	27	the	the	DET
bptjm-17	117	28	brain	brain	NOUN
bptjm-17	117	29	(	(	PUNCT
bptjm-17	117	30	subbiah	subbiah	NOUN
bptjm-17	117	31	et	et	PROPN
bptjm-17	117	32	al	al	PROPN
bptjm-17	117	33	.	.	PROPN
bptjm-17	117	34	,	,	PUNCT
bptjm-17	117	35	2015	2015	NUM
bptjm-17	117	36	)	)	PUNCT
bptjm-17	117	37	.	.	PUNCT
bptjm-17	118	1	in	in	ADP
bptjm-17	118	2	addition	addition	NOUN
bptjm-17	118	3	,	,	PUNCT
bptjm-17	118	4	kodama	kodama	PROPN
bptjm-17	118	5	et	et	PROPN
bptjm-17	118	6	al	al	PROPN
bptjm-17	118	7	.	.	PROPN
bptjm-17	118	8	assessed	assess	VERB
bptjm-17	118	9	the	the	DET
bptjm-17	118	10	e	e	PROPN
bptjm-17	118	11	cacy	cacy	NOUN
bptjm-17	118	12	of	of	ADP
bptjm-17	118	13	alectinib	alectinib	NOUN
bptjm-17	118	14	in	in	ADP
bptjm-17	118	15	ret	ret	NOUN
bptjm-17	118	16	fusion	fusion	NOUN
bptjm-17	118	17	-	-	PUNCT
bptjm-17	118	18	positive	positive	ADJ
bptjm-17	118	19	ccdc6	ccdc6	NOUN
bptjm-17	118	20	-	-	PUNCT
bptjm-17	118	21	ret	ret	NOUN
bptjm-17	118	22	and	and	CCONJ
bptjm-17	118	23	kif5b	kif5b	ADJ
bptjm-17	118	24	-	-	PUNCT
bptjm-17	118	25	ret	ret	NOUN
bptjm-17	118	26	genes	gene	NOUN
bptjm-17	118	27	.	.	PUNCT
bptjm-17	119	1	the	the	DET
bptjm-17	119	2	researchers	researcher	NOUN
bptjm-17	119	3	determined	determine	VERB
bptjm-17	119	4	that	that	SCONJ
bptjm-17	119	5	alectinib	alectinib	NOUN
bptjm-17	119	6	can	can	AUX
bptjm-17	119	7	preclude	preclude	VERB
bptjm-17	119	8	phosphorylation	phosphorylation	NOUN
bptjm-17	119	9	of	of	ADP
bptjm-17	119	10	ret	ret	NOUN
bptjm-17	119	11	,	,	PUNCT
bptjm-17	119	12	thus	thus	ADV
bptjm-17	119	13	providing	provide	VERB
bptjm-17	119	14	substantial	substantial	ADJ
bptjm-17	119	15	inhibitory	inhibitory	ADJ
bptjm-17	119	16	control	control	NOUN
bptjm-17	119	17	.	.	PUNCT
bptjm-17	120	1	furthermore	furthermore	ADV
bptjm-17	120	2	,	,	PUNCT
bptjm-17	120	3	alectinib	alectinib	NOUN
bptjm-17	120	4	demonstrated	demonstrate	VERB
bptjm-17	120	5	substantial	substantial	ADJ
bptjm-17	120	6	e	e	NOUN
bptjm-17	120	7	cacy	cacy	NOUN
bptjm-17	120	8	in	in	ADP
bptjm-17	120	9	treating	treat	VERB
bptjm-17	120	10	v804l	v804l	NOUN
bptjm-17	120	11	and	and	CCONJ
bptjm-17	120	12	v804	v804	PROPN
bptjm-17	120	13	m	m	NUM
bptjm-17	120	14	mutated	mutate	VERB
bptjm-17	120	15	cancers	cancer	NOUN
bptjm-17	120	16	compared	compare	VERB
bptjm-17	120	17	to	to	ADP
bptjm-17	120	18	cabozantinib	cabozantinib	NOUN
bptjm-17	120	19	and	and	CCONJ
bptjm-17	120	20	vandetanib	vandetanib	PROPN
bptjm-17	120	21	.	.	PUNCT
bptjm-17	121	1	the	the	DET
bptjm-17	121	2	suggested	suggested	ADJ
bptjm-17	121	3	basis	basis	NOUN
bptjm-17	121	4	of	of	ADP
bptjm-17	121	5	this	this	DET
bptjm-17	121	6	di	di	NOUN
bptjm-17	121	7	erence	erence	NOUN
bptjm-17	121	8	is	be	AUX
bptjm-17	121	9	supported	support	VERB
bptjm-17	121	10	by	by	ADP
bptjm-17	121	11	alectinib	alectinib	NOUN
bptjm-17	121	12	’s	’s	PART
bptjm-17	121	13	structure	structure	NOUN
bptjm-17	121	14	,	,	PUNCT
bptjm-17	121	15	which	which	PRON
bptjm-17	121	16	is	be	AUX
bptjm-17	121	17	not	not	PART
bptjm-17	121	18	in	in	ADP
bptjm-17	121	19	uenced	uence	VERB
bptjm-17	121	20	by	by	ADP
bptjm-17	121	21	the	the	DET
bptjm-17	121	22	steric	steric	ADJ
bptjm-17	121	23	e	e	NOUN
bptjm-17	121	24	ects	ect	NOUN
bptjm-17	121	25	of	of	ADP
bptjm-17	121	26	the	the	DET
bptjm-17	121	27	v804l	v804l	NOUN
bptjm-17	121	28	and	and	CCONJ
bptjm-17	121	29	v804	v804	PROPN
bptjm-17	121	30	m	m	NOUN
bptjm-17	121	31	gatekeeper	gatekeeper	NOUN
bptjm-17	121	32	mutations	mutation	NOUN
bptjm-17	121	33	(	(	PUNCT
bptjm-17	121	34	kodama	kodama	PROPN
bptjm-17	121	35	et	et	PROPN
bptjm-17	121	36	al	al	PROPN
bptjm-17	121	37	.	.	PROPN
bptjm-17	121	38	,	,	PUNCT
bptjm-17	121	39	2014	2014	NUM
bptjm-17	121	40	)	)	PUNCT
bptjm-17	121	41	.	.	PUNCT
bptjm-17	122	1	mao	mao	PROPN
bptjm-17	122	2	et	et	PROPN
bptjm-17	123	1	al	al	PROPN
bptjm-17	123	2	.	.	PROPN
bptjm-17	123	3	found	find	VERB
bptjm-17	123	4	that	that	SCONJ
bptjm-17	123	5	plasma	plasma	NOUN
bptjm-17	123	6	samples	sample	NOUN
bptjm-17	123	7	of	of	ADP
bptjm-17	123	8	ret	ret	NOUN
bptjm-17	123	9	ctdna	ctdna	NOUN
bptjm-17	123	10	from	from	ADP
bptjm-17	123	11	patients	patient	NOUN
bptjm-17	123	12	with	with	ADP
bptjm-17	123	13	histologically	histologically	PROPN
bptjm-17	123	14	con	con	PROPN
bptjm-17	123	15	rmed	rme	VERB
bptjm-17	123	16	lung	lung	NOUN
bptjm-17	123	17	cancer	cancer	NOUN
bptjm-17	123	18	demonstrated	demonstrate	VERB
bptjm-17	123	19	96.2	96.2	NUM
bptjm-17	123	20	%	%	NOUN
bptjm-17	123	21	concurrence	concurrence	NOUN
bptjm-17	123	22	with	with	ADP
bptjm-17	123	23	solid	solid	ADJ
bptjm-17	123	24	tumor	tumor	NOUN
bptjm-17	123	25	tissue	tissue	NOUN
bptjm-17	123	26	dna	dna	NOUN
bptjm-17	123	27	samples	sample	NOUN
bptjm-17	123	28	.	.	PUNCT
bptjm-17	124	1	concordance	concordance	NOUN
bptjm-17	124	2	rates	rate	NOUN
bptjm-17	124	3	in	in	ADP
bptjm-17	124	4	this	this	DET
bptjm-17	124	5	study	study	NOUN
bptjm-17	124	6	were	be	AUX
bptjm-17	124	7	determined	determine	VERB
bptjm-17	124	8	by	by	ADP
bptjm-17	124	9	an	an	DET
bptjm-17	124	10	analysis	analysis	NOUN
bptjm-17	124	11	of	of	ADP
bptjm-17	124	12	40	40	NUM
bptjm-17	124	13	tissue	tissue	NOUN
bptjm-17	124	14	and	and	CCONJ
bptjm-17	124	15	plasma	plasma	NOUN
bptjm-17	124	16	samples	sample	NOUN
bptjm-17	124	17	collected	collect	VERB
bptjm-17	124	18	from	from	ADP
bptjm-17	124	19	participants	participant	NOUN
bptjm-17	124	20	aged	age	VERB
bptjm-17	124	21	18	18	NUM
bptjm-17	124	22	-	-	SYM
bptjm-17	124	23	80	80	NUM
bptjm-17	124	24	who	who	PRON
bptjm-17	124	25	did	do	AUX
bptjm-17	124	26	not	not	PART
bptjm-17	124	27	qualify	qualify	VERB
bptjm-17	124	28	for	for	ADP
bptjm-17	124	29	rst	rst	NOUN
bptjm-17	124	30	-	-	PUNCT
bptjm-17	124	31	line	line	NOUN
bptjm-17	124	32	surgical	surgical	ADJ
bptjm-17	124	33	treatment	treatment	NOUN
bptjm-17	124	34	(	(	PUNCT
bptjm-17	124	35	mao	mao	NOUN
bptjm-17	124	36	et	et	PROPN
bptjm-17	124	37	al	al	PROPN
bptjm-17	124	38	.	.	PROPN
bptjm-17	124	39	,	,	PUNCT
bptjm-17	124	40	2017	2017	NUM
bptjm-17	124	41	)	)	PUNCT
bptjm-17	124	42	.	.	PUNCT
bptjm-17	125	1	similar	similar	ADJ
bptjm-17	125	2	studies	study	NOUN
bptjm-17	125	3	have	have	AUX
bptjm-17	125	4	also	also	ADV
bptjm-17	125	5	demonstrated	demonstrate	VERB
bptjm-17	125	6	high	high	ADJ
bptjm-17	125	7	concurrence	concurrence	NOUN
bptjm-17	125	8	rates	rate	NOUN
bptjm-17	125	9	between	between	ADP
bptjm-17	125	10	tissue	tissue	NOUN
bptjm-17	125	11	and	and	CCONJ
bptjm-17	125	12	liquid	liquid	ADJ
bptjm-17	125	13	biopsies	biopsy	NOUN
bptjm-17	125	14	,	,	PUNCT
bptjm-17	125	15	although	although	SCONJ
bptjm-17	125	16	the	the	DET
bptjm-17	125	17	concurrence	concurrence	NOUN
bptjm-17	125	18	percentage	percentage	NOUN
bptjm-17	125	19	was	be	AUX
bptjm-17	125	20	shown	show	VERB
bptjm-17	125	21	to	to	PART
bptjm-17	125	22	drop	drop	VERB
bptjm-17	125	23	signi	signi	ADV
bptjm-17	125	24	cantly	cantly	ADV
bptjm-17	125	25	in	in	ADP
bptjm-17	125	26	one	one	NUM
bptjm-17	125	27	study	study	NOUN
bptjm-17	125	28	when	when	SCONJ
bptjm-17	125	29	analysis	analysis	NOUN
bptjm-17	125	30	was	be	AUX
bptjm-17	125	31	limited	limit	VERB
bptjm-17	125	32	to	to	ADP
bptjm-17	125	33	speci	speci	PROPN
bptjm-17	125	34	c	c	PROPN
bptjm-17	125	35	subtypes	subtype	NOUN
bptjm-17	125	36	of	of	ADP
bptjm-17	125	37	genomic	genomic	NOUN
bptjm-17	125	38	alterations	alteration	NOUN
bptjm-17	125	39	,	,	PUNCT
bptjm-17	125	40	such	such	ADJ
bptjm-17	125	41	as	as	ADP
bptjm-17	125	42	copy	copy	NOUN
bptjm-17	125	43	number	number	NOUN
bptjm-17	125	44	variations	variation	NOUN
bptjm-17	125	45	,	,	PUNCT
bptjm-17	125	46	which	which	PRON
bptjm-17	125	47	demonstrated	demonstrate	VERB
bptjm-17	125	48	concordance	concordance	NOUN
bptjm-17	125	49	rates	rate	NOUN
bptjm-17	125	50	as	as	ADV
bptjm-17	125	51	low	low	ADJ
bptjm-17	125	52	as	as	ADP
bptjm-17	125	53	3.5	3.5	NUM
bptjm-17	125	54	%	%	NOUN
bptjm-17	125	55	;	;	PUNCT
bptjm-17	125	56	however	however	ADV
bptjm-17	125	57	,	,	PUNCT
bptjm-17	125	58	sample	sample	NOUN
bptjm-17	125	59	size	size	NOUN
bptjm-17	125	60	in	in	ADP
bptjm-17	125	61	this	this	DET
bptjm-17	125	62	cohort	cohort	NOUN
bptjm-17	125	63	was	be	AUX
bptjm-17	125	64	limited	limit	VERB
bptjm-17	125	65	to	to	ADP
bptjm-17	125	66	45	45	NUM
bptjm-17	125	67	patients	patient	NOUN
bptjm-17	125	68	(	(	PUNCT
bptjm-17	125	69	chae	chae	PROPN
bptjm-17	125	70	et	et	PROPN
bptjm-17	125	71	al	al	PROPN
bptjm-17	125	72	.	.	PROPN
bptjm-17	125	73	,	,	PUNCT
bptjm-17	125	74	2017	2017	NUM
bptjm-17	125	75	)	)	PUNCT
bptjm-17	125	76	.	.	PUNCT
bptjm-17	126	1	the	the	DET
bptjm-17	126	2	variability	variability	NOUN
bptjm-17	126	3	in	in	ADP
bptjm-17	126	4	concordance	concordance	NOUN
bptjm-17	126	5	rates	rate	NOUN
bptjm-17	126	6	between	between	ADP
bptjm-17	126	7	ctdna	ctdna	NOUN
bptjm-17	126	8	and	and	CCONJ
bptjm-17	126	9	tissue	tissue	NOUN
bptjm-17	126	10	biopsy	biopsy	NOUN
bptjm-17	126	11	shows	show	VERB
bptjm-17	126	12	that	that	SCONJ
bptjm-17	126	13	further	further	ADJ
bptjm-17	126	14	analysis	analysis	NOUN
bptjm-17	126	15	is	be	AUX
bptjm-17	126	16	required	require	VERB
bptjm-17	126	17	to	to	PART
bptjm-17	126	18	determine	determine	VERB
bptjm-17	126	19	whether	whether	SCONJ
bptjm-17	126	20	ctdna	ctdna	NOUN
bptjm-17	126	21	is	be	AUX
bptjm-17	126	22	a	a	DET
bptjm-17	126	23	viable	viable	ADJ
bptjm-17	126	24	standalone	standalone	NOUN
bptjm-17	126	25	method	method	NOUN
bptjm-17	126	26	of	of	ADP
bptjm-17	126	27	detection	detection	NOUN
bptjm-17	126	28	for	for	ADP
bptjm-17	126	29	ret	ret	NOUN
bptjm-17	126	30	-	-	PUNCT
bptjm-17	126	31	altered	alter	VERB
bptjm-17	126	32	cancers	cancer	NOUN
bptjm-17	126	33	,	,	PUNCT
bptjm-17	126	34	given	give	VERB
bptjm-17	126	35	that	that	SCONJ
bptjm-17	126	36	ret	ret	PROPN
bptjm-17	126	37	mutations	mutation	NOUN
bptjm-17	126	38	are	be	AUX
bptjm-17	126	39	included	include	VERB
bptjm-17	126	40	in	in	ADP
bptjm-17	126	41	the	the	DET
bptjm-17	126	42	national	national	ADJ
bptjm-17	126	43	comprehensive	comprehensive	ADJ
bptjm-17	126	44	cancer	cancer	NOUN
bptjm-17	126	45	network	network	NOUN
bptjm-17	126	46	’s	’s	PART
bptjm-17	126	47	recommendation	recommendation	NOUN
bptjm-17	126	48	for	for	ADP
bptjm-17	126	49	genomic	genomic	ADJ
bptjm-17	126	50	targets	target	NOUN
bptjm-17	126	51	in	in	ADP
bptjm-17	126	52	nsclc	nsclc	NOUN
bptjm-17	126	53	(	(	PUNCT
bptjm-17	126	54	yang	yang	PROPN
bptjm-17	126	55	et	et	PROPN
bptjm-17	126	56	al	al	PROPN
bptjm-17	126	57	.	.	PROPN
bptjm-17	126	58	,	,	PUNCT
bptjm-17	126	59	2018	2018	NUM
bptjm-17	126	60	;	;	PUNCT
bptjm-17	126	61	thompson	thompson	PROPN
bptjm-17	126	62	et	et	PROPN
bptjm-17	126	63	al	al	PROPN
bptjm-17	126	64	.	.	PROPN
bptjm-17	126	65	,	,	PUNCT
bptjm-17	126	66	2016	2016	NUM
bptjm-17	126	67	)	)	PUNCT
bptjm-17	126	68	.	.	PUNCT
bptjm-17	127	1	erbb2	erbb2	PROPN
bptjm-17	127	2	(	(	PUNCT
bptjm-17	127	3	her2	her2	PROPN
bptjm-17	127	4	)	)	PUNCT
bptjm-17	127	5	erb	erb	ADJ
bptjm-17	127	6	-	-	PUNCT
bptjm-17	127	7	b2	b2	NOUN
bptjm-17	127	8	receptor	receptor	NOUN
bptjm-17	127	9	tyrosine	tyrosine	NOUN
bptjm-17	127	10	kinase	kinase	NOUN
bptjm-17	127	11	2	2	NUM
bptjm-17	127	12	(	(	PUNCT
bptjm-17	127	13	erbb2	erbb2	PROPN
bptjm-17	127	14	)	)	PUNCT
bptjm-17	127	15	,	,	PUNCT
bptjm-17	127	16	human	human	ADJ
bptjm-17	127	17	epidermal	epidermal	ADJ
bptjm-17	127	18	growth	growth	NOUN
bptjm-17	127	19	factor	factor	NOUN
bptjm-17	127	20	receptor	receptor	NOUN
bptjm-17	127	21	2	2	NUM
bptjm-17	127	22	(	(	PUNCT
bptjm-17	127	23	her2	her2	PROPN
bptjm-17	127	24	)	)	PUNCT
bptjm-17	127	25	,	,	PUNCT
bptjm-17	127	26	has	have	AUX
bptjm-17	127	27	become	become	AUX
bptjm-17	127	28	widely	widely	ADV
bptjm-17	127	29	acknowledged	acknowledge	VERB
bptjm-17	127	30	as	as	ADP
bptjm-17	127	31	a	a	DET
bptjm-17	127	32	potential	potential	ADJ
bptjm-17	127	33	berkeley	berkeley	PROPN
bptjm-17	127	34	pharma	pharma	PROPN
bptjm-17	127	35	tech	tech	NOUN
bptjm-17	127	36	journal	journal	NOUN
bptjm-17	127	37	of	of	ADP
bptjm-17	127	38	medicine	medicine	NOUN
bptjm-17	127	39	|	|	ADV
bptjm-17	127	40	124	124	NUM
bptjm-17	127	41	target	target	NOUN
bptjm-17	127	42	for	for	ADP
bptjm-17	127	43	therapy	therapy	NOUN
bptjm-17	127	44	(	(	PUNCT
bptjm-17	127	45	kirs	kir	NOUN
bptjm-17	127	46	et	et	PROPN
bptjm-17	127	47	al	al	PROPN
bptjm-17	127	48	.	.	PROPN
bptjm-17	127	49	,	,	PUNCT
bptjm-17	127	50	2015	2015	NUM
bptjm-17	127	51	;	;	PUNCT
bptjm-17	128	1	chuang	chuang	PROPN
bptjm-17	128	2	et	et	PROPN
bptjm-17	128	3	al	al	PROPN
bptjm-17	128	4	.	.	PROPN
bptjm-17	128	5	,	,	PUNCT
bptjm-17	128	6	2017	2017	NUM
bptjm-17	128	7	)	)	PUNCT
bptjm-17	128	8	.	.	PUNCT
bptjm-17	129	1	while	while	SCONJ
bptjm-17	129	2	alterations	alteration	NOUN
bptjm-17	129	3	in	in	ADP
bptjm-17	129	4	erbb2	erbb2	PROPN
bptjm-17	129	5	/	/	SYM
bptjm-17	129	6	her2	her2	PROPN
bptjm-17	129	7	have	have	AUX
bptjm-17	129	8	primarily	primarily	ADV
bptjm-17	129	9	been	be	AUX
bptjm-17	129	10	studied	study	VERB
bptjm-17	129	11	in	in	ADP
bptjm-17	129	12	breast	breast	NOUN
bptjm-17	129	13	cancer	cancer	NOUN
bptjm-17	129	14	,	,	PUNCT
bptjm-17	129	15	recent	recent	ADJ
bptjm-17	129	16	research	research	NOUN
bptjm-17	129	17	has	have	AUX
bptjm-17	129	18	assessed	assess	VERB
bptjm-17	129	19	the	the	DET
bptjm-17	129	20	potential	potential	NOUN
bptjm-17	129	21	for	for	ADP
bptjm-17	129	22	targeted	target	VERB
bptjm-17	129	23	therapies	therapy	NOUN
bptjm-17	129	24	in	in	ADP
bptjm-17	129	25	treating	treat	VERB
bptjm-17	129	26	erbb2	erbb2	PROPN
bptjm-17	129	27	/	/	SYM
bptjm-17	129	28	her2positive	her2positive	PROPN
bptjm-17	129	29	lung	lung	NOUN
bptjm-17	129	30	cancers	cancer	NOUN
bptjm-17	129	31	(	(	PUNCT
bptjm-17	129	32	de	de	X
bptjm-17	129	33	melo	melo	PROPN
bptjm-17	129	34	gagliato	gagliato	PROPN
bptjm-17	129	35	et	et	PROPN
bptjm-17	129	36	al	al	PROPN
bptjm-17	129	37	.	.	PROPN
bptjm-17	129	38	,	,	PUNCT
bptjm-17	129	39	2016	2016	NUM
bptjm-17	129	40	;	;	PUNCT
bptjm-17	129	41	chuang	chuang	PROPN
bptjm-17	129	42	et	et	PROPN
bptjm-17	129	43	al	al	PROPN
bptjm-17	129	44	.	.	PROPN
bptjm-17	129	45	,	,	PUNCT
bptjm-17	129	46	2017	2017	NUM
bptjm-17	129	47	;	;	PUNCT
bptjm-17	129	48	veatch	veatch	NOUN
bptjm-17	129	49	et	et	PROPN
bptjm-17	129	50	al	al	PROPN
bptjm-17	129	51	.	.	PROPN
bptjm-17	129	52	,	,	PUNCT
bptjm-17	129	53	2019	2019	NUM
bptjm-17	129	54	)	)	PUNCT
bptjm-17	129	55	.	.	PUNCT
bptjm-17	130	1	some	some	DET
bptjm-17	130	2	studies	study	NOUN
bptjm-17	130	3	have	have	AUX
bptjm-17	130	4	shown	show	VERB
bptjm-17	130	5	that	that	PRON
bptjm-17	130	6	her2	her2	VERB
bptjm-17	130	7	commonly	commonly	ADV
bptjm-17	130	8	presents	present	VERB
bptjm-17	130	9	in	in	ADP
bptjm-17	130	10	female	female	ADJ
bptjm-17	130	11	patients	patient	NOUN
bptjm-17	130	12	with	with	ADP
bptjm-17	130	13	adenocarcinoma	adenocarcinoma	NOUN
bptjm-17	130	14	histology	histology	NOUN
bptjm-17	130	15	with	with	ADP
bptjm-17	130	16	no	no	DET
bptjm-17	130	17	history	history	NOUN
bptjm-17	130	18	of	of	ADP
bptjm-17	130	19	smoking	smoking	NOUN
bptjm-17	130	20	(	(	PUNCT
bptjm-17	130	21	garrido	garrido	X
bptjm-17	130	22	-	-	PUNCT
bptjm-17	130	23	castro	castro	PROPN
bptjm-17	130	24	and	and	CCONJ
bptjm-17	130	25	enriqueta	enriqueta	ADV
bptjm-17	130	26	felip	felip	PROPN
bptjm-17	130	27	,	,	PUNCT
bptjm-17	130	28	2004	2004	NUM
bptjm-17	130	29	)	)	PUNCT
bptjm-17	130	30	.	.	PUNCT
bptjm-17	131	1	erbb2	erbb2	PROPN
bptjm-17	131	2	/	/	SYM
bptjm-17	131	3	her2	her2	PROPN
bptjm-17	131	4	receptors	receptor	NOUN
bptjm-17	131	5	can	can	AUX
bptjm-17	131	6	also	also	ADV
bptjm-17	131	7	be	be	AUX
bptjm-17	131	8	phosphorylated	phosphorylate	VERB
bptjm-17	131	9	to	to	PART
bptjm-17	131	10	form	form	VERB
bptjm-17	131	11	heterodimers	heterodimer	NOUN
bptjm-17	131	12	with	with	ADP
bptjm-17	131	13	other	other	ADJ
bptjm-17	131	14	epidermal	epidermal	ADJ
bptjm-17	131	15	growth	growth	NOUN
bptjm-17	131	16	factor	factor	NOUN
bptjm-17	131	17	receptors	receptor	NOUN
bptjm-17	131	18	(	(	PUNCT
bptjm-17	131	19	egfr	egfr	NOUN
bptjm-17	131	20	)	)	PUNCT
bptjm-17	131	21	,	,	PUNCT
bptjm-17	131	22	such	such	ADJ
bptjm-17	131	23	as	as	ADP
bptjm-17	131	24	her1	her1	NOUN
bptjm-17	131	25	,	,	PUNCT
bptjm-17	131	26	and	and	CCONJ
bptjm-17	131	27	play	play	VERB
bptjm-17	131	28	a	a	DET
bptjm-17	131	29	critical	critical	ADJ
bptjm-17	131	30	role	role	NOUN
bptjm-17	131	31	in	in	ADP
bptjm-17	131	32	signaling	signal	VERB
bptjm-17	131	33	pathways	pathway	NOUN
bptjm-17	131	34	that	that	PRON
bptjm-17	131	35	regulate	regulate	VERB
bptjm-17	131	36	transcription	transcription	NOUN
bptjm-17	131	37	,	,	PUNCT
bptjm-17	131	38	cell	cell	NOUN
bptjm-17	131	39	proliferation	proliferation	NOUN
bptjm-17	131	40	,	,	PUNCT
bptjm-17	131	41	and	and	CCONJ
bptjm-17	131	42	prevention	prevention	NOUN
bptjm-17	131	43	of	of	ADP
bptjm-17	131	44	apoptosis	apoptosis	NOUN
bptjm-17	131	45	(	(	PUNCT
bptjm-17	131	46	de	de	X
bptjm-17	131	47	melo	melo	PROPN
bptjm-17	131	48	gagliato	gagliato	PROPN
bptjm-17	131	49	et	et	PROPN
bptjm-17	131	50	al	al	PROPN
bptjm-17	131	51	.	.	PROPN
bptjm-17	131	52	,	,	PUNCT
bptjm-17	131	53	2016	2016	NUM
bptjm-17	131	54	)	)	PUNCT
bptjm-17	131	55	.	.	PUNCT
bptjm-17	132	1	approximately	approximately	ADV
bptjm-17	132	2	1	1	NUM
bptjm-17	132	3	-	-	SYM
bptjm-17	132	4	5	5	NUM
bptjm-17	132	5	%	%	NOUN
bptjm-17	132	6	of	of	ADP
bptjm-17	132	7	lung	lung	NOUN
bptjm-17	132	8	cancers	cancer	NOUN
bptjm-17	132	9	were	be	AUX
bptjm-17	132	10	found	find	VERB
bptjm-17	132	11	to	to	PART
bptjm-17	132	12	harbor	harbor	VERB
bptjm-17	132	13	erbb2/	erbb2/	PROPN
bptjm-17	132	14	her2	her2	VERB
bptjm-17	132	15	aberrations	aberration	NOUN
bptjm-17	132	16	,	,	PUNCT
bptjm-17	132	17	but	but	CCONJ
bptjm-17	132	18	some	some	DET
bptjm-17	132	19	studies	study	NOUN
bptjm-17	132	20	have	have	AUX
bptjm-17	132	21	demonstrated	demonstrate	VERB
bptjm-17	132	22	that	that	SCONJ
bptjm-17	132	23	the	the	DET
bptjm-17	132	24	percentage	percentage	NOUN
bptjm-17	132	25	for	for	ADP
bptjm-17	132	26	the	the	DET
bptjm-17	132	27	nsclc	nsclc	NOUN
bptjm-17	132	28	subtype	subtype	NOUN
bptjm-17	132	29	likely	likely	ADV
bptjm-17	132	30	lies	lie	VERB
bptjm-17	132	31	between	between	ADP
bptjm-17	132	32	1	1	NUM
bptjm-17	132	33	-	-	SYM
bptjm-17	132	34	2	2	NUM
bptjm-17	132	35	%	%	NOUN
bptjm-17	132	36	(	(	PUNCT
bptjm-17	132	37	kris	kris	PROPN
bptjm-17	132	38	et	et	PROPN
bptjm-17	132	39	al	al	PROPN
bptjm-17	132	40	.	.	PROPN
bptjm-17	132	41	,	,	PUNCT
bptjm-17	132	42	2015	2015	NUM
bptjm-17	132	43	;	;	PUNCT
bptjm-17	132	44	chuang	chuang	PROPN
bptjm-17	132	45	et	et	PROPN
bptjm-17	132	46	al	al	PROPN
bptjm-17	132	47	.	.	PROPN
bptjm-17	132	48	,	,	PUNCT
bptjm-17	132	49	2017	2017	NUM
bptjm-17	132	50	)	)	PUNCT
bptjm-17	132	51	.	.	PUNCT
bptjm-17	133	1	regarding	regard	VERB
bptjm-17	133	2	detection	detection	NOUN
bptjm-17	133	3	methods	method	NOUN
bptjm-17	133	4	,	,	PUNCT
bptjm-17	133	5	mao	mao	NOUN
bptjm-17	133	6	et	et	PROPN
bptjm-17	133	7	al	al	PROPN
bptjm-17	133	8	.	.	PROPN
bptjm-17	133	9	demonstrated	demonstrate	VERB
bptjm-17	133	10	that	that	SCONJ
bptjm-17	133	11	erbb2	erbb2	PROPN
bptjm-17	133	12	,	,	PUNCT
bptjm-17	133	13	along	along	ADP
bptjm-17	133	14	with	with	ADP
bptjm-17	133	15	other	other	ADJ
bptjm-17	133	16	driver	driver	NOUN
bptjm-17	133	17	genes	gene	NOUN
bptjm-17	133	18	,	,	PUNCT
bptjm-17	133	19	exhibits	exhibit	VERB
bptjm-17	133	20	a	a	DET
bptjm-17	133	21	96.2	96.2	NUM
bptjm-17	133	22	%	%	NOUN
bptjm-17	133	23	concordance	concordance	NOUN
bptjm-17	133	24	between	between	ADP
bptjm-17	133	25	tissue	tissue	NOUN
bptjm-17	133	26	and	and	CCONJ
bptjm-17	133	27	liquid	liquid	ADJ
bptjm-17	133	28	biopsy	biopsy	NOUN
bptjm-17	133	29	methods	method	NOUN
bptjm-17	133	30	(	(	PUNCT
bptjm-17	133	31	2017	2017	NUM
bptjm-17	133	32	)	)	PUNCT
bptjm-17	133	33	.	.	PUNCT
bptjm-17	134	1	chuang	chuang	PROPN
bptjm-17	134	2	et	et	PROPN
bptjm-17	134	3	al	al	PROPN
bptjm-17	134	4	.	.	PROPN
bptjm-17	134	5	performed	perform	VERB
bptjm-17	134	6	a	a	DET
bptjm-17	134	7	retrospective	retrospective	ADJ
bptjm-17	134	8	assessment	assessment	NOUN
bptjm-17	134	9	with	with	ADP
bptjm-17	134	10	nine	nine	NUM
bptjm-17	134	11	patients	patient	NOUN
bptjm-17	134	12	,	,	PUNCT
bptjm-17	134	13	seven	seven	NUM
bptjm-17	134	14	of	of	ADP
bptjm-17	134	15	whom	whom	PRON
bptjm-17	134	16	presented	present	VERB
bptjm-17	134	17	with	with	ADP
bptjm-17	134	18	erbb2	erbb2	ADJ
bptjm-17	134	19	mutations	mutation	NOUN
bptjm-17	134	20	and	and	CCONJ
bptjm-17	134	21	advanced	advanced	ADJ
bptjm-17	134	22	nsclc	nsclc	NOUN
bptjm-17	134	23	between	between	ADP
bptjm-17	134	24	2013	2013	NUM
bptjm-17	134	25	-	-	SYM
bptjm-17	134	26	2016	2016	NUM
bptjm-17	134	27	and	and	CCONJ
bptjm-17	134	28	two	two	NUM
bptjm-17	134	29	of	of	ADP
bptjm-17	134	30	whom	whom	PRON
bptjm-17	134	31	met	meet	VERB
bptjm-17	134	32	similar	similar	ADJ
bptjm-17	134	33	criteria	criterion	NOUN
bptjm-17	134	34	from	from	ADP
bptjm-17	134	35	a	a	DET
bptjm-17	134	36	2014	2014	NUM
bptjm-17	134	37	-	-	SYM
bptjm-17	134	38	2015	2015	NUM
bptjm-17	134	39	cohort	cohort	NOUN
bptjm-17	134	40	.	.	PUNCT
bptjm-17	135	1	all	all	DET
bptjm-17	135	2	patients	patient	NOUN
bptjm-17	135	3	were	be	AUX
bptjm-17	135	4	treated	treat	VERB
bptjm-17	135	5	with	with	ADP
bptjm-17	135	6	a	a	DET
bptjm-17	135	7	regimen	regimen	NOUN
bptjm-17	135	8	of	of	ADP
bptjm-17	135	9	paclitaxel	paclitaxel	PROPN
bptjm-17	135	10	,	,	PUNCT
bptjm-17	135	11	vinorelbine	vinorelbine	NOUN
bptjm-17	135	12	,	,	PUNCT
bptjm-17	135	13	and	and	CCONJ
bptjm-17	135	14	trastuzumab	trastuzumab	NOUN
bptjm-17	135	15	.	.	PUNCT
bptjm-17	136	1	to	to	PART
bptjm-17	136	2	pinpoint	pinpoint	VERB
bptjm-17	136	3	erbb2	erbb2	ADJ
bptjm-17	136	4	mutations	mutation	NOUN
bptjm-17	136	5	,	,	PUNCT
bptjm-17	136	6	ngs	ng	NOUN
bptjm-17	136	7	-	-	PUNCT
bptjm-17	136	8	based	base	VERB
bptjm-17	136	9	methods	method	NOUN
bptjm-17	136	10	solid	solid	ADJ
bptjm-17	136	11	tumor	tumor	NOUN
bptjm-17	136	12	actionable	actionable	ADJ
bptjm-17	136	13	mutation	mutation	NOUN
bptjm-17	136	14	panel	panel	NOUN
bptjm-17	136	15	,	,	PUNCT
bptjm-17	136	16	pcr	pcr	NOUN
bptjm-17	136	17	-	-	PUNCT
bptjm-17	136	18	based	base	VERB
bptjm-17	136	19	erbb2	erbb2	PROPN
bptjm-17	136	20	sizing	sizing	PROPN
bptjm-17	136	21	assay	assay	NOUN
bptjm-17	136	22	,	,	PUNCT
bptjm-17	136	23	geneseq	geneseq	NOUN
bptjm-17	136	24	assay	assay	NOUN
bptjm-17	136	25	,	,	PUNCT
bptjm-17	136	26	or	or	CCONJ
bptjm-17	136	27	ngs	ng	NOUN
bptjm-17	136	28	-	-	PUNCT
bptjm-17	136	29	based	base	VERB
bptjm-17	136	30	foundationone	foundationone	NOUN
bptjm-17	136	31	assay	assay	NOUN
bptjm-17	136	32	were	be	AUX
bptjm-17	136	33	executed	execute	VERB
bptjm-17	136	34	on	on	ADP
bptjm-17	136	35	tissue	tissue	NOUN
bptjm-17	136	36	samples	sample	NOUN
bptjm-17	136	37	,	,	PUNCT
bptjm-17	136	38	while	while	SCONJ
bptjm-17	136	39	ngs	ng	NOUN
bptjm-17	136	40	-	-	PUNCT
bptjm-17	136	41	based	base	VERB
bptjm-17	136	42	pro	pro	ADJ
bptjm-17	136	43	ling	ling	NOUN
bptjm-17	136	44	using	use	VERB
bptjm-17	136	45	deep	deep	ADJ
bptjm-17	136	46	sequencing	sequencing	NOUN
bptjm-17	136	47	was	be	AUX
bptjm-17	136	48	performed	perform	VERB
bptjm-17	136	49	on	on	ADP
bptjm-17	136	50	ctdna	ctdna	NOUN
bptjm-17	136	51	samples	sample	NOUN
bptjm-17	136	52	.	.	PUNCT
bptjm-17	137	1	therapeutic	therapeutic	ADJ
bptjm-17	137	2	response	response	NOUN
bptjm-17	137	3	was	be	AUX
bptjm-17	137	4	assessed	assess	VERB
bptjm-17	137	5	according	accord	VERB
bptjm-17	137	6	to	to	ADP
bptjm-17	137	7	response	response	NOUN
bptjm-17	137	8	evaluation	evaluation	NOUN
bptjm-17	137	9	criteria	criterion	NOUN
bptjm-17	137	10	in	in	ADP
bptjm-17	137	11	solid	solid	ADJ
bptjm-17	137	12	tumors	tumor	NOUN
bptjm-17	137	13	(	(	PUNCT
bptjm-17	137	14	recist	recist	NOUN
bptjm-17	137	15	)	)	PUNCT
bptjm-17	137	16	version	version	NOUN
bptjm-17	137	17	1.1	1.1	NUM
bptjm-17	137	18	.	.	PUNCT
bptjm-17	138	1	the	the	DET
bptjm-17	138	2	results	result	NOUN
bptjm-17	138	3	of	of	ADP
bptjm-17	138	4	this	this	DET
bptjm-17	138	5	study	study	NOUN
bptjm-17	138	6	demonstrated	demonstrate	VERB
bptjm-17	138	7	that	that	SCONJ
bptjm-17	138	8	44	44	NUM
bptjm-17	138	9	%	%	NOUN
bptjm-17	138	10	of	of	ADP
bptjm-17	138	11	the	the	DET
bptjm-17	138	12	patients	patient	NOUN
bptjm-17	138	13	exhibited	exhibit	VERB
bptjm-17	138	14	response	response	NOUN
bptjm-17	138	15	to	to	ADP
bptjm-17	138	16	targeted	target	VERB
bptjm-17	138	17	therapies	therapy	NOUN
bptjm-17	138	18	.	.	PUNCT
bptjm-17	139	1	although	although	SCONJ
bptjm-17	139	2	the	the	DET
bptjm-17	139	3	sample	sample	NOUN
bptjm-17	139	4	size	size	NOUN
bptjm-17	139	5	was	be	AUX
bptjm-17	139	6	small	small	ADJ
bptjm-17	139	7	,	,	PUNCT
bptjm-17	139	8	clinical	clinical	ADJ
bptjm-17	139	9	indications	indication	NOUN
bptjm-17	139	10	and	and	CCONJ
bptjm-17	139	11	availability	availability	NOUN
bptjm-17	139	12	of	of	ADP
bptjm-17	139	13	targeted	target	VERB
bptjm-17	139	14	therapies	therapy	NOUN
bptjm-17	139	15	for	for	ADP
bptjm-17	139	16	erbb2/	erbb2/	PROPN
bptjm-17	139	17	her2	her2	NOUN
bptjm-17	139	18	may	may	AUX
bptjm-17	139	19	warrant	warrant	VERB
bptjm-17	139	20	the	the	DET
bptjm-17	139	21	use	use	NOUN
bptjm-17	139	22	of	of	ADP
bptjm-17	139	23	these	these	DET
bptjm-17	139	24	treatments	treatment	NOUN
bptjm-17	139	25	.	.	PUNCT
bptjm-17	140	1	the	the	DET
bptjm-17	140	2	authors	author	NOUN
bptjm-17	140	3	caution	caution	VERB
bptjm-17	140	4	that	that	SCONJ
bptjm-17	140	5	genotypic	genotypic	NOUN
bptjm-17	140	6	di	di	NOUN
bptjm-17	140	7	erences	erence	NOUN
bptjm-17	140	8	in	in	ADP
bptjm-17	140	9	erbb2	erbb2	ADJ
bptjm-17	140	10	mutations	mutation	NOUN
bptjm-17	140	11	may	may	AUX
bptjm-17	140	12	result	result	VERB
bptjm-17	140	13	in	in	ADP
bptjm-17	140	14	di	di	X
bptjm-17	140	15	erential	erential	ADJ
bptjm-17	140	16	e	e	PROPN
bptjm-17	140	17	cacy	cacy	NOUN
bptjm-17	140	18	of	of	ADP
bptjm-17	140	19	targeted	target	VERB
bptjm-17	140	20	therapies	therapy	NOUN
bptjm-17	140	21	.	.	PUNCT
bptjm-17	141	1	trastuzumab	trastuzumab	NOUN
bptjm-17	141	2	in	in	ADP
bptjm-17	141	3	conjunction	conjunction	NOUN
bptjm-17	141	4	with	with	ADP
bptjm-17	141	5	chemotherapy	chemotherapy	NOUN
bptjm-17	141	6	has	have	AUX
bptjm-17	141	7	demonstrated	demonstrate	VERB
bptjm-17	141	8	therapeutic	therapeutic	ADJ
bptjm-17	141	9	promise	promise	NOUN
bptjm-17	141	10	in	in	ADP
bptjm-17	141	11	clinical	clinical	ADJ
bptjm-17	141	12	settings	setting	NOUN
bptjm-17	141	13	,	,	PUNCT
bptjm-17	141	14	although	although	SCONJ
bptjm-17	141	15	it	it	PRON
bptjm-17	141	16	has	have	AUX
bptjm-17	141	17	not	not	PART
bptjm-17	141	18	been	be	AUX
bptjm-17	141	19	shown	show	VERB
bptjm-17	141	20	to	to	PART
bptjm-17	141	21	penetrate	penetrate	VERB
bptjm-17	141	22	the	the	DET
bptjm-17	141	23	blood	blood	NOUN
bptjm-17	141	24	-	-	PUNCT
bptjm-17	141	25	brain	brain	NOUN
bptjm-17	141	26	barrier	barrier	NOUN
bptjm-17	141	27	,	,	PUNCT
bptjm-17	141	28	rendering	render	VERB
bptjm-17	141	29	it	it	PRON
bptjm-17	141	30	less	less	ADV
bptjm-17	141	31	useful	useful	ADJ
bptjm-17	141	32	for	for	ADP
bptjm-17	141	33	metastases	metastasis	NOUN
bptjm-17	141	34	to	to	ADP
bptjm-17	141	35	the	the	DET
bptjm-17	141	36	brain	brain	NOUN
bptjm-17	141	37	and	and	CCONJ
bptjm-17	141	38	spinal	spinal	ADJ
bptjm-17	141	39	cord	cord	NOUN
bptjm-17	141	40	.	.	PUNCT
bptjm-17	142	1	other	other	ADJ
bptjm-17	142	2	potential	potential	ADJ
bptjm-17	142	3	therapies	therapy	NOUN
bptjm-17	142	4	include	include	VERB
bptjm-17	142	5	dacomitinib	dacomitinib	NOUN
bptjm-17	142	6	and	and	CCONJ
bptjm-17	142	7	neratinib	neratinib	NOUN
bptjm-17	142	8	(	(	PUNCT
bptjm-17	142	9	nct01953926	nct01953926	NOUN
bptjm-17	142	10	)	)	PUNCT
bptjm-17	142	11	(	(	PUNCT
bptjm-17	142	12	chuang	chuang	PROPN
bptjm-17	142	13	et	et	PROPN
bptjm-17	142	14	al	al	PROPN
bptjm-17	142	15	.	.	PROPN
bptjm-17	142	16	,	,	PUNCT
bptjm-17	142	17	2017	2017	NUM
bptjm-17	142	18	)	)	PUNCT
bptjm-17	142	19	.	.	PUNCT
bptjm-17	143	1	berkeley	berkeley	PROPN
bptjm-17	143	2	pharma	pharma	PROPN
bptjm-17	143	3	tech	tech	PROPN
bptjm-17	143	4	journal	journal	NOUN
bptjm-17	143	5	of	of	ADP
bptjm-17	143	6	medicine	medicine	NOUN
bptjm-17	143	7	|125	|125	PUNCT
bptjm-17	144	1	in	in	ADP
bptjm-17	144	2	conjunction	conjunction	NOUN
bptjm-17	144	3	with	with	ADP
bptjm-17	144	4	targeted	target	VERB
bptjm-17	144	5	therapies	therapy	NOUN
bptjm-17	144	6	,	,	PUNCT
bptjm-17	144	7	detection	detection	NOUN
bptjm-17	144	8	remains	remain	VERB
bptjm-17	144	9	a	a	DET
bptjm-17	144	10	critical	critical	ADJ
bptjm-17	144	11	factor	factor	NOUN
bptjm-17	144	12	in	in	ADP
bptjm-17	144	13	prognosis	prognosis	NOUN
bptjm-17	144	14	.	.	PUNCT
bptjm-17	145	1	early	early	ADJ
bptjm-17	145	2	detection	detection	NOUN
bptjm-17	145	3	is	be	AUX
bptjm-17	145	4	optimal	optimal	ADJ
bptjm-17	145	5	,	,	PUNCT
bptjm-17	145	6	but	but	CCONJ
bptjm-17	145	7	tissue	tissue	NOUN
bptjm-17	145	8	sampling	sampling	NOUN
bptjm-17	145	9	can	can	AUX
bptjm-17	145	10	be	be	AUX
bptjm-17	145	11	di	di	NOUN
bptjm-17	145	12	cult	cult	NOUN
bptjm-17	145	13	at	at	ADP
bptjm-17	145	14	certain	certain	ADJ
bptjm-17	145	15	periods	period	NOUN
bptjm-17	145	16	of	of	ADP
bptjm-17	145	17	cancer	cancer	NOUN
bptjm-17	145	18	development	development	NOUN
bptjm-17	145	19	.	.	PUNCT
bptjm-17	146	1	as	as	ADP
bptjm-17	146	2	such	such	ADJ
bptjm-17	146	3	,	,	PUNCT
bptjm-17	146	4	ctdna	ctdna	NOUN
bptjm-17	146	5	analysis	analysis	NOUN
bptjm-17	146	6	may	may	AUX
bptjm-17	146	7	provide	provide	VERB
bptjm-17	146	8	a	a	DET
bptjm-17	146	9	reliable	reliable	ADJ
bptjm-17	146	10	baseline	baseline	NOUN
bptjm-17	146	11	for	for	ADP
bptjm-17	146	12	determining	determine	VERB
bptjm-17	146	13	tumor	tumor	ADJ
bptjm-17	146	14	mutational	mutational	ADJ
bptjm-17	146	15	landscape	landscape	NOUN
bptjm-17	146	16	.	.	PUNCT
bptjm-17	147	1	in	in	ADP
bptjm-17	147	2	other	other	ADJ
bptjm-17	147	3	cancer	cancer	NOUN
bptjm-17	147	4	types	type	NOUN
bptjm-17	147	5	,	,	PUNCT
bptjm-17	147	6	such	such	ADJ
bptjm-17	147	7	as	as	ADP
bptjm-17	147	8	cholangiosarcoma	cholangiosarcoma	NOUN
bptjm-17	147	9	,	,	PUNCT
bptjm-17	147	10	ctdna	ctdna	NOUN
bptjm-17	147	11	analysis	analysis	NOUN
bptjm-17	147	12	resulted	result	VERB
bptjm-17	147	13	in	in	ADP
bptjm-17	147	14	the	the	DET
bptjm-17	147	15	successful	successful	ADJ
bptjm-17	147	16	detection	detection	NOUN
bptjm-17	147	17	of	of	ADP
bptjm-17	147	18	erbb2	erbb2	PROPN
bptjm-17	147	19	(	(	PUNCT
bptjm-17	147	20	her2	her2	PROPN
bptjm-17	147	21	)	)	PUNCT
bptjm-17	147	22	mutations	mutation	NOUN
bptjm-17	147	23	.	.	PUNCT
bptjm-17	148	1	liquid	liquid	ADJ
bptjm-17	148	2	biopsy	biopsy	NOUN
bptjm-17	148	3	was	be	AUX
bptjm-17	148	4	selected	select	VERB
bptjm-17	148	5	in	in	ADP
bptjm-17	148	6	one	one	NUM
bptjm-17	148	7	case	case	NOUN
bptjm-17	148	8	study	study	NOUN
bptjm-17	148	9	in	in	ADP
bptjm-17	148	10	lieu	lieu	NOUN
bptjm-17	148	11	of	of	ADP
bptjm-17	148	12	tissue	tissue	NOUN
bptjm-17	148	13	biopsy	biopsy	NOUN
bptjm-17	148	14	due	due	ADP
bptjm-17	148	15	to	to	ADP
bptjm-17	148	16	challenges	challenge	NOUN
bptjm-17	148	17	in	in	ADP
bptjm-17	148	18	tissue	tissue	NOUN
bptjm-17	148	19	acquisition	acquisition	NOUN
bptjm-17	148	20	.	.	PUNCT
bptjm-17	149	1	as	as	ADP
bptjm-17	149	2	a	a	DET
bptjm-17	149	3	result	result	NOUN
bptjm-17	149	4	of	of	ADP
bptjm-17	149	5	erbb2	erbb2	PROPN
bptjm-17	149	6	(	(	PUNCT
bptjm-17	149	7	her2	her2	PROPN
bptjm-17	149	8	)	)	PUNCT
bptjm-17	149	9	mutation	mutation	NOUN
bptjm-17	149	10	detection	detection	NOUN
bptjm-17	149	11	via	via	ADP
bptjm-17	149	12	liquid	liquid	ADJ
bptjm-17	149	13	biopsy	biopsy	NOUN
bptjm-17	149	14	,	,	PUNCT
bptjm-17	149	15	the	the	DET
bptjm-17	149	16	patient	patient	NOUN
bptjm-17	149	17	was	be	AUX
bptjm-17	149	18	able	able	ADJ
bptjm-17	149	19	to	to	PART
bptjm-17	149	20	begin	begin	VERB
bptjm-17	149	21	dual	dual	ADJ
bptjm-17	149	22	anti	anti	ADJ
bptjm-17	149	23	-	-	ADJ
bptjm-17	149	24	her2	her2	ADJ
bptjm-17	149	25	pertuzumab	pertuzumab	NOUN
bptjm-17	149	26	/	/	SYM
bptjm-17	149	27	trastuzumab	trastuzumab	NOUN
bptjm-17	149	28	therapy	therapy	NOUN
bptjm-17	149	29	as	as	ADP
bptjm-17	149	30	an	an	DET
bptjm-17	149	31	o	o	NOUN
bptjm-17	149	32	-label	-label	PROPN
bptjm-17	149	33	treatment	treatment	NOUN
bptjm-17	149	34	regimen	regiman	NOUN
bptjm-17	149	35	(	(	PUNCT
bptjm-17	149	36	yarlagadda	yarlagadda	NOUN
bptjm-17	149	37	et	et	PROPN
bptjm-17	149	38	al	al	PROPN
bptjm-17	149	39	.	.	PROPN
bptjm-17	149	40	,	,	PUNCT
bptjm-17	149	41	2019	2019	NUM
bptjm-17	149	42	)	)	PUNCT
bptjm-17	149	43	.	.	PUNCT
bptjm-17	150	1	another	another	DET
bptjm-17	150	2	study	study	NOUN
bptjm-17	150	3	in	in	ADP
bptjm-17	150	4	29	29	NUM
bptjm-17	150	5	colon	colon	NOUN
bptjm-17	150	6	cancer	cancer	NOUN
bptjm-17	150	7	patients	patient	NOUN
bptjm-17	150	8	demonstrated	demonstrate	VERB
bptjm-17	150	9	that	that	SCONJ
bptjm-17	150	10	proper	proper	ADJ
bptjm-17	150	11	clinically	clinically	ADV
bptjm-17	150	12	veri	veri	PROPN
bptjm-17	150	13	ed	ed	NOUN
bptjm-17	150	14	circulating	circulate	VERB
bptjm-17	150	15	free	free	ADJ
bptjm-17	150	16	tumor	tumor	NOUN
bptjm-17	150	17	dna	dna	PROPN
bptjm-17	150	18	analysis	analysis	NOUN
bptjm-17	150	19	may	may	AUX
bptjm-17	150	20	provide	provide	VERB
bptjm-17	150	21	a	a	DET
bptjm-17	150	22	method	method	NOUN
bptjm-17	150	23	of	of	ADP
bptjm-17	150	24	detection	detection	NOUN
bptjm-17	150	25	for	for	ADP
bptjm-17	150	26	her2	her2	PROPN
bptjm-17	150	27	copy	copy	VERB
bptjm-17	150	28	number	number	NOUN
bptjm-17	150	29	changes	change	NOUN
bptjm-17	150	30	(	(	PUNCT
bptjm-17	150	31	concordance	concordance	NOUN
bptjm-17	150	32	with	with	ADP
bptjm-17	150	33	tissue	tissue	NOUN
bptjm-17	150	34	equaled	equal	VERB
bptjm-17	150	35	96.6	96.6	NUM
bptjm-17	150	36	%	%	NOUN
bptjm-17	150	37	)	)	PUNCT
bptjm-17	150	38	,	,	PUNCT
bptjm-17	150	39	allowing	allow	VERB
bptjm-17	150	40	clinicians	clinician	NOUN
bptjm-17	150	41	to	to	PART
bptjm-17	150	42	identify	identify	VERB
bptjm-17	150	43	patients	patient	NOUN
bptjm-17	150	44	who	who	PRON
bptjm-17	150	45	may	may	AUX
bptjm-17	150	46	bene	bene	VERB
bptjm-17	150	47	t	t	PROPN
bptjm-17	150	48	from	from	ADP
bptjm-17	150	49	anti	anti	ADJ
bptjm-17	150	50	-	-	ADJ
bptjm-17	150	51	her2	her2	ADJ
bptjm-17	150	52	therapies	therapy	NOUN
bptjm-17	150	53	.	.	PUNCT
bptjm-17	151	1	in	in	ADP
bptjm-17	151	2	addition	addition	NOUN
bptjm-17	151	3	to	to	ADP
bptjm-17	151	4	high	high	ADJ
bptjm-17	151	5	concurrence	concurrence	NOUN
bptjm-17	151	6	rates	rate	NOUN
bptjm-17	151	7	,	,	PUNCT
bptjm-17	151	8	ctdna	ctdna	NOUN
bptjm-17	151	9	has	have	AUX
bptjm-17	151	10	also	also	ADV
bptjm-17	151	11	been	be	AUX
bptjm-17	151	12	suggested	suggest	VERB
bptjm-17	151	13	to	to	PART
bptjm-17	151	14	surmount	surmount	VERB
bptjm-17	151	15	the	the	DET
bptjm-17	151	16	issue	issue	NOUN
bptjm-17	151	17	of	of	ADP
bptjm-17	151	18	tumor	tumor	NOUN
bptjm-17	151	19	heterogeneity	heterogeneity	NOUN
bptjm-17	151	20	.	.	PUNCT
bptjm-17	152	1	nevertheless	nevertheless	ADV
bptjm-17	152	2	,	,	PUNCT
bptjm-17	152	3	more	more	ADJ
bptjm-17	152	4	studies	study	NOUN
bptjm-17	152	5	are	be	AUX
bptjm-17	152	6	required	require	VERB
bptjm-17	152	7	to	to	PART
bptjm-17	152	8	determine	determine	VERB
bptjm-17	152	9	whether	whether	SCONJ
bptjm-17	152	10	the	the	DET
bptjm-17	152	11	observed	observed	ADJ
bptjm-17	152	12	concordance	concordance	NOUN
bptjm-17	152	13	rates	rate	NOUN
bptjm-17	152	14	are	be	AUX
bptjm-17	152	15	a	a	DET
bptjm-17	152	16	ected	ecte	VERB
bptjm-17	152	17	by	by	ADP
bptjm-17	152	18	di	di	X
bptjm-17	152	19	erential	erential	ADJ
bptjm-17	152	20	release	release	NOUN
bptjm-17	152	21	of	of	ADP
bptjm-17	152	22	tumor	tumor	NOUN
bptjm-17	152	23	dna	dna	PROPN
bptjm-17	152	24	into	into	ADP
bptjm-17	152	25	circulation	circulation	NOUN
bptjm-17	152	26	(	(	PUNCT
bptjm-17	152	27	siravegna	siravegna	PROPN
bptjm-17	152	28	et	et	PROPN
bptjm-17	152	29	al	al	PROPN
bptjm-17	152	30	.	.	PROPN
bptjm-17	152	31	,	,	PUNCT
bptjm-17	152	32	2019	2019	NUM
bptjm-17	152	33	)	)	PUNCT
bptjm-17	152	34	.	.	PUNCT
bptjm-17	153	1	brca1/2	brca1/2	PROPN
bptjm-17	153	2	accurate	accurate	ADJ
bptjm-17	153	3	dna	dna	PROPN
bptjm-17	153	4	replication	replication	NOUN
bptjm-17	153	5	is	be	AUX
bptjm-17	153	6	integral	integral	ADJ
bptjm-17	153	7	to	to	ADP
bptjm-17	153	8	genomic	genomic	ADJ
bptjm-17	153	9	integrity	integrity	NOUN
bptjm-17	153	10	and	and	CCONJ
bptjm-17	153	11	protection	protection	NOUN
bptjm-17	153	12	against	against	ADP
bptjm-17	153	13	deleterious	deleterious	ADJ
bptjm-17	153	14	mutations	mutation	NOUN
bptjm-17	153	15	.	.	PUNCT
bptjm-17	154	1	the	the	DET
bptjm-17	154	2	brca1/2	brca1/2	PROPN
bptjm-17	154	3	genes	gene	NOUN
bptjm-17	154	4	work	work	VERB
bptjm-17	154	5	sequentially	sequentially	ADV
bptjm-17	154	6	to	to	PART
bptjm-17	154	7	ensure	ensure	VERB
bptjm-17	154	8	that	that	SCONJ
bptjm-17	154	9	this	this	DET
bptjm-17	154	10	integrity	integrity	NOUN
bptjm-17	154	11	is	be	AUX
bptjm-17	154	12	maintained	maintain	VERB
bptjm-17	154	13	,	,	PUNCT
bptjm-17	154	14	speci	speci	PROPN
bptjm-17	154	15	cally	cally	ADV
bptjm-17	154	16	by	by	ADP
bptjm-17	154	17	assisting	assist	VERB
bptjm-17	154	18	in	in	ADP
bptjm-17	154	19	dna	dna	PROPN
bptjm-17	154	20	lesion	lesion	NOUN
bptjm-17	154	21	repair	repair	NOUN
bptjm-17	154	22	.	.	PUNCT
bptjm-17	155	1	despite	despite	SCONJ
bptjm-17	155	2	deriving	derive	VERB
bptjm-17	155	3	its	its	PRON
bptjm-17	155	4	name	name	NOUN
bptjm-17	155	5	from	from	ADP
bptjm-17	155	6	its	its	PRON
bptjm-17	155	7	frequent	frequent	ADJ
bptjm-17	155	8	association	association	NOUN
bptjm-17	155	9	with	with	ADP
bptjm-17	155	10	breast	breast	NOUN
bptjm-17	155	11	cancer	cancer	NOUN
bptjm-17	155	12	,	,	PUNCT
bptjm-17	155	13	brca1/2	brca1/2	ADJ
bptjm-17	155	14	genes	gene	NOUN
bptjm-17	155	15	have	have	AUX
bptjm-17	155	16	also	also	ADV
bptjm-17	155	17	been	be	AUX
bptjm-17	155	18	implicated	implicate	VERB
bptjm-17	155	19	in	in	ADP
bptjm-17	155	20	nsclc	nsclc	NOUN
bptjm-17	155	21	(	(	PUNCT
bptjm-17	155	22	hu	hu	PROPN
bptjm-17	155	23	et	et	PROPN
bptjm-17	155	24	al	al	PROPN
bptjm-17	155	25	.	.	PROPN
bptjm-17	155	26	,	,	PUNCT
bptjm-17	155	27	2019	2019	NUM
bptjm-17	155	28	;	;	PUNCT
bptjm-17	155	29	remon	remon	PROPN
bptjm-17	155	30	et	et	PROPN
bptjm-17	155	31	al	al	PROPN
bptjm-17	155	32	.	.	PROPN
bptjm-17	155	33	,	,	PUNCT
bptjm-17	155	34	2020	2020	NUM
bptjm-17	155	35	;	;	PUNCT
bptjm-17	155	36	ji	ji	PROPN
bptjm-17	155	37	et	et	PROPN
bptjm-17	155	38	al	al	PROPN
bptjm-17	155	39	.	.	PROPN
bptjm-17	155	40	,	,	PUNCT
bptjm-17	155	41	2020	2020	NUM
bptjm-17	155	42	)	)	PUNCT
bptjm-17	155	43	.	.	PUNCT
bptjm-17	156	1	with	with	ADP
bptjm-17	156	2	regards	regard	NOUN
bptjm-17	156	3	to	to	ADP
bptjm-17	156	4	targetability	targetability	NOUN
bptjm-17	156	5	,	,	PUNCT
bptjm-17	156	6	germline	germline	PROPN
bptjm-17	156	7	brca	brca	PROPN
bptjm-17	156	8	-	-	PUNCT
bptjm-17	156	9	mutated	mutate	VERB
bptjm-17	156	10	(	(	PUNCT
bptjm-17	156	11	gbrcam	gbrcam	NOUN
bptjm-17	156	12	)	)	PUNCT
bptjm-17	156	13	cancers	cancer	NOUN
bptjm-17	156	14	have	have	AUX
bptjm-17	156	15	demonstrated	demonstrate	VERB
bptjm-17	156	16	promising	promising	ADJ
bptjm-17	156	17	responses	response	NOUN
bptjm-17	156	18	in	in	ADP
bptjm-17	156	19	poly-(adp	poly-(adp	PROPN
bptjm-17	156	20	ribose	ribose	NOUN
bptjm-17	156	21	)	)	PUNCT
bptjm-17	156	22	polymerase	polymerase	NOUN
bptjm-17	156	23	(	(	PUNCT
bptjm-17	156	24	parp	parp	NOUN
bptjm-17	156	25	)	)	PUNCT
bptjm-17	156	26	clinical	clinical	ADJ
bptjm-17	156	27	trials	trial	NOUN
bptjm-17	156	28	and	and	CCONJ
bptjm-17	156	29	other	other	ADJ
bptjm-17	156	30	studies	study	NOUN
bptjm-17	156	31	(	(	PUNCT
bptjm-17	156	32	hu	hu	PROPN
bptjm-17	156	33	et	et	PROPN
bptjm-17	156	34	al	al	PROPN
bptjm-17	156	35	.	.	PROPN
bptjm-17	156	36	,	,	PUNCT
bptjm-17	156	37	2019	2019	NUM
bptjm-17	156	38	;	;	PUNCT
bptjm-17	156	39	ji	ji	PROPN
bptjm-17	156	40	et	et	PROPN
bptjm-17	156	41	al	al	PROPN
bptjm-17	156	42	.	.	PROPN
bptjm-17	156	43	,	,	PUNCT
bptjm-17	156	44	2020	2020	NUM
bptjm-17	156	45	)	)	PUNCT
bptjm-17	156	46	.	.	PUNCT
bptjm-17	157	1	in	in	ADP
bptjm-17	157	2	a	a	DET
bptjm-17	157	3	study	study	NOUN
bptjm-17	157	4	by	by	ADP
bptjm-17	157	5	remon	remon	PROPN
bptjm-17	157	6	et	et	PROPN
bptjm-17	157	7	al	al	PROPN
bptjm-17	157	8	.	.	PROPN
bptjm-17	157	9	,	,	PUNCT
bptjm-17	157	10	analysis	analysis	NOUN
bptjm-17	157	11	was	be	AUX
bptjm-17	157	12	performed	perform	VERB
bptjm-17	157	13	on	on	ADP
bptjm-17	157	14	advanced	advanced	ADJ
bptjm-17	157	15	nsclc	nsclc	NOUN
bptjm-17	157	16	patient	patient	ADJ
bptjm-17	157	17	specimens	specimen	NOUN
bptjm-17	157	18	negative	negative	ADJ
bptjm-17	157	19	for	for	ADP
bptjm-17	157	20	alk	alk	NOUN
bptjm-17	157	21	rearrangements	rearrangement	NOUN
bptjm-17	157	22	and	and	CCONJ
bptjm-17	157	23	positive	positive	ADJ
bptjm-17	157	24	for	for	ADP
bptjm-17	157	25	activating	activate	VERB
bptjm-17	157	26	egfr	egfr	ADJ
bptjm-17	157	27	mutations	mutation	NOUN
bptjm-17	157	28	.	.	PUNCT
bptjm-17	158	1	ngs	ng	NOUN
bptjm-17	158	2	and	and	CCONJ
bptjm-17	158	3	single	single	ADJ
bptjm-17	158	4	nucleotide	nucleotide	ADJ
bptjm-17	158	5	polymorphism	polymorphism	NOUN
bptjm-17	158	6	(	(	PUNCT
bptjm-17	158	7	snp	snp	ADJ
bptjm-17	158	8	)	)	PUNCT
bptjm-17	158	9	arrays	array	NOUN
bptjm-17	158	10	were	be	AUX
bptjm-17	158	11	performed	perform	VERB
bptjm-17	158	12	on	on	ADP
bptjm-17	158	13	the	the	DET
bptjm-17	158	14	samples	sample	NOUN
bptjm-17	158	15	in	in	ADP
bptjm-17	158	16	order	order	NOUN
bptjm-17	158	17	to	to	PART
bptjm-17	158	18	assess	assess	VERB
bptjm-17	158	19	genomic	genomic	NOUN
bptjm-17	158	20	features	feature	NOUN
bptjm-17	158	21	in	in	ADP
bptjm-17	158	22	patients	patient	NOUN
bptjm-17	158	23	new	new	ADJ
bptjm-17	158	24	to	to	ADP
bptjm-17	158	25	targeted	target	VERB
bptjm-17	158	26	therapy	therapy	NOUN
bptjm-17	158	27	.	.	PUNCT
bptjm-17	159	1	using	use	VERB
bptjm-17	159	2	molecular	molecular	ADJ
bptjm-17	159	3	data	datum	NOUN
bptjm-17	159	4	,	,	PUNCT
bptjm-17	159	5	the	the	DET
bptjm-17	159	6	authors	author	NOUN
bptjm-17	159	7	determined	determine	VERB
bptjm-17	159	8	the	the	DET
bptjm-17	159	9	prevalence	prevalence	NOUN
bptjm-17	159	10	of	of	ADP
bptjm-17	159	11	pathogenic	pathogenic	ADJ
bptjm-17	159	12	mutations	mutation	NOUN
bptjm-17	159	13	in	in	ADP
bptjm-17	159	14	brca	brca	PROPN
bptjm-17	159	15	genes	gene	NOUN
bptjm-17	159	16	,	,	PUNCT
bptjm-17	159	17	recist	recist	NOUN
bptjm-17	159	18	-	-	PUNCT
bptjm-17	159	19	assessed	assess	VERB
bptjm-17	159	20	response	response	NOUN
bptjm-17	159	21	rate	rate	NOUN
bptjm-17	159	22	to	to	ADP
bptjm-17	159	23	platinum	platinum	NOUN
bptjm-17	159	24	-	-	PUNCT
bptjm-17	159	25	based	base	VERB
bptjm-17	159	26	chemotherapy	chemotherapy	NOUN
bptjm-17	159	27	,	,	PUNCT
bptjm-17	159	28	and	and	CCONJ
bptjm-17	159	29	characteristic	characteristic	ADJ
bptjm-17	159	30	berkeley	berkeley	PROPN
bptjm-17	159	31	pharma	pharma	PROPN
bptjm-17	159	32	tech	tech	NOUN
bptjm-17	159	33	journal	journal	NOUN
bptjm-17	159	34	of	of	ADP
bptjm-17	159	35	medicine	medicine	NOUN
bptjm-17	159	36	|	|	ADV
bptjm-17	159	37	126	126	NUM
bptjm-17	159	38	clinicopathological	clinicopathological	ADJ
bptjm-17	159	39	features	feature	NOUN
bptjm-17	159	40	of	of	ADP
bptjm-17	159	41	brca	brca	PROPN
bptjm-17	159	42	mutated	mutate	VERB
bptjm-17	159	43	patient	patient	NOUN
bptjm-17	159	44	subgroups	subgroup	NOUN
bptjm-17	159	45	.	.	PUNCT
bptjm-17	160	1	reported	report	VERB
bptjm-17	160	2	brca	brca	PROPN
bptjm-17	160	3	prevalence	prevalence	NOUN
bptjm-17	160	4	without	without	ADP
bptjm-17	160	5	respect	respect	NOUN
bptjm-17	160	6	to	to	ADP
bptjm-17	160	7	mutation	mutation	NOUN
bptjm-17	160	8	type	type	NOUN
bptjm-17	160	9	was	be	AUX
bptjm-17	160	10	5.3	5.3	NUM
bptjm-17	160	11	%	%	NOUN
bptjm-17	160	12	(	(	PUNCT
bptjm-17	160	13	20	20	NUM
bptjm-17	160	14	out	out	ADP
bptjm-17	160	15	of	of	ADP
bptjm-17	160	16	379	379	NUM
bptjm-17	160	17	patients	patient	NOUN
bptjm-17	160	18	)	)	PUNCT
bptjm-17	160	19	,	,	PUNCT
bptjm-17	160	20	although	although	SCONJ
bptjm-17	160	21	pathogenic	pathogenic	ADJ
bptjm-17	160	22	mutations	mutation	NOUN
bptjm-17	160	23	in	in	ADP
bptjm-17	160	24	brca1/2	brca1/2	PROPN
bptjm-17	160	25	constituted	constitute	VERB
bptjm-17	160	26	only	only	ADV
bptjm-17	160	27	2.1	2.1	NUM
bptjm-17	160	28	%	%	NOUN
bptjm-17	160	29	of	of	ADP
bptjm-17	160	30	advanced	advanced	ADJ
bptjm-17	160	31	nsclc	nsclc	NOUN
bptjm-17	160	32	patients	patient	NOUN
bptjm-17	160	33	.	.	PUNCT
bptjm-17	161	1	the	the	DET
bptjm-17	161	2	results	result	NOUN
bptjm-17	161	3	of	of	ADP
bptjm-17	161	4	ramon	ramon	NOUN
bptjm-17	161	5	et	et	PROPN
bptjm-17	161	6	al	al	PROPN
bptjm-17	161	7	.	.	PROPN
bptjm-17	161	8	’s	’s	PART
bptjm-17	161	9	study	study	NOUN
bptjm-17	161	10	demonstrated	demonstrate	VERB
bptjm-17	161	11	that	that	SCONJ
bptjm-17	161	12	there	there	PRON
bptjm-17	161	13	may	may	AUX
bptjm-17	161	14	not	not	PART
bptjm-17	161	15	be	be	AUX
bptjm-17	161	16	a	a	DET
bptjm-17	161	17	signi	signi	NOUN
bptjm-17	161	18	ca	can	AUX
bptjm-17	161	19	nt	not	PART
bptjm-17	161	20	link	link	VERB
bptjm-17	161	21	between	between	ADP
bptjm-17	161	22	brca	brca	PROPN
bptjm-17	161	23	mutation	mutation	NOUN
bptjm-17	161	24	in	in	ADP
bptjm-17	161	25	nsclc	nsclc	NOUN
bptjm-17	161	26	and	and	CCONJ
bptjm-17	161	27	improved	improved	ADJ
bptjm-17	161	28	response	response	NOUN
bptjm-17	161	29	to	to	ADP
bptjm-17	161	30	platinum	platinum	NOUN
bptjm-17	161	31	based	base	VERB
bptjm-17	161	32	chemotherapy	chemotherapy	NOUN
bptjm-17	161	33	;	;	PUNCT
bptjm-17	161	34	a	a	DET
bptjm-17	161	35	similar	similar	ADJ
bptjm-17	161	36	inconclusiveness	inconclusiveness	NOUN
bptjm-17	161	37	on	on	ADP
bptjm-17	161	38	brca	brca	PROPN
bptjm-17	161	39	’s	’s	PART
bptjm-17	161	40	role	role	NOUN
bptjm-17	161	41	in	in	ADP
bptjm-17	161	42	predicting	predict	VERB
bptjm-17	161	43	treatment	treatment	NOUN
bptjm-17	161	44	outcomes	outcome	NOUN
bptjm-17	161	45	was	be	AUX
bptjm-17	161	46	noted	note	VERB
bptjm-17	161	47	in	in	ADP
bptjm-17	161	48	another	another	DET
bptjm-17	161	49	study	study	NOUN
bptjm-17	161	50	on	on	ADP
bptjm-17	161	51	tumor	tumor	NOUN
bptjm-17	161	52	samples	sample	NOUN
bptjm-17	161	53	that	that	PRON
bptjm-17	161	54	exhibited	exhibit	VERB
bptjm-17	161	55	positive	positive	ADJ
bptjm-17	161	56	ihc	ihc	NOUN
bptjm-17	161	57	staining	stain	VERB
bptjm-17	161	58	for	for	ADP
bptjm-17	161	59	brca1	brca1	PROPN
bptjm-17	161	60	(	(	PUNCT
bptjm-17	161	61	ramon	ramon	NOUN
bptjm-17	161	62	et	et	PROPN
bptjm-17	161	63	al	al	PROPN
bptjm-17	161	64	.	.	PROPN
bptjm-17	161	65	,	,	PUNCT
bptjm-17	161	66	2020	2020	NUM
bptjm-17	161	67	;	;	PUNCT
bptjm-17	162	1	watchers	watcher	NOUN
bptjm-17	162	2	et	et	PROPN
bptjm-17	162	3	al	al	PROPN
bptjm-17	162	4	.	.	PROPN
bptjm-17	162	5	,	,	PUNCT
bptjm-17	162	6	2005	2005	NUM
bptjm-17	162	7	)	)	PUNCT
bptjm-17	162	8	.	.	PUNCT
bptjm-17	163	1	based	base	VERB
bptjm-17	163	2	on	on	ADP
bptjm-17	163	3	study	study	NOUN
bptjm-17	163	4	data	datum	NOUN
bptjm-17	163	5	,	,	PUNCT
bptjm-17	163	6	it	it	PRON
bptjm-17	163	7	appeared	appear	VERB
bptjm-17	163	8	that	that	SCONJ
bptjm-17	163	9	brca	brca	PROPN
bptjm-17	163	10	variants	variant	NOUN
bptjm-17	163	11	of	of	ADP
bptjm-17	163	12	unknown	unknown	ADJ
bptjm-17	163	13	signi	signi	ADJ
bptjm-17	163	14	cance	cance	NOUN
bptjm-17	163	15	(	(	PUNCT
bptjm-17	163	16	vus	vus	NOUN
bptjm-17	163	17	)	)	PUNCT
bptjm-17	163	18	exhibit	exhibit	VERB
bptjm-17	163	19	longer	long	ADJ
bptjm-17	163	20	os	os	NOUN
bptjm-17	163	21	(	(	PUNCT
bptjm-17	163	22	p=0.07	p=0.07	ADJ
bptjm-17	163	23	)	)	PUNCT
bptjm-17	163	24	,	,	PUNCT
bptjm-17	163	25	whereas	whereas	SCONJ
bptjm-17	163	26	tumor	tumor	NOUN
bptjm-17	163	27	protein	protein	NOUN
bptjm-17	163	28	p53	p53	NOUN
bptjm-17	163	29	(	(	PUNCT
bptjm-17	163	30	tp53	tp53	PROPN
bptjm-17	163	31	)	)	PUNCT
bptjm-17	163	32	mutation	mutation	NOUN
bptjm-17	163	33	status	status	NOUN
bptjm-17	163	34	in	in	ADP
bptjm-17	163	35	brca	brca	PROPN
bptjm-17	163	36	-	-	PUNCT
bptjm-17	163	37	positive	positive	ADJ
bptjm-17	163	38	subgroups	subgroup	NOUN
bptjm-17	163	39	did	do	AUX
bptjm-17	163	40	not	not	PART
bptjm-17	163	41	yield	yield	VERB
bptjm-17	163	42	a	a	DET
bptjm-17	163	43	statistically	statistically	ADV
bptjm-17	163	44	signi	signi	ADJ
bptjm-17	163	45	ca	can	AUX
bptjm-17	163	46	nt	not	PART
bptjm-17	163	47	di	di	VERB
bptjm-17	163	48	erence	erence	NOUN
bptjm-17	163	49	in	in	ADP
bptjm-17	163	50	prognosis	prognosis	NOUN
bptjm-17	163	51	(	(	PUNCT
bptjm-17	163	52	p=0.3	p=0.3	NOUN
bptjm-17	163	53	)	)	PUNCT
bptjm-17	163	54	.	.	PUNCT
bptjm-17	164	1	although	although	SCONJ
bptjm-17	164	2	the	the	DET
bptjm-17	164	3	authors	author	NOUN
bptjm-17	164	4	found	find	VERB
bptjm-17	164	5	that	that	SCONJ
bptjm-17	164	6	biallelic	biallelic	ADJ
bptjm-17	164	7	mutations	mutation	NOUN
bptjm-17	164	8	in	in	ADP
bptjm-17	164	9	brcamay	brcamay	ADV
bptjm-17	164	10	warrant	warrant	VERB
bptjm-17	164	11	further	further	ADJ
bptjm-17	164	12	study	study	NOUN
bptjm-17	164	13	to	to	PART
bptjm-17	164	14	determine	determine	VERB
bptjm-17	164	15	their	their	PRON
bptjm-17	164	16	prognostic	prognostic	ADJ
bptjm-17	164	17	signi	signi	ADJ
bptjm-17	164	18	cance	cance	NOUN
bptjm-17	164	19	,	,	PUNCT
bptjm-17	164	20	they	they	PRON
bptjm-17	164	21	noted	note	VERB
bptjm-17	164	22	that	that	SCONJ
bptjm-17	164	23	data	datum	NOUN
bptjm-17	164	24	gathered	gather	VERB
bptjm-17	164	25	in	in	ADP
bptjm-17	164	26	their	their	PRON
bptjm-17	164	27	patient	patient	ADJ
bptjm-17	164	28	cohort	cohort	NOUN
bptjm-17	164	29	did	do	AUX
bptjm-17	164	30	not	not	PART
bptjm-17	164	31	yield	yield	VERB
bptjm-17	164	32	su	su	PROPN
bptjm-17	164	33	ciently	ciently	ADV
bptjm-17	164	34	robust	robust	ADJ
bptjm-17	164	35	evidence	evidence	NOUN
bptjm-17	164	36	to	to	PART
bptjm-17	164	37	support	support	VERB
bptjm-17	164	38	implementation	implementation	NOUN
bptjm-17	164	39	of	of	ADP
bptjm-17	164	40	speci	speci	PROPN
bptjm-17	164	41	c	c	PROPN
bptjm-17	164	42	targeted	target	VERB
bptjm-17	164	43	therapies	therapy	NOUN
bptjm-17	164	44	in	in	ADP
bptjm-17	164	45	monoallelic	monoallelic	ADJ
bptjm-17	164	46	brca1/2	brca1/2	ADJ
bptjm-17	164	47	patients	patient	NOUN
bptjm-17	164	48	(	(	PUNCT
bptjm-17	164	49	remon	remon	PROPN
bptjm-17	164	50	et	et	PROPN
bptjm-17	164	51	al	al	PROPN
bptjm-17	164	52	.	.	PROPN
bptjm-17	164	53	,	,	PUNCT
bptjm-17	164	54	2020	2020	NUM
bptjm-17	164	55	)	)	PUNCT
bptjm-17	164	56	.	.	PUNCT
bptjm-17	165	1	in	in	ADP
bptjm-17	165	2	contrast	contrast	NOUN
bptjm-17	165	3	to	to	ADP
bptjm-17	165	4	the	the	DET
bptjm-17	165	5	data	datum	NOUN
bptjm-17	165	6	presented	present	VERB
bptjm-17	165	7	by	by	ADP
bptjm-17	165	8	ramon	ramon	PROPN
bptjm-17	165	9	et	et	PROPN
bptjm-17	165	10	al	al	PROPN
bptjm-17	165	11	.	.	PROPN
bptjm-17	165	12	,	,	PUNCT
bptjm-17	165	13	ji	ji	PROPN
bptjm-17	165	14	et	et	PROPN
bptjm-17	165	15	al	al	PROPN
bptjm-17	165	16	.	.	PROPN
bptjm-17	165	17	also	also	ADV
bptjm-17	165	18	analyzed	analyze	VERB
bptjm-17	165	19	brca1/2	brca1/2	NOUN
bptjm-17	165	20	in	in	ADP
bptjm-17	165	21	determining	determine	VERB
bptjm-17	165	22	e	e	NOUN
bptjm-17	165	23	cacy	cacy	NOUN
bptjm-17	165	24	of	of	ADP
bptjm-17	165	25	targeted	target	VERB
bptjm-17	165	26	olaparib	olaparib	NOUN
bptjm-17	165	27	(	(	PUNCT
bptjm-17	165	28	parp	parp	ADJ
bptjm-17	165	29	inhibitor	inhibitor	NOUN
bptjm-17	165	30	)	)	PUNCT
bptjm-17	165	31	therapy	therapy	NOUN
bptjm-17	165	32	.	.	PUNCT
bptjm-17	166	1	assessment	assessment	NOUN
bptjm-17	166	2	of	of	ADP
bptjm-17	166	3	data	datum	NOUN
bptjm-17	166	4	demonstrated	demonstrate	VERB
bptjm-17	166	5	that	that	SCONJ
bptjm-17	166	6	brca1	brca1	PROPN
bptjm-17	166	7	and	and	CCONJ
bptjm-17	166	8	brca2	brca2	NOUN
bptjm-17	166	9	depleted	deplete	VERB
bptjm-17	166	10	cells	cell	NOUN
bptjm-17	166	11	are	be	AUX
bptjm-17	166	12	more	more	ADV
bptjm-17	166	13	susceptible	susceptible	ADJ
bptjm-17	166	14	to	to	ADP
bptjm-17	166	15	olaparib	olaparib	PROPN
bptjm-17	166	16	.	.	PUNCT
bptjm-17	167	1	similar	similar	ADJ
bptjm-17	167	2	to	to	ADP
bptjm-17	167	3	its	its	PRON
bptjm-17	167	4	role	role	NOUN
bptjm-17	167	5	in	in	ADP
bptjm-17	167	6	breast	breast	NOUN
bptjm-17	167	7	cancer	cancer	NOUN
bptjm-17	167	8	cells	cell	NOUN
bptjm-17	167	9	,	,	PUNCT
bptjm-17	167	10	olaparib	olaparib	PROPN
bptjm-17	167	11	was	be	AUX
bptjm-17	167	12	found	find	VERB
bptjm-17	167	13	to	to	PART
bptjm-17	167	14	exhibit	exhibit	VERB
bptjm-17	167	15	a	a	DET
bptjm-17	167	16	similar	similar	ADJ
bptjm-17	167	17	apoptosis	apoptosis	NOUN
bptjm-17	167	18	-	-	PUNCT
bptjm-17	167	19	inducing	induce	VERB
bptjm-17	167	20	function	function	NOUN
bptjm-17	167	21	in	in	ADP
bptjm-17	167	22	brca	brca	PROPN
bptjm-17	167	23	-	-	PUNCT
bptjm-17	167	24	mutated	mutate	VERB
bptjm-17	167	25	nsclc	nsclc	NOUN
bptjm-17	167	26	cells	cell	NOUN
bptjm-17	167	27	(	(	PUNCT
bptjm-17	167	28	ji	ji	X
bptjm-17	167	29	et	et	PROPN
bptjm-17	167	30	al	al	PROPN
bptjm-17	167	31	.	.	PROPN
bptjm-17	167	32	,	,	PUNCT
bptjm-17	167	33	2020	2020	NUM
bptjm-17	167	34	)	)	PUNCT
bptjm-17	167	35	.	.	PUNCT
bptjm-17	168	1	moreover	moreover	ADV
bptjm-17	168	2	,	,	PUNCT
bptjm-17	168	3	other	other	ADJ
bptjm-17	168	4	studies	study	NOUN
bptjm-17	168	5	have	have	AUX
bptjm-17	168	6	demonstrated	demonstrate	VERB
bptjm-17	168	7	that	that	SCONJ
bptjm-17	168	8	heightened	heightened	ADJ
bptjm-17	168	9	brca1	brca1	NOUN
bptjm-17	168	10	expression	expression	NOUN
bptjm-17	168	11	correlates	correlate	VERB
bptjm-17	168	12	with	with	ADP
bptjm-17	168	13	lower	low	ADJ
bptjm-17	168	14	overall	overall	ADJ
bptjm-17	168	15	survival	survival	NOUN
bptjm-17	168	16	rates	rate	NOUN
bptjm-17	168	17	(	(	PUNCT
bptjm-17	168	18	joerger	joerger	NOUN
bptjm-17	168	19	et	et	PROPN
bptjm-17	168	20	al	al	PROPN
bptjm-17	168	21	.	.	PROPN
bptjm-17	168	22	,	,	PUNCT
bptjm-17	168	23	2011	2011	NUM
bptjm-17	168	24	)	)	PUNCT
bptjm-17	168	25	.	.	PUNCT
bptjm-17	169	1	while	while	SCONJ
bptjm-17	169	2	a	a	DET
bptjm-17	169	3	common	common	ADJ
bptjm-17	169	4	concern	concern	NOUN
bptjm-17	169	5	with	with	ADP
bptjm-17	169	6	the	the	DET
bptjm-17	169	7	use	use	NOUN
bptjm-17	169	8	of	of	ADP
bptjm-17	169	9	ctdna	ctdna	NOUN
bptjm-17	169	10	assays	assay	NOUN
bptjm-17	169	11	is	be	AUX
bptjm-17	169	12	their	their	PRON
bptjm-17	169	13	ability	ability	NOUN
bptjm-17	169	14	to	to	PART
bptjm-17	169	15	provide	provide	VERB
bptjm-17	169	16	an	an	DET
bptjm-17	169	17	accurate	accurate	ADJ
bptjm-17	169	18	indication	indication	NOUN
bptjm-17	169	19	of	of	ADP
bptjm-17	169	20	a	a	DET
bptjm-17	169	21	patient	patient	NOUN
bptjm-17	169	22	’s	’s	PART
bptjm-17	169	23	mutational	mutational	ADJ
bptjm-17	169	24	landscape	landscape	NOUN
bptjm-17	169	25	,	,	PUNCT
bptjm-17	169	26	recent	recent	ADJ
bptjm-17	169	27	studies	study	NOUN
bptjm-17	169	28	have	have	AUX
bptjm-17	169	29	assessed	assess	VERB
bptjm-17	169	30	the	the	DET
bptjm-17	169	31	utility	utility	NOUN
bptjm-17	169	32	of	of	ADP
bptjm-17	169	33	a	a	DET
bptjm-17	169	34	brca1	brca1	NOUN
bptjm-17	169	35	selective	selective	ADJ
bptjm-17	169	36	polyethylene	polyethylene	NOUN
bptjm-17	169	37	glycol	glycol	NOUN
bptjm-17	169	38	,	,	PUNCT
bptjm-17	169	39	gold	gold	NOUN
bptjm-17	169	40	nanoparticle	nanoparticle	NOUN
bptjm-17	169	41	-	-	PUNCT
bptjm-17	169	42	infused	infuse	VERB
bptjm-17	169	43	biosensor	biosensor	NOUN
bptjm-17	169	44	.	.	PUNCT
bptjm-17	170	1	this	this	DET
bptjm-17	170	2	biosensor	biosensor	NOUN
bptjm-17	170	3	showed	show	VERB
bptjm-17	170	4	substantial	substantial	ADJ
bptjm-17	170	5	selectivity	selectivity	NOUN
bptjm-17	170	6	and	and	CCONJ
bptjm-17	170	7	a	a	DET
bptjm-17	170	8	brca1	brca1	NOUN
bptjm-17	170	9	lower	low	ADJ
bptjm-17	170	10	limit	limit	NOUN
bptjm-17	170	11	of	of	ADP
bptjm-17	170	12	detection	detection	NOUN
bptjm-17	170	13	of	of	ADP
bptjm-17	170	14	1.72	1.72	NUM
bptjm-17	170	15	femtomolar	femtomolar	ADJ
bptjm-17	170	16	(	(	PUNCT
bptjm-17	170	17	wang	wang	PROPN
bptjm-17	170	18	et	et	PROPN
bptjm-17	170	19	al	al	PROPN
bptjm-17	170	20	.	.	PROPN
bptjm-17	170	21	,	,	PUNCT
bptjm-17	170	22	2015	2015	NUM
bptjm-17	170	23	)	)	PUNCT
bptjm-17	170	24	.	.	PUNCT
bptjm-17	171	1	these	these	DET
bptjm-17	171	2	results	result	NOUN
bptjm-17	171	3	suggest	suggest	VERB
bptjm-17	171	4	that	that	SCONJ
bptjm-17	171	5	biosensor	biosensor	NOUN
bptjm-17	171	6	-	-	PUNCT
bptjm-17	171	7	based	base	VERB
bptjm-17	171	8	detection	detection	NOUN
bptjm-17	171	9	of	of	ADP
bptjm-17	171	10	speci	speci	PROPN
bptjm-17	171	11	c	c	PROPN
bptjm-17	171	12	biomarker	biomarker	VERB
bptjm-17	171	13	sequences	sequence	NOUN
bptjm-17	171	14	may	may	AUX
bptjm-17	171	15	serve	serve	VERB
bptjm-17	171	16	as	as	ADP
bptjm-17	171	17	a	a	DET
bptjm-17	171	18	viable	viable	ADJ
bptjm-17	171	19	method	method	NOUN
bptjm-17	171	20	of	of	ADP
bptjm-17	171	21	detection	detection	NOUN
bptjm-17	171	22	to	to	PART
bptjm-17	171	23	address	address	VERB
bptjm-17	171	24	the	the	DET
bptjm-17	171	25	issue	issue	NOUN
bptjm-17	171	26	of	of	ADP
bptjm-17	171	27	sensitivity	sensitivity	NOUN
bptjm-17	171	28	in	in	ADP
bptjm-17	171	29	liquid	liquid	ADJ
bptjm-17	171	30	biopsies	biopsy	NOUN
bptjm-17	171	31	(	(	PUNCT
bptjm-17	171	32	wang	wang	PROPN
bptjm-17	171	33	et	et	PROPN
bptjm-17	171	34	al	al	PROPN
bptjm-17	171	35	.	.	PROPN
bptjm-17	171	36	,	,	PUNCT
bptjm-17	171	37	2015	2015	NUM
bptjm-17	171	38	;	;	PUNCT
bptjm-17	172	1	yang	yang	PROPN
bptjm-17	172	2	et	et	PROPN
bptjm-17	172	3	al	al	PROPN
bptjm-17	172	4	.	.	PROPN
bptjm-17	172	5	,	,	PUNCT
bptjm-17	172	6	2016	2016	NUM
bptjm-17	172	7	)	)	PUNCT
bptjm-17	172	8	.	.	PUNCT
bptjm-17	173	1	berkeley	berkeley	PROPN
bptjm-17	173	2	pharma	pharma	PROPN
bptjm-17	173	3	tech	tech	PROPN
bptjm-17	173	4	journal	journal	NOUN
bptjm-17	173	5	of	of	ADP
bptjm-17	173	6	medicine	medicine	NOUN
bptjm-17	173	7	|	|	ADV
bptjm-17	173	8	127	127	NUM
bptjm-17	173	9	pten	pten	ADJ
bptjm-17	173	10	phosphatase	phosphatase	NOUN
bptjm-17	173	11	and	and	CCONJ
bptjm-17	173	12	tensin	tensin	PROPN
bptjm-17	173	13	homolog	homolog	PROPN
bptjm-17	173	14	(	(	PUNCT
bptjm-17	173	15	pten	pten	NOUN
bptjm-17	173	16	)	)	PUNCT
bptjm-17	173	17	serves	serve	VERB
bptjm-17	173	18	as	as	ADP
bptjm-17	173	19	a	a	DET
bptjm-17	173	20	phosphatase	phosphatase	NOUN
bptjm-17	173	21	for	for	ADP
bptjm-17	173	22	phosphatidylinositol-(3,4,5)-triphosphate	phosphatidylinositol-(3,4,5)-triphosphate	PROPN
bptjm-17	173	23	(	(	PUNCT
bptjm-17	173	24	pip3	pip3	PROPN
bptjm-17	173	25	)	)	PUNCT
bptjm-17	173	26	.	.	PUNCT
bptjm-17	174	1	pten	pten	VERB
bptjm-17	174	2	decreases	decrease	VERB
bptjm-17	174	3	pip3	pip3	NOUN
bptjm-17	174	4	concentration	concentration	NOUN
bptjm-17	174	5	,	,	PUNCT
bptjm-17	174	6	which	which	PRON
bptjm-17	174	7	in	in	ADP
bptjm-17	174	8	turn	turn	NOUN
bptjm-17	174	9	serves	serve	VERB
bptjm-17	174	10	to	to	ADP
bptjm-17	174	11	downregulate	downregulate	PROPN
bptjm-17	174	12	phosphorylated	phosphorylate	VERB
bptjm-17	174	13	akt	akt	PROPN
bptjm-17	174	14	(	(	PUNCT
bptjm-17	174	15	p	p	NOUN
bptjm-17	174	16	-	-	PUNCT
bptjm-17	174	17	akt	akt	NOUN
bptjm-17	174	18	)	)	PUNCT
bptjm-17	174	19	.	.	PUNCT
bptjm-17	175	1	in	in	ADP
bptjm-17	175	2	healthy	healthy	ADJ
bptjm-17	175	3	cells	cell	NOUN
bptjm-17	175	4	,	,	PUNCT
bptjm-17	175	5	pten	pten	NOUN
bptjm-17	175	6	serves	serve	VERB
bptjm-17	175	7	as	as	ADP
bptjm-17	175	8	an	an	DET
bptjm-17	175	9	indirect	indirect	ADJ
bptjm-17	175	10	downregulator	downregulator	NOUN
bptjm-17	175	11	of	of	ADP
bptjm-17	175	12	p	p	NOUN
bptjm-17	175	13	-	-	PUNCT
bptjm-17	175	14	mapk	mapk	NOUN
bptjm-17	175	15	and	and	CCONJ
bptjm-17	175	16	p	p	NOUN
bptjm-17	175	17	-	-	PUNCT
bptjm-17	175	18	akt	akt	PROPN
bptjm-17	175	19	,	,	PUNCT
bptjm-17	175	20	resulting	result	VERB
bptjm-17	175	21	in	in	ADP
bptjm-17	175	22	lower	low	ADJ
bptjm-17	175	23	rates	rate	NOUN
bptjm-17	175	24	of	of	ADP
bptjm-17	175	25	cell	cell	NOUN
bptjm-17	175	26	division	division	NOUN
bptjm-17	175	27	and	and	CCONJ
bptjm-17	175	28	increases	increase	NOUN
bptjm-17	175	29	in	in	ADP
bptjm-17	175	30	apoptosis	apoptosis	NOUN
bptjm-17	175	31	(	(	PUNCT
bptjm-17	175	32	teresi	teresi	X
bptjm-17	175	33	et	et	PROPN
bptjm-17	175	34	al	al	PROPN
bptjm-17	175	35	.	.	PROPN
bptjm-17	175	36	,	,	PUNCT
bptjm-17	175	37	2006	2006	NUM
bptjm-17	175	38	)	)	PUNCT
bptjm-17	175	39	.	.	PUNCT
bptjm-17	176	1	patients	patient	NOUN
bptjm-17	176	2	carrying	carry	VERB
bptjm-17	176	3	egfr	egfr	ADJ
bptjm-17	176	4	mutations	mutation	NOUN
bptjm-17	176	5	have	have	AUX
bptjm-17	176	6	reaped	reap	VERB
bptjm-17	176	7	signi	signi	NOUN
bptjm-17	176	8	ca	can	AUX
bptjm-17	176	9	nt	not	PART
bptjm-17	176	10	bene	bene	VERB
bptjm-17	176	11	t	t	NOUN
bptjm-17	176	12	from	from	ADP
bptjm-17	176	13	egfr	egfr	NOUN
bptjm-17	176	14	-	-	PUNCT
bptjm-17	176	15	tkis	tkis	NOUN
bptjm-17	176	16	;	;	PUNCT
bptjm-17	176	17	however	however	ADV
bptjm-17	176	18	,	,	PUNCT
bptjm-17	176	19	resistance	resistance	NOUN
bptjm-17	176	20	to	to	ADP
bptjm-17	176	21	these	these	DET
bptjm-17	176	22	tkis	tkis	NOUN
bptjm-17	176	23	poses	pose	VERB
bptjm-17	176	24	a	a	DET
bptjm-17	176	25	signi	signi	NOUN
bptjm-17	176	26	ca	can	AUX
bptjm-17	176	27	nt	not	PART
bptjm-17	176	28	obstacle	obstacle	VERB
bptjm-17	176	29	in	in	ADP
bptjm-17	176	30	treating	treat	VERB
bptjm-17	176	31	patients	patient	NOUN
bptjm-17	176	32	.	.	PUNCT
bptjm-17	177	1	pten	pten	VERB
bptjm-17	177	2	loss	loss	NOUN
bptjm-17	177	3	represents	represent	VERB
bptjm-17	177	4	one	one	NUM
bptjm-17	177	5	mechanism	mechanism	NOUN
bptjm-17	177	6	of	of	ADP
bptjm-17	177	7	resistance	resistance	NOUN
bptjm-17	177	8	to	to	ADP
bptjm-17	177	9	tkis	tkis	NOUN
bptjm-17	177	10	such	such	ADJ
bptjm-17	177	11	as	as	ADP
bptjm-17	177	12	ge	ge	PROPN
bptjm-17	177	13	tinib	tinib	NOUN
bptjm-17	177	14	and	and	CCONJ
bptjm-17	177	15	erlotinib	erlotinib	NOUN
bptjm-17	177	16	,	,	PUNCT
bptjm-17	177	17	and	and	CCONJ
bptjm-17	177	18	continuing	continue	VERB
bptjm-17	177	19	studies	study	NOUN
bptjm-17	177	20	have	have	AUX
bptjm-17	177	21	set	set	VERB
bptjm-17	177	22	out	out	ADP
bptjm-17	177	23	to	to	PART
bptjm-17	177	24	discover	discover	VERB
bptjm-17	177	25	methods	method	NOUN
bptjm-17	177	26	to	to	PART
bptjm-17	177	27	circumvent	circumvent	VERB
bptjm-17	177	28	the	the	DET
bptjm-17	177	29	e	e	NOUN
bptjm-17	177	30	ects	ect	NOUN
bptjm-17	177	31	of	of	ADP
bptjm-17	177	32	this	this	DET
bptjm-17	177	33	resistance	resistance	NOUN
bptjm-17	177	34	mechanism	mechanism	NOUN
bptjm-17	177	35	(	(	PUNCT
bptjm-17	177	36	to	to	PART
bptjm-17	177	37	et	et	PROPN
bptjm-17	177	38	al	al	PROPN
bptjm-17	177	39	.	.	PROPN
bptjm-17	177	40	,	,	PUNCT
bptjm-17	177	41	2018	2018	NUM
bptjm-17	177	42	)	)	PUNCT
bptjm-17	177	43	.	.	PUNCT
bptjm-17	178	1	peroxisome	peroxisome	VERB
bptjm-17	178	2	proliferator	proliferator	NOUN
bptjm-17	178	3	-	-	PUNCT
bptjm-17	178	4	activated	activate	VERB
bptjm-17	178	5	receptor	receptor	NOUN
bptjm-17	178	6	agonists	agonist	NOUN
bptjm-17	178	7	(	(	PUNCT
bptjm-17	178	8	ppars	ppar	NOUN
bptjm-17	178	9	)	)	PUNCT
bptjm-17	178	10	are	be	AUX
bptjm-17	178	11	implicated	implicate	VERB
bptjm-17	178	12	in	in	ADP
bptjm-17	178	13	the	the	DET
bptjm-17	178	14	development	development	NOUN
bptjm-17	178	15	and	and	CCONJ
bptjm-17	178	16	di	di	NOUN
bptjm-17	178	17	erentiation	erentiation	NOUN
bptjm-17	178	18	of	of	ADP
bptjm-17	178	19	cells	cell	NOUN
bptjm-17	178	20	,	,	PUNCT
bptjm-17	178	21	tumorigenesis	tumorigenesis	NOUN
bptjm-17	178	22	,	,	PUNCT
bptjm-17	178	23	and	and	CCONJ
bptjm-17	178	24	metabolism	metabolism	NOUN
bptjm-17	178	25	.	.	PUNCT
bptjm-17	179	1	studies	study	NOUN
bptjm-17	179	2	have	have	AUX
bptjm-17	179	3	demonstrated	demonstrate	VERB
bptjm-17	179	4	that	that	SCONJ
bptjm-17	179	5	pten	pten	NOUN
bptjm-17	179	6	loss	loss	NOUN
bptjm-17	179	7	is	be	AUX
bptjm-17	179	8	correlated	correlate	VERB
bptjm-17	179	9	with	with	ADP
bptjm-17	179	10	resistance	resistance	NOUN
bptjm-17	179	11	to	to	ADP
bptjm-17	179	12	ge	ge	PROPN
bptjm-17	179	13	tinib	tinib	PROPN
bptjm-17	179	14	(	(	PUNCT
bptjm-17	179	15	to	to	PART
bptjm-17	179	16	,	,	PUNCT
bptjm-17	179	17	wu	wu	PROPN
bptjm-17	179	18	,	,	PUNCT
bptjm-17	179	19	and	and	CCONJ
bptjm-17	179	20	loong	loong	PROPN
bptjm-17	179	21	,	,	PUNCT
bptjm-17	179	22	2018	2018	NUM
bptjm-17	179	23	;	;	PUNCT
bptjm-17	179	24	lee	lee	PROPN
bptjm-17	179	25	et	et	PROPN
bptjm-17	179	26	al	al	PROPN
bptjm-17	179	27	.	.	PROPN
bptjm-17	179	28	,	,	PUNCT
bptjm-17	179	29	2006	2006	NUM
bptjm-17	179	30	)	)	PUNCT
bptjm-17	179	31	.	.	PUNCT
bptjm-17	180	1	increases	increase	NOUN
bptjm-17	180	2	in	in	ADP
bptjm-17	180	3	apoptosis	apoptosis	NOUN
bptjm-17	180	4	were	be	AUX
bptjm-17	180	5	observed	observe	VERB
bptjm-17	180	6	in	in	ADP
bptjm-17	180	7	cell	cell	NOUN
bptjm-17	180	8	lines	line	NOUN
bptjm-17	180	9	treated	treat	VERB
bptjm-17	180	10	concurrently	concurrently	ADV
bptjm-17	180	11	with	with	ADP
bptjm-17	180	12	pparγ	pparγ	ADJ
bptjm-17	180	13	agonists	agonist	NOUN
bptjm-17	180	14	and	and	CCONJ
bptjm-17	180	15	ge	ge	PROPN
bptjm-17	180	16	tinib	tinib	NOUN
bptjm-17	180	17	(	(	PUNCT
bptjm-17	180	18	p<0.017	p<0.017	ADV
bptjm-17	180	19	)	)	PUNCT
bptjm-17	180	20	(	(	PUNCT
bptjm-17	180	21	to	to	PART
bptjm-17	180	22	et	et	PROPN
bptjm-17	180	23	al	al	PROPN
bptjm-17	180	24	.	.	PROPN
bptjm-17	180	25	,	,	PUNCT
bptjm-17	180	26	2018	2018	NUM
bptjm-17	180	27	)	)	PUNCT
bptjm-17	180	28	.	.	PUNCT
bptjm-17	181	1	hence	hence	ADV
bptjm-17	181	2	,	,	PUNCT
bptjm-17	181	3	pparγ	pparγ	ADJ
bptjm-17	181	4	agonists	agonist	NOUN
bptjm-17	181	5	in	in	ADP
bptjm-17	181	6	conjunction	conjunction	NOUN
bptjm-17	181	7	with	with	ADP
bptjm-17	181	8	egfr	egfr	ADJ
bptjm-17	181	9	-	-	PUNCT
bptjm-17	181	10	tkis	tkis	NOUN
bptjm-17	181	11	may	may	AUX
bptjm-17	181	12	serve	serve	VERB
bptjm-17	181	13	as	as	ADP
bptjm-17	181	14	a	a	DET
bptjm-17	181	15	viable	viable	ADJ
bptjm-17	181	16	treatment	treatment	NOUN
bptjm-17	181	17	strategy	strategy	NOUN
bptjm-17	181	18	to	to	PART
bptjm-17	181	19	circumvent	circumvent	VERB
bptjm-17	181	20	egfr	egfr	ADJ
bptjm-17	181	21	-	-	PUNCT
bptjm-17	181	22	tki	tki	NOUN
bptjm-17	181	23	resistance	resistance	NOUN
bptjm-17	181	24	in	in	ADP
bptjm-17	181	25	patient	patient	ADJ
bptjm-17	181	26	subsets	subset	NOUN
bptjm-17	181	27	that	that	PRON
bptjm-17	181	28	exhibit	exhibit	VERB
bptjm-17	181	29	pten	pten	VERB
bptjm-17	181	30	loss	loss	NOUN
bptjm-17	181	31	(	(	PUNCT
bptjm-17	181	32	to	to	PART
bptjm-17	181	33	,	,	PUNCT
bptjm-17	181	34	wu	wu	PROPN
bptjm-17	181	35	,	,	PUNCT
bptjm-17	181	36	and	and	CCONJ
bptjm-17	181	37	loong	loong	PROPN
bptjm-17	181	38	,	,	PUNCT
bptjm-17	181	39	2018	2018	NUM
bptjm-17	181	40	;	;	PUNCT
bptjm-17	181	41	ni	ni	PROPN
bptjm-17	181	42	et	et	PROPN
bptjm-17	181	43	al	al	PROPN
bptjm-17	181	44	.	.	PROPN
bptjm-17	181	45	,	,	PUNCT
bptjm-17	181	46	2017	2017	NUM
bptjm-17	181	47	;	;	PUNCT
bptjm-17	181	48	lee	lee	PROPN
bptjm-17	181	49	et	et	PROPN
bptjm-17	181	50	al	al	PROPN
bptjm-17	181	51	.	.	PROPN
bptjm-17	181	52	,	,	PUNCT
bptjm-17	181	53	2006	2006	NUM
bptjm-17	181	54	)	)	PUNCT
bptjm-17	181	55	.	.	PUNCT
bptjm-17	182	1	although	although	SCONJ
bptjm-17	182	2	future	future	ADJ
bptjm-17	182	3	studies	study	NOUN
bptjm-17	182	4	require	require	VERB
bptjm-17	182	5	further	further	ADJ
bptjm-17	182	6	analysis	analysis	NOUN
bptjm-17	182	7	of	of	ADP
bptjm-17	182	8	pten	pten	NOUN
bptjm-17	182	9	’s	’s	PART
bptjm-17	182	10	ctdna	ctdna	NOUN
bptjm-17	182	11	and	and	CCONJ
bptjm-17	182	12	solid	solid	ADJ
bptjm-17	182	13	tumor	tumor	NOUN
bptjm-17	182	14	concordance	concordance	NOUN
bptjm-17	182	15	rates	rate	NOUN
bptjm-17	182	16	in	in	ADP
bptjm-17	182	17	nsclc	nsclc	NOUN
bptjm-17	182	18	,	,	PUNCT
bptjm-17	182	19	comparative	comparative	ADJ
bptjm-17	182	20	analysis	analysis	NOUN
bptjm-17	182	21	of	of	ADP
bptjm-17	182	22	liquid	liquid	ADJ
bptjm-17	182	23	and	and	CCONJ
bptjm-17	182	24	tissue	tissue	NOUN
bptjm-17	182	25	biopsies	biopsy	NOUN
bptjm-17	182	26	in	in	ADP
bptjm-17	182	27	prostate	prostate	NOUN
bptjm-17	182	28	cancer	cancer	NOUN
bptjm-17	182	29	patients	patient	NOUN
bptjm-17	182	30	revealed	reveal	VERB
bptjm-17	182	31	an	an	DET
bptjm-17	182	32	88.9	88.9	NUM
bptjm-17	182	33	%	%	NOUN
bptjm-17	182	34	agreement	agreement	NOUN
bptjm-17	182	35	between	between	ADP
bptjm-17	182	36	individual	individual	ADJ
bptjm-17	182	37	copy	copy	NOUN
bptjm-17	182	38	number	number	NOUN
bptjm-17	182	39	calls	call	NOUN
bptjm-17	182	40	of	of	ADP
bptjm-17	182	41	pten	pten	NOUN
bptjm-17	182	42	(	(	PUNCT
bptjm-17	182	43	wyatt	wyatt	PROPN
bptjm-17	182	44	et	et	PROPN
bptjm-17	182	45	al	al	PROPN
bptjm-17	182	46	.	.	PROPN
bptjm-17	182	47	,	,	PUNCT
bptjm-17	182	48	2017	2017	NUM
bptjm-17	182	49	)	)	PUNCT
bptjm-17	182	50	.	.	PUNCT
bptjm-17	183	1	despite	despite	SCONJ
bptjm-17	183	2	the	the	DET
bptjm-17	183	3	higher	high	ADJ
bptjm-17	183	4	concordance	concordance	NOUN
bptjm-17	183	5	rate	rate	NOUN
bptjm-17	183	6	observed	observe	VERB
bptjm-17	183	7	in	in	ADP
bptjm-17	183	8	some	some	DET
bptjm-17	183	9	studies	study	NOUN
bptjm-17	183	10	,	,	PUNCT
bptjm-17	183	11	others	other	NOUN
bptjm-17	183	12	caution	caution	VERB
bptjm-17	183	13	that	that	PRON
bptjm-17	183	14	pten	pten	AUX
bptjm-17	183	15	copy	copy	NOUN
bptjm-17	183	16	number	number	NOUN
bptjm-17	183	17	alterations	alteration	NOUN
bptjm-17	183	18	,	,	PUNCT
bptjm-17	183	19	when	when	SCONJ
bptjm-17	183	20	present	present	ADJ
bptjm-17	183	21	in	in	ADP
bptjm-17	183	22	low	low	ADJ
bptjm-17	183	23	circulating	circulate	VERB
bptjm-17	183	24	concentrations	concentration	NOUN
bptjm-17	183	25	,	,	PUNCT
bptjm-17	183	26	can	can	AUX
bptjm-17	183	27	go	go	VERB
bptjm-17	183	28	undetected	undetected	ADJ
bptjm-17	183	29	(	(	PUNCT
bptjm-17	183	30	vandekerkhove	vandekerkhove	VERB
bptjm-17	183	31	et	et	PROPN
bptjm-17	183	32	al	al	PROPN
bptjm-17	183	33	.	.	PROPN
bptjm-17	183	34	,	,	PUNCT
bptjm-17	183	35	2019	2019	NUM
bptjm-17	183	36	)	)	PUNCT
bptjm-17	183	37	.	.	PUNCT
bptjm-17	184	1	thus	thus	ADV
bptjm-17	184	2	,	,	PUNCT
bptjm-17	184	3	a	a	DET
bptjm-17	184	4	predominant	predominant	ADJ
bptjm-17	184	5	factor	factor	NOUN
bptjm-17	184	6	in	in	ADP
bptjm-17	184	7	the	the	DET
bptjm-17	184	8	standardization	standardization	NOUN
bptjm-17	184	9	of	of	ADP
bptjm-17	184	10	ctdna	ctdna	NOUN
bptjm-17	184	11	assessment	assessment	NOUN
bptjm-17	184	12	is	be	AUX
bptjm-17	184	13	the	the	DET
bptjm-17	184	14	development	development	NOUN
bptjm-17	184	15	of	of	ADP
bptjm-17	184	16	su	su	PROPN
bptjm-17	184	17	ciently	ciently	ADV
bptjm-17	184	18	sensitive	sensitive	ADJ
bptjm-17	184	19	assays	assay	NOUN
bptjm-17	184	20	that	that	PRON
bptjm-17	184	21	have	have	VERB
bptjm-17	184	22	lower	low	ADJ
bptjm-17	184	23	limits	limit	NOUN
bptjm-17	184	24	of	of	ADP
bptjm-17	184	25	detection	detection	NOUN
bptjm-17	184	26	,	,	PUNCT
bptjm-17	184	27	which	which	PRON
bptjm-17	184	28	may	may	AUX
bptjm-17	184	29	preclude	preclude	VERB
bptjm-17	184	30	the	the	DET
bptjm-17	184	31	aforementioned	aforementioned	ADJ
bptjm-17	184	32	issue	issue	NOUN
bptjm-17	184	33	.	.	PUNCT
bptjm-17	185	1	braf	braf	NOUN
bptjm-17	185	2	(	(	PUNCT
bptjm-17	185	3	v600e	v600e	PROPN
bptjm-17	185	4	and	and	CCONJ
bptjm-17	185	5	non	non	ADJ
bptjm-17	185	6	-	-	ADJ
bptjm-17	185	7	v600e	v600e	ADJ
bptjm-17	185	8	)	)	PUNCT
bptjm-17	185	9	braf	braf	NOUN
bptjm-17	185	10	(	(	PUNCT
bptjm-17	185	11	v	v	NOUN
bptjm-17	185	12	-	-	PUNCT
bptjm-17	185	13	raf	raf	NOUN
bptjm-17	185	14	murine	murine	ADJ
bptjm-17	185	15	sarcoma	sarcoma	NOUN
bptjm-17	185	16	viral	viral	ADJ
bptjm-17	185	17	oncogene	oncogene	NOUN
bptjm-17	185	18	homolog	homolog	PROPN
bptjm-17	185	19	b	b	NOUN
bptjm-17	185	20	)	)	PUNCT
bptjm-17	185	21	is	be	AUX
bptjm-17	185	22	a	a	DET
bptjm-17	185	23	serine	serine	NOUN
bptjm-17	185	24	/	/	SYM
bptjm-17	185	25	threonine	threonine	ADJ
bptjm-17	185	26	kinase	kinase	NOUN
bptjm-17	185	27	involved	involve	VERB
bptjm-17	185	28	in	in	ADP
bptjm-17	185	29	the	the	DET
bptjm-17	185	30	ras	ras	PROPN
bptjm-17	185	31	/	/	SYM
bptjm-17	185	32	raf	raf	PROPN
bptjm-17	185	33	/	/	SYM
bptjm-17	185	34	mapk	mapk	NOUN
bptjm-17	185	35	pathway	pathway	NOUN
bptjm-17	185	36	.	.	PUNCT
bptjm-17	186	1	braf	braf	NOUN
bptjm-17	186	2	mutations	mutation	NOUN
bptjm-17	186	3	can	can	AUX
bptjm-17	186	4	be	be	AUX
bptjm-17	186	5	categorized	categorize	VERB
bptjm-17	186	6	in	in	ADP
bptjm-17	186	7	three	three	NUM
bptjm-17	186	8	classes	class	NOUN
bptjm-17	186	9	.	.	PUNCT
bptjm-17	187	1	braf	braf	PROPN
bptjm-17	187	2	v600	v600	PROPN
bptjm-17	187	3	/	/	SYM
bptjm-17	187	4	e	e	NOUN
bptjm-17	187	5	/	/	SYM
bptjm-17	187	6	r	r	NOUN
bptjm-17	187	7	/	/	SYM
bptjm-17	187	8	k	k	PROPN
bptjm-17	187	9	berkeley	berkeley	PROPN
bptjm-17	187	10	pharma	pharma	PROPN
bptjm-17	187	11	tech	tech	NOUN
bptjm-17	187	12	journal	journal	NOUN
bptjm-17	187	13	of	of	ADP
bptjm-17	187	14	medicine	medicine	NOUN
bptjm-17	187	15	|	|	ADV
bptjm-17	187	16	128	128	NUM
bptjm-17	187	17	mutations	mutation	NOUN
bptjm-17	187	18	are	be	AUX
bptjm-17	187	19	class	class	NOUN
bptjm-17	187	20	i	i	PRON
bptjm-17	187	21	mutations	mutation	NOUN
bptjm-17	187	22	that	that	PRON
bptjm-17	187	23	result	result	VERB
bptjm-17	187	24	in	in	ADP
bptjm-17	187	25	strong	strong	ADJ
bptjm-17	187	26	activation	activation	NOUN
bptjm-17	187	27	of	of	ADP
bptjm-17	187	28	braf	braf	NOUN
bptjm-17	187	29	’s	’s	PART
bptjm-17	187	30	kinase	kinase	NOUN
bptjm-17	187	31	activity	activity	NOUN
bptjm-17	187	32	and	and	CCONJ
bptjm-17	187	33	mapk	mapk	NOUN
bptjm-17	187	34	pathway	pathway	NOUN
bptjm-17	187	35	.	.	PUNCT
bptjm-17	188	1	the	the	DET
bptjm-17	188	2	mechanism	mechanism	NOUN
bptjm-17	188	3	of	of	ADP
bptjm-17	188	4	v600e	v600e	NOUN
bptjm-17	188	5	mutations	mutation	NOUN
bptjm-17	188	6	is	be	AUX
bptjm-17	188	7	that	that	SCONJ
bptjm-17	188	8	it	it	PRON
bptjm-17	188	9	can	can	AUX
bptjm-17	188	10	form	form	VERB
bptjm-17	188	11	salt	salt	NOUN
bptjm-17	188	12	bridges	bridge	NOUN
bptjm-17	188	13	with	with	ADP
bptjm-17	188	14	k507	k507	PROPN
bptjm-17	188	15	and	and	CCONJ
bptjm-17	188	16	the	the	DET
bptjm-17	188	17	c	c	NOUN
bptjm-17	188	18	-	-	PUNCT
bptjm-17	188	19	terminal	terminal	NOUN
bptjm-17	188	20	of	of	ADP
bptjm-17	188	21	the	the	DET
bptjm-17	188	22	alpha	alpha	NOUN
bptjm-17	188	23	-	-	PUNCT
bptjm-17	188	24	c	c	NOUN
bptjm-17	188	25	helix	helix	NOUN
bptjm-17	188	26	.	.	PUNCT
bptjm-17	189	1	they	they	PRON
bptjm-17	189	2	signal	signal	VERB
bptjm-17	189	3	as	as	ADP
bptjm-17	189	4	monomers	monomer	NOUN
bptjm-17	189	5	but	but	CCONJ
bptjm-17	189	6	mimic	mimic	VERB
bptjm-17	189	7	the	the	DET
bptjm-17	189	8	dimerization	dimerization	NOUN
bptjm-17	189	9	process	process	NOUN
bptjm-17	189	10	and	and	CCONJ
bptjm-17	189	11	respond	respond	VERB
bptjm-17	189	12	to	to	ADP
bptjm-17	189	13	braf	braf	NOUN
bptjm-17	189	14	inhibitors	inhibitor	NOUN
bptjm-17	189	15	(	(	PUNCT
bptjm-17	189	16	dankner	dankner	NOUN
bptjm-17	189	17	et	et	PROPN
bptjm-17	189	18	al	al	PROPN
bptjm-17	189	19	.	.	PROPN
bptjm-17	189	20	,	,	PUNCT
bptjm-17	189	21	2018	2018	NUM
bptjm-17	189	22	)	)	PUNCT
bptjm-17	189	23	.	.	PUNCT
bptjm-17	190	1	class	class	NOUN
bptjm-17	190	2	ii	ii	PROPN
bptjm-17	190	3	and	and	CCONJ
bptjm-17	190	4	class	class	NOUN
bptjm-17	190	5	iii	iii	NOUN
bptjm-17	190	6	mutations	mutation	NOUN
bptjm-17	190	7	are	be	AUX
bptjm-17	190	8	non	non	ADJ
bptjm-17	190	9	-	-	ADJ
bptjm-17	190	10	v600e	v600e	ADJ
bptjm-17	190	11	mutations	mutation	NOUN
bptjm-17	190	12	.	.	PUNCT
bptjm-17	191	1	class	class	NOUN
bptjm-17	191	2	ii	ii	PROPN
bptjm-17	191	3	mutations	mutation	NOUN
bptjm-17	191	4	have	have	VERB
bptjm-17	191	5	high	high	ADJ
bptjm-17	191	6	or	or	CCONJ
bptjm-17	191	7	intermediate	intermediate	ADJ
bptjm-17	191	8	kinase	kinase	NOUN
bptjm-17	191	9	activity	activity	NOUN
bptjm-17	191	10	and	and	CCONJ
bptjm-17	191	11	serve	serve	VERB
bptjm-17	191	12	as	as	ADP
bptjm-17	191	13	rasindependent	rasindependent	NOUN
bptjm-17	191	14	mutations	mutation	NOUN
bptjm-17	191	15	,	,	PUNCT
bptjm-17	191	16	which	which	PRON
bptjm-17	191	17	signal	signal	VERB
bptjm-17	191	18	as	as	ADP
bptjm-17	191	19	dimers	dimer	NOUN
bptjm-17	191	20	and	and	CCONJ
bptjm-17	191	21	can	can	AUX
bptjm-17	191	22	respond	respond	VERB
bptjm-17	191	23	to	to	ADP
bptjm-17	191	24	mek	mek	PROPN
bptjm-17	191	25	and	and	CCONJ
bptjm-17	191	26	pan	pan	NOUN
bptjm-17	191	27	-	-	ADJ
bptjm-17	191	28	raf	raf	ADJ
bptjm-17	191	29	inhibitors	inhibitor	NOUN
bptjm-17	191	30	.	.	PUNCT
bptjm-17	192	1	class	class	NOUN
bptjm-17	192	2	iii	iii	NUM
bptjm-17	192	3	mutations	mutation	NOUN
bptjm-17	192	4	show	show	VERB
bptjm-17	192	5	low	low	ADJ
bptjm-17	192	6	kinase	kinase	NOUN
bptjm-17	192	7	activity	activity	NOUN
bptjm-17	192	8	and	and	CCONJ
bptjm-17	192	9	are	be	AUX
bptjm-17	192	10	also	also	ADV
bptjm-17	192	11	called	call	VERB
bptjm-17	192	12	ras	ra	VERB
bptjm-17	192	13	-	-	ADJ
bptjm-17	192	14	dependent	dependent	ADJ
bptjm-17	192	15	mutant	mutant	ADJ
bptjm-17	192	16	braf	braf	NOUN
bptjm-17	192	17	-	-	PUNCT
bptjm-17	192	18	wild	wild	NOUN
bptjm-17	192	19	-	-	PUNCT
bptjm-17	192	20	type	type	NOUN
bptjm-17	192	21	.	.	PUNCT
bptjm-17	193	1	class	class	NOUN
bptjm-17	193	2	ii	ii	PROPN
bptjm-17	193	3	and	and	CCONJ
bptjm-17	193	4	class	class	PROPN
bptjm-17	193	5	iii	iii	NUM
bptjm-17	193	6	non	non	ADJ
bptjm-17	193	7	-	-	ADJ
bptjm-17	193	8	v600	v600	ADJ
bptjm-17	193	9	braf	braf	NOUN
bptjm-17	193	10	mutants	mutant	NOUN
bptjm-17	193	11	dimerize	dimerize	VERB
bptjm-17	193	12	with	with	ADP
bptjm-17	193	13	braf	braf	NOUN
bptjm-17	193	14	or	or	CCONJ
bptjm-17	193	15	craf	craf	NOUN
bptjm-17	193	16	(	(	PUNCT
bptjm-17	193	17	dankner	dankner	NOUN
bptjm-17	193	18	et	et	PROPN
bptjm-17	193	19	al	al	PROPN
bptjm-17	193	20	.	.	PROPN
bptjm-17	193	21	,	,	PUNCT
bptjm-17	193	22	2018	2018	NUM
bptjm-17	193	23	)	)	PUNCT
bptjm-17	193	24	.	.	PUNCT
bptjm-17	194	1	a	a	DET
bptjm-17	194	2	study	study	NOUN
bptjm-17	194	3	by	by	ADP
bptjm-17	194	4	lin	lin	PROPN
bptjm-17	194	5	et	et	PROPN
bptjm-17	194	6	al	al	PROPN
bptjm-17	194	7	.	.	PROPN
bptjm-17	194	8	was	be	AUX
bptjm-17	194	9	performed	perform	VERB
bptjm-17	194	10	to	to	PART
bptjm-17	194	11	determine	determine	VERB
bptjm-17	194	12	the	the	DET
bptjm-17	194	13	frequency	frequency	NOUN
bptjm-17	194	14	of	of	ADP
bptjm-17	194	15	braf	braf	NOUN
bptjm-17	194	16	mutations	mutation	NOUN
bptjm-17	194	17	in	in	ADP
bptjm-17	194	18	chinese	chinese	ADJ
bptjm-17	194	19	individuals	individual	NOUN
bptjm-17	194	20	.	.	PUNCT
bptjm-17	195	1	the	the	DET
bptjm-17	195	2	study	study	NOUN
bptjm-17	195	3	determined	determine	VERB
bptjm-17	195	4	that	that	SCONJ
bptjm-17	195	5	1.2	1.2	NUM
bptjm-17	195	6	%	%	NOUN
bptjm-17	195	7	to	to	PART
bptjm-17	195	8	4.2	4.2	NUM
bptjm-17	195	9	%	%	NOUN
bptjm-17	195	10	of	of	ADP
bptjm-17	195	11	nsclc	nsclc	NOUN
bptjm-17	195	12	patients	patient	NOUN
bptjm-17	195	13	in	in	ADP
bptjm-17	195	14	the	the	DET
bptjm-17	195	15	chinese	chinese	ADJ
bptjm-17	195	16	population	population	NOUN
bptjm-17	195	17	had	have	VERB
bptjm-17	195	18	the	the	DET
bptjm-17	195	19	braf	braf	NOUN
bptjm-17	195	20	mutations	mutation	NOUN
bptjm-17	195	21	.	.	PUNCT
bptjm-17	196	1	authors	author	NOUN
bptjm-17	196	2	also	also	ADV
bptjm-17	196	3	determined	determine	VERB
bptjm-17	196	4	that	that	SCONJ
bptjm-17	196	5	only	only	ADV
bptjm-17	196	6	30	30	NUM
bptjm-17	196	7	%	%	NOUN
bptjm-17	196	8	of	of	ADP
bptjm-17	196	9	patients	patient	NOUN
bptjm-17	196	10	with	with	ADP
bptjm-17	196	11	braf	braf	NOUN
bptjm-17	196	12	v600e	v600e	PROPN
bptjm-17	196	13	mutation	mutation	NOUN
bptjm-17	196	14	bene	bene	PROPN
bptjm-17	196	15	ted	te	VERB
bptjm-17	196	16	from	from	ADP
bptjm-17	196	17	braf	braf	NOUN
bptjm-17	196	18	inhibitors	inhibitor	NOUN
bptjm-17	196	19	.	.	PUNCT
bptjm-17	197	1	furthermore	furthermore	ADV
bptjm-17	197	2	,	,	PUNCT
bptjm-17	197	3	lin	lin	PROPN
bptjm-17	197	4	et	et	PROPN
bptjm-17	197	5	al	al	PROPN
bptjm-17	197	6	.	.	PROPN
bptjm-17	197	7	also	also	ADV
bptjm-17	197	8	reported	report	VERB
bptjm-17	197	9	that	that	SCONJ
bptjm-17	197	10	the	the	DET
bptjm-17	197	11	class	class	NOUN
bptjm-17	197	12	i	i	PRON
bptjm-17	197	13	mutation	mutation	NOUN
bptjm-17	197	14	is	be	AUX
bptjm-17	197	15	predominantly	predominantly	ADV
bptjm-17	197	16	found	find	VERB
bptjm-17	197	17	in	in	ADP
bptjm-17	197	18	females	female	NOUN
bptjm-17	197	19	,	,	PUNCT
bptjm-17	197	20	while	while	SCONJ
bptjm-17	197	21	class	class	PROPN
bptjm-17	197	22	ii	ii	PROPN
bptjm-17	197	23	and	and	CCONJ
bptjm-17	197	24	iii	iii	NUM
bptjm-17	197	25	mutations	mutation	NOUN
bptjm-17	197	26	co	co	VERB
bptjm-17	197	27	-	-	VERB
bptjm-17	197	28	occur	occur	VERB
bptjm-17	197	29	with	with	ADP
bptjm-17	197	30	the	the	DET
bptjm-17	197	31	kras	kras	PROPN
bptjm-17	197	32	mutation	mutation	NOUN
bptjm-17	197	33	.	.	PUNCT
bptjm-17	198	1	this	this	DET
bptjm-17	198	2	study	study	NOUN
bptjm-17	198	3	’s	’s	PART
bptjm-17	198	4	impact	impact	NOUN
bptjm-17	198	5	is	be	AUX
bptjm-17	198	6	limited	limit	VERB
bptjm-17	198	7	because	because	SCONJ
bptjm-17	198	8	of	of	ADP
bptjm-17	198	9	its	its	PRON
bptjm-17	198	10	analysis	analysis	NOUN
bptjm-17	198	11	of	of	ADP
bptjm-17	198	12	the	the	DET
bptjm-17	198	13	braf	braf	NOUN
bptjm-17	198	14	mutation	mutation	NOUN
bptjm-17	198	15	in	in	ADP
bptjm-17	198	16	speci	speci	PROPN
bptjm-17	198	17	c	c	PROPN
bptjm-17	198	18	races	race	NOUN
bptjm-17	198	19	and	and	CCONJ
bptjm-17	198	20	ethnicities	ethnicity	NOUN
bptjm-17	198	21	,	,	PUNCT
bptjm-17	198	22	and	and	CCONJ
bptjm-17	198	23	thus	thus	ADV
bptjm-17	198	24	the	the	DET
bptjm-17	198	25	ndings	nding	NOUN
bptjm-17	198	26	can	can	AUX
bptjm-17	198	27	not	not	PART
bptjm-17	198	28	be	be	AUX
bptjm-17	198	29	readily	readily	ADV
bptjm-17	198	30	extrapolated	extrapolate	VERB
bptjm-17	198	31	to	to	ADP
bptjm-17	198	32	other	other	ADJ
bptjm-17	198	33	groups	group	NOUN
bptjm-17	198	34	(	(	PUNCT
bptjm-17	198	35	lin	lin	PROPN
bptjm-17	198	36	et	et	PROPN
bptjm-17	198	37	al	al	PROPN
bptjm-17	198	38	.	.	PROPN
bptjm-17	198	39	,	,	PUNCT
bptjm-17	198	40	2019	2019	NUM
bptjm-17	198	41	)	)	PUNCT
bptjm-17	198	42	.	.	PUNCT
bptjm-17	199	1	in	in	ADP
bptjm-17	199	2	the	the	DET
bptjm-17	199	3	clinical	clinical	ADJ
bptjm-17	199	4	setting	setting	NOUN
bptjm-17	199	5	,	,	PUNCT
bptjm-17	199	6	detection	detection	NOUN
bptjm-17	199	7	of	of	ADP
bptjm-17	199	8	braf	braf	NOUN
bptjm-17	199	9	mutation	mutation	NOUN
bptjm-17	199	10	via	via	ADP
bptjm-17	199	11	liquid	liquid	ADJ
bptjm-17	199	12	or	or	CCONJ
bptjm-17	199	13	tissue	tissue	NOUN
bptjm-17	199	14	biopsy	biopsy	NOUN
bptjm-17	199	15	appears	appear	VERB
bptjm-17	199	16	equally	equally	ADV
bptjm-17	199	17	reliable	reliable	ADJ
bptjm-17	199	18	,	,	PUNCT
bptjm-17	199	19	as	as	SCONJ
bptjm-17	199	20	one	one	NUM
bptjm-17	199	21	study	study	NOUN
bptjm-17	199	22	demonstrated	demonstrate	VERB
bptjm-17	199	23	that	that	SCONJ
bptjm-17	199	24	assessment	assessment	NOUN
bptjm-17	199	25	of	of	ADP
bptjm-17	199	26	braf	braf	NOUN
bptjm-17	199	27	alteration	alteration	NOUN
bptjm-17	199	28	yields	yield	NOUN
bptjm-17	199	29	a	a	DET
bptjm-17	199	30	96.2	96.2	NUM
bptjm-17	199	31	%	%	NOUN
bptjm-17	199	32	concordance	concordance	NOUN
bptjm-17	199	33	rate	rate	NOUN
bptjm-17	199	34	between	between	ADP
bptjm-17	199	35	liquid	liquid	ADJ
bptjm-17	199	36	and	and	CCONJ
bptjm-17	199	37	tissue	tissue	NOUN
bptjm-17	199	38	biopsies	biopsy	NOUN
bptjm-17	199	39	(	(	PUNCT
bptjm-17	199	40	mao	mao	X
bptjm-17	199	41	et	et	PROPN
bptjm-17	199	42	al	al	PROPN
bptjm-17	199	43	.	.	PROPN
bptjm-17	199	44	,	,	PUNCT
bptjm-17	199	45	2017	2017	NUM
bptjm-17	199	46	)	)	PUNCT
bptjm-17	199	47	.	.	PUNCT
bptjm-17	200	1	nf1	nf1	NOUN
bptjm-17	200	2	nf1	nf1	NOUN
bptjm-17	200	3	is	be	AUX
bptjm-17	200	4	a	a	DET
bptjm-17	200	5	tumor	tumor	NOUN
bptjm-17	200	6	suppressor	suppressor	NOUN
bptjm-17	200	7	gene	gene	NOUN
bptjm-17	200	8	that	that	PRON
bptjm-17	200	9	shuts	shut	VERB
bptjm-17	200	10	down	down	ADP
bptjm-17	200	11	activity	activity	NOUN
bptjm-17	200	12	of	of	ADP
bptjm-17	200	13	ras	ras	X
bptjm-17	200	14	protein	protein	NOUN
bptjm-17	200	15	via	via	ADP
bptjm-17	200	16	a	a	DET
bptjm-17	200	17	protein	protein	NOUN
bptjm-17	200	18	called	call	VERB
bptjm-17	200	19	neuro	neuro	PROPN
bptjm-17	200	20	bromin	bromin	PROPN
bptjm-17	200	21	,	,	PUNCT
bptjm-17	200	22	which	which	PRON
bptjm-17	200	23	under	under	ADP
bptjm-17	200	24	normal	normal	ADJ
bptjm-17	200	25	physiological	physiological	ADJ
bptjm-17	200	26	conditions	condition	NOUN
bptjm-17	200	27	stimulates	stimulate	VERB
bptjm-17	200	28	gtpase	gtpase	NOUN
bptjm-17	200	29	activity	activity	NOUN
bptjm-17	200	30	of	of	ADP
bptjm-17	200	31	ras	ra	NOUN
bptjm-17	200	32	and	and	CCONJ
bptjm-17	200	33	converts	convert	VERB
bptjm-17	200	34	active	active	ADJ
bptjm-17	200	35	ras	ras	ADJ
bptjm-17	200	36	-	-	ADJ
bptjm-17	200	37	gtp	gtp	NOUN
bptjm-17	200	38	complex	complex	NOUN
bptjm-17	200	39	to	to	ADP
bptjm-17	200	40	its	its	PRON
bptjm-17	200	41	inactive	inactive	ADJ
bptjm-17	200	42	ras	ras	ADJ
bptjm-17	200	43	-	-	ADJ
bptjm-17	200	44	gdp	gdp	NOUN
bptjm-17	200	45	complex	complex	NOUN
bptjm-17	200	46	.	.	PUNCT
bptjm-17	201	1	this	this	DET
bptjm-17	201	2	inactivation	inactivation	NOUN
bptjm-17	201	3	can	can	AUX
bptjm-17	201	4	lead	lead	VERB
bptjm-17	201	5	to	to	ADP
bptjm-17	201	6	the	the	DET
bptjm-17	201	7	shutdown	shutdown	NOUN
bptjm-17	201	8	of	of	ADP
bptjm-17	201	9	ras	ras	PROPN
bptjm-17	201	10	associated	associated	ADJ
bptjm-17	201	11	gtpases	gtpase	NOUN
bptjm-17	201	12	(	(	PUNCT
bptjm-17	201	13	i.e.	i.e.	X
bptjm-17	201	14	kras	kras	PROPN
bptjm-17	201	15	,	,	PUNCT
bptjm-17	201	16	nras	nras	PROPN
bptjm-17	201	17	,	,	PUNCT
bptjm-17	201	18	mras	mra	NOUN
bptjm-17	201	19	,	,	PUNCT
bptjm-17	201	20	hras	hra	NOUN
bptjm-17	201	21	,	,	PUNCT
bptjm-17	201	22	rras	rra	NOUN
bptjm-17	201	23	,	,	PUNCT
bptjm-17	201	24	and	and	CCONJ
bptjm-17	201	25	rras2	rras2	PROPN
bptjm-17	201	26	)	)	PUNCT
bptjm-17	201	27	.	.	PUNCT
bptjm-17	202	1	in	in	ADP
bptjm-17	202	2	patients	patient	NOUN
bptjm-17	202	3	with	with	ADP
bptjm-17	202	4	the	the	DET
bptjm-17	202	5	nf1	nf1	NOUN
bptjm-17	202	6	mutation	mutation	NOUN
bptjm-17	202	7	,	,	PUNCT
bptjm-17	202	8	there	there	PRON
bptjm-17	202	9	is	be	VERB
bptjm-17	202	10	a	a	DET
bptjm-17	202	11	loss	loss	NOUN
bptjm-17	202	12	of	of	ADP
bptjm-17	202	13	functional	functional	ADJ
bptjm-17	202	14	neuro	neuro	PROPN
bptjm-17	202	15	bromin	bromin	PROPN
bptjm-17	202	16	,	,	PUNCT
bptjm-17	202	17	which	which	PRON
bptjm-17	202	18	can	can	AUX
bptjm-17	202	19	lead	lead	VERB
bptjm-17	202	20	to	to	ADP
bptjm-17	202	21	accumulation	accumulation	NOUN
bptjm-17	202	22	of	of	ADP
bptjm-17	202	23	active	active	ADJ
bptjm-17	202	24	ras	ras	PROPN
bptjm-17	202	25	gtpases	gtpase	NOUN
bptjm-17	202	26	.	.	PUNCT
bptjm-17	203	1	this	this	DET
bptjm-17	203	2	results	result	NOUN
bptjm-17	203	3	in	in	ADP
bptjm-17	203	4	excessive	excessive	ADJ
bptjm-17	203	5	cellular	cellular	ADJ
bptjm-17	203	6	proliferation	proliferation	NOUN
bptjm-17	203	7	and	and	CCONJ
bptjm-17	203	8	tumor	tumor	NOUN
bptjm-17	203	9	formation	formation	NOUN
bptjm-17	203	10	which	which	PRON
bptjm-17	203	11	can	can	AUX
bptjm-17	203	12	lead	lead	VERB
bptjm-17	203	13	to	to	ADP
bptjm-17	203	14	the	the	DET
bptjm-17	203	15	development	development	NOUN
bptjm-17	203	16	of	of	ADP
bptjm-17	203	17	additional	additional	ADJ
bptjm-17	203	18	mutations	mutation	NOUN
bptjm-17	203	19	,	,	PUNCT
bptjm-17	203	20	apart	apart	ADV
bptjm-17	203	21	from	from	ADP
bptjm-17	203	22	those	those	DET
bptjm-17	203	23	a	a	DET
bptjm-17	203	24	ecting	ecte	VERB
bptjm-17	203	25	ras	ras	NOUN
bptjm-17	203	26	activity	activity	NOUN
bptjm-17	203	27	.	.	PUNCT
bptjm-17	204	1	beau	beau	PROPN
bptjm-17	204	2	-	-	PUNCT
bptjm-17	204	3	champ	champ	NOUN
bptjm-17	204	4	et	et	PROPN
bptjm-17	204	5	al	al	PROPN
bptjm-17	204	6	.	.	PROPN
bptjm-17	205	1	berkeley	berkeley	PROPN
bptjm-17	205	2	pharma	pharma	PROPN
bptjm-17	205	3	tech	tech	PROPN
bptjm-17	205	4	journal	journal	NOUN
bptjm-17	205	5	of	of	ADP
bptjm-17	205	6	medicine	medicine	NOUN
bptjm-17	205	7	|	|	ADV
bptjm-17	205	8	129	129	NUM
bptjm-17	205	9	found	find	VERB
bptjm-17	205	10	that	that	SCONJ
bptjm-17	205	11	loss	loss	NOUN
bptjm-17	205	12	of	of	ADP
bptjm-17	205	13	nf1	nf1	NOUN
bptjm-17	205	14	has	have	AUX
bptjm-17	205	15	shown	show	VERB
bptjm-17	205	16	response	response	NOUN
bptjm-17	205	17	to	to	ADP
bptjm-17	205	18	dasatinib	dasatinib	NOUN
bptjm-17	205	19	in	in	ADP
bptjm-17	205	20	dasatinib	dasatinib	NOUN
bptjm-17	205	21	-	-	PUNCT
bptjm-17	205	22	resistant	resistant	ADJ
bptjm-17	205	23	lung	lung	NOUN
bptjm-17	205	24	cancer	cancer	NOUN
bptjm-17	205	25	(	(	PUNCT
bptjm-17	205	26	2014	2014	NUM
bptjm-17	205	27	)	)	PUNCT
bptjm-17	205	28	.	.	PUNCT
bptjm-17	206	1	furthermore	furthermore	ADV
bptjm-17	206	2	,	,	PUNCT
bptjm-17	206	3	low	low	ADJ
bptjm-17	206	4	levels	level	NOUN
bptjm-17	206	5	of	of	ADP
bptjm-17	206	6	nf1	nf1	NOUN
bptjm-17	206	7	with	with	ADP
bptjm-17	206	8	map	map	NOUN
bptjm-17	206	9	-	-	PUNCT
bptjm-17	206	10	erk	erk	NOUN
bptjm-17	206	11	expression	expression	NOUN
bptjm-17	206	12	can	can	AUX
bptjm-17	206	13	be	be	AUX
bptjm-17	206	14	sensitive	sensitive	ADJ
bptjm-17	206	15	to	to	ADP
bptjm-17	206	16	erlotinib	erlotinib	VERB
bptjm-17	206	17	and	and	CCONJ
bptjm-17	206	18	reverse	reverse	VERB
bptjm-17	206	19	the	the	DET
bptjm-17	206	20	erlotinib	erlotinib	ADJ
bptjm-17	206	21	resistance	resistance	NOUN
bptjm-17	206	22	(	(	PUNCT
bptjm-17	206	23	tao	tao	PROPN
bptjm-17	206	24	et	et	PROPN
bptjm-17	206	25	al	al	PROPN
bptjm-17	206	26	.	.	PROPN
bptjm-17	206	27	,	,	PUNCT
bptjm-17	206	28	2020	2020	NUM
bptjm-17	206	29	)	)	PUNCT
bptjm-17	206	30	.	.	PUNCT
bptjm-17	207	1	tki	tki	PROPN
bptjm-17	207	2	resistant	resistant	ADJ
bptjm-17	207	3	nf1	nf1	NOUN
bptjm-17	207	4	mutations	mutation	NOUN
bptjm-17	207	5	develop	develop	VERB
bptjm-17	207	6	by	by	ADP
bptjm-17	207	7	the	the	DET
bptjm-17	207	8	following	follow	VERB
bptjm-17	207	9	mechanisms	mechanism	NOUN
bptjm-17	207	10	:	:	PUNCT
bptjm-17	207	11	1	1	X
bptjm-17	207	12	.	.	X
bptjm-17	207	13	activation	activation	NOUN
bptjm-17	207	14	of	of	ADP
bptjm-17	207	15	heat	heat	NOUN
bptjm-17	207	16	shock	shock	NOUN
bptjm-17	207	17	factor	factor	NOUN
bptjm-17	207	18	1	1	NUM
bptjm-17	207	19	2	2	NUM
bptjm-17	207	20	.	.	PUNCT
bptjm-17	207	21	inhibition	inhibition	NOUN
bptjm-17	207	22	of	of	ADP
bptjm-17	207	23	tumor	tumor	NOUN
bptjm-17	207	24	cell	cell	NOUN
bptjm-17	207	25	apoptosis	apoptosis	NOUN
bptjm-17	207	26	3	3	NUM
bptjm-17	207	27	.	.	PUNCT
bptjm-17	207	28	promotion	promotion	NOUN
bptjm-17	207	29	of	of	ADP
bptjm-17	207	30	epithelial	epithelial	ADJ
bptjm-17	207	31	-	-	PUNCT
bptjm-17	207	32	mesenchymal	mesenchymal	NOUN
bptjm-17	207	33	transformation	transformation	NOUN
bptjm-17	207	34	4	4	NUM
bptjm-17	207	35	.	.	PUNCT
bptjm-17	207	36	promotion	promotion	NOUN
bptjm-17	207	37	of	of	ADP
bptjm-17	207	38	sustained	sustained	ADJ
bptjm-17	207	39	angiogenesis	angiogenesis	NOUN
bptjm-17	207	40	chian	chian	NOUN
bptjm-17	207	41	et	et	PROPN
bptjm-17	207	42	al	al	PROPN
bptjm-17	207	43	.	.	PROPN
bptjm-17	207	44	performed	perform	VERB
bptjm-17	207	45	a	a	DET
bptjm-17	207	46	case	case	NOUN
bptjm-17	207	47	-	-	PUNCT
bptjm-17	207	48	control	control	NOUN
bptjm-17	207	49	study	study	NOUN
bptjm-17	207	50	in	in	ADP
bptjm-17	207	51	the	the	DET
bptjm-17	207	52	blood	blood	NOUN
bptjm-17	207	53	samples	sample	NOUN
bptjm-17	207	54	of	of	ADP
bptjm-17	207	55	187	187	NUM
bptjm-17	207	56	patients	patient	NOUN
bptjm-17	207	57	with	with	ADP
bptjm-17	207	58	nsclc	nsclc	NOUN
bptjm-17	207	59	and	and	CCONJ
bptjm-17	207	60	310	310	NUM
bptjm-17	207	61	non	non	ADJ
bptjm-17	207	62	-	-	ADJ
bptjm-17	207	63	cancer	cancer	ADJ
bptjm-17	207	64	patients	patient	NOUN
bptjm-17	207	65	.	.	PUNCT
bptjm-17	208	1	authors	author	NOUN
bptjm-17	208	2	used	use	VERB
bptjm-17	208	3	quantitative	quantitative	ADJ
bptjm-17	208	4	pcr	pcr	NOUN
bptjm-17	208	5	to	to	PART
bptjm-17	208	6	identify	identify	VERB
bptjm-17	208	7	age	age	NOUN
bptjm-17	208	8	and	and	CCONJ
bptjm-17	208	9	gender	gender	NOUN
bptjm-17	208	10	-	-	PUNCT
bptjm-17	208	11	based	base	VERB
bptjm-17	208	12	biomarkers	biomarker	NOUN
bptjm-17	208	13	(	(	PUNCT
bptjm-17	208	14	cpeb4	cpeb4	NOUN
bptjm-17	208	15	,	,	PUNCT
bptjm-17	208	16	dusp6	dusp6	PROPN
bptjm-17	208	17	,	,	PUNCT
bptjm-17	208	18	eif2s3	eif2s3	NOUN
bptjm-17	208	19	,	,	PUNCT
bptjm-17	208	20	grb2	grb2	PROPN
bptjm-17	208	21	,	,	PUNCT
bptjm-17	208	22	mcm4	mcm4	PROPN
bptjm-17	208	23	,	,	PUNCT
bptjm-17	208	24	mdm2	mdm2	PROPN
bptjm-17	208	25	,	,	PUNCT
bptjm-17	208	26	nf1	nf1	NOUN
bptjm-17	208	27	,	,	PUNCT
bptjm-17	208	28	poldip2	poldip2	PROPN
bptjm-17	208	29	,	,	PUNCT
bptjm-17	208	30	rnf4	rnf4	VERB
bptjm-17	208	31	,	,	PUNCT
bptjm-17	208	32	stat2	stat2	NOUN
bptjm-17	208	33	,	,	PUNCT
bptjm-17	208	34	and	and	CCONJ
bptjm-17	208	35	wee1	wee1	PROPN
bptjm-17	208	36	)	)	PUNCT
bptjm-17	208	37	.	.	PUNCT
bptjm-17	209	1	the	the	DET
bptjm-17	209	2	majority	majority	NOUN
bptjm-17	209	3	of	of	ADP
bptjm-17	209	4	the	the	DET
bptjm-17	209	5	population	population	NOUN
bptjm-17	209	6	was	be	AUX
bptjm-17	209	7	comprised	comprise	VERB
bptjm-17	209	8	of	of	ADP
bptjm-17	209	9	males	male	NOUN
bptjm-17	209	10	66	66	NUM
bptjm-17	209	11	years	year	NOUN
bptjm-17	209	12	and	and	CCONJ
bptjm-17	209	13	older	old	ADJ
bptjm-17	209	14	,	,	PUNCT
bptjm-17	209	15	as	as	ADV
bptjm-17	209	16	well	well	ADV
bptjm-17	209	17	as	as	ADP
bptjm-17	209	18	smokers	smoker	NOUN
bptjm-17	209	19	.	.	PUNCT
bptjm-17	210	1	participants	participant	NOUN
bptjm-17	210	2	who	who	PRON
bptjm-17	210	3	never	never	ADV
bptjm-17	210	4	smoked	smoke	VERB
bptjm-17	210	5	expressed	express	VERB
bptjm-17	210	6	nf1	nf1	NOUN
bptjm-17	210	7	at	at	ADP
bptjm-17	210	8	lower	low	ADJ
bptjm-17	210	9	levels	level	NOUN
bptjm-17	210	10	.	.	PUNCT
bptjm-17	211	1	nf1	nf1	NOUN
bptjm-17	211	2	also	also	ADV
bptjm-17	211	3	had	have	VERB
bptjm-17	211	4	protective	protective	ADJ
bptjm-17	211	5	e	e	NOUN
bptjm-17	211	6	ects	ect	NOUN
bptjm-17	211	7	compared	compare	VERB
bptjm-17	211	8	to	to	ADP
bptjm-17	211	9	mdm2	mdm2	NOUN
bptjm-17	211	10	gene	gene	NOUN
bptjm-17	211	11	.	.	PUNCT
bptjm-17	212	1	nf1	nf1	NOUN
bptjm-17	212	2	was	be	AUX
bptjm-17	212	3	shown	show	VERB
bptjm-17	212	4	to	to	PART
bptjm-17	212	5	be	be	AUX
bptjm-17	212	6	an	an	DET
bptjm-17	212	7	age	age	NOUN
bptjm-17	212	8	-	-	PUNCT
bptjm-17	212	9	dependent	dependent	ADJ
bptjm-17	212	10	marker	marker	NOUN
bptjm-17	212	11	(	(	PUNCT
bptjm-17	212	12	or	or	CCONJ
bptjm-17	212	13	:	:	PUNCT
bptjm-17	212	14	0.16	0.16	NUM
bptjm-17	212	15	,	,	PUNCT
bptjm-17	212	16	ci	ci	NOUN
bptjm-17	212	17	:	:	PUNCT
bptjm-17	212	18	0.14	0.14	NUM
bptjm-17	212	19	to	to	ADP
bptjm-17	212	20	0.88	0.88	NUM
bptjm-17	212	21	,	,	PUNCT
bptjm-17	212	22	p	p	NOUN
bptjm-17	212	23	-	-	PUNCT
bptjm-17	212	24	value	value	NOUN
bptjm-17	212	25	:	:	PUNCT
bptjm-17	212	26	0.0255	0.0255	NUM
bptjm-17	212	27	)	)	PUNCT
bptjm-17	212	28	.	.	PUNCT
bptjm-17	213	1	pik3ca	pik3ca	VERB
bptjm-17	213	2	hyperactivation	hyperactivation	NOUN
bptjm-17	213	3	of	of	ADP
bptjm-17	213	4	the	the	DET
bptjm-17	213	5	pi3k	pi3k	PROPN
bptjm-17	213	6	/	/	SYM
bptjm-17	213	7	akt	akt	PROPN
bptjm-17	213	8	pathway	pathway	NOUN
bptjm-17	213	9	is	be	AUX
bptjm-17	213	10	common	common	ADJ
bptjm-17	213	11	in	in	ADP
bptjm-17	213	12	nsclc	nsclc	NOUN
bptjm-17	213	13	patients	patient	NOUN
bptjm-17	213	14	.	.	PUNCT
bptjm-17	214	1	this	this	DET
bptjm-17	214	2	pathway	pathway	NOUN
bptjm-17	214	3	is	be	AUX
bptjm-17	214	4	involved	involve	VERB
bptjm-17	214	5	in	in	ADP
bptjm-17	214	6	interfering	interfere	VERB
bptjm-17	214	7	with	with	ADP
bptjm-17	214	8	various	various	ADJ
bptjm-17	214	9	cellular	cellular	ADJ
bptjm-17	214	10	mechanisms	mechanism	NOUN
bptjm-17	214	11	such	such	ADJ
bptjm-17	214	12	as	as	ADP
bptjm-17	214	13	proliferation	proliferation	NOUN
bptjm-17	214	14	,	,	PUNCT
bptjm-17	214	15	migration	migration	NOUN
bptjm-17	214	16	,	,	PUNCT
bptjm-17	214	17	invasion	invasion	NOUN
bptjm-17	214	18	,	,	PUNCT
bptjm-17	214	19	and	and	CCONJ
bptjm-17	214	20	resistance	resistance	NOUN
bptjm-17	214	21	to	to	ADP
bptjm-17	214	22	therapy	therapy	NOUN
bptjm-17	214	23	.	.	PUNCT
bptjm-17	215	1	mutations	mutation	NOUN
bptjm-17	215	2	in	in	ADP
bptjm-17	215	3	akt	akt	PROPN
bptjm-17	215	4	,	,	PUNCT
bptjm-17	215	5	the	the	DET
bptjm-17	215	6	catalytic	catalytic	ADJ
bptjm-17	215	7	subunit	subunit	NOUN
bptjm-17	215	8	of	of	ADP
bptjm-17	215	9	pik3ca	pik3ca	PROPN
bptjm-17	215	10	,	,	PUNCT
bptjm-17	215	11	or	or	CCONJ
bptjm-17	215	12	pten	pten	VERB
bptjm-17	215	13	downregulation	downregulation	NOUN
bptjm-17	215	14	can	can	AUX
bptjm-17	215	15	activate	activate	VERB
bptjm-17	215	16	the	the	DET
bptjm-17	215	17	akt	akt	PROPN
bptjm-17	215	18	pathway	pathway	NOUN
bptjm-17	215	19	.	.	PUNCT
bptjm-17	216	1	sawa	sawa	PROPN
bptjm-17	216	2	et	et	PROPN
bptjm-17	216	3	al	al	PROPN
bptjm-17	216	4	.	.	PROPN
bptjm-17	216	5	determined	determine	VERB
bptjm-17	216	6	a	a	DET
bptjm-17	216	7	relationship	relationship	NOUN
bptjm-17	216	8	between	between	ADP
bptjm-17	216	9	pik3ca	pik3ca	NOUN
bptjm-17	216	10	mutation	mutation	NOUN
bptjm-17	216	11	and	and	CCONJ
bptjm-17	216	12	lung	lung	NOUN
bptjm-17	216	13	cancer	cancer	NOUN
bptjm-17	216	14	in	in	ADP
bptjm-17	216	15	patients	patient	NOUN
bptjm-17	216	16	with	with	ADP
bptjm-17	216	17	copd	copd	NOUN
bptjm-17	216	18	.	.	PUNCT
bptjm-17	217	1	the	the	DET
bptjm-17	217	2	researchers	researcher	NOUN
bptjm-17	217	3	extracted	extract	VERB
bptjm-17	217	4	dna	dna	NOUN
bptjm-17	217	5	from	from	ADP
bptjm-17	217	6	the	the	DET
bptjm-17	217	7	surgical	surgical	ADJ
bptjm-17	217	8	specimens	specimen	NOUN
bptjm-17	217	9	of	of	ADP
bptjm-17	217	10	197	197	NUM
bptjm-17	217	11	patients	patient	NOUN
bptjm-17	217	12	and	and	CCONJ
bptjm-17	217	13	analyzed	analyze	VERB
bptjm-17	217	14	using	use	VERB
bptjm-17	217	15	deep	deep	ADJ
bptjm-17	217	16	sequencing	sequencing	NOUN
bptjm-17	217	17	techniques	technique	NOUN
bptjm-17	217	18	.	.	PUNCT
bptjm-17	218	1	the	the	DET
bptjm-17	218	2	frequency	frequency	NOUN
bptjm-17	218	3	of	of	ADP
bptjm-17	218	4	pik3camutation	pik3camutation	PROPN
bptjm-17	218	5	was	be	AUX
bptjm-17	218	6	signi	signi	ADJ
bptjm-17	218	7	cantly	cantly	ADV
bptjm-17	218	8	higher	high	ADJ
bptjm-17	218	9	in	in	ADP
bptjm-17	218	10	the	the	DET
bptjm-17	218	11	copd	copd	NOUN
bptjm-17	218	12	group	group	NOUN
bptjm-17	218	13	than	than	ADP
bptjm-17	218	14	in	in	ADP
bptjm-17	218	15	the	the	DET
bptjm-17	218	16	non	non	ADJ
bptjm-17	218	17	-	-	ADJ
bptjm-17	218	18	copd	copd	ADJ
bptjm-17	218	19	group	group	NOUN
bptjm-17	218	20	(	(	PUNCT
bptjm-17	218	21	10.4	10.4	NUM
bptjm-17	218	22	%	%	NOUN
bptjm-17	218	23	vs.	vs.	ADP
bptjm-17	218	24	1.7	1.7	NUM
bptjm-17	218	25	%	%	NOUN
bptjm-17	218	26	,	,	PUNCT
bptjm-17	218	27	p	p	X
bptjm-17	218	28	=	=	NOUN
bptjm-17	218	29	0.015	0.015	NUM
bptjm-17	218	30	)	)	PUNCT
bptjm-17	218	31	.	.	PUNCT
bptjm-17	219	1	the	the	DET
bptjm-17	219	2	pik3ca	pik3ca	PROPN
bptjm-17	219	3	gene	gene	NOUN
bptjm-17	219	4	mutation	mutation	NOUN
bptjm-17	219	5	can	can	AUX
bptjm-17	219	6	a	a	DET
bptjm-17	219	7	ect	ect	VERB
bptjm-17	219	8	the	the	DET
bptjm-17	219	9	prognosis	prognosis	NOUN
bptjm-17	219	10	of	of	ADP
bptjm-17	219	11	nsclc	nsclc	NOUN
bptjm-17	219	12	through	through	ADP
bptjm-17	219	13	several	several	ADJ
bptjm-17	219	14	mechanisms	mechanism	NOUN
bptjm-17	219	15	.	.	PUNCT
bptjm-17	220	1	a	a	DET
bptjm-17	220	2	systematic	systematic	ADJ
bptjm-17	220	3	review	review	NOUN
bptjm-17	220	4	and	and	CCONJ
bptjm-17	220	5	meta	meta	ADJ
bptjm-17	220	6	-	-	PUNCT
bptjm-17	220	7	analysis	analysis	NOUN
bptjm-17	220	8	performed	perform	VERB
bptjm-17	220	9	by	by	ADP
bptjm-17	220	10	wang	wang	PROPN
bptjm-17	220	11	et	et	PROPN
bptjm-17	220	12	al	al	PROPN
bptjm-17	220	13	.	.	PROPN
bptjm-17	220	14	showed	show	VERB
bptjm-17	220	15	that	that	SCONJ
bptjm-17	220	16	pik3ca	pik3ca	NOUN
bptjm-17	220	17	expression	expression	NOUN
bptjm-17	220	18	status	status	NOUN
bptjm-17	220	19	was	be	AUX
bptjm-17	220	20	not	not	PART
bptjm-17	220	21	an	an	DET
bptjm-17	220	22	independent	independent	ADJ
bptjm-17	220	23	risk	risk	NOUN
bptjm-17	220	24	factor	factor	NOUN
bptjm-17	220	25	for	for	ADP
bptjm-17	220	26	os	os	NOUN
bptjm-17	220	27	of	of	ADP
bptjm-17	220	28	nsclc	nsclc	NOUN
bptjm-17	220	29	patients	patient	NOUN
bptjm-17	220	30	(	(	PUNCT
bptjm-17	220	31	hr	hr	NOUN
bptjm-17	220	32	=	=	SYM
bptjm-17	220	33	0:80	0:80	NUM
bptjm-17	220	34	;	;	PUNCT
bptjm-17	220	35	95	95	NUM
bptjm-17	220	36	%	%	NOUN
bptjm-17	220	37	ci	ci	NOUN
bptjm-17	220	38	:	:	PUNCT
bptjm-17	220	39	0.58	0.58	NUM
bptjm-17	220	40	-	-	SYM
bptjm-17	220	41	1.12	1.12	NUM
bptjm-17	220	42	;	;	PUNCT
bptjm-17	220	43	p	p	X
bptjm-17	220	44	=	=	PUNCT
bptjm-17	220	45	0:193	0:193	NUM
bptjm-17	220	46	)	)	PUNCT
bptjm-17	220	47	,	,	PUNCT
bptjm-17	220	48	which	which	PRON
bptjm-17	220	49	is	be	AUX
bptjm-17	220	50	consistent	consistent	ADJ
bptjm-17	220	51	with	with	ADP
bptjm-17	220	52	the	the	DET
bptjm-17	220	53	results	result	NOUN
bptjm-17	220	54	of	of	ADP
bptjm-17	220	55	3	3	NUM
bptjm-17	220	56	included	include	VERB
bptjm-17	220	57	studies	study	NOUN
bptjm-17	220	58	.	.	PUNCT
bptjm-17	221	1	berkeley	berkeley	PROPN
bptjm-17	221	2	pharma	pharma	PROPN
bptjm-17	221	3	tech	tech	PROPN
bptjm-17	221	4	journal	journal	NOUN
bptjm-17	221	5	of	of	ADP
bptjm-17	221	6	medicine	medicine	NOUN
bptjm-17	221	7	|	|	ADV
bptjm-17	221	8	130	130	NUM
bptjm-17	221	9	ros1	ros1	PROPN
bptjm-17	221	10	ros1	ros1	PROPN
bptjm-17	221	11	is	be	AUX
bptjm-17	221	12	a	a	DET
bptjm-17	221	13	receptor	receptor	NOUN
bptjm-17	221	14	tyrosine	tyrosine	NOUN
bptjm-17	221	15	kinase	kinase	PROPN
bptjm-17	221	16	similar	similar	ADJ
bptjm-17	221	17	to	to	PART
bptjm-17	221	18	alk	alk	VERB
bptjm-17	221	19	.	.	PUNCT
bptjm-17	222	1	it	it	PRON
bptjm-17	222	2	is	be	AUX
bptjm-17	222	3	a	a	DET
bptjm-17	222	4	single	single	ADJ
bptjm-17	222	5	-	-	PUNCT
bptjm-17	222	6	pass	pass	NOUN
bptjm-17	222	7	transmembrane	transmembrane	ADJ
bptjm-17	222	8	protein	protein	NOUN
bptjm-17	222	9	with	with	ADP
bptjm-17	222	10	an	an	DET
bptjm-17	222	11	intracellular	intracellular	ADJ
bptjm-17	222	12	c	c	NOUN
bptjm-17	222	13	-	-	PUNCT
bptjm-17	222	14	terminal	terminal	ADJ
bptjm-17	222	15	tyrosine	tyrosine	NOUN
bptjm-17	222	16	kinase	kinase	PROPN
bptjm-17	222	17	domain	domain	PROPN
bptjm-17	222	18	and	and	CCONJ
bptjm-17	222	19	an	an	DET
bptjm-17	222	20	extracellular	extracellular	ADJ
bptjm-17	222	21	n	n	CCONJ
bptjm-17	222	22	-	-	PUNCT
bptjm-17	222	23	terminal	terminal	ADJ
bptjm-17	222	24	domain	domain	NOUN
bptjm-17	222	25	.	.	PUNCT
bptjm-17	223	1	ros1	ros1	PROPN
bptjm-17	223	2	’s	’s	PART
bptjm-17	223	3	extracellular	extracellular	ADJ
bptjm-17	223	4	domain	domain	NOUN
bptjm-17	223	5	has	have	VERB
bptjm-17	223	6	similar	similar	ADJ
bptjm-17	223	7	amino	amino	NOUN
bptjm-17	223	8	acid	acid	NOUN
bptjm-17	223	9	sequences	sequence	NOUN
bptjm-17	223	10	to	to	ADP
bptjm-17	223	11	that	that	PRON
bptjm-17	223	12	of	of	ADP
bptjm-17	223	13	cell	cell	NOUN
bptjm-17	223	14	adhesion	adhesion	NOUN
bptjm-17	223	15	molecules	molecule	NOUN
bptjm-17	223	16	and	and	CCONJ
bptjm-17	223	17	the	the	DET
bptjm-17	223	18	extracellular	extracellular	ADJ
bptjm-17	223	19	matrix	matrix	NOUN
bptjm-17	223	20	.	.	PUNCT
bptjm-17	224	1	typically	typically	ADV
bptjm-17	224	2	,	,	PUNCT
bptjm-17	224	3	ros1	ros1	PROPN
bptjm-17	224	4	is	be	AUX
bptjm-17	224	5	expressed	express	VERB
bptjm-17	224	6	more	more	ADV
bptjm-17	224	7	in	in	ADP
bptjm-17	224	8	the	the	DET
bptjm-17	224	9	kidneys	kidney	NOUN
bptjm-17	224	10	than	than	ADP
bptjm-17	224	11	in	in	ADP
bptjm-17	224	12	the	the	DET
bptjm-17	224	13	lungs	lung	NOUN
bptjm-17	224	14	.	.	PUNCT
bptjm-17	225	1	the	the	DET
bptjm-17	225	2	mechanism	mechanism	NOUN
bptjm-17	225	3	of	of	ADP
bptjm-17	225	4	ros1	ros1	PROPN
bptjm-17	225	5	mutations	mutation	NOUN
bptjm-17	225	6	is	be	AUX
bptjm-17	225	7	currently	currently	ADV
bptjm-17	225	8	unknown	unknown	ADJ
bptjm-17	225	9	.	.	PUNCT
bptjm-17	226	1	in	in	ADP
bptjm-17	226	2	general	general	ADJ
bptjm-17	226	3	,	,	PUNCT
bptjm-17	226	4	ros1	ros1	PROPN
bptjm-17	226	5	rearrangement	rearrangement	NOUN
bptjm-17	226	6	occurs	occur	VERB
bptjm-17	226	7	in	in	ADP
bptjm-17	226	8	the	the	DET
bptjm-17	226	9	absence	absence	NOUN
bptjm-17	226	10	of	of	ADP
bptjm-17	226	11	other	other	ADJ
bptjm-17	226	12	known	know	VERB
bptjm-17	226	13	oncogenic	oncogenic	ADJ
bptjm-17	226	14	drivers	driver	NOUN
bptjm-17	226	15	(	(	PUNCT
bptjm-17	226	16	egfr	egfr	ADJ
bptjm-17	226	17	mutations	mutation	NOUN
bptjm-17	226	18	,	,	PUNCT
bptjm-17	226	19	kras	kras	PROPN
bptjm-17	226	20	mutations	mutation	NOUN
bptjm-17	226	21	,	,	PUNCT
bptjm-17	226	22	alk	alk	VERB
bptjm-17	226	23	rearrangements	rearrangement	NOUN
bptjm-17	226	24	)	)	PUNCT
bptjm-17	226	25	.	.	PUNCT
bptjm-17	227	1	there	there	PRON
bptjm-17	227	2	are	be	VERB
bptjm-17	227	3	some	some	DET
bptjm-17	227	4	exceptions	exception	NOUN
bptjm-17	227	5	as	as	ADV
bptjm-17	227	6	well	well	ADV
bptjm-17	227	7	,	,	PUNCT
bptjm-17	227	8	which	which	PRON
bptjm-17	227	9	exclude	exclude	VERB
bptjm-17	227	10	it	it	PRON
bptjm-17	227	11	to	to	PART
bptjm-17	227	12	be	be	AUX
bptjm-17	227	13	useful	useful	ADJ
bptjm-17	227	14	in	in	ADP
bptjm-17	227	15	screening	screen	VERB
bptjm-17	227	16	.	.	PUNCT
bptjm-17	228	1	ros1	ros1	PROPN
bptjm-17	228	2	can	can	AUX
bptjm-17	228	3	be	be	AUX
bptjm-17	228	4	identi	identi	ADJ
bptjm-17	228	5	ed	ed	NOUN
bptjm-17	228	6	via	via	ADP
bptjm-17	228	7	the	the	DET
bptjm-17	228	8	fish	fish	NOUN
bptjm-17	228	9	and	and	CCONJ
bptjm-17	228	10	rt	rt	ADJ
bptjm-17	228	11	-	-	PUNCT
bptjm-17	228	12	pcr	pcr	NOUN
bptjm-17	228	13	techniques	technique	NOUN
bptjm-17	228	14	,	,	PUNCT
bptjm-17	228	15	but	but	CCONJ
bptjm-17	228	16	rt	rt	NOUN
bptjm-17	228	17	-	-	PUNCT
bptjm-17	228	18	pcr	pcr	NOUN
bptjm-17	228	19	sometimes	sometimes	ADV
bptjm-17	228	20	yields	yield	VERB
bptjm-17	228	21	false	false	ADJ
bptjm-17	228	22	negatives	negative	NOUN
bptjm-17	228	23	.	.	PUNCT
bptjm-17	229	1	ihc	ihc	PROPN
bptjm-17	229	2	is	be	AUX
bptjm-17	229	3	another	another	DET
bptjm-17	229	4	technique	technique	NOUN
bptjm-17	229	5	used	use	VERB
bptjm-17	229	6	to	to	PART
bptjm-17	229	7	detect	detect	VERB
bptjm-17	229	8	mutations	mutation	NOUN
bptjm-17	229	9	of	of	ADP
bptjm-17	229	10	ros1	ros1	PROPN
bptjm-17	229	11	(	(	PUNCT
bptjm-17	229	12	luk	luk	PROPN
bptjm-17	229	13	et	et	PROPN
bptjm-17	229	14	al	al	PROPN
bptjm-17	229	15	.	.	PROPN
bptjm-17	229	16	,	,	PUNCT
bptjm-17	229	17	2018	2018	NUM
bptjm-17	229	18	)	)	PUNCT
bptjm-17	229	19	.	.	PUNCT
bptjm-17	230	1	concordance	concordance	NOUN
bptjm-17	230	2	rates	rate	NOUN
bptjm-17	230	3	for	for	ADP
bptjm-17	230	4	detecting	detect	VERB
bptjm-17	230	5	ros1	ros1	PROPN
bptjm-17	230	6	alteration	alteration	NOUN
bptjm-17	230	7	is	be	AUX
bptjm-17	230	8	96.2	96.2	NUM
bptjm-17	230	9	%	%	NOUN
bptjm-17	230	10	between	between	ADP
bptjm-17	230	11	liquid	liquid	ADJ
bptjm-17	230	12	and	and	CCONJ
bptjm-17	230	13	tissue	tissue	NOUN
bptjm-17	230	14	biopsies	biopsy	NOUN
bptjm-17	230	15	,	,	PUNCT
bptjm-17	230	16	according	accord	VERB
bptjm-17	230	17	to	to	ADP
bptjm-17	230	18	analysis	analysis	NOUN
bptjm-17	230	19	by	by	ADP
bptjm-17	230	20	mao	mao	PROPN
bptjm-17	230	21	et	et	PROPN
bptjm-17	230	22	al	al	PROPN
bptjm-17	230	23	.	.	PROPN
bptjm-17	230	24	(	(	PUNCT
bptjm-17	230	25	2017	2017	NUM
bptjm-17	230	26	)	)	PUNCT
bptjm-17	230	27	.	.	PUNCT
bptjm-17	231	1	a	a	DET
bptjm-17	231	2	multicenter	multicenter	ADJ
bptjm-17	231	3	prospective	prospective	ADJ
bptjm-17	231	4	cohort	cohort	NOUN
bptjm-17	231	5	study	study	NOUN
bptjm-17	231	6	by	by	ADP
bptjm-17	231	7	mezquita	mezquita	PROPN
bptjm-17	231	8	et	et	PROPN
bptjm-17	231	9	al	al	PROPN
bptjm-17	231	10	.	.	PROPN
bptjm-17	231	11	was	be	AUX
bptjm-17	231	12	conducted	conduct	VERB
bptjm-17	231	13	on	on	ADP
bptjm-17	231	14	128	128	NUM
bptjm-17	231	15	patients	patient	NOUN
bptjm-17	231	16	to	to	PART
bptjm-17	231	17	determine	determine	VERB
bptjm-17	231	18	liquid	liquid	ADJ
bptjm-17	231	19	biopsy	biopsy	NOUN
bptjm-17	231	20	’s	’s	PART
bptjm-17	231	21	clinical	clinical	ADJ
bptjm-17	231	22	usefulness	usefulness	NOUN
bptjm-17	231	23	in	in	ADP
bptjm-17	231	24	detection	detection	NOUN
bptjm-17	231	25	of	of	ADP
bptjm-17	231	26	alk	alk	PROPN
bptjm-17	231	27	/	/	SYM
bptjm-17	231	28	ros1	ros1	NOUN
bptjm-17	231	29	fusion	fusion	NOUN
bptjm-17	231	30	and	and	CCONJ
bptjm-17	231	31	mutation	mutation	NOUN
bptjm-17	231	32	to	to	PART
bptjm-17	231	33	extrapolate	extrapolate	VERB
bptjm-17	231	34	with	with	ADP
bptjm-17	231	35	e	e	NOUN
bptjm-17	231	36	cacy	cacy	NOUN
bptjm-17	231	37	of	of	ADP
bptjm-17	231	38	tyrosine	tyrosine	NOUN
bptjm-17	231	39	kinase	kinase	PROPN
bptjm-17	231	40	inhibitors	inhibitor	NOUN
bptjm-17	231	41	.	.	PUNCT
bptjm-17	232	1	patients	patient	NOUN
bptjm-17	232	2	aged	age	VERB
bptjm-17	232	3	18	18	NUM
bptjm-17	232	4	years	year	NOUN
bptjm-17	232	5	and	and	CCONJ
bptjm-17	232	6	older	old	ADJ
bptjm-17	232	7	with	with	ADP
bptjm-17	232	8	alk	alk	NOUN
bptjm-17	232	9	and	and	CCONJ
bptjm-17	232	10	ros1	ros1	NOUN
bptjm-17	232	11	-	-	PUNCT
bptjm-17	232	12	fusion	fusion	NOUN
bptjm-17	232	13	-	-	PUNCT
bptjm-17	232	14	positive	positive	ADJ
bptjm-17	232	15	were	be	AUX
bptjm-17	232	16	enrolled	enrol	VERB
bptjm-17	232	17	during	during	ADP
bptjm-17	232	18	october	october	PROPN
bptjm-17	232	19	2015	2015	NUM
bptjm-17	232	20	and	and	CCONJ
bptjm-17	232	21	august	august	PROPN
bptjm-17	232	22	2018	2018	NUM
bptjm-17	232	23	.	.	PUNCT
bptjm-17	233	1	samples	sample	NOUN
bptjm-17	233	2	were	be	AUX
bptjm-17	233	3	collected	collect	VERB
bptjm-17	233	4	at	at	ADP
bptjm-17	233	5	diagnosis	diagnosis	NOUN
bptjm-17	233	6	and	and	CCONJ
bptjm-17	233	7	during	during	ADP
bptjm-17	233	8	radiation	radiation	NOUN
bptjm-17	233	9	therapy	therapy	NOUN
bptjm-17	233	10	.	.	PUNCT
bptjm-17	234	1	blood	blood	NOUN
bptjm-17	234	2	samples	sample	NOUN
bptjm-17	234	3	were	be	AUX
bptjm-17	234	4	collected	collect	VERB
bptjm-17	234	5	,	,	PUNCT
bptjm-17	234	6	and	and	CCONJ
bptjm-17	234	7	ct	ct	X
bptjm-17	234	8	-	-	PUNCT
bptjm-17	234	9	dna	dna	PROPN
bptjm-17	234	10	analysis	analysis	NOUN
bptjm-17	234	11	as	as	ADV
bptjm-17	234	12	well	well	ADV
bptjm-17	234	13	as	as	ADP
bptjm-17	234	14	fusion	fusion	NOUN
bptjm-17	234	15	load	load	NOUN
bptjm-17	234	16	were	be	AUX
bptjm-17	234	17	evaluated	evaluate	VERB
bptjm-17	234	18	.	.	PUNCT
bptjm-17	235	1	absent	absent	ADJ
bptjm-17	235	2	mutation	mutation	NOUN
bptjm-17	235	3	showed	show	VERB
bptjm-17	235	4	better	well	ADJ
bptjm-17	235	5	os	os	NOUN
bptjm-17	235	6	.	.	PUNCT
bptjm-17	236	1	the	the	DET
bptjm-17	236	2	median	median	PROPN
bptjm-17	236	3	os	os	PROPN
bptjm-17	236	4	was	be	AUX
bptjm-17	236	5	58.5	58.5	NUM
bptjm-17	236	6	months	month	NOUN
bptjm-17	236	7	in	in	ADP
bptjm-17	236	8	patients	patient	NOUN
bptjm-17	236	9	with	with	ADP
bptjm-17	236	10	alkmutations	alkmutation	NOUN
bptjm-17	236	11	(	(	PUNCT
bptjm-17	236	12	95	95	NUM
bptjm-17	236	13	%	%	NOUN
bptjm-17	236	14	ci	ci	NOUN
bptjm-17	236	15	,	,	PUNCT
bptjm-17	236	16	26.9	26.9	NUM
bptjm-17	236	17	to	to	PART
bptjm-17	236	18	not	not	PART
bptjm-17	236	19	reached	reach	VERB
bptjm-17	236	20	[	[	X
bptjm-17	236	21	nr	nr	X
bptjm-17	236	22	]	]	X
bptjm-17	236	23	)	)	PUNCT
bptjm-17	236	24	while	while	SCONJ
bptjm-17	236	25	44.1	44.1	NUM
bptjm-17	236	26	months	month	NOUN
bptjm-17	236	27	in	in	ADP
bptjm-17	236	28	patients	patient	NOUN
bptjm-17	236	29	with	with	ADP
bptjm-17	236	30	non	non	ADJ
bptjm-17	236	31	-	-	ADJ
bptjm-17	236	32	alk	alk	ADJ
bptjm-17	236	33	mutations	mutation	NOUN
bptjm-17	236	34	(	(	PUNCT
bptjm-17	236	35	95	95	NUM
bptjm-17	236	36	%	%	NOUN
bptjm-17	236	37	ci	ci	NOUN
bptjm-17	236	38	,	,	PUNCT
bptjm-17	236	39	21.7	21.7	NUM
bptjm-17	236	40	to	to	ADP
bptjm-17	236	41	nr	nr	PRON
bptjm-17	236	42	)	)	PUNCT
bptjm-17	236	43	and	and	CCONJ
bptjm-17	236	44	it	it	PRON
bptjm-17	236	45	was	be	AUX
bptjm-17	236	46	found	find	VERB
bptjm-17	236	47	to	to	PART
bptjm-17	236	48	be	be	AUX
bptjm-17	236	49	105	105	NUM
bptjm-17	236	50	months	month	NOUN
bptjm-17	236	51	in	in	ADP
bptjm-17	236	52	patients	patient	NOUN
bptjm-17	236	53	who	who	PRON
bptjm-17	236	54	were	be	AUX
bptjm-17	236	55	detected	detect	VERB
bptjm-17	236	56	negative	negative	ADJ
bptjm-17	236	57	for	for	ADP
bptjm-17	236	58	ctdna	ctdna	NOUN
bptjm-17	236	59	(	(	PUNCT
bptjm-17	236	60	p	p	NOUN
bptjm-17	236	61	=	=	NOUN
bptjm-17	236	62	.001	.001	NUM
bptjm-17	236	63	)	)	PUNCT
bptjm-17	236	64	.	.	PUNCT
bptjm-17	237	1	also	also	ADV
bptjm-17	237	2	,	,	PUNCT
bptjm-17	237	3	patients	patient	NOUN
bptjm-17	237	4	who	who	PRON
bptjm-17	237	5	had	have	VERB
bptjm-17	237	6	complex	complex	ADJ
bptjm-17	237	7	alk	alk	NOUN
bptjm-17	237	8	mutations	mutation	NOUN
bptjm-17	237	9	showed	show	VERB
bptjm-17	237	10	poor	poor	ADJ
bptjm-17	237	11	os	os	NOUN
bptjm-17	237	12	(	(	PUNCT
bptjm-17	237	13	median	median	NOUN
bptjm-17	237	14	:	:	PUNCT
bptjm-17	237	15	26.9	26.9	NUM
bptjm-17	237	16	months	month	NOUN
bptjm-17	237	17	;	;	PUNCT
bptjm-17	237	18	95	95	NUM
bptjm-17	237	19	%	%	NOUN
bptjm-17	237	20	ci	ci	NOUN
bptjm-17	237	21	,	,	PUNCT
bptjm-17	237	22	13.9	13.9	NUM
bptjm-17	237	23	months	month	NOUN
bptjm-17	237	24	to	to	ADP
bptjm-17	237	25	nr	nr	PRON
bptjm-17	237	26	)	)	PUNCT
bptjm-17	237	27	compared	compare	VERB
bptjm-17	237	28	to	to	ADP
bptjm-17	237	29	patients	patient	NOUN
bptjm-17	237	30	with	with	ADP
bptjm-17	237	31	single	single	ADJ
bptjm-17	237	32	alkmutations	alkmutation	NOUN
bptjm-17	237	33	(	(	PUNCT
bptjm-17	237	34	median	median	NOUN
bptjm-17	237	35	:	:	PUNCT
bptjm-17	237	36	nr	nr	PROPN
bptjm-17	237	37	;	;	PUNCT
bptjm-17	237	38	95	95	NUM
bptjm-17	237	39	%	%	NOUN
bptjm-17	237	40	ci	ci	NOUN
bptjm-17	237	41	,	,	PUNCT
bptjm-17	237	42	57.0	57.0	NUM
bptjm-17	237	43	months	month	NOUN
bptjm-17	237	44	to	to	ADP
bptjm-17	237	45	nr	nr	PRON
bptjm-17	237	46	;	;	PUNCT
bptjm-17	237	47	p	p	X
bptjm-17	237	48	=	=	NOUN
bptjm-17	237	49	.003	.003	NUM
bptjm-17	237	50	)	)	PUNCT
bptjm-17	237	51	.	.	PUNCT
bptjm-17	238	1	the	the	DET
bptjm-17	238	2	median	median	PROPN
bptjm-17	238	3	pfs	pfs	PROPN
bptjm-17	238	4	was	be	AUX
bptjm-17	238	5	20.7	20.7	NUM
bptjm-17	238	6	months	month	NOUN
bptjm-17	238	7	(	(	PUNCT
bptjm-17	238	8	95	95	NUM
bptjm-17	238	9	%	%	NOUN
bptjm-17	238	10	ci	ci	NOUN
bptjm-17	238	11	,	,	PUNCT
bptjm-17	238	12	6.3	6.3	NUM
bptjm-17	238	13	to	to	ADP
bptjm-17	238	14	nr	nr	PRON
bptjm-17	238	15	)	)	PUNCT
bptjm-17	238	16	in	in	ADP
bptjm-17	238	17	the	the	DET
bptjm-17	238	18	negative	negative	ADJ
bptjm-17	238	19	ctdna	ctdna	NOUN
bptjm-17	238	20	group	group	NOUN
bptjm-17	238	21	while	while	SCONJ
bptjm-17	238	22	it	it	PRON
bptjm-17	238	23	was	be	AUX
bptjm-17	238	24	found	find	VERB
bptjm-17	238	25	to	to	PART
bptjm-17	238	26	be	be	AUX
bptjm-17	238	27	2.8	2.8	NUM
bptjm-17	238	28	months	month	NOUN
bptjm-17	238	29	(	(	PUNCT
bptjm-17	238	30	95	95	NUM
bptjm-17	238	31	%	%	NOUN
bptjm-17	238	32	ci	ci	NOUN
bptjm-17	238	33	,	,	PUNCT
bptjm-17	238	34	1.2	1.2	NUM
bptjm-17	238	35	to	to	ADP
bptjm-17	238	36	nr	nr	PRON
bptjm-17	238	37	)	)	PUNCT
bptjm-17	238	38	in	in	ADP
bptjm-17	238	39	the	the	DET
bptjm-17	238	40	patients	patient	NOUN
bptjm-17	238	41	with	with	ADP
bptjm-17	238	42	one	one	NUM
bptjm-17	238	43	or	or	CCONJ
bptjm-17	238	44	more	more	ADJ
bptjm-17	238	45	alk	alk	NOUN
bptjm-17	238	46	mutations	mutation	NOUN
bptjm-17	238	47	(	(	PUNCT
bptjm-17	238	48	p	p	X
bptjm-17	238	49	=	=	NOUN
bptjm-17	238	50	.03	.03	NUM
bptjm-17	238	51	)	)	PUNCT
bptjm-17	238	52	.	.	PUNCT
bptjm-17	239	1	berkeley	berkeley	PROPN
bptjm-17	239	2	pharma	pharma	PROPN
bptjm-17	239	3	tech	tech	PROPN
bptjm-17	239	4	journal	journal	NOUN
bptjm-17	239	5	of	of	ADP
bptjm-17	239	6	medicine	medicine	NOUN
bptjm-17	239	7	|	|	ADV
bptjm-17	239	8	131	131	NUM
bptjm-17	239	9	alk	alk	NOUN
bptjm-17	239	10	alk	alk	PROPN
bptjm-17	239	11	is	be	AUX
bptjm-17	239	12	most	most	ADV
bptjm-17	239	13	common	common	ADJ
bptjm-17	239	14	in	in	ADP
bptjm-17	239	15	nsclc	nsclc	NOUN
bptjm-17	239	16	patients	patient	NOUN
bptjm-17	239	17	,	,	PUNCT
bptjm-17	239	18	presenting	present	VERB
bptjm-17	239	19	itself	itself	PRON
bptjm-17	239	20	in	in	ADP
bptjm-17	239	21	about	about	ADV
bptjm-17	239	22	3	3	NUM
bptjm-17	239	23	-	-	SYM
bptjm-17	239	24	5	5	NUM
bptjm-17	239	25	%	%	NOUN
bptjm-17	239	26	of	of	ADP
bptjm-17	239	27	cases	case	NOUN
bptjm-17	239	28	per	per	ADP
bptjm-17	239	29	year	year	NOUN
bptjm-17	239	30	.	.	PUNCT
bptjm-17	240	1	alk	alk	PROPN
bptjm-17	240	2	alteration	alteration	NOUN
bptjm-17	240	3	is	be	AUX
bptjm-17	240	4	not	not	PART
bptjm-17	240	5	hereditary	hereditary	ADJ
bptjm-17	240	6	and	and	CCONJ
bptjm-17	240	7	is	be	AUX
bptjm-17	240	8	most	most	ADV
bptjm-17	240	9	commonly	commonly	ADV
bptjm-17	240	10	present	present	ADJ
bptjm-17	240	11	in	in	ADP
bptjm-17	240	12	younger	young	ADJ
bptjm-17	240	13	patients	patient	NOUN
bptjm-17	240	14	(	(	PUNCT
bptjm-17	240	15	55	55	NUM
bptjm-17	240	16	years	year	NOUN
bptjm-17	240	17	old	old	ADJ
bptjm-17	240	18	or	or	CCONJ
bptjm-17	240	19	below	below	ADV
bptjm-17	240	20	)	)	PUNCT
bptjm-17	240	21	or	or	CCONJ
bptjm-17	240	22	patients	patient	NOUN
bptjm-17	240	23	who	who	PRON
bptjm-17	240	24	have	have	AUX
bptjm-17	240	25	never	never	ADV
bptjm-17	240	26	smoked	smoke	VERB
bptjm-17	240	27	.	.	PUNCT
bptjm-17	241	1	ihc	ihc	PROPN
bptjm-17	241	2	or	or	CCONJ
bptjm-17	241	3	fish	fish	NOUN
bptjm-17	241	4	remain	remain	VERB
bptjm-17	241	5	the	the	DET
bptjm-17	241	6	most	most	ADV
bptjm-17	241	7	common	common	ADJ
bptjm-17	241	8	strategies	strategy	NOUN
bptjm-17	241	9	to	to	PART
bptjm-17	241	10	identify	identify	VERB
bptjm-17	241	11	this	this	DET
bptjm-17	241	12	biomarker	biomarker	NOUN
bptjm-17	241	13	.	.	PUNCT
bptjm-17	242	1	alk	alk	VERB
bptjm-17	242	2	normally	normally	ADV
bptjm-17	242	3	encodes	encode	VERB
bptjm-17	242	4	for	for	ADP
bptjm-17	242	5	a	a	DET
bptjm-17	242	6	protein	protein	NOUN
bptjm-17	242	7	that	that	PRON
bptjm-17	242	8	plays	play	VERB
bptjm-17	242	9	a	a	DET
bptjm-17	242	10	role	role	NOUN
bptjm-17	242	11	in	in	ADP
bptjm-17	242	12	neural	neural	ADJ
bptjm-17	242	13	development	development	NOUN
bptjm-17	242	14	.	.	PUNCT
bptjm-17	243	1	alterations	alteration	NOUN
bptjm-17	243	2	in	in	ADP
bptjm-17	243	3	this	this	DET
bptjm-17	243	4	gene	gene	NOUN
bptjm-17	243	5	are	be	AUX
bptjm-17	243	6	caused	cause	VERB
bptjm-17	243	7	by	by	ADP
bptjm-17	243	8	chromosomal	chromosomal	ADJ
bptjm-17	243	9	translocations	translocation	NOUN
bptjm-17	243	10	and	and	CCONJ
bptjm-17	243	11	are	be	AUX
bptjm-17	243	12	almost	almost	ADV
bptjm-17	243	13	always	always	ADV
bptjm-17	243	14	mutually	mutually	ADV
bptjm-17	243	15	exclusive	exclusive	ADJ
bptjm-17	243	16	to	to	PART
bptjm-17	243	17	egfr	egfr	VERB
bptjm-17	243	18	and	and	CCONJ
bptjm-17	243	19	kras	kras	PROPN
bptjm-17	243	20	.	.	PUNCT
bptjm-17	244	1	alkmutations	alkmutation	NOUN
bptjm-17	244	2	are	be	AUX
bptjm-17	244	3	most	most	ADV
bptjm-17	244	4	common	common	ADJ
bptjm-17	244	5	among	among	ADP
bptjm-17	244	6	patients	patient	NOUN
bptjm-17	244	7	with	with	ADP
bptjm-17	244	8	a	a	DET
bptjm-17	244	9	never	never	ADV
bptjm-17	244	10	/	/	SYM
bptjm-17	244	11	light	light	ADJ
bptjm-17	244	12	smoking	smoking	NOUN
bptjm-17	244	13	history	history	NOUN
bptjm-17	244	14	,	,	PUNCT
bptjm-17	244	15	an	an	DET
bptjm-17	244	16	adenocarcinoma	adenocarcinoma	ADJ
bptjm-17	244	17	histology	histology	NOUN
bptjm-17	244	18	,	,	PUNCT
bptjm-17	244	19	of	of	ADP
bptjm-17	244	20	a	a	DET
bptjm-17	244	21	younger	young	ADJ
bptjm-17	244	22	age	age	NOUN
bptjm-17	244	23	,	,	PUNCT
bptjm-17	244	24	of	of	ADP
bptjm-17	244	25	the	the	DET
bptjm-17	244	26	female	female	ADJ
bptjm-17	244	27	gender	gender	NOUN
bptjm-17	244	28	,	,	PUNCT
bptjm-17	244	29	and	and	CCONJ
bptjm-17	244	30	in	in	ADP
bptjm-17	244	31	tumours	tumour	NOUN
bptjm-17	244	32	with	with	ADP
bptjm-17	244	33	the	the	DET
bptjm-17	244	34	wild	wild	ADJ
bptjm-17	244	35	type	type	NOUN
bptjm-17	244	36	for	for	ADP
bptjm-17	244	37	egfr	egfr	NOUN
bptjm-17	244	38	and	and	CCONJ
bptjm-17	244	39	kras	kras	PROPN
bptjm-17	244	40	.	.	PUNCT
bptjm-17	245	1	the	the	DET
bptjm-17	245	2	most	most	ADV
bptjm-17	245	3	common	common	ADJ
bptjm-17	245	4	rearrangement	rearrangement	NOUN
bptjm-17	245	5	of	of	ADP
bptjm-17	245	6	alk	alk	NOUN
bptjm-17	245	7	in	in	ADP
bptjm-17	245	8	nsclc	nsclc	NOUN
bptjm-17	245	9	is	be	AUX
bptjm-17	245	10	eml4	eml4	PROPN
bptjm-17	245	11	-	-	PUNCT
bptjm-17	245	12	alk	alk	PROPN
bptjm-17	245	13	(	(	PUNCT
bptjm-17	245	14	echinoderm	echinoderm	NOUN
bptjm-17	245	15	microtubule	microtubule	NOUN
bptjm-17	245	16	-	-	PUNCT
bptjm-17	245	17	associated	associate	VERB
bptjm-17	245	18	protein	protein	NOUN
bptjm-17	245	19	-	-	PUNCT
bptjm-17	245	20	like	like	ADJ
bptjm-17	245	21	4	4	NUM
bptjm-17	245	22	(	(	PUNCT
bptjm-17	245	23	eml4)alk	eml4)alk	NOUN
bptjm-17	245	24	)	)	PUNCT
bptjm-17	245	25	.	.	PUNCT
bptjm-17	246	1	this	this	DET
bptjm-17	246	2	mutation	mutation	NOUN
bptjm-17	246	3	leads	lead	VERB
bptjm-17	246	4	to	to	ADP
bptjm-17	246	5	uncontrolled	uncontrolled	ADJ
bptjm-17	246	6	proliferation	proliferation	NOUN
bptjm-17	246	7	,	,	PUNCT
bptjm-17	246	8	migration	migration	NOUN
bptjm-17	246	9	,	,	PUNCT
bptjm-17	246	10	and	and	CCONJ
bptjm-17	246	11	tumorigenesis	tumorigenesis	NOUN
bptjm-17	246	12	.	.	PUNCT
bptjm-17	247	1	increasing	increase	VERB
bptjm-17	247	2	research	research	NOUN
bptjm-17	247	3	in	in	ADP
bptjm-17	247	4	fusion	fusion	NOUN
bptjm-17	247	5	genes	gene	NOUN
bptjm-17	247	6	such	such	ADJ
bptjm-17	247	7	as	as	ADP
bptjm-17	247	8	elm4	elm4	NOUN
bptjm-17	247	9	-	-	PUNCT
bptjm-17	247	10	alk	alk	NOUN
bptjm-17	247	11	show	show	VERB
bptjm-17	247	12	that	that	SCONJ
bptjm-17	247	13	alongside	alongside	ADP
bptjm-17	247	14	coding	code	VERB
bptjm-17	247	15	for	for	ADP
bptjm-17	247	16	proteins	protein	NOUN
bptjm-17	247	17	,	,	PUNCT
bptjm-17	247	18	they	they	PRON
bptjm-17	247	19	generate	generate	VERB
bptjm-17	247	20	non	non	ADJ
bptjm-17	247	21	-	-	ADJ
bptjm-17	247	22	coding	coding	ADJ
bptjm-17	247	23	rnas	rna	NOUN
bptjm-17	247	24	that	that	PRON
bptjm-17	247	25	contribute	contribute	VERB
bptjm-17	247	26	to	to	ADP
bptjm-17	247	27	tumor	tumor	NOUN
bptjm-17	247	28	progression	progression	NOUN
bptjm-17	247	29	(	(	PUNCT
bptjm-17	247	30	camidge	camidge	NOUN
bptjm-17	247	31	et	et	PROPN
bptjm-17	247	32	al	al	PROPN
bptjm-17	247	33	.	.	PROPN
bptjm-17	247	34	,	,	PUNCT
bptjm-17	247	35	2010	2010	NUM
bptjm-17	247	36	)	)	PUNCT
bptjm-17	247	37	.	.	PUNCT
bptjm-17	248	1	in	in	ADP
bptjm-17	248	2	2011	2011	NUM
bptjm-17	248	3	,	,	PUNCT
bptjm-17	248	4	the	the	DET
bptjm-17	248	5	fda	fda	PROPN
bptjm-17	248	6	approved	approve	VERB
bptjm-17	248	7	the	the	DET
bptjm-17	248	8	rst	rst	PROPN
bptjm-17	248	9	tki	tki	NOUN
bptjm-17	248	10	for	for	ADP
bptjm-17	248	11	alk	alk	NOUN
bptjm-17	248	12	mutations	mutation	NOUN
bptjm-17	248	13	,	,	PUNCT
bptjm-17	248	14	crizotinib	crizotinib	PROPN
bptjm-17	248	15	.	.	PUNCT
bptjm-17	249	1	since	since	SCONJ
bptjm-17	249	2	then	then	ADV
bptjm-17	249	3	,	,	PUNCT
bptjm-17	249	4	researchers	researcher	NOUN
bptjm-17	249	5	began	begin	VERB
bptjm-17	249	6	studying	study	VERB
bptjm-17	249	7	alk	alk	NOUN
bptjm-17	249	8	as	as	ADP
bptjm-17	249	9	a	a	DET
bptjm-17	249	10	predictive	predictive	ADJ
bptjm-17	249	11	biomarker	biomarker	NOUN
bptjm-17	249	12	.	.	PUNCT
bptjm-17	250	1	for	for	ADP
bptjm-17	250	2	instance	instance	NOUN
bptjm-17	250	3	,	,	PUNCT
bptjm-17	250	4	vincent	vincent	PROPN
bptjm-17	250	5	et	et	PROPN
bptjm-17	250	6	al	al	PROPN
bptjm-17	250	7	.	.	PROPN
bptjm-17	250	8	outlined	outline	VERB
bptjm-17	250	9	biomarkers	biomarker	NOUN
bptjm-17	250	10	involved	involve	VERB
bptjm-17	250	11	in	in	ADP
bptjm-17	250	12	clinical	clinical	ADJ
bptjm-17	250	13	practice	practice	NOUN
bptjm-17	250	14	in	in	ADP
bptjm-17	250	15	2012	2012	NUM
bptjm-17	250	16	,	,	PUNCT
bptjm-17	250	17	indicating	indicate	VERB
bptjm-17	250	18	the	the	DET
bptjm-17	250	19	importance	importance	NOUN
bptjm-17	250	20	and	and	CCONJ
bptjm-17	250	21	extensive	extensive	ADJ
bptjm-17	250	22	research	research	NOUN
bptjm-17	250	23	that	that	PRON
bptjm-17	250	24	has	have	AUX
bptjm-17	250	25	been	be	AUX
bptjm-17	250	26	done	do	VERB
bptjm-17	250	27	on	on	ADP
bptjm-17	250	28	alk	alk	NOUN
bptjm-17	250	29	over	over	ADP
bptjm-17	250	30	the	the	DET
bptjm-17	250	31	past	past	ADJ
bptjm-17	250	32	couple	couple	NOUN
bptjm-17	250	33	years	year	NOUN
bptjm-17	250	34	.	.	PUNCT
bptjm-17	251	1	currently	currently	ADV
bptjm-17	251	2	,	,	PUNCT
bptjm-17	251	3	ihc	ihc	PROPN
bptjm-17	251	4	combined	combine	VERB
bptjm-17	251	5	with	with	ADP
bptjm-17	251	6	crizotinib	crizotinib	NOUN
bptjm-17	251	7	is	be	AUX
bptjm-17	251	8	considered	consider	VERB
bptjm-17	251	9	a	a	DET
bptjm-17	251	10	gold	gold	NOUN
bptjm-17	251	11	standard	standard	NOUN
bptjm-17	251	12	for	for	ADP
bptjm-17	251	13	the	the	DET
bptjm-17	251	14	detection	detection	NOUN
bptjm-17	251	15	and	and	CCONJ
bptjm-17	251	16	treatment	treatment	NOUN
bptjm-17	251	17	of	of	ADP
bptjm-17	251	18	alk	alk	NOUN
bptjm-17	251	19	-	-	PUNCT
bptjm-17	251	20	positive	positive	ADJ
bptjm-17	251	21	nsclc	nsclc	NOUN
bptjm-17	251	22	(	(	PUNCT
bptjm-17	251	23	shaw	shaw	PROPN
bptjm-17	251	24	et	et	PROPN
bptjm-17	251	25	al	al	PROPN
bptjm-17	251	26	.	.	PROPN
bptjm-17	251	27	,	,	PUNCT
bptjm-17	251	28	2011	2011	NUM
bptjm-17	251	29	)	)	PUNCT
bptjm-17	251	30	.	.	PUNCT
bptjm-17	252	1	eml4	eml4	PROPN
bptjm-17	252	2	-	-	PUNCT
bptjm-17	252	3	alk	alk	PROPN
bptjm-17	252	4	fusion	fusion	NOUN
bptjm-17	252	5	variant	variant	NOUN
bptjm-17	252	6	3	3	NUM
bptjm-17	252	7	(	(	PUNCT
bptjm-17	252	8	v3	v3	PROPN
bptjm-17	252	9	)	)	PUNCT
bptjm-17	252	10	serves	serve	VERB
bptjm-17	252	11	as	as	ADP
bptjm-17	252	12	a	a	DET
bptjm-17	252	13	new	new	ADJ
bptjm-17	252	14	potentially	potentially	ADV
bptjm-17	252	15	targetable	targetable	ADJ
bptjm-17	252	16	biomarker	biomarker	NOUN
bptjm-17	252	17	for	for	ADP
bptjm-17	252	18	higher	high	ADJ
bptjm-17	252	19	-	-	PUNCT
bptjm-17	252	20	risk	risk	NOUN
bptjm-17	252	21	cases	case	NOUN
bptjm-17	252	22	.	.	PUNCT
bptjm-17	253	1	evidence	evidence	NOUN
bptjm-17	253	2	shows	show	VERB
bptjm-17	253	3	that	that	SCONJ
bptjm-17	253	4	the	the	DET
bptjm-17	253	5	presence	presence	NOUN
bptjm-17	253	6	of	of	ADP
bptjm-17	253	7	the	the	DET
bptjm-17	253	8	v3	v3	PROPN
bptjm-17	253	9	protein	protein	NOUN
bptjm-17	253	10	in	in	ADP
bptjm-17	253	11	elm4	elm4	PROPN
bptjm-17	253	12	-	-	PUNCT
bptjm-17	253	13	alk	alk	PROPN
bptjm-17	253	14	leads	lead	VERB
bptjm-17	253	15	to	to	ADP
bptjm-17	253	16	acceleration	acceleration	NOUN
bptjm-17	253	17	of	of	ADP
bptjm-17	253	18	disease	disease	NOUN
bptjm-17	253	19	,	,	PUNCT
bptjm-17	253	20	failure	failure	NOUN
bptjm-17	253	21	at	at	ADP
bptjm-17	253	22	early	early	ADJ
bptjm-17	253	23	stages	stage	NOUN
bptjm-17	253	24	of	of	ADP
bptjm-17	253	25	treatment	treatment	NOUN
bptjm-17	253	26	,	,	PUNCT
bptjm-17	253	27	and	and	CCONJ
bptjm-17	253	28	a	a	DET
bptjm-17	253	29	poorer	poor	ADJ
bptjm-17	253	30	os	os	NOUN
bptjm-17	253	31	.	.	PUNCT
bptjm-17	254	1	elm4	elm4	PROPN
bptjm-17	254	2	-	-	PUNCT
bptjm-17	254	3	alk	alk	PROPN
bptjm-17	254	4	v3	v3	PROPN
bptjm-17	254	5	is	be	AUX
bptjm-17	254	6	also	also	ADV
bptjm-17	254	7	associated	associate	VERB
bptjm-17	254	8	with	with	ADP
bptjm-17	254	9	shorter	short	ADJ
bptjm-17	254	10	pfs	pf	NOUN
bptjm-17	254	11	,	,	PUNCT
bptjm-17	254	12	even	even	ADV
bptjm-17	254	13	after	after	ADP
bptjm-17	254	14	non	non	ADJ
bptjm-17	254	15	-	-	ADJ
bptjm-17	254	16	tki	tki	ADJ
bptjm-17	254	17	treatments	treatment	NOUN
bptjm-17	254	18	and	and	CCONJ
bptjm-17	254	19	chemotherapy	chemotherapy	NOUN
bptjm-17	254	20	(	(	PUNCT
bptjm-17	254	21	christopoulos	christopoulo	NOUN
bptjm-17	254	22	et	et	PROPN
bptjm-17	254	23	al	al	PROPN
bptjm-17	254	24	.	.	PROPN
bptjm-17	254	25	,	,	PUNCT
bptjm-17	254	26	2018	2018	NUM
bptjm-17	254	27	)	)	PUNCT
bptjm-17	254	28	.	.	PUNCT
bptjm-17	255	1	this	this	PRON
bptjm-17	255	2	suggests	suggest	VERB
bptjm-17	255	3	the	the	DET
bptjm-17	255	4	di	di	NOUN
bptjm-17	255	5	erences	erence	NOUN
bptjm-17	255	6	between	between	ADP
bptjm-17	255	7	the	the	DET
bptjm-17	255	8	v3	v3	PROPN
bptjm-17	255	9	variant	variant	NOUN
bptjm-17	255	10	and	and	CCONJ
bptjm-17	255	11	other	other	ADJ
bptjm-17	255	12	more	more	ADV
bptjm-17	255	13	common	common	ADJ
bptjm-17	255	14	variants	variant	NOUN
bptjm-17	255	15	,	,	PUNCT
bptjm-17	255	16	such	such	ADJ
bptjm-17	255	17	as	as	ADP
bptjm-17	255	18	eml4	eml4	NOUN
bptjm-17	255	19	-	-	PUNCT
bptjm-17	255	20	alk	alk	PROPN
bptjm-17	255	21	v2	v2	PROPN
bptjm-17	255	22	,	,	PUNCT
bptjm-17	255	23	are	be	AUX
bptjm-17	255	24	clinically	clinically	ADV
bptjm-17	255	25	distinguishable	distinguishable	ADJ
bptjm-17	255	26	due	due	ADP
bptjm-17	255	27	to	to	ADP
bptjm-17	255	28	v3	v3	PROPN
bptjm-17	255	29	’s	’s	PART
bptjm-17	255	30	stark	stark	PROPN
bptjm-17	255	31	di	di	NOUN
bptjm-17	255	32	erences	erence	NOUN
bptjm-17	255	33	(	(	PUNCT
bptjm-17	255	34	p<0.001	p<0.001	X
bptjm-17	255	35	)	)	PUNCT
bptjm-17	255	36	in	in	ADP
bptjm-17	255	37	pfs	pfs	PROPN
bptjm-17	255	38	regardless	regardless	ADV
bptjm-17	255	39	of	of	ADP
bptjm-17	255	40	previous	previous	ADJ
bptjm-17	255	41	treatment	treatment	NOUN
bptjm-17	255	42	to	to	ADP
bptjm-17	255	43	other	other	ADJ
bptjm-17	255	44	alk	alk	NOUN
bptjm-17	255	45	tumor	tumor	NOUN
bptjm-17	255	46	types	type	NOUN
bptjm-17	255	47	.	.	PUNCT
bptjm-17	256	1	v3	v3	PROPN
bptjm-17	256	2	variants	variant	NOUN
bptjm-17	256	3	progress	progress	VERB
bptjm-17	256	4	faster	fast	ADV
bptjm-17	256	5	in	in	ADP
bptjm-17	256	6	response	response	NOUN
bptjm-17	256	7	to	to	ADP
bptjm-17	256	8	tki	tki	PROPN
bptjm-17	256	9	treatments	treatment	NOUN
bptjm-17	256	10	,	,	PUNCT
bptjm-17	256	11	which	which	PRON
bptjm-17	256	12	is	be	AUX
bptjm-17	256	13	likely	likely	ADJ
bptjm-17	256	14	due	due	ADP
bptjm-17	256	15	to	to	ADP
bptjm-17	256	16	the	the	DET
bptjm-17	256	17	developments	development	NOUN
bptjm-17	256	18	of	of	ADP
bptjm-17	256	19	tki	tki	NOUN
bptjm-17	256	20	resistant	resistant	ADJ
bptjm-17	256	21	mutations	mutation	NOUN
bptjm-17	256	22	.	.	PUNCT
bptjm-17	257	1	a	a	DET
bptjm-17	257	2	study	study	NOUN
bptjm-17	257	3	conducted	conduct	VERB
bptjm-17	257	4	by	by	ADP
bptjm-17	257	5	madsen	madsen	PROPN
bptjm-17	257	6	et	et	PROPN
bptjm-17	257	7	al	al	PROPN
bptjm-17	257	8	.	.	PROPN
bptjm-17	257	9	,	,	PUNCT
bptjm-17	257	10	analyzed	analyze	VERB
bptjm-17	257	11	ctdna	ctdna	NOUN
bptjm-17	257	12	of	of	ADP
bptjm-17	257	13	nsclc	nsclc	NOUN
bptjm-17	257	14	patients	patient	NOUN
bptjm-17	257	15	with	with	ADP
bptjm-17	257	16	the	the	DET
bptjm-17	257	17	alk	alk	NOUN
bptjm-17	257	18	gene	gene	NOUN
bptjm-17	257	19	.	.	PUNCT
bptjm-17	258	1	the	the	DET
bptjm-17	258	2	results	result	NOUN
bptjm-17	258	3	showed	show	VERB
bptjm-17	258	4	the	the	DET
bptjm-17	258	5	presence	presence	NOUN
bptjm-17	258	6	of	of	ADP
bptjm-17	258	7	ctdna	ctdna	NOUN
bptjm-17	258	8	before	before	SCONJ
bptjm-17	258	9	treatment	treatment	NOUN
bptjm-17	258	10	initiation	initiation	NOUN
bptjm-17	258	11	is	be	AUX
bptjm-17	258	12	associated	associate	VERB
bptjm-17	258	13	with	with	ADP
bptjm-17	258	14	inferior	inferior	ADJ
bptjm-17	258	15	pfs	pfs	PROPN
bptjm-17	258	16	as	as	ADV
bptjm-17	258	17	well	well	ADV
bptjm-17	258	18	as	as	ADP
bptjm-17	258	19	the	the	DET
bptjm-17	258	20	presence	presence	NOUN
bptjm-17	258	21	of	of	ADP
bptjm-17	258	22	ctdna	ctdna	NOUN
bptjm-17	258	23	shortly	shortly	ADV
bptjm-17	258	24	after	after	ADP
bptjm-17	258	25	the	the	DET
bptjm-17	258	26	start	start	NOUN
bptjm-17	258	27	of	of	ADP
bptjm-17	258	28	alk	alk	NOUN
bptjm-17	258	29	tki	tki	PROPN
bptjm-17	258	30	treatment	treatment	NOUN
bptjm-17	258	31	.	.	PUNCT
bptjm-17	259	1	this	this	DET
bptjm-17	259	2	study	study	NOUN
bptjm-17	259	3	berkeley	berkeley	PROPN
bptjm-17	259	4	pharma	pharma	PROPN
bptjm-17	259	5	tech	tech	NOUN
bptjm-17	259	6	journal	journal	NOUN
bptjm-17	259	7	of	of	ADP
bptjm-17	259	8	medicine	medicine	NOUN
bptjm-17	259	9	|	|	ADV
bptjm-17	259	10	132	132	NUM
bptjm-17	259	11	emphasizes	emphasize	VERB
bptjm-17	259	12	the	the	DET
bptjm-17	259	13	value	value	NOUN
bptjm-17	259	14	of	of	ADP
bptjm-17	259	15	genomic	genomic	ADJ
bptjm-17	259	16	pro	pro	X
bptjm-17	259	17	ling	ling	NOUN
bptjm-17	259	18	through	through	ADP
bptjm-17	259	19	ctdna	ctdna	NOUN
bptjm-17	259	20	during	during	ADP
bptjm-17	259	21	all	all	DET
bptjm-17	259	22	stages	stage	NOUN
bptjm-17	259	23	of	of	ADP
bptjm-17	259	24	the	the	DET
bptjm-17	259	25	treatment	treatment	NOUN
bptjm-17	259	26	.	.	PUNCT
bptjm-17	260	1	although	although	SCONJ
bptjm-17	260	2	there	there	PRON
bptjm-17	260	3	are	be	VERB
bptjm-17	260	4	multiple	multiple	ADJ
bptjm-17	260	5	targeted	target	VERB
bptjm-17	260	6	therapies	therapy	NOUN
bptjm-17	260	7	for	for	ADP
bptjm-17	260	8	alk	alk	NOUN
bptjm-17	260	9	,	,	PUNCT
bptjm-17	260	10	fusion	fusion	NOUN
bptjm-17	260	11	variants	variant	NOUN
bptjm-17	260	12	of	of	ADP
bptjm-17	260	13	alk	alk	NOUN
bptjm-17	260	14	that	that	PRON
bptjm-17	260	15	show	show	VERB
bptjm-17	260	16	poorer	poor	ADJ
bptjm-17	260	17	pfs	pfs	PROPN
bptjm-17	260	18	and	and	CCONJ
bptjm-17	260	19	os	os	PROPN
bptjm-17	260	20	still	still	ADV
bptjm-17	260	21	need	need	VERB
bptjm-17	260	22	to	to	PART
bptjm-17	260	23	be	be	AUX
bptjm-17	260	24	studied	study	VERB
bptjm-17	260	25	(	(	PUNCT
bptjm-17	260	26	madsen	madsen	PROPN
bptjm-17	260	27	et	et	PROPN
bptjm-17	260	28	al	al	PROPN
bptjm-17	260	29	.	.	PROPN
bptjm-17	260	30	,	,	PUNCT
bptjm-17	260	31	2020	2020	NUM
bptjm-17	260	32	)	)	PUNCT
bptjm-17	260	33	.	.	PUNCT
bptjm-17	261	1	kras	kras	PROPN
bptjm-17	261	2	kirsten	kirsten	PROPN
bptjm-17	261	3	rat	rat	PROPN
bptjm-17	261	4	sarcoma	sarcoma	NOUN
bptjm-17	261	5	viral	viral	ADJ
bptjm-17	261	6	oncogene	oncogene	NOUN
bptjm-17	261	7	homolog	homolog	NOUN
bptjm-17	261	8	(	(	PUNCT
bptjm-17	261	9	kras	kras	PROPN
bptjm-17	261	10	)	)	PUNCT
bptjm-17	261	11	is	be	AUX
bptjm-17	261	12	the	the	DET
bptjm-17	261	13	most	most	ADV
bptjm-17	261	14	frequent	frequent	ADJ
bptjm-17	261	15	oncogenic	oncogenic	ADJ
bptjm-17	261	16	mutation	mutation	NOUN
bptjm-17	261	17	in	in	ADP
bptjm-17	261	18	western	western	ADJ
bptjm-17	261	19	countries	country	NOUN
bptjm-17	261	20	for	for	ADP
bptjm-17	261	21	nsclc	nsclc	NOUN
bptjm-17	261	22	(	(	PUNCT
bptjm-17	261	23	liu	liu	PROPN
bptjm-17	261	24	et	et	PROPN
bptjm-17	261	25	al	al	PROPN
bptjm-17	261	26	.	.	PROPN
bptjm-17	261	27	,	,	PUNCT
bptjm-17	261	28	2020	2020	NUM
bptjm-17	261	29	)	)	PUNCT
bptjm-17	261	30	.	.	PUNCT
bptjm-17	262	1	it	it	PRON
bptjm-17	262	2	is	be	AUX
bptjm-17	262	3	involved	involve	VERB
bptjm-17	262	4	in	in	ADP
bptjm-17	262	5	the	the	DET
bptjm-17	262	6	ras	ras	PROPN
bptjm-17	262	7	/	/	SYM
bptjm-17	262	8	mapk	mapk	NOUN
bptjm-17	262	9	pathway	pathway	NOUN
bptjm-17	262	10	and	and	CCONJ
bptjm-17	262	11	codes	code	NOUN
bptjm-17	262	12	for	for	ADP
bptjm-17	262	13	the	the	DET
bptjm-17	262	14	k	k	PROPN
bptjm-17	262	15	-	-	PUNCT
bptjm-17	262	16	ras	ras	ADJ
bptjm-17	262	17	protein	protein	NOUN
bptjm-17	262	18	(	(	PUNCT
bptjm-17	262	19	gtpase	gtpase	NOUN
bptjm-17	262	20	)	)	PUNCT
bptjm-17	262	21	,	,	PUNCT
bptjm-17	262	22	the	the	DET
bptjm-17	262	23	most	most	ADV
bptjm-17	262	24	commonly	commonly	ADV
bptjm-17	262	25	mutated	mutate	VERB
bptjm-17	262	26	gene	gene	NOUN
bptjm-17	262	27	in	in	ADP
bptjm-17	262	28	its	its	PRON
bptjm-17	262	29	pathway	pathway	NOUN
bptjm-17	262	30	.	.	PUNCT
bptjm-17	263	1	mutations	mutation	NOUN
bptjm-17	263	2	in	in	ADP
bptjm-17	263	3	the	the	DET
bptjm-17	263	4	kras	kras	PROPN
bptjm-17	263	5	gene	gene	NOUN
bptjm-17	263	6	impair	impair	VERB
bptjm-17	263	7	the	the	DET
bptjm-17	263	8	gtpase	gtpase	NOUN
bptjm-17	263	9	activity	activity	NOUN
bptjm-17	263	10	,	,	PUNCT
bptjm-17	263	11	resulting	result	VERB
bptjm-17	263	12	in	in	ADP
bptjm-17	263	13	a	a	DET
bptjm-17	263	14	constantly	constantly	ADV
bptjm-17	263	15	active	active	ADJ
bptjm-17	263	16	gtpase	gtpase	NOUN
bptjm-17	263	17	,	,	PUNCT
bptjm-17	263	18	which	which	PRON
bptjm-17	263	19	leads	lead	VERB
bptjm-17	263	20	to	to	ADP
bptjm-17	263	21	cell	cell	NOUN
bptjm-17	263	22	survival	survival	NOUN
bptjm-17	263	23	,	,	PUNCT
bptjm-17	263	24	proliferation	proliferation	NOUN
bptjm-17	263	25	,	,	PUNCT
bptjm-17	263	26	and	and	CCONJ
bptjm-17	263	27	di	di	NOUN
bptjm-17	263	28	erentiation	erentiation	NOUN
bptjm-17	263	29	.	.	PUNCT
bptjm-17	264	1	the	the	DET
bptjm-17	264	2	most	most	ADV
bptjm-17	264	3	common	common	ADJ
bptjm-17	264	4	nucleotide	nucleotide	NOUN
bptjm-17	264	5	mutation	mutation	NOUN
bptjm-17	264	6	in	in	ADP
bptjm-17	264	7	kras	kras	PROPN
bptjm-17	264	8	is	be	AUX
bptjm-17	264	9	the	the	DET
bptjm-17	264	10	g12c	g12c	PROPN
bptjm-17	264	11	mutation	mutation	NOUN
bptjm-17	264	12	,	,	PUNCT
bptjm-17	264	13	which	which	PRON
bptjm-17	264	14	has	have	AUX
bptjm-17	264	15	been	be	AUX
bptjm-17	264	16	directly	directly	ADV
bptjm-17	264	17	linked	link	VERB
bptjm-17	264	18	to	to	ADP
bptjm-17	264	19	smoking	smoking	NOUN
bptjm-17	264	20	.	.	PUNCT
bptjm-17	265	1	further	further	ADJ
bptjm-17	265	2	research	research	NOUN
bptjm-17	265	3	is	be	AUX
bptjm-17	265	4	necessary	necessary	ADJ
bptjm-17	265	5	to	to	PART
bptjm-17	265	6	establish	establish	VERB
bptjm-17	265	7	a	a	DET
bptjm-17	265	8	relationship	relationship	NOUN
bptjm-17	265	9	between	between	ADP
bptjm-17	265	10	variant	variant	ADJ
bptjm-17	265	11	kras	kra	NOUN
bptjm-17	265	12	types	type	NOUN
bptjm-17	265	13	and	and	CCONJ
bptjm-17	265	14	prognosis	prognosis	NOUN
bptjm-17	265	15	.	.	PUNCT
bptjm-17	266	1	cox	cox	PROPN
bptjm-17	266	2	regression	regression	PROPN
bptjm-17	266	3	and	and	CCONJ
bptjm-17	266	4	multinomial	multinomial	ADJ
bptjm-17	266	5	logistic	logistic	ADJ
bptjm-17	266	6	regression	regression	NOUN
bptjm-17	266	7	were	be	AUX
bptjm-17	266	8	used	use	VERB
bptjm-17	266	9	to	to	PART
bptjm-17	266	10	di	di	VERB
bptjm-17	266	11	erentiate	erentiate	VERB
bptjm-17	266	12	the	the	DET
bptjm-17	266	13	e	e	X
bptjm-17	266	14	ect	ect	X
bptjm-17	266	15	of	of	ADP
bptjm-17	266	16	kras	kras	PROPN
bptjm-17	266	17	mutation	mutation	NOUN
bptjm-17	266	18	subtype	subtype	NOUN
bptjm-17	266	19	on	on	ADP
bptjm-17	266	20	os	os	PROPN
bptjm-17	266	21	.	.	PUNCT
bptjm-17	267	1	g12c	g12c	NOUN
bptjm-17	267	2	subtype	subtype	NOUN
bptjm-17	267	3	was	be	AUX
bptjm-17	267	4	associated	associate	VERB
bptjm-17	267	5	with	with	ADP
bptjm-17	267	6	poor	poor	ADJ
bptjm-17	267	7	os	os	NOUN
bptjm-17	267	8	(	(	PUNCT
bptjm-17	267	9	p	p	X
bptjm-17	267	10	=	=	PROPN
bptjm-17	267	11	0.021	0.021	NUM
bptjm-17	267	12	)	)	PUNCT
bptjm-17	267	13	,	,	PUNCT
bptjm-17	267	14	compared	compare	VERB
bptjm-17	267	15	to	to	ADP
bptjm-17	267	16	g12d	g12d	VERB
bptjm-17	267	17	(	(	PUNCT
bptjm-17	267	18	aredo	aredo	PROPN
bptjm-17	267	19	et	et	PROPN
bptjm-17	267	20	al	al	PROPN
bptjm-17	267	21	.	.	PROPN
bptjm-17	267	22	,	,	PUNCT
bptjm-17	267	23	2019	2019	NUM
bptjm-17	267	24	)	)	PUNCT
bptjm-17	267	25	.	.	PUNCT
bptjm-17	268	1	data	datum	NOUN
bptjm-17	268	2	was	be	AUX
bptjm-17	268	3	extracted	extract	VERB
bptjm-17	268	4	from	from	ADP
bptjm-17	268	5	patients	patient	NOUN
bptjm-17	268	6	in	in	ADP
bptjm-17	268	7	the	the	DET
bptjm-17	268	8	thoracic	thoracic	NOUN
bptjm-17	268	9	malignancies	malignancy	NOUN
bptjm-17	268	10	cohort	cohort	NOUN
bptjm-17	268	11	(	(	PUNCT
bptjm-17	268	12	tmc	tmc	NOUN
bptjm-17	268	13	)	)	PUNCT
bptjm-17	268	14	to	to	PART
bptjm-17	268	15	compare	compare	VERB
bptjm-17	268	16	clinical	clinical	ADJ
bptjm-17	268	17	features	feature	NOUN
bptjm-17	268	18	and	and	CCONJ
bptjm-17	268	19	os	os	NOUN
bptjm-17	268	20	of	of	ADP
bptjm-17	268	21	the	the	DET
bptjm-17	268	22	wild	wild	ADJ
bptjm-17	268	23	type	type	NOUN
bptjm-17	268	24	kras	kra	NOUN
bptjm-17	268	25	to	to	ADP
bptjm-17	268	26	kras	kras	PROPN
bptjm-17	268	27	g12c	g12c	PROPN
bptjm-17	268	28	,	,	PUNCT
bptjm-17	268	29	amongst	amongst	ADP
bptjm-17	268	30	other	other	ADJ
bptjm-17	268	31	mutated	mutate	VERB
bptjm-17	268	32	types	type	NOUN
bptjm-17	268	33	.	.	PUNCT
bptjm-17	269	1	100	100	NUM
bptjm-17	269	2	%	%	NOUN
bptjm-17	269	3	of	of	ADP
bptjm-17	269	4	the	the	DET
bptjm-17	269	5	patients	patient	NOUN
bptjm-17	269	6	with	with	ADP
bptjm-17	269	7	the	the	DET
bptjm-17	269	8	kras	kra	NOUN
bptjm-17	269	9	g12c	g12c	PROPN
bptjm-17	269	10	subtype	subtype	NOUN
bptjm-17	269	11	were	be	AUX
bptjm-17	269	12	active	active	ADJ
bptjm-17	269	13	smokers	smoker	NOUN
bptjm-17	269	14	.	.	PUNCT
bptjm-17	270	1	results	result	NOUN
bptjm-17	270	2	showed	show	VERB
bptjm-17	270	3	that	that	SCONJ
bptjm-17	270	4	the	the	DET
bptjm-17	270	5	treatment	treatment	NOUN
bptjm-17	270	6	and	and	CCONJ
bptjm-17	270	7	survival	survival	NOUN
bptjm-17	270	8	of	of	ADP
bptjm-17	270	9	kras	kras	PROPN
bptjm-17	270	10	mutant	mutant	ADJ
bptjm-17	270	11	subtypes	subtype	NOUN
bptjm-17	270	12	were	be	AUX
bptjm-17	270	13	similar	similar	ADJ
bptjm-17	270	14	(	(	PUNCT
bptjm-17	270	15	cui	cui	NOUN
bptjm-17	270	16	et	et	PROPN
bptjm-17	270	17	al	al	PROPN
bptjm-17	270	18	.	.	PROPN
bptjm-17	270	19	,	,	PUNCT
bptjm-17	270	20	2020	2020	NUM
bptjm-17	270	21	)	)	PUNCT
bptjm-17	270	22	.	.	PUNCT
bptjm-17	271	1	however	however	ADV
bptjm-17	271	2	,	,	PUNCT
bptjm-17	271	3	kras	kras	PROPN
bptjm-17	271	4	g12c	g12c	PROPN
bptjm-17	271	5	in	in	ADP
bptjm-17	271	6	particular	particular	ADJ
bptjm-17	271	7	proved	prove	VERB
bptjm-17	271	8	to	to	PART
bptjm-17	271	9	be	be	AUX
bptjm-17	271	10	an	an	DET
bptjm-17	271	11	important	important	ADJ
bptjm-17	271	12	predictive	predictive	ADJ
bptjm-17	271	13	biomarker	biomarker	NOUN
bptjm-17	271	14	compared	compare	VERB
bptjm-17	271	15	to	to	ADP
bptjm-17	271	16	the	the	DET
bptjm-17	271	17	other	other	ADJ
bptjm-17	271	18	kras	kras	PROPN
bptjm-17	271	19	mutant	mutant	ADJ
bptjm-17	271	20	types	type	NOUN
bptjm-17	271	21	,	,	PUNCT
bptjm-17	271	22	such	such	ADJ
bptjm-17	271	23	as	as	ADP
bptjm-17	271	24	wildtype	wildtype	PROPN
bptjm-17	271	25	kras	kra	NOUN
bptjm-17	271	26	and	and	CCONJ
bptjm-17	271	27	mutated	mutate	VERB
bptjm-17	271	28	kras	kra	NOUN
bptjm-17	271	29	(	(	PUNCT
bptjm-17	271	30	p	p	X
bptjm-17	271	31	=	=	NOUN
bptjm-17	271	32	0.74	0.74	NUM
bptjm-17	271	33	)	)	PUNCT
bptjm-17	271	34	(	(	PUNCT
bptjm-17	271	35	cui	cui	VERB
bptjm-17	271	36	et	et	PROPN
bptjm-17	271	37	al	al	PROPN
bptjm-17	271	38	.	.	PROPN
bptjm-17	271	39	,	,	PUNCT
bptjm-17	271	40	2020	2020	NUM
bptjm-17	271	41	)	)	PUNCT
bptjm-17	271	42	.	.	PUNCT
bptjm-17	272	1	although	although	SCONJ
bptjm-17	272	2	there	there	PRON
bptjm-17	272	3	are	be	VERB
bptjm-17	272	4	no	no	DET
bptjm-17	272	5	current	current	ADJ
bptjm-17	272	6	kras	kra	NOUN
bptjm-17	272	7	inhibitors	inhibitor	NOUN
bptjm-17	272	8	on	on	ADP
bptjm-17	272	9	the	the	DET
bptjm-17	272	10	market	market	NOUN
bptjm-17	272	11	,	,	PUNCT
bptjm-17	272	12	it	it	PRON
bptjm-17	272	13	has	have	AUX
bptjm-17	272	14	been	be	AUX
bptjm-17	272	15	marked	mark	VERB
bptjm-17	272	16	as	as	ADP
bptjm-17	272	17	a	a	DET
bptjm-17	272	18	clinically	clinically	ADV
bptjm-17	272	19	applicable	applicable	ADJ
bptjm-17	272	20	biomarker	biomarker	NOUN
bptjm-17	272	21	in	in	ADP
bptjm-17	272	22	a	a	DET
bptjm-17	272	23	paper	paper	NOUN
bptjm-17	272	24	by	by	ADP
bptjm-17	272	25	vincent	vincent	PROPN
bptjm-17	272	26	et	et	PROPN
bptjm-17	272	27	al	al	PROPN
bptjm-17	272	28	.	.	PROPN
bptjm-17	273	1	in	in	ADP
bptjm-17	273	2	2012	2012	NUM
bptjm-17	273	3	.	.	PUNCT
bptjm-17	274	1	subsequently	subsequently	ADV
bptjm-17	274	2	,	,	PUNCT
bptjm-17	274	3	research	research	NOUN
bptjm-17	274	4	conducted	conduct	VERB
bptjm-17	274	5	since	since	SCONJ
bptjm-17	274	6	then	then	ADV
bptjm-17	274	7	corroborates	corroborate	VERB
bptjm-17	274	8	the	the	DET
bptjm-17	274	9	potential	potential	NOUN
bptjm-17	274	10	for	for	SCONJ
bptjm-17	274	11	kras	kra	NOUN
bptjm-17	274	12	to	to	PART
bptjm-17	274	13	serve	serve	VERB
bptjm-17	274	14	as	as	ADP
bptjm-17	274	15	a	a	DET
bptjm-17	274	16	potential	potential	ADJ
bptjm-17	274	17	predictive	predictive	ADJ
bptjm-17	274	18	biomarker	biomarker	NOUN
bptjm-17	274	19	in	in	ADP
bptjm-17	274	20	nsclc	nsclc	NOUN
bptjm-17	274	21	.	.	PUNCT
bptjm-17	275	1	data	datum	NOUN
bptjm-17	275	2	collected	collect	VERB
bptjm-17	275	3	from	from	ADP
bptjm-17	275	4	plasma	plasma	NOUN
bptjm-17	275	5	based	base	VERB
bptjm-17	275	6	liquid	liquid	ADJ
bptjm-17	275	7	biopsies	biopsy	NOUN
bptjm-17	275	8	by	by	ADP
bptjm-17	275	9	ngs	ng	NOUN
bptjm-17	275	10	showed	show	VERB
bptjm-17	275	11	that	that	SCONJ
bptjm-17	275	12	36	36	NUM
bptjm-17	275	13	(	(	PUNCT
bptjm-17	275	14	18.6	18.6	NUM
bptjm-17	275	15	%	%	NOUN
bptjm-17	275	16	)	)	PUNCT
bptjm-17	275	17	out	out	ADP
bptjm-17	275	18	of	of	ADP
bptjm-17	275	19	the	the	DET
bptjm-17	275	20	194	194	NUM
bptjm-17	275	21	liquid	liquid	ADJ
bptjm-17	275	22	biopsies	biopsy	NOUN
bptjm-17	275	23	were	be	AUX
bptjm-17	275	24	a	a	DET
bptjm-17	275	25	kras	kra	NOUN
bptjm-17	275	26	g12c	g12c	PROPN
bptjm-17	275	27	variant	variant	NOUN
bptjm-17	275	28	.	.	PUNCT
bptjm-17	276	1	since	since	SCONJ
bptjm-17	276	2	tissue	tissue	NOUN
bptjm-17	276	3	biopsies	biopsy	NOUN
bptjm-17	276	4	are	be	AUX
bptjm-17	276	5	often	often	ADV
bptjm-17	276	6	rejected	reject	VERB
bptjm-17	276	7	(	(	PUNCT
bptjm-17	276	8	17	17	NUM
bptjm-17	276	9	%	%	NOUN
bptjm-17	276	10	)	)	PUNCT
bptjm-17	276	11	due	due	ADP
bptjm-17	276	12	to	to	ADP
bptjm-17	276	13	insu	insu	PROPN
bptjm-17	276	14	cient	cient	PROPN
bptjm-17	276	15	cellularity	cellularity	PROPN
bptjm-17	276	16	,	,	PUNCT
bptjm-17	276	17	kras	kras	PROPN
bptjm-17	276	18	detection	detection	NOUN
bptjm-17	276	19	in	in	ADP
bptjm-17	276	20	ctdna	ctdna	NOUN
bptjm-17	276	21	may	may	AUX
bptjm-17	276	22	bene	bene	VERB
bptjm-17	276	23	t	t	PROPN
bptjm-17	276	24	from	from	ADP
bptjm-17	276	25	clinical	clinical	ADJ
bptjm-17	276	26	implementation	implementation	NOUN
bptjm-17	276	27	.	.	PUNCT
bptjm-17	277	1	tsc1/2	tsc1/2	PROPN
bptjm-17	278	1	the	the	DET
bptjm-17	278	2	tsc1	tsc1	PROPN
bptjm-17	278	3	-	-	PUNCT
bptjm-17	278	4	tsc2	tsc2	PROPN
bptjm-17	278	5	complex	complex	NOUN
bptjm-17	278	6	is	be	AUX
bptjm-17	278	7	a	a	DET
bptjm-17	278	8	key	key	ADJ
bptjm-17	278	9	regulator	regulator	NOUN
bptjm-17	278	10	of	of	ADP
bptjm-17	278	11	the	the	DET
bptjm-17	278	12	mtorc1	mtorc1	NOUN
bptjm-17	278	13	(	(	PUNCT
bptjm-17	278	14	mammalian	mammalian	ADJ
bptjm-17	278	15	target	target	NOUN
bptjm-17	278	16	of	of	ADP
bptjm-17	278	17	rapamycin	rapamycin	NOUN
bptjm-17	278	18	complex	complex	ADJ
bptjm-17	278	19	1	1	NUM
bptjm-17	278	20	)	)	PUNCT
bptjm-17	278	21	,	,	PUNCT
bptjm-17	278	22	which	which	PRON
bptjm-17	278	23	controls	control	VERB
bptjm-17	278	24	cell	cell	NOUN
bptjm-17	278	25	growth	growth	NOUN
bptjm-17	278	26	.	.	PUNCT
bptjm-17	279	1	hamartin	hamartin	NOUN
bptjm-17	279	2	(	(	PUNCT
bptjm-17	279	3	tsc1	tsc1	PROPN
bptjm-17	279	4	)	)	PUNCT
bptjm-17	279	5	and	and	CCONJ
bptjm-17	279	6	tuberin	tuberin	NOUN
bptjm-17	279	7	(	(	PUNCT
bptjm-17	279	8	tsc2	tsc2	PROPN
bptjm-17	279	9	)	)	PUNCT
bptjm-17	279	10	are	be	AUX
bptjm-17	279	11	the	the	DET
bptjm-17	279	12	mutations	mutation	NOUN
bptjm-17	279	13	of	of	ADP
bptjm-17	279	14	genes	gene	NOUN
bptjm-17	279	15	found	find	VERB
bptjm-17	279	16	in	in	ADP
bptjm-17	279	17	the	the	DET
bptjm-17	279	18	berkeley	berkeley	PROPN
bptjm-17	279	19	pharma	pharma	PROPN
bptjm-17	279	20	tech	tech	NOUN
bptjm-17	279	21	journal	journal	NOUN
bptjm-17	279	22	of	of	ADP
bptjm-17	279	23	medicine	medicine	NOUN
bptjm-17	279	24	|	|	ADV
bptjm-17	279	25	133	133	NUM
bptjm-17	279	26	tuberous	tuberous	ADJ
bptjm-17	279	27	sclerosis	sclerosis	NOUN
bptjm-17	279	28	complex	complex	NOUN
bptjm-17	279	29	(	(	PUNCT
bptjm-17	279	30	tsc	tsc	PROPN
bptjm-17	279	31	)	)	PUNCT
bptjm-17	279	32	.	.	PUNCT
bptjm-17	280	1	inhibition	inhibition	NOUN
bptjm-17	280	2	of	of	ADP
bptjm-17	280	3	tsc1/2	tsc1/2	PROPN
bptjm-17	280	4	results	result	NOUN
bptjm-17	280	5	in	in	ADP
bptjm-17	280	6	inactive	inactive	ADJ
bptjm-17	280	7	mtorc1	mtorc1	NOUN
bptjm-17	280	8	,	,	PUNCT
bptjm-17	280	9	leading	lead	VERB
bptjm-17	280	10	to	to	ADP
bptjm-17	280	11	uncontrolled	uncontrolled	ADJ
bptjm-17	280	12	cell	cell	NOUN
bptjm-17	280	13	growth	growth	NOUN
bptjm-17	280	14	.	.	PUNCT
bptjm-17	281	1	fuchs	fuchs	PROPN
bptjm-17	281	2	et	et	PROPN
bptjm-17	281	3	al	al	PROPN
bptjm-17	281	4	.	.	PROPN
bptjm-17	281	5	,	,	PUNCT
bptjm-17	281	6	determined	determine	VERB
bptjm-17	281	7	the	the	DET
bptjm-17	281	8	inverse	inverse	NOUN
bptjm-17	281	9	correlation	correlation	NOUN
bptjm-17	281	10	between	between	ADP
bptjm-17	281	11	hamartin	hamartin	NOUN
bptjm-17	281	12	and	and	CCONJ
bptjm-17	281	13	p	p	NOUN
bptjm-17	281	14	-	-	PUNCT
bptjm-17	281	15	mtor	mtor	NOUN
bptjm-17	281	16	(	(	PUNCT
bptjm-17	281	17	the	the	DET
bptjm-17	281	18	catalytic	catalytic	ADJ
bptjm-17	281	19	subunit	subunit	NOUN
bptjm-17	281	20	of	of	ADP
bptjm-17	281	21	two	two	NUM
bptjm-17	281	22	distinct	distinct	ADJ
bptjm-17	281	23	protein	protein	NOUN
bptjm-17	281	24	complexes	complex	NOUN
bptjm-17	281	25	which	which	PRON
bptjm-17	281	26	controls	control	VERB
bptjm-17	281	27	cell	cell	NOUN
bptjm-17	281	28	proliferation	proliferation	NOUN
bptjm-17	281	29	)	)	PUNCT
bptjm-17	281	30	expression	expression	NOUN
bptjm-17	281	31	in	in	ADP
bptjm-17	281	32	nsclc	nsclc	NOUN
bptjm-17	281	33	and	and	CCONJ
bptjm-17	281	34	sclc	sclc	PROPN
bptjm-17	281	35	samples	sample	NOUN
bptjm-17	281	36	.	.	PUNCT
bptjm-17	282	1	fish	fish	NOUN
bptjm-17	282	2	and	and	CCONJ
bptjm-17	282	3	western	western	ADJ
bptjm-17	282	4	blot	blot	NOUN
bptjm-17	282	5	analysis	analysis	NOUN
bptjm-17	282	6	were	be	AUX
bptjm-17	282	7	performed	perform	VERB
bptjm-17	282	8	on	on	ADP
bptjm-17	282	9	166	166	NUM
bptjm-17	282	10	nsclc	nsclc	NOUN
bptjm-17	282	11	and	and	CCONJ
bptjm-17	282	12	sclc	sclc	PROPN
bptjm-17	282	13	cell	cell	NOUN
bptjm-17	282	14	lines	line	NOUN
bptjm-17	282	15	.	.	PUNCT
bptjm-17	283	1	furthermore	furthermore	ADV
bptjm-17	283	2	,	,	PUNCT
bptjm-17	283	3	cytoplasmic	cytoplasmic	ADJ
bptjm-17	283	4	hamartin	hamartin	NOUN
bptjm-17	283	5	expression	expression	NOUN
bptjm-17	283	6	was	be	AUX
bptjm-17	283	7	expressed	express	VERB
bptjm-17	283	8	in	in	ADP
bptjm-17	283	9	greater	great	ADJ
bptjm-17	283	10	than	than	ADP
bptjm-17	283	11	50	50	NUM
bptjm-17	283	12	%	%	NOUN
bptjm-17	283	13	of	of	ADP
bptjm-17	283	14	nsclc	nsclc	NOUN
bptjm-17	283	15	cell	cell	NOUN
bptjm-17	283	16	lines	line	NOUN
bptjm-17	283	17	(	(	PUNCT
bptjm-17	283	18	fuchs	fuchs	PROPN
bptjm-17	283	19	et	et	PROPN
bptjm-17	283	20	al	al	PROPN
bptjm-17	283	21	.	.	PROPN
bptjm-17	283	22	,	,	PUNCT
bptjm-17	283	23	2014	2014	NUM
bptjm-17	283	24	)	)	PUNCT
bptjm-17	283	25	.	.	PUNCT
bptjm-17	284	1	fuchs	fuchs	PROPN
bptjm-17	284	2	et	et	PROPN
bptjm-17	284	3	al	al	PROPN
bptjm-17	284	4	.	.	PROPN
bptjm-17	284	5	,	,	PUNCT
bptjm-17	284	6	concluded	conclude	VERB
bptjm-17	284	7	that	that	SCONJ
bptjm-17	284	8	activation	activation	NOUN
bptjm-17	284	9	of	of	ADP
bptjm-17	284	10	lung	lung	NOUN
bptjm-17	284	11	cancer	cancer	NOUN
bptjm-17	284	12	cell	cell	NOUN
bptjm-17	284	13	lines	line	NOUN
bptjm-17	284	14	is	be	AUX
bptjm-17	284	15	caused	cause	VERB
bptjm-17	284	16	by	by	ADP
bptjm-17	284	17	the	the	DET
bptjm-17	284	18	inhibition	inhibition	NOUN
bptjm-17	284	19	of	of	ADP
bptjm-17	284	20	the	the	DET
bptjm-17	284	21	mtorc	mtorc	NOUN
bptjm-17	284	22	by	by	ADP
bptjm-17	284	23	the	the	DET
bptjm-17	284	24	tsc	tsc	PROPN
bptjm-17	284	25	.	.	PUNCT
bptjm-17	285	1	unlike	unlike	ADP
bptjm-17	285	2	most	most	ADJ
bptjm-17	285	3	other	other	ADJ
bptjm-17	285	4	nsclcmutations	nsclcmutation	NOUN
bptjm-17	285	5	,	,	PUNCT
bptjm-17	285	6	tsc1/2	tsc1/2	PROPN
bptjm-17	285	7	may	may	AUX
bptjm-17	285	8	be	be	AUX
bptjm-17	285	9	caused	cause	VERB
bptjm-17	285	10	by	by	ADP
bptjm-17	285	11	egfr	egfr	ADJ
bptjm-17	285	12	expression	expression	NOUN
bptjm-17	285	13	,	,	PUNCT
bptjm-17	285	14	but	but	CCONJ
bptjm-17	285	15	is	be	AUX
bptjm-17	285	16	not	not	PART
bptjm-17	285	17	dependent	dependent	ADJ
bptjm-17	285	18	on	on	ADP
bptjm-17	285	19	it	it	PRON
bptjm-17	285	20	.	.	PUNCT
bptjm-17	286	1	wang	wang	PROPN
bptjm-17	286	2	et	et	PROPN
bptjm-17	286	3	al	al	PROPN
bptjm-17	286	4	.	.	PROPN
bptjm-17	286	5	utilized	utilize	VERB
bptjm-17	286	6	144	144	NUM
bptjm-17	286	7	nsclc	nsclc	NOUN
bptjm-17	286	8	patients	patient	NOUN
bptjm-17	286	9	to	to	PART
bptjm-17	286	10	study	study	VERB
bptjm-17	286	11	the	the	DET
bptjm-17	286	12	characteristics	characteristic	NOUN
bptjm-17	286	13	of	of	ADP
bptjm-17	286	14	tsc1	tsc1	PROPN
bptjm-17	286	15	and	and	CCONJ
bptjm-17	286	16	tsc2	tsc2	NOUN
bptjm-17	286	17	in	in	ADP
bptjm-17	286	18	nsclc	nsclc	NOUN
bptjm-17	286	19	.	.	PUNCT
bptjm-17	287	1	the	the	DET
bptjm-17	287	2	researchers	researcher	NOUN
bptjm-17	287	3	found	find	VERB
bptjm-17	287	4	27	27	NUM
bptjm-17	287	5	of	of	ADP
bptjm-17	287	6	the	the	DET
bptjm-17	287	7	144	144	NUM
bptjm-17	287	8	nsclc	nsclc	NOUN
bptjm-17	287	9	patients	patient	NOUN
bptjm-17	287	10	exhibited	exhibit	VERB
bptjm-17	287	11	tsc1	tsc1	PROPN
bptjm-17	287	12	mutation	mutation	NOUN
bptjm-17	287	13	and	and	CCONJ
bptjm-17	287	14	40	40	NUM
bptjm-17	287	15	exhibited	exhibit	VERB
bptjm-17	287	16	tsc2	tsc2	NOUN
bptjm-17	287	17	mutation	mutation	NOUN
bptjm-17	287	18	.	.	PUNCT
bptjm-17	288	1	it	it	PRON
bptjm-17	288	2	must	must	AUX
bptjm-17	288	3	also	also	ADV
bptjm-17	288	4	be	be	AUX
bptjm-17	288	5	noted	note	VERB
bptjm-17	288	6	that	that	SCONJ
bptjm-17	288	7	most	most	ADJ
bptjm-17	288	8	patients	patient	NOUN
bptjm-17	288	9	with	with	ADP
bptjm-17	288	10	tsc	tsc	PROPN
bptjm-17	288	11	mutations	mutation	NOUN
bptjm-17	288	12	expressed	express	VERB
bptjm-17	288	13	other	other	ADJ
bptjm-17	288	14	oncogenic	oncogenic	ADJ
bptjm-17	288	15	gene	gene	NOUN
bptjm-17	288	16	alterations	alteration	NOUN
bptjm-17	288	17	as	as	ADV
bptjm-17	288	18	well	well	ADV
bptjm-17	288	19	.	.	PUNCT
bptjm-17	289	1	the	the	DET
bptjm-17	289	2	expression	expression	NOUN
bptjm-17	289	3	of	of	ADP
bptjm-17	289	4	tsc1/2	tsc1/2	PROPN
bptjm-17	289	5	was	be	AUX
bptjm-17	289	6	slightly	slightly	ADV
bptjm-17	289	7	more	more	ADV
bptjm-17	289	8	common	common	ADJ
bptjm-17	289	9	in	in	ADP
bptjm-17	289	10	nsclc	nsclc	NOUN
bptjm-17	289	11	compared	compare	VERB
bptjm-17	289	12	to	to	ADP
bptjm-17	289	13	sclc	sclc	PROPN
bptjm-17	289	14	(	(	PUNCT
bptjm-17	289	15	53.7	53.7	NUM
bptjm-17	289	16	%	%	NOUN
bptjm-17	289	17	vs.	vs.	ADP
bptjm-17	289	18	43.6	43.6	NUM
bptjm-17	289	19	%	%	NOUN
bptjm-17	289	20	)	)	PUNCT
bptjm-17	290	1	(	(	PUNCT
bptjm-17	290	2	wang	wang	PROPN
bptjm-17	290	3	et	et	PROPN
bptjm-17	290	4	al	al	PROPN
bptjm-17	290	5	.	.	PROPN
bptjm-17	290	6	,	,	PUNCT
bptjm-17	290	7	2020	2020	NUM
bptjm-17	290	8	)	)	PUNCT
bptjm-17	290	9	.	.	PUNCT
bptjm-17	291	1	furthermore	furthermore	ADV
bptjm-17	291	2	,	,	PUNCT
bptjm-17	291	3	the	the	DET
bptjm-17	291	4	tsc1	tsc1	PROPN
bptjm-17	291	5	mutation	mutation	NOUN
bptjm-17	291	6	had	have	VERB
bptjm-17	291	7	a	a	DET
bptjm-17	291	8	median	median	ADJ
bptjm-17	291	9	os	os	NOUN
bptjm-17	291	10	of	of	ADP
bptjm-17	291	11	14.1	14.1	NUM
bptjm-17	291	12	months	month	NOUN
bptjm-17	291	13	,	,	PUNCT
bptjm-17	291	14	whereas	whereas	SCONJ
bptjm-17	291	15	patients	patient	NOUN
bptjm-17	291	16	with	with	ADP
bptjm-17	291	17	tsc2	tsc2	PROPN
bptjm-17	291	18	mutation	mutation	NOUN
bptjm-17	291	19	had	have	VERB
bptjm-17	291	20	a	a	DET
bptjm-17	291	21	median	median	ADJ
bptjm-17	291	22	os	os	NOUN
bptjm-17	291	23	110.6	110.6	NUM
bptjm-17	291	24	months	month	NOUN
bptjm-17	291	25	;	;	PUNCT
bptjm-17	291	26	however	however	ADV
bptjm-17	291	27	,	,	PUNCT
bptjm-17	291	28	the	the	DET
bptjm-17	291	29	di	di	NOUN
bptjm-17	291	30	erence	erence	NOUN
bptjm-17	291	31	was	be	AUX
bptjm-17	291	32	not	not	PART
bptjm-17	291	33	statistically	statistically	ADV
bptjm-17	291	34	signi	signi	ADJ
bptjm-17	291	35	ca	can	AUX
bptjm-17	291	36	nt	not	PART
bptjm-17	291	37	(	(	PUNCT
bptjm-17	291	38	p	p	NOUN
bptjm-17	291	39	=	=	NOUN
bptjm-17	291	40	0.201	0.201	NUM
bptjm-17	291	41	)	)	PUNCT
bptjm-17	291	42	.	.	PUNCT
bptjm-17	292	1	wang	wang	PROPN
bptjm-17	292	2	et	et	PROPN
bptjm-17	292	3	al	al	PROPN
bptjm-17	292	4	.	.	PROPN
bptjm-17	292	5	concluded	conclude	VERB
bptjm-17	292	6	that	that	SCONJ
bptjm-17	292	7	tsc1/2	tsc1/2	PROPN
bptjm-17	292	8	de	de	X
bptjm-17	292	9	nes	nes	PROPN
bptjm-17	292	10	a	a	DET
bptjm-17	292	11	unique	unique	ADJ
bptjm-17	292	12	nsclc	nsclc	NOUN
bptjm-17	292	13	population	population	NOUN
bptjm-17	292	14	and	and	CCONJ
bptjm-17	292	15	often	often	ADV
bptjm-17	292	16	coincides	coincide	VERB
bptjm-17	292	17	with	with	ADP
bptjm-17	292	18	other	other	ADJ
bptjm-17	292	19	mutations	mutation	NOUN
bptjm-17	292	20	such	such	ADJ
bptjm-17	292	21	as	as	ADP
bptjm-17	292	22	tp53	tp53	PROPN
bptjm-17	292	23	.	.	PUNCT
bptjm-17	293	1	in	in	ADP
bptjm-17	293	2	an	an	DET
bptjm-17	293	3	experiment	experiment	NOUN
bptjm-17	293	4	conducted	conduct	VERB
bptjm-17	293	5	by	by	ADP
bptjm-17	293	6	rulli	rulli	PROPN
bptjm-17	293	7	et	et	PROPN
bptjm-17	293	8	al	al	PROPN
bptjm-17	293	9	.	.	PROPN
bptjm-17	293	10	,	,	PUNCT
bptjm-17	293	11	liquid	liquid	ADJ
bptjm-17	293	12	biopsies	biopsy	NOUN
bptjm-17	293	13	were	be	AUX
bptjm-17	293	14	used	use	VERB
bptjm-17	293	15	to	to	PART
bptjm-17	293	16	measure	measure	VERB
bptjm-17	293	17	the	the	DET
bptjm-17	293	18	number	number	NOUN
bptjm-17	293	19	of	of	ADP
bptjm-17	293	20	circulating	circulate	VERB
bptjm-17	293	21	tumor	tumor	NOUN
bptjm-17	293	22	cells	cell	NOUN
bptjm-17	293	23	(	(	PUNCT
bptjm-17	293	24	ctcs	ctcs	NOUN
bptjm-17	293	25	)	)	PUNCT
bptjm-17	293	26	,	,	PUNCT
bptjm-17	293	27	the	the	DET
bptjm-17	293	28	quantity	quantity	NOUN
bptjm-17	293	29	of	of	ADP
bptjm-17	293	30	cell	cell	NOUN
bptjm-17	293	31	free	free	ADJ
bptjm-17	293	32	tumor	tumor	NOUN
bptjm-17	293	33	dna	dna	PROPN
bptjm-17	293	34	(	(	PUNCT
bptjm-17	293	35	cftdna	cftdna	NOUN
bptjm-17	293	36	)	)	PUNCT
bptjm-17	293	37	,	,	PUNCT
bptjm-17	293	38	and	and	CCONJ
bptjm-17	293	39	the	the	DET
bptjm-17	293	40	mutational	mutational	ADJ
bptjm-17	293	41	pro	pro	X
bptjm-17	293	42	le	le	X
bptjm-17	293	43	of	of	ADP
bptjm-17	293	44	dna	dna	PROPN
bptjm-17	293	45	from	from	ADP
bptjm-17	293	46	ctcs	ctcs	PROPN
bptjm-17	293	47	(	(	PUNCT
bptjm-17	293	48	ctcdna	ctcdna	ADJ
bptjm-17	293	49	)	)	PUNCT
bptjm-17	293	50	and	and	CCONJ
bptjm-17	293	51	cftdna	cftdna	NOUN
bptjm-17	293	52	in	in	ADP
bptjm-17	293	53	early	early	ADJ
bptjm-17	293	54	stage	stage	NOUN
bptjm-17	293	55	breast	breast	NOUN
bptjm-17	293	56	cancer	cancer	NOUN
bptjm-17	293	57	patients	patient	NOUN
bptjm-17	293	58	.	.	PUNCT
bptjm-17	294	1	ngs	ng	NOUN
bptjm-17	294	2	of	of	ADP
bptjm-17	294	3	ctcdna	ctcdna	NOUN
bptjm-17	294	4	and	and	CCONJ
bptjm-17	294	5	cftdna	cftdna	NOUN
bptjm-17	294	6	showed	show	VERB
bptjm-17	294	7	that	that	SCONJ
bptjm-17	294	8	52	52	NUM
bptjm-17	294	9	%	%	NOUN
bptjm-17	294	10	of	of	ADP
bptjm-17	294	11	the	the	DET
bptjm-17	294	12	patients	patient	NOUN
bptjm-17	294	13	expressed	express	VERB
bptjm-17	294	14	mutations	mutation	NOUN
bptjm-17	294	15	in	in	ADP
bptjm-17	294	16	multiple	multiple	ADJ
bptjm-17	294	17	genes	gene	NOUN
bptjm-17	294	18	including	include	VERB
bptjm-17	294	19	tsc1	tsc1	PROPN
bptjm-17	294	20	(	(	PUNCT
bptjm-17	294	21	rulli	rulli	PROPN
bptjm-17	294	22	et	et	NOUN
bptjm-17	294	23	al	al	PROPN
bptjm-17	294	24	.	.	PROPN
bptjm-17	294	25	,	,	PUNCT
bptjm-17	294	26	2020	2020	NUM
bptjm-17	294	27	)	)	PUNCT
bptjm-17	294	28	.	.	PUNCT
bptjm-17	295	1	in	in	ADP
bptjm-17	295	2	addition	addition	NOUN
bptjm-17	295	3	to	to	ADP
bptjm-17	295	4	the	the	DET
bptjm-17	295	5	signi	signi	ADJ
bptjm-17	295	6	cance	cance	NOUN
bptjm-17	295	7	of	of	ADP
bptjm-17	295	8	tsc	tsc	PROPN
bptjm-17	295	9	in	in	ADP
bptjm-17	295	10	nsclc	nsclc	NOUN
bptjm-17	295	11	prognosis	prognosis	NOUN
bptjm-17	295	12	and	and	CCONJ
bptjm-17	295	13	treatment	treatment	NOUN
bptjm-17	295	14	,	,	PUNCT
bptjm-17	295	15	initial	initial	ADJ
bptjm-17	295	16	research	research	NOUN
bptjm-17	295	17	shows	show	VERB
bptjm-17	295	18	strong	strong	ADJ
bptjm-17	295	19	promise	promise	NOUN
bptjm-17	295	20	for	for	SCONJ
bptjm-17	295	21	it	it	PRON
bptjm-17	295	22	to	to	PART
bptjm-17	295	23	be	be	AUX
bptjm-17	295	24	implemented	implement	VERB
bptjm-17	295	25	via	via	ADP
bptjm-17	295	26	liquid	liquid	ADJ
bptjm-17	295	27	biopsies	biopsy	NOUN
bptjm-17	295	28	.	.	PUNCT
bptjm-17	296	1	currently	currently	ADV
bptjm-17	296	2	,	,	PUNCT
bptjm-17	296	3	there	there	PRON
bptjm-17	296	4	are	be	VERB
bptjm-17	296	5	no	no	DET
bptjm-17	296	6	targeted	targeted	ADJ
bptjm-17	296	7	therapies	therapy	NOUN
bptjm-17	296	8	on	on	ADP
bptjm-17	296	9	the	the	DET
bptjm-17	296	10	market	market	NOUN
bptjm-17	296	11	for	for	ADP
bptjm-17	296	12	tsc1/2	tsc1/2	PROPN
bptjm-17	296	13	,	,	PUNCT
bptjm-17	296	14	although	although	SCONJ
bptjm-17	296	15	pd-1	pd-1	VERB
bptjm-17	296	16	and/or	and/or	CCONJ
bptjm-17	296	17	ctla-4	ctla-4	NOUN
bptjm-17	296	18	inhibitors	inhibitor	NOUN
bptjm-17	296	19	show	show	VERB
bptjm-17	296	20	success	success	NOUN
bptjm-17	296	21	in	in	ADP
bptjm-17	296	22	clinical	clinical	ADJ
bptjm-17	296	23	trials	trial	NOUN
bptjm-17	296	24	for	for	ADP
bptjm-17	296	25	tsc1/2	tsc1/2	NUM
bptjm-17	296	26	associated	associated	ADJ
bptjm-17	296	27	tumors	tumor	NOUN
bptjm-17	296	28	(	(	PUNCT
bptjm-17	296	29	liu	liu	PROPN
bptjm-17	296	30	et	et	PROPN
bptjm-17	296	31	al	al	PROPN
bptjm-17	296	32	.	.	PROPN
bptjm-17	296	33	,	,	PUNCT
bptjm-17	296	34	2018	2018	NUM
bptjm-17	296	35	)	)	PUNCT
bptjm-17	296	36	.	.	PUNCT
bptjm-17	297	1	fgfr1/2	fgfr1/2	ADJ
bptjm-17	297	2	fibroblast	fibroblast	ADJ
bptjm-17	297	3	growth	growth	NOUN
bptjm-17	297	4	factor	factor	NOUN
bptjm-17	297	5	receptor	receptor	NOUN
bptjm-17	297	6	1	1	NUM
bptjm-17	297	7	and	and	CCONJ
bptjm-17	297	8	broblast	broblast	ADJ
bptjm-17	297	9	growth	growth	NOUN
bptjm-17	297	10	factor	factor	NOUN
bptjm-17	297	11	receptor	receptor	NOUN
bptjm-17	297	12	2	2	NUM
bptjm-17	297	13	are	be	AUX
bptjm-17	297	14	members	member	NOUN
bptjm-17	297	15	of	of	ADP
bptjm-17	297	16	the	the	DET
bptjm-17	297	17	broblast	broblast	ADJ
bptjm-17	297	18	growth	growth	NOUN
bptjm-17	297	19	factor	factor	NOUN
bptjm-17	297	20	receptor	receptor	NOUN
bptjm-17	297	21	family	family	NOUN
bptjm-17	297	22	.	.	PUNCT
bptjm-17	298	1	fgfr1	fgfr1	NOUN
bptjm-17	298	2	and	and	CCONJ
bptjm-17	298	3	fgfr2	fgfr2	ADJ
bptjm-17	298	4	span	span	NOUN
bptjm-17	298	5	the	the	DET
bptjm-17	298	6	cell	cell	NOUN
bptjm-17	298	7	membrane	membrane	NOUN
bptjm-17	298	8	and	and	CCONJ
bptjm-17	298	9	interact	interact	VERB
bptjm-17	298	10	with	with	ADP
bptjm-17	298	11	broblast	broblast	ADJ
bptjm-17	298	12	growth	growth	NOUN
bptjm-17	298	13	factors	factor	NOUN
bptjm-17	298	14	outside	outside	ADP
bptjm-17	298	15	the	the	DET
bptjm-17	298	16	cell	cell	NOUN
bptjm-17	298	17	.	.	PUNCT
bptjm-17	299	1	this	this	DET
bptjm-17	299	2	results	result	VERB
bptjm-17	299	3	in	in	ADP
bptjm-17	299	4	a	a	DET
bptjm-17	299	5	cascade	cascade	NOUN
bptjm-17	299	6	of	of	ADP
bptjm-17	299	7	downstream	downstream	NOUN
bptjm-17	299	8	signaling	signal	VERB
bptjm-17	299	9	within	within	ADP
bptjm-17	299	10	berkeley	berkeley	PROPN
bptjm-17	299	11	pharma	pharma	PROPN
bptjm-17	299	12	tech	tech	NOUN
bptjm-17	299	13	journal	journal	NOUN
bptjm-17	299	14	of	of	ADP
bptjm-17	299	15	medicine	medicine	NOUN
bptjm-17	299	16	|	|	ADV
bptjm-17	299	17	134	134	NUM
bptjm-17	299	18	the	the	DET
bptjm-17	299	19	pi3k	pi3k	NOUN
bptjm-17	299	20	and	and	CCONJ
bptjm-17	299	21	mapk	mapk	NOUN
bptjm-17	299	22	pathways	pathway	NOUN
bptjm-17	299	23	,	,	PUNCT
bptjm-17	299	24	which	which	PRON
bptjm-17	299	25	control	control	VERB
bptjm-17	299	26	embryonic	embryonic	ADJ
bptjm-17	299	27	development	development	NOUN
bptjm-17	299	28	,	,	PUNCT
bptjm-17	299	29	cell	cell	NOUN
bptjm-17	299	30	proliferation	proliferation	NOUN
bptjm-17	299	31	,	,	PUNCT
bptjm-17	299	32	di	di	NOUN
bptjm-17	299	33	erentiation	erentiation	NOUN
bptjm-17	299	34	,	,	PUNCT
bptjm-17	299	35	and	and	CCONJ
bptjm-17	299	36	migration	migration	NOUN
bptjm-17	299	37	(	(	PUNCT
bptjm-17	299	38	theelen	theelen	VERB
bptjm-17	299	39	et	et	PROPN
bptjm-17	299	40	al	al	PROPN
bptjm-17	299	41	.	.	PROPN
bptjm-17	299	42	,	,	PUNCT
bptjm-17	299	43	2016	2016	NUM
bptjm-17	299	44	)	)	PUNCT
bptjm-17	299	45	.	.	PUNCT
bptjm-17	300	1	in	in	ADP
bptjm-17	300	2	a	a	DET
bptjm-17	300	3	study	study	NOUN
bptjm-17	300	4	conducted	conduct	VERB
bptjm-17	300	5	by	by	ADP
bptjm-17	300	6	theelen	theelen	VERB
bptjm-17	300	7	et	et	PROPN
bptjm-17	300	8	al	al	PROPN
bptjm-17	300	9	.	.	PROPN
bptjm-17	300	10	,	,	PUNCT
bptjm-17	300	11	653	653	NUM
bptjm-17	300	12	early	early	ADJ
bptjm-17	300	13	stage	stage	NOUN
bptjm-17	300	14	nsclc	nsclc	NOUN
bptjm-17	300	15	samples	sample	NOUN
bptjm-17	300	16	were	be	AUX
bptjm-17	300	17	assessed	assess	VERB
bptjm-17	300	18	.	.	PUNCT
bptjm-17	301	1	the	the	DET
bptjm-17	301	2	levels	level	NOUN
bptjm-17	301	3	of	of	ADP
bptjm-17	301	4	expression	expression	NOUN
bptjm-17	301	5	in	in	ADP
bptjm-17	301	6	fgfr1	fgfr1	NOUN
bptjm-17	301	7	and	and	CCONJ
bptjm-17	301	8	fgfr2	fgfr2	NOUN
bptjm-17	301	9	directly	directly	ADV
bptjm-17	301	10	correlated	correlate	VERB
bptjm-17	301	11	to	to	ADP
bptjm-17	301	12	clinicopathological	clinicopathological	ADJ
bptjm-17	301	13	features	feature	NOUN
bptjm-17	301	14	.	.	PUNCT
bptjm-17	302	1	fgfr1	fgfr1	NOUN
bptjm-17	302	2	expression	expression	NOUN
bptjm-17	302	3	was	be	AUX
bptjm-17	302	4	associated	associate	VERB
bptjm-17	302	5	with	with	ADP
bptjm-17	302	6	light	light	ADJ
bptjm-17	302	7	smoking	smoking	NOUN
bptjm-17	302	8	(	(	PUNCT
bptjm-17	302	9	p	p	NOUN
bptjm-17	302	10	=	=	NOUN
bptjm-17	302	11	0.02	0.02	NUM
bptjm-17	302	12	)	)	PUNCT
bptjm-17	302	13	,	,	PUNCT
bptjm-17	302	14	fgfr2	fgfr2	NOUN
bptjm-17	302	15	correlated	correlate	VERB
bptjm-17	302	16	negatively	negatively	ADV
bptjm-17	302	17	with	with	ADP
bptjm-17	302	18	age	age	NOUN
bptjm-17	302	19	for	for	ADP
bptjm-17	302	20	the	the	DET
bptjm-17	302	21	whole	whole	ADJ
bptjm-17	302	22	cohort	cohort	NOUN
bptjm-17	302	23	(	(	PUNCT
bptjm-17	302	24	p	p	NOUN
bptjm-17	302	25	=	=	NOUN
bptjm-17	302	26	0.27	0.27	NUM
bptjm-17	302	27	)	)	PUNCT
bptjm-17	302	28	,	,	PUNCT
bptjm-17	302	29	and	and	CCONJ
bptjm-17	302	30	there	there	PRON
bptjm-17	302	31	was	be	VERB
bptjm-17	302	32	a	a	DET
bptjm-17	302	33	negative	negative	ADJ
bptjm-17	302	34	correlation	correlation	NOUN
bptjm-17	302	35	between	between	ADP
bptjm-17	302	36	tumour	tumour	NOUN
bptjm-17	302	37	stage	stage	NOUN
bptjm-17	302	38	and	and	CCONJ
bptjm-17	302	39	fgfr2	fgfr2	ADJ
bptjm-17	302	40	expression	expression	NOUN
bptjm-17	302	41	(	(	PUNCT
bptjm-17	302	42	p	p	NOUN
bptjm-17	302	43	=	=	NOUN
bptjm-17	302	44	0.002	0.002	NUM
bptjm-17	302	45	)	)	PUNCT
bptjm-17	302	46	.	.	PUNCT
bptjm-17	303	1	fgfr1	fgfr1	PROPN
bptjm-17	303	2	was	be	AUX
bptjm-17	303	3	expressed	express	VERB
bptjm-17	303	4	in	in	ADP
bptjm-17	303	5	10.6	10.6	NUM
bptjm-17	303	6	%	%	NOUN
bptjm-17	303	7	and	and	CCONJ
bptjm-17	303	8	fgfr2	fgfr2	ADJ
bptjm-17	303	9	in	in	ADP
bptjm-17	303	10	12.9	12.9	NUM
bptjm-17	303	11	%	%	NOUN
bptjm-17	303	12	of	of	ADP
bptjm-17	303	13	all	all	DET
bptjm-17	303	14	nsclc	nsclc	NOUN
bptjm-17	303	15	tumor	tumor	NOUN
bptjm-17	303	16	samples	sample	NOUN
bptjm-17	303	17	(	(	PUNCT
bptjm-17	303	18	theelen	theelen	VERB
bptjm-17	303	19	et	et	PROPN
bptjm-17	303	20	al	al	PROPN
bptjm-17	303	21	.	.	PROPN
bptjm-17	303	22	,	,	PUNCT
bptjm-17	303	23	2016	2016	NUM
bptjm-17	303	24	)	)	PUNCT
bptjm-17	303	25	.	.	PUNCT
bptjm-17	304	1	protein	protein	NOUN
bptjm-17	304	2	expression	expression	NOUN
bptjm-17	304	3	of	of	ADP
bptjm-17	304	4	fgfr	fgfr	ADJ
bptjm-17	304	5	is	be	AUX
bptjm-17	304	6	related	relate	VERB
bptjm-17	304	7	to	to	PART
bptjm-17	304	8	worse	bad	ADJ
bptjm-17	304	9	os	os	NOUN
bptjm-17	304	10	.	.	PUNCT
bptjm-17	305	1	moreover	moreover	ADV
bptjm-17	305	2	,	,	PUNCT
bptjm-17	305	3	while	while	SCONJ
bptjm-17	305	4	fgfr1	fgfr1	PROPN
bptjm-17	305	5	is	be	AUX
bptjm-17	305	6	associated	associate	VERB
bptjm-17	305	7	with	with	ADP
bptjm-17	305	8	light	light	ADJ
bptjm-17	305	9	smoking	smoking	NOUN
bptjm-17	305	10	,	,	PUNCT
bptjm-17	305	11	fgfr2	fgfr2	ADJ
bptjm-17	305	12	is	be	AUX
bptjm-17	305	13	more	more	ADV
bptjm-17	305	14	common	common	ADJ
bptjm-17	305	15	in	in	ADP
bptjm-17	305	16	females	female	NOUN
bptjm-17	305	17	and	and	CCONJ
bptjm-17	305	18	younger	young	ADJ
bptjm-17	305	19	age	age	NOUN
bptjm-17	305	20	patients	patient	NOUN
bptjm-17	305	21	(	(	PUNCT
bptjm-17	305	22	age	age	NOUN
bptjm-17	305	23	31	31	NUM
bptjm-17	305	24	to	to	PART
bptjm-17	305	25	53	53	NUM
bptjm-17	305	26	years	year	NOUN
bptjm-17	305	27	)	)	PUNCT
bptjm-17	305	28	.	.	PUNCT
bptjm-17	306	1	the	the	DET
bptjm-17	306	2	study	study	NOUN
bptjm-17	306	3	by	by	ADP
bptjm-17	306	4	theelen	theelen	VERB
bptjm-17	306	5	et	et	PROPN
bptjm-17	306	6	al	al	PROPN
bptjm-17	306	7	.	.	PROPN
bptjm-17	306	8	demonstrated	demonstrate	VERB
bptjm-17	306	9	an	an	DET
bptjm-17	306	10	abundance	abundance	NOUN
bptjm-17	306	11	of	of	ADP
bptjm-17	306	12	fgfr	fgfr	ADJ
bptjm-17	306	13	mutations	mutation	NOUN
bptjm-17	306	14	present	present	ADJ
bptjm-17	306	15	in	in	ADP
bptjm-17	306	16	nsclc	nsclc	NOUN
bptjm-17	306	17	,	,	PUNCT
bptjm-17	306	18	suggesting	suggest	VERB
bptjm-17	306	19	that	that	SCONJ
bptjm-17	306	20	they	they	PRON
bptjm-17	306	21	play	play	VERB
bptjm-17	306	22	a	a	DET
bptjm-17	306	23	role	role	NOUN
bptjm-17	306	24	in	in	ADP
bptjm-17	306	25	growth	growth	NOUN
bptjm-17	306	26	and	and	CCONJ
bptjm-17	306	27	malignant	malignant	ADJ
bptjm-17	306	28	progression	progression	NOUN
bptjm-17	306	29	of	of	ADP
bptjm-17	306	30	nsclc	nsclc	NOUN
bptjm-17	306	31	.	.	PUNCT
bptjm-17	307	1	a	a	DET
bptjm-17	307	2	study	study	NOUN
bptjm-17	307	3	by	by	ADP
bptjm-17	307	4	santiago	santiago	PROPN
bptjm-17	307	5	-	-	PUNCT
bptjm-17	307	6	walker	walker	PROPN
bptjm-17	307	7	et	et	PROPN
bptjm-17	307	8	al	al	PROPN
bptjm-17	307	9	.	.	PROPN
bptjm-17	307	10	demonstrated	demonstrate	VERB
bptjm-17	307	11	a	a	DET
bptjm-17	307	12	63	63	NUM
bptjm-17	307	13	%	%	NOUN
bptjm-17	307	14	concordance	concordance	NOUN
bptjm-17	307	15	rate	rate	NOUN
bptjm-17	307	16	for	for	ADP
bptjm-17	307	17	detecting	detect	VERB
bptjm-17	307	18	fgfr	fgfr	ADJ
bptjm-17	307	19	mutations	mutation	NOUN
bptjm-17	307	20	in	in	ADP
bptjm-17	307	21	temporally	temporally	ADV
bptjm-17	307	22	unmatched	unmatched	ADJ
bptjm-17	307	23	blood	blood	NOUN
bptjm-17	307	24	and	and	CCONJ
bptjm-17	307	25	tissue	tissue	NOUN
bptjm-17	307	26	,	,	PUNCT
bptjm-17	307	27	which	which	PRON
bptjm-17	307	28	supports	support	VERB
bptjm-17	307	29	the	the	DET
bptjm-17	307	30	potential	potential	NOUN
bptjm-17	307	31	for	for	ADP
bptjm-17	307	32	patient	patient	ADJ
bptjm-17	307	33	selection	selection	NOUN
bptjm-17	307	34	with	with	ADP
bptjm-17	307	35	blood	blood	NOUN
bptjm-17	307	36	-	-	PUNCT
bptjm-17	307	37	based	base	VERB
bptjm-17	307	38	testing	testing	NOUN
bptjm-17	307	39	.	.	PUNCT
bptjm-17	308	1	clinical	clinical	ADJ
bptjm-17	308	2	di	di	NOUN
bptjm-17	308	3	erences	erence	NOUN
bptjm-17	308	4	were	be	AUX
bptjm-17	308	5	observed	observe	VERB
bptjm-17	308	6	between	between	ADP
bptjm-17	308	7	ctdna	ctdna	NOUN
bptjm-17	308	8	-	-	PUNCT
bptjm-17	308	9	fgfr	fgfr	ADJ
bptjm-17	308	10	positive	positive	ADJ
bptjm-17	308	11	and	and	CCONJ
bptjm-17	308	12	negative	negative	ADJ
bptjm-17	308	13	patients	patient	NOUN
bptjm-17	308	14	,	,	PUNCT
bptjm-17	308	15	but	but	CCONJ
bptjm-17	308	16	they	they	PRON
bptjm-17	308	17	were	be	AUX
bptjm-17	308	18	not	not	PART
bptjm-17	308	19	statistically	statistically	ADV
bptjm-17	308	20	signi	signi	ADJ
bptjm-17	309	1	ca	can	AUX
bptjm-17	309	2	nt	not	PART
bptjm-17	309	3	(	(	PUNCT
bptjm-17	309	4	santiago	santiago	PROPN
bptjm-17	309	5	-	-	PUNCT
bptjm-17	309	6	walker	walker	PROPN
bptjm-17	309	7	et	et	PROPN
bptjm-17	309	8	al	al	PROPN
bptjm-17	309	9	.	.	PROPN
bptjm-17	309	10	,	,	PUNCT
bptjm-17	309	11	2019	2019	NUM
bptjm-17	309	12	)	)	PUNCT
bptjm-17	309	13	.	.	PUNCT
bptjm-17	310	1	furthermore	furthermore	ADV
bptjm-17	310	2	,	,	PUNCT
bptjm-17	310	3	fgfr1	fgfr1	PROPN
bptjm-17	310	4	’s	’s	PART
bptjm-17	310	5	indication	indication	NOUN
bptjm-17	310	6	of	of	ADP
bptjm-17	310	7	a	a	DET
bptjm-17	310	8	worse	bad	ADJ
bptjm-17	310	9	os	os	NOUN
bptjm-17	310	10	suggests	suggest	VERB
bptjm-17	310	11	that	that	SCONJ
bptjm-17	310	12	it	it	PRON
bptjm-17	310	13	may	may	AUX
bptjm-17	310	14	serve	serve	VERB
bptjm-17	310	15	as	as	ADP
bptjm-17	310	16	a	a	DET
bptjm-17	310	17	prognostic	prognostic	ADJ
bptjm-17	310	18	biomarker	biomarker	NOUN
bptjm-17	310	19	(	(	PUNCT
bptjm-17	310	20	theelen	theelen	VERB
bptjm-17	310	21	et	et	PROPN
bptjm-17	310	22	al	al	PROPN
bptjm-17	310	23	.	.	PROPN
bptjm-17	310	24	,	,	PUNCT
bptjm-17	310	25	2016	2016	NUM
bptjm-17	310	26	)	)	PUNCT
bptjm-17	310	27	.	.	PUNCT
bptjm-17	311	1	egfr	egfr	ADJ
bptjm-17	311	2	epidermal	epidermal	ADJ
bptjm-17	311	3	growth	growth	NOUN
bptjm-17	311	4	factor	factor	NOUN
bptjm-17	311	5	receptor	receptor	NOUN
bptjm-17	311	6	(	(	PUNCT
bptjm-17	311	7	egfr	egfr	ADJ
bptjm-17	311	8	)	)	PUNCT
bptjm-17	311	9	mutations	mutation	NOUN
bptjm-17	311	10	are	be	AUX
bptjm-17	311	11	observed	observe	VERB
bptjm-17	311	12	in	in	ADP
bptjm-17	311	13	10	10	NUM
bptjm-17	311	14	-	-	SYM
bptjm-17	311	15	35	35	NUM
bptjm-17	311	16	%	%	NOUN
bptjm-17	311	17	of	of	ADP
bptjm-17	311	18	all	all	DET
bptjm-17	311	19	patients	patient	NOUN
bptjm-17	311	20	with	with	ADP
bptjm-17	311	21	adenocarcinomas	adenocarcinoma	NOUN
bptjm-17	311	22	.	.	PUNCT
bptjm-17	312	1	egfr	egfr	NOUN
bptjm-17	312	2	-	-	PUNCT
bptjm-17	312	3	targeting	target	VERB
bptjm-17	312	4	tkis	tkis	NOUN
bptjm-17	312	5	(	(	PUNCT
bptjm-17	312	6	egfr	egfr	X
bptjm-17	312	7	-	-	PUNCT
bptjm-17	312	8	tkis	tkis	NOUN
bptjm-17	312	9	)	)	PUNCT
bptjm-17	312	10	have	have	AUX
bptjm-17	312	11	shown	show	VERB
bptjm-17	312	12	higher	high	ADJ
bptjm-17	312	13	objective	objective	ADJ
bptjm-17	312	14	response	response	NOUN
bptjm-17	312	15	rates	rate	NOUN
bptjm-17	312	16	and	and	CCONJ
bptjm-17	312	17	longer	long	ADV
bptjm-17	312	18	pfs	pfs	PROPN
bptjm-17	312	19	.	.	PUNCT
bptjm-17	312	20	egfr	egfr	PROPN
bptjm-17	312	21	-	-	PUNCT
bptjm-17	312	22	tkis	tkis	NOUN
bptjm-17	312	23	are	be	AUX
bptjm-17	312	24	considered	consider	VERB
bptjm-17	312	25	more	more	ADV
bptjm-17	312	26	successful	successful	ADJ
bptjm-17	312	27	than	than	ADP
bptjm-17	312	28	chemotherapy	chemotherapy	VERB
bptjm-17	312	29	for	for	ADP
bptjm-17	312	30	egfr	egfr	ADJ
bptjm-17	312	31	mutated	mutate	VERB
bptjm-17	312	32	patients	patient	NOUN
bptjm-17	312	33	.	.	PUNCT
bptjm-17	313	1	unfortunately	unfortunately	ADV
bptjm-17	313	2	,	,	PUNCT
bptjm-17	313	3	about	about	ADV
bptjm-17	313	4	30	30	NUM
bptjm-17	313	5	%	%	NOUN
bptjm-17	313	6	of	of	ADP
bptjm-17	313	7	patients	patient	NOUN
bptjm-17	313	8	develop	develop	VERB
bptjm-17	313	9	resistance	resistance	NOUN
bptjm-17	313	10	to	to	ADP
bptjm-17	313	11	these	these	DET
bptjm-17	313	12	egfr	egfr	ADJ
bptjm-17	313	13	tkis	tkis	PROPN
bptjm-17	313	14	.	.	PUNCT
bptjm-17	314	1	a	a	DET
bptjm-17	314	2	study	study	NOUN
bptjm-17	314	3	done	do	VERB
bptjm-17	314	4	with	with	ADP
bptjm-17	314	5	502	502	NUM
bptjm-17	314	6	egfr	egfr	ADV
bptjm-17	314	7	-	-	PUNCT
bptjm-17	314	8	mutated	mutate	VERB
bptjm-17	314	9	nsclc	nsclc	NOUN
bptjm-17	314	10	patients	patient	NOUN
bptjm-17	314	11	was	be	AUX
bptjm-17	314	12	conducted	conduct	VERB
bptjm-17	314	13	between	between	ADP
bptjm-17	314	14	2003	2003	NUM
bptjm-17	314	15	and	and	CCONJ
bptjm-17	314	16	2014	2014	NUM
bptjm-17	314	17	to	to	PART
bptjm-17	314	18	examine	examine	VERB
bptjm-17	314	19	the	the	DET
bptjm-17	314	20	relationship	relationship	NOUN
bptjm-17	314	21	between	between	ADP
bptjm-17	314	22	egfr	egfr	ADJ
bptjm-17	314	23	mutations	mutation	NOUN
bptjm-17	314	24	and	and	CCONJ
bptjm-17	314	25	tp53	tp53	PROPN
bptjm-17	314	26	mutations	mutation	NOUN
bptjm-17	314	27	.	.	PUNCT
bptjm-17	315	1	tp53	tp53	PROPN
bptjm-17	315	2	is	be	AUX
bptjm-17	315	3	a	a	DET
bptjm-17	315	4	tumor	tumor	NOUN
bptjm-17	315	5	suppressor	suppressor	NOUN
bptjm-17	315	6	that	that	PRON
bptjm-17	315	7	is	be	AUX
bptjm-17	315	8	commonly	commonly	ADV
bptjm-17	315	9	mutated	mutate	VERB
bptjm-17	315	10	in	in	ADP
bptjm-17	315	11	many	many	ADJ
bptjm-17	315	12	cancers	cancer	NOUN
bptjm-17	315	13	including	include	VERB
bptjm-17	315	14	nsclc	nsclc	NOUN
bptjm-17	315	15	.	.	PUNCT
bptjm-17	316	1	tp53	tp53	PROPN
bptjm-17	316	2	mutations	mutation	NOUN
bptjm-17	316	3	are	be	AUX
bptjm-17	316	4	found	find	VERB
bptjm-17	316	5	in	in	ADP
bptjm-17	316	6	35	35	NUM
bptjm-17	316	7	-	-	SYM
bptjm-17	316	8	55	55	NUM
bptjm-17	316	9	%	%	NOUN
bptjm-17	316	10	of	of	ADP
bptjm-17	316	11	nsclc	nsclc	NOUN
bptjm-17	316	12	patients	patient	NOUN
bptjm-17	316	13	.	.	PUNCT
bptjm-17	317	1	of	of	ADP
bptjm-17	317	2	the	the	DET
bptjm-17	317	3	502	502	NUM
bptjm-17	317	4	,	,	PUNCT
bptjm-17	317	5	43	43	NUM
bptjm-17	317	6	had	have	VERB
bptjm-17	317	7	both	both	PRON
bptjm-17	317	8	tp53	tp53	PROPN
bptjm-17	317	9	and	and	CCONJ
bptjm-17	317	10	egfr	egfr	ADJ
bptjm-17	317	11	mutations	mutation	NOUN
bptjm-17	317	12	.	.	PUNCT
bptjm-17	318	1	those	those	PRON
bptjm-17	318	2	with	with	ADP
bptjm-17	318	3	mutant	mutant	ADJ
bptjm-17	318	4	tp53	tp53	PROPN
bptjm-17	318	5	had	have	VERB
bptjm-17	318	6	relapse	relapse	NOUN
bptjm-17	318	7	-	-	PUNCT
bptjm-17	318	8	free	free	ADJ
bptjm-17	318	9	survival	survival	NOUN
bptjm-17	318	10	(	(	PUNCT
bptjm-17	318	11	rfs	rfs	PROPN
bptjm-17	318	12	)	)	PUNCT
bptjm-17	318	13	for	for	ADP
bptjm-17	318	14	a	a	DET
bptjm-17	318	15	median	median	NOUN
bptjm-17	318	16	of	of	ADP
bptjm-17	318	17	42.2	42.2	NUM
bptjm-17	318	18	months	month	NOUN
bptjm-17	318	19	whereas	whereas	SCONJ
bptjm-17	318	20	those	those	PRON
bptjm-17	318	21	with	with	ADP
bptjm-17	318	22	wildtype	wildtype	NOUN
bptjm-17	318	23	had	have	VERB
bptjm-17	318	24	rfs	rf	VERB
bptjm-17	318	25	for	for	ADP
bptjm-17	318	26	a	a	DET
bptjm-17	318	27	median	median	NOUN
bptjm-17	318	28	of	of	ADP
bptjm-17	318	29	37.7	37.7	NUM
bptjm-17	318	30	months	month	NOUN
bptjm-17	318	31	(	(	PUNCT
bptjm-17	318	32	p=0.59	p=0.59	NOUN
bptjm-17	318	33	)	)	PUNCT
bptjm-17	318	34	.	.	PUNCT
bptjm-17	319	1	60	60	NUM
bptjm-17	319	2	patients	patient	NOUN
bptjm-17	319	3	received	receive	VERB
bptjm-17	319	4	egfr	egfr	NOUN
bptjm-17	319	5	-	-	PUNCT
bptjm-17	319	6	tkis	tkis	NOUN
bptjm-17	319	7	as	as	ADP
bptjm-17	319	8	treatment	treatment	NOUN
bptjm-17	319	9	.	.	PUNCT
bptjm-17	320	1	of	of	ADP
bptjm-17	320	2	these	these	DET
bptjm-17	320	3	60	60	NUM
bptjm-17	320	4	patients	patient	NOUN
bptjm-17	320	5	,	,	PUNCT
bptjm-17	320	6	24	24	NUM
bptjm-17	320	7	had	have	VERB
bptjm-17	320	8	mutant	mutant	NOUN
bptjm-17	320	9	tp53	tp53	PROPN
bptjm-17	320	10	and	and	CCONJ
bptjm-17	320	11	36	36	NUM
bptjm-17	320	12	had	have	VERB
bptjm-17	320	13	wildtype	wildtype	PROPN
bptjm-17	320	14	tp53	tp53	PROPN
bptjm-17	320	15	.	.	PUNCT
bptjm-17	321	1	the	the	DET
bptjm-17	321	2	results	result	NOUN
bptjm-17	321	3	of	of	ADP
bptjm-17	321	4	the	the	DET
bptjm-17	321	5	treatment	treatment	NOUN
bptjm-17	321	6	were	be	AUX
bptjm-17	321	7	not	not	PART
bptjm-17	321	8	berkeley	berkeley	PROPN
bptjm-17	321	9	pharma	pharma	PROPN
bptjm-17	321	10	tech	tech	NOUN
bptjm-17	321	11	journal	journal	NOUN
bptjm-17	321	12	of	of	ADP
bptjm-17	321	13	medicine	medicine	NOUN
bptjm-17	321	14	|	|	ADV
bptjm-17	321	15	135	135	NUM
bptjm-17	321	16	statistically	statistically	ADV
bptjm-17	321	17	di	di	X
bptjm-17	321	18	erent	erent	NOUN
bptjm-17	321	19	(	(	PUNCT
bptjm-17	321	20	labbe	labbe	NOUN
bptjm-17	321	21	et	et	PROPN
bptjm-17	321	22	al	al	PROPN
bptjm-17	321	23	.	.	PROPN
bptjm-17	321	24	,	,	PUNCT
bptjm-17	321	25	2017	2017	NUM
bptjm-17	321	26	)	)	PUNCT
bptjm-17	321	27	.	.	PUNCT
bptjm-17	322	1	egfr	egfr	PROPN
bptjm-17	322	2	can	can	AUX
bptjm-17	322	3	be	be	AUX
bptjm-17	322	4	used	use	VERB
bptjm-17	322	5	to	to	PART
bptjm-17	322	6	direct	direct	VERB
bptjm-17	322	7	the	the	DET
bptjm-17	322	8	course	course	NOUN
bptjm-17	322	9	of	of	ADP
bptjm-17	322	10	treatment	treatment	NOUN
bptjm-17	322	11	.	.	PUNCT
bptjm-17	323	1	rrm1	rrm1	PROPN
bptjm-17	323	2	ribonucleotide	ribonucleotide	PROPN
bptjm-17	323	3	reductase	reductase	NOUN
bptjm-17	323	4	catalytic	catalytic	ADJ
bptjm-17	323	5	subunit	subunit	NOUN
bptjm-17	323	6	m1	m1	PROPN
bptjm-17	323	7	(	(	PUNCT
bptjm-17	323	8	rrm1	rrm1	PROPN
bptjm-17	323	9	)	)	PUNCT
bptjm-17	323	10	is	be	AUX
bptjm-17	323	11	a	a	DET
bptjm-17	323	12	biomarker	biomarker	NOUN
bptjm-17	323	13	involved	involve	VERB
bptjm-17	323	14	in	in	ADP
bptjm-17	323	15	tumor	tumor	NOUN
bptjm-17	323	16	proliferation	proliferation	NOUN
bptjm-17	323	17	,	,	PUNCT
bptjm-17	323	18	invasiveness	invasiveness	ADJ
bptjm-17	323	19	,	,	PUNCT
bptjm-17	323	20	and	and	CCONJ
bptjm-17	323	21	metastasis	metastasis	NOUN
bptjm-17	323	22	.	.	PUNCT
bptjm-17	324	1	in	in	ADP
bptjm-17	324	2	a	a	DET
bptjm-17	324	3	study	study	NOUN
bptjm-17	324	4	done	do	VERB
bptjm-17	324	5	by	by	ADP
bptjm-17	324	6	mlak	mlak	PROPN
bptjm-17	324	7	et	et	PROPN
bptjm-17	324	8	al	al	PROPN
bptjm-17	324	9	.	.	PROPN
bptjm-17	324	10	,	,	PUNCT
bptjm-17	324	11	60	60	NUM
bptjm-17	324	12	nsclc	nsclc	NOUN
bptjm-17	324	13	patients	patient	NOUN
bptjm-17	324	14	’	'	PUNCT
bptjm-17	324	15	rrm1	rrm1	NOUN
bptjm-17	324	16	expression	expression	NOUN
bptjm-17	324	17	was	be	AUX
bptjm-17	324	18	measured	measure	VERB
bptjm-17	324	19	through	through	ADP
bptjm-17	324	20	use	use	NOUN
bptjm-17	324	21	of	of	ADP
bptjm-17	324	22	liquid	liquid	ADJ
bptjm-17	324	23	biopsy	biopsy	NOUN
bptjm-17	324	24	.	.	PUNCT
bptjm-17	325	1	all	all	PRON
bptjm-17	325	2	of	of	ADP
bptjm-17	325	3	the	the	DET
bptjm-17	325	4	patients	patient	NOUN
bptjm-17	325	5	had	have	AUX
bptjm-17	325	6	not	not	PART
bptjm-17	325	7	been	be	AUX
bptjm-17	325	8	treated	treat	VERB
bptjm-17	325	9	for	for	ADP
bptjm-17	325	10	nsclc	nsclc	NOUN
bptjm-17	325	11	yet	yet	ADV
bptjm-17	325	12	.	.	PUNCT
bptjm-17	326	1	high	high	ADJ
bptjm-17	326	2	rrm1	rrm1	NOUN
bptjm-17	326	3	expression	expression	NOUN
bptjm-17	326	4	was	be	AUX
bptjm-17	326	5	associated	associate	VERB
bptjm-17	326	6	with	with	ADP
bptjm-17	326	7	higher	high	ADJ
bptjm-17	326	8	risk	risk	NOUN
bptjm-17	326	9	of	of	ADP
bptjm-17	326	10	oral	oral	ADJ
bptjm-17	326	11	mucositis	mucositis	NOUN
bptjm-17	326	12	,	,	PUNCT
bptjm-17	326	13	but	but	CCONJ
bptjm-17	326	14	it	it	PRON
bptjm-17	326	15	was	be	AUX
bptjm-17	326	16	not	not	PART
bptjm-17	326	17	signi	signi	ADV
bptjm-17	326	18	cantly	cantly	ADV
bptjm-17	326	19	associated	associate	VERB
bptjm-17	326	20	with	with	ADP
bptjm-17	326	21	disease	disease	NOUN
bptjm-17	326	22	-	-	PUNCT
bptjm-17	326	23	free	free	ADJ
bptjm-17	326	24	survival	survival	NOUN
bptjm-17	326	25	(	(	PUNCT
bptjm-17	326	26	dfs	dfs	NOUN
bptjm-17	326	27	)	)	PUNCT
bptjm-17	326	28	or	or	CCONJ
bptjm-17	326	29	os	os	NOUN
bptjm-17	326	30	shortening	shortening	NOUN
bptjm-17	326	31	(	(	PUNCT
bptjm-17	326	32	mlak	mlak	PROPN
bptjm-17	326	33	et	et	PROPN
bptjm-17	326	34	al	al	PROPN
bptjm-17	326	35	.	.	PROPN
bptjm-17	326	36	,	,	PUNCT
bptjm-17	326	37	2018	2018	NUM
bptjm-17	326	38	)	)	PUNCT
bptjm-17	326	39	.	.	PUNCT
bptjm-17	327	1	in	in	ADP
bptjm-17	327	2	another	another	DET
bptjm-17	327	3	study	study	NOUN
bptjm-17	327	4	done	do	VERB
bptjm-17	327	5	by	by	ADP
bptjm-17	327	6	zhang	zhang	PROPN
bptjm-17	327	7	et	et	PROPN
bptjm-17	327	8	al	al	PROPN
bptjm-17	327	9	.	.	PROPN
bptjm-17	327	10	,	,	PUNCT
bptjm-17	327	11	rrm1	rrm1	PROPN
bptjm-17	327	12	and	and	CCONJ
bptjm-17	327	13	ercc1	ercc1	NOUN
bptjm-17	327	14	levels	level	NOUN
bptjm-17	327	15	were	be	AUX
bptjm-17	327	16	measured	measure	VERB
bptjm-17	327	17	through	through	ADP
bptjm-17	327	18	liquid	liquid	ADJ
bptjm-17	327	19	and	and	CCONJ
bptjm-17	327	20	tissue	tissue	NOUN
bptjm-17	327	21	biopsy	biopsy	NOUN
bptjm-17	327	22	in	in	ADP
bptjm-17	327	23	nsclc	nsclc	NOUN
bptjm-17	327	24	patients	patient	NOUN
bptjm-17	327	25	using	use	VERB
bptjm-17	327	26	pcr	pcr	NOUN
bptjm-17	327	27	.	.	PUNCT
bptjm-17	328	1	patients	patient	NOUN
bptjm-17	328	2	with	with	ADP
bptjm-17	328	3	lower	low	ADJ
bptjm-17	328	4	level	level	NOUN
bptjm-17	328	5	rrm1	rrm1	NOUN
bptjm-17	328	6	expression	expression	NOUN
bptjm-17	328	7	,	,	PUNCT
bptjm-17	328	8	as	as	SCONJ
bptjm-17	328	9	seen	see	VERB
bptjm-17	328	10	in	in	ADP
bptjm-17	328	11	the	the	DET
bptjm-17	328	12	liquid	liquid	ADJ
bptjm-17	328	13	biopsy	biopsy	NOUN
bptjm-17	328	14	,	,	PUNCT
bptjm-17	328	15	had	have	VERB
bptjm-17	328	16	longer	long	ADJ
bptjm-17	328	17	median	median	VERB
bptjm-17	328	18	os	os	ADV
bptjm-17	328	19	.	.	PUNCT
bptjm-17	329	1	their	their	PRON
bptjm-17	329	2	os	os	NOUN
bptjm-17	329	3	was	be	AUX
bptjm-17	329	4	18.5	18.5	NUM
bptjm-17	329	5	months	month	NOUN
bptjm-17	329	6	,	,	PUNCT
bptjm-17	329	7	as	as	SCONJ
bptjm-17	329	8	opposed	oppose	VERB
bptjm-17	329	9	to	to	ADP
bptjm-17	329	10	patients	patient	NOUN
bptjm-17	329	11	who	who	PRON
bptjm-17	329	12	had	have	VERB
bptjm-17	329	13	higher	high	ADJ
bptjm-17	329	14	level	level	NOUN
bptjm-17	329	15	expression	expression	NOUN
bptjm-17	329	16	whose	whose	DET
bptjm-17	329	17	os	os	NOUN
bptjm-17	329	18	was	be	AUX
bptjm-17	329	19	13.0	13.0	NUM
bptjm-17	329	20	months	month	NOUN
bptjm-17	329	21	(	(	PUNCT
bptjm-17	329	22	p	p	X
bptjm-17	329	23	=	=	NOUN
bptjm-17	329	24	0.043	0.043	NUM
bptjm-17	329	25	)	)	PUNCT
bptjm-17	329	26	.	.	PUNCT
bptjm-17	330	1	higher	high	ADJ
bptjm-17	330	2	level	level	NOUN
bptjm-17	330	3	rrm1	rrm1	NOUN
bptjm-17	330	4	was	be	AUX
bptjm-17	330	5	also	also	ADV
bptjm-17	330	6	associated	associate	VERB
bptjm-17	330	7	with	with	ADP
bptjm-17	330	8	prolonged	prolong	VERB
bptjm-17	330	9	pfs	pf	NOUN
bptjm-17	330	10	.	.	PUNCT
bptjm-17	331	1	patients	patient	NOUN
bptjm-17	331	2	with	with	ADP
bptjm-17	331	3	low	low	ADJ
bptjm-17	331	4	expression	expression	NOUN
bptjm-17	331	5	level	level	NOUN
bptjm-17	331	6	had	have	VERB
bptjm-17	331	7	a	a	DET
bptjm-17	331	8	median	median	ADJ
bptjm-17	331	9	pfs	pf	NOUN
bptjm-17	331	10	of	of	ADP
bptjm-17	331	11	6.0	6.0	NUM
bptjm-17	331	12	months	month	NOUN
bptjm-17	331	13	whereas	whereas	SCONJ
bptjm-17	331	14	patients	patient	NOUN
bptjm-17	331	15	who	who	PRON
bptjm-17	331	16	had	have	VERB
bptjm-17	331	17	lower	low	ADJ
bptjm-17	331	18	expression	expression	NOUN
bptjm-17	331	19	level	level	NOUN
bptjm-17	331	20	had	have	VERB
bptjm-17	331	21	a	a	DET
bptjm-17	331	22	median	median	ADJ
bptjm-17	331	23	pfs	pf	NOUN
bptjm-17	331	24	of	of	ADP
bptjm-17	331	25	4.0	4.0	NUM
bptjm-17	331	26	months	month	NOUN
bptjm-17	331	27	(	(	PUNCT
bptjm-17	331	28	p	p	NOUN
bptjm-17	331	29	=	=	NOUN
bptjm-17	331	30	0.044	0.044	NUM
bptjm-17	331	31	)	)	PUNCT
bptjm-17	331	32	(	(	PUNCT
bptjm-17	331	33	zhang	zhang	PROPN
bptjm-17	331	34	et	et	PROPN
bptjm-17	331	35	al	al	PROPN
bptjm-17	331	36	.	.	PROPN
bptjm-17	331	37	,	,	PUNCT
bptjm-17	331	38	2012	2012	NUM
bptjm-17	331	39	)	)	PUNCT
bptjm-17	331	40	.	.	PUNCT
bptjm-17	332	1	rrm1	rrm1	NOUN
bptjm-17	332	2	levels	level	NOUN
bptjm-17	332	3	,	,	PUNCT
bptjm-17	332	4	measured	measure	VERB
bptjm-17	332	5	through	through	ADP
bptjm-17	332	6	use	use	NOUN
bptjm-17	332	7	of	of	ADP
bptjm-17	332	8	liquid	liquid	ADJ
bptjm-17	332	9	and	and	CCONJ
bptjm-17	332	10	tissue	tissue	NOUN
bptjm-17	332	11	biopsy	biopsy	NOUN
bptjm-17	332	12	,	,	PUNCT
bptjm-17	332	13	can	can	AUX
bptjm-17	332	14	be	be	AUX
bptjm-17	332	15	used	use	VERB
bptjm-17	332	16	to	to	PART
bptjm-17	332	17	predict	predict	VERB
bptjm-17	332	18	outcomes	outcome	NOUN
bptjm-17	332	19	such	such	ADJ
bptjm-17	332	20	as	as	ADP
bptjm-17	332	21	os	os	PROPN
bptjm-17	332	22	and	and	CCONJ
bptjm-17	332	23	pfs	pfs	PROPN
bptjm-17	332	24	.	.	PUNCT
bptjm-17	333	1	wip1	wip1	PROPN
bptjm-17	333	2	overexpression	overexpression	NOUN
bptjm-17	333	3	of	of	ADP
bptjm-17	333	4	wildtype	wildtype	NOUN
bptjm-17	333	5	p53	p53	NOUN
bptjm-17	333	6	-	-	PUNCT
bptjm-17	333	7	induced	induce	VERB
bptjm-17	333	8	phosphatase	phosphatase	NOUN
bptjm-17	333	9	1	1	NUM
bptjm-17	333	10	(	(	PUNCT
bptjm-17	333	11	wip1	wip1	PROPN
bptjm-17	333	12	)	)	PUNCT
bptjm-17	333	13	is	be	AUX
bptjm-17	333	14	commonly	commonly	ADV
bptjm-17	333	15	found	find	VERB
bptjm-17	333	16	in	in	ADP
bptjm-17	333	17	many	many	ADJ
bptjm-17	333	18	types	type	NOUN
bptjm-17	333	19	of	of	ADP
bptjm-17	333	20	tumors	tumor	NOUN
bptjm-17	333	21	and	and	CCONJ
bptjm-17	333	22	is	be	AUX
bptjm-17	333	23	associated	associate	VERB
bptjm-17	333	24	with	with	ADP
bptjm-17	333	25	poor	poor	ADJ
bptjm-17	333	26	prognosis	prognosis	NOUN
bptjm-17	333	27	.	.	PUNCT
bptjm-17	334	1	in	in	ADP
bptjm-17	334	2	a	a	DET
bptjm-17	334	3	study	study	NOUN
bptjm-17	334	4	by	by	ADP
bptjm-17	334	5	zhao	zhao	PROPN
bptjm-17	334	6	et	et	PROPN
bptjm-17	334	7	al	al	PROPN
bptjm-17	334	8	.	.	PROPN
bptjm-17	334	9	,	,	PUNCT
bptjm-17	334	10	117	117	NUM
bptjm-17	334	11	nsclc	nsclc	NOUN
bptjm-17	334	12	patients	patient	NOUN
bptjm-17	334	13	were	be	AUX
bptjm-17	334	14	examined	examine	VERB
bptjm-17	334	15	and	and	CCONJ
bptjm-17	334	16	wip1	wip1	NOUN
bptjm-17	334	17	expression	expression	NOUN
bptjm-17	334	18	was	be	AUX
bptjm-17	334	19	determined	determine	VERB
bptjm-17	334	20	through	through	ADP
bptjm-17	334	21	ihc	ihc	PROPN
bptjm-17	334	22	.	.	PUNCT
bptjm-17	335	1	the	the	DET
bptjm-17	335	2	patient	patient	ADJ
bptjm-17	335	3	cohort	cohort	NOUN
bptjm-17	335	4	had	have	VERB
bptjm-17	335	5	a	a	DET
bptjm-17	335	6	mean	mean	ADJ
bptjm-17	335	7	age	age	NOUN
bptjm-17	335	8	of	of	ADP
bptjm-17	335	9	56.9	56.9	NUM
bptjm-17	335	10	years	year	NOUN
bptjm-17	335	11	,	,	PUNCT
bptjm-17	335	12	of	of	ADP
bptjm-17	335	13	which	which	PRON
bptjm-17	335	14	87	87	NUM
bptjm-17	335	15	were	be	AUX
bptjm-17	335	16	male	male	ADJ
bptjm-17	335	17	and	and	CCONJ
bptjm-17	335	18	30	30	NUM
bptjm-17	335	19	were	be	AUX
bptjm-17	335	20	female	female	ADJ
bptjm-17	335	21	.	.	PUNCT
bptjm-17	336	1	in	in	ADP
bptjm-17	336	2	normal	normal	ADJ
bptjm-17	336	3	lungs	lung	NOUN
bptjm-17	336	4	,	,	PUNCT
bptjm-17	336	5	wip1	wip1	PROPN
bptjm-17	336	6	is	be	AUX
bptjm-17	336	7	not	not	PART
bptjm-17	336	8	expressed	express	VERB
bptjm-17	336	9	;	;	PUNCT
bptjm-17	336	10	the	the	DET
bptjm-17	336	11	results	result	NOUN
bptjm-17	336	12	of	of	ADP
bptjm-17	336	13	this	this	DET
bptjm-17	336	14	study	study	NOUN
bptjm-17	336	15	showed	show	VERB
bptjm-17	336	16	that	that	SCONJ
bptjm-17	336	17	wip1	wip1	PROPN
bptjm-17	336	18	was	be	AUX
bptjm-17	336	19	expressed	express	VERB
bptjm-17	336	20	in	in	ADP
bptjm-17	336	21	69.3	69.3	NUM
bptjm-17	336	22	%	%	NOUN
bptjm-17	336	23	of	of	ADP
bptjm-17	336	24	the	the	DET
bptjm-17	336	25	nsclc	nsclc	NOUN
bptjm-17	336	26	patients	patient	NOUN
bptjm-17	336	27	.	.	PUNCT
bptjm-17	337	1	wip1	wip1	NOUN
bptjm-17	337	2	overexpression	overexpression	NOUN
bptjm-17	337	3	was	be	AUX
bptjm-17	337	4	observed	observe	VERB
bptjm-17	337	5	more	more	ADV
bptjm-17	337	6	in	in	ADP
bptjm-17	337	7	lung	lung	NOUN
bptjm-17	337	8	adenocarcinomas	adenocarcinoma	NOUN
bptjm-17	337	9	than	than	ADP
bptjm-17	337	10	other	other	ADJ
bptjm-17	337	11	subtypes	subtype	NOUN
bptjm-17	337	12	of	of	ADP
bptjm-17	337	13	nsclc	nsclc	NOUN
bptjm-17	337	14	.	.	PUNCT
bptjm-17	338	1	wip1	wip1	PROPN
bptjm-17	338	2	negative	negative	ADJ
bptjm-17	338	3	patients	patient	NOUN
bptjm-17	338	4	survived	survive	VERB
bptjm-17	338	5	for	for	ADP
bptjm-17	338	6	a	a	DET
bptjm-17	338	7	longer	long	ADJ
bptjm-17	338	8	time	time	NOUN
bptjm-17	338	9	than	than	ADP
bptjm-17	338	10	wip1	wip1	PROPN
bptjm-17	338	11	positive	positive	ADJ
bptjm-17	338	12	patients	patient	NOUN
bptjm-17	338	13	.	.	PUNCT
bptjm-17	339	1	after	after	ADP
bptjm-17	339	2	80	80	NUM
bptjm-17	339	3	months	month	NOUN
bptjm-17	339	4	,	,	PUNCT
bptjm-17	339	5	the	the	DET
bptjm-17	339	6	survival	survival	NOUN
bptjm-17	339	7	of	of	ADP
bptjm-17	339	8	wip1	wip1	PROPN
bptjm-17	339	9	positive	positive	ADJ
bptjm-17	339	10	patients	patient	NOUN
bptjm-17	339	11	was	be	AUX
bptjm-17	339	12	less	less	ADJ
bptjm-17	339	13	than	than	ADP
bptjm-17	339	14	20	20	NUM
bptjm-17	339	15	%	%	NOUN
bptjm-17	339	16	but	but	CCONJ
bptjm-17	339	17	the	the	DET
bptjm-17	339	18	survival	survival	NOUN
bptjm-17	339	19	of	of	ADP
bptjm-17	339	20	wip1	wip1	PROPN
bptjm-17	339	21	negative	negative	ADJ
bptjm-17	339	22	patients	patient	NOUN
bptjm-17	339	23	was	be	AUX
bptjm-17	339	24	over	over	ADP
bptjm-17	339	25	40	40	NUM
bptjm-17	339	26	%	%	NOUN
bptjm-17	339	27	(	(	PUNCT
bptjm-17	339	28	p=0.014	p=0.014	X
bptjm-17	339	29	)	)	PUNCT
bptjm-17	339	30	(	(	PUNCT
bptjm-17	339	31	zhao	zhao	X
bptjm-17	339	32	et	et	PROPN
bptjm-17	339	33	al	al	PROPN
bptjm-17	339	34	.	.	PROPN
bptjm-17	339	35	,	,	PUNCT
bptjm-17	339	36	2016	2016	NUM
bptjm-17	339	37	)	)	PUNCT
bptjm-17	339	38	.	.	PUNCT
bptjm-17	340	1	in	in	ADP
bptjm-17	340	2	another	another	DET
bptjm-17	340	3	study	study	NOUN
bptjm-17	340	4	,	,	PUNCT
bptjm-17	340	5	84	84	NUM
bptjm-17	340	6	patients	patient	NOUN
bptjm-17	340	7	,	,	PUNCT
bptjm-17	340	8	comprising	comprise	VERB
bptjm-17	340	9	46	46	NUM
bptjm-17	340	10	males	male	NOUN
bptjm-17	340	11	and	and	CCONJ
bptjm-17	340	12	38	38	NUM
bptjm-17	340	13	females	female	NOUN
bptjm-17	340	14	,	,	PUNCT
bptjm-17	340	15	were	be	AUX
bptjm-17	340	16	examined	examine	VERB
bptjm-17	340	17	and	and	CCONJ
bptjm-17	340	18	treated	treat	VERB
bptjm-17	340	19	.	.	PUNCT
bptjm-17	341	1	all	all	PRON
bptjm-17	341	2	of	of	ADP
bptjm-17	341	3	them	they	PRON
bptjm-17	341	4	had	have	VERB
bptjm-17	341	5	lung	lung	NOUN
bptjm-17	341	6	adenocarcinomas	adenocarcinoma	NOUN
bptjm-17	341	7	.	.	PUNCT
bptjm-17	342	1	wip1	wip1	PROPN
bptjm-17	342	2	levels	level	NOUN
bptjm-17	342	3	were	be	AUX
bptjm-17	342	4	examined	examine	VERB
bptjm-17	342	5	through	through	ADP
bptjm-17	342	6	ihc	ihc	PROPN
bptjm-17	342	7	.	.	PUNCT
bptjm-17	343	1	patients	patient	NOUN
bptjm-17	343	2	were	be	AUX
bptjm-17	343	3	considered	consider	VERB
bptjm-17	343	4	wip1	wip1	PROPN
bptjm-17	343	5	positive	positive	ADJ
bptjm-17	343	6	if	if	SCONJ
bptjm-17	343	7	10	10	NUM
bptjm-17	343	8	%	%	NOUN
bptjm-17	343	9	or	or	CCONJ
bptjm-17	343	10	more	more	ADJ
bptjm-17	343	11	cancer	cancer	NOUN
bptjm-17	343	12	cells	cell	NOUN
bptjm-17	343	13	within	within	ADP
bptjm-17	343	14	the	the	DET
bptjm-17	343	15	tumor	tumor	NOUN
bptjm-17	343	16	were	be	AUX
bptjm-17	343	17	strongly	strongly	ADV
bptjm-17	343	18	stained	stain	VERB
bptjm-17	343	19	for	for	ADP
bptjm-17	343	20	wip1	wip1	PROPN
bptjm-17	343	21	after	after	ADP
bptjm-17	343	22	ihc	ihc	PROPN
bptjm-17	343	23	.	.	PUNCT
bptjm-17	344	1	wip1	wip1	PROPN
bptjm-17	344	2	expression	expression	NOUN
bptjm-17	344	3	was	be	AUX
bptjm-17	344	4	positive	positive	ADJ
bptjm-17	344	5	in	in	ADP
bptjm-17	344	6	berkeley	berkeley	PROPN
bptjm-17	344	7	pharma	pharma	PROPN
bptjm-17	344	8	tech	tech	NOUN
bptjm-17	344	9	journal	journal	NOUN
bptjm-17	344	10	of	of	ADP
bptjm-17	344	11	medicine	medicine	NOUN
bptjm-17	344	12	|	|	ADV
bptjm-17	344	13	136	136	NUM
bptjm-17	344	14	64.3	64.3	NUM
bptjm-17	344	15	%	%	NOUN
bptjm-17	344	16	of	of	ADP
bptjm-17	344	17	the	the	DET
bptjm-17	344	18	patients	patient	NOUN
bptjm-17	344	19	.	.	PUNCT
bptjm-17	345	1	the	the	DET
bptjm-17	345	2	survival	survival	NOUN
bptjm-17	345	3	of	of	ADP
bptjm-17	345	4	wip1	wip1	PROPN
bptjm-17	345	5	negative	negative	ADJ
bptjm-17	345	6	patients	patient	NOUN
bptjm-17	345	7	was	be	AUX
bptjm-17	345	8	signi	signi	ADJ
bptjm-17	345	9	cantly	cantly	ADV
bptjm-17	345	10	greater	great	ADJ
bptjm-17	345	11	than	than	ADP
bptjm-17	345	12	wip1	wip1	ADJ
bptjm-17	345	13	positive	positive	ADJ
bptjm-17	345	14	patients	patient	NOUN
bptjm-17	345	15	.	.	PUNCT
bptjm-17	346	1	the	the	DET
bptjm-17	346	2	os	os	PROPN
bptjm-17	346	3	rate	rate	NOUN
bptjm-17	346	4	was	be	AUX
bptjm-17	346	5	around	around	ADV
bptjm-17	346	6	50	50	NUM
bptjm-17	346	7	%	%	NOUN
bptjm-17	346	8	for	for	ADP
bptjm-17	346	9	wip1	wip1	PROPN
bptjm-17	346	10	positive	positive	ADJ
bptjm-17	346	11	patients	patient	NOUN
bptjm-17	346	12	100	100	NUM
bptjm-17	346	13	months	month	NOUN
bptjm-17	346	14	after	after	ADP
bptjm-17	346	15	surgery	surgery	NOUN
bptjm-17	346	16	whereas	whereas	SCONJ
bptjm-17	346	17	the	the	DET
bptjm-17	346	18	os	os	NOUN
bptjm-17	346	19	rate	rate	NOUN
bptjm-17	346	20	was	be	AUX
bptjm-17	346	21	around	around	ADV
bptjm-17	346	22	90	90	NUM
bptjm-17	346	23	%	%	NOUN
bptjm-17	346	24	for	for	ADP
bptjm-17	346	25	wip1	wip1	PROPN
bptjm-17	346	26	negative	negative	ADJ
bptjm-17	346	27	patients	patient	NOUN
bptjm-17	346	28	(	(	PUNCT
bptjm-17	346	29	p	p	X
bptjm-17	346	30	=	=	NOUN
bptjm-17	346	31	0.0099	0.0099	NUM
bptjm-17	346	32	)	)	PUNCT
bptjm-17	346	33	.	.	PUNCT
bptjm-17	347	1	these	these	DET
bptjm-17	347	2	results	result	NOUN
bptjm-17	347	3	demonstrate	demonstrate	VERB
bptjm-17	347	4	that	that	SCONJ
bptjm-17	347	5	wip1	wip1	NOUN
bptjm-17	347	6	expression	expression	NOUN
bptjm-17	347	7	correlates	correlate	VERB
bptjm-17	347	8	with	with	ADP
bptjm-17	347	9	negative	negative	ADJ
bptjm-17	347	10	prognosis	prognosis	NOUN
bptjm-17	347	11	(	(	PUNCT
bptjm-17	347	12	satoh	satoh	NOUN
bptjm-17	347	13	et	et	NOUN
bptjm-17	347	14	al	al	PROPN
bptjm-17	347	15	.	.	PROPN
bptjm-17	347	16	,	,	PUNCT
bptjm-17	347	17	2011	2011	NUM
bptjm-17	347	18	)	)	PUNCT
bptjm-17	347	19	.	.	PUNCT
bptjm-17	348	1	wip1	wip1	PROPN
bptjm-17	348	2	can	can	AUX
bptjm-17	348	3	be	be	AUX
bptjm-17	348	4	used	use	VERB
bptjm-17	348	5	as	as	ADP
bptjm-17	348	6	a	a	DET
bptjm-17	348	7	predictive	predictive	ADJ
bptjm-17	348	8	outcome	outcome	NOUN
bptjm-17	348	9	biomarker	biomarker	NOUN
bptjm-17	348	10	in	in	ADP
bptjm-17	348	11	order	order	NOUN
bptjm-17	348	12	to	to	PART
bptjm-17	348	13	foresee	foresee	VERB
bptjm-17	348	14	the	the	DET
bptjm-17	348	15	prognosis	prognosis	NOUN
bptjm-17	348	16	of	of	ADP
bptjm-17	348	17	the	the	DET
bptjm-17	348	18	patients	patient	NOUN
bptjm-17	348	19	.	.	PUNCT
bptjm-17	349	1	mirna	mirna	PROPN
bptjm-17	349	2	based	base	VERB
bptjm-17	349	3	biomarkers	biomarker	NOUN
bptjm-17	349	4	figure	figure	VERB
bptjm-17	349	5	3	3	NUM
bptjm-17	349	6	.	.	PUNCT
bptjm-17	350	1	this	this	DET
bptjm-17	350	2	figure	figure	NOUN
bptjm-17	350	3	depicts	depict	VERB
bptjm-17	350	4	the	the	DET
bptjm-17	350	5	mirna	mirna	PROPN
bptjm-17	350	6	pathway	pathway	NOUN
bptjm-17	350	7	.	.	PUNCT
bptjm-17	351	1	3a	3a	NUM
bptjm-17	351	2	:	:	PUNCT
bptjm-17	351	3	mirna	mirna	NOUN
bptjm-17	351	4	genes	gene	NOUN
bptjm-17	351	5	are	be	AUX
bptjm-17	351	6	transcribed	transcribe	VERB
bptjm-17	351	7	to	to	ADP
bptjm-17	351	8	primary	primary	ADJ
bptjm-17	351	9	mirna	mirna	PROPN
bptjm-17	351	10	(	(	PUNCT
bptjm-17	351	11	pri	pri	NOUN
bptjm-17	351	12	-	-	PUNCT
bptjm-17	351	13	mirna	mirna	NOUN
bptjm-17	351	14	)	)	PUNCT
bptjm-17	351	15	.	.	PUNCT
bptjm-17	352	1	3b	3b	NUM
bptjm-17	352	2	,	,	PUNCT
bptjm-17	352	3	3c	3c	NUM
bptjm-17	352	4	:	:	PUNCT
bptjm-17	352	5	pri	pri	NOUN
bptjm-17	352	6	-	-	PUNCT
bptjm-17	352	7	mirna	mirna	NOUN
bptjm-17	352	8	is	be	AUX
bptjm-17	352	9	processed	process	VERB
bptjm-17	352	10	to	to	ADP
bptjm-17	352	11	precursor	precursor	NOUN
bptjm-17	352	12	mirna	mirna	NOUN
bptjm-17	352	13	(	(	PUNCT
bptjm-17	352	14	pre	pre	NOUN
bptjm-17	352	15	-	-	NOUN
bptjm-17	352	16	mirna	mirna	NOUN
bptjm-17	352	17	)	)	PUNCT
bptjm-17	352	18	.	.	PUNCT
bptjm-17	353	1	3d	3d	NUM
bptjm-17	353	2	:	:	PUNCT
bptjm-17	354	1	pre	pre	ADJ
bptjm-17	354	2	-	-	NOUN
bptjm-17	354	3	mirna	mirna	NOUN
bptjm-17	354	4	is	be	AUX
bptjm-17	354	5	exported	export	VERB
bptjm-17	354	6	from	from	ADP
bptjm-17	354	7	the	the	DET
bptjm-17	354	8	nucleus	nucleus	NOUN
bptjm-17	354	9	to	to	ADP
bptjm-17	354	10	the	the	DET
bptjm-17	354	11	cytoplasm	cytoplasm	NOUN
bptjm-17	354	12	,	,	PUNCT
bptjm-17	354	13	maturing	mature	VERB
bptjm-17	354	14	into	into	ADP
bptjm-17	354	15	mirna	mirna	PROPN
bptjm-17	354	16	duplex	duplex	NOUN
bptjm-17	354	17	.	.	PUNCT
bptjm-17	355	1	3e	3e	NOUN
bptjm-17	355	2	:	:	PUNCT
bptjm-17	355	3	mirna	mirna	PROPN
bptjm-17	355	4	duplex	duplex	PROPN
bptjm-17	355	5	is	be	AUX
bptjm-17	355	6	cleaved	cleave	VERB
bptjm-17	355	7	to	to	PART
bptjm-17	355	8	produce	produce	VERB
bptjm-17	355	9	mature	mature	ADJ
bptjm-17	355	10	mirna	mirna	PROPN
bptjm-17	355	11	.	.	PUNCT
bptjm-17	356	1	3f	3f	PROPN
bptjm-17	356	2	:	:	PUNCT
bptjm-17	357	1	mature	mature	ADJ
bptjm-17	357	2	mirna	mirna	PROPN
bptjm-17	357	3	participates	participate	VERB
bptjm-17	357	4	in	in	ADP
bptjm-17	357	5	the	the	DET
bptjm-17	357	6	regulation	regulation	NOUN
bptjm-17	357	7	of	of	ADP
bptjm-17	357	8	cellular	cellular	ADJ
bptjm-17	357	9	pathways	pathway	NOUN
bptjm-17	357	10	(	(	PUNCT
bptjm-17	357	11	kwak	kwak	PROPN
bptjm-17	357	12	et	et	PROPN
bptjm-17	357	13	al	al	PROPN
bptjm-17	357	14	.	.	PROPN
bptjm-17	357	15	,	,	PUNCT
bptjm-17	357	16	2010	2010	NUM
bptjm-17	357	17	)	)	PUNCT
bptjm-17	357	18	.	.	PUNCT
bptjm-17	358	1	let-7	let-7	PUNCT
bptjm-17	358	2	the	the	DET
bptjm-17	358	3	mir	mir	PROPN
bptjm-17	358	4	let-7	let-7	ADJ
bptjm-17	358	5	family	family	NOUN
bptjm-17	358	6	regulates	regulate	VERB
bptjm-17	358	7	components	component	NOUN
bptjm-17	358	8	of	of	ADP
bptjm-17	358	9	cellular	cellular	ADJ
bptjm-17	358	10	development	development	NOUN
bptjm-17	358	11	and	and	CCONJ
bptjm-17	358	12	di	di	NOUN
bptjm-17	358	13	erentiation	erentiation	NOUN
bptjm-17	358	14	.	.	PUNCT
bptjm-17	359	1	although	although	SCONJ
bptjm-17	359	2	typically	typically	ADV
bptjm-17	359	3	a	a	DET
bptjm-17	359	4	tumor	tumor	NOUN
bptjm-17	359	5	suppressor	suppressor	NOUN
bptjm-17	359	6	,	,	PUNCT
bptjm-17	359	7	some	some	DET
bptjm-17	359	8	cases	case	NOUN
bptjm-17	359	9	have	have	AUX
bptjm-17	359	10	been	be	AUX
bptjm-17	359	11	recorded	record	VERB
bptjm-17	359	12	in	in	ADP
bptjm-17	359	13	which	which	PRON
bptjm-17	359	14	let-7	let-7	PUNCT
bptjm-17	359	15	acts	act	NOUN
bptjm-17	359	16	as	as	ADP
bptjm-17	359	17	an	an	DET
bptjm-17	359	18	oncogene	oncogene	NOUN
bptjm-17	359	19	(	(	PUNCT
bptjm-17	359	20	chirshev	chirshev	PROPN
bptjm-17	359	21	et	et	PROPN
bptjm-17	359	22	al	al	PROPN
bptjm-17	359	23	.	.	PROPN
bptjm-17	359	24	,	,	PUNCT
bptjm-17	359	25	2019	2019	NUM
bptjm-17	359	26	)	)	PUNCT
bptjm-17	359	27	.	.	PUNCT
bptjm-17	360	1	xie	xie	PROPN
bptjm-17	360	2	et	et	PROPN
bptjm-17	360	3	al	al	PROPN
bptjm-17	360	4	.	.	PROPN
bptjm-17	360	5	examined	examine	VERB
bptjm-17	360	6	the	the	DET
bptjm-17	360	7	role	role	NOUN
bptjm-17	360	8	of	of	ADP
bptjm-17	360	9	let-7	let-7	VERB
bptjm-17	360	10	in	in	ADP
bptjm-17	360	11	detecting	detect	VERB
bptjm-17	360	12	time	time	NOUN
bptjm-17	360	13	of	of	ADP
bptjm-17	360	14	acceleration	acceleration	NOUN
bptjm-17	360	15	re	re	NOUN
bptjm-17	360	16	-	-	NOUN
bptjm-17	360	17	proliferation	proliferation	NOUN
bptjm-17	360	18	,	,	PUNCT
bptjm-17	360	19	a	a	DET
bptjm-17	360	20	key	key	ADJ
bptjm-17	360	21	contributor	contributor	NOUN
bptjm-17	360	22	to	to	PART
bptjm-17	360	23	radiotherapy	radiotherapy	VERB
bptjm-17	360	24	failure	failure	NOUN
bptjm-17	360	25	.	.	PUNCT
bptjm-17	361	1	the	the	DET
bptjm-17	361	2	study	study	NOUN
bptjm-17	361	3	enrolled	enrol	VERB
bptjm-17	361	4	19	19	NUM
bptjm-17	361	5	eligible	eligible	ADJ
bptjm-17	361	6	patients	patient	NOUN
bptjm-17	361	7	and	and	CCONJ
bptjm-17	361	8	via	via	ADP
bptjm-17	361	9	qrt	qrt	NOUN
bptjm-17	361	10	-	-	PUNCT
bptjm-17	361	11	pcr	pcr	ADJ
bptjm-17	361	12	and	and	CCONJ
bptjm-17	361	13	statistical	statistical	ADJ
bptjm-17	361	14	analyses	analysis	NOUN
bptjm-17	361	15	found	find	VERB
bptjm-17	361	16	a	a	DET
bptjm-17	361	17	high	high	ADJ
bptjm-17	361	18	level	level	NOUN
bptjm-17	361	19	of	of	ADP
bptjm-17	361	20	serum	serum	NOUN
bptjm-17	361	21	let-7	let-7	PUNCT
bptjm-17	361	22	was	be	AUX
bptjm-17	361	23	associated	associate	VERB
bptjm-17	361	24	with	with	ADP
bptjm-17	361	25	a	a	DET
bptjm-17	361	26	better	well	ADJ
bptjm-17	361	27	os	os	NOUN
bptjm-17	361	28	rate	rate	NOUN
bptjm-17	361	29	(	(	PUNCT
bptjm-17	361	30	p=0.024	p=0.024	NOUN
bptjm-17	361	31	)	)	PUNCT
bptjm-17	361	32	,	,	PUNCT
bptjm-17	361	33	suggesting	suggest	VERB
bptjm-17	361	34	that	that	SCONJ
bptjm-17	361	35	serum	serum	NOUN
bptjm-17	361	36	let-7	let-7	PUNCT
bptjm-17	361	37	could	could	AUX
bptjm-17	361	38	re	re	AUX
bptjm-17	361	39	ect	ect	VERB
bptjm-17	361	40	the	the	DET
bptjm-17	361	41	proliferation	proliferation	NOUN
bptjm-17	361	42	of	of	ADP
bptjm-17	361	43	tumor	tumor	NOUN
bptjm-17	361	44	tissue	tissue	NOUN
bptjm-17	361	45	(	(	PUNCT
bptjm-17	361	46	xie	xie	PROPN
bptjm-17	361	47	et	et	PROPN
bptjm-17	361	48	al	al	PROPN
bptjm-17	361	49	.	.	PROPN
bptjm-17	361	50	,	,	PUNCT
bptjm-17	361	51	2016	2016	NUM
bptjm-17	361	52	)	)	PUNCT
bptjm-17	361	53	.	.	PUNCT
bptjm-17	362	1	another	another	DET
bptjm-17	362	2	study	study	NOUN
bptjm-17	362	3	tested	test	VERB
bptjm-17	362	4	let-7	let-7	PUNCT
bptjm-17	362	5	prognostic	prognostic	ADJ
bptjm-17	362	6	capability	capability	NOUN
bptjm-17	362	7	as	as	ADP
bptjm-17	362	8	part	part	NOUN
bptjm-17	362	9	of	of	ADP
bptjm-17	362	10	a	a	DET
bptjm-17	362	11	mir	mir	ADJ
bptjm-17	362	12	panel	panel	NOUN
bptjm-17	362	13	consisting	consist	VERB
bptjm-17	362	14	of	of	ADP
bptjm-17	362	15	let-7e	let-7e	PROPN
bptjm-17	362	16	,	,	PUNCT
bptjm-17	362	17	125a-5p	125a-5p	NUM
bptjm-17	362	18	,	,	PUNCT
bptjm-17	362	19	mir-30a	mir-30a	NUM
bptjm-17	362	20	,	,	PUNCT
bptjm-17	362	21	mir-30e	mir-30e	NUM
bptjm-17	362	22	,	,	PUNCT
bptjm-17	362	23	and	and	CCONJ
bptjm-17	362	24	berkeley	berkeley	PROPN
bptjm-17	362	25	pharma	pharma	PROPN
bptjm-17	362	26	tech	tech	NOUN
bptjm-17	362	27	journal	journal	NOUN
bptjm-17	362	28	of	of	ADP
bptjm-17	362	29	medicine	medicine	NOUN
bptjm-17	362	30	|	|	ADV
bptjm-17	362	31	137	137	NUM
bptjm-17	362	32	mir-30	mir-30	NOUN
bptjm-17	362	33	-	-	PUNCT
bptjm-17	362	34	3p	3p	NUM
bptjm-17	362	35	.	.	PUNCT
bptjm-17	363	1	the	the	DET
bptjm-17	363	2	study	study	NOUN
bptjm-17	363	3	found	find	VERB
bptjm-17	363	4	nsclc	nsclc	NOUN
bptjm-17	363	5	dedi	dedi	PROPN
bptjm-17	363	6	erentiation	erentiation	PROPN
bptjm-17	363	7	was	be	AUX
bptjm-17	363	8	associated	associate	VERB
bptjm-17	363	9	with	with	ADP
bptjm-17	363	10	reduced	reduced	ADJ
bptjm-17	363	11	expression	expression	NOUN
bptjm-17	363	12	of	of	ADP
bptjm-17	363	13	mir-125a-5p	mir-125a-5p	PROPN
bptjm-17	363	14	,	,	PUNCT
bptjm-17	363	15	let-7e	let-7e	PROPN
bptjm-17	363	16	and	and	CCONJ
bptjm-17	363	17	mir-30e	mir-30e	NUM
bptjm-17	363	18	(	(	PUNCT
bptjm-17	363	19	p=0.038	p=0.038	NOUN
bptjm-17	363	20	)	)	PUNCT
bptjm-17	363	21	;	;	PUNCT
bptjm-17	363	22	the	the	DET
bptjm-17	363	23	loss	loss	NOUN
bptjm-17	363	24	of	of	ADP
bptjm-17	363	25	expression	expression	NOUN
bptjm-17	363	26	of	of	ADP
bptjm-17	363	27	let-7e	let-7e	PROPN
bptjm-17	363	28	and	and	CCONJ
bptjm-17	363	29	mir-125a-5p	mir-125a-5p	PROPN
bptjm-17	363	30	was	be	AUX
bptjm-17	363	31	associated	associate	VERB
bptjm-17	363	32	with	with	ADP
bptjm-17	363	33	shorter	short	ADJ
bptjm-17	363	34	postoperative	postoperative	ADJ
bptjm-17	363	35	survival	survival	NOUN
bptjm-17	363	36	in	in	ADP
bptjm-17	363	37	nsclc	nsclc	NOUN
bptjm-17	363	38	patients	patient	NOUN
bptjm-17	363	39	(	(	PUNCT
bptjm-17	363	40	p=0.007	p=0.007	ADP
bptjm-17	363	41	)	)	PUNCT
bptjm-17	363	42	(	(	PUNCT
bptjm-17	363	43	zhu	zhu	X
bptjm-17	363	44	et	et	PROPN
bptjm-17	363	45	al	al	PROPN
bptjm-17	363	46	.	.	PROPN
bptjm-17	363	47	,	,	PUNCT
bptjm-17	363	48	2014	2014	NUM
bptjm-17	363	49	)	)	PUNCT
bptjm-17	363	50	.	.	PUNCT
bptjm-17	364	1	dedi	dedi	PROPN
bptjm-17	364	2	erentiation	erentiation	PROPN
bptjm-17	364	3	is	be	AUX
bptjm-17	364	4	a	a	DET
bptjm-17	364	5	process	process	NOUN
bptjm-17	364	6	required	require	VERB
bptjm-17	364	7	for	for	ADP
bptjm-17	364	8	tumorigenesis	tumorigenesis	NOUN
bptjm-17	364	9	,	,	PUNCT
bptjm-17	364	10	occurring	occur	VERB
bptjm-17	364	11	when	when	SCONJ
bptjm-17	364	12	specialized	specialized	ADJ
bptjm-17	364	13	cells	cell	NOUN
bptjm-17	364	14	become	become	VERB
bptjm-17	364	15	less	less	ADV
bptjm-17	364	16	specialized	specialized	ADJ
bptjm-17	364	17	and	and	CCONJ
bptjm-17	364	18	acquire	acquire	VERB
bptjm-17	364	19	tumor	tumor	NOUN
bptjm-17	364	20	cell	cell	NOUN
bptjm-17	364	21	plasticity	plasticity	NOUN
bptjm-17	364	22	or	or	CCONJ
bptjm-17	364	23	self	self	NOUN
bptjm-17	364	24	-	-	PUNCT
bptjm-17	364	25	renewal	renewal	NOUN
bptjm-17	364	26	ability	ability	NOUN
bptjm-17	364	27	(	(	PUNCT
bptjm-17	364	28	friedmann	friedmann	NOUN
bptjm-17	364	29	-	-	PUNCT
bptjm-17	364	30	morvinski	morvinski	NOUN
bptjm-17	364	31	&	&	CCONJ
bptjm-17	364	32	verma	verma	PROPN
bptjm-17	364	33	,	,	PUNCT
bptjm-17	364	34	2014	2014	NUM
bptjm-17	364	35	,	,	PUNCT
bptjm-17	364	36	p.	p.	NOUN
bptjm-17	364	37	245	245	NUM
bptjm-17	364	38	)	)	PUNCT
bptjm-17	364	39	.	.	PUNCT
bptjm-17	365	1	a	a	DET
bptjm-17	365	2	more	more	ADV
bptjm-17	365	3	recent	recent	ADJ
bptjm-17	365	4	study	study	NOUN
bptjm-17	365	5	performed	perform	VERB
bptjm-17	365	6	qrt	qrt	ADJ
bptjm-17	365	7	-	-	PUNCT
bptjm-17	365	8	pcr	pcr	ADJ
bptjm-17	365	9	analysis	analysis	NOUN
bptjm-17	365	10	on	on	ADP
bptjm-17	365	11	120	120	NUM
bptjm-17	365	12	nsclc	nsclc	NOUN
bptjm-17	365	13	patients	patient	NOUN
bptjm-17	365	14	and	and	CCONJ
bptjm-17	365	15	360	360	NUM
bptjm-17	365	16	healthy	healthy	ADJ
bptjm-17	365	17	controls	control	NOUN
bptjm-17	365	18	and	and	CCONJ
bptjm-17	365	19	found	find	VERB
bptjm-17	365	20	plasma	plasma	NOUN
bptjm-17	365	21	let-7c	let-7c	PROPN
bptjm-17	365	22	and	and	CCONJ
bptjm-17	365	23	mir-152	mir-152	NOUN
bptjm-17	365	24	expressions	expression	NOUN
bptjm-17	365	25	were	be	AUX
bptjm-17	365	26	lower	low	ADJ
bptjm-17	365	27	in	in	ADP
bptjm-17	365	28	nsclc	nsclc	NOUN
bptjm-17	365	29	patients	patient	NOUN
bptjm-17	365	30	.	.	PUNCT
bptjm-17	366	1	furthermore	furthermore	ADV
bptjm-17	366	2	,	,	PUNCT
bptjm-17	366	3	receiver	receiver	ADV
bptjm-17	366	4	operating	operate	VERB
bptjm-17	366	5	characteristic	characteristic	ADJ
bptjm-17	366	6	curves	curve	NOUN
bptjm-17	366	7	displayed	display	VERB
bptjm-17	366	8	an	an	DET
bptjm-17	366	9	association	association	NOUN
bptjm-17	366	10	between	between	ADP
bptjm-17	366	11	low	low	ADJ
bptjm-17	366	12	let-7c	let-7c	NOUN
bptjm-17	366	13	level	level	NOUN
bptjm-17	366	14	and	and	CCONJ
bptjm-17	366	15	poor	poor	ADJ
bptjm-17	366	16	di	di	X
bptjm-17	366	17	erentiation	erentiation	NOUN
bptjm-17	366	18	status	status	NOUN
bptjm-17	366	19	(	(	PUNCT
bptjm-17	366	20	p<0.001	p<0.001	PROPN
bptjm-17	366	21	)	)	PUNCT
bptjm-17	366	22	,	,	PUNCT
bptjm-17	366	23	cancer	cancer	NOUN
bptjm-17	366	24	metastasis	metastasis	NOUN
bptjm-17	366	25	(	(	PUNCT
bptjm-17	366	26	p=0.021	p=0.021	NOUN
bptjm-17	366	27	)	)	PUNCT
bptjm-17	366	28	,	,	PUNCT
bptjm-17	366	29	and	and	CCONJ
bptjm-17	366	30	advanced	advanced	ADJ
bptjm-17	366	31	stage	stage	NOUN
bptjm-17	366	32	classi	classi	ADJ
bptjm-17	366	33	cation	cation	NOUN
bptjm-17	366	34	(	(	PUNCT
bptjm-17	366	35	p=0.013	p=0.013	NOUN
bptjm-17	366	36	)	)	PUNCT
bptjm-17	366	37	.	.	PUNCT
bptjm-17	367	1	lastly	lastly	ADV
bptjm-17	367	2	,	,	PUNCT
bptjm-17	367	3	comparing	compare	VERB
bptjm-17	367	4	postoperative	postoperative	ADJ
bptjm-17	367	5	and	and	CCONJ
bptjm-17	367	6	preoperative	preoperative	ADJ
bptjm-17	367	7	plasma	plasma	NOUN
bptjm-17	367	8	from	from	ADP
bptjm-17	367	9	96	96	NUM
bptjm-17	367	10	nsclc	nsclc	NOUN
bptjm-17	367	11	cases	case	NOUN
bptjm-17	367	12	showed	show	VERB
bptjm-17	367	13	an	an	DET
bptjm-17	367	14	increase	increase	NOUN
bptjm-17	367	15	in	in	ADP
bptjm-17	367	16	let-7c	let-7c	NOUN
bptjm-17	367	17	expression	expression	NOUN
bptjm-17	367	18	level	level	NOUN
bptjm-17	367	19	post	post	NOUN
bptjm-17	367	20	-	-	NOUN
bptjm-17	367	21	operation	operation	NOUN
bptjm-17	367	22	:	:	PUNCT
bptjm-17	367	23	suggesting	suggest	VERB
bptjm-17	367	24	the	the	DET
bptjm-17	367	25	potential	potential	NOUN
bptjm-17	367	26	of	of	ADP
bptjm-17	367	27	let-7c	let-7c	PROPN
bptjm-17	367	28	as	as	ADP
bptjm-17	367	29	a	a	DET
bptjm-17	367	30	prognosis	prognosis	NOUN
bptjm-17	367	31	biomarker	biomarker	NOUN
bptjm-17	367	32	for	for	ADP
bptjm-17	367	33	nsclc	nsclc	NOUN
bptjm-17	367	34	(	(	PUNCT
bptjm-17	367	35	dou	dou	X
bptjm-17	367	36	et	et	PROPN
bptjm-17	367	37	al	al	PROPN
bptjm-17	367	38	.	.	PROPN
bptjm-17	367	39	,	,	PUNCT
bptjm-17	367	40	2015	2015	NUM
bptjm-17	367	41	)	)	PUNCT
bptjm-17	367	42	.	.	PUNCT
bptjm-17	368	1	mir-21	mir-21	PROPN
bptjm-17	368	2	mir-21	mir-21	PROPN
bptjm-17	368	3	is	be	AUX
bptjm-17	368	4	an	an	DET
bptjm-17	368	5	extensively	extensively	ADV
bptjm-17	368	6	studied	study	VERB
bptjm-17	368	7	oncogenic	oncogenic	ADJ
bptjm-17	368	8	mirna	mirna	NOUN
bptjm-17	368	9	due	due	ADP
bptjm-17	368	10	to	to	ADP
bptjm-17	368	11	its	its	PRON
bptjm-17	368	12	association	association	NOUN
bptjm-17	368	13	with	with	ADP
bptjm-17	368	14	tumor	tumor	NOUN
bptjm-17	368	15	suppressor	suppressor	NOUN
bptjm-17	368	16	genes	gene	NOUN
bptjm-17	368	17	that	that	PRON
bptjm-17	368	18	regulate	regulate	VERB
bptjm-17	368	19	proliferation	proliferation	NOUN
bptjm-17	368	20	,	,	PUNCT
bptjm-17	368	21	apoptosis	apoptosis	NOUN
bptjm-17	368	22	,	,	PUNCT
bptjm-17	368	23	and	and	CCONJ
bptjm-17	368	24	invasion	invasion	NOUN
bptjm-17	368	25	(	(	PUNCT
bptjm-17	368	26	feng	feng	PROPN
bptjm-17	368	27	et	et	PROPN
bptjm-17	368	28	al	al	PROPN
bptjm-17	368	29	.	.	PROPN
bptjm-17	368	30	,	,	PUNCT
bptjm-17	368	31	2016	2016	NUM
bptjm-17	368	32	)	)	PUNCT
bptjm-17	368	33	more	more	ADV
bptjm-17	368	34	recently	recently	ADV
bptjm-17	368	35	,	,	PUNCT
bptjm-17	368	36	researchers	researcher	NOUN
bptjm-17	368	37	have	have	AUX
bptjm-17	368	38	sought	seek	VERB
bptjm-17	368	39	to	to	PART
bptjm-17	368	40	utilize	utilize	VERB
bptjm-17	368	41	the	the	DET
bptjm-17	368	42	presence	presence	NOUN
bptjm-17	368	43	of	of	ADP
bptjm-17	368	44	mir-21	mir-21	PROPN
bptjm-17	368	45	as	as	ADP
bptjm-17	368	46	a	a	DET
bptjm-17	368	47	predictive	predictive	ADJ
bptjm-17	368	48	marker	marker	NOUN
bptjm-17	368	49	of	of	ADP
bptjm-17	368	50	nsclc	nsclc	NOUN
bptjm-17	368	51	.	.	PUNCT
bptjm-17	369	1	wang	wang	PROPN
bptjm-17	369	2	et	et	PROPN
bptjm-17	369	3	al	al	PROPN
bptjm-17	369	4	.	.	PROPN
bptjm-17	369	5	utilized	utilize	VERB
bptjm-17	369	6	serum	serum	NOUN
bptjm-17	369	7	samples	sample	NOUN
bptjm-17	369	8	of	of	ADP
bptjm-17	369	9	88	88	NUM
bptjm-17	369	10	nsclc	nsclc	NOUN
bptjm-17	369	11	patients	patient	NOUN
bptjm-17	369	12	and	and	CCONJ
bptjm-17	369	13	17	17	NUM
bptjm-17	369	14	healthy	healthy	ADJ
bptjm-17	369	15	controls	control	NOUN
bptjm-17	369	16	obtained	obtain	VERB
bptjm-17	369	17	from	from	ADP
bptjm-17	369	18	jiangsu	jiangsu	PROPN
bptjm-17	369	19	province	province	PROPN
bptjm-17	369	20	people	people	PROPN
bptjm-17	369	21	hospital	hospital	PROPN
bptjm-17	369	22	.	.	PUNCT
bptjm-17	370	1	the	the	DET
bptjm-17	370	2	researchers	researcher	NOUN
bptjm-17	370	3	found	find	VERB
bptjm-17	370	4	that	that	SCONJ
bptjm-17	370	5	the	the	DET
bptjm-17	370	6	3	3	NUM
bptjm-17	370	7	-	-	PUNCT
bptjm-17	370	8	year	year	NOUN
bptjm-17	370	9	os	os	NOUN
bptjm-17	370	10	in	in	ADP
bptjm-17	370	11	nsclc	nsclc	NOUN
bptjm-17	370	12	patients	patient	NOUN
bptjm-17	370	13	with	with	ADP
bptjm-17	370	14	high	high	ADJ
bptjm-17	370	15	serummir-21	serummir-21	ADJ
bptjm-17	370	16	expression	expression	NOUN
bptjm-17	370	17	was	be	AUX
bptjm-17	370	18	lower	low	ADJ
bptjm-17	370	19	(	(	PUNCT
bptjm-17	370	20	39.8	39.8	NUM
bptjm-17	370	21	%	%	NOUN
bptjm-17	370	22	)	)	PUNCT
bptjm-17	370	23	compared	compare	VERB
bptjm-17	370	24	to	to	ADP
bptjm-17	370	25	58.2	58.2	NUM
bptjm-17	370	26	%	%	NOUN
bptjm-17	370	27	in	in	ADP
bptjm-17	370	28	patients	patient	NOUN
bptjm-17	370	29	with	with	ADP
bptjm-17	370	30	low	low	ADJ
bptjm-17	370	31	serummir-21	serummir-21	PROPN
bptjm-17	370	32	(	(	PUNCT
bptjm-17	370	33	p<.001	p<.001	NOUN
bptjm-17	370	34	)	)	PUNCT
bptjm-17	370	35	(	(	PUNCT
bptjm-17	370	36	wang	wang	PROPN
bptjm-17	370	37	et	et	PROPN
bptjm-17	370	38	al	al	PROPN
bptjm-17	370	39	.	.	PROPN
bptjm-17	370	40	,	,	PUNCT
bptjm-17	370	41	2011	2011	NUM
bptjm-17	370	42	)	)	PUNCT
bptjm-17	370	43	.	.	PUNCT
bptjm-17	371	1	liu	liu	PROPN
bptjm-17	371	2	et	et	PROPN
bptjm-17	371	3	al	al	PROPN
bptjm-17	371	4	.	.	PROPN
bptjm-17	371	5	reported	report	VERB
bptjm-17	371	6	consistent	consistent	ADJ
bptjm-17	371	7	results	result	NOUN
bptjm-17	371	8	with	with	ADP
bptjm-17	371	9	the	the	DET
bptjm-17	371	10	prior	prior	ADJ
bptjm-17	371	11	study	study	NOUN
bptjm-17	371	12	regarding	regard	VERB
bptjm-17	371	13	os	os	NOUN
bptjm-17	371	14	,	,	PUNCT
bptjm-17	371	15	but	but	CCONJ
bptjm-17	371	16	noted	note	VERB
bptjm-17	371	17	that	that	SCONJ
bptjm-17	371	18	the	the	DET
bptjm-17	371	19	mir-21	mir-21	PROPN
bptjm-17	371	20	levels	level	NOUN
bptjm-17	371	21	in	in	ADP
bptjm-17	371	22	serum	serum	NOUN
bptjm-17	371	23	and	and	CCONJ
bptjm-17	371	24	tumor	tumor	NOUN
bptjm-17	371	25	mir-21	mir-21	PROPN
bptjm-17	371	26	levels	level	NOUN
bptjm-17	371	27	had	have	VERB
bptjm-17	371	28	no	no	DET
bptjm-17	371	29	signi	signi	NOUN
bptjm-17	371	30	ca	can	AUX
bptjm-17	371	31	nt	not	PART
bptjm-17	371	32	correlation	correlation	VERB
bptjm-17	371	33	(	(	PUNCT
bptjm-17	371	34	2012	2012	NUM
bptjm-17	371	35	)	)	PUNCT
bptjm-17	371	36	.	.	PUNCT
bptjm-17	372	1	mir-21	mir-21	PROPN
bptjm-17	372	2	levels	level	NOUN
bptjm-17	372	3	have	have	AUX
bptjm-17	372	4	also	also	ADV
bptjm-17	372	5	been	be	AUX
bptjm-17	372	6	used	use	VERB
bptjm-17	372	7	to	to	PART
bptjm-17	372	8	predict	predict	VERB
bptjm-17	372	9	nsclc	nsclc	NOUN
bptjm-17	372	10	tumor	tumor	NOUN
bptjm-17	372	11	recurrence	recurrence	NOUN
bptjm-17	372	12	in	in	ADP
bptjm-17	372	13	patients	patient	NOUN
bptjm-17	372	14	post	post	VERB
bptjm-17	372	15	surgical	surgical	ADJ
bptjm-17	372	16	resection	resection	NOUN
bptjm-17	372	17	.	.	PUNCT
bptjm-17	373	1	munagala	munagala	NOUN
bptjm-17	373	2	et	et	PROPN
bptjm-17	373	3	al	al	PROPN
bptjm-17	373	4	.	.	PROPN
bptjm-17	373	5	studied	study	VERB
bptjm-17	373	6	cancer	cancer	NOUN
bptjm-17	373	7	recurrence	recurrence	NOUN
bptjm-17	373	8	in	in	ADP
bptjm-17	373	9	mouse	mouse	NOUN
bptjm-17	373	10	models	model	NOUN
bptjm-17	373	11	and	and	CCONJ
bptjm-17	373	12	found	find	VERB
bptjm-17	373	13	that	that	SCONJ
bptjm-17	373	14	mir-21	mir-21	PROPN
bptjm-17	373	15	was	be	AUX
bptjm-17	373	16	upregulated	upregulate	VERB
bptjm-17	373	17	in	in	ADP
bptjm-17	373	18	recurrent	recurrent	ADJ
bptjm-17	373	19	tumors	tumor	NOUN
bptjm-17	373	20	compared	compare	VERB
bptjm-17	373	21	to	to	ADP
bptjm-17	373	22	primary	primary	ADJ
bptjm-17	373	23	tumor	tumor	NOUN
bptjm-17	373	24	tissue	tissue	NOUN
bptjm-17	373	25	,	,	PUNCT
bptjm-17	373	26	and	and	CCONJ
bptjm-17	373	27	more	more	ADV
bptjm-17	373	28	notably	notably	ADV
bptjm-17	373	29	,	,	PUNCT
bptjm-17	373	30	serum	serum	PROPN
bptjm-17	373	31	mir-21	mir-21	PROPN
bptjm-17	373	32	also	also	ADV
bptjm-17	373	33	mirrored	mirror	VERB
bptjm-17	373	34	the	the	DET
bptjm-17	373	35	tumor	tumor	NOUN
bptjm-17	373	36	pro	pro	X
bptjm-17	373	37	le	le	X
bptjm-17	373	38	tumor	tumor	PROPN
bptjm-17	373	39	mirna	mirna	PROPN
bptjm-17	373	40	results	result	NOUN
bptjm-17	373	41	(	(	PUNCT
bptjm-17	373	42	munagala	munagala	NOUN
bptjm-17	373	43	et	et	PROPN
bptjm-17	373	44	al	al	PROPN
bptjm-17	373	45	.	.	PROPN
bptjm-17	373	46	,	,	PUNCT
bptjm-17	373	47	2011	2011	NUM
bptjm-17	373	48	)	)	PUNCT
bptjm-17	373	49	.	.	PUNCT
bptjm-17	374	1	dejima	dejima	NOUN
bptjm-17	374	2	et	et	PROPN
bptjm-17	374	3	al	al	PROPN
bptjm-17	374	4	.	.	PROPN
bptjm-17	374	5	con	con	PROPN
bptjm-17	374	6	rmed	rme	VERB
bptjm-17	374	7	this	this	DET
bptjm-17	374	8	observation	observation	NOUN
bptjm-17	374	9	by	by	ADP
bptjm-17	374	10	examining	examine	VERB
bptjm-17	374	11	mir-21	mir-21	PROPN
bptjm-17	374	12	levels	level	NOUN
bptjm-17	374	13	in	in	ADP
bptjm-17	374	14	195	195	NUM
bptjm-17	374	15	nsclc	nsclc	NOUN
bptjm-17	374	16	patients	patient	NOUN
bptjm-17	374	17	and	and	CCONJ
bptjm-17	374	18	30	30	NUM
bptjm-17	374	19	healthy	healthy	ADJ
bptjm-17	374	20	patients	patient	NOUN
bptjm-17	374	21	;	;	PUNCT
bptjm-17	374	22	nding	nde	VERB
bptjm-17	374	23	that	that	DET
bptjm-17	374	24	exosomal	exosomal	ADJ
bptjm-17	374	25	mir-21	mir-21	PROPN
bptjm-17	374	26	levels	level	NOUN
bptjm-17	374	27	showed	show	VERB
bptjm-17	374	28	signi	signi	ADJ
bptjm-17	374	29	ca	can	AUX
bptjm-17	374	30	nt	not	PART
bptjm-17	374	31	increase	increase	VERB
bptjm-17	374	32	in	in	ADP
bptjm-17	374	33	nsclc	nsclc	NOUN
bptjm-17	374	34	patients	patient	NOUN
bptjm-17	374	35	with	with	ADP
bptjm-17	374	36	recurrent	recurrent	ADJ
bptjm-17	374	37	tumors	tumor	NOUN
bptjm-17	374	38	(	(	PUNCT
bptjm-17	374	39	p<0.01	p<0.01	PROPN
bptjm-17	374	40	)	)	PUNCT
bptjm-17	374	41	(	(	PUNCT
bptjm-17	374	42	dejima	dejima	NOUN
bptjm-17	374	43	et	et	PROPN
bptjm-17	374	44	al	al	PROPN
bptjm-17	374	45	.	.	PROPN
bptjm-17	374	46	,	,	PUNCT
bptjm-17	374	47	2017	2017	NUM
bptjm-17	374	48	)	)	PUNCT
bptjm-17	374	49	.	.	PUNCT
bptjm-17	375	1	in	in	ADP
bptjm-17	375	2	the	the	DET
bptjm-17	375	3	clinical	clinical	ADJ
bptjm-17	375	4	berkeley	berkeley	PROPN
bptjm-17	375	5	pharma	pharma	PROPN
bptjm-17	375	6	tech	tech	NOUN
bptjm-17	375	7	journal	journal	NOUN
bptjm-17	375	8	of	of	ADP
bptjm-17	375	9	medicine	medicine	NOUN
bptjm-17	375	10	|	|	ADV
bptjm-17	375	11	138	138	NUM
bptjm-17	375	12	setting	setting	NOUN
bptjm-17	375	13	,	,	PUNCT
bptjm-17	375	14	han	han	PROPN
bptjm-17	375	15	-	-	PUNCT
bptjm-17	375	16	bo	bo	PROPN
bptjm-17	375	17	le	le	X
bptjm-17	375	18	et	et	PROPN
bptjm-17	375	19	al	al	PROPN
bptjm-17	375	20	.	.	PROPN
bptjm-17	375	21	found	find	VERB
bptjm-17	375	22	that	that	SCONJ
bptjm-17	375	23	mir-21	mir-21	PROPN
bptjm-17	375	24	levels	level	NOUN
bptjm-17	375	25	in	in	ADP
bptjm-17	375	26	post	post	ADJ
bptjm-17	375	27	-	-	ADJ
bptjm-17	375	28	operative	operative	ADJ
bptjm-17	375	29	patients	patient	NOUN
bptjm-17	375	30	’	'	PUNCT
bptjm-17	375	31	serum	serum	NOUN
bptjm-17	375	32	samples	sample	NOUN
bptjm-17	375	33	was	be	AUX
bptjm-17	375	34	lower	low	ADJ
bptjm-17	375	35	than	than	ADP
bptjm-17	375	36	pre	pre	ADJ
bptjm-17	375	37	-	-	ADJ
bptjm-17	375	38	operative	operative	ADJ
bptjm-17	375	39	levels	level	NOUN
bptjm-17	375	40	,	,	PUNCT
bptjm-17	375	41	which	which	PRON
bptjm-17	375	42	further	far	ADV
bptjm-17	375	43	suggests	suggest	VERB
bptjm-17	375	44	mir-21	mir-21	PROPN
bptjm-17	375	45	’s	’s	PART
bptjm-17	375	46	role	role	NOUN
bptjm-17	375	47	as	as	ADP
bptjm-17	375	48	predictive	predictive	ADJ
bptjm-17	375	49	biomarker	biomarker	NOUN
bptjm-17	375	50	for	for	ADP
bptjm-17	375	51	tumor	tumor	NOUN
bptjm-17	375	52	recurrence	recurrence	NOUN
bptjm-17	375	53	.	.	PUNCT
bptjm-17	376	1	the	the	DET
bptjm-17	376	2	use	use	NOUN
bptjm-17	376	3	of	of	ADP
bptjm-17	376	4	mir-21	mir-21	PROPN
bptjm-17	376	5	to	to	PART
bptjm-17	376	6	evaluate	evaluate	VERB
bptjm-17	376	7	treatment	treatment	NOUN
bptjm-17	376	8	options	option	NOUN
bptjm-17	376	9	has	have	AUX
bptjm-17	376	10	also	also	ADV
bptjm-17	376	11	been	be	AUX
bptjm-17	376	12	investigated	investigate	VERB
bptjm-17	376	13	.	.	PUNCT
bptjm-17	377	1	wei	wei	PROPN
bptjm-17	377	2	j	j	PROPN
bptjm-17	377	3	et	et	PROPN
bptjm-17	377	4	al	al	PROPN
bptjm-17	377	5	.	.	PROPN
bptjm-17	377	6	followed	follow	VERB
bptjm-17	377	7	up	up	ADP
bptjm-17	377	8	with	with	ADP
bptjm-17	377	9	53	53	NUM
bptjm-17	377	10	patients	patient	NOUN
bptjm-17	377	11	who	who	PRON
bptjm-17	377	12	received	receive	VERB
bptjm-17	377	13	platinum	platinum	NOUN
bptjm-17	377	14	-	-	PUNCT
bptjm-17	377	15	based	base	VERB
bptjm-17	377	16	chemotherapy	chemotherapy	NOUN
bptjm-17	377	17	to	to	PART
bptjm-17	377	18	treat	treat	VERB
bptjm-17	377	19	nsclc	nsclc	NOUN
bptjm-17	377	20	.	.	PUNCT
bptjm-17	378	1	they	they	PRON
bptjm-17	378	2	found	find	VERB
bptjm-17	378	3	that	that	SCONJ
bptjm-17	378	4	patients	patient	NOUN
bptjm-17	378	5	with	with	ADP
bptjm-17	378	6	partial	partial	ADJ
bptjm-17	378	7	response	response	NOUN
bptjm-17	378	8	to	to	ADP
bptjm-17	378	9	the	the	DET
bptjm-17	378	10	therapy	therapy	NOUN
bptjm-17	378	11	had	have	VERB
bptjm-17	378	12	mir-21	mir-21	PROPN
bptjm-17	378	13	plasma	plasma	NOUN
bptjm-17	378	14	levels	level	NOUN
bptjm-17	378	15	several	several	ADJ
bptjm-17	378	16	fold	fold	VERB
bptjm-17	378	17	lower	lower	ADV
bptjm-17	378	18	than	than	ADP
bptjm-17	378	19	patients	patient	NOUN
bptjm-17	378	20	with	with	ADP
bptjm-17	378	21	stable	stable	ADJ
bptjm-17	378	22	orprogressive	orprogressive	ADJ
bptjm-17	378	23	disease	disease	NOUN
bptjm-17	378	24	(	(	PUNCT
bptjm-17	378	25	wei	wei	PROPN
bptjm-17	378	26	et	et	PROPN
bptjm-17	378	27	al	al	PROPN
bptjm-17	378	28	.	.	PROPN
bptjm-17	378	29	,	,	PUNCT
bptjm-17	378	30	2011	2011	NUM
bptjm-17	378	31	)	)	PUNCT
bptjm-17	378	32	.	.	PUNCT
bptjm-17	379	1	gao	gao	PROPN
bptjm-17	379	2	et	et	PROPN
bptjm-17	379	3	al	al	PROPN
bptjm-17	379	4	.	.	PROPN
bptjm-17	379	5	noted	note	VERB
bptjm-17	379	6	similar	similar	ADJ
bptjm-17	379	7	results	result	NOUN
bptjm-17	379	8	via	via	ADP
bptjm-17	379	9	tumor	tumor	NOUN
bptjm-17	379	10	mirna	mirna	PROPN
bptjm-17	379	11	analysis	analysis	NOUN
bptjm-17	379	12	of	of	ADP
bptjm-17	379	13	58	58	NUM
bptjm-17	379	14	patients	patient	NOUN
bptjm-17	379	15	,	,	PUNCT
bptjm-17	379	16	with	with	ADP
bptjm-17	379	17	high	high	ADJ
bptjm-17	379	18	levels	level	NOUN
bptjm-17	379	19	of	of	ADP
bptjm-17	379	20	mir-21	mir-21	NOUN
bptjm-17	379	21	expression	expression	NOUN
bptjm-17	379	22	correlating	correlate	VERB
bptjm-17	379	23	with	with	ADP
bptjm-17	379	24	increased	increase	VERB
bptjm-17	379	25	platinum	platinum	NOUN
bptjm-17	379	26	resistance	resistance	NOUN
bptjm-17	379	27	(	(	PUNCT
bptjm-17	379	28	gao	gao	PROPN
bptjm-17	379	29	et	et	PROPN
bptjm-17	379	30	al	al	PROPN
bptjm-17	379	31	.	.	PROPN
bptjm-17	379	32	,	,	PUNCT
bptjm-17	379	33	2012	2012	NUM
bptjm-17	379	34	)	)	PUNCT
bptjm-17	379	35	.	.	PUNCT
bptjm-17	380	1	mir-30	mir-30	NUM
bptjm-17	380	2	the	the	DET
bptjm-17	380	3	mir-30	mir-30	NOUN
bptjm-17	380	4	family	family	NOUN
bptjm-17	380	5	serves	serve	VERB
bptjm-17	380	6	in	in	ADP
bptjm-17	380	7	a	a	DET
bptjm-17	380	8	regulatory	regulatory	ADJ
bptjm-17	380	9	capacity	capacity	NOUN
bptjm-17	380	10	during	during	ADP
bptjm-17	380	11	tissue	tissue	NOUN
bptjm-17	380	12	and	and	CCONJ
bptjm-17	380	13	organ	organ	NOUN
bptjm-17	380	14	development	development	NOUN
bptjm-17	380	15	.	.	PUNCT
bptjm-17	381	1	the	the	DET
bptjm-17	381	2	mir-30	mir-30	NUM
bptjm-17	381	3	family	family	NOUN
bptjm-17	381	4	possesses	possess	VERB
bptjm-17	381	5	tumor	tumor	NOUN
bptjm-17	381	6	suppressor	suppressor	NOUN
bptjm-17	381	7	abilities	ability	NOUN
bptjm-17	381	8	,	,	PUNCT
bptjm-17	381	9	which	which	PRON
bptjm-17	381	10	include	include	VERB
bptjm-17	381	11	its	its	PRON
bptjm-17	381	12	roles	role	NOUN
bptjm-17	381	13	in	in	ADP
bptjm-17	381	14	the	the	DET
bptjm-17	381	15	pathogenesis	pathogenesis	NOUN
bptjm-17	381	16	of	of	ADP
bptjm-17	381	17	cancers	cancer	NOUN
bptjm-17	381	18	,	,	PUNCT
bptjm-17	381	19	including	include	VERB
bptjm-17	381	20	breast	breast	NOUN
bptjm-17	381	21	cancer	cancer	NOUN
bptjm-17	381	22	,	,	PUNCT
bptjm-17	381	23	thyroid	thyroid	NOUN
bptjm-17	381	24	cancer	cancer	NOUN
bptjm-17	381	25	,	,	PUNCT
bptjm-17	381	26	colon	colon	NOUN
bptjm-17	381	27	cancer	cancer	NOUN
bptjm-17	381	28	,	,	PUNCT
bptjm-17	381	29	and	and	CCONJ
bptjm-17	381	30	lung	lung	NOUN
bptjm-17	381	31	cancer	cancer	NOUN
bptjm-17	381	32	(	(	PUNCT
bptjm-17	381	33	mao	mao	NOUN
bptjm-17	381	34	et	et	PROPN
bptjm-17	381	35	al	al	PROPN
bptjm-17	381	36	.	.	PROPN
bptjm-17	381	37	,	,	PUNCT
bptjm-17	381	38	2018	2018	NUM
bptjm-17	381	39	)	)	PUNCT
bptjm-17	381	40	.	.	PUNCT
bptjm-17	382	1	a	a	DET
bptjm-17	382	2	study	study	NOUN
bptjm-17	382	3	investigated	investigate	VERB
bptjm-17	382	4	the	the	DET
bptjm-17	382	5	prognostic	prognostic	ADJ
bptjm-17	382	6	value	value	NOUN
bptjm-17	382	7	of	of	ADP
bptjm-17	382	8	plasma	plasma	NOUN
bptjm-17	382	9	mir-30b	mir-30b	NUM
bptjm-17	382	10	and	and	CCONJ
bptjm-17	382	11	mir-30c	mir-30c	NOUN
bptjm-17	382	12	from	from	ADP
bptjm-17	382	13	egfr	egfr	ADJ
bptjm-17	382	14	-	-	PUNCT
bptjm-17	382	15	mutated	mutate	VERB
bptjm-17	382	16	lung	lung	NOUN
bptjm-17	382	17	cancer	cancer	NOUN
bptjm-17	382	18	patients	patient	NOUN
bptjm-17	382	19	undergoing	undergo	VERB
bptjm-17	382	20	erlotinib	erlotinib	NOUN
bptjm-17	382	21	treatment	treatment	NOUN
bptjm-17	382	22	.	.	PUNCT
bptjm-17	383	1	blood	blood	NOUN
bptjm-17	383	2	qpcr	qpcr	ADV
bptjm-17	383	3	analyses	analyse	VERB
bptjm-17	383	4	from	from	ADP
bptjm-17	383	5	29	29	NUM
bptjm-17	383	6	erlotinib	erlotinib	NOUN
bptjm-17	383	7	-	-	PUNCT
bptjm-17	383	8	treated	treat	VERB
bptjm-17	383	9	,	,	PUNCT
bptjm-17	383	10	egfr	egfr	ADJ
bptjm-17	383	11	-	-	PUNCT
bptjm-17	383	12	mutated	mutate	VERB
bptjm-17	383	13	lung	lung	NOUN
bptjm-17	383	14	cancer	cancer	NOUN
bptjm-17	383	15	patients	patient	NOUN
bptjm-17	383	16	demonstrated	demonstrate	VERB
bptjm-17	383	17	associations	association	NOUN
bptjm-17	383	18	between	between	ADP
bptjm-17	383	19	low	low	ADJ
bptjm-17	383	20	plasma	plasma	NOUN
bptjm-17	383	21	levels	level	NOUN
bptjm-17	383	22	of	of	ADP
bptjm-17	383	23	mir-30b	mir-30b	NUM
bptjm-17	383	24	and	and	CCONJ
bptjm-17	383	25	mir-30c	mir-30c	NOUN
bptjm-17	383	26	and	and	CCONJ
bptjm-17	383	27	increased	increase	VERB
bptjm-17	383	28	e	e	NOUN
bptjm-17	383	29	cacy	cacy	NOUN
bptjm-17	383	30	of	of	ADP
bptjm-17	383	31	erlotinib	erlotinib	NOUN
bptjm-17	383	32	in	in	ADP
bptjm-17	383	33	egfr	egfr	ADJ
bptjm-17	383	34	-	-	PUNCT
bptjm-17	383	35	mutated	mutate	VERB
bptjm-17	383	36	nsclc	nsclc	NOUN
bptjm-17	383	37	patients	patient	NOUN
bptjm-17	383	38	as	as	SCONJ
bptjm-17	383	39	indicated	indicate	VERB
bptjm-17	383	40	by	by	ADP
bptjm-17	383	41	pfs	pfs	PROPN
bptjm-17	383	42	(	(	PUNCT
bptjm-17	383	43	p<0.05	p<0.05	NOUN
bptjm-17	383	44	for	for	ADP
bptjm-17	383	45	both	both	DET
bptjm-17	383	46	mirnas	mirna	NOUN
bptjm-17	383	47	)	)	PUNCT
bptjm-17	383	48	.	.	PUNCT
bptjm-17	384	1	the	the	DET
bptjm-17	384	2	study	study	NOUN
bptjm-17	384	3	concluded	conclude	VERB
bptjm-17	384	4	that	that	SCONJ
bptjm-17	384	5	mir-30b	mir-30b	NUM
bptjm-17	384	6	and	and	CCONJ
bptjm-17	384	7	mir-30c	mir-30c	NOUN
bptjm-17	384	8	may	may	AUX
bptjm-17	384	9	serve	serve	VERB
bptjm-17	384	10	as	as	ADP
bptjm-17	384	11	potential	potential	ADJ
bptjm-17	384	12	biomarkers	biomarker	NOUN
bptjm-17	384	13	to	to	PART
bptjm-17	384	14	predict	predict	VERB
bptjm-17	384	15	erlotinib	erlotinib	NOUN
bptjm-17	384	16	e	e	NOUN
bptjm-17	384	17	cacy	cacy	NOUN
bptjm-17	384	18	in	in	ADP
bptjm-17	384	19	egfr	egfr	NOUN
bptjm-17	384	20	-	-	PUNCT
bptjm-17	384	21	mutated	mutate	VERB
bptjm-17	384	22	nsclc	nsclc	NOUN
bptjm-17	384	23	patients	patient	NOUN
bptjm-17	384	24	(	(	PUNCT
bptjm-17	384	25	hojbjerg	hojbjerg	PROPN
bptjm-17	384	26	et	et	PROPN
bptjm-17	384	27	al	al	PROPN
bptjm-17	384	28	.	.	PROPN
bptjm-17	384	29	,	,	PUNCT
bptjm-17	384	30	2019	2019	NUM
bptjm-17	384	31	)	)	PUNCT
bptjm-17	384	32	.	.	PUNCT
bptjm-17	385	1	another	another	DET
bptjm-17	385	2	study	study	NOUN
bptjm-17	385	3	on	on	ADP
bptjm-17	385	4	104	104	NUM
bptjm-17	385	5	lung	lung	NOUN
bptjm-17	385	6	cancer	cancer	NOUN
bptjm-17	385	7	cases	case	NOUN
bptjm-17	385	8	with	with	ADP
bptjm-17	385	9	benign	benign	ADJ
bptjm-17	385	10	lesions	lesion	NOUN
bptjm-17	385	11	and	and	CCONJ
bptjm-17	385	12	20	20	NUM
bptjm-17	385	13	healthy	healthy	ADJ
bptjm-17	385	14	controls	control	NOUN
bptjm-17	385	15	from	from	ADP
bptjm-17	385	16	west	west	PROPN
bptjm-17	385	17	china	china	PROPN
bptjm-17	385	18	hospital	hospital	PROPN
bptjm-17	385	19	investigated	investigate	VERB
bptjm-17	385	20	the	the	DET
bptjm-17	385	21	prognosis	prognosis	NOUN
bptjm-17	385	22	value	value	NOUN
bptjm-17	385	23	of	of	ADP
bptjm-17	385	24	mir-30a-5p	mir-30a-5p	PROPN
bptjm-17	385	25	.	.	PUNCT
bptjm-17	386	1	through	through	ADP
bptjm-17	386	2	qrt	qrt	NOUN
bptjm-17	386	3	-	-	PUNCT
bptjm-17	386	4	pcr	pcr	ADJ
bptjm-17	386	5	,	,	PUNCT
bptjm-17	386	6	high	high	ADJ
bptjm-17	386	7	plasma	plasma	NOUN
bptjm-17	386	8	mir-30a-5p	mir-30a-5p	PROPN
bptjm-17	386	9	levels	level	NOUN
bptjm-17	386	10	correlated	correlate	VERB
bptjm-17	386	11	with	with	ADP
bptjm-17	386	12	increased	increase	VERB
bptjm-17	386	13	tumor	tumor	NOUN
bptjm-17	386	14	size	size	NOUN
bptjm-17	386	15	(	(	PUNCT
bptjm-17	386	16	p=0.02	p=0.02	NOUN
bptjm-17	386	17	)	)	PUNCT
bptjm-17	386	18	,	,	PUNCT
bptjm-17	386	19	advanced	advanced	ADJ
bptjm-17	386	20	tumor	tumor	NOUN
bptjm-17	386	21	di	di	NOUN
bptjm-17	386	22	erentiation	erentiation	PROPN
bptjm-17	386	23	(	(	PUNCT
bptjm-17	386	24	p=0.03	p=0.03	ADJ
bptjm-17	386	25	)	)	PUNCT
bptjm-17	386	26	,	,	PUNCT
bptjm-17	386	27	and	and	CCONJ
bptjm-17	386	28	advanced	advanced	ADJ
bptjm-17	386	29	tumor	tumor	NOUN
bptjm-17	386	30	node	node	NOUN
bptjm-17	386	31	metastasis	metastasis	NOUN
bptjm-17	386	32	(	(	PUNCT
bptjm-17	386	33	tnm	tnm	NOUN
bptjm-17	386	34	)	)	PUNCT
bptjm-17	386	35	stage	stage	NOUN
bptjm-17	386	36	(	(	PUNCT
bptjm-17	386	37	p=0.0001	p=0.0001	PROPN
bptjm-17	386	38	)	)	PUNCT
bptjm-17	386	39	.	.	PUNCT
bptjm-17	387	1	the	the	DET
bptjm-17	387	2	plasma	plasma	NOUN
bptjm-17	387	3	level	level	NOUN
bptjm-17	387	4	of	of	ADP
bptjm-17	387	5	mir-30a-5p	mir-30a-5p	PROPN
bptjm-17	387	6	was	be	AUX
bptjm-17	387	7	also	also	ADV
bptjm-17	387	8	found	find	VERB
bptjm-17	387	9	to	to	PART
bptjm-17	387	10	signi	signi	AUX
bptjm-17	387	11	cantly	cantly	ADV
bptjm-17	387	12	decrease	decrease	VERB
bptjm-17	387	13	post	post	ADJ
bptjm-17	387	14	-	-	ADJ
bptjm-17	387	15	surgery	surgery	ADJ
bptjm-17	387	16	(	(	PUNCT
bptjm-17	387	17	p<0.0001	p<0.0001	NOUN
bptjm-17	387	18	)	)	PUNCT
bptjm-17	387	19	(	(	PUNCT
bptjm-17	387	20	liang	liang	PROPN
bptjm-17	387	21	et	et	PROPN
bptjm-17	387	22	al	al	PROPN
bptjm-17	387	23	.	.	PROPN
bptjm-17	387	24	,	,	PUNCT
bptjm-17	387	25	2019	2019	NUM
bptjm-17	387	26	)	)	PUNCT
bptjm-17	387	27	.	.	PUNCT
bptjm-17	388	1	through	through	ADP
bptjm-17	388	2	kaplan	kaplan	PROPN
bptjm-17	388	3	–	–	PUNCT
bptjm-17	388	4	meier	meier	PROPN
bptjm-17	388	5	survival	survival	PROPN
bptjm-17	388	6	analysis	analysis	NOUN
bptjm-17	388	7	,	,	PUNCT
bptjm-17	388	8	low	low	ADJ
bptjm-17	388	9	mir-30a-5p	mir-30a-5p	PROPN
bptjm-17	388	10	expression	expression	NOUN
bptjm-17	388	11	was	be	AUX
bptjm-17	388	12	associated	associate	VERB
bptjm-17	388	13	with	with	ADP
bptjm-17	388	14	longer	long	ADJ
bptjm-17	388	15	survival	survival	NOUN
bptjm-17	388	16	compared	compare	VERB
bptjm-17	388	17	to	to	ADP
bptjm-17	388	18	high	high	ADJ
bptjm-17	388	19	mir-30a-5p	mir-30a-5p	PROPN
bptjm-17	388	20	expression	expression	NOUN
bptjm-17	388	21	(	(	PUNCT
bptjm-17	388	22	p=0.0001	p=0.0001	PROPN
bptjm-17	388	23	)	)	PUNCT
bptjm-17	388	24	.	.	PUNCT
bptjm-17	389	1	kaplan	kaplan	PROPN
bptjm-17	389	2	–	–	PUNCT
bptjm-17	389	3	meier	meier	PROPN
bptjm-17	389	4	survival	survival	NOUN
bptjm-17	389	5	analysis	analysis	NOUN
bptjm-17	389	6	is	be	AUX
bptjm-17	389	7	an	an	DET
bptjm-17	389	8	approach	approach	NOUN
bptjm-17	389	9	to	to	PART
bptjm-17	389	10	measure	measure	VERB
bptjm-17	389	11	the	the	DET
bptjm-17	389	12	portion	portion	NOUN
bptjm-17	389	13	of	of	ADP
bptjm-17	389	14	berkeley	berkeley	PROPN
bptjm-17	389	15	pharma	pharma	PROPN
bptjm-17	389	16	tech	tech	NOUN
bptjm-17	389	17	journal	journal	NOUN
bptjm-17	389	18	of	of	ADP
bptjm-17	389	19	medicine	medicine	NOUN
bptjm-17	389	20	|	|	ADV
bptjm-17	389	21	139	139	NUM
bptjm-17	389	22	samples	sample	NOUN
bptjm-17	389	23	surviving	survive	VERB
bptjm-17	389	24	post	post	ADJ
bptjm-17	389	25	-	-	NOUN
bptjm-17	389	26	treatment	treatment	NOUN
bptjm-17	389	27	after	after	ADP
bptjm-17	389	28	a	a	DET
bptjm-17	389	29	certain	certain	ADJ
bptjm-17	389	30	time	time	NOUN
bptjm-17	389	31	period	period	NOUN
bptjm-17	389	32	(	(	PUNCT
bptjm-17	389	33	kishore	kishore	NOUN
bptjm-17	389	34	et	et	PROPN
bptjm-17	389	35	al	al	PROPN
bptjm-17	389	36	.	.	PROPN
bptjm-17	389	37	,	,	PUNCT
bptjm-17	389	38	2010	2010	NUM
bptjm-17	389	39	)	)	PUNCT
bptjm-17	389	40	.	.	PUNCT
bptjm-17	390	1	finally	finally	ADV
bptjm-17	390	2	,	,	PUNCT
bptjm-17	390	3	cox	cox	PROPN
bptjm-17	390	4	multivariate	multivariate	PROPN
bptjm-17	390	5	regression	regression	VERB
bptjm-17	390	6	analysis	analysis	NOUN
bptjm-17	390	7	con	con	NOUN
bptjm-17	390	8	rmed	rme	VERB
bptjm-17	390	9	the	the	DET
bptjm-17	390	10	correlation	correlation	NOUN
bptjm-17	390	11	between	between	ADP
bptjm-17	390	12	mir-30a-5p	mir-30a-5p	PROPN
bptjm-17	390	13	,	,	PUNCT
bptjm-17	390	14	advanced	advanced	ADJ
bptjm-17	390	15	tnm	tnm	NUM
bptjm-17	390	16	stage	stage	NOUN
bptjm-17	390	17	,	,	PUNCT
bptjm-17	390	18	and	and	CCONJ
bptjm-17	390	19	os	os	ADV
bptjm-17	390	20	,	,	PUNCT
bptjm-17	390	21	signifying	signify	VERB
bptjm-17	390	22	the	the	DET
bptjm-17	390	23	prognostic	prognostic	ADJ
bptjm-17	390	24	value	value	NOUN
bptjm-17	390	25	of	of	ADP
bptjm-17	390	26	mir-30a-5p	mir-30a-5p	PROPN
bptjm-17	390	27	in	in	ADP
bptjm-17	390	28	nsclc	nsclc	NOUN
bptjm-17	390	29	(	(	PUNCT
bptjm-17	390	30	liang	liang	PROPN
bptjm-17	390	31	et	et	PROPN
bptjm-17	390	32	al	al	PROPN
bptjm-17	390	33	.	.	PROPN
bptjm-17	390	34	,	,	PUNCT
bptjm-17	390	35	2019	2019	NUM
bptjm-17	390	36	)	)	PUNCT
bptjm-17	390	37	.	.	PUNCT
bptjm-17	391	1	mir-125b	mir-125b	PROPN
bptjm-17	392	1	the	the	DET
bptjm-17	392	2	dysregulation	dysregulation	NOUN
bptjm-17	392	3	of	of	ADP
bptjm-17	392	4	mir-125b	mir-125b	PROPN
bptjm-17	392	5	is	be	AUX
bptjm-17	392	6	a	a	DET
bptjm-17	392	7	common	common	ADJ
bptjm-17	392	8	feature	feature	NOUN
bptjm-17	392	9	across	across	ADP
bptjm-17	392	10	many	many	ADJ
bptjm-17	392	11	cancers	cancer	NOUN
bptjm-17	392	12	that	that	SCONJ
bptjm-17	392	13	a	a	DET
bptjm-17	392	14	ects	ect	VERB
bptjm-17	392	15	tumor	tumor	NOUN
bptjm-17	392	16	cell	cell	NOUN
bptjm-17	392	17	proliferation	proliferation	NOUN
bptjm-17	392	18	,	,	PUNCT
bptjm-17	392	19	di	di	NOUN
bptjm-17	392	20	erentiation	erentiation	NOUN
bptjm-17	392	21	,	,	PUNCT
bptjm-17	392	22	invasion	invasion	NOUN
bptjm-17	392	23	,	,	PUNCT
bptjm-17	392	24	migration	migration	NOUN
bptjm-17	392	25	,	,	PUNCT
bptjm-17	392	26	drug	drug	NOUN
bptjm-17	392	27	resistance	resistance	NOUN
bptjm-17	392	28	,	,	PUNCT
bptjm-17	392	29	and	and	CCONJ
bptjm-17	392	30	tumor	tumor	NOUN
bptjm-17	392	31	immunity	immunity	NOUN
bptjm-17	392	32	.	.	PUNCT
bptjm-17	393	1	due	due	ADP
bptjm-17	393	2	to	to	ADP
bptjm-17	393	3	its	its	PRON
bptjm-17	393	4	tendency	tendency	NOUN
bptjm-17	393	5	to	to	PART
bptjm-17	393	6	act	act	VERB
bptjm-17	393	7	as	as	ADP
bptjm-17	393	8	both	both	PRON
bptjm-17	393	9	tumor	tumor	NOUN
bptjm-17	393	10	-	-	PUNCT
bptjm-17	393	11	suppressor	suppressor	NOUN
bptjm-17	393	12	and	and	CCONJ
bptjm-17	393	13	oncogene	oncogene	NOUN
bptjm-17	393	14	,	,	PUNCT
bptjm-17	393	15	depending	depend	VERB
bptjm-17	393	16	on	on	ADP
bptjm-17	393	17	the	the	DET
bptjm-17	393	18	cancer	cancer	NOUN
bptjm-17	393	19	type	type	NOUN
bptjm-17	393	20	and	and	CCONJ
bptjm-17	393	21	molecular	molecular	ADJ
bptjm-17	393	22	contexts	contexts	NOUN
bptjm-17	393	23	,	,	PUNCT
bptjm-17	393	24	mir-125b	mir-125b	PUNCT
bptjm-17	393	25	has	have	AUX
bptjm-17	393	26	not	not	PART
bptjm-17	393	27	been	be	AUX
bptjm-17	393	28	utilized	utilize	VERB
bptjm-17	393	29	for	for	ADP
bptjm-17	393	30	clinical	clinical	ADJ
bptjm-17	393	31	purposes	purpose	NOUN
bptjm-17	393	32	.	.	PUNCT
bptjm-17	394	1	recently	recently	ADV
bptjm-17	394	2	,	,	PUNCT
bptjm-17	394	3	however	however	ADV
bptjm-17	394	4	,	,	PUNCT
bptjm-17	394	5	several	several	ADJ
bptjm-17	394	6	studies	study	NOUN
bptjm-17	394	7	have	have	AUX
bptjm-17	394	8	noted	note	VERB
bptjm-17	394	9	mir-125b	mir-125b	NOUN
bptjm-17	394	10	’s	’s	PART
bptjm-17	394	11	potential	potential	NOUN
bptjm-17	394	12	as	as	ADP
bptjm-17	394	13	a	a	DET
bptjm-17	394	14	prognostic	prognostic	ADJ
bptjm-17	394	15	biomarker	biomarker	NOUN
bptjm-17	394	16	for	for	ADP
bptjm-17	394	17	advanced	advanced	ADJ
bptjm-17	394	18	nsclc	nsclc	NOUN
bptjm-17	394	19	patients	patient	NOUN
bptjm-17	394	20	.	.	PUNCT
bptjm-17	395	1	cui	cui	VERB
bptjm-17	395	2	et	et	PROPN
bptjm-17	395	3	al	al	PROPN
bptjm-17	395	4	.	.	PROPN
bptjm-17	396	1	compared	compare	VERB
bptjm-17	396	2	serum	serum	PROPN
bptjm-17	396	3	mirna-125b	mirna-125b	PROPN
bptjm-17	396	4	across	across	ADP
bptjm-17	396	5	260	260	NUM
bptjm-17	396	6	inoperable	inoperable	ADJ
bptjm-17	396	7	advanced	advanced	ADJ
bptjm-17	396	8	nsclc	nsclc	NOUN
bptjm-17	396	9	patients	patient	NOUN
bptjm-17	396	10	and	and	CCONJ
bptjm-17	396	11	260	260	NUM
bptjm-17	396	12	healthy	healthy	ADJ
bptjm-17	396	13	patients	patient	NOUN
bptjm-17	396	14	.	.	PUNCT
bptjm-17	397	1	utilizing	utilize	VERB
bptjm-17	397	2	qrt	qrt	NOUN
bptjm-17	397	3	-	-	PUNCT
bptjm-17	397	4	pcr	pcr	NOUN
bptjm-17	397	5	to	to	PART
bptjm-17	397	6	measure	measure	VERB
bptjm-17	397	7	circulating	circulate	VERB
bptjm-17	397	8	mir-125b	mir-125b	NOUN
bptjm-17	397	9	,	,	PUNCT
bptjm-17	397	10	and	and	CCONJ
bptjm-17	397	11	evaluating	evaluate	VERB
bptjm-17	397	12	e	e	NOUN
bptjm-17	397	13	cacy	cacy	NOUN
bptjm-17	397	14	of	of	ADP
bptjm-17	397	15	chemotherapy	chemotherapy	NOUN
bptjm-17	397	16	in	in	ADP
bptjm-17	397	17	accordance	accordance	NOUN
bptjm-17	397	18	with	with	ADP
bptjm-17	397	19	the	the	DET
bptjm-17	397	20	radiologic	radiologic	ADJ
bptjm-17	397	21	recist	recist	NOUN
bptjm-17	397	22	,	,	PUNCT
bptjm-17	397	23	the	the	DET
bptjm-17	397	24	study	study	NOUN
bptjm-17	397	25	found	find	VERB
bptjm-17	397	26	that	that	SCONJ
bptjm-17	397	27	99	99	NUM
bptjm-17	397	28	patients	patient	NOUN
bptjm-17	397	29	(	(	PUNCT
bptjm-17	397	30	38	38	NUM
bptjm-17	397	31	%	%	NOUN
bptjm-17	397	32	)	)	PUNCT
bptjm-17	397	33	responded	respond	VERB
bptjm-17	397	34	to	to	ADP
bptjm-17	397	35	chemotherapy	chemotherapy	NOUN
bptjm-17	397	36	with	with	ADP
bptjm-17	397	37	partial	partial	ADJ
bptjm-17	397	38	or	or	CCONJ
bptjm-17	397	39	complete	complete	ADJ
bptjm-17	397	40	response	response	NOUN
bptjm-17	397	41	;	;	PUNCT
bptjm-17	397	42	161	161	NUM
bptjm-17	397	43	(	(	PUNCT
bptjm-17	397	44	62	62	NUM
bptjm-17	397	45	%	%	NOUN
bptjm-17	397	46	)	)	PUNCT
bptjm-17	397	47	patients	patient	NOUN
bptjm-17	397	48	were	be	AUX
bptjm-17	397	49	not	not	PART
bptjm-17	397	50	responsive	responsive	ADJ
bptjm-17	397	51	,	,	PUNCT
bptjm-17	397	52	but	but	CCONJ
bptjm-17	397	53	instead	instead	ADV
bptjm-17	397	54	exhibited	exhibit	VERB
bptjm-17	397	55	stabilization	stabilization	NOUN
bptjm-17	397	56	or	or	CCONJ
bptjm-17	397	57	disease	disease	NOUN
bptjm-17	397	58	progression	progression	NOUN
bptjm-17	397	59	.	.	PUNCT
bptjm-17	398	1	mir-125b	mir-125b	PROPN
bptjm-17	398	2	was	be	AUX
bptjm-17	398	3	signi	signi	ADV
bptjm-17	398	4	cantly	cantly	ADV
bptjm-17	398	5	associated	associate	VERB
bptjm-17	398	6	with	with	ADP
bptjm-17	398	7	chemotherapeutic	chemotherapeutic	ADJ
bptjm-17	398	8	response	response	NOUN
bptjm-17	398	9	,	,	PUNCT
bptjm-17	398	10	with	with	ADP
bptjm-17	398	11	nonresponsive	nonresponsive	ADJ
bptjm-17	398	12	patients	patient	NOUN
bptjm-17	398	13	exhibiting	exhibit	VERB
bptjm-17	398	14	signi	signi	ADJ
bptjm-17	398	15	cantly	cantly	ADV
bptjm-17	398	16	higher	high	ADJ
bptjm-17	398	17	expression	expression	NOUN
bptjm-17	398	18	levels	level	NOUN
bptjm-17	398	19	than	than	ADP
bptjm-17	398	20	responsive	responsive	ADJ
bptjm-17	398	21	patients	patient	NOUN
bptjm-17	398	22	(	(	PUNCT
bptjm-17	398	23	p=0.003	p=0.003	NOUN
bptjm-17	398	24	)	)	PUNCT
bptjm-17	398	25	.	.	PUNCT
bptjm-17	399	1	the	the	DET
bptjm-17	399	2	authors	author	NOUN
bptjm-17	399	3	postulate	postulate	VERB
bptjm-17	399	4	that	that	SCONJ
bptjm-17	399	5	mir-125b	mir-125b	PROPN
bptjm-17	399	6	may	may	AUX
bptjm-17	399	7	act	act	VERB
bptjm-17	399	8	as	as	ADP
bptjm-17	399	9	a	a	DET
bptjm-17	399	10	viable	viable	ADJ
bptjm-17	399	11	biomarker	biomarker	NOUN
bptjm-17	399	12	to	to	PART
bptjm-17	399	13	predict	predict	VERB
bptjm-17	399	14	chemotherapy	chemotherapy	NOUN
bptjm-17	399	15	resistance	resistance	NOUN
bptjm-17	399	16	.	.	PUNCT
bptjm-17	400	1	con	con	PROPN
bptjm-17	400	2	rming	rme	VERB
bptjm-17	400	3	this	this	DET
bptjm-17	400	4	observation	observation	NOUN
bptjm-17	400	5	,	,	PUNCT
bptjm-17	400	6	shi	shi	PROPN
bptjm-17	400	7	et	et	PROPN
bptjm-17	400	8	al	al	PROPN
bptjm-17	400	9	.	.	PROPN
bptjm-17	400	10	measured	measure	VERB
bptjm-17	400	11	the	the	DET
bptjm-17	400	12	relative	relative	ADJ
bptjm-17	400	13	expression	expression	NOUN
bptjm-17	400	14	of	of	ADP
bptjm-17	400	15	mir-125b	mir-125b	NOUN
bptjm-17	400	16	in	in	ADP
bptjm-17	400	17	74	74	NUM
bptjm-17	400	18	patients	patient	NOUN
bptjm-17	400	19	with	with	ADP
bptjm-17	400	20	advanced	advanced	ADJ
bptjm-17	400	21	nsclc	nsclc	NOUN
bptjm-17	400	22	preand	preand	NOUN
bptjm-17	400	23	post	post	NOUN
bptjm-17	400	24	chemotherapy	chemotherapy	NOUN
bptjm-17	400	25	using	use	VERB
bptjm-17	400	26	rt	rt	NOUN
bptjm-17	400	27	-	-	PUNCT
bptjm-17	400	28	qpcr	qpcr	ADV
bptjm-17	400	29	and	and	CCONJ
bptjm-17	400	30	noted	note	VERB
bptjm-17	400	31	that	that	SCONJ
bptjm-17	400	32	sensitivity	sensitivity	NOUN
bptjm-17	400	33	to	to	PART
bptjm-17	400	34	chemotherapy	chemotherapy	NOUN
bptjm-17	400	35	in	in	ADP
bptjm-17	400	36	nsclc	nsclc	NOUN
bptjm-17	400	37	patients	patient	NOUN
bptjm-17	400	38	with	with	ADP
bptjm-17	400	39	high	high	ADJ
bptjm-17	400	40	expression	expression	NOUN
bptjm-17	400	41	of	of	ADP
bptjm-17	400	42	mir-125b	mir-125b	PROPN
bptjm-17	400	43	was	be	AUX
bptjm-17	400	44	lower	low	ADJ
bptjm-17	400	45	than	than	ADP
bptjm-17	400	46	those	those	PRON
bptjm-17	400	47	with	with	ADP
bptjm-17	400	48	low	low	ADJ
bptjm-17	400	49	expression	expression	NOUN
bptjm-17	400	50	of	of	ADP
bptjm-17	400	51	mir-125b	mir-125b	X
bptjm-17	400	52	(	(	PUNCT
bptjm-17	400	53	p<.05	p<.05	NOUN
bptjm-17	400	54	)	)	PUNCT
bptjm-17	400	55	(	(	PUNCT
bptjm-17	400	56	2020	2020	NUM
bptjm-17	400	57	)	)	PUNCT
bptjm-17	400	58	.	.	PUNCT
bptjm-17	401	1	the	the	DET
bptjm-17	401	2	utility	utility	NOUN
bptjm-17	401	3	of	of	ADP
bptjm-17	401	4	mir-125	mir-125	NOUN
bptjm-17	401	5	to	to	PART
bptjm-17	401	6	predict	predict	VERB
bptjm-17	401	7	survival	survival	NOUN
bptjm-17	401	8	outcomes	outcome	NOUN
bptjm-17	401	9	has	have	AUX
bptjm-17	401	10	also	also	ADV
bptjm-17	401	11	been	be	AUX
bptjm-17	401	12	studied	study	VERB
bptjm-17	401	13	.	.	PUNCT
bptjm-17	402	1	yuxia	yuxia	PROPN
bptjm-17	402	2	et	et	PROPN
bptjm-17	402	3	al	al	PROPN
bptjm-17	402	4	.	.	PROPN
bptjm-17	403	1	compared	compare	VERB
bptjm-17	403	2	mir-125b	mir-125b	PROPN
bptjm-17	403	3	serum	serum	NOUN
bptjm-17	403	4	levels	level	NOUN
bptjm-17	403	5	in	in	ADP
bptjm-17	403	6	193	193	NUM
bptjm-17	403	7	patients	patient	NOUN
bptjm-17	403	8	with	with	ADP
bptjm-17	403	9	varying	vary	VERB
bptjm-17	403	10	stages	stage	NOUN
bptjm-17	403	11	of	of	ADP
bptjm-17	403	12	nsclc	nsclc	NOUN
bptjm-17	403	13	,	,	PUNCT
bptjm-17	403	14	following	follow	VERB
bptjm-17	403	15	surgery	surgery	NOUN
bptjm-17	403	16	and	and	CCONJ
bptjm-17	403	17	therapy	therapy	NOUN
bptjm-17	403	18	.	.	PUNCT
bptjm-17	404	1	patients	patient	NOUN
bptjm-17	404	2	with	with	ADP
bptjm-17	404	3	mir-125	mir-125	NOUN
bptjm-17	404	4	expression	expression	NOUN
bptjm-17	404	5	levels	level	NOUN
bptjm-17	404	6	lower	low	ADJ
bptjm-17	404	7	than	than	ADP
bptjm-17	404	8	2.79	2.79	NUM
bptjm-17	404	9	were	be	AUX
bptjm-17	404	10	put	put	VERB
bptjm-17	404	11	into	into	ADP
bptjm-17	404	12	the	the	DET
bptjm-17	404	13	low	low	ADJ
bptjm-17	404	14	-	-	PUNCT
bptjm-17	404	15	expression	expression	NOUN
bptjm-17	404	16	group	group	NOUN
bptjm-17	404	17	,	,	PUNCT
bptjm-17	404	18	and	and	CCONJ
bptjm-17	404	19	those	those	PRON
bptjm-17	404	20	above	above	ADV
bptjm-17	404	21	,	,	PUNCT
bptjm-17	404	22	in	in	ADP
bptjm-17	404	23	the	the	DET
bptjm-17	404	24	high	high	ADJ
bptjm-17	404	25	expression	expression	NOUN
bptjm-17	404	26	group	group	NOUN
bptjm-17	404	27	.	.	PUNCT
bptjm-17	405	1	kaplan	kaplan	PROPN
bptjm-17	405	2	-	-	PUNCT
bptjm-17	405	3	meier	meier	PROPN
bptjm-17	405	4	survival	survival	PROPN
bptjm-17	405	5	curves	curve	NOUN
bptjm-17	405	6	revealed	reveal	VERB
bptjm-17	405	7	that	that	SCONJ
bptjm-17	405	8	high	high	ADJ
bptjm-17	405	9	expression	expression	NOUN
bptjm-17	405	10	signi	signi	NOUN
bptjm-17	405	11	cantly	cantly	ADV
bptjm-17	405	12	correlated	correlate	VERB
bptjm-17	405	13	with	with	ADP
bptjm-17	405	14	poor	poor	ADJ
bptjm-17	405	15	survival	survival	NOUN
bptjm-17	405	16	(	(	PUNCT
bptjm-17	405	17	p	p	X
bptjm-17	405	18	<	<	X
bptjm-17	405	19	.	.	PROPN
bptjm-17	405	20	00001	00001	NUM
bptjm-17	405	21	)	)	PUNCT
bptjm-17	405	22	.	.	PUNCT
bptjm-17	406	1	multivariate	multivariate	NOUN
bptjm-17	406	2	cox	cox	PROPN
bptjm-17	406	3	hazard	hazard	NOUN
bptjm-17	406	4	analysis	analysis	NOUN
bptjm-17	406	5	also	also	ADV
bptjm-17	406	6	showed	show	VERB
bptjm-17	406	7	mir-125b	mir-125b	PUNCT
bptjm-17	406	8	to	to	PART
bptjm-17	406	9	be	be	AUX
bptjm-17	406	10	an	an	DET
bptjm-17	406	11	independent	independent	ADJ
bptjm-17	406	12	prognostic	prognostic	ADJ
bptjm-17	406	13	marker	marker	NOUN
bptjm-17	406	14	on	on	ADP
bptjm-17	406	15	nsclc	nsclc	NOUN
bptjm-17	406	16	(	(	PUNCT
bptjm-17	406	17	yuxia	yuxia	PROPN
bptjm-17	406	18	et	et	PROPN
bptjm-17	406	19	al	al	PROPN
bptjm-17	406	20	.	.	PROPN
bptjm-17	406	21	,	,	PUNCT
bptjm-17	406	22	2012	2012	NUM
bptjm-17	406	23	)	)	PUNCT
bptjm-17	406	24	.	.	PUNCT
bptjm-17	407	1	berkeley	berkeley	PROPN
bptjm-17	407	2	pharma	pharma	PROPN
bptjm-17	407	3	tech	tech	PROPN
bptjm-17	407	4	journal	journal	NOUN
bptjm-17	407	5	of	of	ADP
bptjm-17	407	6	medicine	medicine	NOUN
bptjm-17	407	7	|	|	ADV
bptjm-17	407	8	140	140	NUM
bptjm-17	407	9	mir-145	mir-145	NOUN
bptjm-17	407	10	mir-145	mir-145	NOUN
bptjm-17	407	11	has	have	AUX
bptjm-17	407	12	been	be	AUX
bptjm-17	407	13	reported	report	VERB
bptjm-17	407	14	to	to	PART
bptjm-17	407	15	have	have	AUX
bptjm-17	407	16	decreased	decrease	VERB
bptjm-17	407	17	levels	level	NOUN
bptjm-17	407	18	in	in	ADP
bptjm-17	407	19	many	many	ADJ
bptjm-17	407	20	di	di	NOUN
bptjm-17	407	21	erent	erent	NOUN
bptjm-17	407	22	cancers	cancer	NOUN
bptjm-17	407	23	,	,	PUNCT
bptjm-17	407	24	such	such	ADJ
bptjm-17	407	25	as	as	ADP
bptjm-17	407	26	pancreatic	pancreatic	ADJ
bptjm-17	407	27	cancer	cancer	NOUN
bptjm-17	407	28	,	,	PUNCT
bptjm-17	407	29	prostate	prostate	NOUN
bptjm-17	407	30	cancer	cancer	NOUN
bptjm-17	407	31	,	,	PUNCT
bptjm-17	407	32	breast	breast	NOUN
bptjm-17	407	33	cancer	cancer	NOUN
bptjm-17	407	34	,	,	PUNCT
bptjm-17	407	35	and	and	CCONJ
bptjm-17	407	36	colorectal	colorectal	ADJ
bptjm-17	407	37	cancer	cancer	NOUN
bptjm-17	407	38	(	(	PUNCT
bptjm-17	407	39	liu	liu	PROPN
bptjm-17	407	40	et	et	PROPN
bptjm-17	407	41	al	al	PROPN
bptjm-17	407	42	.	.	PROPN
bptjm-17	407	43	,	,	PUNCT
bptjm-17	407	44	2018	2018	NUM
bptjm-17	407	45	)	)	PUNCT
bptjm-17	407	46	.	.	PUNCT
bptjm-17	408	1	mir-145	mir-145	PROPN
bptjm-17	408	2	’s	’s	PART
bptjm-17	408	3	tumor	tumor	NOUN
bptjm-17	408	4	suppressive	suppressive	ADJ
bptjm-17	408	5	abilities	ability	NOUN
bptjm-17	408	6	and	and	CCONJ
bptjm-17	408	7	its	its	PRON
bptjm-17	408	8	prevalence	prevalence	NOUN
bptjm-17	408	9	in	in	ADP
bptjm-17	408	10	many	many	ADJ
bptjm-17	408	11	types	type	NOUN
bptjm-17	408	12	of	of	ADP
bptjm-17	408	13	cancer	cancer	NOUN
bptjm-17	408	14	makes	make	VERB
bptjm-17	408	15	it	it	PRON
bptjm-17	408	16	a	a	DET
bptjm-17	408	17	potential	potential	ADJ
bptjm-17	408	18	biomarker	biomarker	NOUN
bptjm-17	408	19	for	for	ADP
bptjm-17	408	20	prognosis	prognosis	NOUN
bptjm-17	408	21	.	.	PUNCT
bptjm-17	409	1	a	a	DET
bptjm-17	409	2	study	study	NOUN
bptjm-17	409	3	on	on	ADP
bptjm-17	409	4	immune	immune	ADJ
bptjm-17	409	5	responses	response	NOUN
bptjm-17	409	6	and	and	CCONJ
bptjm-17	409	7	cancer	cancer	NOUN
bptjm-17	409	8	progression	progression	NOUN
bptjm-17	409	9	assessed	assess	VERB
bptjm-17	409	10	345	345	NUM
bptjm-17	409	11	nsclc	nsclc	NOUN
bptjm-17	409	12	patients	patient	NOUN
bptjm-17	409	13	and	and	CCONJ
bptjm-17	409	14	focused	focus	VERB
bptjm-17	409	15	on	on	ADP
bptjm-17	409	16	a	a	DET
bptjm-17	409	17	5	5	NUM
bptjm-17	409	18	mirna	mirna	NOUN
bptjm-17	409	19	panel	panel	NOUN
bptjm-17	409	20	,	,	PUNCT
bptjm-17	409	21	which	which	PRON
bptjm-17	409	22	consisted	consist	VERB
bptjm-17	409	23	of	of	ADP
bptjm-17	409	24	mir-191	mir-191	NOUN
bptjm-17	409	25	,	,	PUNCT
bptjm-17	409	26	mir-28	mir-28	PROPN
bptjm-17	409	27	-	-	PUNCT
bptjm-17	409	28	3p	3p	NUM
bptjm-17	409	29	,	,	PUNCT
bptjm-17	409	30	mir-145	mir-145	NOUN
bptjm-17	409	31	,	,	PUNCT
bptjm-17	409	32	mir-328	mir-328	NOUN
bptjm-17	409	33	and	and	CCONJ
bptjm-17	409	34	mir-18a	mir-18a	NOUN
bptjm-17	409	35	.	.	PUNCT
bptjm-17	410	1	through	through	ADP
bptjm-17	410	2	the	the	DET
bptjm-17	410	3	use	use	NOUN
bptjm-17	410	4	of	of	ADP
bptjm-17	410	5	liquid	liquid	ADJ
bptjm-17	410	6	biopsy	biopsy	NOUN
bptjm-17	410	7	and	and	CCONJ
bptjm-17	410	8	pcr	pcr	NOUN
bptjm-17	410	9	,	,	PUNCT
bptjm-17	410	10	these	these	DET
bptjm-17	410	11	mirna	mirna	PROPN
bptjm-17	410	12	levels	level	NOUN
bptjm-17	410	13	were	be	AUX
bptjm-17	410	14	measured	measure	VERB
bptjm-17	410	15	;	;	PUNCT
bptjm-17	410	16	a	a	DET
bptjm-17	410	17	high	high	ADJ
bptjm-17	410	18	expression	expression	NOUN
bptjm-17	410	19	level	level	NOUN
bptjm-17	410	20	was	be	AUX
bptjm-17	410	21	de	de	ADV
bptjm-17	410	22	ned	ned	ADJ
bptjm-17	410	23	as	as	ADV
bptjm-17	410	24	greater	great	ADJ
bptjm-17	410	25	than	than	ADP
bptjm-17	410	26	80	80	NUM
bptjm-17	410	27	%	%	NOUN
bptjm-17	410	28	.	.	PUNCT
bptjm-17	411	1	the	the	DET
bptjm-17	411	2	median	median	ADJ
bptjm-17	411	3	survival	survival	NOUN
bptjm-17	411	4	time	time	NOUN
bptjm-17	411	5	for	for	ADP
bptjm-17	411	6	those	those	PRON
bptjm-17	411	7	with	with	ADP
bptjm-17	411	8	high	high	ADJ
bptjm-17	411	9	expression	expression	NOUN
bptjm-17	411	10	of	of	ADP
bptjm-17	411	11	all	all	DET
bptjm-17	411	12	5	5	NUM
bptjm-17	411	13	mirnas	mirna	NOUN
bptjm-17	411	14	was	be	AUX
bptjm-17	411	15	3.6	3.6	NUM
bptjm-17	411	16	to	to	PART
bptjm-17	411	17	5.7	5.7	NUM
bptjm-17	411	18	months	month	NOUN
bptjm-17	411	19	shorter	short	ADJ
bptjm-17	411	20	than	than	ADP
bptjm-17	411	21	those	those	PRON
bptjm-17	411	22	with	with	ADP
bptjm-17	411	23	low	low	ADJ
bptjm-17	411	24	expression	expression	NOUN
bptjm-17	411	25	.	.	PUNCT
bptjm-17	412	1	out	out	ADP
bptjm-17	412	2	of	of	ADP
bptjm-17	412	3	the	the	DET
bptjm-17	412	4	mirnas	mirna	NOUN
bptjm-17	412	5	investigated	investigate	VERB
bptjm-17	412	6	in	in	ADP
bptjm-17	412	7	the	the	DET
bptjm-17	412	8	study	study	NOUN
bptjm-17	412	9	,	,	PUNCT
bptjm-17	412	10	mir-145	mir-145	PROPN
bptjm-17	412	11	demonstrated	demonstrate	VERB
bptjm-17	412	12	higher	high	ADJ
bptjm-17	412	13	expression	expression	NOUN
bptjm-17	412	14	in	in	ADP
bptjm-17	412	15	normal	normal	ADJ
bptjm-17	412	16	patients	patient	NOUN
bptjm-17	412	17	than	than	ADP
bptjm-17	412	18	in	in	ADP
bptjm-17	412	19	nsclc	nsclc	NOUN
bptjm-17	412	20	patients	patient	NOUN
bptjm-17	412	21	.	.	PUNCT
bptjm-17	413	1	nevertheless	nevertheless	ADV
bptjm-17	413	2	,	,	PUNCT
bptjm-17	413	3	higher	high	ADJ
bptjm-17	413	4	levels	level	NOUN
bptjm-17	413	5	of	of	ADP
bptjm-17	413	6	mir-145	mir-145	NOUN
bptjm-17	413	7	in	in	ADP
bptjm-17	413	8	nsclc	nsclc	NOUN
bptjm-17	413	9	patients	patient	NOUN
bptjm-17	413	10	is	be	AUX
bptjm-17	413	11	associated	associate	VERB
bptjm-17	413	12	with	with	ADP
bptjm-17	413	13	poorer	poor	ADJ
bptjm-17	413	14	survival	survival	NOUN
bptjm-17	413	15	.	.	PUNCT
bptjm-17	414	1	high	high	ADJ
bptjm-17	414	2	mir-145	mir-145	NOUN
bptjm-17	414	3	expression	expression	NOUN
bptjm-17	414	4	had	have	VERB
bptjm-17	414	5	an	an	DET
bptjm-17	414	6	88.4	88.4	NUM
bptjm-17	414	7	%	%	NOUN
bptjm-17	414	8	3	3	NUM
bptjm-17	414	9	year	year	NOUN
bptjm-17	414	10	death	death	NOUN
bptjm-17	414	11	rate	rate	NOUN
bptjm-17	414	12	as	as	SCONJ
bptjm-17	414	13	opposed	oppose	VERB
bptjm-17	414	14	to	to	ADP
bptjm-17	414	15	low	low	ADJ
bptjm-17	414	16	mir-145	mir-145	NOUN
bptjm-17	414	17	expression	expression	NOUN
bptjm-17	414	18	which	which	PRON
bptjm-17	414	19	had	have	VERB
bptjm-17	414	20	an	an	DET
bptjm-17	414	21	79.2	79.2	NUM
bptjm-17	414	22	%	%	NOUN
bptjm-17	414	23	3	3	NUM
bptjm-17	414	24	year	year	NOUN
bptjm-17	414	25	death	death	NOUN
bptjm-17	414	26	rate	rate	NOUN
bptjm-17	414	27	(	(	PUNCT
bptjm-17	414	28	p	p	X
bptjm-17	414	29	=	=	SYM
bptjm-17	414	30	5.21e−03	5.21e−03	PROPN
bptjm-17	414	31	)	)	PUNCT
bptjm-17	414	32	.	.	PUNCT
bptjm-17	415	1	mir-145	mir-145	PROPN
bptjm-17	415	2	is	be	AUX
bptjm-17	415	3	associated	associate	VERB
bptjm-17	415	4	with	with	ADP
bptjm-17	415	5	ras	ras	PROPN
bptjm-17	415	6	,	,	PUNCT
bptjm-17	415	7	mitogen	mitogen	NOUN
bptjm-17	415	8	-	-	PUNCT
bptjm-17	415	9	activated	activate	VERB
bptjm-17	415	10	protein	protein	NOUN
bptjm-17	415	11	kinase	kinase	NOUN
bptjm-17	415	12	,	,	PUNCT
bptjm-17	415	13	atm	atm	ADJ
bptjm-17	415	14	and	and	CCONJ
bptjm-17	415	15	estrogen	estrogen	NOUN
bptjm-17	415	16	receptor	receptor	NOUN
bptjm-17	415	17	signaling	signal	VERB
bptjm-17	415	18	pathways	pathway	NOUN
bptjm-17	415	19	,	,	PUNCT
bptjm-17	415	20	which	which	PRON
bptjm-17	415	21	are	be	AUX
bptjm-17	415	22	closely	closely	ADV
bptjm-17	415	23	associated	associate	VERB
bptjm-17	415	24	with	with	ADP
bptjm-17	415	25	resistance	resistance	NOUN
bptjm-17	415	26	to	to	ADP
bptjm-17	415	27	chemoradiotherapy	chemoradiotherapy	PROPN
bptjm-17	415	28	and/or	and/or	CCONJ
bptjm-17	415	29	targeted	target	VERB
bptjm-17	415	30	therapy	therapy	NOUN
bptjm-17	415	31	in	in	ADP
bptjm-17	415	32	advanced	advanced	ADJ
bptjm-17	415	33	nsclc	nsclc	NOUN
bptjm-17	415	34	(	(	PUNCT
bptjm-17	415	35	zhang	zhang	PROPN
bptjm-17	415	36	et	et	PROPN
bptjm-17	415	37	al	al	PROPN
bptjm-17	415	38	.	.	PROPN
bptjm-17	415	39	,	,	PUNCT
bptjm-17	415	40	2019	2019	NUM
bptjm-17	415	41	)	)	PUNCT
bptjm-17	415	42	.	.	PUNCT
bptjm-17	416	1	mir-155	mir-155	PROPN
bptjm-17	416	2	mir-155	mir-155	PROPN
bptjm-17	416	3	is	be	AUX
bptjm-17	416	4	overexpressed	overexpresse	VERB
bptjm-17	416	5	in	in	ADP
bptjm-17	416	6	many	many	ADJ
bptjm-17	416	7	diseases	disease	NOUN
bptjm-17	416	8	and	and	CCONJ
bptjm-17	416	9	is	be	AUX
bptjm-17	416	10	signi	signi	ADJ
bptjm-17	416	11	ca	can	AUX
bptjm-17	416	12	nt	not	PART
bptjm-17	416	13	in	in	ADP
bptjm-17	416	14	carcinogenesis	carcinogenesis	NOUN
bptjm-17	416	15	.	.	PUNCT
bptjm-17	417	1	it	it	PRON
bptjm-17	417	2	is	be	AUX
bptjm-17	417	3	most	most	ADV
bptjm-17	417	4	commonly	commonly	ADV
bptjm-17	417	5	overexpressed	overexpresse	VERB
bptjm-17	417	6	in	in	ADP
bptjm-17	417	7	solid	solid	ADJ
bptjm-17	417	8	tumors	tumor	NOUN
bptjm-17	417	9	and	and	CCONJ
bptjm-17	417	10	hematopoietic	hematopoietic	ADJ
bptjm-17	417	11	malignancies	malignancy	NOUN
bptjm-17	417	12	.	.	PUNCT
bptjm-17	418	1	its	its	PRON
bptjm-17	418	2	overexpression	overexpression	NOUN
bptjm-17	418	3	in	in	ADP
bptjm-17	418	4	nsclc	nsclc	NOUN
bptjm-17	418	5	has	have	AUX
bptjm-17	418	6	foreshadowed	foreshadow	VERB
bptjm-17	418	7	its	its	PRON
bptjm-17	418	8	potential	potential	NOUN
bptjm-17	418	9	as	as	ADP
bptjm-17	418	10	a	a	DET
bptjm-17	418	11	biomarker	biomarker	NOUN
bptjm-17	418	12	for	for	ADP
bptjm-17	418	13	prognosis	prognosis	NOUN
bptjm-17	418	14	and	and	CCONJ
bptjm-17	418	15	predictive	predictive	ADJ
bptjm-17	418	16	purposes	purpose	NOUN
bptjm-17	418	17	.	.	PUNCT
bptjm-17	419	1	mir-155	mir-155	PROPN
bptjm-17	419	2	has	have	AUX
bptjm-17	419	3	exhibited	exhibit	VERB
bptjm-17	419	4	high	high	ADJ
bptjm-17	419	5	expression	expression	NOUN
bptjm-17	419	6	in	in	ADP
bptjm-17	419	7	nsclc	nsclc	NOUN
bptjm-17	419	8	patients	patient	NOUN
bptjm-17	419	9	and	and	CCONJ
bptjm-17	419	10	has	have	AUX
bptjm-17	419	11	been	be	AUX
bptjm-17	419	12	seen	see	VERB
bptjm-17	419	13	to	to	PART
bptjm-17	419	14	induce	induce	VERB
bptjm-17	419	15	proliferation	proliferation	NOUN
bptjm-17	419	16	of	of	ADP
bptjm-17	419	17	nsclc	nsclc	NOUN
bptjm-17	419	18	cancer	cancer	NOUN
bptjm-17	419	19	cells	cell	NOUN
bptjm-17	419	20	.	.	PUNCT
bptjm-17	420	1	in	in	ADP
bptjm-17	420	2	a	a	DET
bptjm-17	420	3	study	study	NOUN
bptjm-17	420	4	with	with	ADP
bptjm-17	420	5	180	180	NUM
bptjm-17	420	6	total	total	ADJ
bptjm-17	420	7	nsclc	nsclc	NOUN
bptjm-17	420	8	patients	patient	NOUN
bptjm-17	420	9	and	and	CCONJ
bptjm-17	420	10	80	80	NUM
bptjm-17	420	11	control	control	NOUN
bptjm-17	420	12	patients	patient	NOUN
bptjm-17	420	13	,	,	PUNCT
bptjm-17	420	14	mir-155	mir-155	NOUN
bptjm-17	420	15	and	and	CCONJ
bptjm-17	420	16	mir-21	mir-21	NOUN
bptjm-17	420	17	expression	expression	NOUN
bptjm-17	420	18	levels	level	NOUN
bptjm-17	420	19	were	be	AUX
bptjm-17	420	20	compared	compare	VERB
bptjm-17	420	21	between	between	ADP
bptjm-17	420	22	one	one	NUM
bptjm-17	420	23	group	group	NOUN
bptjm-17	420	24	of	of	ADP
bptjm-17	420	25	68	68	NUM
bptjm-17	420	26	newly	newly	ADV
bptjm-17	420	27	diagnosed	diagnose	VERB
bptjm-17	420	28	patients	patient	NOUN
bptjm-17	420	29	and	and	CCONJ
bptjm-17	420	30	112	112	NUM
bptjm-17	420	31	patients	patient	NOUN
bptjm-17	420	32	with	with	ADP
bptjm-17	420	33	recurrent	recurrent	ADJ
bptjm-17	420	34	or	or	CCONJ
bptjm-17	420	35	metastasized	metastasize	VERB
bptjm-17	420	36	nsclc	nsclc	NOUN
bptjm-17	420	37	.	.	PUNCT
bptjm-17	421	1	the	the	DET
bptjm-17	421	2	expression	expression	NOUN
bptjm-17	421	3	of	of	ADP
bptjm-17	421	4	mir-155	mir-155	PROPN
bptjm-17	421	5	and	and	CCONJ
bptjm-17	421	6	mir-21	mir-21	PROPN
bptjm-17	421	7	was	be	AUX
bptjm-17	421	8	higher	high	ADJ
bptjm-17	421	9	in	in	ADP
bptjm-17	421	10	those	those	PRON
bptjm-17	421	11	with	with	ADP
bptjm-17	421	12	nsclc	nsclc	NOUN
bptjm-17	421	13	when	when	SCONJ
bptjm-17	421	14	compared	compare	VERB
bptjm-17	421	15	to	to	ADP
bptjm-17	421	16	the	the	DET
bptjm-17	421	17	control	control	NOUN
bptjm-17	421	18	group	group	NOUN
bptjm-17	421	19	(	(	PUNCT
bptjm-17	421	20	p	p	X
bptjm-17	421	21	<	<	X
bptjm-17	421	22	0.01	0.01	NUM
bptjm-17	421	23	)	)	PUNCT
bptjm-17	421	24	,	,	PUNCT
bptjm-17	421	25	while	while	SCONJ
bptjm-17	421	26	expression	expression	NOUN
bptjm-17	421	27	of	of	ADP
bptjm-17	421	28	both	both	DET
bptjm-17	421	29	mir-155	mir-155	NOUN
bptjm-17	421	30	(	(	PUNCT
bptjm-17	421	31	p	p	X
bptjm-17	421	32	<	<	X
bptjm-17	421	33	0.05	0.05	NUM
bptjm-17	421	34	)	)	PUNCT
bptjm-17	421	35	and	and	CCONJ
bptjm-17	421	36	mir-21	mir-21	PROPN
bptjm-17	421	37	(	(	PUNCT
bptjm-17	421	38	p	p	X
bptjm-17	421	39	<	<	X
bptjm-17	421	40	0.01	0.01	NUM
bptjm-17	421	41	)	)	PUNCT
bptjm-17	421	42	was	be	AUX
bptjm-17	421	43	higher	high	ADJ
bptjm-17	421	44	in	in	ADP
bptjm-17	421	45	those	those	PRON
bptjm-17	421	46	in	in	ADP
bptjm-17	421	47	the	the	DET
bptjm-17	421	48	recurrence	recurrence	NOUN
bptjm-17	421	49	group	group	NOUN
bptjm-17	421	50	than	than	ADP
bptjm-17	421	51	those	those	PRON
bptjm-17	421	52	in	in	ADP
bptjm-17	421	53	the	the	DET
bptjm-17	421	54	newly	newly	ADV
bptjm-17	421	55	diagnosed	diagnose	VERB
bptjm-17	421	56	group	group	NOUN
bptjm-17	421	57	.	.	PUNCT
bptjm-17	422	1	higher	high	ADJ
bptjm-17	422	2	levels	level	NOUN
bptjm-17	422	3	of	of	ADP
bptjm-17	422	4	these	these	DET
bptjm-17	422	5	mirnas	mirna	NOUN
bptjm-17	422	6	were	be	AUX
bptjm-17	422	7	found	find	VERB
bptjm-17	422	8	to	to	ADP
bptjm-17	422	9	a	a	DET
bptjm-17	422	10	ect	ect	NOUN
bptjm-17	422	11	the	the	DET
bptjm-17	422	12	prognosis	prognosis	NOUN
bptjm-17	422	13	negatively	negatively	ADV
bptjm-17	422	14	,	,	PUNCT
bptjm-17	422	15	with	with	ADP
bptjm-17	422	16	a	a	DET
bptjm-17	422	17	mortality	mortality	NOUN
bptjm-17	422	18	rate	rate	NOUN
bptjm-17	422	19	of	of	ADP
bptjm-17	422	20	91.96	91.96	NUM
bptjm-17	422	21	%	%	NOUN
bptjm-17	422	22	and	and	CCONJ
bptjm-17	422	23	a	a	DET
bptjm-17	422	24	19	19	NUM
bptjm-17	422	25	month	month	NOUN
bptjm-17	422	26	median	median	ADJ
bptjm-17	422	27	survival	survival	NOUN
bptjm-17	422	28	time	time	NOUN
bptjm-17	422	29	in	in	ADP
bptjm-17	422	30	the	the	DET
bptjm-17	422	31	berkeley	berkeley	PROPN
bptjm-17	422	32	pharma	pharma	PROPN
bptjm-17	422	33	tech	tech	NOUN
bptjm-17	422	34	journal	journal	NOUN
bptjm-17	422	35	of	of	ADP
bptjm-17	422	36	medicine	medicine	NOUN
bptjm-17	422	37	|	|	ADV
bptjm-17	422	38	141	141	NUM
bptjm-17	422	39	recurrence	recurrence	NOUN
bptjm-17	422	40	group	group	NOUN
bptjm-17	422	41	compared	compare	VERB
bptjm-17	422	42	to	to	ADP
bptjm-17	422	43	a	a	DET
bptjm-17	422	44	57.35	57.35	NUM
bptjm-17	422	45	%	%	NOUN
bptjm-17	422	46	mortality	mortality	NOUN
bptjm-17	422	47	rate	rate	NOUN
bptjm-17	422	48	and	and	CCONJ
bptjm-17	422	49	a	a	DET
bptjm-17	422	50	28	28	NUM
bptjm-17	422	51	month	month	NOUN
bptjm-17	422	52	median	median	ADJ
bptjm-17	422	53	survival	survival	NOUN
bptjm-17	422	54	time	time	NOUN
bptjm-17	422	55	in	in	ADP
bptjm-17	422	56	the	the	DET
bptjm-17	422	57	newly	newly	ADV
bptjm-17	422	58	diagnosed	diagnose	VERB
bptjm-17	422	59	group	group	NOUN
bptjm-17	422	60	(	(	PUNCT
bptjm-17	422	61	p	p	X
bptjm-17	422	62	<	<	X
bptjm-17	422	63	0.05	0.05	NUM
bptjm-17	422	64	)	)	PUNCT
bptjm-17	422	65	(	(	PUNCT
bptjm-17	422	66	xu	xu	INTJ
bptjm-17	422	67	et	et	PROPN
bptjm-17	422	68	al	al	PROPN
bptjm-17	422	69	.	.	PROPN
bptjm-17	422	70	,	,	PUNCT
bptjm-17	422	71	2019	2019	NUM
bptjm-17	422	72	)	)	PUNCT
bptjm-17	422	73	.	.	PUNCT
bptjm-17	423	1	in	in	ADP
bptjm-17	423	2	combination	combination	NOUN
bptjm-17	423	3	of	of	ADP
bptjm-17	423	4	a	a	DET
bptjm-17	423	5	three	three	NUM
bptjm-17	423	6	-	-	PUNCT
bptjm-17	423	7	mirna	mirna	NOUN
bptjm-17	423	8	signature	signature	NOUN
bptjm-17	423	9	panel	panel	NOUN
bptjm-17	423	10	of	of	ADP
bptjm-17	423	11	high	high	ADJ
bptjm-17	423	12	level	level	NOUN
bptjm-17	423	13	mir-155	mir-155	NOUN
bptjm-17	423	14	-	-	PUNCT
bptjm-17	423	15	5p	5p	ADJ
bptjm-17	423	16	,	,	PUNCT
bptjm-17	423	17	high	high	ADJ
bptjm-17	423	18	level	level	NOUN
bptjm-17	423	19	mir-223	mir-223	NOUN
bptjm-17	423	20	-	-	PUNCT
bptjm-17	423	21	3p	3p	NUM
bptjm-17	423	22	,	,	PUNCT
bptjm-17	423	23	and	and	CCONJ
bptjm-17	423	24	low	low	ADJ
bptjm-17	423	25	level	level	NOUN
bptjm-17	423	26	mir-199a-5p	mir-199a-5p	NOUN
bptjm-17	423	27	,	,	PUNCT
bptjm-17	423	28	there	there	PRON
bptjm-17	423	29	was	be	VERB
bptjm-17	423	30	a	a	DET
bptjm-17	423	31	mean	mean	ADJ
bptjm-17	423	32	dfs	dfs	NOUN
bptjm-17	423	33	of	of	ADP
bptjm-17	423	34	46	46	NUM
bptjm-17	423	35	months	month	NOUN
bptjm-17	423	36	in	in	ADP
bptjm-17	423	37	52	52	NUM
bptjm-17	423	38	resectable	resectable	ADJ
bptjm-17	423	39	nsclc	nsclc	NOUN
bptjm-17	423	40	patients	patient	NOUN
bptjm-17	423	41	(	(	PUNCT
bptjm-17	423	42	san	san	PROPN
bptjm-17	423	43	orenzo	orenzo	PROPN
bptjm-17	423	44	et	et	PROPN
bptjm-17	423	45	al	al	PROPN
bptjm-17	423	46	.	.	PROPN
bptjm-17	423	47	,	,	PUNCT
bptjm-17	423	48	2013	2013	NUM
bptjm-17	423	49	)	)	PUNCT
bptjm-17	423	50	.	.	PUNCT
bptjm-17	424	1	in	in	ADP
bptjm-17	424	2	three	three	NUM
bptjm-17	424	3	independent	independent	ADJ
bptjm-17	424	4	cohorts	cohort	NOUN
bptjm-17	424	5	of	of	ADP
bptjm-17	424	6	nsclc	nsclc	NOUN
bptjm-17	424	7	patients	patient	NOUN
bptjm-17	424	8	in	in	ADP
bptjm-17	424	9	maryland	maryland	PROPN
bptjm-17	424	10	,	,	PUNCT
bptjm-17	424	11	norway	norway	PROPN
bptjm-17	424	12	,	,	PUNCT
bptjm-17	424	13	and	and	CCONJ
bptjm-17	424	14	japan	japan	PROPN
bptjm-17	424	15	,	,	PUNCT
bptjm-17	424	16	mir-155	mir-155	PROPN
bptjm-17	424	17	was	be	AUX
bptjm-17	424	18	concluded	conclude	VERB
bptjm-17	424	19	in	in	ADP
bptjm-17	424	20	addition	addition	NOUN
bptjm-17	424	21	with	with	ADP
bptjm-17	424	22	mir-17	mir-17	NUM
bptjm-17	424	23	and	and	CCONJ
bptjm-17	424	24	mir-21	mir-21	PROPN
bptjm-17	424	25	in	in	ADP
bptjm-17	424	26	association	association	NOUN
bptjm-17	424	27	with	with	ADP
bptjm-17	424	28	mortality	mortality	NOUN
bptjm-17	424	29	rates	rate	NOUN
bptjm-17	424	30	and	and	CCONJ
bptjm-17	424	31	dfs	dfs	PROPN
bptjm-17	424	32	(	(	PUNCT
bptjm-17	424	33	saito	saito	PROPN
bptjm-17	424	34	et	et	PROPN
bptjm-17	424	35	al	al	PROPN
bptjm-17	424	36	.	.	PROPN
bptjm-17	424	37	,	,	PUNCT
bptjm-17	424	38	2011	2011	NUM
bptjm-17	424	39	)	)	PUNCT
bptjm-17	424	40	.	.	PUNCT
bptjm-17	425	1	the	the	DET
bptjm-17	425	2	prognosis	prognosis	NOUN
bptjm-17	425	3	impact	impact	NOUN
bptjm-17	425	4	of	of	ADP
bptjm-17	425	5	mir-155	mir-155	NOUN
bptjm-17	425	6	expression	expression	NOUN
bptjm-17	425	7	is	be	AUX
bptjm-17	425	8	in	in	SCONJ
bptjm-17	425	9	uenced	uence	VERB
bptjm-17	425	10	by	by	ADP
bptjm-17	425	11	other	other	ADJ
bptjm-17	425	12	factors	factor	NOUN
bptjm-17	425	13	as	as	ADV
bptjm-17	425	14	well	well	ADV
bptjm-17	425	15	.	.	PUNCT
bptjm-17	426	1	in	in	ADP
bptjm-17	426	2	another	another	DET
bptjm-17	426	3	study	study	NOUN
bptjm-17	426	4	,	,	PUNCT
bptjm-17	426	5	335	335	NUM
bptjm-17	426	6	nsclc	nsclc	NOUN
bptjm-17	426	7	patients	patient	NOUN
bptjm-17	426	8	were	be	AUX
bptjm-17	426	9	examined	examine	VERB
bptjm-17	426	10	,	,	PUNCT
bptjm-17	426	11	and	and	CCONJ
bptjm-17	426	12	it	it	PRON
bptjm-17	426	13	was	be	AUX
bptjm-17	426	14	discovered	discover	VERB
bptjm-17	426	15	that	that	SCONJ
bptjm-17	426	16	squamous	squamous	ADJ
bptjm-17	426	17	cell	cell	NOUN
bptjm-17	426	18	carcinoma	carcinoma	NOUN
bptjm-17	426	19	expressed	express	VERB
bptjm-17	426	20	higher	high	ADJ
bptjm-17	426	21	levels	level	NOUN
bptjm-17	426	22	of	of	ADP
bptjm-17	426	23	mir-155	mir-155	NOUN
bptjm-17	426	24	than	than	ADP
bptjm-17	426	25	adenocarcinomas	adenocarcinoma	NOUN
bptjm-17	426	26	.	.	PUNCT
bptjm-17	427	1	higher	high	ADJ
bptjm-17	427	2	mir-155	mir-155	NOUN
bptjm-17	427	3	expression	expression	NOUN
bptjm-17	427	4	has	have	VERB
bptjm-17	427	5	a	a	DET
bptjm-17	427	6	negative	negative	ADJ
bptjm-17	427	7	role	role	NOUN
bptjm-17	427	8	in	in	ADP
bptjm-17	427	9	disease	disease	NOUN
bptjm-17	427	10	speci	speci	PROPN
bptjm-17	427	11	c	c	PROPN
bptjm-17	427	12	survival	survival	PROPN
bptjm-17	427	13	(	(	PUNCT
bptjm-17	427	14	dss	dss	NOUN
bptjm-17	427	15	)	)	PUNCT
bptjm-17	427	16	prognosis	prognosis	NOUN
bptjm-17	427	17	in	in	ADP
bptjm-17	427	18	patients	patient	NOUN
bptjm-17	427	19	with	with	ADP
bptjm-17	427	20	adenocarcinomas	adenocarcinoma	NOUN
bptjm-17	427	21	,	,	PUNCT
bptjm-17	427	22	but	but	CCONJ
bptjm-17	427	23	a	a	DET
bptjm-17	427	24	positive	positive	ADJ
bptjm-17	427	25	role	role	NOUN
bptjm-17	427	26	in	in	ADP
bptjm-17	427	27	dss	dss	NOUN
bptjm-17	427	28	in	in	ADP
bptjm-17	427	29	patients	patient	NOUN
bptjm-17	427	30	with	with	ADP
bptjm-17	427	31	squamous	squamous	ADJ
bptjm-17	427	32	cell	cell	NOUN
bptjm-17	427	33	carcinomas	carcinoma	NOUN
bptjm-17	427	34	.	.	PUNCT
bptjm-17	428	1	the	the	DET
bptjm-17	428	2	median	median	ADJ
bptjm-17	428	3	survival	survival	NOUN
bptjm-17	428	4	for	for	ADP
bptjm-17	428	5	those	those	PRON
bptjm-17	428	6	with	with	ADP
bptjm-17	428	7	high	high	ADJ
bptjm-17	428	8	mir-155	mir-155	NOUN
bptjm-17	428	9	expression	expression	NOUN
bptjm-17	428	10	was	be	AUX
bptjm-17	428	11	84	84	NUM
bptjm-17	428	12	months	month	NOUN
bptjm-17	428	13	whereas	whereas	SCONJ
bptjm-17	428	14	the	the	DET
bptjm-17	428	15	median	median	ADJ
bptjm-17	428	16	survival	survival	NOUN
bptjm-17	428	17	rate	rate	NOUN
bptjm-17	428	18	for	for	ADP
bptjm-17	428	19	those	those	PRON
bptjm-17	428	20	with	with	ADP
bptjm-17	428	21	low	low	ADJ
bptjm-17	428	22	mir-155	mir-155	NOUN
bptjm-17	428	23	expression	expression	NOUN
bptjm-17	428	24	was	be	AUX
bptjm-17	428	25	190	190	NUM
bptjm-17	428	26	months	month	NOUN
bptjm-17	428	27	(	(	PUNCT
bptjm-17	428	28	p=0.43	p=0.43	NOUN
bptjm-17	428	29	)	)	PUNCT
bptjm-17	428	30	.	.	PUNCT
bptjm-17	429	1	thus	thus	ADV
bptjm-17	429	2	the	the	DET
bptjm-17	429	3	prognostic	prognostic	ADJ
bptjm-17	429	4	impact	impact	NOUN
bptjm-17	429	5	of	of	ADP
bptjm-17	429	6	mir-155	mir-155	X
bptjm-17	429	7	di	di	X
bptjm-17	429	8	ers	er	NOUN
bptjm-17	429	9	by	by	ADP
bptjm-17	429	10	histological	histological	ADJ
bptjm-17	429	11	subtype	subtype	NOUN
bptjm-17	429	12	(	(	PUNCT
bptjm-17	429	13	donnem	donnem	PROPN
bptjm-17	429	14	et	et	PROPN
bptjm-17	429	15	al	al	PROPN
bptjm-17	429	16	.	.	PROPN
bptjm-17	429	17	,	,	PUNCT
bptjm-17	429	18	2011	2011	NUM
bptjm-17	429	19	)	)	PUNCT
bptjm-17	429	20	.	.	PUNCT
bptjm-17	430	1	hana	hana	PROPN
bptjm-17	430	2	et	et	PROPN
bptjm-17	430	3	al	al	PROPN
bptjm-17	430	4	.	.	PROPN
bptjm-17	430	5	also	also	ADV
bptjm-17	430	6	found	find	VERB
bptjm-17	430	7	that	that	SCONJ
bptjm-17	430	8	in	in	ADP
bptjm-17	430	9	52	52	NUM
bptjm-17	430	10	patient	patient	NOUN
bptjm-17	430	11	serum	serum	NOUN
bptjm-17	430	12	samples	sample	NOUN
bptjm-17	430	13	high	high	ADJ
bptjm-17	430	14	mir-155	mir-155	NOUN
bptjm-17	430	15	expression	expression	NOUN
bptjm-17	430	16	level	level	NOUN
bptjm-17	430	17	correlated	correlate	VERB
bptjm-17	430	18	with	with	ADP
bptjm-17	430	19	poor	poor	ADJ
bptjm-17	430	20	prognosis	prognosis	NOUN
bptjm-17	430	21	,	,	PUNCT
bptjm-17	430	22	and	and	CCONJ
bptjm-17	430	23	is	be	AUX
bptjm-17	430	24	correlated	correlate	VERB
bptjm-17	430	25	with	with	ADP
bptjm-17	430	26	a	a	DET
bptjm-17	430	27	median	median	ADJ
bptjm-17	430	28	survival	survival	NOUN
bptjm-17	430	29	(	(	PUNCT
bptjm-17	430	30	ms	ms	NOUN
bptjm-17	430	31	)	)	PUNCT
bptjm-17	430	32	of	of	ADP
bptjm-17	430	33	69	69	NUM
bptjm-17	430	34	days	day	NOUN
bptjm-17	430	35	(	(	PUNCT
bptjm-17	430	36	p=0.034	p=0.034	X
bptjm-17	430	37	)	)	PUNCT
bptjm-17	430	38	in	in	ADP
bptjm-17	430	39	adenocarcinomas	adenocarcinoma	NOUN
bptjm-17	430	40	and	and	CCONJ
bptjm-17	430	41	a	a	DET
bptjm-17	430	42	ms	ms	NOUN
bptjm-17	430	43	of	of	ADP
bptjm-17	430	44	58	58	NUM
bptjm-17	430	45	days	day	NOUN
bptjm-17	430	46	(	(	PUNCT
bptjm-17	430	47	p=0.023	p=0.023	NUM
bptjm-17	430	48	)	)	PUNCT
bptjm-17	430	49	in	in	ADP
bptjm-17	430	50	patients	patient	NOUN
bptjm-17	430	51	with	with	ADP
bptjm-17	430	52	positive	positive	ADJ
bptjm-17	430	53	egfr	egfr	ADJ
bptjm-17	430	54	gene	gene	NOUN
bptjm-17	430	55	mutations	mutation	NOUN
bptjm-17	430	56	(	(	PUNCT
bptjm-17	430	57	hana	hana	PROPN
bptjm-17	430	58	et	et	PROPN
bptjm-17	430	59	al	al	PROPN
bptjm-17	430	60	.	.	PROPN
bptjm-17	430	61	,	,	PUNCT
bptjm-17	430	62	2020	2020	NUM
bptjm-17	430	63	)	)	PUNCT
bptjm-17	430	64	.	.	PUNCT
bptjm-17	431	1	mir-486	mir-486	PROPN
bptjm-17	431	2	while	while	SCONJ
bptjm-17	431	3	mir-486	mir-486	PROPN
bptjm-17	431	4	is	be	AUX
bptjm-17	431	5	widely	widely	ADV
bptjm-17	431	6	controversial	controversial	ADJ
bptjm-17	431	7	,	,	PUNCT
bptjm-17	431	8	with	with	ADP
bptjm-17	431	9	many	many	ADJ
bptjm-17	431	10	studies	study	NOUN
bptjm-17	431	11	reporting	report	VERB
bptjm-17	431	12	con	con	NOUN
bptjm-17	431	13	icting	icte	VERB
bptjm-17	431	14	results	result	NOUN
bptjm-17	431	15	in	in	ADP
bptjm-17	431	16	mir-486	mir-486	NOUN
bptjm-17	431	17	’s	’s	PART
bptjm-17	431	18	role	role	NOUN
bptjm-17	431	19	as	as	ADP
bptjm-17	431	20	an	an	DET
bptjm-17	431	21	oncogene	oncogene	NOUN
bptjm-17	431	22	or	or	CCONJ
bptjm-17	431	23	tumor	tumor	NOUN
bptjm-17	431	24	suppressor	suppressor	NOUN
bptjm-17	431	25	,	,	PUNCT
bptjm-17	431	26	it	it	PRON
bptjm-17	431	27	has	have	AUX
bptjm-17	431	28	been	be	AUX
bptjm-17	431	29	proven	prove	VERB
bptjm-17	431	30	to	to	PART
bptjm-17	431	31	be	be	AUX
bptjm-17	431	32	a	a	DET
bptjm-17	431	33	signi	signi	NOUN
bptjm-17	431	34	ca	can	AUX
bptjm-17	431	35	nt	not	PART
bptjm-17	431	36	,	,	PUNCT
bptjm-17	431	37	non	non	ADJ
bptjm-17	431	38	-	-	ADJ
bptjm-17	431	39	invasive	invasive	ADJ
bptjm-17	431	40	biomarker	biomarker	NOUN
bptjm-17	431	41	for	for	ADP
bptjm-17	431	42	prognosis	prognosis	NOUN
bptjm-17	431	43	.	.	PUNCT
bptjm-17	432	1	sromek	sromek	PROPN
bptjm-17	432	2	et	et	PROPN
bptjm-17	432	3	al	al	PROPN
bptjm-17	432	4	.	.	PROPN
bptjm-17	432	5	measured	measure	VERB
bptjm-17	432	6	mir-486	mir-486	ADJ
bptjm-17	432	7	levels	level	NOUN
bptjm-17	432	8	in	in	ADP
bptjm-17	432	9	patients	patient	NOUN
bptjm-17	432	10	that	that	PRON
bptjm-17	432	11	underwent	undergo	VERB
bptjm-17	432	12	tumor	tumor	NOUN
bptjm-17	432	13	resection	resection	NOUN
bptjm-17	432	14	and	and	CCONJ
bptjm-17	432	15	found	find	VERB
bptjm-17	432	16	increased	increase	VERB
bptjm-17	432	17	mir-486	mir-486	ADJ
bptjm-17	432	18	levels	level	NOUN
bptjm-17	432	19	expressed	express	VERB
bptjm-17	432	20	in	in	ADP
bptjm-17	432	21	their	their	PRON
bptjm-17	432	22	plasma	plasma	NOUN
bptjm-17	432	23	samples	sample	NOUN
bptjm-17	432	24	(	(	PUNCT
bptjm-17	432	25	n=14	n=14	NOUN
bptjm-17	432	26	)	)	PUNCT
bptjm-17	432	27	one	one	NUM
bptjm-17	432	28	year	year	NOUN
bptjm-17	432	29	after	after	ADP
bptjm-17	432	30	surgery	surgery	NOUN
bptjm-17	432	31	(	(	PUNCT
bptjm-17	432	32	sromek	sromek	NOUN
bptjm-17	432	33	et	et	PROPN
bptjm-17	432	34	al	al	PROPN
bptjm-17	432	35	.	.	PROPN
bptjm-17	432	36	,	,	PUNCT
bptjm-17	432	37	2017	2017	NUM
bptjm-17	432	38	)	)	PUNCT
bptjm-17	432	39	.	.	PUNCT
bptjm-17	433	1	a	a	DET
bptjm-17	433	2	meta	meta	ADJ
bptjm-17	433	3	-	-	PUNCT
bptjm-17	433	4	analysis	analysis	NOUN
bptjm-17	433	5	conducted	conduct	VERB
bptjm-17	433	6	by	by	ADP
bptjm-17	433	7	jiang	jiang	PROPN
bptjm-17	433	8	et	et	PROPN
bptjm-17	433	9	al	al	PROPN
bptjm-17	433	10	.	.	PUNCT
bptjm-17	434	1	among	among	ADP
bptjm-17	434	2	7	7	NUM
bptjm-17	434	3	studies	study	NOUN
bptjm-17	434	4	demonstrated	demonstrate	VERB
bptjm-17	434	5	that	that	SCONJ
bptjm-17	434	6	there	there	PRON
bptjm-17	434	7	was	be	VERB
bptjm-17	434	8	no	no	DET
bptjm-17	434	9	increased	increased	ADJ
bptjm-17	434	10	risk	risk	NOUN
bptjm-17	434	11	of	of	ADP
bptjm-17	434	12	poor	poor	ADJ
bptjm-17	434	13	outcome	outcome	NOUN
bptjm-17	434	14	with	with	ADP
bptjm-17	434	15	lower	low	ADJ
bptjm-17	434	16	expression	expression	NOUN
bptjm-17	434	17	of	of	ADP
bptjm-17	434	18	mir-486	mir-486	PROPN
bptjm-17	434	19	(	(	PUNCT
bptjm-17	434	20	jiang	jiang	PROPN
bptjm-17	434	21	et	et	PROPN
bptjm-17	434	22	al	al	PROPN
bptjm-17	434	23	.	.	PROPN
bptjm-17	434	24	,	,	PUNCT
bptjm-17	434	25	2018	2018	NUM
bptjm-17	434	26	)	)	PUNCT
bptjm-17	434	27	.	.	PUNCT
bptjm-17	435	1	poor	poor	ADJ
bptjm-17	435	2	outcome	outcome	NOUN
bptjm-17	435	3	was	be	AUX
bptjm-17	435	4	de	de	ADP
bptjm-17	435	5	ned	ned	ADJ
bptjm-17	435	6	using	use	VERB
bptjm-17	435	7	3	3	NUM
bptjm-17	435	8	factors	factor	NOUN
bptjm-17	435	9	:	:	PUNCT
bptjm-17	435	10	os	os	ADJ
bptjm-17	435	11	,	,	PUNCT
bptjm-17	435	12	pfs	pfs	PROPN
bptjm-17	435	13	,	,	PUNCT
bptjm-17	435	14	and	and	CCONJ
bptjm-17	435	15	rfs	rfs	PROPN
bptjm-17	435	16	.	.	X
bptjm-17	436	1	conversely	conversely	ADV
bptjm-17	436	2	,	,	PUNCT
bptjm-17	436	3	in	in	ADP
bptjm-17	436	4	a	a	DET
bptjm-17	436	5	study	study	NOUN
bptjm-17	436	6	by	by	ADP
bptjm-17	436	7	gao	gao	PROPN
bptjm-17	436	8	et	et	PROPN
bptjm-17	436	9	al	al	PROPN
bptjm-17	436	10	.	.	PROPN
bptjm-17	437	1	high	high	ADJ
bptjm-17	437	2	levels	level	NOUN
bptjm-17	437	3	of	of	ADP
bptjm-17	437	4	mir-486	mir-486	NOUN
bptjm-17	437	5	in	in	ADP
bptjm-17	437	6	140	140	NUM
bptjm-17	437	7	nsclc	nsclc	NOUN
bptjm-17	437	8	patients	patient	NOUN
bptjm-17	437	9	was	be	AUX
bptjm-17	437	10	directly	directly	ADV
bptjm-17	437	11	correlated	correlate	VERB
bptjm-17	437	12	with	with	ADP
bptjm-17	437	13	shorter	short	ADJ
bptjm-17	437	14	os	os	NOUN
bptjm-17	437	15	,	,	PUNCT
bptjm-17	437	16	speci	speci	PROPN
bptjm-17	437	17	cally	cally	ADV
bptjm-17	437	18	in	in	ADP
bptjm-17	437	19	stage	stage	NOUN
bptjm-17	437	20	i	i	PRON
bptjm-17	437	21	nsclc	nsclc	NOUN
bptjm-17	437	22	cancer	cancer	NOUN
bptjm-17	437	23	(	(	PUNCT
bptjm-17	437	24	gao	gao	PROPN
bptjm-17	437	25	et	et	PROPN
bptjm-17	437	26	al	al	PROPN
bptjm-17	437	27	.	.	PROPN
bptjm-17	437	28	,	,	PUNCT
bptjm-17	437	29	2020	2020	NUM
bptjm-17	437	30	)	)	PUNCT
bptjm-17	437	31	.	.	PUNCT
bptjm-17	438	1	when	when	SCONJ
bptjm-17	438	2	using	use	VERB
bptjm-17	438	3	berkeley	berkeley	PROPN
bptjm-17	438	4	pharma	pharma	PROPN
bptjm-17	438	5	tech	tech	NOUN
bptjm-17	438	6	journal	journal	NOUN
bptjm-17	438	7	of	of	ADP
bptjm-17	438	8	medicine	medicine	NOUN
bptjm-17	438	9	|	|	ADV
bptjm-17	438	10	142	142	NUM
bptjm-17	438	11	mir-486	mir-486	ADJ
bptjm-17	438	12	in	in	ADP
bptjm-17	438	13	combination	combination	NOUN
bptjm-17	438	14	with	with	ADP
bptjm-17	438	15	mir-30d	mir-30d	NUM
bptjm-17	438	16	,	,	PUNCT
bptjm-17	438	17	mir-1	mir-1	X
bptjm-17	438	18	,	,	PUNCT
bptjm-17	438	19	and	and	CCONJ
bptjm-17	438	20	mir-499	mir-499	X
bptjm-17	438	21	on	on	ADP
bptjm-17	438	22	a	a	DET
bptjm-17	438	23	4	4	NUM
bptjm-17	438	24	signature	signature	NOUN
bptjm-17	438	25	mirna	mirna	PROPN
bptjm-17	438	26	signature	signature	NOUN
bptjm-17	438	27	panel	panel	NOUN
bptjm-17	438	28	,	,	PUNCT
bptjm-17	438	29	high	high	ADJ
bptjm-17	438	30	serum	serum	NOUN
bptjm-17	438	31	levels	level	NOUN
bptjm-17	438	32	of	of	ADP
bptjm-17	438	33	mir-486	mir-486	NOUN
bptjm-17	438	34	also	also	ADV
bptjm-17	438	35	showed	show	VERB
bptjm-17	438	36	similar	similar	ADJ
bptjm-17	438	37	results	result	NOUN
bptjm-17	438	38	of	of	ADP
bptjm-17	438	39	unfavorable	unfavorable	ADJ
bptjm-17	438	40	survival	survival	NOUN
bptjm-17	438	41	.	.	PUNCT
bptjm-17	439	1	more	more	ADJ
bptjm-17	439	2	speci	speci	PROPN
bptjm-17	439	3	cally	cally	ADV
bptjm-17	439	4	,	,	PUNCT
bptjm-17	439	5	it	it	PRON
bptjm-17	439	6	was	be	AUX
bptjm-17	439	7	shown	show	VERB
bptjm-17	439	8	that	that	SCONJ
bptjm-17	439	9	within	within	ADP
bptjm-17	439	10	the	the	DET
bptjm-17	439	11	60	60	NUM
bptjm-17	439	12	patient	patient	ADJ
bptjm-17	439	13	cohort	cohort	NOUN
bptjm-17	439	14	,	,	PUNCT
bptjm-17	439	15	those	those	PRON
bptjm-17	439	16	that	that	PRON
bptjm-17	439	17	carried	carry	VERB
bptjm-17	439	18	two	two	NUM
bptjm-17	439	19	or	or	CCONJ
bptjm-17	439	20	more	more	ADJ
bptjm-17	439	21	of	of	ADP
bptjm-17	439	22	the	the	DET
bptjm-17	439	23	high	high	ADJ
bptjm-17	439	24	-	-	PUNCT
bptjm-17	439	25	risk	risk	NOUN
bptjm-17	439	26	mirna	mirna	NOUN
bptjm-17	439	27	would	would	AUX
bptjm-17	439	28	have	have	VERB
bptjm-17	439	29	signi	signi	VERB
bptjm-17	439	30	cantly	cantly	ADV
bptjm-17	439	31	shorter	short	ADJ
bptjm-17	439	32	survival	survival	NOUN
bptjm-17	439	33	(	(	PUNCT
bptjm-17	439	34	p	p	NOUN
bptjm-17	439	35	all	all	PRON
bptjm-17	439	36	<	<	X
bptjm-17	439	37	0.001	0.001	NUM
bptjm-17	439	38	)	)	PUNCT
bptjm-17	439	39	compared	compare	VERB
bptjm-17	439	40	to	to	ADP
bptjm-17	439	41	those	those	PRON
bptjm-17	439	42	who	who	PRON
bptjm-17	439	43	had	have	VERB
bptjm-17	439	44	none	none	NOUN
bptjm-17	439	45	or	or	CCONJ
bptjm-17	439	46	one	one	NUM
bptjm-17	439	47	high	high	ADJ
bptjm-17	439	48	-	-	PUNCT
bptjm-17	439	49	risk	risk	NOUN
bptjm-17	439	50	mirna	mirna	NOUN
bptjm-17	439	51	(	(	PUNCT
bptjm-17	439	52	hu	hu	PROPN
bptjm-17	439	53	et	et	PROPN
bptjm-17	439	54	al	al	PROPN
bptjm-17	439	55	.	.	PROPN
bptjm-17	439	56	,	,	PUNCT
bptjm-17	439	57	2010	2010	NUM
bptjm-17	439	58	)	)	PUNCT
bptjm-17	439	59	.	.	PUNCT
bptjm-17	440	1	in	in	ADP
bptjm-17	440	2	patients	patient	NOUN
bptjm-17	440	3	that	that	PRON
bptjm-17	440	4	showed	show	VERB
bptjm-17	440	5	down	down	ADV
bptjm-17	440	6	-	-	PUNCT
bptjm-17	440	7	regulated	regulate	VERB
bptjm-17	440	8	mir-486	mir-486	ADJ
bptjm-17	440	9	levels	level	NOUN
bptjm-17	440	10	in	in	ADP
bptjm-17	440	11	plasma	plasma	NOUN
bptjm-17	440	12	after	after	ADP
bptjm-17	440	13	surgical	surgical	ADJ
bptjm-17	440	14	removal	removal	NOUN
bptjm-17	440	15	of	of	ADP
bptjm-17	440	16	tumors	tumor	NOUN
bptjm-17	440	17	,	,	PUNCT
bptjm-17	440	18	the	the	DET
bptjm-17	440	19	recurrence	recurrence	NOUN
bptjm-17	440	20	free	free	ADJ
bptjm-17	440	21	survival	survival	NOUN
bptjm-17	440	22	(	(	PUNCT
bptjm-17	440	23	rfs	rfs	PROPN
bptjm-17	440	24	)	)	PUNCT
bptjm-17	440	25	was	be	AUX
bptjm-17	440	26	higher	high	ADJ
bptjm-17	440	27	than	than	ADP
bptjm-17	440	28	in	in	ADP
bptjm-17	440	29	those	those	PRON
bptjm-17	440	30	that	that	PRON
bptjm-17	440	31	had	have	VERB
bptjm-17	440	32	stagnant	stagnant	ADJ
bptjm-17	440	33	levels	level	NOUN
bptjm-17	440	34	of	of	ADP
bptjm-17	440	35	mir-486	mir-486	NOUN
bptjm-17	440	36	,	,	PUNCT
bptjm-17	440	37	the	the	DET
bptjm-17	440	38	un	un	ADJ
bptjm-17	440	39	-	-	ADJ
bptjm-17	440	40	reduced	reduced	ADJ
bptjm-17	440	41	group	group	NOUN
bptjm-17	440	42	,	,	PUNCT
bptjm-17	440	43	that	that	PRON
bptjm-17	440	44	did	do	AUX
bptjm-17	440	45	not	not	PART
bptjm-17	440	46	have	have	AUX
bptjm-17	440	47	reduced	reduce	VERB
bptjm-17	440	48	mir-486	mir-486	ADJ
bptjm-17	440	49	levels	level	NOUN
bptjm-17	440	50	or	or	CCONJ
bptjm-17	440	51	mir-486	mir-486	ADJ
bptjm-17	440	52	levels	level	NOUN
bptjm-17	440	53	did	do	AUX
bptjm-17	440	54	not	not	PART
bptjm-17	440	55	change	change	VERB
bptjm-17	440	56	.	.	PUNCT
bptjm-17	441	1	the	the	DET
bptjm-17	441	2	group	group	NOUN
bptjm-17	441	3	with	with	ADP
bptjm-17	441	4	down	down	ADV
bptjm-17	441	5	-	-	PUNCT
bptjm-17	441	6	regulated	regulate	VERB
bptjm-17	441	7	mir-486	mir-486	NOUN
bptjm-17	441	8	had	have	VERB
bptjm-17	441	9	a	a	DET
bptjm-17	441	10	median	median	ADJ
bptjm-17	441	11	unreached	unreached	ADJ
bptjm-17	441	12	survival	survival	NOUN
bptjm-17	441	13	,	,	PUNCT
bptjm-17	441	14	while	while	SCONJ
bptjm-17	441	15	the	the	DET
bptjm-17	441	16	un	un	ADJ
bptjm-17	441	17	-	-	ADJ
bptjm-17	441	18	reduced	reduced	ADJ
bptjm-17	441	19	group	group	NOUN
bptjm-17	441	20	had	have	VERB
bptjm-17	441	21	a	a	DET
bptjm-17	441	22	median	median	ADJ
bptjm-17	441	23	survival	survival	NOUN
bptjm-17	441	24	of	of	ADP
bptjm-17	441	25	19	19	NUM
bptjm-17	441	26	months	month	NOUN
bptjm-17	441	27	(	(	PUNCT
bptjm-17	441	28	p=0.056	p=0.056	NOUN
bptjm-17	441	29	)	)	PUNCT
bptjm-17	441	30	(	(	PUNCT
bptjm-17	441	31	li	li	PROPN
bptjm-17	441	32	et	et	PROPN
bptjm-17	441	33	al	al	PROPN
bptjm-17	441	34	.	.	PROPN
bptjm-17	441	35	,	,	PUNCT
bptjm-17	441	36	2015	2015	NUM
bptjm-17	441	37	)	)	PUNCT
bptjm-17	441	38	.	.	PUNCT
bptjm-17	442	1	in	in	ADP
bptjm-17	442	2	studies	study	NOUN
bptjm-17	442	3	that	that	PRON
bptjm-17	442	4	focused	focus	VERB
bptjm-17	442	5	on	on	ADP
bptjm-17	442	6	clinical	clinical	ADJ
bptjm-17	442	7	phenotype	phenotype	NOUN
bptjm-17	442	8	of	of	ADP
bptjm-17	442	9	metastasis	metastasis	NOUN
bptjm-17	442	10	,	,	PUNCT
bptjm-17	442	11	it	it	PRON
bptjm-17	442	12	was	be	AUX
bptjm-17	442	13	shown	show	VERB
bptjm-17	442	14	that	that	SCONJ
bptjm-17	442	15	mir-486	mir-486	ADJ
bptjm-17	442	16	-	-	PUNCT
bptjm-17	442	17	5p	5p	ADJ
bptjm-17	442	18	suppressed	suppress	VERB
bptjm-17	442	19	migration	migration	NOUN
bptjm-17	442	20	and	and	CCONJ
bptjm-17	442	21	invasion	invasion	NOUN
bptjm-17	442	22	abilities	ability	NOUN
bptjm-17	442	23	of	of	ADP
bptjm-17	442	24	nsclc	nsclc	NOUN
bptjm-17	442	25	cells	cell	NOUN
bptjm-17	442	26	,	,	PUNCT
bptjm-17	442	27	preventing	prevent	VERB
bptjm-17	442	28	cancer	cancer	NOUN
bptjm-17	442	29	progression	progression	NOUN
bptjm-17	442	30	and	and	CCONJ
bptjm-17	442	31	metastasis	metastasis	NOUN
bptjm-17	442	32	.	.	PUNCT
bptjm-17	443	1	in	in	ADP
bptjm-17	443	2	one	one	NUM
bptjm-17	443	3	study	study	NOUN
bptjm-17	443	4	,	,	PUNCT
bptjm-17	443	5	mir-486	mir-486	ADJ
bptjm-17	443	6	-	-	PUNCT
bptjm-17	443	7	5p	5p	NUM
bptjm-17	443	8	downregulated	downregulate	VERB
bptjm-17	443	9	nsclc	nsclc	NOUN
bptjm-17	443	10	through	through	ADP
bptjm-17	443	11	arhgap5	arhgap5	PROPN
bptjm-17	443	12	,	,	PUNCT
bptjm-17	443	13	a	a	DET
bptjm-17	443	14	protumorigenic	protumorigenic	ADJ
bptjm-17	443	15	gene	gene	NOUN
bptjm-17	443	16	.	.	PUNCT
bptjm-17	444	1	mir-486	mir-486	ADJ
bptjm-17	444	2	-	-	PUNCT
bptjm-17	444	3	5p	5p	PROPN
bptjm-17	444	4	had	have	VERB
bptjm-17	444	5	a	a	DET
bptjm-17	444	6	statistically	statistically	ADV
bptjm-17	444	7	signi	signi	NOUN
bptjm-17	444	8	ca	can	AUX
bptjm-17	444	9	nt	not	PART
bptjm-17	444	10	inverse	inverse	VERB
bptjm-17	444	11	relationship	relationship	NOUN
bptjm-17	444	12	with	with	ADP
bptjm-17	444	13	arhgap5	arhgap5	PROPN
bptjm-17	444	14	(	(	PUNCT
bptjm-17	444	15	p=0.0156	p=0.0156	PROPN
bptjm-17	444	16	)	)	PUNCT
bptjm-17	444	17	,	,	PUNCT
bptjm-17	444	18	which	which	PRON
bptjm-17	444	19	correlated	correlate	VERB
bptjm-17	444	20	with	with	ADP
bptjm-17	444	21	further	further	ADJ
bptjm-17	444	22	cancer	cancer	NOUN
bptjm-17	444	23	progression	progression	NOUN
bptjm-17	444	24	(	(	PUNCT
bptjm-17	444	25	n=76	n=76	ADJ
bptjm-17	444	26	,	,	PUNCT
bptjm-17	444	27	frozen	frozen	ADJ
bptjm-17	444	28	nsclc	nsclc	NOUN
bptjm-17	444	29	samples	sample	NOUN
bptjm-17	444	30	)	)	PUNCT
bptjm-17	445	1	(	(	PUNCT
bptjm-17	445	2	wang	wang	PROPN
bptjm-17	445	3	et	et	PROPN
bptjm-17	445	4	al	al	PROPN
bptjm-17	445	5	.	.	PROPN
bptjm-17	445	6	,	,	PUNCT
bptjm-17	445	7	2014	2014	NUM
bptjm-17	445	8	)	)	PUNCT
bptjm-17	445	9	.	.	PUNCT
bptjm-17	446	1	moreover	moreover	ADV
bptjm-17	446	2	,	,	PUNCT
bptjm-17	446	3	in	in	ADP
bptjm-17	446	4	correlation	correlation	NOUN
bptjm-17	446	5	with	with	ADP
bptjm-17	446	6	the	the	DET
bptjm-17	446	7	p13k	p13k	NOUN
bptjm-17	446	8	-	-	PUNCT
bptjm-17	446	9	akt	akt	NOUN
bptjm-17	446	10	signaling	signal	VERB
bptjm-17	446	11	pathway	pathway	NOUN
bptjm-17	446	12	,	,	PUNCT
bptjm-17	446	13	mir-486	mir-486	ADJ
bptjm-17	446	14	-	-	PUNCT
bptjm-17	446	15	5p	5p	NOUN
bptjm-17	446	16	and	and	CCONJ
bptjm-17	446	17	the	the	DET
bptjm-17	446	18	p13r1	p13r1	ADJ
bptjm-17	446	19	gene	gene	NOUN
bptjm-17	446	20	had	have	VERB
bptjm-17	446	21	regulatory	regulatory	ADJ
bptjm-17	446	22	e	e	NOUN
bptjm-17	446	23	ects	ect	NOUN
bptjm-17	446	24	.	.	PUNCT
bptjm-17	447	1	in	in	ADP
bptjm-17	447	2	a549	a549	PROPN
bptjm-17	447	3	and	and	CCONJ
bptjm-17	447	4	h1299	h1299	CCONJ
bptjm-17	447	5	mir-486	mir-486	ADJ
bptjm-17	447	6	-	-	PUNCT
bptjm-17	447	7	5p	5p	ADJ
bptjm-17	447	8	transfected	transfecte	VERB
bptjm-17	447	9	nsclc	nsclc	NOUN
bptjm-17	447	10	cell	cell	NOUN
bptjm-17	447	11	lines	line	NOUN
bptjm-17	447	12	,	,	PUNCT
bptjm-17	447	13	inhibited	inhibit	VERB
bptjm-17	447	14	a549	a549	PROPN
bptjm-17	447	15	and	and	CCONJ
bptjm-17	447	16	h1299	h1299	NOUN
bptjm-17	447	17	’s	’s	PART
bptjm-17	447	18	abilities	ability	NOUN
bptjm-17	447	19	of	of	ADP
bptjm-17	447	20	migration	migration	NOUN
bptjm-17	447	21	and	and	CCONJ
bptjm-17	447	22	invasion	invasion	NOUN
bptjm-17	447	23	after	after	ADP
bptjm-17	447	24	48	48	NUM
bptjm-17	447	25	hours	hour	NOUN
bptjm-17	447	26	(	(	PUNCT
bptjm-17	447	27	p	p	X
bptjm-17	447	28	<	<	X
bptjm-17	447	29	0.05	0.05	NUM
bptjm-17	447	30	)	)	PUNCT
bptjm-17	447	31	,	,	PUNCT
bptjm-17	447	32	showed	show	VERB
bptjm-17	447	33	higher	high	ADJ
bptjm-17	447	34	apoptosis	apoptosis	NOUN
bptjm-17	447	35	rates	rate	NOUN
bptjm-17	447	36	after	after	ADP
bptjm-17	447	37	72	72	NUM
bptjm-17	447	38	hours	hour	NOUN
bptjm-17	447	39	(	(	PUNCT
bptjm-17	447	40	p	p	X
bptjm-17	447	41	<	<	X
bptjm-17	447	42	0.05	0.05	NUM
bptjm-17	447	43	)	)	PUNCT
bptjm-17	447	44	,	,	PUNCT
bptjm-17	447	45	and	and	CCONJ
bptjm-17	447	46	inhibited	inhibit	VERB
bptjm-17	447	47	cell	cell	NOUN
bptjm-17	447	48	proliferation	proliferation	NOUN
bptjm-17	447	49	through	through	ADP
bptjm-17	447	50	mir-486	mir-486	ADJ
bptjm-17	447	51	-	-	PUNCT
bptjm-17	447	52	5p	5p	ADJ
bptjm-17	447	53	suppression	suppression	NOUN
bptjm-17	447	54	of	of	ADP
bptjm-17	447	55	p13r1	p13r1	ADJ
bptjm-17	447	56	(	(	PUNCT
bptjm-17	447	57	p	p	X
bptjm-17	447	58	<	<	X
bptjm-17	447	59	0.001	0.001	NUM
bptjm-17	447	60	)	)	PUNCT
bptjm-17	447	61	(	(	PUNCT
bptjm-17	447	62	tian	tian	PROPN
bptjm-17	447	63	et	et	PROPN
bptjm-17	447	64	al	al	PROPN
bptjm-17	447	65	.	.	PROPN
bptjm-17	447	66	,	,	PUNCT
bptjm-17	447	67	2019	2019	NUM
bptjm-17	447	68	)	)	PUNCT
bptjm-17	447	69	.	.	PUNCT
bptjm-17	448	1	furthermore	furthermore	ADV
bptjm-17	448	2	,	,	PUNCT
bptjm-17	448	3	it	it	PRON
bptjm-17	448	4	was	be	AUX
bptjm-17	448	5	found	find	VERB
bptjm-17	448	6	that	that	SCONJ
bptjm-17	448	7	mir-486	mir-486	ADJ
bptjm-17	448	8	-	-	PUNCT
bptjm-17	448	9	5p	5p	NUM
bptjm-17	448	10	was	be	AUX
bptjm-17	448	11	an	an	DET
bptjm-17	448	12	e	e	NOUN
bptjm-17	448	13	ective	ective	ADJ
bptjm-17	448	14	therapeutic	therapeutic	ADJ
bptjm-17	448	15	agent	agent	NOUN
bptjm-17	448	16	for	for	ADP
bptjm-17	448	17	cisplatin	cisplatin	NOUN
bptjm-17	448	18	resistant	resistant	ADJ
bptjm-17	448	19	nsclc	nsclc	NOUN
bptjm-17	448	20	treatment	treatment	NOUN
bptjm-17	448	21	.	.	PUNCT
bptjm-17	449	1	mir-486	mir-486	ADJ
bptjm-17	449	2	-	-	PUNCT
bptjm-17	449	3	5p	5p	PROPN
bptjm-17	449	4	improved	improve	VERB
bptjm-17	449	5	the	the	DET
bptjm-17	449	6	susceptibility	susceptibility	NOUN
bptjm-17	449	7	to	to	PART
bptjm-17	449	8	cisplatin	cisplatin	VERB
bptjm-17	449	9	through	through	ADP
bptjm-17	449	10	mir-486	mir-486	ADJ
bptjm-17	449	11	-	-	PUNCT
bptjm-17	449	12	5p	5p	VERB
bptjm-17	449	13	’s	’s	PART
bptjm-17	449	14	suppression	suppression	NOUN
bptjm-17	449	15	of	of	ADP
bptjm-17	449	16	twf1	twf1	NOUN
bptjm-17	449	17	,	,	PUNCT
bptjm-17	449	18	twin	twin	PROPN
bptjm-17	449	19	lin	lin	PROPN
bptjm-17	449	20	actin	actin	NOUN
bptjm-17	449	21	binding	bind	VERB
bptjm-17	449	22	protein	protein	NOUN
bptjm-17	449	23	1	1	NUM
bptjm-17	449	24	,	,	PUNCT
bptjm-17	449	25	a	a	DET
bptjm-17	449	26	gene	gene	NOUN
bptjm-17	449	27	that	that	PRON
bptjm-17	449	28	plays	play	VERB
bptjm-17	449	29	a	a	DET
bptjm-17	449	30	role	role	NOUN
bptjm-17	449	31	in	in	ADP
bptjm-17	449	32	tumor	tumor	NOUN
bptjm-17	449	33	invasion	invasion	NOUN
bptjm-17	449	34	and	and	CCONJ
bptjm-17	449	35	chemotherapy	chemotherapy	NOUN
bptjm-17	449	36	resistance	resistance	NOUN
bptjm-17	449	37	.	.	PUNCT
bptjm-17	450	1	an	an	DET
bptjm-17	450	2	in	in	ADP
bptjm-17	450	3	vivo	vivo	ADJ
bptjm-17	450	4	investigation	investigation	NOUN
bptjm-17	450	5	of	of	ADP
bptjm-17	450	6	cisplatin	cisplatin	NOUN
bptjm-17	450	7	resistance	resistance	NOUN
bptjm-17	450	8	showed	show	VERB
bptjm-17	450	9	that	that	SCONJ
bptjm-17	450	10	mir-486	mir-486	ADJ
bptjm-17	450	11	-	-	PUNCT
bptjm-17	450	12	5p	5p	ADJ
bptjm-17	450	13	expression	expression	NOUN
bptjm-17	450	14	correlated	correlate	VERB
bptjm-17	450	15	with	with	ADP
bptjm-17	450	16	reduced	reduced	ADJ
bptjm-17	450	17	tumor	tumor	NOUN
bptjm-17	450	18	size	size	NOUN
bptjm-17	450	19	in	in	ADP
bptjm-17	450	20	nude	nude	ADJ
bptjm-17	450	21	mice	mouse	NOUN
bptjm-17	450	22	(	(	PUNCT
bptjm-17	450	23	p	p	X
bptjm-17	450	24	<	<	X
bptjm-17	450	25	0.001	0.001	NUM
bptjm-17	450	26	)	)	PUNCT
bptjm-17	450	27	(	(	PUNCT
bptjm-17	450	28	jin	jin	NOUN
bptjm-17	450	29	et	et	PROPN
bptjm-17	450	30	al	al	PROPN
bptjm-17	450	31	.	.	PROPN
bptjm-17	450	32	,	,	PUNCT
bptjm-17	450	33	2019	2019	NUM
bptjm-17	450	34	)	)	PUNCT
bptjm-17	450	35	.	.	PUNCT
bptjm-17	451	1	conclusion	conclusion	NOUN
bptjm-17	451	2	in	in	ADP
bptjm-17	451	3	the	the	DET
bptjm-17	451	4	literature	literature	NOUN
bptjm-17	451	5	about	about	ADP
bptjm-17	451	6	mir	mir	PROPN
bptjm-17	451	7	,	,	PUNCT
bptjm-17	451	8	we	we	PRON
bptjm-17	451	9	found	find	VERB
bptjm-17	451	10	several	several	ADJ
bptjm-17	451	11	articles	article	NOUN
bptjm-17	451	12	that	that	PRON
bptjm-17	451	13	indicate	indicate	VERB
bptjm-17	451	14	signi	signi	NOUN
bptjm-17	451	15	ca	can	AUX
bptjm-17	451	16	nt	not	PART
bptjm-17	451	17	promise	promise	VERB
bptjm-17	451	18	for	for	ADP
bptjm-17	451	19	their	their	PRON
bptjm-17	451	20	utility	utility	NOUN
bptjm-17	451	21	as	as	ADP
bptjm-17	451	22	a	a	DET
bptjm-17	451	23	biomarker	biomarker	NOUN
bptjm-17	451	24	for	for	ADP
bptjm-17	451	25	prognosis	prognosis	NOUN
bptjm-17	451	26	,	,	PUNCT
bptjm-17	451	27	outcome	outcome	NOUN
bptjm-17	451	28	prediction	prediction	NOUN
bptjm-17	451	29	,	,	PUNCT
bptjm-17	451	30	or	or	CCONJ
bptjm-17	451	31	treatment	treatment	NOUN
bptjm-17	451	32	strategies	strategy	NOUN
bptjm-17	451	33	.	.	PUNCT
bptjm-17	452	1	first	first	ADV
bptjm-17	452	2	,	,	PUNCT
bptjm-17	452	3	recent	recent	ADJ
bptjm-17	452	4	studies	study	NOUN
bptjm-17	452	5	regarding	regard	VERB
bptjm-17	452	6	mir	mir	PROPN
bptjm-17	452	7	berkeley	berkeley	PROPN
bptjm-17	452	8	pharma	pharma	PROPN
bptjm-17	452	9	tech	tech	NOUN
bptjm-17	452	10	journal	journal	NOUN
bptjm-17	452	11	of	of	ADP
bptjm-17	452	12	medicine	medicine	NOUN
bptjm-17	452	13	|	|	ADV
bptjm-17	452	14	143	143	NUM
bptjm-17	452	15	biomarkers	biomarker	NOUN
bptjm-17	452	16	have	have	AUX
bptjm-17	452	17	begun	begin	VERB
bptjm-17	452	18	to	to	PART
bptjm-17	452	19	diversify	diversify	VERB
bptjm-17	452	20	from	from	ADP
bptjm-17	452	21	general	general	ADJ
bptjm-17	452	22	metrics	metric	NOUN
bptjm-17	452	23	such	such	ADJ
bptjm-17	452	24	as	as	ADP
bptjm-17	452	25	os	os	NOUN
bptjm-17	452	26	.	.	PUNCT
bptjm-17	453	1	more	more	ADJ
bptjm-17	453	2	speci	speci	NOUN
bptjm-17	453	3	c	c	NOUN
bptjm-17	453	4	metrics	metric	NOUN
bptjm-17	453	5	now	now	ADV
bptjm-17	453	6	include	include	VERB
bptjm-17	453	7	predicting	predict	VERB
bptjm-17	453	8	tumor	tumor	NOUN
bptjm-17	453	9	recurrence	recurrence	NOUN
bptjm-17	453	10	,	,	PUNCT
bptjm-17	453	11	resistance	resistance	NOUN
bptjm-17	453	12	to	to	ADP
bptjm-17	453	13	treatments	treatment	NOUN
bptjm-17	453	14	,	,	PUNCT
bptjm-17	453	15	medication	medication	NOUN
bptjm-17	453	16	performance	performance	NOUN
bptjm-17	453	17	,	,	PUNCT
bptjm-17	453	18	and	and	CCONJ
bptjm-17	453	19	much	much	ADV
bptjm-17	453	20	more	more	ADJ
bptjm-17	453	21	.	.	PUNCT
bptjm-17	454	1	second	second	ADV
bptjm-17	454	2	,	,	PUNCT
bptjm-17	454	3	the	the	DET
bptjm-17	454	4	articles	article	NOUN
bptjm-17	454	5	we	we	PRON
bptjm-17	454	6	reviewed	review	VERB
bptjm-17	454	7	have	have	AUX
bptjm-17	454	8	indicated	indicate	VERB
bptjm-17	454	9	mir	mir	NOUN
bptjm-17	454	10	testing	testing	NOUN
bptjm-17	454	11	to	to	PART
bptjm-17	454	12	be	be	AUX
bptjm-17	454	13	feasible	feasible	ADJ
bptjm-17	454	14	in	in	ADP
bptjm-17	454	15	most	most	ADJ
bptjm-17	454	16	clinical	clinical	ADJ
bptjm-17	454	17	settings	setting	NOUN
bptjm-17	454	18	.	.	PUNCT
bptjm-17	455	1	we	we	PRON
bptjm-17	455	2	found	find	VERB
bptjm-17	455	3	the	the	DET
bptjm-17	455	4	measurement	measurement	NOUN
bptjm-17	455	5	of	of	ADP
bptjm-17	455	6	mir	mir	PROPN
bptjm-17	455	7	typically	typically	ADV
bptjm-17	455	8	involves	involve	VERB
bptjm-17	455	9	some	some	DET
bptjm-17	455	10	variation	variation	NOUN
bptjm-17	455	11	of	of	ADP
bptjm-17	455	12	pcr	pcr	ADJ
bptjm-17	455	13	procedure	procedure	NOUN
bptjm-17	455	14	performed	perform	VERB
bptjm-17	455	15	on	on	ADP
bptjm-17	455	16	plasma	plasma	NOUN
bptjm-17	455	17	,	,	PUNCT
bptjm-17	455	18	serum	serum	NOUN
bptjm-17	455	19	,	,	PUNCT
bptjm-17	455	20	and	and	CCONJ
bptjm-17	455	21	saliva	saliva	NOUN
bptjm-17	455	22	samples	sample	NOUN
bptjm-17	455	23	.	.	PUNCT
bptjm-17	456	1	lastly	lastly	ADV
bptjm-17	456	2	,	,	PUNCT
bptjm-17	456	3	while	while	SCONJ
bptjm-17	456	4	we	we	PRON
bptjm-17	456	5	failed	fail	VERB
bptjm-17	456	6	to	to	PART
bptjm-17	456	7	observe	observe	VERB
bptjm-17	456	8	standardization	standardization	NOUN
bptjm-17	456	9	in	in	ADP
bptjm-17	456	10	the	the	DET
bptjm-17	456	11	studies	study	NOUN
bptjm-17	456	12	we	we	PRON
bptjm-17	456	13	reviewed	review	VERB
bptjm-17	456	14	,	,	PUNCT
bptjm-17	456	15	each	each	DET
bptjm-17	456	16	independent	independent	ADJ
bptjm-17	456	17	study	study	NOUN
bptjm-17	456	18	demonstrated	demonstrate	VERB
bptjm-17	456	19	signi	signi	ADJ
bptjm-17	456	20	ca	can	AUX
bptjm-17	456	21	nt	not	PART
bptjm-17	456	22	promise	promise	VERB
bptjm-17	456	23	for	for	ADP
bptjm-17	456	24	mir	mir	NOUN
bptjm-17	456	25	utility	utility	NOUN
bptjm-17	456	26	as	as	ADP
bptjm-17	456	27	a	a	DET
bptjm-17	456	28	biomarker	biomarker	NOUN
bptjm-17	456	29	for	for	ADP
bptjm-17	456	30	prognosis	prognosis	NOUN
bptjm-17	456	31	,	,	PUNCT
bptjm-17	456	32	outcome	outcome	NOUN
bptjm-17	456	33	prediction	prediction	NOUN
bptjm-17	456	34	,	,	PUNCT
bptjm-17	456	35	or	or	CCONJ
bptjm-17	456	36	treatment	treatment	NOUN
bptjm-17	456	37	strategies	strategy	NOUN
bptjm-17	456	38	.	.	PUNCT
bptjm-17	457	1	these	these	DET
bptjm-17	457	2	studies	study	NOUN
bptjm-17	457	3	consisted	consist	VERB
bptjm-17	457	4	of	of	ADP
bptjm-17	457	5	large	large	ADJ
bptjm-17	457	6	sample	sample	NOUN
bptjm-17	457	7	sizes	size	NOUN
bptjm-17	457	8	with	with	ADP
bptjm-17	457	9	little	little	ADJ
bptjm-17	457	10	error	error	NOUN
bptjm-17	457	11	indicated	indicate	VERB
bptjm-17	457	12	in	in	ADP
bptjm-17	457	13	the	the	DET
bptjm-17	457	14	observed	observe	VERB
bptjm-17	457	15	results	result	NOUN
bptjm-17	457	16	.	.	PUNCT
bptjm-17	458	1	if	if	SCONJ
bptjm-17	458	2	these	these	DET
bptjm-17	458	3	studies	study	NOUN
bptjm-17	458	4	are	be	AUX
bptjm-17	458	5	veri	veri	PROPN
bptjm-17	458	6	ed	ed	NOUN
bptjm-17	458	7	,	,	PUNCT
bptjm-17	458	8	they	they	PRON
bptjm-17	458	9	present	present	VERB
bptjm-17	458	10	great	great	ADJ
bptjm-17	458	11	potential	potential	NOUN
bptjm-17	458	12	for	for	ADP
bptjm-17	458	13	mir	mir	ADJ
bptjm-17	458	14	biomarkers	biomarker	NOUN
bptjm-17	458	15	that	that	PRON
bptjm-17	458	16	would	would	AUX
bptjm-17	458	17	assist	assist	VERB
bptjm-17	458	18	clinicians	clinician	NOUN
bptjm-17	458	19	in	in	ADP
bptjm-17	458	20	determining	determine	VERB
bptjm-17	458	21	treatment	treatment	NOUN
bptjm-17	458	22	strategies	strategy	NOUN
bptjm-17	458	23	.	.	PUNCT
bptjm-17	459	1	similar	similar	ADJ
bptjm-17	459	2	trends	trend	NOUN
bptjm-17	459	3	were	be	AUX
bptjm-17	459	4	found	find	VERB
bptjm-17	459	5	in	in	ADP
bptjm-17	459	6	the	the	DET
bptjm-17	459	7	ctdna	ctdna	NOUN
bptjm-17	459	8	literature	literature	NOUN
bptjm-17	459	9	.	.	PUNCT
bptjm-17	460	1	our	our	PRON
bptjm-17	460	2	review	review	NOUN
bptjm-17	460	3	paper	paper	NOUN
bptjm-17	460	4	noted	note	VERB
bptjm-17	460	5	that	that	SCONJ
bptjm-17	460	6	many	many	ADJ
bptjm-17	460	7	ctdna	ctdna	NOUN
bptjm-17	460	8	biomarkers	biomarker	NOUN
bptjm-17	460	9	indicate	indicate	VERB
bptjm-17	460	10	predictive	predictive	ADJ
bptjm-17	460	11	outcomes	outcome	NOUN
bptjm-17	460	12	including	include	VERB
bptjm-17	460	13	pfs	pfs	PROPN
bptjm-17	460	14	and	and	CCONJ
bptjm-17	460	15	os	os	NOUN
bptjm-17	460	16	.	.	PUNCT
bptjm-17	461	1	many	many	ADJ
bptjm-17	461	2	ctdnas	ctdna	NOUN
bptjm-17	461	3	are	be	AUX
bptjm-17	461	4	used	use	VERB
bptjm-17	461	5	for	for	ADP
bptjm-17	461	6	directing	direct	VERB
bptjm-17	461	7	the	the	DET
bptjm-17	461	8	course	course	NOUN
bptjm-17	461	9	of	of	ADP
bptjm-17	461	10	treatment	treatment	NOUN
bptjm-17	461	11	,	,	PUNCT
bptjm-17	461	12	including	include	VERB
bptjm-17	461	13	met	meet	VERB
bptjm-17	461	14	,	,	PUNCT
bptjm-17	461	15	brca	brca	PROPN
bptjm-17	461	16	,	,	PUNCT
bptjm-17	461	17	pten	pten	ADJ
bptjm-17	461	18	,	,	PUNCT
bptjm-17	461	19	and	and	CCONJ
bptjm-17	461	20	egfr	egfr	X
bptjm-17	461	21	.	.	PUNCT
bptjm-17	462	1	this	this	PRON
bptjm-17	462	2	is	be	AUX
bptjm-17	462	3	often	often	ADV
bptjm-17	462	4	because	because	SCONJ
bptjm-17	462	5	abnormal	abnormal	ADJ
bptjm-17	462	6	expression	expression	NOUN
bptjm-17	462	7	of	of	ADP
bptjm-17	462	8	these	these	DET
bptjm-17	462	9	biomarkers	biomarker	NOUN
bptjm-17	462	10	can	can	AUX
bptjm-17	462	11	lead	lead	VERB
bptjm-17	462	12	to	to	ADP
bptjm-17	462	13	resistance	resistance	NOUN
bptjm-17	462	14	,	,	PUNCT
bptjm-17	462	15	which	which	PRON
bptjm-17	462	16	requires	require	VERB
bptjm-17	462	17	the	the	DET
bptjm-17	462	18	use	use	NOUN
bptjm-17	462	19	of	of	ADP
bptjm-17	462	20	alternate	alternate	ADJ
bptjm-17	462	21	therapies	therapy	NOUN
bptjm-17	462	22	.	.	PUNCT
bptjm-17	463	1	furthermore	furthermore	ADV
bptjm-17	463	2	,	,	PUNCT
bptjm-17	463	3	while	while	SCONJ
bptjm-17	463	4	comparing	compare	VERB
bptjm-17	463	5	ctdna	ctdna	NOUN
bptjm-17	463	6	from	from	ADP
bptjm-17	463	7	liquid	liquid	ADJ
bptjm-17	463	8	biopsies	biopsy	NOUN
bptjm-17	463	9	with	with	ADP
bptjm-17	463	10	tissue	tissue	NOUN
bptjm-17	463	11	biopsies	biopsy	NOUN
bptjm-17	463	12	,	,	PUNCT
bptjm-17	463	13	we	we	PRON
bptjm-17	463	14	found	find	VERB
bptjm-17	463	15	high	high	ADJ
bptjm-17	463	16	concordance	concordance	NOUN
bptjm-17	463	17	rates	rate	NOUN
bptjm-17	463	18	between	between	ADP
bptjm-17	463	19	liquid	liquid	ADJ
bptjm-17	463	20	biopsies	biopsy	NOUN
bptjm-17	463	21	and	and	CCONJ
bptjm-17	463	22	tissue	tissue	NOUN
bptjm-17	463	23	biopsies	biopsy	NOUN
bptjm-17	463	24	.	.	PUNCT
bptjm-17	464	1	there	there	PRON
bptjm-17	464	2	is	be	VERB
bptjm-17	464	3	a	a	DET
bptjm-17	464	4	96.2	96.2	NUM
bptjm-17	464	5	%	%	NOUN
bptjm-17	464	6	concordance	concordance	NOUN
bptjm-17	464	7	rate	rate	NOUN
bptjm-17	464	8	between	between	ADP
bptjm-17	464	9	liquid	liquid	ADJ
bptjm-17	464	10	and	and	CCONJ
bptjm-17	464	11	tissue	tissue	NOUN
bptjm-17	464	12	biopsies	biopsy	NOUN
bptjm-17	464	13	for	for	ADP
bptjm-17	464	14	ret	ret	NOUN
bptjm-17	464	15	and	and	CCONJ
bptjm-17	464	16	ros1	ros1	PROPN
bptjm-17	464	17	and	and	CCONJ
bptjm-17	464	18	an	an	DET
bptjm-17	464	19	81.6	81.6	NUM
bptjm-17	464	20	%	%	NOUN
bptjm-17	464	21	concordance	concordance	NOUN
bptjm-17	464	22	rate	rate	NOUN
bptjm-17	464	23	for	for	ADP
bptjm-17	464	24	cdk2na	cdk2na	NOUN
bptjm-17	464	25	.	.	PUNCT
bptjm-17	465	1	high	high	ADJ
bptjm-17	465	2	concordance	concordance	NOUN
bptjm-17	465	3	rates	rate	NOUN
bptjm-17	465	4	between	between	ADP
bptjm-17	465	5	tissue	tissue	NOUN
bptjm-17	465	6	and	and	CCONJ
bptjm-17	465	7	liquid	liquid	ADJ
bptjm-17	465	8	biopsies	biopsy	NOUN
bptjm-17	465	9	furthers	further	VERB
bptjm-17	465	10	the	the	DET
bptjm-17	465	11	case	case	NOUN
bptjm-17	465	12	for	for	ADP
bptjm-17	465	13	clinical	clinical	ADJ
bptjm-17	465	14	implementation	implementation	NOUN
bptjm-17	465	15	of	of	ADP
bptjm-17	465	16	liquid	liquid	ADJ
bptjm-17	465	17	biopsy	biopsy	NOUN
bptjm-17	465	18	as	as	ADP
bptjm-17	465	19	a	a	DET
bptjm-17	465	20	means	means	NOUN
bptjm-17	465	21	to	to	PART
bptjm-17	465	22	detect	detect	VERB
bptjm-17	465	23	genetic	genetic	ADJ
bptjm-17	465	24	alterations	alteration	NOUN
bptjm-17	465	25	in	in	ADP
bptjm-17	465	26	ctdna	ctdna	NOUN
bptjm-17	465	27	.	.	PUNCT
bptjm-17	466	1	unlike	unlike	ADP
bptjm-17	466	2	standard	standard	ADJ
bptjm-17	466	3	tissue	tissue	NOUN
bptjm-17	466	4	biopsy	biopsy	NOUN
bptjm-17	466	5	options	option	NOUN
bptjm-17	466	6	,	,	PUNCT
bptjm-17	466	7	ctdna	ctdna	NOUN
bptjm-17	466	8	and	and	CCONJ
bptjm-17	466	9	mirna	mirna	PROPN
bptjm-17	466	10	are	be	AUX
bptjm-17	466	11	obtained	obtain	VERB
bptjm-17	466	12	through	through	ADP
bptjm-17	466	13	less	less	ADJ
bptjm-17	466	14	invasive	invasive	ADJ
bptjm-17	466	15	methods	method	NOUN
bptjm-17	466	16	(	(	PUNCT
bptjm-17	466	17	usually	usually	ADV
bptjm-17	466	18	via	via	ADP
bptjm-17	466	19	a	a	DET
bptjm-17	466	20	simple	simple	ADJ
bptjm-17	466	21	blood	blood	NOUN
bptjm-17	466	22	test	test	NOUN
bptjm-17	466	23	)	)	PUNCT
bptjm-17	466	24	.	.	PUNCT
bptjm-17	467	1	however	however	ADV
bptjm-17	467	2	,	,	PUNCT
bptjm-17	467	3	the	the	DET
bptjm-17	467	4	question	question	NOUN
bptjm-17	467	5	remains	remain	VERB
bptjm-17	467	6	whether	whether	SCONJ
bptjm-17	467	7	ctdna	ctdna	NOUN
bptjm-17	467	8	or	or	CCONJ
bptjm-17	467	9	mirna	mirna	NOUN
bptjm-17	467	10	will	will	AUX
bptjm-17	467	11	serve	serve	VERB
bptjm-17	467	12	as	as	ADP
bptjm-17	467	13	viable	viable	ADJ
bptjm-17	467	14	standalone	standalone	ADJ
bptjm-17	467	15	methods	method	NOUN
bptjm-17	467	16	in	in	ADP
bptjm-17	467	17	the	the	DET
bptjm-17	467	18	detection	detection	NOUN
bptjm-17	467	19	of	of	ADP
bptjm-17	467	20	actionable	actionable	ADJ
bptjm-17	467	21	or	or	CCONJ
bptjm-17	467	22	prognostic	prognostic	ADJ
bptjm-17	467	23	biomarkers	biomarker	NOUN
bptjm-17	467	24	.	.	PUNCT
bptjm-17	468	1	based	base	VERB
bptjm-17	468	2	on	on	ADP
bptjm-17	468	3	current	current	ADJ
bptjm-17	468	4	literature	literature	NOUN
bptjm-17	468	5	,	,	PUNCT
bptjm-17	468	6	circulating	circulate	VERB
bptjm-17	468	7	nucleic	nucleic	ADJ
bptjm-17	468	8	acid	acid	NOUN
bptjm-17	468	9	biomarkers	biomarker	NOUN
bptjm-17	468	10	appear	appear	VERB
bptjm-17	468	11	to	to	PART
bptjm-17	468	12	hold	hold	VERB
bptjm-17	468	13	promise	promise	NOUN
bptjm-17	468	14	in	in	ADP
bptjm-17	468	15	indicating	indicate	VERB
bptjm-17	468	16	targeted	target	VERB
bptjm-17	468	17	treatment	treatment	NOUN
bptjm-17	468	18	plans	plan	NOUN
bptjm-17	468	19	for	for	ADP
bptjm-17	468	20	nsclc	nsclc	NOUN
bptjm-17	468	21	patients	patient	NOUN
bptjm-17	468	22	presenting	present	VERB
bptjm-17	468	23	with	with	ADP
bptjm-17	468	24	speci	speci	PROPN
bptjm-17	468	25	c	c	PROPN
bptjm-17	468	26	genomic	genomic	ADJ
bptjm-17	468	27	pro	pro	X
bptjm-17	468	28	les	les	X
bptjm-17	468	29	.	.	PUNCT
bptjm-17	469	1	with	with	ADP
bptjm-17	469	2	the	the	DET
bptjm-17	469	3	increasing	increase	VERB
bptjm-17	469	4	number	number	NOUN
bptjm-17	469	5	of	of	ADP
bptjm-17	469	6	emerging	emerge	VERB
bptjm-17	469	7	biomarkers	biomarker	NOUN
bptjm-17	469	8	,	,	PUNCT
bptjm-17	469	9	it	it	PRON
bptjm-17	469	10	is	be	AUX
bptjm-17	469	11	critical	critical	ADJ
bptjm-17	469	12	to	to	PART
bptjm-17	469	13	analyze	analyze	VERB
bptjm-17	469	14	the	the	DET
bptjm-17	469	15	clinical	clinical	ADJ
bptjm-17	469	16	utility	utility	NOUN
bptjm-17	469	17	of	of	ADP
bptjm-17	469	18	these	these	DET
bptjm-17	469	19	biomarkers	biomarker	NOUN
bptjm-17	469	20	in	in	ADP
bptjm-17	469	21	light	light	NOUN
bptjm-17	469	22	of	of	ADP
bptjm-17	469	23	their	their	PRON
bptjm-17	469	24	prognostic	prognostic	ADJ
bptjm-17	469	25	value	value	NOUN
bptjm-17	469	26	and	and	CCONJ
bptjm-17	469	27	clinical	clinical	ADJ
bptjm-17	469	28	indications	indication	NOUN
bptjm-17	469	29	.	.	PUNCT
bptjm-17	470	1	clinical	clinical	ADJ
bptjm-17	470	2	actionability	actionability	NOUN
bptjm-17	470	3	remains	remain	VERB
bptjm-17	470	4	a	a	DET
bptjm-17	470	5	signi	signi	NOUN
bptjm-17	470	6	ca	can	AUX
bptjm-17	470	7	nt	not	PART
bptjm-17	470	8	factor	factor	VERB
bptjm-17	470	9	in	in	ADP
bptjm-17	470	10	determining	determine	VERB
bptjm-17	470	11	biomarker	biomarker	NOUN
bptjm-17	470	12	value	value	NOUN
bptjm-17	470	13	.	.	PUNCT
bptjm-17	471	1	berkeley	berkeley	PROPN
bptjm-17	471	2	pharma	pharma	PROPN
bptjm-17	471	3	tech	tech	PROPN
bptjm-17	471	4	journal	journal	NOUN
bptjm-17	471	5	of	of	ADP
bptjm-17	471	6	medicine	medicine	NOUN
bptjm-17	471	7	|	|	ADV
bptjm-17	471	8	144	144	NUM
bptjm-17	471	9	ease	ease	NOUN
bptjm-17	471	10	of	of	ADP
bptjm-17	471	11	implementation	implementation	NOUN
bptjm-17	471	12	and	and	CCONJ
bptjm-17	471	13	invasiveness	invasiveness	NOUN
bptjm-17	471	14	of	of	ADP
bptjm-17	471	15	testing	testing	NOUN
bptjm-17	471	16	procedures	procedure	NOUN
bptjm-17	471	17	are	be	AUX
bptjm-17	471	18	important	important	ADJ
bptjm-17	471	19	considerations	consideration	NOUN
bptjm-17	471	20	in	in	ADP
bptjm-17	471	21	developing	develop	VERB
bptjm-17	471	22	assay	assay	NOUN
bptjm-17	471	23	methods	method	NOUN
bptjm-17	471	24	that	that	PRON
bptjm-17	471	25	ease	ease	VERB
bptjm-17	471	26	patient	patient	ADJ
bptjm-17	471	27	discomfort	discomfort	NOUN
bptjm-17	471	28	without	without	ADP
bptjm-17	471	29	diminishing	diminish	VERB
bptjm-17	471	30	speci	speci	PROPN
bptjm-17	471	31	city	city	NOUN
bptjm-17	471	32	and	and	CCONJ
bptjm-17	471	33	accuracy	accuracy	NOUN
bptjm-17	471	34	of	of	ADP
bptjm-17	471	35	detection	detection	NOUN
bptjm-17	471	36	.	.	PUNCT
bptjm-17	472	1	the	the	DET
bptjm-17	472	2	impetus	impetus	NOUN
bptjm-17	472	3	to	to	PART
bptjm-17	472	4	ensure	ensure	VERB
bptjm-17	472	5	reliable	reliable	ADJ
bptjm-17	472	6	and	and	CCONJ
bptjm-17	472	7	streamlined	streamlined	ADJ
bptjm-17	472	8	testing	testing	NOUN
bptjm-17	472	9	measures	measure	NOUN
bptjm-17	472	10	is	be	AUX
bptjm-17	472	11	paramount	paramount	ADJ
bptjm-17	472	12	,	,	PUNCT
bptjm-17	472	13	as	as	SCONJ
bptjm-17	472	14	the	the	DET
bptjm-17	472	15	current	current	ADJ
bptjm-17	472	16	literature	literature	NOUN
bptjm-17	472	17	suggests	suggest	VERB
bptjm-17	472	18	that	that	SCONJ
bptjm-17	472	19	early	early	ADJ
bptjm-17	472	20	detection	detection	NOUN
bptjm-17	472	21	of	of	ADP
bptjm-17	472	22	speci	speci	PROPN
bptjm-17	472	23	c	c	PROPN
bptjm-17	472	24	biomarkers	biomarker	NOUN
bptjm-17	472	25	can	can	AUX
bptjm-17	472	26	provide	provide	VERB
bptjm-17	472	27	a	a	DET
bptjm-17	472	28	remarkable	remarkable	ADJ
bptjm-17	472	29	clinical	clinical	ADJ
bptjm-17	472	30	bene	bene	NOUN
bptjm-17	472	31	t.	t.	PROPN
bptjm-17	472	32	moreover	moreover	ADV
bptjm-17	472	33	,	,	PUNCT
bptjm-17	472	34	in	in	ADP
bptjm-17	472	35	an	an	DET
bptjm-17	472	36	e	e	NOUN
bptjm-17	472	37	ort	ort	NOUN
bptjm-17	472	38	to	to	PART
bptjm-17	472	39	ensure	ensure	VERB
bptjm-17	472	40	equal	equal	ADJ
bptjm-17	472	41	access	access	NOUN
bptjm-17	472	42	to	to	ADP
bptjm-17	472	43	advanced	advanced	ADJ
bptjm-17	472	44	cancer	cancer	NOUN
bptjm-17	472	45	care	care	NOUN
bptjm-17	472	46	,	,	PUNCT
bptjm-17	472	47	the	the	DET
bptjm-17	472	48	nancial	nancial	ADJ
bptjm-17	472	49	burden	burden	NOUN
bptjm-17	472	50	of	of	ADP
bptjm-17	472	51	testing	testing	NOUN
bptjm-17	472	52	should	should	AUX
bptjm-17	472	53	be	be	AUX
bptjm-17	472	54	assessed	assess	VERB
bptjm-17	472	55	.	.	PUNCT
bptjm-17	473	1	ultimately	ultimately	ADV
bptjm-17	473	2	,	,	PUNCT
bptjm-17	473	3	the	the	DET
bptjm-17	473	4	prognostic	prognostic	ADJ
bptjm-17	473	5	signi	signi	ADJ
bptjm-17	473	6	cance	cance	NOUN
bptjm-17	473	7	of	of	ADP
bptjm-17	473	8	ctdna	ctdna	NOUN
bptjm-17	473	9	and	and	CCONJ
bptjm-17	473	10	mirna	mirna	PROPN
bptjm-17	473	11	biomarkers	biomarker	NOUN
bptjm-17	473	12	in	in	ADP
bptjm-17	473	13	nsclc	nsclc	NOUN
bptjm-17	473	14	care	care	NOUN
bptjm-17	473	15	has	have	AUX
bptjm-17	473	16	demonstrated	demonstrate	VERB
bptjm-17	473	17	that	that	SCONJ
bptjm-17	473	18	liquid	liquid	ADJ
bptjm-17	473	19	biopsy	biopsy	NOUN
bptjm-17	473	20	and	and	CCONJ
bptjm-17	473	21	molecular	molecular	ADJ
bptjm-17	473	22	diagnostic	diagnostic	ADJ
bptjm-17	473	23	testing	testing	NOUN
bptjm-17	473	24	hold	hold	VERB
bptjm-17	473	25	promise	promise	NOUN
bptjm-17	473	26	for	for	ADP
bptjm-17	473	27	the	the	DET
bptjm-17	473	28	future	future	NOUN
bptjm-17	473	29	of	of	ADP
bptjm-17	473	30	personalized	personalized	ADJ
bptjm-17	473	31	cancer	cancer	NOUN
bptjm-17	473	32	care	care	NOUN
bptjm-17	473	33	.	.	PUNCT
bptjm-17	474	1	further	further	ADJ
bptjm-17	474	2	testing	testing	NOUN
bptjm-17	474	3	must	must	AUX
bptjm-17	474	4	be	be	AUX
bptjm-17	474	5	conducted	conduct	VERB
bptjm-17	474	6	to	to	PART
bptjm-17	474	7	analyze	analyze	VERB
bptjm-17	474	8	the	the	DET
bptjm-17	474	9	signi	signi	ADJ
bptjm-17	474	10	cance	cance	NOUN
bptjm-17	474	11	of	of	ADP
bptjm-17	474	12	ctdna	ctdna	NOUN
bptjm-17	474	13	and	and	CCONJ
bptjm-17	474	14	mirna	mirna	PROPN
bptjm-17	474	15	biomarkers	biomarker	NOUN
bptjm-17	474	16	in	in	ADP
bptjm-17	474	17	larger	large	ADJ
bptjm-17	474	18	cohorts	cohort	NOUN
bptjm-17	474	19	and	and	CCONJ
bptjm-17	474	20	to	to	PART
bptjm-17	474	21	determine	determine	VERB
bptjm-17	474	22	the	the	DET
bptjm-17	474	23	precise	precise	ADJ
bptjm-17	474	24	clinical	clinical	ADJ
bptjm-17	474	25	bene	bene	NOUN
bptjm-17	474	26	t	t	NOUN
bptjm-17	474	27	of	of	ADP
bptjm-17	474	28	their	their	PRON
bptjm-17	474	29	standardization	standardization	NOUN
bptjm-17	474	30	in	in	ADP
bptjm-17	474	31	clinical	clinical	ADJ
bptjm-17	474	32	practice	practice	NOUN
bptjm-17	474	33	.	.	PUNCT
bptjm-17	475	1	berkeley	berkeley	PROPN
bptjm-17	475	2	pharma	pharma	PROPN
bptjm-17	475	3	tech	tech	PROPN
bptjm-17	475	4	journal	journal	NOUN
bptjm-17	475	5	of	of	ADP
bptjm-17	475	6	medicine	medicine	NOUN
bptjm-17	475	7	|	|	ADV
bptjm-17	475	8	145	145	NUM
bptjm-17	475	9	references	reference	NOUN
bptjm-17	475	10	1	1	NUM
bptjm-17	475	11	.	.	NOUN
bptjm-17	475	12	aredo	aredo	PROPN
bptjm-17	475	13	,	,	PUNCT
bptjm-17	475	14	j.	j.	PROPN
bptjm-17	475	15	v.	v.	PROPN
bptjm-17	475	16	,	,	PUNCT
bptjm-17	475	17	padda	padda	NOUN
bptjm-17	475	18	,	,	PUNCT
bptjm-17	475	19	s.	s.	PROPN
bptjm-17	475	20	k.	k.	PROPN
bptjm-17	475	21	,	,	PUNCT
bptjm-17	475	22	kunder	kunder	PROPN
bptjm-17	475	23	,	,	PUNCT
bptjm-17	475	24	c.	c.	PROPN
bptjm-17	475	25	a.	a.	PROPN
bptjm-17	475	26	,	,	PUNCT
bptjm-17	475	27	han	han	PROPN
bptjm-17	475	28	,	,	PUNCT
bptjm-17	475	29	s.	s.	PROPN
bptjm-17	475	30	s.	s.	PROPN
bptjm-17	475	31	,	,	PUNCT
bptjm-17	475	32	neal	neal	PROPN
bptjm-17	475	33	,	,	PUNCT
bptjm-17	475	34	j.	j.	PROPN
bptjm-17	475	35	w.	w.	PROPN
bptjm-17	475	36	,	,	PUNCT
bptjm-17	475	37	shrager	shrager	NOUN
bptjm-17	475	38	,	,	PUNCT
bptjm-17	475	39	j.	j.	PROPN
bptjm-17	475	40	b.	b.	PROPN
bptjm-17	475	41	,	,	PUNCT
bptjm-17	475	42	&	&	CCONJ
bptjm-17	475	43	wakelee	wakelee	PROPN
bptjm-17	475	44	,	,	PUNCT
bptjm-17	475	45	h.	h.	PROPN
bptjm-17	475	46	a.	a.	PROPN
bptjm-17	475	47	(	(	PUNCT
bptjm-17	475	48	2019	2019	NUM
bptjm-17	475	49	)	)	PUNCT
bptjm-17	475	50	.	.	PUNCT
bptjm-17	476	1	impact	impact	NOUN
bptjm-17	476	2	of	of	ADP
bptjm-17	476	3	kras	kras	PROPN
bptjm-17	476	4	mutation	mutation	NOUN
bptjm-17	476	5	subtype	subtype	NOUN
bptjm-17	476	6	and	and	CCONJ
bptjm-17	476	7	concurrent	concurrent	ADJ
bptjm-17	476	8	pathogenic	pathogenic	ADJ
bptjm-17	476	9	mutations	mutation	NOUN
bptjm-17	476	10	on	on	ADP
bptjm-17	476	11	non	non	ADJ
bptjm-17	476	12	-	-	ADJ
bptjm-17	476	13	small	small	ADJ
bptjm-17	476	14	cell	cell	NOUN
bptjm-17	476	15	lung	lung	NOUN
bptjm-17	476	16	cancer	cancer	NOUN
bptjm-17	476	17	outcomes	outcome	NOUN
bptjm-17	476	18	.	.	PUNCT
bptjm-17	477	1	lung	lung	NOUN
bptjm-17	477	2	cancer	cancer	NOUN
bptjm-17	477	3	(	(	PUNCT
bptjm-17	477	4	amsterdam	amsterdam	PROPN
bptjm-17	477	5	,	,	PUNCT
bptjm-17	477	6	netherlands	netherlands	PROPN
bptjm-17	477	7	)	)	PUNCT
bptjm-17	477	8	,	,	PUNCT
bptjm-17	477	9	133	133	NUM
bptjm-17	477	10	,	,	PUNCT
bptjm-17	477	11	144–150	144–150	NUM
bptjm-17	477	12	.	.	PUNCT
bptjm-17	478	1	https://doi.org/10.1016/j.lungcan.2019.05.015	https://doi.org/10.1016/j.lungcan.2019.05.015	NUM
bptjm-17	478	2	2	2	NUM
bptjm-17	478	3	.	.	X
bptjm-17	478	4	bardelli	bardelli	NOUN
bptjm-17	478	5	,	,	PUNCT
bptjm-17	478	6	a.	a.	NOUN
bptjm-17	478	7	,	,	PUNCT
bptjm-17	478	8	corso	corso	PROPN
bptjm-17	478	9	,	,	PUNCT
bptjm-17	478	10	s.	s.	PROPN
bptjm-17	478	11	,	,	PUNCT
bptjm-17	478	12	bertotti	bertotti	PROPN
bptjm-17	478	13	,	,	PUNCT
bptjm-17	478	14	a.	a.	PROPN
bptjm-17	478	15	,	,	PUNCT
bptjm-17	478	16	hobor	hobor	PROPN
bptjm-17	478	17	,	,	PUNCT
bptjm-17	478	18	s.	s.	PROPN
bptjm-17	478	19	,	,	PUNCT
bptjm-17	478	20	valtorta	valtorta	PROPN
bptjm-17	478	21	,	,	PUNCT
bptjm-17	478	22	e.	e.	PROPN
bptjm-17	478	23	,	,	PUNCT
bptjm-17	478	24	siravegna	siravegna	PROPN
bptjm-17	478	25	,	,	PUNCT
bptjm-17	478	26	g.	g.	PROPN
bptjm-17	478	27	,	,	PUNCT
bptjm-17	478	28	sartore	sartore	ADP
bptjm-17	478	29	bianchi	bianchi	NOUN
bptjm-17	478	30	,	,	PUNCT
bptjm-17	478	31	a.	a.	PROPN
bptjm-17	478	32	,	,	PUNCT
bptjm-17	478	33	scala	scala	PROPN
bptjm-17	478	34	,	,	PUNCT
bptjm-17	478	35	e.	e.	PROPN
bptjm-17	478	36	,	,	PUNCT
bptjm-17	478	37	cassingena	cassingena	NOUN
bptjm-17	478	38	,	,	PUNCT
bptjm-17	478	39	a.	a.	NOUN
bptjm-17	478	40	,	,	PUNCT
bptjm-17	478	41	zecchin	zecchin	PROPN
bptjm-17	478	42	,	,	PUNCT
bptjm-17	478	43	d.	d.	PROPN
bptjm-17	478	44	,	,	PUNCT
bptjm-17	478	45	apicella	apicella	NOUN
bptjm-17	478	46	,	,	PUNCT
bptjm-17	478	47	m.	m.	NOUN
bptjm-17	478	48	,	,	PUNCT
bptjm-17	478	49	migliardi	migliardi	PROPN
bptjm-17	478	50	,	,	PUNCT
bptjm-17	478	51	g.	g.	PROPN
bptjm-17	478	52	,	,	PUNCT
bptjm-17	478	53	galimi	galimi	PROPN
bptjm-17	478	54	,	,	PUNCT
bptjm-17	478	55	f.	f.	PROPN
bptjm-17	478	56	,	,	PUNCT
bptjm-17	478	57	lauricella	lauricella	PROPN
bptjm-17	478	58	,	,	PUNCT
bptjm-17	478	59	c.	c.	NOUN
bptjm-17	478	60	,	,	PUNCT
bptjm-17	478	61	zanon	zanon	NOUN
bptjm-17	478	62	,	,	PUNCT
bptjm-17	478	63	c.	c.	PROPN
bptjm-17	478	64	,	,	PUNCT
bptjm-17	478	65	perera	perera	PROPN
bptjm-17	478	66	,	,	PUNCT
bptjm-17	478	67	t.	t.	PROPN
bptjm-17	478	68	,	,	PUNCT
bptjm-17	478	69	veronese	veronese	NOUN
bptjm-17	478	70	,	,	PUNCT
bptjm-17	478	71	s.	s.	PROPN
bptjm-17	478	72	,	,	PUNCT
bptjm-17	478	73	corti	corti	PROPN
bptjm-17	478	74	,	,	PUNCT
bptjm-17	478	75	g.	g.	PROPN
bptjm-17	478	76	,	,	PUNCT
bptjm-17	478	77	amatu	amatu	PROPN
bptjm-17	478	78	,	,	PUNCT
bptjm-17	478	79	a.	a.	NOUN
bptjm-17	478	80	,	,	PUNCT
bptjm-17	478	81	gambacorta	gambacorta	NOUN
bptjm-17	478	82	,	,	PUNCT
bptjm-17	478	83	m.	m.	NOUN
bptjm-17	478	84	,	,	PUNCT
bptjm-17	478	85	…	…	PUNCT
bptjm-17	478	86	siena	siena	PROPN
bptjm-17	478	87	,	,	PUNCT
bptjm-17	478	88	s.	s.	PROPN
bptjm-17	478	89	(	(	PUNCT
bptjm-17	478	90	2013	2013	NUM
bptjm-17	478	91	)	)	PUNCT
bptjm-17	478	92	.	.	PUNCT
bptjm-17	479	1	ampli	ampli	PROPN
bptjm-17	479	2	�	�	PROPN
bptjm-17	479	3	cation	cation	NOUN
bptjm-17	479	4	of	of	ADP
bptjm-17	479	5	the	the	DET
bptjm-17	479	6	met	meet	VERB
bptjm-17	479	7	receptor	receptor	NOUN
bptjm-17	479	8	drives	drive	VERB
bptjm-17	479	9	resistance	resistance	NOUN
bptjm-17	479	10	to	to	ADP
bptjm-17	479	11	anti	anti	ADJ
bptjm-17	479	12	egfr	egfr	ADJ
bptjm-17	479	13	therapies	therapy	NOUN
bptjm-17	479	14	in	in	ADP
bptjm-17	479	15	colorectal	colorectal	ADJ
bptjm-17	479	16	cancer	cancer	NOUN
bptjm-17	479	17	.	.	PUNCT
bptjm-17	480	1	cancer	cancer	NOUN
bptjm-17	480	2	discovery	discovery	PROPN
bptjm-17	480	3	,	,	PUNCT
bptjm-17	480	4	3(6	3(6	NUM
bptjm-17	480	5	)	)	PUNCT
bptjm-17	480	6	,	,	PUNCT
bptjm-17	480	7	658–673	658–673	PROPN
bptjm-17	480	8	.	.	PUNCT
bptjm-17	481	1	https://doi.org/	https://doi.org/	PROPN
bptjm-17	481	2	10.1158/2159	10.1158/2159	NUM
bptjm-17	481	3	-	-	PUNCT
bptjm-17	481	4	8290.cd-12	8290.cd-12	NOUN
bptjm-17	481	5	-	-	PUNCT
bptjm-17	481	6	0558	0558	NUM
bptjm-17	481	7	3	3	NUM
bptjm-17	481	8	.	.	X
bptjm-17	481	9	beauchamp	beauchamp	PROPN
bptjm-17	481	10	,	,	PUNCT
bptjm-17	481	11	e.	e.	PROPN
bptjm-17	481	12	m.	m.	PROPN
bptjm-17	481	13	,	,	PUNCT
bptjm-17	481	14	woods	woods	PROPN
bptjm-17	481	15	,	,	PUNCT
bptjm-17	481	16	b.	b.	PROPN
bptjm-17	481	17	a.	a.	PROPN
bptjm-17	481	18	,	,	PUNCT
bptjm-17	481	19	dulak	dulak	NOUN
bptjm-17	481	20	,	,	PUNCT
bptjm-17	481	21	a.	a.	NOUN
bptjm-17	481	22	m.	m.	NOUN
bptjm-17	481	23	,	,	PUNCT
bptjm-17	481	24	tan	tan	PROPN
bptjm-17	481	25	,	,	PUNCT
bptjm-17	481	26	l.	l.	PROPN
bptjm-17	481	27	,	,	PUNCT
bptjm-17	481	28	xu	xu	PROPN
bptjm-17	481	29	,	,	PUNCT
bptjm-17	481	30	c.	c.	PROPN
bptjm-17	481	31	,	,	PUNCT
bptjm-17	481	32	gray	gray	ADJ
bptjm-17	481	33	,	,	PUNCT
bptjm-17	481	34	n.	n.	PROPN
bptjm-17	481	35	s.	s.	PROPN
bptjm-17	481	36	,	,	PUNCT
bptjm-17	481	37	bass	bass	NOUN
bptjm-17	481	38	,	,	PUNCT
bptjm-17	481	39	a.	a.	PROPN
bptjm-17	481	40	j.	j.	PROPN
bptjm-17	481	41	,	,	PUNCT
bptjm-17	481	42	wong	wong	PROPN
bptjm-17	481	43	,	,	PUNCT
bptjm-17	481	44	k.	k.	PROPN
bptjm-17	481	45	k.	k.	PROPN
bptjm-17	481	46	,	,	PUNCT
bptjm-17	481	47	meyerson	meyerson	PROPN
bptjm-17	481	48	,	,	PUNCT
bptjm-17	481	49	m.	m.	NOUN
bptjm-17	481	50	,	,	PUNCT
bptjm-17	481	51	&	&	CCONJ
bptjm-17	481	52	hammerman	hammerman	PROPN
bptjm-17	481	53	,	,	PUNCT
bptjm-17	481	54	p.	p.	PROPN
bptjm-17	481	55	s.	s.	PROPN
bptjm-17	481	56	(	(	PUNCT
bptjm-17	481	57	2014	2014	NUM
bptjm-17	481	58	)	)	PUNCT
bptjm-17	481	59	.	.	PUNCT
bptjm-17	482	1	acquired	acquire	VERB
bptjm-17	482	2	resistance	resistance	NOUN
bptjm-17	482	3	to	to	ADP
bptjm-17	482	4	dasatinib	dasatinib	NOUN
bptjm-17	482	5	in	in	ADP
bptjm-17	482	6	lung	lung	NOUN
bptjm-17	482	7	cancer	cancer	NOUN
bptjm-17	482	8	cell	cell	NOUN
bptjm-17	482	9	lines	line	NOUN
bptjm-17	482	10	conferred	confer	VERB
bptjm-17	482	11	by	by	ADP
bptjm-17	482	12	ddr2	ddr2	NOUN
bptjm-17	482	13	gatekeeper	gatekeeper	NOUN
bptjm-17	482	14	mutation	mutation	NOUN
bptjm-17	482	15	and	and	CCONJ
bptjm-17	482	16	nf1	nf1	NOUN
bptjm-17	482	17	loss	loss	NOUN
bptjm-17	482	18	.	.	PUNCT
bptjm-17	483	1	molecular	molecular	ADJ
bptjm-17	483	2	cancer	cancer	NOUN
bptjm-17	483	3	therapeutics	therapeutic	NOUN
bptjm-17	483	4	,	,	PUNCT
bptjm-17	483	5	13(2	13(2	NOUN
bptjm-17	483	6	)	)	PUNCT
bptjm-17	483	7	,	,	PUNCT
bptjm-17	483	8	475–482	475–482	NUM
bptjm-17	483	9	.	.	PUNCT
bptjm-17	483	10	https://doi.org/10.1158/1535-7163.mct-13-0817	https://doi.org/10.1158/1535-7163.mct-13-0817	X
bptjm-17	484	1	4	4	X
bptjm-17	484	2	.	.	X
bptjm-17	484	3	bettegowda	bettegowda	NOUN
bptjm-17	484	4	,	,	PUNCT
bptjm-17	484	5	c.	c.	PROPN
bptjm-17	484	6	,	,	PUNCT
bptjm-17	484	7	sausen	sausen	ADJ
bptjm-17	484	8	,	,	PUNCT
bptjm-17	484	9	m.	m.	NOUN
bptjm-17	484	10	,	,	PUNCT
bptjm-17	484	11	leary	leary	PROPN
bptjm-17	484	12	,	,	PUNCT
bptjm-17	484	13	r.	r.	PROPN
bptjm-17	484	14	j.	j.	PROPN
bptjm-17	484	15	,	,	PUNCT
bptjm-17	484	16	kinde	kinde	PROPN
bptjm-17	484	17	,	,	PUNCT
bptjm-17	484	18	i.	i.	PROPN
bptjm-17	484	19	,	,	PUNCT
bptjm-17	484	20	wang	wang	PROPN
bptjm-17	484	21	,	,	PUNCT
bptjm-17	484	22	y.	y.	PROPN
bptjm-17	484	23	,	,	PUNCT
bptjm-17	484	24	agrawal	agrawal	PROPN
bptjm-17	484	25	,	,	PUNCT
bptjm-17	484	26	n.	n.	NOUN
bptjm-17	484	27	,	,	PUNCT
bptjm-17	484	28	bartlett	bartlett	PROPN
bptjm-17	484	29	,	,	PUNCT
bptjm-17	484	30	b.	b.	PROPN
bptjm-17	484	31	r.	r.	PROPN
bptjm-17	484	32	,	,	PUNCT
bptjm-17	484	33	wang	wang	PROPN
bptjm-17	484	34	,	,	PUNCT
bptjm-17	484	35	h.	h.	PROPN
bptjm-17	484	36	,	,	PUNCT
bptjm-17	484	37	luber	luber	PROPN
bptjm-17	484	38	,	,	PUNCT
bptjm-17	484	39	b.	b.	PROPN
bptjm-17	484	40	,	,	PUNCT
bptjm-17	484	41	alani	alani	PROPN
bptjm-17	484	42	,	,	PUNCT
bptjm-17	484	43	r.	r.	PROPN
bptjm-17	484	44	m.	m.	PROPN
bptjm-17	484	45	,	,	PUNCT
bptjm-17	484	46	antonarakis	antonarakis	PROPN
bptjm-17	484	47	,	,	PUNCT
bptjm-17	484	48	e.	e.	PROPN
bptjm-17	484	49	s.	s.	PROPN
bptjm-17	484	50	,	,	PUNCT
bptjm-17	484	51	azad	azad	PROPN
bptjm-17	484	52	,	,	PUNCT
bptjm-17	484	53	n.	n.	PROPN
bptjm-17	484	54	s.	s.	PROPN
bptjm-17	484	55	,	,	PUNCT
bptjm-17	484	56	bardelli	bardelli	NOUN
bptjm-17	484	57	,	,	PUNCT
bptjm-17	484	58	a.	a.	NOUN
bptjm-17	484	59	,	,	PUNCT
bptjm-17	484	60	brem	brem	PROPN
bptjm-17	484	61	,	,	PUNCT
bptjm-17	484	62	h.	h.	PROPN
bptjm-17	484	63	,	,	PUNCT
bptjm-17	484	64	cameron	cameron	PROPN
bptjm-17	484	65	,	,	PUNCT
bptjm-17	484	66	j.	j.	PROPN
bptjm-17	484	67	l.	l.	PROPN
bptjm-17	484	68	,	,	PUNCT
bptjm-17	484	69	lee	lee	PROPN
bptjm-17	484	70	,	,	PUNCT
bptjm-17	484	71	c.	c.	PROPN
bptjm-17	484	72	c.	c.	PROPN
bptjm-17	484	73	,	,	PUNCT
bptjm-17	484	74	fecher	fecher	ADV
bptjm-17	484	75	,	,	PUNCT
bptjm-17	484	76	l.	l.	PROPN
bptjm-17	484	77	a.	a.	PROPN
bptjm-17	484	78	,	,	PUNCT
bptjm-17	484	79	gallia	gallia	PROPN
bptjm-17	484	80	,	,	PUNCT
bptjm-17	484	81	g.	g.	PROPN
bptjm-17	484	82	l.	l.	PROPN
bptjm-17	484	83	,	,	PUNCT
bptjm-17	484	84	gibbs	gibbs	PROPN
bptjm-17	484	85	,	,	PUNCT
bptjm-17	484	86	p.	p.	PROPN
bptjm-17	484	87	,	,	PUNCT
bptjm-17	484	88	…	…	PUNCT
bptjm-17	485	1	diaz	diaz	PROPN
bptjm-17	485	2	,	,	PUNCT
bptjm-17	485	3	l.	l.	PROPN
bptjm-17	485	4	a.	a.	PROPN
bptjm-17	485	5	(	(	PUNCT
bptjm-17	485	6	2014	2014	NUM
bptjm-17	485	7	)	)	PUNCT
bptjm-17	485	8	.	.	PUNCT
bptjm-17	486	1	detection	detection	NOUN
bptjm-17	486	2	of	of	ADP
bptjm-17	486	3	circulating	circulate	VERB
bptjm-17	486	4	tumor	tumor	NOUN
bptjm-17	486	5	dna	dna	PROPN
bptjm-17	486	6	in	in	ADP
bptjm-17	486	7	earlyand	earlyand	NOUN
bptjm-17	486	8	late	late	ADJ
bptjm-17	486	9	-	-	PUNCT
bptjm-17	486	10	stage	stage	NOUN
bptjm-17	486	11	human	human	ADJ
bptjm-17	486	12	malignancies	malignancy	NOUN
bptjm-17	486	13	.	.	PUNCT
bptjm-17	487	1	science	science	NOUN
bptjm-17	487	2	translational	translational	ADJ
bptjm-17	487	3	medicine	medicine	NOUN
bptjm-17	487	4	,	,	PUNCT
bptjm-17	487	5	6(224	6(224	NUM
bptjm-17	487	6	)	)	PUNCT
bptjm-17	487	7	,	,	PUNCT
bptjm-17	487	8	224ra24	224ra24	PROPN
bptjm-17	487	9	.	.	PUNCT
bptjm-17	488	1	https://doi.org/10.1126/	https://doi.org/10.1126/	PROPN
bptjm-17	488	2	scitranslmed.3007094	scitranslmed.3007094	PROPN
bptjm-17	488	3	5	5	NUM
bptjm-17	488	4	.	.	NOUN
bptjm-17	488	5	buderath	buderath	NOUN
bptjm-17	488	6	,	,	PUNCT
bptjm-17	489	1	p.	p.	PROPN
bptjm-17	489	2	,	,	PUNCT
bptjm-17	489	3	schwich	schwich	PROPN
bptjm-17	489	4	,	,	PUNCT
bptjm-17	489	5	e.	e.	PROPN
bptjm-17	489	6	,	,	PUNCT
bptjm-17	489	7	jensen	jensen	PROPN
bptjm-17	489	8	,	,	PUNCT
bptjm-17	489	9	c.	c.	PROPN
bptjm-17	489	10	,	,	PUNCT
bptjm-17	489	11	horn	horn	NOUN
bptjm-17	489	12	,	,	PUNCT
bptjm-17	489	13	p.	p.	NOUN
bptjm-17	489	14	a.	a.	NOUN
bptjm-17	489	15	,	,	PUNCT
bptjm-17	489	16	kimmig	kimmig	PROPN
bptjm-17	489	17	,	,	PUNCT
bptjm-17	489	18	r.	r.	PROPN
bptjm-17	489	19	,	,	PUNCT
bptjm-17	489	20	kasimir	kasimir	PROPN
bptjm-17	489	21	-	-	PROPN
bptjm-17	489	22	bauer	bauer	PROPN
bptjm-17	489	23	,	,	PUNCT
bptjm-17	489	24	s.	s.	PROPN
bptjm-17	489	25	,	,	PUNCT
bptjm-17	489	26	&	&	CCONJ
bptjm-17	489	27	rebmann	rebmann	PROPN
bptjm-17	489	28	,	,	PUNCT
bptjm-17	489	29	v.	v.	PROPN
bptjm-17	489	30	(	(	PUNCT
bptjm-17	489	31	2019	2019	NUM
bptjm-17	489	32	)	)	PUNCT
bptjm-17	489	33	.	.	PUNCT
bptjm-17	490	1	soluble	soluble	ADJ
bptjm-17	490	2	programmed	program	VERB
bptjm-17	490	3	death	death	NOUN
bptjm-17	490	4	receptor	receptor	NOUN
bptjm-17	490	5	ligands	ligand	VERB
bptjm-17	490	6	spd	spd	NOUN
bptjm-17	490	7	-	-	PUNCT
bptjm-17	490	8	l1	l1	NOUN
bptjm-17	490	9	and	and	CCONJ
bptjm-17	490	10	spd	spd	NOUN
bptjm-17	490	11	-	-	PUNCT
bptjm-17	490	12	l2	l2	NOUN
bptjm-17	490	13	as	as	ADP
bptjm-17	490	14	liquid	liquid	ADJ
bptjm-17	490	15	biopsy	biopsy	NOUN
bptjm-17	490	16	markers	marker	NOUN
bptjm-17	490	17	for	for	ADP
bptjm-17	490	18	prognosis	prognosis	NOUN
bptjm-17	490	19	and	and	CCONJ
bptjm-17	490	20	platinum	platinum	NOUN
bptjm-17	490	21	response	response	NOUN
bptjm-17	490	22	in	in	ADP
bptjm-17	490	23	epithelial	epithelial	ADJ
bptjm-17	490	24	ovarian	ovarian	ADJ
bptjm-17	490	25	cancer	cancer	NOUN
bptjm-17	490	26	.	.	PUNCT
bptjm-17	491	1	frontiers	frontier	NOUN
bptjm-17	491	2	in	in	ADP
bptjm-17	491	3	oncology	oncology	NOUN
bptjm-17	491	4	,	,	PUNCT
bptjm-17	491	5	9	9	NUM
bptjm-17	491	6	,	,	PUNCT
bptjm-17	491	7	1015	1015	NUM
bptjm-17	491	8	.	.	PUNCT
bptjm-17	492	1	https://doi.org/10.3389/fonc.2019.01015	https://doi.org/10.3389/fonc.2019.01015	PROPN
bptjm-17	492	2	6	6	NUM
bptjm-17	492	3	.	.	PUNCT
bptjm-17	492	4	camidge	camidge	NOUN
bptjm-17	492	5	,	,	PUNCT
bptjm-17	492	6	d.	d.	PROPN
bptjm-17	492	7	r.	r.	PROPN
bptjm-17	492	8	,	,	PUNCT
bptjm-17	492	9	kono	kono	PROPN
bptjm-17	492	10	,	,	PUNCT
bptjm-17	492	11	s.	s.	PROPN
bptjm-17	492	12	a.	a.	PROPN
bptjm-17	492	13	,	,	PUNCT
bptjm-17	492	14	flacco	flacco	PROPN
bptjm-17	492	15	,	,	PUNCT
bptjm-17	492	16	a.	a.	PROPN
bptjm-17	492	17	,	,	PUNCT
bptjm-17	492	18	tan	tan	PROPN
bptjm-17	492	19	,	,	PUNCT
bptjm-17	492	20	a.	a.	PROPN
bptjm-17	492	21	c.	c.	PROPN
bptjm-17	492	22	,	,	PUNCT
bptjm-17	492	23	doebele	doebele	PROPN
bptjm-17	492	24	,	,	PUNCT
bptjm-17	492	25	r.	r.	PROPN
bptjm-17	492	26	c.	c.	PROPN
bptjm-17	492	27	,	,	PUNCT
bptjm-17	492	28	zhou	zhou	PROPN
bptjm-17	492	29	,	,	PUNCT
bptjm-17	492	30	q.	q.	PROPN
bptjm-17	492	31	,	,	PUNCT
bptjm-17	492	32	crino	crino	PROPN
bptjm-17	492	33	,	,	PUNCT
bptjm-17	492	34	l.	l.	PROPN
bptjm-17	492	35	,	,	PUNCT
bptjm-17	492	36	franklin	franklin	PROPN
bptjm-17	492	37	,	,	PUNCT
bptjm-17	492	38	w.	w.	PROPN
bptjm-17	492	39	a.	a.	PROPN
bptjm-17	492	40	,	,	PUNCT
bptjm-17	492	41	&	&	CCONJ
bptjm-17	492	42	varella	varella	NOUN
bptjm-17	492	43	-	-	PUNCT
bptjm-17	492	44	garcia	garcia	PROPN
bptjm-17	492	45	,	,	PUNCT
bptjm-17	492	46	m.	m.	NOUN
bptjm-17	492	47	(	(	PUNCT
bptjm-17	492	48	2010	2010	NUM
bptjm-17	492	49	)	)	PUNCT
bptjm-17	492	50	.	.	PUNCT
bptjm-17	493	1	optimizing	optimize	VERB
bptjm-17	493	2	the	the	DET
bptjm-17	493	3	detection	detection	NOUN
bptjm-17	493	4	of	of	ADP
bptjm-17	493	5	lung	lung	NOUN
bptjm-17	493	6	cancer	cancer	NOUN
bptjm-17	493	7	patients	patient	NOUN
bptjm-17	493	8	harboring	harbor	VERB
bptjm-17	493	9	anaplastic	anaplastic	ADJ
bptjm-17	493	10	lymphoma	lymphoma	NOUN
bptjm-17	493	11	kinase	kinase	PROPN
bptjm-17	493	12	(	(	PUNCT
bptjm-17	493	13	alk	alk	PROPN
bptjm-17	493	14	)	)	PUNCT
bptjm-17	493	15	gene	gene	NOUN
bptjm-17	493	16	rearrangements	rearrangement	NOUN
bptjm-17	493	17	potentially	potentially	ADV
bptjm-17	493	18	suitable	suitable	ADJ
bptjm-17	493	19	for	for	ADP
bptjm-17	493	20	alk	alk	NOUN
bptjm-17	493	21	inhibitor	inhibitor	NOUN
bptjm-17	493	22	treatment	treatment	NOUN
bptjm-17	493	23	.	.	PUNCT
bptjm-17	494	1	clinical	clinical	ADJ
bptjm-17	494	2	cancer	cancer	NOUN
bptjm-17	494	3	research	research	NOUN
bptjm-17	494	4	:	:	PUNCT
bptjm-17	494	5	an	an	DET
bptjm-17	494	6	official	official	ADJ
bptjm-17	494	7	journal	journal	NOUN
bptjm-17	494	8	of	of	ADP
bptjm-17	494	9	the	the	DET
bptjm-17	494	10	american	american	PROPN
bptjm-17	494	11	association	association	PROPN
bptjm-17	494	12	for	for	ADP
bptjm-17	494	13	cancer	cancer	NOUN
bptjm-17	494	14	research	research	NOUN
bptjm-17	494	15	,	,	PUNCT
bptjm-17	494	16	16(22	16(22	NUM
bptjm-17	494	17	)	)	PUNCT
bptjm-17	494	18	,	,	PUNCT
bptjm-17	494	19	5581–5590	5581–5590	NUM
bptjm-17	494	20	.	.	PUNCT
bptjm-17	495	1	https://doi.org/	https://doi.org/	VERB
bptjm-17	495	2	10.1158/1078	10.1158/1078	NUM
bptjm-17	495	3	-	-	PUNCT
bptjm-17	495	4	0432.ccr-10	0432.ccr-10	NUM
bptjm-17	495	5	-	-	PUNCT
bptjm-17	495	6	0851	0851	NUM
bptjm-17	495	7	7	7	NUM
bptjm-17	495	8	.	.	PUNCT
bptjm-17	496	1	chae	chae	NOUN
bptjm-17	496	2	,	,	PUNCT
bptjm-17	496	3	y.	y.	PROPN
bptjm-17	496	4	k.	k.	PROPN
bptjm-17	496	5	,	,	PUNCT
bptjm-17	496	6	andrew	andrew	PROPN
bptjm-17	496	7	a.	a.	PROPN
bptjm-17	496	8	d.	d.	PROPN
bptjm-17	496	9	,	,	PUNCT
bptjm-17	496	10	sarika	sarika	PROPN
bptjm-17	496	11	,	,	PUNCT
bptjm-17	496	12	j.	j.	PROPN
bptjm-17	496	13	,	,	PUNCT
bptjm-17	496	14	cesar	cesar	PROPN
bptjm-17	496	15	,	,	PUNCT
bptjm-17	496	16	s.m	s.m	PROPN
bptjm-17	496	17	.	.	PROPN
bptjm-17	496	18	,	,	PUNCT
bptjm-17	496	19	lisa	lisa	PROPN
bptjm-17	496	20	,	,	PUNCT
bptjm-17	496	21	f.	f.	PROPN
bptjm-17	496	22	,	,	PUNCT
bptjm-17	496	23	nike	nike	PROPN
bptjm-17	496	24	,	,	PUNCT
bptjm-17	496	25	b.	b.	PROPN
bptjm-17	496	26	,	,	PUNCT
bptjm-17	496	27	leonidas	leonidas	PROPN
bptjm-17	496	28	,	,	PUNCT
bptjm-17	496	29	c.	c.	PROPN
bptjm-17	496	30	p.	p.	PROPN
bptjm-17	496	31	,	,	PUNCT
bptjm-17	496	32	william	william	PROPN
bptjm-17	496	33	,	,	PUNCT
bptjm-17	496	34	g.	g.	PROPN
bptjm-17	496	35	,	,	PUNCT
bptjm-17	496	36	francis	francis	PROPN
bptjm-17	496	37	j.	j.	PROPN
bptjm-17	496	38	g.	g.	PROPN
bptjm-17	496	39	,	,	PUNCT
bptjm-17	496	40	and	and	CCONJ
bptjm-17	496	41	massimo	massimo	PROPN
bptjm-17	496	42	,	,	PUNCT
bptjm-17	496	43	c.	c.	PROPN
bptjm-17	496	44	(	(	PUNCT
bptjm-17	496	45	2017	2017	NUM
bptjm-17	496	46	)	)	PUNCT
bptjm-17	496	47	.	.	PUNCT
bptjm-17	497	1	concordance	concordance	NOUN
bptjm-17	497	2	of	of	ADP
bptjm-17	497	3	genomic	genomic	ADJ
bptjm-17	497	4	alterations	alteration	NOUN
bptjm-17	497	5	by	by	ADP
bptjm-17	497	6	next	next	ADJ
bptjm-17	497	7	-	-	PUNCT
bptjm-17	497	8	generation	generation	NOUN
bptjm-17	497	9	sequencing	sequencing	NOUN
bptjm-17	497	10	in	in	ADP
bptjm-17	497	11	tumor	tumor	NOUN
bptjm-17	497	12	tissue	tissue	NOUN
bptjm-17	497	13	versus	versus	ADP
bptjm-17	497	14	circulating	circulate	VERB
bptjm-17	497	15	tumor	tumor	NOUN
bptjm-17	497	16	dna	dna	NOUN
bptjm-17	497	17	in	in	ADP
bptjm-17	497	18	breast	breast	NOUN
bptjm-17	497	19	cancer	cancer	NOUN
bptjm-17	497	20	.	.	PUNCT
bptjm-17	498	1	molecular	molecular	ADJ
bptjm-17	498	2	cancer	cancer	NOUN
bptjm-17	498	3	therapeutics	therapeutic	NOUN
bptjm-17	498	4	,	,	PUNCT
bptjm-17	498	5	16(7	16(7	NUM
bptjm-17	498	6	)	)	PUNCT
bptjm-17	498	7	,	,	PUNCT
bptjm-17	498	8	1412–1420	1412–1420	NUM
bptjm-17	498	9	.	.	PUNCT
bptjm-17	499	1	https://doi.org/10.1158/1535-7163.mct-17-0061	https://doi.org/10.1158/1535-7163.mct-17-0061	PROPN
bptjm-17	500	1	8	8	X
bptjm-17	500	2	.	.	X
bptjm-17	500	3	chian	chian	PROPN
bptjm-17	500	4	,	,	PUNCT
bptjm-17	500	5	c.	c.	PROPN
bptjm-17	500	6	f.	f.	PROPN
bptjm-17	500	7	,	,	PUNCT
bptjm-17	500	8	hwang	hwang	PROPN
bptjm-17	500	9	,	,	PUNCT
bptjm-17	500	10	y.	y.	PROPN
bptjm-17	500	11	t.	t.	PROPN
bptjm-17	500	12	,	,	PUNCT
bptjm-17	500	13	terng	terng	NOUN
bptjm-17	500	14	,	,	PUNCT
bptjm-17	500	15	h.	h.	PROPN
bptjm-17	500	16	j.	j.	PROPN
bptjm-17	500	17	,	,	PUNCT
bptjm-17	500	18	lee	lee	PROPN
bptjm-17	500	19	,	,	PUNCT
bptjm-17	500	20	s.	s.	PROPN
bptjm-17	500	21	c.	c.	PROPN
bptjm-17	500	22	,	,	PUNCT
bptjm-17	500	23	chao	chao	PROPN
bptjm-17	500	24	,	,	PUNCT
bptjm-17	500	25	t.	t.	PROPN
bptjm-17	500	26	y.	y.	PROPN
bptjm-17	500	27	,	,	PUNCT
bptjm-17	500	28	chang	chang	PROPN
bptjm-17	500	29	,	,	PUNCT
bptjm-17	500	30	h.	h.	PROPN
bptjm-17	500	31	,	,	PUNCT
bptjm-17	500	32	ho	ho	PROPN
bptjm-17	500	33	,	,	PUNCT
bptjm-17	500	34	c.	c.	PROPN
bptjm-17	500	35	l.	l.	PROPN
bptjm-17	500	36	,	,	PUNCT
bptjm-17	500	37	wu	wu	PROPN
bptjm-17	500	38	,	,	PUNCT
bptjm-17	500	39	y.	y.	PROPN
bptjm-17	500	40	y.	y.	PROPN
bptjm-17	500	41	,	,	PUNCT
bptjm-17	500	42	&	&	CCONJ
bptjm-17	500	43	perng	perng	PROPN
bptjm-17	500	44	,	,	PUNCT
bptjm-17	500	45	w.	w.	PROPN
bptjm-17	500	46	c.	c.	PROPN
bptjm-17	500	47	(	(	PUNCT
bptjm-17	500	48	2016	2016	NUM
bptjm-17	500	49	)	)	PUNCT
bptjm-17	500	50	.	.	PUNCT
bptjm-17	501	1	panels	panel	NOUN
bptjm-17	501	2	of	of	ADP
bptjm-17	501	3	tumor	tumor	NOUN
bptjm-17	501	4	-	-	PUNCT
bptjm-17	501	5	derived	derive	VERB
bptjm-17	501	6	rna	rna	NOUN
bptjm-17	501	7	markers	marker	NOUN
bptjm-17	501	8	in	in	ADP
bptjm-17	501	9	peripheral	peripheral	ADJ
bptjm-17	501	10	blood	blood	NOUN
bptjm-17	501	11	of	of	ADP
bptjm-17	501	12	patients	patient	NOUN
bptjm-17	501	13	with	with	ADP
bptjm-17	501	14	non	non	ADJ
bptjm-17	501	15	-	-	ADJ
bptjm-17	501	16	small	small	ADJ
bptjm-17	501	17	cell	cell	NOUN
bptjm-17	501	18	lung	lung	NOUN
bptjm-17	501	19	cancer	cancer	NOUN
bptjm-17	501	20	:	:	PUNCT
bptjm-17	501	21	their	their	PRON
bptjm-17	501	22	dependence	dependence	NOUN
bptjm-17	501	23	on	on	ADP
bptjm-17	501	24	age	age	NOUN
bptjm-17	501	25	,	,	PUNCT
bptjm-17	501	26	gender	gender	NOUN
bptjm-17	501	27	and	and	CCONJ
bptjm-17	501	28	clinical	clinical	ADJ
bptjm-17	501	29	stages	stage	NOUN
bptjm-17	501	30	.	.	PUNCT
bptjm-17	502	1	oncotarget	oncotarget	NOUN
bptjm-17	502	2	,	,	PUNCT
bptjm-17	502	3	7(31	7(31	NUM
bptjm-17	502	4	)	)	PUNCT
bptjm-17	502	5	,	,	PUNCT
bptjm-17	502	6	50582–50595	50582–50595	NUM
bptjm-17	502	7	.	.	NOUN
bptjm-17	502	8	https://doi.org/10.18632/oncotarget.10558	https://doi.org/10.18632/oncotarget.10558	ADJ
bptjm-17	502	9	9	9	NUM
bptjm-17	502	10	.	.	X
bptjm-17	502	11	chirshev	chirshev	PROPN
bptjm-17	502	12	,	,	PUNCT
bptjm-17	502	13	e.	e.	PROPN
bptjm-17	502	14	,	,	PUNCT
bptjm-17	502	15	oberg	oberg	PROPN
bptjm-17	502	16	,	,	PUNCT
bptjm-17	502	17	k.	k.	PROPN
bptjm-17	502	18	c.	c.	PROPN
bptjm-17	502	19	,	,	PUNCT
bptjm-17	502	20	io	io	PROPN
bptjm-17	502	21	�	�	PROPN
bptjm-17	502	22	e	e	PROPN
bptjm-17	502	23	,	,	PUNCT
bptjm-17	502	24	y.	y.	PROPN
bptjm-17	502	25	j.	j.	PROPN
bptjm-17	502	26	,	,	PUNCT
bptjm-17	502	27	&	&	CCONJ
bptjm-17	502	28	amp	amp	PROPN
bptjm-17	502	29	;	;	PUNCT
bptjm-17	502	30	unternaehrer	unternaehrer	NOUN
bptjm-17	502	31	,	,	PUNCT
bptjm-17	502	32	j.	j.	PROPN
bptjm-17	502	33	j.	j.	PROPN
bptjm-17	502	34	(	(	PUNCT
bptjm-17	502	35	2019	2019	NUM
bptjm-17	502	36	)	)	PUNCT
bptjm-17	502	37	.	.	PUNCT
bptjm-17	503	1	let	let	VERB
bptjm-17	503	2	7	7	NUM
bptjm-17	503	3	as	as	ADP
bptjm-17	503	4	biomarker	biomarker	NOUN
bptjm-17	503	5	,	,	PUNCT
bptjm-17	503	6	prognostic	prognostic	ADJ
bptjm-17	503	7	indicator	indicator	NOUN
bptjm-17	503	8	,	,	PUNCT
bptjm-17	503	9	and	and	CCONJ
bptjm-17	503	10	therapy	therapy	NOUN
bptjm-17	503	11	for	for	ADP
bptjm-17	503	12	precision	precision	NOUN
bptjm-17	503	13	medicine	medicine	NOUN
bptjm-17	503	14	in	in	ADP
bptjm-17	503	15	cancer	cancer	NOUN
bptjm-17	503	16	.	.	PUNCT
bptjm-17	504	1	clinical	clinical	ADJ
bptjm-17	504	2	and	and	CCONJ
bptjm-17	504	3	translational	translational	ADJ
bptjm-17	504	4	medicine	medicine	NOUN
bptjm-17	504	5	,	,	PUNCT
bptjm-17	504	6	8(1	8(1	NOUN
bptjm-17	504	7	)	)	PUNCT
bptjm-17	504	8	.	.	PUNCT
bptjm-17	505	1	doi:10.1186	doi:10.1186	PROPN
bptjm-17	505	2	/	/	SYM
bptjm-17	505	3	s40169	s40169	PROPN
bptjm-17	505	4	-	-	PUNCT
bptjm-17	505	5	019	019	NUM
bptjm-17	505	6	-	-	PUNCT
bptjm-17	505	7	0240	0240	NUM
bptjm-17	505	8	-	-	PUNCT
bptjm-17	505	9	y	y	PROPN
bptjm-17	505	10	10	10	NUM
bptjm-17	505	11	.	.	PUNCT
bptjm-17	506	1	christopoulos	christopoulo	NOUN
bptjm-17	506	2	,	,	PUNCT
bptjm-17	506	3	p.	p.	NOUN
bptjm-17	506	4	,	,	PUNCT
bptjm-17	506	5	kirchner	kirchner	PROPN
bptjm-17	506	6	,	,	PUNCT
bptjm-17	506	7	m.	m.	NOUN
bptjm-17	506	8	,	,	PUNCT
bptjm-17	506	9	endris	endris	PROPN
bptjm-17	506	10	,	,	PUNCT
bptjm-17	506	11	v.	v.	ADV
bptjm-17	506	12	,	,	PUNCT
bptjm-17	506	13	stenzinger	stenzinger	NOUN
bptjm-17	506	14	,	,	PUNCT
bptjm-17	506	15	a.	a.	PROPN
bptjm-17	506	16	,	,	PUNCT
bptjm-17	506	17	&	&	CCONJ
bptjm-17	506	18	thomas	thomas	PROPN
bptjm-17	506	19	,	,	PUNCT
bptjm-17	506	20	m.	m.	NOUN
bptjm-17	506	21	(	(	PUNCT
bptjm-17	506	22	2018	2018	NUM
bptjm-17	506	23	)	)	PUNCT
bptjm-17	506	24	.	.	PUNCT
bptjm-17	507	1	eml4alk	eml4alk	VERB
bptjm-17	507	2	v3	v3	PROPN
bptjm-17	507	3	,	,	PUNCT
bptjm-17	507	4	treatment	treatment	NOUN
bptjm-17	507	5	resistance	resistance	NOUN
bptjm-17	507	6	,	,	PUNCT
bptjm-17	507	7	and	and	CCONJ
bptjm-17	507	8	survival	survival	NOUN
bptjm-17	507	9	:	:	PUNCT
bptjm-17	507	10	re	re	VERB
bptjm-17	507	11	�	�	VERB
bptjm-17	507	12	ning	ne	VERB
bptjm-17	507	13	the	the	DET
bptjm-17	507	14	diagnosis	diagnosis	NOUN
bptjm-17	507	15	of	of	ADP
bptjm-17	507	16	alk+	alk+	NOUN
bptjm-17	507	17	nsclc	nsclc	NOUN
bptjm-17	507	18	.	.	PUNCT
bptjm-17	508	1	journal	journal	PROPN
bptjm-17	508	2	of	of	ADP
bptjm-17	508	3	thoracic	thoracic	NOUN
bptjm-17	508	4	disease	disease	NOUN
bptjm-17	508	5	,	,	PUNCT
bptjm-17	508	6	10(suppl	10(suppl	NOUN
bptjm-17	508	7	17	17	NUM
bptjm-17	508	8	)	)	PUNCT
bptjm-17	508	9	,	,	PUNCT
bptjm-17	508	10	s1989	s1989	NOUN
bptjm-17	508	11	–	–	PUNCT
bptjm-17	508	12	s1991	s1991	NOUN
bptjm-17	508	13	.	.	PUNCT
bptjm-17	509	1	berkeley	berkeley	PROPN
bptjm-17	509	2	pharma	pharma	PROPN
bptjm-17	509	3	tech	tech	PROPN
bptjm-17	509	4	journal	journal	NOUN
bptjm-17	509	5	of	of	ADP
bptjm-17	509	6	medicine	medicine	NOUN
bptjm-17	509	7	|	|	ADV
bptjm-17	509	8	146	146	NUM
bptjm-17	509	9	https://doi.org/10.21037/jtd.2018.05.61	https://doi.org/10.21037/jtd.2018.05.61	ADP
bptjm-17	509	10	11	11	NUM
bptjm-17	509	11	.	.	PUNCT
bptjm-17	510	1	chuang	chuang	PROPN
bptjm-17	510	2	,	,	PUNCT
bptjm-17	510	3	j.	j.	PROPN
bptjm-17	510	4	c.	c.	PROPN
bptjm-17	510	5	,	,	PUNCT
bptjm-17	510	6	henning	henning	PROPN
bptjm-17	510	7	,	,	PUNCT
bptjm-17	510	8	s.	s.	PROPN
bptjm-17	510	9	,	,	PUNCT
bptjm-17	510	10	ying	ying	PROPN
bptjm-17	510	11	,	,	PUNCT
bptjm-17	510	12	l.	l.	PROPN
bptjm-17	510	13	,	,	PUNCT
bptjm-17	510	14	millie	millie	PROPN
bptjm-17	510	15	,	,	PUNCT
bptjm-17	510	16	d.	d.	PROPN
bptjm-17	510	17	,	,	PUNCT
bptjm-17	510	18	jane	jane	PROPN
bptjm-17	510	19	,	,	PUNCT
bptjm-17	510	20	h.	h.	PROPN
bptjm-17	510	21	,	,	PUNCT
bptjm-17	510	22	maximilian	maximilian	PROPN
bptjm-17	510	23	,	,	PUNCT
bptjm-17	510	24	d.	d.	PROPN
bptjm-17	510	25	,	,	PUNCT
bptjm-17	510	26	heather	heather	PROPN
bptjm-17	510	27	,	,	PUNCT
bptjm-17	510	28	a.	a.	PROPN
bptjm-17	510	29	w.	w.	PROPN
bptjm-17	510	30	and	and	CCONJ
bptjm-17	510	31	joel	joel	PROPN
bptjm-17	510	32	,	,	PUNCT
bptjm-17	510	33	w.	w.	PROPN
bptjm-17	510	34	n.	n.	PROPN
bptjm-17	510	35	(	(	PUNCT
bptjm-17	510	36	2017	2017	NUM
bptjm-17	510	37	)	)	PUNCT
bptjm-17	510	38	.	.	PUNCT
bptjm-17	511	1	erbb2	erbb2	PROPN
bptjm-17	511	2	-	-	PUNCT
bptjm-17	511	3	mutated	mutate	VERB
bptjm-17	511	4	metastatic	metastatic	ADJ
bptjm-17	511	5	non	non	ADJ
bptjm-17	511	6	–	–	ADJ
bptjm-17	511	7	small	small	ADJ
bptjm-17	511	8	cell	cell	NOUN
bptjm-17	511	9	lung	lung	NOUN
bptjm-17	511	10	cancer	cancer	NOUN
bptjm-17	511	11	:	:	PUNCT
bptjm-17	511	12	response	response	NOUN
bptjm-17	511	13	and	and	CCONJ
bptjm-17	511	14	resistance	resistance	NOUN
bptjm-17	511	15	to	to	ADP
bptjm-17	511	16	targeted	target	VERB
bptjm-17	511	17	therapies	therapy	NOUN
bptjm-17	511	18	.	.	PUNCT
bptjm-17	512	1	journal	journal	PROPN
bptjm-17	512	2	of	of	ADP
bptjm-17	512	3	thoracic	thoracic	NOUN
bptjm-17	512	4	oncology	oncology	NOUN
bptjm-17	512	5	,	,	PUNCT
bptjm-17	512	6	12(5	12(5	NUM
bptjm-17	512	7	)	)	PUNCT
bptjm-17	512	8	,	,	PUNCT
bptjm-17	512	9	833–842	833–842	NUM
bptjm-17	512	10	.	.	PUNCT
bptjm-17	513	1	https://doi.org/10.1016/j.jtho.2017.01.023	https://doi.org/10.1016/j.jtho.2017.01.023	PROPN
bptjm-17	513	2	.	.	PROPN
bptjm-17	514	1	12	12	NUM
bptjm-17	514	2	.	.	PUNCT
bptjm-17	514	3	cui	cui	PROPN
bptjm-17	514	4	,	,	PUNCT
bptjm-17	514	5	e.	e.	PROPN
bptjm-17	514	6	h.	h.	PROPN
bptjm-17	514	7	,	,	PUNCT
bptjm-17	514	8	li	li	PROPN
bptjm-17	514	9	,	,	PUNCT
bptjm-17	514	10	h.	h.	PROPN
bptjm-17	514	11	j.	j.	PROPN
bptjm-17	514	12	,	,	PUNCT
bptjm-17	514	13	hua	hua	PROPN
bptjm-17	514	14	,	,	PUNCT
bptjm-17	514	15	f.	f.	PROPN
bptjm-17	514	16	,	,	PUNCT
bptjm-17	514	17	wang	wang	PROPN
bptjm-17	514	18	,	,	PUNCT
bptjm-17	514	19	b.	b.	PROPN
bptjm-17	514	20	,	,	PUNCT
bptjm-17	514	21	mao	mao	PROPN
bptjm-17	514	22	,	,	PUNCT
bptjm-17	514	23	w.	w.	PROPN
bptjm-17	514	24	,	,	PUNCT
bptjm-17	514	25	feng	feng	PROPN
bptjm-17	514	26	,	,	PUNCT
bptjm-17	514	27	x.	x.	PROPN
bptjm-17	514	28	r.	r.	PROPN
bptjm-17	514	29	,	,	PUNCT
bptjm-17	514	30	et	et	PROPN
bptjm-17	514	31	al	al	PROPN
bptjm-17	514	32	.	.	PROPN
bptjm-17	514	33	(	(	PUNCT
bptjm-17	514	34	2013	2013	NUM
bptjm-17	514	35	)	)	PUNCT
bptjm-17	514	36	.	.	PUNCT
bptjm-17	515	1	serum	serum	PROPN
bptjm-17	515	2	microrna	microrna	PROPN
bptjm-17	515	3	125b	125b	PROPN
bptjm-17	515	4	as	as	ADP
bptjm-17	515	5	a	a	DET
bptjm-17	515	6	diagnostic	diagnostic	ADJ
bptjm-17	515	7	or	or	CCONJ
bptjm-17	515	8	prognostic	prognostic	ADJ
bptjm-17	515	9	biomarker	biomarker	NOUN
bptjm-17	515	10	for	for	ADP
bptjm-17	515	11	advanced	advanced	ADJ
bptjm-17	515	12	nsclc	nsclc	NOUN
bptjm-17	515	13	patients	patient	NOUN
bptjm-17	515	14	receiving	receive	VERB
bptjm-17	515	15	cisplatin	cisplatin	NOUN
bptjm-17	515	16	-	-	PUNCT
bptjm-17	515	17	based	base	VERB
bptjm-17	515	18	chemotherapy	chemotherapy	NOUN
bptjm-17	515	19	.	.	PUNCT
bptjm-17	516	1	acta	acta	PROPN
bptjm-17	516	2	pharmacol	pharmacol	PROPN
bptjm-17	516	3	.	.	PUNCT
bptjm-17	517	1	sin	sin	PROPN
bptjm-17	517	2	.	.	PUNCT
bptjm-17	518	1	34	34	NUM
bptjm-17	518	2	(	(	PUNCT
bptjm-17	518	3	2	2	NUM
bptjm-17	518	4	)	)	PUNCT
bptjm-17	518	5	,	,	PUNCT
bptjm-17	518	6	309–313	309–313	NUM
bptjm-17	518	7	.	.	PUNCT
bptjm-17	519	1	doi	doi	NOUN
bptjm-17	519	2	:	:	PUNCT
bptjm-17	519	3	10.1038	10.1038	NUM
bptjm-17	519	4	/	/	SYM
bptjm-17	519	5	aps.2012.125	aps.2012.125	PROPN
bptjm-17	519	6	13	13	NUM
bptjm-17	519	7	.	.	PUNCT
bptjm-17	520	1	dacic	dacic	NOUN
bptjm-17	520	2	,	,	PUNCT
bptjm-17	520	3	sanja	sanja	PROPN
bptjm-17	520	4	,	,	PUNCT
bptjm-17	520	5	hannelore	hannelore	NOUN
bptjm-17	520	6	kothmaier	kothmaier	PROPN
bptjm-17	520	7	,	,	PUNCT
bptjm-17	520	8	stephanie	stephanie	PROPN
bptjm-17	520	9	land	land	PROPN
bptjm-17	520	10	,	,	PUNCT
bptjm-17	520	11	yongli	yongli	PROPN
bptjm-17	520	12	shuai	shuai	PROPN
bptjm-17	520	13	,	,	PUNCT
bptjm-17	520	14	iris	iris	NOUN
bptjm-17	520	15	halbwedl	halbwedl	PROPN
bptjm-17	520	16	,	,	PUNCT
bptjm-17	520	17	patrizia	patrizia	PROPN
bptjm-17	520	18	morbini	morbini	PROPN
bptjm-17	520	19	,	,	PUNCT
bptjm-17	520	20	bruno	bruno	PROPN
bptjm-17	520	21	murer	murer	NOUN
bptjm-17	520	22	,	,	PUNCT
bptjm-17	520	23	et	et	PROPN
bptjm-17	520	24	al	al	PROPN
bptjm-17	520	25	.	.	PUNCT
bptjm-17	521	1	“	"	PUNCT
bptjm-17	521	2	prognostic	prognostic	ADJ
bptjm-17	521	3	signi	signi	PROPN
bptjm-17	521	4	�	�	PROPN
bptjm-17	521	5	cance	cance	NOUN
bptjm-17	521	6	of	of	ADP
bptjm-17	521	7	p16	p16	NOUN
bptjm-17	521	8	/	/	SYM
bptjm-17	521	9	cdkn2a	cdkn2a	NOUN
bptjm-17	521	10	loss	loss	NOUN
bptjm-17	521	11	in	in	ADP
bptjm-17	521	12	pleural	pleural	ADJ
bptjm-17	521	13	malignant	malignant	ADJ
bptjm-17	521	14	mesotheliomas	mesothelioma	NOUN
bptjm-17	521	15	.	.	PUNCT
bptjm-17	521	16	”	"	PUNCT
bptjm-17	521	17	virchows	virchow	VERB
bptjm-17	521	18	archiv	archiv	PROPN
bptjm-17	521	19	453	453	NUM
bptjm-17	521	20	,	,	PUNCT
bptjm-17	521	21	no	no	INTJ
bptjm-17	521	22	.	.	NOUN
bptjm-17	521	23	6	6	NUM
bptjm-17	521	24	(	(	PUNCT
bptjm-17	521	25	december	december	PROPN
bptjm-17	521	26	1	1	NUM
bptjm-17	521	27	,	,	PUNCT
bptjm-17	521	28	2008	2008	NUM
bptjm-17	521	29	):	):	PUNCT
bptjm-17	521	30	627–35	627–35	NUM
bptjm-17	521	31	.	.	PUNCT
bptjm-17	522	1	https://doi.org/10.1007/s00428-008-0689-3	https://doi.org/10.1007/s00428-008-0689-3	PROPN
bptjm-17	522	2	.	.	PUNCT
bptjm-17	523	1	14	14	NUM
bptjm-17	523	2	.	.	PUNCT
bptjm-17	524	1	dankner	dankner	NOUN
bptjm-17	524	2	,	,	PUNCT
bptjm-17	524	3	m.	m.	NOUN
bptjm-17	524	4	,	,	PUNCT
bptjm-17	524	5	rose	rise	VERB
bptjm-17	524	6	,	,	PUNCT
bptjm-17	524	7	a.	a.	NOUN
bptjm-17	524	8	,	,	PUNCT
bptjm-17	524	9	rajkumar	rajkumar	PROPN
bptjm-17	524	10	,	,	PUNCT
bptjm-17	524	11	s.	s.	PROPN
bptjm-17	524	12	,	,	PUNCT
bptjm-17	524	13	siegel	siegel	PROPN
bptjm-17	524	14	,	,	PUNCT
bptjm-17	524	15	p.	p.	NOUN
bptjm-17	524	16	m.	m.	NOUN
bptjm-17	524	17	,	,	PUNCT
bptjm-17	524	18	&	&	CCONJ
bptjm-17	524	19	watson	watson	PROPN
bptjm-17	524	20	,	,	PUNCT
bptjm-17	524	21	i.	i.	PROPN
bptjm-17	524	22	r.	r.	PROPN
bptjm-17	524	23	(	(	PUNCT
bptjm-17	524	24	2018	2018	NUM
bptjm-17	524	25	)	)	PUNCT
bptjm-17	524	26	.	.	PUNCT
bptjm-17	525	1	classifying	classify	VERB
bptjm-17	525	2	braf	braf	NOUN
bptjm-17	525	3	alterations	alteration	NOUN
bptjm-17	525	4	in	in	ADP
bptjm-17	525	5	cancer	cancer	NOUN
bptjm-17	525	6	:	:	PUNCT
bptjm-17	525	7	new	new	ADJ
bptjm-17	525	8	rational	rational	ADJ
bptjm-17	525	9	therapeutic	therapeutic	ADJ
bptjm-17	525	10	strategies	strategy	NOUN
bptjm-17	525	11	for	for	ADP
bptjm-17	525	12	actionable	actionable	ADJ
bptjm-17	525	13	mutations	mutation	NOUN
bptjm-17	525	14	.	.	PUNCT
bptjm-17	526	1	oncogene	oncogene	NOUN
bptjm-17	526	2	,	,	PUNCT
bptjm-17	526	3	37(24	37(24	NUM
bptjm-17	526	4	)	)	PUNCT
bptjm-17	526	5	,	,	PUNCT
bptjm-17	526	6	3183–3199	3183–3199	NUM
bptjm-17	526	7	.	.	PUNCT
bptjm-17	527	1	https://doi.org/10.1038/s41388-018-0171-x	https://doi.org/10.1038/s41388-018-0171-x	NOUN
bptjm-17	527	2	15	15	NUM
bptjm-17	527	3	.	.	PUNCT
bptjm-17	527	4	de	de	PROPN
bptjm-17	527	5	marco	marco	PROPN
bptjm-17	527	6	,	,	PUNCT
bptjm-17	527	7	c.	c.	PROPN
bptjm-17	527	8	,	,	PUNCT
bptjm-17	527	9	laudanna	laudanna	PROPN
bptjm-17	527	10	,	,	PUNCT
bptjm-17	527	11	c.	c.	PROPN
bptjm-17	527	12	,	,	PUNCT
bptjm-17	527	13	rinaldo	rinaldo	PROPN
bptjm-17	527	14	,	,	PUNCT
bptjm-17	527	15	n.	n.	PROPN
bptjm-17	527	16	,	,	PUNCT
bptjm-17	527	17	oliveira	oliveira	PROPN
bptjm-17	527	18	,	,	PUNCT
bptjm-17	527	19	d.	d.	PROPN
bptjm-17	527	20	m.	m.	PROPN
bptjm-17	527	21	,	,	PUNCT
bptjm-17	527	22	ravo	ravo	NOUN
bptjm-17	527	23	,	,	PUNCT
bptjm-17	527	24	m.	m.	NOUN
bptjm-17	527	25	,	,	PUNCT
bptjm-17	527	26	weisz	weisz	NOUN
bptjm-17	527	27	,	,	PUNCT
bptjm-17	527	28	a.	a.	PROPN
bptjm-17	527	29	,	,	PUNCT
bptjm-17	527	30	ceccarelli	ceccarelli	ADV
bptjm-17	527	31	,	,	PUNCT
bptjm-17	527	32	m.	m.	NOUN
bptjm-17	527	33	,	,	PUNCT
bptjm-17	527	34	caira	caira	PROPN
bptjm-17	527	35	,	,	PUNCT
bptjm-17	527	36	e.	e.	PROPN
bptjm-17	527	37	,	,	PUNCT
bptjm-17	527	38	rizzuto	rizzuto	PROPN
bptjm-17	527	39	,	,	PUNCT
bptjm-17	527	40	a.	a.	PROPN
bptjm-17	527	41	,	,	PUNCT
bptjm-17	527	42	zoppoli	zoppoli	PROPN
bptjm-17	527	43	,	,	PUNCT
bptjm-17	527	44	p.	p.	NOUN
bptjm-17	527	45	,	,	PUNCT
bptjm-17	527	46	malanga	malanga	PROPN
bptjm-17	527	47	,	,	PUNCT
bptjm-17	527	48	d.	d.	PROPN
bptjm-17	527	49	,	,	PUNCT
bptjm-17	527	50	&	&	CCONJ
bptjm-17	527	51	viglietto	viglietto	NOUN
bptjm-17	527	52	,	,	PUNCT
bptjm-17	527	53	g.	g.	PROPN
bptjm-17	527	54	(	(	PUNCT
bptjm-17	527	55	2017	2017	NUM
bptjm-17	527	56	)	)	PUNCT
bptjm-17	527	57	.	.	PUNCT
bptjm-17	528	1	speci	speci	PROPN
bptjm-17	528	2	�	�	PROPN
bptjm-17	528	3	c	c	PROPN
bptjm-17	528	4	gene	gene	NOUN
bptjm-17	528	5	expression	expression	NOUN
bptjm-17	528	6	signatures	signature	NOUN
bptjm-17	528	7	induced	induce	VERB
bptjm-17	528	8	by	by	ADP
bptjm-17	528	9	the	the	DET
bptjm-17	528	10	multiple	multiple	ADJ
bptjm-17	528	11	oncogenic	oncogenic	ADJ
bptjm-17	528	12	alterations	alteration	NOUN
bptjm-17	528	13	that	that	PRON
bptjm-17	528	14	occur	occur	VERB
bptjm-17	528	15	within	within	ADP
bptjm-17	528	16	the	the	DET
bptjm-17	528	17	pten	pten	NOUN
bptjm-17	528	18	/	/	SYM
bptjm-17	528	19	pi3k	pi3k	NOUN
bptjm-17	528	20	/	/	SYM
bptjm-17	528	21	akt	akt	PROPN
bptjm-17	528	22	pathway	pathway	NOUN
bptjm-17	528	23	in	in	ADP
bptjm-17	528	24	lung	lung	NOUN
bptjm-17	528	25	cancer	cancer	NOUN
bptjm-17	528	26	.	.	PUNCT
bptjm-17	529	1	plos	plos	PROPN
bptjm-17	529	2	one	one	NUM
bptjm-17	529	3	,	,	PUNCT
bptjm-17	529	4	12(6	12(6	NUM
bptjm-17	529	5	)	)	PUNCT
bptjm-17	529	6	,	,	PUNCT
bptjm-17	529	7	e0178865	e0178865	X
bptjm-17	529	8	.	.	PUNCT
bptjm-17	530	1	https://doi.org/10.1371/journal.pone.0178865	https://doi.org/10.1371/journal.pone.0178865	VERB
bptjm-17	530	2	16	16	NUM
bptjm-17	530	3	.	.	PUNCT
bptjm-17	531	1	delmonico	delmonico	PROPN
bptjm-17	531	2	,	,	PUNCT
bptjm-17	531	3	l.	l.	PROPN
bptjm-17	531	4	et	et	PROPN
bptjm-17	531	5	al	al	PROPN
bptjm-17	531	6	.	.	PROPN
bptjm-17	532	1	(	(	PUNCT
bptjm-17	532	2	2019	2019	NUM
bptjm-17	532	3	)	)	PUNCT
bptjm-17	532	4	.	.	PUNCT
bptjm-17	533	1	mutation	mutation	NOUN
bptjm-17	533	2	pro	pro	PROPN
bptjm-17	533	3	�	�	VERB
bptjm-17	533	4	ling	ling	NOUN
bptjm-17	533	5	in	in	ADP
bptjm-17	533	6	the	the	DET
bptjm-17	533	7	pik3ca	pik3ca	PROPN
bptjm-17	533	8	,	,	PUNCT
bptjm-17	533	9	tp53	tp53	PROPN
bptjm-17	533	10	,	,	PUNCT
bptjm-17	533	11	and	and	CCONJ
bptjm-17	533	12	cdkn2a	cdkn2a	PROPN
bptjm-17	533	13	genes	gene	NOUN
bptjm-17	533	14	in	in	ADP
bptjm-17	533	15	circulating	circulate	VERB
bptjm-17	533	16	free	free	ADJ
bptjm-17	533	17	dna	dna	NOUN
bptjm-17	533	18	and	and	CCONJ
bptjm-17	533	19	impalpable	impalpable	ADJ
bptjm-17	533	20	breast	breast	NOUN
bptjm-17	533	21	lesions	lesion	NOUN
bptjm-17	533	22	.	.	PUNCT
bptjm-17	534	1	annals	annal	NOUN
bptjm-17	534	2	of	of	ADP
bptjm-17	534	3	diagnostic	diagnostic	ADJ
bptjm-17	534	4	pathology	pathology	NOUN
bptjm-17	534	5	,	,	PUNCT
bptjm-17	534	6	39	39	NUM
bptjm-17	534	7	,	,	PUNCT
bptjm-17	534	8	30–35	30–35	NUM
bptjm-17	534	9	.	.	PUNCT
bptjm-17	535	1	https://doi.org/10.1016/j.anndiagpath.2018.12.008	https://doi.org/10.1016/j.anndiagpath.2018.12.008	NOUN
bptjm-17	535	2	.	.	PUNCT
bptjm-17	536	1	17	17	NUM
bptjm-17	536	2	.	.	PUNCT
bptjm-17	537	1	gagliato	gagliato	PROPN
bptjm-17	537	2	d.	d.	PROPN
bptjm-17	537	3	de	de	PROPN
bptjm-17	537	4	melo	melo	PROPN
bptjm-17	537	5	,	,	PUNCT
bptjm-17	537	6	jardim	jardim	PROPN
bptjm-17	537	7	d.	d.	PROPN
bptjm-17	537	8	leonardo	leonardo	PROPN
bptjm-17	537	9	fontes	fontes	PROPN
bptjm-17	537	10	,	,	PUNCT
bptjm-17	537	11	marchesi	marchesi	PROPN
bptjm-17	537	12	m.	m.	PROPN
bptjm-17	537	13	sergio	sergio	PROPN
bptjm-17	537	14	pereira	pereira	PROPN
bptjm-17	537	15	,	,	PUNCT
bptjm-17	537	16	hortobagyi	hortobagyi	PROPN
bptjm-17	537	17	g.	g.	PROPN
bptjm-17	537	18	n.	n.	PROPN
bptjm-17	537	19	(	(	PUNCT
bptjm-17	537	20	2016	2016	NUM
bptjm-17	537	21	)	)	PUNCT
bptjm-17	537	22	.	.	PUNCT
bptjm-17	538	1	mechanisms	mechanism	NOUN
bptjm-17	538	2	of	of	ADP
bptjm-17	538	3	resistance	resistance	NOUN
bptjm-17	538	4	and	and	CCONJ
bptjm-17	538	5	sensitivity	sensitivity	NOUN
bptjm-17	538	6	to	to	ADP
bptjm-17	538	7	anti	anti	ADJ
bptjm-17	538	8	-	-	ADJ
bptjm-17	538	9	her2	her2	ADJ
bptjm-17	538	10	therapies	therapy	NOUN
bptjm-17	538	11	in	in	ADP
bptjm-17	538	12	her2	her2	PROPN
bptjm-17	538	13	+	+	CCONJ
bptjm-17	538	14	breast	breast	NOUN
bptjm-17	538	15	cancer	cancer	NOUN
bptjm-17	538	16	.	.	PUNCT
bptjm-17	539	1	oncotarget	oncotarget	NOUN
bptjm-17	539	2	.	.	PUNCT
bptjm-17	540	1	7	7	NUM
bptjm-17	540	2	,	,	PUNCT
bptjm-17	540	3	64431	64431	NUM
bptjm-17	540	4	-	-	SYM
bptjm-17	540	5	64446	64446	NUM
bptjm-17	540	6	.	.	PUNCT
bptjm-17	541	1	retrieved	retrieve	VERB
bptjm-17	541	2	from	from	ADP
bptjm-17	541	3	https://www.oncotarget.com/article/7043/text/	https://www.oncotarget.com/article/7043/text/	PROPN
bptjm-17	541	4	18	18	NUM
bptjm-17	541	5	.	.	PUNCT
bptjm-17	542	1	dejima	dejima	PROPN
bptjm-17	542	2	,	,	PUNCT
bptjm-17	542	3	h.	h.	PROPN
bptjm-17	542	4	,	,	PUNCT
bptjm-17	542	5	iinuma	iinuma	PROPN
bptjm-17	542	6	,	,	PUNCT
bptjm-17	542	7	h.	h.	PROPN
bptjm-17	542	8	,	,	PUNCT
bptjm-17	542	9	kanaoka	kanaoka	PROPN
bptjm-17	542	10	,	,	PUNCT
bptjm-17	542	11	r.	r.	PROPN
bptjm-17	542	12	,	,	PUNCT
bptjm-17	542	13	matsutani	matsutani	PROPN
bptjm-17	542	14	,	,	PUNCT
bptjm-17	542	15	n.	n.	NOUN
bptjm-17	542	16	,	,	PUNCT
bptjm-17	542	17	&	&	CCONJ
bptjm-17	542	18	kawamura	kawamura	PROPN
bptjm-17	542	19	,	,	PUNCT
bptjm-17	542	20	m.	m.	NOUN
bptjm-17	542	21	(	(	PUNCT
bptjm-17	542	22	2017	2017	NUM
bptjm-17	542	23	)	)	PUNCT
bptjm-17	542	24	.	.	PUNCT
bptjm-17	543	1	exosomal	exosomal	PROPN
bptjm-17	543	2	microrna	microrna	PROPN
bptjm-17	543	3	in	in	ADP
bptjm-17	543	4	plasma	plasma	NOUN
bptjm-17	543	5	as	as	ADP
bptjm-17	543	6	a	a	DET
bptjm-17	543	7	non	non	ADJ
bptjm-17	543	8	-	-	ADJ
bptjm-17	543	9	invasive	invasive	ADJ
bptjm-17	543	10	biomarker	biomarker	NOUN
bptjm-17	543	11	for	for	ADP
bptjm-17	543	12	the	the	DET
bptjm-17	543	13	recurrence	recurrence	NOUN
bptjm-17	543	14	of	of	ADP
bptjm-17	543	15	non	non	ADJ
bptjm-17	543	16	-	-	ADJ
bptjm-17	543	17	small	small	ADJ
bptjm-17	543	18	cell	cell	NOUN
bptjm-17	543	19	lung	lung	NOUN
bptjm-17	543	20	cancer	cancer	NOUN
bptjm-17	543	21	.	.	PUNCT
bptjm-17	544	1	oncology	oncology	NOUN
bptjm-17	544	2	letters	letter	NOUN
bptjm-17	544	3	,	,	PUNCT
bptjm-17	544	4	13(3	13(3	NUM
bptjm-17	544	5	)	)	PUNCT
bptjm-17	544	6	,	,	PUNCT
bptjm-17	544	7	1256–1263	1256–1263	NUM
bptjm-17	544	8	.	.	PUNCT
bptjm-17	545	1	https://doi.org/10.3892/ol.2017.5569	https://doi.org/10.3892/ol.2017.5569	PROPN
bptjm-17	545	2	19	19	NUM
bptjm-17	545	3	.	.	PUNCT
bptjm-17	545	4	deng	deng	PROPN
bptjm-17	545	5	,	,	PUNCT
bptjm-17	545	6	l.	l.	PROPN
bptjm-17	545	7	,	,	PUNCT
bptjm-17	545	8	kiedrowski	kiedrowski	PROPN
bptjm-17	545	9	,	,	PUNCT
bptjm-17	545	10	l.	l.	PROPN
bptjm-17	545	11	a.	a.	PROPN
bptjm-17	545	12	,	,	PUNCT
bptjm-17	545	13	ravera	ravera	PROPN
bptjm-17	545	14	,	,	PUNCT
bptjm-17	545	15	e.	e.	PROPN
bptjm-17	545	16	,	,	PUNCT
bptjm-17	545	17	cheng	cheng	PROPN
bptjm-17	545	18	,	,	PUNCT
bptjm-17	545	19	h.	h.	PROPN
bptjm-17	545	20	,	,	PUNCT
bptjm-17	545	21	&	&	CCONJ
bptjm-17	545	22	halmos	halmos	PROPN
bptjm-17	545	23	,	,	PUNCT
bptjm-17	545	24	b.	b.	PROPN
bptjm-17	545	25	(	(	PUNCT
bptjm-17	545	26	2018	2018	NUM
bptjm-17	545	27	)	)	PUNCT
bptjm-17	545	28	.	.	PUNCT
bptjm-17	546	1	response	response	NOUN
bptjm-17	546	2	to	to	ADP
bptjm-17	546	3	dual	dual	ADJ
bptjm-17	546	4	crizotinib	crizotinib	NOUN
bptjm-17	546	5	and	and	CCONJ
bptjm-17	546	6	osimertinib	osimertinib	VERB
bptjm-17	546	7	treatment	treatment	NOUN
bptjm-17	546	8	in	in	ADP
bptjm-17	546	9	a	a	DET
bptjm-17	546	10	lung	lung	NOUN
bptjm-17	546	11	cancer	cancer	NOUN
bptjm-17	546	12	patient	patient	NOUN
bptjm-17	546	13	with	with	ADP
bptjm-17	546	14	met	meet	VERB
bptjm-17	546	15	ampli	ampli	NOUN
bptjm-17	546	16	�	�	NOUN
bptjm-17	546	17	cation	cation	NOUN
bptjm-17	546	18	detected	detect	VERB
bptjm-17	546	19	by	by	ADP
bptjm-17	546	20	liquid	liquid	ADJ
bptjm-17	546	21	biopsy	biopsy	NOUN
bptjm-17	546	22	who	who	PRON
bptjm-17	546	23	acquired	acquire	VERB
bptjm-17	546	24	secondary	secondary	ADJ
bptjm-17	546	25	resistance	resistance	NOUN
bptjm-17	546	26	to	to	ADP
bptjm-17	546	27	egfr	egfr	PROPN
bptjm-17	546	28	tyrosine	tyrosine	PROPN
bptjm-17	546	29	kinase	kinase	PROPN
bptjm-17	546	30	inhibition	inhibition	NOUN
bptjm-17	546	31	.	.	PUNCT
bptjm-17	547	1	journal	journal	NOUN
bptjm-17	547	2	of	of	ADP
bptjm-17	547	3	thoracic	thoracic	NOUN
bptjm-17	547	4	oncology	oncology	NOUN
bptjm-17	547	5	:	:	PUNCT
bptjm-17	547	6	official	official	ADJ
bptjm-17	547	7	publication	publication	NOUN
bptjm-17	547	8	of	of	ADP
bptjm-17	547	9	the	the	DET
bptjm-17	547	10	international	international	ADJ
bptjm-17	547	11	association	association	NOUN
bptjm-17	547	12	for	for	ADP
bptjm-17	547	13	the	the	DET
bptjm-17	547	14	study	study	NOUN
bptjm-17	547	15	of	of	ADP
bptjm-17	547	16	lung	lung	NOUN
bptjm-17	547	17	cancer	cancer	NOUN
bptjm-17	547	18	,	,	PUNCT
bptjm-17	547	19	13(9	13(9	NUM
bptjm-17	547	20	)	)	PUNCT
bptjm-17	547	21	,	,	PUNCT
bptjm-17	547	22	e169	e169	PROPN
bptjm-17	547	23	–	–	PUNCT
bptjm-17	547	24	e172	e172	NUM
bptjm-17	547	25	.	.	PUNCT
bptjm-17	548	1	https://doi.org/10.1016/j.jtho.2018.04.007	https://doi.org/10.1016/j.jtho.2018.04.007	PROPN
bptjm-17	548	2	20	20	NUM
bptjm-17	548	3	.	.	PUNCT
bptjm-17	549	1	donnem	donnem	PROPN
bptjm-17	549	2	,	,	PUNCT
bptjm-17	549	3	t.	t.	PROPN
bptjm-17	549	4	,	,	PUNCT
bptjm-17	549	5	eklo	eklo	PROPN
bptjm-17	549	6	,	,	PUNCT
bptjm-17	549	7	k.	k.	PROPN
bptjm-17	549	8	,	,	PUNCT
bptjm-17	549	9	berg	berg	PROPN
bptjm-17	549	10	,	,	PUNCT
bptjm-17	549	11	t.	t.	PROPN
bptjm-17	549	12	et	et	PROPN
bptjm-17	549	13	al	al	PROPN
bptjm-17	549	14	.	.	PROPN
bptjm-17	550	1	(	(	PUNCT
bptjm-17	550	2	2011	2011	NUM
bptjm-17	550	3	)	)	PUNCT
bptjm-17	550	4	.	.	PUNCT
bptjm-17	551	1	prognostic	prognostic	ADJ
bptjm-17	551	2	impact	impact	NOUN
bptjm-17	551	3	of	of	ADP
bptjm-17	551	4	mir-155	mir-155	NOUN
bptjm-17	551	5	in	in	ADP
bptjm-17	551	6	non	non	ADJ
bptjm-17	551	7	-	-	ADJ
bptjm-17	551	8	small	small	ADJ
bptjm-17	551	9	cell	cell	NOUN
bptjm-17	551	10	lung	lung	NOUN
bptjm-17	551	11	cancer	cancer	NOUN
bptjm-17	551	12	evaluated	evaluate	VERB
bptjm-17	551	13	by	by	ADP
bptjm-17	551	14	in	in	ADP
bptjm-17	551	15	situ	situ	ADJ
bptjm-17	551	16	hybridization	hybridization	NOUN
bptjm-17	551	17	.	.	PUNCT
bptjm-17	552	1	journal	journal	NOUN
bptjm-17	552	2	of	of	ADP
bptjm-17	552	3	translational	translational	ADJ
bptjm-17	552	4	medicine	medicine	NOUN
bptjm-17	552	5	,	,	PUNCT
bptjm-17	552	6	9(6	9(6	NUM
bptjm-17	552	7	)	)	PUNCT
bptjm-17	552	8	.	.	PUNCT
bptjm-17	553	1	https://doi.org/10.1186/1479-5876-9-6	https://doi.org/10.1186/1479-5876-9-6	PROPN
bptjm-17	553	2	.	.	PUNCT
bptjm-17	554	1	21	21	NUM
bptjm-17	554	2	.	.	PUNCT
bptjm-17	555	1	dou	dou	PROPN
bptjm-17	555	2	,	,	PUNCT
bptjm-17	555	3	h.	h.	PROPN
bptjm-17	555	4	,	,	PUNCT
bptjm-17	555	5	wang	wang	PROPN
bptjm-17	555	6	,	,	PUNCT
bptjm-17	555	7	y.	y.	PROPN
bptjm-17	555	8	,	,	PUNCT
bptjm-17	555	9	su	su	PROPN
bptjm-17	555	10	,	,	PUNCT
bptjm-17	555	11	g.	g.	PROPN
bptjm-17	555	12	,	,	PUNCT
bptjm-17	555	13	&	&	CCONJ
bptjm-17	555	14	zhao	zhao	PROPN
bptjm-17	555	15	,	,	PUNCT
bptjm-17	555	16	s.	s.	PROPN
bptjm-17	555	17	(	(	PUNCT
bptjm-17	555	18	2015	2015	NUM
bptjm-17	555	19	)	)	PUNCT
bptjm-17	555	20	.	.	PUNCT
bptjm-17	556	1	decreased	decrease	VERB
bptjm-17	556	2	plasma	plasma	NOUN
bptjm-17	556	3	let-7c	let-7c	PROPN
bptjm-17	556	4	and	and	CCONJ
bptjm-17	556	5	mir-152	mir-152	NOUN
bptjm-17	556	6	as	as	ADP
bptjm-17	556	7	noninvasive	noninvasive	ADJ
bptjm-17	556	8	biomarker	biomarker	NOUN
bptjm-17	556	9	for	for	ADP
bptjm-17	556	10	non	non	ADJ
bptjm-17	556	11	-	-	ADJ
bptjm-17	556	12	small	small	ADJ
bptjm-17	556	13	-	-	PUNCT
bptjm-17	556	14	cell	cell	NOUN
bptjm-17	556	15	lung	lung	NOUN
bptjm-17	556	16	cancer	cancer	NOUN
bptjm-17	556	17	.	.	PUNCT
bptjm-17	557	1	international	international	ADJ
bptjm-17	557	2	journal	journal	NOUN
bptjm-17	557	3	of	of	ADP
bptjm-17	557	4	clinical	clinical	ADJ
bptjm-17	557	5	and	and	CCONJ
bptjm-17	557	6	experimental	experimental	ADJ
bptjm-17	557	7	medicine	medicine	NOUN
bptjm-17	557	8	,	,	PUNCT
bptjm-17	557	9	8(6	8(6	NUM
bptjm-17	557	10	)	)	PUNCT
bptjm-17	557	11	,	,	PUNCT
bptjm-17	557	12	9291–9298	9291–9298	NUM
bptjm-17	557	13	.	.	PUNCT
bptjm-17	558	1	22	22	NUM
bptjm-17	558	2	.	.	PUNCT
bptjm-17	559	1	embl	embl	NOUN
bptjm-17	559	2	-	-	PUNCT
bptjm-17	559	3	ebi	ebi	PROPN
bptjm-17	559	4	.	.	PUNCT
bptjm-17	560	1	(	(	PUNCT
bptjm-17	560	2	n.d	n.d	PROPN
bptjm-17	560	3	.	.	PROPN
bptjm-17	560	4	)	)	PUNCT
bptjm-17	560	5	.	.	PUNCT
bptjm-17	561	1	what	what	PRON
bptjm-17	561	2	is	be	AUX
bptjm-17	561	3	next	next	ADJ
bptjm-17	561	4	generation	generation	NOUN
bptjm-17	561	5	dna	dna	NOUN
bptjm-17	561	6	sequencing	sequencing	NOUN
bptjm-17	561	7	?	?	PUNCT
bptjm-17	562	1	retrieved	retrieve	VERB
bptjm-17	562	2	december	december	PROPN
bptjm-17	562	3	08	08	NUM
bptjm-17	562	4	,	,	PUNCT
bptjm-17	562	5	2020	2020	NUM
bptjm-17	562	6	,	,	PUNCT
bptjm-17	562	7	from	from	ADP
bptjm-17	562	8	https://www.ebi.ac.uk/training-beta/online/courses/fu	https://www.ebi.ac.uk/training-beta/online/courses/fu	PROPN
bptjm-17	562	9	nctional	nctional	ADJ
bptjm-17	562	10	-	-	PUNCT
bptjm-17	562	11	genomics	genomics	NOUN
bptjm-17	562	12	-	-	PUNCT
bptjm-17	562	13	iicommon	iicommon	NOUN
bptjm-17	562	14	-	-	PUNCT
bptjm-17	562	15	technologies	technology	NOUN
bptjm-17	562	16	-	-	PUNCT
bptjm-17	562	17	and	and	CCONJ
bptjm-17	562	18	-	-	PUNCT
bptjm-17	562	19	data	data	NOUN
bptjm-17	562	20	-	-	PUNCT
bptjm-17	562	21	an	an	DET
bptjm-17	562	22	alysis	alysis	NOUN
bptjm-17	562	23	-	-	PUNCT
bptjm-17	562	24	methods	method	NOUN
bptjm-17	562	25	/	/	SYM
bptjm-17	562	26	next	next	ADJ
bptjm-17	562	27	-	-	PUNCT
bptjm-17	562	28	generation	generation	NOUN
bptjm-17	562	29	-	-	PUNCT
bptjm-17	562	30	sequencing/	sequencing/	NUM
bptjm-17	562	31	berkeley	berkeley	PROPN
bptjm-17	562	32	pharma	pharma	PROPN
bptjm-17	562	33	tech	tech	NOUN
bptjm-17	562	34	journal	journal	NOUN
bptjm-17	562	35	of	of	ADP
bptjm-17	562	36	medicine	medicine	NOUN
bptjm-17	562	37	|	|	ADV
bptjm-17	562	38	147	147	NUM
bptjm-17	562	39	https://doi.org/10.1371/journal.pone.0178865	https://doi.org/10.1371/journal.pone.0178865	VERB
bptjm-17	562	40	https://doi.org/10.1186/1479-5876-9-6	https://doi.org/10.1186/1479-5876-9-6	VERB
bptjm-17	562	41	http://www.ebi.ac.uk/training-beta/online/courses/functional-genomics-ii	http://www.ebi.ac.uk/training-beta/online/courses/functional-genomics-ii	PROPN
bptjm-17	562	42	http://www.ebi.ac.uk/training-beta/online/courses/functional-genomics-ii	http://www.ebi.ac.uk/training-beta/online/courses/functional-genomics-ii	PROPN
bptjm-17	562	43	http://www.ebi.ac.uk/training-beta/online/courses/functional-genomics-ii	http://www.ebi.ac.uk/training-beta/online/courses/functional-genomics-ii	PROPN
bptjm-17	562	44	23	23	NUM
bptjm-17	562	45	.	.	PUNCT
bptjm-17	563	1	farago	farago	PROPN
bptjm-17	563	2	,	,	PUNCT
bptjm-17	563	3	a.	a.	PROPN
bptjm-17	563	4	f.	f.	PROPN
bptjm-17	563	5	,	,	PUNCT
bptjm-17	563	6	le	le	PROPN
bptjm-17	563	7	,	,	PUNCT
bptjm-17	563	8	l.	l.	PROPN
bptjm-17	563	9	p.	p.	PROPN
bptjm-17	563	10	,	,	PUNCT
bptjm-17	563	11	zheng	zheng	PROPN
bptjm-17	563	12	,	,	PUNCT
bptjm-17	563	13	z.	z.	PROPN
bptjm-17	563	14	,	,	PUNCT
bptjm-17	563	15	muzikansky	muzikansky	PROPN
bptjm-17	563	16	,	,	PUNCT
bptjm-17	563	17	a.	a.	NOUN
bptjm-17	563	18	,	,	PUNCT
bptjm-17	563	19	drilon	drilon	NOUN
bptjm-17	563	20	,	,	PUNCT
bptjm-17	563	21	a.	a.	NOUN
bptjm-17	563	22	,	,	PUNCT
bptjm-17	563	23	patel	patel	PROPN
bptjm-17	563	24	,	,	PUNCT
bptjm-17	563	25	m.	m.	NOUN
bptjm-17	563	26	,	,	PUNCT
bptjm-17	563	27	bauer	bauer	PROPN
bptjm-17	563	28	,	,	PUNCT
bptjm-17	563	29	t.	t.	PROPN
bptjm-17	563	30	m.	m.	NOUN
bptjm-17	563	31	,	,	PUNCT
bptjm-17	563	32	liu	liu	PROPN
bptjm-17	563	33	,	,	PUNCT
bptjm-17	563	34	s.	s.	PROPN
bptjm-17	563	35	v.	v.	PROPN
bptjm-17	563	36	,	,	PUNCT
bptjm-17	563	37	ou	ou	PROPN
bptjm-17	563	38	,	,	PUNCT
bptjm-17	563	39	s.	s.	PROPN
bptjm-17	563	40	h.	h.	PROPN
bptjm-17	563	41	,	,	PUNCT
bptjm-17	563	42	jackman	jackman	PROPN
bptjm-17	563	43	,	,	PUNCT
bptjm-17	563	44	d.	d.	PROPN
bptjm-17	563	45	,	,	PUNCT
bptjm-17	563	46	costa	costa	PROPN
bptjm-17	563	47	,	,	PUNCT
bptjm-17	563	48	d.	d.	PROPN
bptjm-17	563	49	b.	b.	PROPN
bptjm-17	563	50	,	,	PUNCT
bptjm-17	563	51	multani	multani	PROPN
bptjm-17	563	52	,	,	PUNCT
bptjm-17	563	53	p.	p.	PROPN
bptjm-17	563	54	s.	s.	PROPN
bptjm-17	563	55	,	,	PUNCT
bptjm-17	563	56	li	li	PROPN
bptjm-17	563	57	,	,	PUNCT
bptjm-17	563	58	g.	g.	PROPN
bptjm-17	563	59	g.	g.	PROPN
bptjm-17	563	60	,	,	PUNCT
bptjm-17	563	61	hornby	hornby	PROPN
bptjm-17	563	62	,	,	PUNCT
bptjm-17	563	63	z.	z.	PROPN
bptjm-17	563	64	,	,	PUNCT
bptjm-17	563	65	chow	chow	NOUN
bptjm-17	563	66	-	-	PUNCT
bptjm-17	563	67	maneval	maneval	NOUN
bptjm-17	563	68	,	,	PUNCT
bptjm-17	563	69	e.	e.	PROPN
bptjm-17	563	70	,	,	PUNCT
bptjm-17	563	71	luo	luo	PROPN
bptjm-17	563	72	,	,	PUNCT
bptjm-17	563	73	d.	d.	PROPN
bptjm-17	563	74	,	,	PUNCT
bptjm-17	563	75	lim	lim	PROPN
bptjm-17	563	76	,	,	PUNCT
bptjm-17	563	77	j.	j.	PROPN
bptjm-17	563	78	e.	e.	PROPN
bptjm-17	563	79	,	,	PUNCT
bptjm-17	563	80	iafrate	iafrate	ADJ
bptjm-17	563	81	,	,	PUNCT
bptjm-17	563	82	a.	a.	PROPN
bptjm-17	563	83	j.	j.	PROPN
bptjm-17	563	84	,	,	PUNCT
bptjm-17	563	85	&	&	CCONJ
bptjm-17	563	86	shaw	shaw	PROPN
bptjm-17	563	87	,	,	PUNCT
bptjm-17	563	88	a.	a.	NOUN
bptjm-17	563	89	t.	t.	PROPN
bptjm-17	563	90	(	(	PUNCT
bptjm-17	563	91	2015	2015	NUM
bptjm-17	563	92	)	)	PUNCT
bptjm-17	563	93	.	.	PUNCT
bptjm-17	564	1	durable	durable	ADJ
bptjm-17	564	2	clinical	clinical	ADJ
bptjm-17	564	3	response	response	NOUN
bptjm-17	564	4	to	to	ADP
bptjm-17	564	5	entrectinib	entrectinib	VERB
bptjm-17	564	6	in	in	ADP
bptjm-17	564	7	ntrk1	ntrk1	NOUN
bptjm-17	564	8	-	-	PUNCT
bptjm-17	564	9	rearranged	rearrange	VERB
bptjm-17	564	10	non	non	ADJ
bptjm-17	564	11	-	-	ADJ
bptjm-17	564	12	small	small	ADJ
bptjm-17	564	13	cell	cell	NOUN
bptjm-17	564	14	lung	lung	NOUN
bptjm-17	564	15	cancer	cancer	NOUN
bptjm-17	564	16	.	.	PUNCT
bptjm-17	565	1	journal	journal	PROPN
bptjm-17	565	2	of	of	ADP
bptjm-17	565	3	thoracic	thoracic	NOUN
bptjm-17	565	4	oncology	oncology	NOUN
bptjm-17	565	5	:	:	PUNCT
bptjm-17	565	6	official	official	ADJ
bptjm-17	565	7	publication	publication	NOUN
bptjm-17	565	8	of	of	ADP
bptjm-17	565	9	the	the	DET
bptjm-17	565	10	international	international	ADJ
bptjm-17	565	11	association	association	NOUN
bptjm-17	565	12	for	for	ADP
bptjm-17	565	13	the	the	DET
bptjm-17	565	14	study	study	NOUN
bptjm-17	565	15	of	of	ADP
bptjm-17	565	16	lung	lung	NOUN
bptjm-17	565	17	cancer	cancer	NOUN
bptjm-17	565	18	,	,	PUNCT
bptjm-17	565	19	10(12	10(12	NUM
bptjm-17	565	20	)	)	PUNCT
bptjm-17	565	21	,	,	PUNCT
bptjm-17	565	22	1670–1674	1670–1674	NUM
bptjm-17	565	23	.	.	PUNCT
bptjm-17	566	1	https://doi.org/10.1097/01.jto	https://doi.org/10.1097/01.jto	NOUN
bptjm-17	566	2	.	.	PUNCT
bptjm-17	567	1	0000473485.38553.f0	0000473485.38553.f0	PROPN
bptjm-17	567	2	.	.	PUNCT
bptjm-17	568	1	24	24	NUM
bptjm-17	568	2	.	.	PUNCT
bptjm-17	569	1	feng	feng	PROPN
bptjm-17	569	2	,	,	PUNCT
bptjm-17	569	3	y.	y.	PROPN
bptjm-17	569	4	h.	h.	PROPN
bptjm-17	569	5	,	,	PUNCT
bptjm-17	569	6	&	&	CCONJ
bptjm-17	569	7	tsao	tsao	PROPN
bptjm-17	569	8	,	,	PUNCT
bptjm-17	569	9	c.	c.	PROPN
bptjm-17	569	10	j.	j.	PROPN
bptjm-17	569	11	(	(	PUNCT
bptjm-17	569	12	2016	2016	NUM
bptjm-17	569	13	)	)	PUNCT
bptjm-17	569	14	.	.	PUNCT
bptjm-17	570	1	emerging	emerge	VERB
bptjm-17	570	2	role	role	NOUN
bptjm-17	570	3	of	of	ADP
bptjm-17	570	4	microrna-21	microrna-21	PROPN
bptjm-17	570	5	in	in	ADP
bptjm-17	570	6	cancer	cancer	NOUN
bptjm-17	570	7	.	.	PUNCT
bptjm-17	571	1	biomedical	biomedical	ADJ
bptjm-17	571	2	reports	report	NOUN
bptjm-17	571	3	,	,	PUNCT
bptjm-17	571	4	5(4	5(4	NUM
bptjm-17	571	5	)	)	PUNCT
bptjm-17	571	6	,	,	PUNCT
bptjm-17	571	7	395–402	395–402	NUM
bptjm-17	571	8	.	.	PUNCT
bptjm-17	572	1	https://doi.org/10.3892/br.2016.747	https://doi.org/10.3892/br.2016.747	X
bptjm-17	573	1	25	25	NUM
bptjm-17	573	2	.	.	PUNCT
bptjm-17	574	1	fuchs	fuchs	PROPN
bptjm-17	574	2	,	,	PUNCT
bptjm-17	574	3	a.	a.	PROPN
bptjm-17	574	4	,	,	PUNCT
bptjm-17	574	5	könig	könig	PROPN
bptjm-17	574	6	,	,	PUNCT
bptjm-17	574	7	k.	k.	PROPN
bptjm-17	574	8	,	,	PUNCT
bptjm-17	574	9	heukamp	heukamp	PROPN
bptjm-17	574	10	,	,	PUNCT
bptjm-17	574	11	l.	l.	PROPN
bptjm-17	574	12	c.	c.	PROPN
bptjm-17	574	13	,	,	PUNCT
bptjm-17	574	14	fassunke	fassunke	NOUN
bptjm-17	574	15	,	,	PUNCT
bptjm-17	574	16	j.	j.	PROPN
bptjm-17	574	17	,	,	PUNCT
bptjm-17	574	18	kirfel	kirfel	PROPN
bptjm-17	574	19	,	,	PUNCT
bptjm-17	574	20	j.	j.	PROPN
bptjm-17	574	21	,	,	PUNCT
bptjm-17	574	22	huss	huss	PROPN
bptjm-17	574	23	,	,	PUNCT
bptjm-17	574	24	s.	s.	PROPN
bptjm-17	574	25	,	,	PUNCT
bptjm-17	574	26	becker	becker	PROPN
bptjm-17	574	27	,	,	PUNCT
bptjm-17	574	28	a.	a.	PROPN
bptjm-17	574	29	j.	j.	PROPN
bptjm-17	574	30	,	,	PUNCT
bptjm-17	574	31	büttner	büttner	PROPN
bptjm-17	574	32	,	,	PUNCT
bptjm-17	574	33	r.	r.	PROPN
bptjm-17	574	34	,	,	PUNCT
bptjm-17	574	35	&	&	CCONJ
bptjm-17	574	36	majores	majore	NOUN
bptjm-17	574	37	,	,	PUNCT
bptjm-17	574	38	m.	m.	NOUN
bptjm-17	574	39	(	(	PUNCT
bptjm-17	574	40	2014	2014	NUM
bptjm-17	574	41	)	)	PUNCT
bptjm-17	574	42	.	.	PUNCT
bptjm-17	575	1	tuberous	tuberous	ADJ
bptjm-17	575	2	-	-	PUNCT
bptjm-17	575	3	sclerosis	sclerosis	NOUN
bptjm-17	575	4	complex	complex	ADJ
bptjm-17	575	5	-	-	PUNCT
bptjm-17	575	6	related	relate	VERB
bptjm-17	575	7	cell	cell	NOUN
bptjm-17	575	8	signaling	signal	VERB
bptjm-17	575	9	in	in	ADP
bptjm-17	575	10	the	the	DET
bptjm-17	575	11	pathogenesis	pathogenesis	NOUN
bptjm-17	575	12	of	of	ADP
bptjm-17	575	13	lung	lung	NOUN
bptjm-17	575	14	cancer	cancer	NOUN
bptjm-17	575	15	.	.	PUNCT
bptjm-17	576	1	diagnostic	diagnostic	ADJ
bptjm-17	576	2	pathology	pathology	NOUN
bptjm-17	576	3	,	,	PUNCT
bptjm-17	576	4	9(48	9(48	NUM
bptjm-17	576	5	)	)	PUNCT
bptjm-17	576	6	.	.	PUNCT
bptjm-17	577	1	https://doi.org/10.1186/1746-1596-9-48	https://doi.org/10.1186/1746-1596-9-48	VERB
bptjm-17	577	2	26	26	NUM
bptjm-17	577	3	.	.	PUNCT
bptjm-17	578	1	friedmann	friedmann	NOUN
bptjm-17	578	2	-	-	PUNCT
bptjm-17	578	3	morvinski	morvinski	PROPN
bptjm-17	578	4	,	,	PUNCT
bptjm-17	578	5	d.	d.	PROPN
bptjm-17	578	6	,	,	PUNCT
bptjm-17	578	7	&	&	CCONJ
bptjm-17	578	8	verma	verma	PROPN
bptjm-17	578	9	,	,	PUNCT
bptjm-17	578	10	i.	i.	PROPN
bptjm-17	578	11	m.	m.	PROPN
bptjm-17	578	12	(	(	PUNCT
bptjm-17	578	13	2014	2014	NUM
bptjm-17	578	14	)	)	PUNCT
bptjm-17	578	15	.	.	PUNCT
bptjm-17	579	1	dedi	dedi	PROPN
bptjm-17	579	2	�	�	PROPN
bptjm-17	579	3	erentiation	erentiation	NOUN
bptjm-17	579	4	and	and	CCONJ
bptjm-17	579	5	reprogramming	reprogramme	VERB
bptjm-17	579	6	:	:	PUNCT
bptjm-17	579	7	origins	origin	NOUN
bptjm-17	579	8	of	of	ADP
bptjm-17	579	9	cancer	cancer	NOUN
bptjm-17	579	10	stem	stem	NOUN
bptjm-17	579	11	cells	cell	NOUN
bptjm-17	579	12	.	.	PUNCT
bptjm-17	580	1	embo	embo	PROPN
bptjm-17	580	2	reports	report	NOUN
bptjm-17	580	3	,	,	PUNCT
bptjm-17	580	4	15(3	15(3	NUM
bptjm-17	580	5	)	)	PUNCT
bptjm-17	580	6	,	,	PUNCT
bptjm-17	580	7	244–253	244–253	NUM
bptjm-17	580	8	.	.	PUNCT
bptjm-17	581	1	https://doi.org/10.1002/	https://doi.org/10.1002/	PROPN
bptjm-17	581	2	embr.201338254	embr.201338254	PROPN
bptjm-17	581	3	27	27	NUM
bptjm-17	581	4	.	.	PUNCT
bptjm-17	582	1	gao	gao	PROPN
bptjm-17	582	2	,	,	PUNCT
bptjm-17	582	3	w.	w.	PROPN
bptjm-17	582	4	,	,	PUNCT
bptjm-17	582	5	lu	lu	PROPN
bptjm-17	582	6	,	,	PUNCT
bptjm-17	582	7	x.	x.	PROPN
bptjm-17	582	8	,	,	PUNCT
bptjm-17	582	9	liu	liu	PROPN
bptjm-17	582	10	,	,	PUNCT
bptjm-17	582	11	l.	l.	PROPN
bptjm-17	582	12	,	,	PUNCT
bptjm-17	582	13	xu	xu	PROPN
bptjm-17	582	14	,	,	PUNCT
bptjm-17	582	15	j.	j.	PROPN
bptjm-17	582	16	,	,	PUNCT
bptjm-17	582	17	feng	feng	PROPN
bptjm-17	582	18	,	,	PUNCT
bptjm-17	582	19	d.	d.	PROPN
bptjm-17	582	20	,	,	PUNCT
bptjm-17	582	21	&	&	CCONJ
bptjm-17	582	22	shu	shu	PROPN
bptjm-17	582	23	,	,	PUNCT
bptjm-17	582	24	y.	y.	PROPN
bptjm-17	582	25	(	(	PUNCT
bptjm-17	582	26	2012	2012	NUM
bptjm-17	582	27	)	)	PUNCT
bptjm-17	582	28	.	.	PUNCT
bptjm-17	583	1	mirna-21	mirna-21	NOUN
bptjm-17	583	2	:	:	PUNCT
bptjm-17	583	3	a	a	DET
bptjm-17	583	4	biomarker	biomarker	NOUN
bptjm-17	583	5	predictive	predictive	NOUN
bptjm-17	583	6	for	for	ADP
bptjm-17	583	7	platinum	platinum	NOUN
bptjm-17	583	8	-	-	PUNCT
bptjm-17	583	9	based	base	VERB
bptjm-17	583	10	adjuvant	adjuvant	ADJ
bptjm-17	583	11	chemotherapy	chemotherapy	NOUN
bptjm-17	583	12	response	response	NOUN
bptjm-17	583	13	in	in	ADP
bptjm-17	583	14	patients	patient	NOUN
bptjm-17	583	15	with	with	ADP
bptjm-17	583	16	non	non	ADJ
bptjm-17	583	17	-	-	ADJ
bptjm-17	583	18	small	small	ADJ
bptjm-17	583	19	cell	cell	NOUN
bptjm-17	583	20	lung	lung	NOUN
bptjm-17	583	21	cancer	cancer	NOUN
bptjm-17	583	22	.	.	PUNCT
bptjm-17	584	1	cancer	cancer	NOUN
bptjm-17	584	2	biology	biology	NOUN
bptjm-17	584	3	&	&	CCONJ
bptjm-17	584	4	therapy	therapy	NOUN
bptjm-17	584	5	,	,	PUNCT
bptjm-17	584	6	13(5	13(5	NUM
bptjm-17	584	7	)	)	PUNCT
bptjm-17	584	8	,	,	PUNCT
bptjm-17	584	9	330–340	330–340	NUM
bptjm-17	584	10	.	.	PUNCT
bptjm-17	585	1	https://doi.org/10.4161/cbt.19073	https://doi.org/10.4161/cbt.19073	NOUN
bptjm-17	585	2	28	28	NUM
bptjm-17	585	3	.	.	PUNCT
bptjm-17	586	1	gao	gao	PROPN
bptjm-17	586	2	,	,	PUNCT
bptjm-17	586	3	z.j	z.j	PROPN
bptjm-17	586	4	.	.	PROPN
bptjm-17	586	5	,	,	PUNCT
bptjm-17	586	6	et	et	PROPN
bptjm-17	586	7	al	al	PROPN
bptjm-17	586	8	.	.	PROPN
bptjm-17	586	9	(	(	PUNCT
bptjm-17	586	10	2020	2020	NUM
bptjm-17	586	11	)	)	PUNCT
bptjm-17	586	12	.	.	PUNCT
bptjm-17	587	1	mir-486	mir-486	PROPN
bptjm-17	587	2	as	as	ADP
bptjm-17	587	3	an	an	DET
bptjm-17	587	4	unfavorable	unfavorable	ADJ
bptjm-17	587	5	prognostic	prognostic	ADJ
bptjm-17	587	6	biomarker	biomarker	NOUN
bptjm-17	587	7	for	for	ADP
bptjm-17	587	8	patients	patient	NOUN
bptjm-17	587	9	with	with	ADP
bptjm-17	587	10	non	non	ADJ
bptjm-17	587	11	-	-	ADJ
bptjm-17	587	12	small	small	ADJ
bptjm-17	587	13	cell	cell	NOUN
bptjm-17	587	14	lung	lung	NOUN
bptjm-17	587	15	cancer	cancer	NOUN
bptjm-17	587	16	.	.	PUNCT
bptjm-17	588	1	translational	translational	ADJ
bptjm-17	588	2	cancer	cancer	NOUN
bptjm-17	588	3	research	research	NOUN
bptjm-17	588	4	,	,	PUNCT
bptjm-17	588	5	9(1	9(1	NUM
bptjm-17	588	6	)	)	PUNCT
bptjm-17	588	7	,	,	PUNCT
bptjm-17	588	8	104–110	104–110	NUM
bptjm-17	588	9	.	.	NOUN
bptjm-17	588	10	,	,	PUNCT
bptjm-17	588	11	doi:10.21037	doi:10.21037	NOUN
bptjm-17	588	12	/	/	SYM
bptjm-17	588	13	tcr.2019.11.19	tcr.2019.11.19	NUM
bptjm-17	588	14	.	.	PUNCT
bptjm-17	589	1	gilkes	gilkes	PROPN
bptjm-17	589	2	,	,	PUNCT
bptjm-17	589	3	m.d	m.d	PROPN
bptjm-17	589	4	.	.	PROPN
bptjm-17	589	5	,	,	PUNCT
bptjm-17	589	6	gregg	gregg	PROPN
bptjm-17	589	7	s.l	s.l	PROPN
bptjm-17	589	8	.	.	PROPN
bptjm-17	589	9	,	,	PUNCT
bptjm-17	589	10	and	and	CCONJ
bptjm-17	589	11	denis	denis	PROPN
bptjm-17	589	12	w.	w.	PROPN
bptjm-17	589	13	(	(	PUNCT
bptjm-17	589	14	june	june	PROPN
bptjm-17	589	15	2014	2014	NUM
bptjm-17	589	16	)	)	PUNCT
bptjm-17	589	17	.	.	PUNCT
bptjm-17	590	1	hypoxia	hypoxia	NOUN
bptjm-17	590	2	and	and	CCONJ
bptjm-17	590	3	the	the	DET
bptjm-17	590	4	extracellular	extracellular	ADJ
bptjm-17	590	5	matrix	matrix	NOUN
bptjm-17	590	6	:	:	PUNCT
bptjm-17	590	7	drivers	driver	NOUN
bptjm-17	590	8	of	of	ADP
bptjm-17	590	9	tumour	tumour	NOUN
bptjm-17	590	10	metastasis	metastasis	NOUN
bptjm-17	590	11	.	.	PUNCT
bptjm-17	591	1	nature	nature	NOUN
bptjm-17	591	2	reviews	review	VERB
bptjm-17	591	3	cancer	cancer	NOUN
bptjm-17	591	4	,	,	PUNCT
bptjm-17	591	5	14(6	14(6	NOUN
bptjm-17	591	6	)	)	PUNCT
bptjm-17	591	7	,	,	PUNCT
bptjm-17	591	8	430–39	430–39	NUM
bptjm-17	591	9	.	.	PUNCT
bptjm-17	592	1	https://doi.org/10.1038/nrc3726	https://doi.org/10.1038/nrc3726	PROPN
bptjm-17	592	2	.	.	PUNCT
bptjm-17	593	1	29	29	NUM
bptjm-17	593	2	.	.	PUNCT
bptjm-17	594	1	hamilton	hamilton	PROPN
bptjm-17	594	2	,	,	PUNCT
bptjm-17	594	3	g.	g.	PROPN
bptjm-17	594	4	,	,	PUNCT
bptjm-17	594	5	&	&	CCONJ
bptjm-17	594	6	rath	rath	PROPN
bptjm-17	594	7	,	,	PUNCT
bptjm-17	594	8	b.	b.	PROPN
bptjm-17	594	9	(	(	PUNCT
bptjm-17	594	10	2018	2018	NUM
bptjm-17	594	11	)	)	PUNCT
bptjm-17	594	12	.	.	PUNCT
bptjm-17	595	1	pharmacogenetics	pharmacogenetic	NOUN
bptjm-17	595	2	of	of	ADP
bptjm-17	595	3	platinum	platinum	NOUN
bptjm-17	595	4	-	-	PUNCT
bptjm-17	595	5	based	base	VERB
bptjm-17	595	6	chemotherapy	chemotherapy	NOUN
bptjm-17	595	7	in	in	ADP
bptjm-17	595	8	non	non	ADJ
bptjm-17	595	9	-	-	ADJ
bptjm-17	595	10	small	small	ADJ
bptjm-17	595	11	cell	cell	NOUN
bptjm-17	595	12	lung	lung	NOUN
bptjm-17	595	13	cancer	cancer	NOUN
bptjm-17	595	14	:	:	PUNCT
bptjm-17	595	15	predictive	predictive	ADJ
bptjm-17	595	16	validity	validity	NOUN
bptjm-17	595	17	of	of	ADP
bptjm-17	595	18	polymorphisms	polymorphism	NOUN
bptjm-17	595	19	of	of	ADP
bptjm-17	595	20	ercc1	ercc1	PROPN
bptjm-17	595	21	.	.	PUNCT
bptjm-17	596	1	expert	expert	ADJ
bptjm-17	596	2	opinion	opinion	NOUN
bptjm-17	596	3	on	on	ADP
bptjm-17	596	4	drug	drug	NOUN
bptjm-17	596	5	metabolism	metabolism	NOUN
bptjm-17	596	6	&	&	CCONJ
bptjm-17	596	7	toxicology	toxicology	NOUN
bptjm-17	596	8	,	,	PUNCT
bptjm-17	596	9	14(1	14(1	NUM
bptjm-17	596	10	)	)	PUNCT
bptjm-17	596	11	,	,	PUNCT
bptjm-17	596	12	17–24	17–24	NUM
bptjm-17	596	13	.	.	PUNCT
bptjm-17	597	1	https://doi.org/	https://doi.org/	NOUN
bptjm-17	597	2	10.1080/17425255.2018.1416095	10.1080/17425255.2018.1416095	NUM
bptjm-17	597	3	.	.	PUNCT
bptjm-17	597	4	30	30	NUM
bptjm-17	597	5	.	.	PUNCT
bptjm-17	598	1	hana	hana	PROPN
bptjm-17	598	2	�	�	PROPN
bptjm-17	598	3	,	,	PUNCT
bptjm-17	598	4	a.	a.	PROPN
bptjm-17	598	5	r.	r.	PROPN
bptjm-17	598	6	,	,	PUNCT
bptjm-17	598	7	jayusman	jayusman	NOUN
bptjm-17	598	8	,	,	PUNCT
bptjm-17	598	9	a.	a.	NOUN
bptjm-17	598	10	m.	m.	NOUN
bptjm-17	598	11	,	,	PUNCT
bptjm-17	598	12	alfasunu	alfasunu	ADJ
bptjm-17	598	13	,	,	PUNCT
bptjm-17	598	14	s.	s.	PROPN
bptjm-17	598	15	,	,	PUNCT
bptjm-17	598	16	sadewa	sadewa	PROPN
bptjm-17	598	17	,	,	PUNCT
bptjm-17	598	18	a.	a.	PROPN
bptjm-17	598	19	h.	h.	PROPN
bptjm-17	598	20	,	,	PUNCT
bptjm-17	598	21	pramono	pramono	PROPN
bptjm-17	598	22	,	,	PUNCT
bptjm-17	598	23	d.	d.	PROPN
bptjm-17	598	24	,	,	PUNCT
bptjm-17	598	25	heriyanto	heriyanto	PROPN
bptjm-17	598	26	,	,	PUNCT
bptjm-17	598	27	d.	d.	PROPN
bptjm-17	598	28	s.	s.	PROPN
bptjm-17	598	29	,	,	PUNCT
bptjm-17	598	30	&	&	CCONJ
bptjm-17	598	31	haryana	haryana	PROPN
bptjm-17	598	32	,	,	PUNCT
bptjm-17	598	33	s.	s.	PROPN
bptjm-17	598	34	m.	m.	PROPN
bptjm-17	598	35	(	(	PUNCT
bptjm-17	598	36	2020	2020	NUM
bptjm-17	598	37	)	)	PUNCT
bptjm-17	598	38	.	.	PUNCT
bptjm-17	599	1	serum	serum	PROPN
bptjm-17	599	2	mirna	mirna	PROPN
bptjm-17	599	3	as	as	ADP
bptjm-17	599	4	predictive	predictive	ADJ
bptjm-17	599	5	and	and	CCONJ
bptjm-17	599	6	prognosis	prognosis	NOUN
bptjm-17	599	7	biomarker	biomarker	NOUN
bptjm-17	599	8	in	in	ADP
bptjm-17	599	9	advanced	advanced	ADJ
bptjm-17	599	10	stage	stage	NOUN
bptjm-17	599	11	non	non	ADJ
bptjm-17	599	12	-	-	ADJ
bptjm-17	599	13	small	small	ADJ
bptjm-17	599	14	cell	cell	NOUN
bptjm-17	599	15	lung	lung	NOUN
bptjm-17	599	16	cancer	cancer	NOUN
bptjm-17	599	17	in	in	ADP
bptjm-17	599	18	indonesia	indonesia	PROPN
bptjm-17	599	19	.	.	PUNCT
bptjm-17	600	1	zhongguo	zhongguo	PROPN
bptjm-17	600	2	fei	fei	PROPN
bptjm-17	600	3	ai	ai	VERB
bptjm-17	600	4	za	za	PROPN
bptjm-17	600	5	zhi	zhi	PROPN
bptjm-17	601	1	=	=	PROPN
bptjm-17	602	1	chinese	chinese	PROPN
bptjm-17	602	2	journal	journal	PROPN
bptjm-17	602	3	of	of	ADP
bptjm-17	602	4	lung	lung	NOUN
bptjm-17	602	5	cancer	cancer	NOUN
bptjm-17	602	6	,	,	PUNCT
bptjm-17	602	7	23(5	23(5	NUM
bptjm-17	602	8	)	)	PUNCT
bptjm-17	602	9	,	,	PUNCT
bptjm-17	602	10	321–332	321–332	NUM
bptjm-17	602	11	.	.	PUNCT
bptjm-17	603	1	https://doi.org/10.3779/j.issn	https://doi.org/10.3779/j.issn	X
bptjm-17	603	2	.	.	PUNCT
bptjm-17	604	1	1009	1009	NUM
bptjm-17	604	2	-	-	SYM
bptjm-17	604	3	3419.2020.104.02	3419.2020.104.02	NUM
bptjm-17	604	4	31	31	NUM
bptjm-17	604	5	.	.	PUNCT
bptjm-17	605	1	hojbjerg	hojbjerg	PROPN
bptjm-17	605	2	,	,	PUNCT
bptjm-17	605	3	j.	j.	PROPN
bptjm-17	605	4	a.	a.	PROPN
bptjm-17	605	5	,	,	PUNCT
bptjm-17	605	6	ebert	ebert	PROPN
bptjm-17	605	7	,	,	PUNCT
bptjm-17	605	8	e.	e.	PROPN
bptjm-17	605	9	b.	b.	PROPN
bptjm-17	605	10	f.	f.	PROPN
bptjm-17	605	11	,	,	PUNCT
bptjm-17	605	12	clement	clement	PROPN
bptjm-17	605	13	,	,	PUNCT
bptjm-17	605	14	m.	m.	PROPN
bptjm-17	605	15	s.	s.	PROPN
bptjm-17	605	16	,	,	PUNCT
bptjm-17	605	17	winther	winther	PROPN
bptjm-17	605	18	-	-	PUNCT
bptjm-17	605	19	larsen	larsen	PROPN
bptjm-17	605	20	,	,	PUNCT
bptjm-17	605	21	a.	a.	PROPN
bptjm-17	605	22	,	,	PUNCT
bptjm-17	605	23	meldgaard	meldgaard	NOUN
bptjm-17	605	24	,	,	PUNCT
bptjm-17	605	25	p.	p.	PROPN
bptjm-17	605	26	,	,	PUNCT
bptjm-17	605	27	&	&	CCONJ
bptjm-17	605	28	sorensen	sorensen	PROPN
bptjm-17	605	29	,	,	PUNCT
bptjm-17	605	30	b.	b.	PROPN
bptjm-17	605	31	(	(	PUNCT
bptjm-17	605	32	2019	2019	NUM
bptjm-17	605	33	)	)	PUNCT
bptjm-17	605	34	.	.	PUNCT
bptjm-17	606	1	circulating	circulate	VERB
bptjm-17	606	2	mir-30b	mir-30b	NUM
bptjm-17	606	3	and	and	CCONJ
bptjm-17	606	4	mir-30c	mir-30c	NOUN
bptjm-17	606	5	predict	predict	VERB
bptjm-17	606	6	erlotinib	erlotinib	NOUN
bptjm-17	606	7	response	response	NOUN
bptjm-17	606	8	in	in	ADP
bptjm-17	606	9	egfr	egfr	NOUN
bptjm-17	606	10	-	-	PUNCT
bptjm-17	606	11	mutated	mutate	VERB
bptjm-17	606	12	non	non	ADJ
bptjm-17	606	13	-	-	ADJ
bptjm-17	606	14	small	small	ADJ
bptjm-17	606	15	cell	cell	NOUN
bptjm-17	606	16	lung	lung	NOUN
bptjm-17	606	17	cancer	cancer	NOUN
bptjm-17	606	18	patients	patient	NOUN
bptjm-17	606	19	.	.	PUNCT
bptjm-17	607	1	lung	lung	NOUN
bptjm-17	607	2	cancer	cancer	NOUN
bptjm-17	607	3	,	,	PUNCT
bptjm-17	607	4	135	135	NUM
bptjm-17	607	5	,	,	PUNCT
bptjm-17	607	6	92–96	92–96	NUM
bptjm-17	607	7	.	.	PUNCT
bptjm-17	608	1	https://	https://	NOUN
bptjm-17	608	2	doi.org/10.1016/j.lungcan.2019.07.005	doi.org/10.1016/j.lungcan.2019.07.005	ADP
bptjm-17	608	3	32	32	NUM
bptjm-17	608	4	.	.	PUNCT
bptjm-17	609	1	howlader	howlader	PROPN
bptjm-17	609	2	,	,	PUNCT
bptjm-17	609	3	n.	n.	NOUN
bptjm-17	609	4	,	,	PUNCT
bptjm-17	609	5	noone	noone	NOUN
bptjm-17	609	6	,	,	PUNCT
bptjm-17	609	7	a.m.	a.m.	ADV
bptjm-17	609	8	,	,	PUNCT
bptjm-17	609	9	krapcho	krapcho	NOUN
bptjm-17	609	10	,	,	PUNCT
bptjm-17	609	11	m.	m.	NOUN
bptjm-17	609	12	,	,	PUNCT
bptjm-17	609	13	mille	mille	PROPN
bptjm-17	609	14	,	,	PUNCT
bptjm-17	609	15	r	r	PROPN
bptjm-17	609	16	d.	d.	PROPN
bptjm-17	609	17	,	,	PUNCT
bptjm-17	609	18	bresi	bresi	PROPN
bptjm-17	609	19	,	,	PUNCT
bptjm-17	609	20	a.	a.	PROPN
bptjm-17	609	21	,	,	PUNCT
bptjm-17	609	22	yu	yu	PROPN
bptjm-17	609	23	,	,	PUNCT
bptjm-17	609	24	m.	m.	NOUN
bptjm-17	609	25	,	,	PUNCT
bptjm-17	609	26	ruhl	ruhl	PROPN
bptjm-17	609	27	,	,	PUNCT
bptjm-17	609	28	j.	j.	PROPN
bptjm-17	609	29	,	,	PUNCT
bptjm-17	609	30	tatalovich	tatalovich	PROPN
bptjm-17	609	31	,	,	PUNCT
bptjm-17	609	32	z.	z.	PROPN
bptjm-17	609	33	,	,	PUNCT
bptjm-17	609	34	mariotto	mariotto	NOUN
bptjm-17	609	35	,	,	PUNCT
bptjm-17	609	36	a.	a.	NOUN
bptjm-17	609	37	,	,	PUNCT
bptjm-17	609	38	lewis	lewis	PROPN
bptjm-17	609	39	,	,	PUNCT
bptjm-17	609	40	d.r	d.r	PROPN
bptjm-17	609	41	.	.	PROPN
bptjm-17	609	42	,	,	PUNCT
bptjm-17	609	43	chen	chen	PROPN
bptjm-17	609	44	,	,	PUNCT
bptjm-17	609	45	h.s	h.s	PROPN
bptjm-17	609	46	.	.	PROPN
bptjm-17	609	47	,	,	PUNCT
bptjm-17	609	48	feuer	feuer	PROPN
bptjm-17	609	49	,	,	PUNCT
bptjm-17	609	50	e.j	e.j	PROPN
bptjm-17	609	51	.	.	PROPN
bptjm-17	609	52	,	,	PUNCT
bptjm-17	609	53	cronin	cronin	PROPN
bptjm-17	609	54	,	,	PUNCT
bptjm-17	609	55	k.a	k.a	PROPN
bptjm-17	609	56	.	.	PROPN
bptjm-17	609	57	(	(	PUNCT
bptjm-17	609	58	eds	ed	NOUN
bptjm-17	609	59	)	)	PUNCT
bptjm-17	609	60	.	.	PUNCT
bptjm-17	610	1	(	(	PUNCT
bptjm-17	610	2	2017	2017	NUM
bptjm-17	610	3	)	)	PUNCT
bptjm-17	610	4	.	.	PUNCT
bptjm-17	611	1	seer	seer	PROPN
bptjm-17	611	2	cancer	cancer	PROPN
bptjm-17	611	3	statistics	statistics	PROPN
bptjm-17	611	4	review	review	PROPN
bptjm-17	611	5	,	,	PUNCT
bptjm-17	611	6	1975	1975	NUM
bptjm-17	611	7	-	-	SYM
bptjm-17	611	8	2018	2018	NUM
bptjm-17	611	9	,	,	PUNCT
bptjm-17	611	10	national	national	PROPN
bptjm-17	611	11	cancer	cancer	PROPN
bptjm-17	611	12	institute	institute	PROPN
bptjm-17	611	13	.	.	PUNCT
bptjm-17	612	1	bethesda	bethesda	PROPN
bptjm-17	612	2	,	,	PUNCT
bptjm-17	612	3	md	md	PROPN
bptjm-17	612	4	,	,	PUNCT
bptjm-17	612	5	http://seer.cancer.gov/csr/	http://seer.cancer.gov/csr/	PROPN
bptjm-17	612	6	1975_2017	1975_2017	NUM
bptjm-17	612	7	,	,	PUNCT
bptjm-17	612	8	based	base	VERB
bptjm-17	612	9	on	on	ADP
bptjm-17	612	10	november	november	PROPN
bptjm-17	612	11	2019	2019	NUM
bptjm-17	612	12	seer	seer	NOUN
bptjm-17	612	13	data	datum	NOUN
bptjm-17	612	14	submission	submission	PROPN
bptjm-17	612	15	,	,	PUNCT
bptjm-17	612	16	posted	post	VERB
bptjm-17	612	17	to	to	ADP
bptjm-17	612	18	the	the	DET
bptjm-17	612	19	seer	seer	NOUN
bptjm-17	612	20	website	website	NOUN
bptjm-17	612	21	,	,	PUNCT
bptjm-17	612	22	april	april	PROPN
bptjm-17	612	23	2020	2020	NUM
bptjm-17	612	24	.	.	PUNCT
bptjm-17	613	1	33	33	NUM
bptjm-17	613	2	.	.	PUNCT
bptjm-17	613	3	hu	hu	PROPN
bptjm-17	613	4	,	,	PUNCT
bptjm-17	613	5	x.	x.	PROPN
bptjm-17	613	6	,	,	PUNCT
bptjm-17	613	7	dongyong	dongyong	PROPN
bptjm-17	613	8	,	,	PUNCT
bptjm-17	613	9	y.	y.	PROPN
bptjm-17	613	10	,	,	PUNCT
bptjm-17	613	11	yalun	yalun	NOUN
bptjm-17	613	12	,	,	PUNCT
bptjm-17	613	13	l.	l.	PROPN
bptjm-17	613	14	,	,	PUNCT
bptjm-17	613	15	li	li	PROPN
bptjm-17	613	16	,	,	PUNCT
bptjm-17	613	17	l.	l.	PROPN
bptjm-17	613	18	,	,	PUNCT
bptjm-17	613	19	yan	yan	PROPN
bptjm-17	613	20	,	,	PUNCT
bptjm-17	613	21	w.	w.	PROPN
bptjm-17	613	22	,	,	PUNCT
bptjm-17	613	23	peng	peng	PROPN
bptjm-17	613	24	,	,	PUNCT
bptjm-17	613	25	c.	c.	PROPN
bptjm-17	613	26	,	,	PUNCT
bptjm-17	613	27	song	song	NOUN
bptjm-17	613	28	,	,	PUNCT
bptjm-17	613	29	x.	x.	PROPN
bptjm-17	613	30	,	,	PUNCT
bptjm-17	613	31	et	et	PROPN
bptjm-17	613	32	al	al	PROPN
bptjm-17	613	33	.	.	PUNCT
bptjm-17	614	1	(	(	PUNCT
bptjm-17	614	2	august	august	PROPN
bptjm-17	614	3	2019	2019	NUM
bptjm-17	614	4	)	)	PUNCT
bptjm-17	614	5	.	.	PUNCT
bptjm-17	615	1	prevalence	prevalence	NOUN
bptjm-17	615	2	and	and	CCONJ
bptjm-17	615	3	clinical	clinical	ADJ
bptjm-17	615	4	signi	signi	PROPN
bptjm-17	615	5	�	�	PROPN
bptjm-17	615	6	cance	cance	NOUN
bptjm-17	615	7	of	of	ADP
bptjm-17	615	8	pathogenic	pathogenic	ADJ
bptjm-17	615	9	germline	germline	NOUN
bptjm-17	615	10	brca1/2	brca1/2	ADJ
bptjm-17	615	11	mutations	mutation	NOUN
bptjm-17	615	12	in	in	ADP
bptjm-17	615	13	chinese	chinese	ADJ
bptjm-17	615	14	non	non	ADJ
bptjm-17	615	15	-	-	ADJ
bptjm-17	615	16	small	small	ADJ
bptjm-17	615	17	cell	cell	NOUN
bptjm-17	615	18	lung	lung	NOUN
bptjm-17	615	19	cancer	cancer	NOUN
bptjm-17	615	20	patients	patient	NOUN
bptjm-17	615	21	.	.	PUNCT
bptjm-17	616	1	cancer	cancer	NOUN
bptjm-17	616	2	biology	biology	NOUN
bptjm-17	616	3	&	&	CCONJ
bptjm-17	616	4	medicine	medicine	PROPN
bptjm-17	616	5	16(3	16(3	PROPN
bptjm-17	616	6	)	)	PUNCT
bptjm-17	616	7	:	:	PUNCT
bptjm-17	617	1	556–64	556–64	NUM
bptjm-17	617	2	.	.	PUNCT
bptjm-17	617	3	https://doi.org/10.20892/j.issn.2095-3941.2018.0506	https://doi.org/10.20892/j.issn.2095-3941.2018.0506	PROPN
bptjm-17	617	4	.	.	PUNCT
bptjm-17	618	1	34	34	NUM
bptjm-17	618	2	.	.	PUNCT
bptjm-17	618	3	hu	hu	PROPN
bptjm-17	618	4	,	,	PUNCT
bptjm-17	618	5	z.	z.	PROPN
bptjm-17	618	6	,	,	PUNCT
bptjm-17	618	7	chen	chen	PROPN
bptjm-17	618	8	,	,	PUNCT
bptjm-17	618	9	x.	x.	PROPN
bptjm-17	618	10	,	,	PUNCT
bptjm-17	618	11	zhao	zhao	PROPN
bptjm-17	618	12	,	,	PUNCT
bptjm-17	618	13	y.	y.	PROPN
bptjm-17	618	14	,	,	PUNCT
bptjm-17	618	15	tian	tian	ADJ
bptjm-17	618	16	,	,	PUNCT
bptjm-17	618	17	t.	t.	PROPN
bptjm-17	618	18	,	,	PUNCT
bptjm-17	618	19	jin	jin	PROPN
bptjm-17	618	20	,	,	PUNCT
bptjm-17	618	21	g.	g.	PROPN
bptjm-17	618	22	,	,	PUNCT
bptjm-17	618	23	shu	shu	PROPN
bptjm-17	618	24	,	,	PUNCT
bptjm-17	618	25	y.	y.	PROPN
bptjm-17	618	26	,	,	PUNCT
bptjm-17	618	27	berkeley	berkeley	PROPN
bptjm-17	618	28	pharma	pharma	PROPN
bptjm-17	618	29	tech	tech	NOUN
bptjm-17	618	30	journal	journal	NOUN
bptjm-17	618	31	of	of	ADP
bptjm-17	618	32	medicine	medicine	NOUN
bptjm-17	618	33	|	|	ADV
bptjm-17	618	34	148	148	NUM
bptjm-17	618	35	https://doi.org/10.1038/nrc3726	https://doi.org/10.1038/nrc3726	NOUN
bptjm-17	618	36	https://doi.org/	https://doi.org/	VERB
bptjm-17	618	37	http://seer.cancer.gov/csr/	http://seer.cancer.gov/csr/	PROPN
bptjm-17	618	38	http://seer.cancer.gov/csr/	http://seer.cancer.gov/csr/	PROPN
bptjm-17	618	39	chen	chen	PROPN
bptjm-17	618	40	,	,	PUNCT
bptjm-17	618	41	y.	y.	PROPN
bptjm-17	618	42	,	,	PUNCT
bptjm-17	618	43	xu	xu	PROPN
bptjm-17	618	44	,	,	PUNCT
bptjm-17	618	45	l.	l.	PROPN
bptjm-17	618	46	,	,	PUNCT
bptjm-17	618	47	zen	zen	PROPN
bptjm-17	618	48	,	,	PUNCT
bptjm-17	618	49	k.	k.	PROPN
bptjm-17	618	50	,	,	PUNCT
bptjm-17	618	51	zhang	zhang	PROPN
bptjm-17	618	52	,	,	PUNCT
bptjm-17	618	53	c.	c.	PROPN
bptjm-17	618	54	,	,	PUNCT
bptjm-17	618	55	shen	shen	PROPN
bptjm-17	618	56	,	,	PUNCT
bptjm-17	618	57	h.	h.	PROPN
bptjm-17	618	58	(	(	PUNCT
bptjm-17	618	59	april	april	PROPN
bptjm-17	618	60	1	1	NUM
bptjm-17	618	61	,	,	PUNCT
bptjm-17	618	62	2010	2010	NUM
bptjm-17	618	63	)	)	PUNCT
bptjm-17	618	64	.	.	PUNCT
bptjm-17	619	1	serum	serum	PROPN
bptjm-17	619	2	microrna	microrna	PROPN
bptjm-17	619	3	signatures	signatures	PROPN
bptjm-17	619	4	identi	identi	PROPN
bptjm-17	619	5	�	�	PROPN
bptjm-17	619	6	ed	ed	NOUN
bptjm-17	619	7	in	in	ADP
bptjm-17	619	8	a	a	DET
bptjm-17	619	9	genome	genome	NOUN
bptjm-17	619	10	-	-	PUNCT
bptjm-17	619	11	wide	wide	ADJ
bptjm-17	619	12	serum	serum	NOUN
bptjm-17	619	13	microrna	microrna	PROPN
bptjm-17	619	14	expression	expression	NOUN
bptjm-17	619	15	pro	pro	X
bptjm-17	619	16	�	�	PROPN
bptjm-17	619	17	ling	ling	NOUN
bptjm-17	619	18	predict	predict	VERB
bptjm-17	619	19	survival	survival	NOUN
bptjm-17	619	20	of	of	ADP
bptjm-17	619	21	non	non	ADJ
bptjm-17	619	22	-	-	ADJ
bptjm-17	619	23	small	small	ADJ
bptjm-17	619	24	-	-	PUNCT
bptjm-17	619	25	cell	cell	NOUN
bptjm-17	619	26	lung	lung	NOUN
bptjm-17	619	27	cancer	cancer	NOUN
bptjm-17	619	28	.	.	PUNCT
bptjm-17	620	1	journal	journal	NOUN
bptjm-17	620	2	of	of	ADP
bptjm-17	620	3	clinical	clinical	ADJ
bptjm-17	620	4	oncology	oncology	NOUN
bptjm-17	620	5	,	,	PUNCT
bptjm-17	620	6	28(10	28(10	NUM
bptjm-17	620	7	)	)	PUNCT
bptjm-17	620	8	,	,	PUNCT
bptjm-17	620	9	1721	1721	NUM
bptjm-17	620	10	-	-	SYM
bptjm-17	620	11	1726	1726	NUM
bptjm-17	620	12	.	.	PUNCT
bptjm-17	621	1	doi:10.1200	doi:10.1200	PROPN
bptjm-17	621	2	/	/	SYM
bptjm-17	621	3	jco.2009.24.9342	jco.2009.24.9342	PROPN
bptjm-17	621	4	.	.	PUNCT
bptjm-17	622	1	epub	epub	PROPN
bptjm-17	622	2	2010	2010	NUM
bptjm-17	622	3	mar	mar	PROPN
bptjm-17	622	4	1	1	NUM
bptjm-17	622	5	.	.	PUNCT
bptjm-17	623	1	pmid	pmid	NOUN
bptjm-17	623	2	:	:	PUNCT
bptjm-17	623	3	20194856	20194856	NUM
bptjm-17	623	4	.	.	PUNCT
bptjm-17	624	1	35	35	NUM
bptjm-17	624	2	.	.	PUNCT
bptjm-17	625	1	jeong	jeong	PROPN
bptjm-17	625	2	,	,	PUNCT
bptjm-17	625	3	e.	e.	PROPN
bptjm-17	625	4	h.	h.	PROPN
bptjm-17	625	5	,	,	PUNCT
bptjm-17	625	6	lee	lee	PROPN
bptjm-17	625	7	,	,	PUNCT
bptjm-17	625	8	t.	t.	PROPN
bptjm-17	625	9	g.	g.	PROPN
bptjm-17	625	10	,	,	PUNCT
bptjm-17	625	11	ko	ko	PROPN
bptjm-17	625	12	,	,	PUNCT
bptjm-17	625	13	y.	y.	PROPN
bptjm-17	625	14	j.	j.	PROPN
bptjm-17	625	15	,	,	PUNCT
bptjm-17	625	16	kim	kim	PROPN
bptjm-17	625	17	,	,	PUNCT
bptjm-17	625	18	s.	s.	PROPN
bptjm-17	625	19	y.	y.	PROPN
bptjm-17	625	20	,	,	PUNCT
bptjm-17	625	21	kim	kim	PROPN
bptjm-17	625	22	,	,	PUNCT
bptjm-17	625	23	h.	h.	PROPN
bptjm-17	625	24	r.	r.	PROPN
bptjm-17	625	25	,	,	PUNCT
bptjm-17	625	26	kim	kim	PROPN
bptjm-17	625	27	,	,	PUNCT
bptjm-17	625	28	h.	h.	PROPN
bptjm-17	625	29	,	,	PUNCT
bptjm-17	625	30	&	&	CCONJ
bptjm-17	625	31	kim	kim	PROPN
bptjm-17	625	32	,	,	PUNCT
bptjm-17	625	33	c.	c.	PROPN
bptjm-17	625	34	h.	h.	PROPN
bptjm-17	625	35	(	(	PUNCT
bptjm-17	625	36	2018	2018	NUM
bptjm-17	625	37	)	)	PUNCT
bptjm-17	625	38	.	.	PUNCT
bptjm-17	626	1	anti	anti	ADJ
bptjm-17	626	2	-	-	ADJ
bptjm-17	626	3	tumor	tumor	ADJ
bptjm-17	626	4	e	e	NOUN
bptjm-17	626	5	�	�	NOUN
bptjm-17	626	6	ect	ect	VERB
bptjm-17	626	7	of	of	ADP
bptjm-17	626	8	cdk	cdk	NOUN
bptjm-17	626	9	inhibitors	inhibitor	NOUN
bptjm-17	626	10	on	on	ADP
bptjm-17	626	11	cdkn2a	cdkn2a	ADJ
bptjm-17	626	12	-	-	PUNCT
bptjm-17	626	13	defective	defective	ADJ
bptjm-17	626	14	squamous	squamous	ADJ
bptjm-17	626	15	cell	cell	NOUN
bptjm-17	626	16	lung	lung	NOUN
bptjm-17	626	17	cancer	cancer	NOUN
bptjm-17	626	18	cells	cell	NOUN
bptjm-17	626	19	.	.	PUNCT
bptjm-17	627	1	cellular	cellular	ADJ
bptjm-17	627	2	oncology	oncology	NOUN
bptjm-17	627	3	(	(	PUNCT
bptjm-17	627	4	dordrecht	dordrecht	PROPN
bptjm-17	627	5	)	)	PUNCT
bptjm-17	627	6	,	,	PUNCT
bptjm-17	627	7	41(6	41(6	NOUN
bptjm-17	627	8	)	)	PUNCT
bptjm-17	627	9	,	,	PUNCT
bptjm-17	627	10	663–675	663–675	NUM
bptjm-17	627	11	.	.	PUNCT
bptjm-17	627	12	https://doi.org/10.1007/s13402-018-0404-6	https://doi.org/10.1007/s13402-018-0404-6	PROPN
bptjm-17	627	13	36	36	NUM
bptjm-17	627	14	.	.	PUNCT
bptjm-17	628	1	ji	ji	PROPN
bptjm-17	628	2	,	,	PUNCT
bptjm-17	628	3	w.	w.	PROPN
bptjm-17	628	4	,	,	PUNCT
bptjm-17	628	5	xiang	xiang	PROPN
bptjm-17	628	6	,	,	PUNCT
bptjm-17	628	7	w.	w.	PROPN
bptjm-17	628	8	,	,	PUNCT
bptjm-17	628	9	danhua	danhua	PROPN
bptjm-17	628	10	,	,	PUNCT
bptjm-17	628	11	x.	x.	NOUN
bptjm-17	628	12	,	,	PUNCT
bptjm-17	628	13	shufan	shufan	PROPN
bptjm-17	628	14	,	,	PUNCT
bptjm-17	628	15	c.	c.	PROPN
bptjm-17	628	16	,	,	PUNCT
bptjm-17	628	17	honggang	honggang	PROPN
bptjm-17	628	18	,	,	PUNCT
bptjm-17	628	19	l.	l.	PROPN
bptjm-17	628	20	,	,	PUNCT
bptjm-17	628	21	and	and	CCONJ
bptjm-17	628	22	ling	ling	PROPN
bptjm-17	628	23	,	,	PUNCT
bptjm-17	628	24	d.	d.	PROPN
bptjm-17	628	25	(	(	PUNCT
bptjm-17	628	26	january	january	PROPN
bptjm-17	628	27	29	29	NUM
bptjm-17	628	28	,	,	PUNCT
bptjm-17	628	29	2020	2020	NUM
bptjm-17	628	30	)	)	PUNCT
bptjm-17	628	31	.	.	PUNCT
bptjm-17	629	1	non	non	ADJ
bptjm-17	629	2	-	-	ADJ
bptjm-17	629	3	small	small	ADJ
bptjm-17	629	4	cell	cell	NOUN
bptjm-17	629	5	lung	lung	NOUN
bptjm-17	629	6	cancer	cancer	NOUN
bptjm-17	629	7	cells	cell	NOUN
bptjm-17	629	8	with	with	ADP
bptjm-17	629	9	de	de	PROPN
bptjm-17	629	10	�	�	NOUN
bptjm-17	629	11	ciencies	ciencie	NOUN
bptjm-17	629	12	in	in	ADP
bptjm-17	629	13	homologous	homologous	ADJ
bptjm-17	629	14	recombination	recombination	NOUN
bptjm-17	629	15	genes	gene	NOUN
bptjm-17	629	16	are	be	AUX
bptjm-17	629	17	sensitive	sensitive	ADJ
bptjm-17	629	18	to	to	ADP
bptjm-17	629	19	parp	parp	ADJ
bptjm-17	629	20	inhibitors	inhibitor	NOUN
bptjm-17	629	21	.	.	PUNCT
bptjm-17	630	1	biochemical	biochemical	ADJ
bptjm-17	630	2	and	and	CCONJ
bptjm-17	630	3	biophysical	biophysical	ADJ
bptjm-17	630	4	research	research	NOUN
bptjm-17	630	5	communications	communication	NOUN
bptjm-17	630	6	,	,	PUNCT
bptjm-17	630	7	522(1	522(1	NUM
bptjm-17	630	8	)	)	PUNCT
bptjm-17	630	9	,	,	PUNCT
bptjm-17	630	10	:	:	PUNCT
bptjm-17	631	1	121–26	121–26	NUM
bptjm-17	631	2	.	.	PUNCT
bptjm-17	632	1	https://doi.org/10.1016/j.bbrc	https://doi.org/10.1016/j.bbrc	NOUN
bptjm-17	632	2	.	.	NOUN
bptjm-17	633	1	2019.11.050	2019.11.050	NUM
bptjm-17	633	2	.	.	PUNCT
bptjm-17	634	1	37	37	NUM
bptjm-17	634	2	.	.	PUNCT
bptjm-17	635	1	jiang	jiang	PROPN
bptjm-17	635	2	,	,	PUNCT
bptjm-17	635	3	m.	m.	NOUN
bptjm-17	635	4	,	,	PUNCT
bptjm-17	635	5	li	li	PROPN
bptjm-17	635	6	,	,	PUNCT
bptjm-17	635	7	x.	x.	PROPN
bptjm-17	635	8	,	,	PUNCT
bptjm-17	635	9	quan	quan	PROPN
bptjm-17	635	10	,	,	PUNCT
bptjm-17	635	11	x.	x.	PROPN
bptjm-17	635	12	,	,	PUNCT
bptjm-17	635	13	et	et	PROPN
bptjm-17	635	14	al	al	PROPN
bptjm-17	635	15	.	.	PUNCT
bptjm-17	635	16	(	(	PUNCT
bptjm-17	635	17	2018	2018	NUM
bptjm-17	635	18	)	)	PUNCT
bptjm-17	635	19	.	.	PUNCT
bptjm-17	636	1	mir-486	mir-486	PROPN
bptjm-17	636	2	as	as	ADP
bptjm-17	636	3	an	an	DET
bptjm-17	636	4	e	e	NOUN
bptjm-17	636	5	�	�	NOUN
bptjm-17	636	6	ective	ective	ADJ
bptjm-17	636	7	biomarker	biomarker	NOUN
bptjm-17	636	8	in	in	ADP
bptjm-17	636	9	cancer	cancer	NOUN
bptjm-17	636	10	diagnosis	diagnosis	NOUN
bptjm-17	636	11	and	and	CCONJ
bptjm-17	636	12	prognosis	prognosis	NOUN
bptjm-17	636	13	:	:	PUNCT
bptjm-17	636	14	a	a	DET
bptjm-17	636	15	systematic	systematic	ADJ
bptjm-17	636	16	review	review	NOUN
bptjm-17	636	17	and	and	CCONJ
bptjm-17	636	18	meta	meta	ADJ
bptjm-17	636	19	-	-	PUNCT
bptjm-17	636	20	analysis	analysis	NOUN
bptjm-17	636	21	.	.	PUNCT
bptjm-17	637	1	oncotarget	oncotarget	NOUN
bptjm-17	637	2	,	,	PUNCT
bptjm-17	637	3	9(17	9(17	NUM
bptjm-17	637	4	)	)	PUNCT
bptjm-17	637	5	,	,	PUNCT
bptjm-17	637	6	13948	13948	NUM
bptjm-17	637	7	-	-	SYM
bptjm-17	637	8	13958	13958	NUM
bptjm-17	637	9	.	.	PUNCT
bptjm-17	638	1	published	publish	VERB
bptjm-17	638	2	2018	2018	NUM
bptjm-17	638	3	jan	jan	PROPN
bptjm-17	638	4	12	12	NUM
bptjm-17	638	5	.	.	PUNCT
bptjm-17	639	1	doi:10.18632	doi:10.18632	PROPN
bptjm-17	639	2	/	/	SYM
bptjm-17	639	3	oncotarget.24189	oncotarget.24189	PROPN
bptjm-17	639	4	38	38	NUM
bptjm-17	639	5	.	.	PUNCT
bptjm-17	640	1	joerger	joerger	NOUN
bptjm-17	640	2	,	,	PUNCT
bptjm-17	640	3	m.	m.	NOUN
bptjm-17	640	4	,	,	PUNCT
bptjm-17	640	5	d.	d.	PROPN
bptjm-17	640	6	dejong	dejong	PROPN
bptjm-17	640	7	,	,	PUNCT
bptjm-17	640	8	a.	a.	NOUN
bptjm-17	640	9	burylo	burylo	PROPN
bptjm-17	640	10	,	,	PUNCT
bptjm-17	640	11	j.	j.	PROPN
bptjm-17	640	12	a.	a.	PROPN
bptjm-17	640	13	burgers	burgers	PROPN
bptjm-17	640	14	,	,	PUNCT
bptjm-17	640	15	p.	p.	NOUN
bptjm-17	640	16	baas	baas	NOUN
bptjm-17	640	17	,	,	PUNCT
bptjm-17	640	18	a.	a.	PROPN
bptjm-17	640	19	d.	d.	PROPN
bptjm-17	640	20	r.	r.	PROPN
bptjm-17	640	21	huitema	huitema	PROPN
bptjm-17	640	22	,	,	PUNCT
bptjm-17	640	23	j.	j.	PROPN
bptjm-17	640	24	h.	h.	PROPN
bptjm-17	640	25	beijnen	beijnen	PROPN
bptjm-17	640	26	,	,	PUNCT
bptjm-17	640	27	and	and	CCONJ
bptjm-17	640	28	j.	j.	PROPN
bptjm-17	640	29	h.	h.	PROPN
bptjm-17	640	30	m.	m.	PROPN
bptjm-17	640	31	schellens	schellen	VERB
bptjm-17	640	32	.	.	PUNCT
bptjm-17	641	1	(	(	PUNCT
bptjm-17	641	2	november	november	PROPN
bptjm-17	641	3	1	1	NUM
bptjm-17	641	4	,	,	PUNCT
bptjm-17	641	5	2011	2011	NUM
bptjm-17	641	6	)	)	PUNCT
bptjm-17	641	7	.	.	PUNCT
bptjm-17	642	1	tubuline	tubuline	PROPN
bptjm-17	642	2	,	,	PUNCT
bptjm-17	642	3	brca1	brca1	PROPN
bptjm-17	642	4	,	,	PUNCT
bptjm-17	642	5	ercc1	ercc1	PROPN
bptjm-17	642	6	,	,	PUNCT
bptjm-17	642	7	abraxas	abraxas	PROPN
bptjm-17	642	8	,	,	PUNCT
bptjm-17	642	9	rap80	rap80	NOUN
bptjm-17	642	10	mrna	mrna	PROPN
bptjm-17	642	11	expression	expression	NOUN
bptjm-17	642	12	,	,	PUNCT
bptjm-17	642	13	p53	p53	NOUN
bptjm-17	642	14	/	/	SYM
bptjm-17	642	15	p21	p21	NOUN
bptjm-17	642	16	immunohistochemistry	immunohistochemistry	NOUN
bptjm-17	642	17	and	and	CCONJ
bptjm-17	642	18	clinical	clinical	ADJ
bptjm-17	642	19	outcome	outcome	NOUN
bptjm-17	642	20	in	in	ADP
bptjm-17	642	21	patients	patient	NOUN
bptjm-17	642	22	with	with	ADP
bptjm-17	642	23	advanced	advanced	ADJ
bptjm-17	642	24	non	non	ADJ
bptjm-17	642	25	small	small	ADJ
bptjm-17	642	26	-	-	PUNCT
bptjm-17	642	27	cell	cell	NOUN
bptjm-17	642	28	lung	lung	NOUN
bptjm-17	642	29	cancer	cancer	NOUN
bptjm-17	642	30	receiving	receive	VERB
bptjm-17	642	31	first	first	ADJ
bptjm-17	642	32	-	-	PUNCT
bptjm-17	642	33	line	line	NOUN
bptjm-17	642	34	platinum	platinum	NOUN
bptjm-17	642	35	–	–	PUNCT
bptjm-17	642	36	gemcitabine	gemcitabine	NOUN
bptjm-17	642	37	chemotherapy	chemotherapy	NOUN
bptjm-17	642	38	.	.	PUNCT
bptjm-17	643	1	lung	lung	NOUN
bptjm-17	643	2	cancer	cancer	NOUN
bptjm-17	643	3	,	,	PUNCT
bptjm-17	643	4	74(2	74(2	NUM
bptjm-17	643	5	)	)	PUNCT
bptjm-17	643	6	,	,	PUNCT
bptjm-17	643	7	310–17	310–17	NUM
bptjm-17	643	8	.	.	PUNCT
bptjm-17	644	1	https://doi.org/	https://doi.org/	VERB
bptjm-17	644	2	10.1016	10.1016	NUM
bptjm-17	644	3	/	/	SYM
bptjm-17	644	4	j.lungcan.2011.03.016	j.lungcan.2011.03.016	PROPN
bptjm-17	644	5	.	.	PROPN
bptjm-17	645	1	39	39	NUM
bptjm-17	645	2	.	.	PUNCT
bptjm-17	646	1	kato	kato	PROPN
bptjm-17	646	2	,	,	PUNCT
bptjm-17	646	3	shumei	shumei	PROPN
bptjm-17	646	4	,	,	PUNCT
bptjm-17	646	5	vivek	vivek	PROPN
bptjm-17	646	6	subbiah	subbiah	PROPN
bptjm-17	646	7	,	,	PUNCT
bptjm-17	646	8	erica	erica	PROPN
bptjm-17	646	9	marchlik	marchlik	PROPN
bptjm-17	646	10	,	,	PUNCT
bptjm-17	646	11	sheryl	sheryl	PROPN
bptjm-17	646	12	k.	k.	PROPN
bptjm-17	646	13	elkin	elkin	PROPN
bptjm-17	646	14	,	,	PUNCT
bptjm-17	646	15	jennifer	jennifer	PROPN
bptjm-17	646	16	l.	l.	PROPN
bptjm-17	646	17	carter	carter	PROPN
bptjm-17	646	18	,	,	PUNCT
bptjm-17	646	19	and	and	CCONJ
bptjm-17	646	20	razelle	razelle	NOUN
bptjm-17	646	21	kurzrock	kurzrock	NOUN
bptjm-17	646	22	.	.	PUNCT
bptjm-17	647	1	(	(	PUNCT
bptjm-17	647	2	april	april	PROPN
bptjm-17	647	3	15	15	NUM
bptjm-17	647	4	,	,	PUNCT
bptjm-17	647	5	2017	2017	NUM
bptjm-17	647	6	)	)	PUNCT
bptjm-17	647	7	.	.	PUNCT
bptjm-17	648	1	ret	ret	NOUN
bptjm-17	648	2	aberrations	aberration	NOUN
bptjm-17	648	3	in	in	ADP
bptjm-17	648	4	diverse	diverse	ADJ
bptjm-17	648	5	cancers	cancer	NOUN
bptjm-17	648	6	:	:	PUNCT
bptjm-17	648	7	next	next	ADJ
bptjm-17	648	8	-	-	PUNCT
bptjm-17	648	9	generation	generation	NOUN
bptjm-17	648	10	sequencing	sequencing	NOUN
bptjm-17	648	11	of	of	ADP
bptjm-17	648	12	4,871	4,871	NUM
bptjm-17	648	13	patients	patient	NOUN
bptjm-17	648	14	.	.	PUNCT
bptjm-17	649	1	clinical	clinical	ADJ
bptjm-17	649	2	cancer	cancer	NOUN
bptjm-17	649	3	research	research	NOUN
bptjm-17	649	4	,	,	PUNCT
bptjm-17	649	5	23(8	23(8	NOUN
bptjm-17	649	6	)	)	PUNCT
bptjm-17	649	7	,	,	PUNCT
bptjm-17	649	8	1988–97	1988–97	NUM
bptjm-17	649	9	.	.	PUNCT
bptjm-17	650	1	https://	https://	PROPN
bptjm-17	650	2	doi.org/10.1158/1078-0432.ccr-16-1679	doi.org/10.1158/1078-0432.ccr-16-1679	PROPN
bptjm-17	650	3	.	.	PUNCT
bptjm-17	651	1	40	40	NUM
bptjm-17	651	2	.	.	PUNCT
bptjm-17	652	1	kwak	kwak	PROPN
bptjm-17	652	2	,	,	PUNCT
bptjm-17	652	3	p.	p.	PROPN
bptjm-17	652	4	b.	b.	PROPN
bptjm-17	652	5	,	,	PUNCT
bptjm-17	652	6	iwasaki	iwasaki	PROPN
bptjm-17	652	7	,	,	PUNCT
bptjm-17	652	8	s.	s.	PROPN
bptjm-17	652	9	,	,	PUNCT
bptjm-17	652	10	&	&	CCONJ
bptjm-17	652	11	tomari	tomari	NOUN
bptjm-17	652	12	,	,	PUNCT
bptjm-17	652	13	y.	y.	PROPN
bptjm-17	652	14	(	(	PUNCT
bptjm-17	652	15	2010	2010	NUM
bptjm-17	652	16	)	)	PUNCT
bptjm-17	652	17	.	.	PUNCT
bptjm-17	653	1	the	the	DET
bptjm-17	653	2	microrna	microrna	PROPN
bptjm-17	653	3	pathway	pathway	NOUN
bptjm-17	653	4	and	and	CCONJ
bptjm-17	653	5	cancer	cancer	NOUN
bptjm-17	653	6	.	.	PUNCT
bptjm-17	654	1	cancer	cancer	NOUN
bptjm-17	654	2	science	science	NOUN
bptjm-17	654	3	,	,	PUNCT
bptjm-17	654	4	101(11	101(11	NUM
bptjm-17	654	5	)	)	PUNCT
bptjm-17	654	6	,	,	PUNCT
bptjm-17	654	7	2309–2315	2309–2315	NUM
bptjm-17	654	8	.	.	PUNCT
bptjm-17	655	1	https://doi.org/10.1111/j.1349-7006.2010.01683.x	https://doi.org/10.1111/j.1349-7006.2010.01683.x	NOUN
bptjm-17	655	2	41	41	NUM
bptjm-17	655	3	.	.	PUNCT
bptjm-17	656	1	kim	kim	PROPN
bptjm-17	656	2	,	,	PUNCT
bptjm-17	656	3	nayoung	nayoung	PROPN
bptjm-17	656	4	,	,	PUNCT
bptjm-17	656	5	mee	mee	PROPN
bptjm-17	656	6	song	song	NOUN
bptjm-17	656	7	,	,	PUNCT
bptjm-17	656	8	somin	somin	VERB
bptjm-17	656	9	kim	kim	PROPN
bptjm-17	656	10	,	,	PUNCT
bptjm-17	656	11	yujeong	yujeong	ADJ
bptjm-17	656	12	seo	seo	PROPN
bptjm-17	656	13	,	,	PUNCT
bptjm-17	656	14	yonghwan	yonghwan	PROPN
bptjm-17	656	15	kim	kim	PROPN
bptjm-17	656	16	,	,	PUNCT
bptjm-17	656	17	and	and	CCONJ
bptjm-17	656	18	sukjoon	sukjoon	PROPN
bptjm-17	656	19	yoon	yoon	PROPN
bptjm-17	656	20	.	.	PUNCT
bptjm-17	657	1	(	(	PUNCT
bptjm-17	657	2	november	november	PROPN
bptjm-17	657	3	20	20	NUM
bptjm-17	657	4	,	,	PUNCT
bptjm-17	657	5	2015	2015	NUM
bptjm-17	657	6	)	)	PUNCT
bptjm-17	657	7	.	.	PUNCT
bptjm-17	658	1	di	di	PROPN
bptjm-17	658	2	�	�	PROPN
bptjm-17	658	3	erential	erential	ADJ
bptjm-17	658	4	regulation	regulation	NOUN
bptjm-17	658	5	and	and	CCONJ
bptjm-17	658	6	synthetic	synthetic	ADJ
bptjm-17	658	7	lethality	lethality	NOUN
bptjm-17	658	8	of	of	ADP
bptjm-17	658	9	exclusive	exclusive	ADJ
bptjm-17	658	10	rb1	rb1	NOUN
bptjm-17	658	11	and	and	CCONJ
bptjm-17	658	12	cdkn2a	cdkn2a	PROPN
bptjm-17	658	13	mutations	mutation	NOUN
bptjm-17	658	14	in	in	ADP
bptjm-17	658	15	lung	lung	NOUN
bptjm-17	658	16	cancer	cancer	NOUN
bptjm-17	658	17	.	.	PUNCT
bptjm-17	659	1	international	international	ADJ
bptjm-17	659	2	journal	journal	PROPN
bptjm-17	659	3	of	of	ADP
bptjm-17	659	4	oncology	oncology	NOUN
bptjm-17	659	5	,	,	PUNCT
bptjm-17	659	6	48,(1	48,(1	PROPN
bptjm-17	659	7	)	)	PUNCT
bptjm-17	659	8	,	,	PUNCT
bptjm-17	659	9	367–75	367–75	NUM
bptjm-17	659	10	.	.	PUNCT
bptjm-17	660	1	https://doi.org/10.3892/ijo.2015.3262	https://doi.org/10.3892/ijo.2015.3262	NOUN
bptjm-17	660	2	.	.	PUNCT
bptjm-17	661	1	42	42	NUM
bptjm-17	661	2	.	.	PUNCT
bptjm-17	661	3	kishore	kishore	PROPN
bptjm-17	661	4	,	,	PUNCT
bptjm-17	661	5	j.	j.	PROPN
bptjm-17	661	6	,	,	PUNCT
bptjm-17	661	7	goel	goel	PROPN
bptjm-17	661	8	,	,	PUNCT
bptjm-17	661	9	m.	m.	PROPN
bptjm-17	661	10	k.	k.	PROPN
bptjm-17	661	11	,	,	PUNCT
bptjm-17	661	12	&	&	CCONJ
bptjm-17	661	13	khanna	khanna	PROPN
bptjm-17	661	14	,	,	PUNCT
bptjm-17	661	15	p.	p.	NOUN
bptjm-17	661	16	(	(	PUNCT
bptjm-17	661	17	2010	2010	NUM
bptjm-17	661	18	)	)	PUNCT
bptjm-17	661	19	.	.	PUNCT
bptjm-17	662	1	understanding	understand	VERB
bptjm-17	662	2	survival	survival	NOUN
bptjm-17	662	3	analysis	analysis	NOUN
bptjm-17	662	4	:	:	PUNCT
bptjm-17	662	5	kaplan	kaplan	PROPN
bptjm-17	662	6	meier	meier	PROPN
bptjm-17	662	7	estimate	estimate	PROPN
bptjm-17	662	8	.	.	PUNCT
bptjm-17	663	1	international	international	ADJ
bptjm-17	663	2	journal	journal	PROPN
bptjm-17	663	3	of	of	ADP
bptjm-17	663	4	ayurveda	ayurveda	PROPN
bptjm-17	663	5	research	research	NOUN
bptjm-17	663	6	,	,	PUNCT
bptjm-17	663	7	1(4	1(4	NUM
bptjm-17	663	8	)	)	PUNCT
bptjm-17	663	9	,	,	PUNCT
bptjm-17	663	10	274	274	NUM
bptjm-17	663	11	.	.	PUNCT
bptjm-17	663	12	https://doi.org/10.4103/0974-7788.76794	https://doi.org/10.4103/0974-7788.76794	PROPN
bptjm-17	663	13	43	43	NUM
bptjm-17	663	14	.	.	PUNCT
bptjm-17	664	1	krichevsky	krichevsky	PROPN
bptjm-17	664	2	,	,	PUNCT
bptjm-17	664	3	a.m.	a.m.	ADV
bptjm-17	664	4	,	,	PUNCT
bptjm-17	664	5	gabriely	gabriely	ADV
bptjm-17	664	6	,	,	PUNCT
bptjm-17	664	7	g.	g.	PROPN
bptjm-17	664	8	(	(	PUNCT
bptjm-17	664	9	2009	2009	NUM
bptjm-17	664	10	)	)	PUNCT
bptjm-17	664	11	.	.	PUNCT
bptjm-17	665	1	mir-21	mir-21	NOUN
bptjm-17	665	2	:	:	PUNCT
bptjm-17	665	3	a	a	DET
bptjm-17	665	4	small	small	ADJ
bptjm-17	665	5	multi	multi	ADJ
bptjm-17	665	6	-	-	ADJ
bptjm-17	665	7	faceted	faceted	ADJ
bptjm-17	665	8	rna	rna	PROPN
bptjm-17	665	9	.	.	PUNCT
bptjm-17	666	1	journal	journal	PROPN
bptjm-17	666	2	of	of	ADP
bptjm-17	666	3	cellular	cellular	ADJ
bptjm-17	666	4	and	and	CCONJ
bptjm-17	666	5	molecular	molecular	ADJ
bptjm-17	666	6	medicine	medicine	NOUN
bptjm-17	666	7	;	;	PUNCT
bptjm-17	666	8	13(1	13(1	X
bptjm-17	666	9	)	)	PUNCT
bptjm-17	666	10	,	,	PUNCT
bptjm-17	666	11	39	39	NUM
bptjm-17	666	12	-	-	SYM
bptjm-17	666	13	53	53	NUM
bptjm-17	666	14	.	.	PUNCT
bptjm-17	667	1	doi:10.1111	doi:10.1111	ADJ
bptjm-17	667	2	/	/	SYM
bptjm-17	667	3	j.1582	j.1582	NOUN
bptjm-17	667	4	-	-	PUNCT
bptjm-17	667	5	4934.2008.00556.x	4934.2008.00556.x	NUM
bptjm-17	667	6	44	44	NUM
bptjm-17	667	7	.	.	PUNCT
bptjm-17	668	1	kris	kris	PROPN
bptjm-17	668	2	,	,	PUNCT
bptjm-17	668	3	m.	m.	PROPN
bptjm-17	668	4	g.	g.	PROPN
bptjm-17	668	5	,	,	PUNCT
bptjm-17	668	6	d.	d.	PROPN
bptjm-17	668	7	r.	r.	PROPN
bptjm-17	668	8	camidge	camidge	PROPN
bptjm-17	668	9	,	,	PUNCT
bptjm-17	668	10	g.	g.	PROPN
bptjm-17	668	11	giaccone	giaccone	PROPN
bptjm-17	668	12	,	,	PUNCT
bptjm-17	668	13	t.	t.	PROPN
bptjm-17	668	14	hida	hida	PROPN
bptjm-17	668	15	,	,	PUNCT
bptjm-17	668	16	b.	b.	PROPN
bptjm-17	668	17	t.	t.	PROPN
bptjm-17	668	18	li	li	PROPN
bptjm-17	668	19	,	,	PUNCT
bptjm-17	668	20	j.	j.	PROPN
bptjm-17	668	21	o’connell	o’connell	PROPN
bptjm-17	668	22	,	,	PUNCT
bptjm-17	668	23	i.	i.	PROPN
bptjm-17	668	24	taylor	taylor	PROPN
bptjm-17	668	25	,	,	PUNCT
bptjm-17	668	26	et	et	PROPN
bptjm-17	668	27	al	al	PROPN
bptjm-17	668	28	.	.	PUNCT
bptjm-17	669	1	(	(	PUNCT
bptjm-17	669	2	july	july	PROPN
bptjm-17	669	3	1	1	NUM
bptjm-17	669	4	,	,	PUNCT
bptjm-17	669	5	2015	2015	NUM
bptjm-17	669	6	)	)	PUNCT
bptjm-17	669	7	.	.	PUNCT
bptjm-17	670	1	targeting	target	VERB
bptjm-17	670	2	her2	her2	NOUN
bptjm-17	670	3	aberrations	aberration	NOUN
bptjm-17	670	4	as	as	ADP
bptjm-17	670	5	actionable	actionable	ADJ
bptjm-17	670	6	drivers	driver	NOUN
bptjm-17	670	7	in	in	ADP
bptjm-17	670	8	lung	lung	NOUN
bptjm-17	670	9	cancers	cancer	NOUN
bptjm-17	670	10	:	:	PUNCT
bptjm-17	670	11	phase	phase	NOUN
bptjm-17	670	12	ii	ii	NOUN
bptjm-17	670	13	trial	trial	NOUN
bptjm-17	670	14	of	of	ADP
bptjm-17	670	15	the	the	DET
bptjm-17	670	16	pan	pan	NOUN
bptjm-17	670	17	-	-	ADJ
bptjm-17	670	18	her	her	PRON
bptjm-17	670	19	tyrosine	tyrosine	NOUN
bptjm-17	670	20	kinase	kinase	PROPN
bptjm-17	670	21	inhibitor	inhibitor	PROPN
bptjm-17	670	22	dacomitinib	dacomitinib	PROPN
bptjm-17	670	23	in	in	ADP
bptjm-17	670	24	patients	patient	NOUN
bptjm-17	670	25	with	with	ADP
bptjm-17	670	26	her2	her2	NOUN
bptjm-17	670	27	-	-	PUNCT
bptjm-17	670	28	mutant	mutant	ADJ
bptjm-17	670	29	or	or	CCONJ
bptjm-17	670	30	ampli	ampli	VERB
bptjm-17	670	31	�	�	NOUN
bptjm-17	670	32	ed	ed	NOUN
bptjm-17	670	33	tumors	tumor	NOUN
bptjm-17	670	34	.	.	PUNCT
bptjm-17	671	1	annals	annal	NOUN
bptjm-17	671	2	of	of	ADP
bptjm-17	671	3	oncology	oncology	NOUN
bptjm-17	671	4	,	,	PUNCT
bptjm-17	671	5	26(7	26(7	NOUN
bptjm-17	671	6	)	)	PUNCT
bptjm-17	671	7	,	,	PUNCT
bptjm-17	671	8	1421–27	1421–27	NUM
bptjm-17	671	9	.	.	PUNCT
bptjm-17	672	1	https://	https://	PROPN
bptjm-17	672	2	doi.org/10.1093/annonc/mdv186	doi.org/10.1093/annonc/mdv186	PROPN
bptjm-17	672	3	.	.	PUNCT
bptjm-17	672	4	45	45	NUM
bptjm-17	672	5	.	.	PUNCT
bptjm-17	672	6	kodama	kodama	PROPN
bptjm-17	672	7	,	,	PUNCT
bptjm-17	672	8	tatsushi	tatsushi	PROPN
bptjm-17	672	9	,	,	PUNCT
bptjm-17	672	10	toshiyuki	toshiyuki	PROPN
bptjm-17	672	11	tsukaguchi	tsukaguchi	NOUN
bptjm-17	672	12	,	,	PUNCT
bptjm-17	672	13	yasuko	yasuko	PROPN
bptjm-17	672	14	satoh	satoh	PROPN
bptjm-17	672	15	,	,	PUNCT
bptjm-17	672	16	miyuki	miyuki	PROPN
bptjm-17	672	17	yoshida	yoshida	PROPN
bptjm-17	672	18	,	,	PUNCT
bptjm-17	672	19	yoshiaki	yoshiaki	PROPN
bptjm-17	672	20	watanabe	watanabe	PROPN
bptjm-17	672	21	,	,	PUNCT
bptjm-17	672	22	osamu	osamu	PROPN
bptjm-17	672	23	kondoh	kondoh	PROPN
bptjm-17	672	24	,	,	PUNCT
bptjm-17	672	25	and	and	CCONJ
bptjm-17	672	26	hiroshi	hiroshi	PROPN
bptjm-17	672	27	sakamoto	sakamoto	PROPN
bptjm-17	672	28	.	.	PUNCT
bptjm-17	673	1	(	(	PUNCT
bptjm-17	673	2	december	december	PROPN
bptjm-17	673	3	1	1	NUM
bptjm-17	673	4	,	,	PUNCT
bptjm-17	673	5	2014	2014	NUM
bptjm-17	673	6	)	)	PUNCT
bptjm-17	673	7	.	.	PUNCT
bptjm-17	674	1	alectinib	alectinib	PROPN
bptjm-17	674	2	shows	show	VERB
bptjm-17	674	3	potent	potent	ADJ
bptjm-17	674	4	antitumor	antitumor	PROPN
bptjm-17	674	5	activity	activity	NOUN
bptjm-17	674	6	against	against	ADP
bptjm-17	674	7	ret	ret	NOUN
bptjm-17	674	8	-	-	PUNCT
bptjm-17	674	9	rearranged	rearrange	VERB
bptjm-17	674	10	non	non	ADJ
bptjm-17	674	11	–	–	ADJ
bptjm-17	674	12	small	small	ADJ
bptjm-17	674	13	cell	cell	NOUN
bptjm-17	674	14	lung	lung	NOUN
bptjm-17	674	15	cancer	cancer	NOUN
bptjm-17	674	16	.	.	PUNCT
bptjm-17	675	1	molecular	molecular	ADJ
bptjm-17	675	2	cancer	cancer	NOUN
bptjm-17	675	3	therapeutics	therapeutic	NOUN
bptjm-17	675	4	,	,	PUNCT
bptjm-17	675	5	13(12	13(12	NUM
bptjm-17	675	6	)	)	PUNCT
bptjm-17	675	7	:	:	PUNCT
bptjm-17	676	1	2910–18	2910–18	X
bptjm-17	676	2	.	.	PUNCT
bptjm-17	676	3	https://doi.org/	https://doi.org/	VERB
bptjm-17	676	4	10.1158/1535	10.1158/1535	NUM
bptjm-17	676	5	-	-	PUNCT
bptjm-17	676	6	7163.mct-14	7163.mct-14	NUM
bptjm-17	676	7	-	-	PUNCT
bptjm-17	676	8	0274	0274	NUM
bptjm-17	676	9	.	.	PUNCT
bptjm-17	677	1	berkeley	berkeley	PROPN
bptjm-17	677	2	pharma	pharma	PROPN
bptjm-17	677	3	tech	tech	PROPN
bptjm-17	677	4	journal	journal	NOUN
bptjm-17	677	5	of	of	ADP
bptjm-17	677	6	medicine	medicine	NOUN
bptjm-17	677	7	|	|	ADV
bptjm-17	677	8	149	149	NUM
bptjm-17	677	9	46	46	NUM
bptjm-17	677	10	.	.	PUNCT
bptjm-17	678	1	kohno	kohno	PROPN
bptjm-17	678	2	,	,	PUNCT
bptjm-17	678	3	takashi	takashi	PROPN
bptjm-17	678	4	,	,	PUNCT
bptjm-17	678	5	koji	koji	PROPN
bptjm-17	678	6	tsuta	tsuta	PROPN
bptjm-17	678	7	,	,	PUNCT
bptjm-17	678	8	katsuya	katsuya	PROPN
bptjm-17	678	9	tsuchihara	tsuchihara	PROPN
bptjm-17	678	10	,	,	PUNCT
bptjm-17	678	11	takashi	takashi	PROPN
bptjm-17	678	12	nakaoku	nakaoku	PROPN
bptjm-17	678	13	,	,	PUNCT
bptjm-17	678	14	kiyotaka	kiyotaka	PROPN
bptjm-17	678	15	yoh	yoh	PROPN
bptjm-17	678	16	,	,	PUNCT
bptjm-17	678	17	and	and	CCONJ
bptjm-17	678	18	koichi	koichi	PROPN
bptjm-17	678	19	goto	goto	NOUN
bptjm-17	678	20	.	.	PUNCT
bptjm-17	679	1	(	(	PUNCT
bptjm-17	679	2	2013	2013	NUM
bptjm-17	679	3	)	)	PUNCT
bptjm-17	679	4	.	.	PUNCT
bptjm-17	680	1	ret	ret	NOUN
bptjm-17	680	2	fusion	fusion	NOUN
bptjm-17	680	3	gene	gene	NOUN
bptjm-17	680	4	:	:	PUNCT
bptjm-17	680	5	translation	translation	NOUN
bptjm-17	680	6	to	to	ADP
bptjm-17	680	7	personalized	personalize	VERB
bptjm-17	680	8	lung	lung	NOUN
bptjm-17	680	9	cancer	cancer	NOUN
bptjm-17	680	10	therapy	therapy	NOUN
bptjm-17	680	11	.	.	PUNCT
bptjm-17	681	1	cancer	cancer	NOUN
bptjm-17	681	2	science	science	PROPN
bptjm-17	681	3	,	,	PUNCT
bptjm-17	681	4	104(11	104(11	NUM
bptjm-17	681	5	)	)	PUNCT
bptjm-17	681	6	:	:	PUNCT
bptjm-17	681	7	1396–1400	1396–1400	X
bptjm-17	681	8	.	.	PUNCT
bptjm-17	682	1	https://doi.org/10.1111/cas.12275	https://doi.org/10.1111/cas.12275	PROPN
bptjm-17	682	2	.	.	PROPN
bptjm-17	683	1	47	47	NUM
bptjm-17	683	2	.	.	PUNCT
bptjm-17	684	1	labbé	labbé	PROPN
bptjm-17	684	2	,	,	PUNCT
bptjm-17	684	3	c.	c.	NOUN
bptjm-17	684	4	,	,	PUNCT
bptjm-17	684	5	cabanero	cabanero	NOUN
bptjm-17	684	6	,	,	PUNCT
bptjm-17	684	7	m.	m.	NOUN
bptjm-17	684	8	,	,	PUNCT
bptjm-17	684	9	korpanty	korpanty	NOUN
bptjm-17	684	10	,	,	PUNCT
bptjm-17	684	11	g.	g.	PROPN
bptjm-17	684	12	j.	j.	PROPN
bptjm-17	684	13	,	,	PUNCT
bptjm-17	684	14	tomasini	tomasini	PROPN
bptjm-17	684	15	,	,	PUNCT
bptjm-17	684	16	p.	p.	PROPN
bptjm-17	684	17	,	,	PUNCT
bptjm-17	684	18	doherty	doherty	PROPN
bptjm-17	684	19	,	,	PUNCT
bptjm-17	684	20	m.	m.	PROPN
bptjm-17	684	21	k.	k.	PROPN
bptjm-17	684	22	,	,	PUNCT
bptjm-17	684	23	mascaux	mascaux	PROPN
bptjm-17	684	24	,	,	PUNCT
bptjm-17	684	25	c.	c.	PROPN
bptjm-17	684	26	,	,	PUNCT
bptjm-17	684	27	jao	jao	PROPN
bptjm-17	684	28	,	,	PUNCT
bptjm-17	684	29	k.	k.	PROPN
bptjm-17	684	30	,	,	PUNCT
bptjm-17	684	31	pitcher	pitcher	PROPN
bptjm-17	684	32	,	,	PUNCT
bptjm-17	684	33	b.	b.	PROPN
bptjm-17	684	34	,	,	PUNCT
bptjm-17	684	35	wang	wang	PROPN
bptjm-17	684	36	,	,	PUNCT
bptjm-17	684	37	r.	r.	PROPN
bptjm-17	684	38	,	,	PUNCT
bptjm-17	684	39	pintilie	pintilie	NOUN
bptjm-17	684	40	,	,	PUNCT
bptjm-17	684	41	m.	m.	NOUN
bptjm-17	684	42	,	,	PUNCT
bptjm-17	684	43	leighl	leighl	NOUN
bptjm-17	684	44	,	,	PUNCT
bptjm-17	684	45	n.	n.	PROPN
bptjm-17	684	46	b.	b.	PROPN
bptjm-17	684	47	,	,	PUNCT
bptjm-17	684	48	feld	feld	PROPN
bptjm-17	684	49	,	,	PUNCT
bptjm-17	684	50	r.	r.	PROPN
bptjm-17	684	51	,	,	PUNCT
bptjm-17	684	52	liu	liu	PROPN
bptjm-17	684	53	,	,	PUNCT
bptjm-17	684	54	g.	g.	PROPN
bptjm-17	684	55	,	,	PUNCT
bptjm-17	684	56	bradbury	bradbury	PROPN
bptjm-17	684	57	,	,	PUNCT
bptjm-17	684	58	p.	p.	PROPN
bptjm-17	684	59	a.	a.	PROPN
bptjm-17	684	60	,	,	PUNCT
bptjm-17	684	61	kamel	kamel	PROPN
bptjm-17	684	62	-	-	PUNCT
bptjm-17	684	63	reid	reid	PROPN
bptjm-17	684	64	,	,	PUNCT
bptjm-17	684	65	s.	s.	PROPN
bptjm-17	684	66	,	,	PUNCT
bptjm-17	684	67	tsao	tsao	PROPN
bptjm-17	684	68	,	,	PUNCT
bptjm-17	684	69	m.	m.	NOUN
bptjm-17	684	70	s.	s.	PROPN
bptjm-17	684	71	,	,	PUNCT
bptjm-17	684	72	&	&	CCONJ
bptjm-17	684	73	shepherd	shepherd	PROPN
bptjm-17	684	74	,	,	PUNCT
bptjm-17	684	75	f.	f.	PROPN
bptjm-17	684	76	a.	a.	PROPN
bptjm-17	684	77	(	(	PUNCT
bptjm-17	684	78	2017	2017	NUM
bptjm-17	684	79	)	)	PUNCT
bptjm-17	684	80	.	.	PUNCT
bptjm-17	685	1	prognostic	prognostic	ADJ
bptjm-17	685	2	and	and	CCONJ
bptjm-17	685	3	predictive	predictive	ADJ
bptjm-17	685	4	e	e	NOUN
bptjm-17	685	5	�	�	NOUN
bptjm-17	685	6	ects	ect	NOUN
bptjm-17	685	7	of	of	ADP
bptjm-17	685	8	tp53	tp53	PROPN
bptjm-17	685	9	co	co	NOUN
bptjm-17	685	10	-	-	NOUN
bptjm-17	685	11	mutation	mutation	NOUN
bptjm-17	685	12	in	in	ADP
bptjm-17	685	13	patients	patient	NOUN
bptjm-17	685	14	with	with	ADP
bptjm-17	685	15	egfr	egfr	NOUN
bptjm-17	685	16	-	-	PUNCT
bptjm-17	685	17	mutated	mutate	VERB
bptjm-17	685	18	non	non	ADJ
bptjm-17	685	19	-	-	ADJ
bptjm-17	685	20	small	small	ADJ
bptjm-17	685	21	cell	cell	NOUN
bptjm-17	685	22	lung	lung	NOUN
bptjm-17	685	23	cancer	cancer	NOUN
bptjm-17	685	24	(	(	PUNCT
bptjm-17	685	25	nsclc	nsclc	NOUN
bptjm-17	685	26	)	)	PUNCT
bptjm-17	685	27	.	.	PUNCT
bptjm-17	686	1	lung	lung	NOUN
bptjm-17	686	2	cancer	cancer	NOUN
bptjm-17	686	3	(	(	PUNCT
bptjm-17	686	4	amsterdam	amsterdam	PROPN
bptjm-17	686	5	,	,	PUNCT
bptjm-17	686	6	netherlands	netherlands	PROPN
bptjm-17	686	7	)	)	PUNCT
bptjm-17	686	8	,	,	PUNCT
bptjm-17	686	9	111	111	NUM
bptjm-17	686	10	,	,	PUNCT
bptjm-17	686	11	23–29	23–29	NUM
bptjm-17	686	12	.	.	PUNCT
bptjm-17	687	1	https://doi.org/10.1016/	https://doi.org/10.1016/	PROPN
bptjm-17	687	2	j.lungcan.2017.06.014	j.lungcan.2017.06.014	PROPN
bptjm-17	687	3	.	.	PUNCT
bptjm-17	688	1	48	48	NUM
bptjm-17	688	2	.	.	PUNCT
bptjm-17	689	1	le	le	PROPN
bptjm-17	689	2	,	,	PUNCT
bptjm-17	689	3	h.	h.	PROPN
bptjm-17	689	4	b.	b.	PROPN
bptjm-17	689	5	,	,	PUNCT
bptjm-17	689	6	zhu	zhu	PROPN
bptjm-17	689	7	,	,	PUNCT
bptjm-17	689	8	w.	w.	PROPN
bptjm-17	689	9	y.	y.	PROPN
bptjm-17	689	10	,	,	PUNCT
bptjm-17	689	11	chen	chen	PROPN
bptjm-17	689	12	,	,	PUNCT
bptjm-17	689	13	d.	d.	PROPN
bptjm-17	689	14	d.	d.	PROPN
bptjm-17	689	15	,	,	PUNCT
bptjm-17	689	16	he	he	PRON
bptjm-17	689	17	,	,	PUNCT
bptjm-17	689	18	j.	j.	PROPN
bptjm-17	689	19	y.	y.	PROPN
bptjm-17	689	20	,	,	PUNCT
bptjm-17	689	21	huang	huang	PROPN
bptjm-17	689	22	,	,	PUNCT
bptjm-17	689	23	y.	y.	PROPN
bptjm-17	689	24	y.	y.	PROPN
bptjm-17	689	25	,	,	PUNCT
bptjm-17	689	26	liu	liu	PROPN
bptjm-17	689	27	,	,	PUNCT
bptjm-17	689	28	x.	x.	PROPN
bptjm-17	689	29	g.	g.	PROPN
bptjm-17	689	30	,	,	PUNCT
bptjm-17	689	31	&	&	CCONJ
bptjm-17	689	32	zhang	zhang	PROPN
bptjm-17	689	33	,	,	PUNCT
bptjm-17	689	34	y.	y.	PROPN
bptjm-17	689	35	k.	k.	PROPN
bptjm-17	689	36	(	(	PUNCT
bptjm-17	689	37	2012	2012	NUM
bptjm-17	689	38	)	)	PUNCT
bptjm-17	689	39	.	.	PUNCT
bptjm-17	690	1	evaluation	evaluation	NOUN
bptjm-17	690	2	of	of	ADP
bptjm-17	690	3	dynamic	dynamic	ADJ
bptjm-17	690	4	change	change	NOUN
bptjm-17	690	5	of	of	ADP
bptjm-17	690	6	serum	serum	PROPN
bptjm-17	690	7	mir-21	mir-21	PROPN
bptjm-17	690	8	and	and	CCONJ
bptjm-17	690	9	mir-24	mir-24	NOUN
bptjm-17	690	10	in	in	ADP
bptjm-17	690	11	preand	preand	NOUN
bptjm-17	690	12	post	post	ADJ
bptjm-17	690	13	-	-	ADJ
bptjm-17	690	14	operative	operative	ADJ
bptjm-17	690	15	lung	lung	NOUN
bptjm-17	690	16	carcinoma	carcinoma	NOUN
bptjm-17	690	17	patients	patient	NOUN
bptjm-17	690	18	.	.	PUNCT
bptjm-17	691	1	medical	medical	ADJ
bptjm-17	691	2	oncology	oncology	NOUN
bptjm-17	691	3	(	(	PUNCT
bptjm-17	691	4	northwood	northwood	PROPN
bptjm-17	691	5	,	,	PUNCT
bptjm-17	691	6	london	london	PROPN
bptjm-17	691	7	,	,	PUNCT
bptjm-17	691	8	england	england	PROPN
bptjm-17	691	9	)	)	PUNCT
bptjm-17	691	10	,	,	PUNCT
bptjm-17	691	11	29(5	29(5	NUM
bptjm-17	691	12	)	)	PUNCT
bptjm-17	691	13	,	,	PUNCT
bptjm-17	691	14	3190–3197	3190–3197	NUM
bptjm-17	691	15	.	.	PUNCT
bptjm-17	692	1	https://doi.org/10.1007/s12032-012-0303-z	https://doi.org/10.1007/s12032-012-0303-z	PROPN
bptjm-17	692	2	49	49	NUM
bptjm-17	692	3	.	.	PUNCT
bptjm-17	693	1	li	li	PROPN
bptjm-17	693	2	,	,	PUNCT
bptjm-17	693	3	m.	m.	NOUN
bptjm-17	693	4	x.	x.	PROPN
bptjm-17	693	5	,	,	PUNCT
bptjm-17	693	6	bi	bi	PROPN
bptjm-17	693	7	,	,	PUNCT
bptjm-17	693	8	x.	x.	NOUN
bptjm-17	693	9	y.	y.	PROPN
bptjm-17	693	10	,	,	PUNCT
bptjm-17	693	11	zhao	zhao	PROPN
bptjm-17	693	12	,	,	PUNCT
bptjm-17	693	13	h.	h.	PROPN
bptjm-17	693	14	,	,	PUNCT
bptjm-17	693	15	huang	huang	PROPN
bptjm-17	693	16	,	,	PUNCT
bptjm-17	693	17	z.	z.	PROPN
bptjm-17	693	18	,	,	PUNCT
bptjm-17	693	19	han	han	PROPN
bptjm-17	693	20	,	,	PUNCT
bptjm-17	693	21	y.	y.	PROPN
bptjm-17	693	22	,	,	PUNCT
bptjm-17	693	23	zhao	zhao	PROPN
bptjm-17	693	24	,	,	PUNCT
bptjm-17	693	25	d.	d.	PROPN
bptjm-17	693	26	b.	b.	PROPN
bptjm-17	693	27	,	,	PUNCT
bptjm-17	693	28	zhao	zhao	PROPN
bptjm-17	693	29	,	,	PUNCT
bptjm-17	693	30	j.	j.	PROPN
bptjm-17	693	31	j.	j.	PROPN
bptjm-17	693	32	,	,	PUNCT
bptjm-17	693	33	&	&	CCONJ
bptjm-17	693	34	cai	cai	PROPN
bptjm-17	693	35	,	,	PUNCT
bptjm-17	693	36	j.	j.	PROPN
bptjm-17	693	37	q.	q.	PROPN
bptjm-17	693	38	(	(	PUNCT
bptjm-17	693	39	2016	2016	NUM
bptjm-17	693	40	)	)	PUNCT
bptjm-17	693	41	.	.	PUNCT
bptjm-17	694	1	excision	excision	NOUN
bptjm-17	694	2	repair	repair	NOUN
bptjm-17	694	3	cross	cross	ADJ
bptjm-17	694	4	-	-	ADJ
bptjm-17	694	5	complementation	complementation	ADJ
bptjm-17	694	6	group	group	NOUN
bptjm-17	694	7	1	1	NUM
bptjm-17	694	8	is	be	AUX
bptjm-17	694	9	a	a	DET
bptjm-17	694	10	prognostic	prognostic	ADJ
bptjm-17	694	11	biomarker	biomarker	NOUN
bptjm-17	694	12	in	in	ADP
bptjm-17	694	13	patients	patient	NOUN
bptjm-17	694	14	with	with	ADP
bptjm-17	694	15	colorectal	colorectal	ADJ
bptjm-17	694	16	cancer	cancer	NOUN
bptjm-17	694	17	receiving	receive	VERB
bptjm-17	694	18	chemotherapy	chemotherapy	NOUN
bptjm-17	694	19	.	.	PUNCT
bptjm-17	695	1	chinese	chinese	ADJ
bptjm-17	695	2	medical	medical	ADJ
bptjm-17	695	3	journal	journal	NOUN
bptjm-17	695	4	,	,	PUNCT
bptjm-17	695	5	129(5	129(5	NUM
bptjm-17	695	6	)	)	PUNCT
bptjm-17	695	7	,	,	PUNCT
bptjm-17	695	8	586–593	586–593	NUM
bptjm-17	695	9	.	.	PUNCT
bptjm-17	696	1	https://doi.org/10.4103/0366-6999.176993	https://doi.org/10.4103/0366-6999.176993	NOUN
bptjm-17	696	2	.	.	PUNCT
bptjm-17	697	1	50	50	NUM
bptjm-17	697	2	.	.	PUNCT
bptjm-17	698	1	li	li	PROPN
bptjm-17	698	2	,	,	PUNCT
bptjm-17	698	3	w.	w.	PROPN
bptjm-17	698	4	,	,	PUNCT
bptjm-17	698	5	wang	wang	PROPN
bptjm-17	698	6	,	,	PUNCT
bptjm-17	698	7	y.	y.	PROPN
bptjm-17	698	8	,	,	PUNCT
bptjm-17	698	9	zhang	zhang	PROPN
bptjm-17	698	10	,	,	PUNCT
bptjm-17	698	11	q.	q.	PROPN
bptjm-17	698	12	,	,	PUNCT
bptjm-17	698	13	tang	tang	PROPN
bptjm-17	698	14	,	,	PUNCT
bptjm-17	698	15	l.	l.	PROPN
bptjm-17	698	16	,	,	PUNCT
bptjm-17	698	17	liu	liu	PROPN
bptjm-17	698	18	,	,	PUNCT
bptjm-17	698	19	x.	x.	PROPN
bptjm-17	698	20	,	,	PUNCT
bptjm-17	698	21	dai	dai	PROPN
bptjm-17	698	22	,	,	PUNCT
bptjm-17	698	23	y.	y.	PROPN
bptjm-17	698	24	,	,	PUNCT
bptjm-17	698	25	et	et	PROPN
bptjm-17	698	26	al	al	PROPN
bptjm-17	698	27	.	.	PROPN
bptjm-17	698	28	(	(	PUNCT
bptjm-17	698	29	2015	2015	NUM
bptjm-17	698	30	)	)	PUNCT
bptjm-17	698	31	microrna-486	microrna-486	ADJ
bptjm-17	698	32	as	as	ADP
bptjm-17	698	33	a	a	DET
bptjm-17	698	34	biomarker	biomarker	NOUN
bptjm-17	698	35	for	for	ADP
bptjm-17	698	36	early	early	ADJ
bptjm-17	698	37	diagnosis	diagnosis	NOUN
bptjm-17	698	38	and	and	CCONJ
bptjm-17	698	39	recurrence	recurrence	NOUN
bptjm-17	698	40	of	of	ADP
bptjm-17	698	41	non	non	ADJ
bptjm-17	698	42	-	-	ADJ
bptjm-17	698	43	small	small	ADJ
bptjm-17	698	44	cell	cell	NOUN
bptjm-17	698	45	lung	lung	NOUN
bptjm-17	698	46	cancer	cancer	NOUN
bptjm-17	698	47	.	.	PUNCT
bptjm-17	699	1	plos	plos	PROPN
bptjm-17	699	2	one	one	NUM
bptjm-17	699	3	,	,	PUNCT
bptjm-17	699	4	10(8	10(8	NUM
bptjm-17	699	5	):	):	PUNCT
bptjm-17	699	6	e0134220	e0134220	NOUN
bptjm-17	699	7	.	.	PROPN
bptjm-17	699	8	https://doi.org/10.1371/journal.pone.0134220	https://doi.org/10.1371/journal.pone.0134220	PROPN
bptjm-17	699	9	51	51	NUM
bptjm-17	699	10	.	.	PUNCT
bptjm-17	700	1	liang	liang	PROPN
bptjm-17	700	2	,	,	PUNCT
bptjm-17	700	3	l.	l.	PROPN
bptjm-17	700	4	,	,	PUNCT
bptjm-17	700	5	zhu	zhu	PROPN
bptjm-17	700	6	,	,	PUNCT
bptjm-17	700	7	w.	w.	PROPN
bptjm-17	700	8	,	,	PUNCT
bptjm-17	700	9	chen	chen	PROPN
bptjm-17	700	10	,	,	PUNCT
bptjm-17	700	11	x.	x.	PROPN
bptjm-17	700	12	,	,	PUNCT
bptjm-17	700	13	&	&	CCONJ
bptjm-17	700	14	amp	amp	PROPN
bptjm-17	700	15	;	;	PUNCT
bptjm-17	700	16	luo	luo	PROPN
bptjm-17	700	17	,	,	PUNCT
bptjm-17	700	18	f.	f.	PROPN
bptjm-17	700	19	(	(	PUNCT
bptjm-17	700	20	2019	2019	NUM
bptjm-17	700	21	)	)	PUNCT
bptjm-17	700	22	.	.	PUNCT
bptjm-17	701	1	plasma	plasma	PROPN
bptjm-17	701	2	mir-30a-5p	mir-30a-5p	PROPN
bptjm-17	701	3	as	as	ADP
bptjm-17	701	4	an	an	DET
bptjm-17	701	5	early	early	ADJ
bptjm-17	701	6	novel	novel	NOUN
bptjm-17	701	7	noninvasive	noninvasive	ADJ
bptjm-17	701	8	diagnostic	diagnostic	ADJ
bptjm-17	701	9	and	and	CCONJ
bptjm-17	701	10	prognostic	prognostic	ADJ
bptjm-17	701	11	biomarker	biomarker	NOUN
bptjm-17	701	12	for	for	ADP
bptjm-17	701	13	lung	lung	NOUN
bptjm-17	701	14	cancer	cancer	NOUN
bptjm-17	701	15	.	.	PUNCT
bptjm-17	702	1	future	future	ADJ
bptjm-17	702	2	oncology	oncology	NOUN
bptjm-17	702	3	,	,	PUNCT
bptjm-17	702	4	15(32	15(32	NUM
bptjm-17	702	5	)	)	PUNCT
bptjm-17	702	6	,	,	PUNCT
bptjm-17	702	7	3711	3711	NUM
bptjm-17	702	8	-	-	SYM
bptjm-17	702	9	3721	3721	NUM
bptjm-17	702	10	.	.	PUNCT
bptjm-17	703	1	doi:10.2217	doi:10.2217	NOUN
bptjm-17	703	2	/	/	SYM
bptjm-17	703	3	fon-2019	fon-2019	NOUN
bptjm-17	703	4	-	-	PUNCT
bptjm-17	703	5	0393	0393	NUM
bptjm-17	703	6	52	52	NUM
bptjm-17	703	7	.	.	PUNCT
bptjm-17	704	1	lin	lin	PROPN
bptjm-17	704	2	,	,	PUNCT
bptjm-17	704	3	q.	q.	PROPN
bptjm-17	704	4	,	,	PUNCT
bptjm-17	704	5	zhang	zhang	PROPN
bptjm-17	704	6	,	,	PUNCT
bptjm-17	704	7	h.	h.	PROPN
bptjm-17	704	8	,	,	PUNCT
bptjm-17	704	9	ding	ding	PROPN
bptjm-17	704	10	,	,	PUNCT
bptjm-17	704	11	h.	h.	PROPN
bptjm-17	704	12	,	,	PUNCT
bptjm-17	704	13	qian	qian	PROPN
bptjm-17	704	14	,	,	PUNCT
bptjm-17	704	15	j.	j.	PROPN
bptjm-17	704	16	,	,	PUNCT
bptjm-17	704	17	lizaso	lizaso	PROPN
bptjm-17	704	18	,	,	PUNCT
bptjm-17	704	19	a.	a.	PROPN
bptjm-17	704	20	,	,	PUNCT
bptjm-17	704	21	lin	lin	PROPN
bptjm-17	704	22	,	,	PUNCT
bptjm-17	704	23	j.	j.	PROPN
bptjm-17	704	24	,	,	PUNCT
bptjm-17	704	25	han	han	PROPN
bptjm-17	704	26	-	-	PUNCT
bptjm-17	704	27	zhang	zhang	PROPN
bptjm-17	704	28	,	,	PUNCT
bptjm-17	704	29	h.	h.	PROPN
bptjm-17	704	30	,	,	PUNCT
bptjm-17	704	31	xiang	xiang	PROPN
bptjm-17	704	32	,	,	PUNCT
bptjm-17	704	33	j.	j.	PROPN
bptjm-17	704	34	,	,	PUNCT
bptjm-17	704	35	li	li	PROPN
bptjm-17	704	36	,	,	PUNCT
bptjm-17	704	37	y.	y.	PROPN
bptjm-17	704	38	,	,	PUNCT
bptjm-17	704	39	&	&	CCONJ
bptjm-17	704	40	zhu	zhu	PROPN
bptjm-17	704	41	,	,	PUNCT
bptjm-17	704	42	h.	h.	PROPN
bptjm-17	704	43	(	(	PUNCT
bptjm-17	704	44	2019	2019	NUM
bptjm-17	704	45	)	)	PUNCT
bptjm-17	704	46	.	.	PUNCT
bptjm-17	705	1	the	the	DET
bptjm-17	705	2	association	association	NOUN
bptjm-17	705	3	between	between	ADP
bptjm-17	705	4	braf	braf	NOUN
bptjm-17	705	5	mutation	mutation	NOUN
bptjm-17	705	6	class	class	NOUN
bptjm-17	705	7	and	and	CCONJ
bptjm-17	705	8	clinical	clinical	ADJ
bptjm-17	705	9	features	feature	NOUN
bptjm-17	705	10	in	in	ADP
bptjm-17	705	11	braf	braf	NOUN
bptjm-17	705	12	-	-	PUNCT
bptjm-17	705	13	mutant	mutant	ADJ
bptjm-17	705	14	chinese	chinese	ADJ
bptjm-17	705	15	non	non	ADJ
bptjm-17	705	16	-	-	ADJ
bptjm-17	705	17	small	small	ADJ
bptjm-17	705	18	cell	cell	NOUN
bptjm-17	705	19	lung	lung	NOUN
bptjm-17	705	20	cancer	cancer	NOUN
bptjm-17	705	21	patients	patient	NOUN
bptjm-17	705	22	.	.	PUNCT
bptjm-17	706	1	journal	journal	NOUN
bptjm-17	706	2	of	of	ADP
bptjm-17	706	3	translational	translational	ADJ
bptjm-17	706	4	medicine	medicine	NOUN
bptjm-17	706	5	,	,	PUNCT
bptjm-17	706	6	17(1	17(1	NUM
bptjm-17	706	7	)	)	PUNCT
bptjm-17	706	8	,	,	PUNCT
bptjm-17	706	9	298	298	NUM
bptjm-17	706	10	.	.	PUNCT
bptjm-17	707	1	https://doi.org/10.1186/s12967-019-2036-7	https://doi.org/10.1186/s12967-019-2036-7	NUM
bptjm-17	707	2	53	53	NUM
bptjm-17	707	3	.	.	PUNCT
bptjm-17	708	1	liu	liu	PROPN
bptjm-17	708	2	,	,	PUNCT
bptjm-17	708	3	w.	w.	PROPN
bptjm-17	708	4	,	,	PUNCT
bptjm-17	708	5	zhuang	zhuang	PROPN
bptjm-17	708	6	,	,	PUNCT
bptjm-17	708	7	c.	c.	PROPN
bptjm-17	708	8	,	,	PUNCT
bptjm-17	708	9	huang	huang	PROPN
bptjm-17	708	10	,	,	PUNCT
bptjm-17	708	11	t.	t.	PROPN
bptjm-17	708	12	,	,	PUNCT
bptjm-17	708	13	yang	yang	PROPN
bptjm-17	708	14	,	,	PUNCT
bptjm-17	708	15	s.	s.	PROPN
bptjm-17	708	16	,	,	PUNCT
bptjm-17	708	17	zhang	zhang	PROPN
bptjm-17	708	18	,	,	PUNCT
bptjm-17	708	19	m.	m.	NOUN
bptjm-17	708	20	,	,	PUNCT
bptjm-17	708	21	lin	lin	PROPN
bptjm-17	708	22	,	,	PUNCT
bptjm-17	708	23	b.	b.	PROPN
bptjm-17	708	24	and	and	CCONJ
bptjm-17	708	25	jiang	jiang	PROPN
bptjm-17	708	26	,	,	PUNCT
bptjm-17	708	27	y.	y.	PROPN
bptjm-17	708	28	(	(	PUNCT
bptjm-17	708	29	2020	2020	NUM
bptjm-17	708	30	)	)	PUNCT
bptjm-17	708	31	,	,	PUNCT
bptjm-17	708	32	loss	loss	NOUN
bptjm-17	708	33	of	of	ADP
bptjm-17	708	34	cdkn2a	cdkn2a	PROPN
bptjm-17	708	35	at	at	ADP
bptjm-17	708	36	chromosome	chromosome	NOUN
bptjm-17	708	37	9	9	NUM
bptjm-17	708	38	has	have	VERB
bptjm-17	708	39	a	a	DET
bptjm-17	708	40	poor	poor	ADJ
bptjm-17	708	41	clinical	clinical	ADJ
bptjm-17	708	42	prognosis	prognosis	NOUN
bptjm-17	708	43	and	and	CCONJ
bptjm-17	708	44	promotes	promote	VERB
bptjm-17	708	45	lung	lung	NOUN
bptjm-17	708	46	cancer	cancer	NOUN
bptjm-17	708	47	progression	progression	NOUN
bptjm-17	708	48	.	.	PUNCT
bptjm-17	709	1	mol	mol	ADP
bptjm-17	709	2	genet	genet	PROPN
bptjm-17	709	3	genomic	genomic	NOUN
bptjm-17	709	4	med	me	VERB
bptjm-17	709	5	,	,	PUNCT
bptjm-17	709	6	8(1521	8(1521	NOUN
bptjm-17	709	7	)	)	PUNCT
bptjm-17	709	8	.	.	PUNCT
bptjm-17	710	1	https://doi.org/10.1002/mgg3.1521	https://doi.org/10.1002/mgg3.1521	PROPN
bptjm-17	710	2	.	.	PROPN
bptjm-17	711	1	54	54	NUM
bptjm-17	711	2	.	.	PUNCT
bptjm-17	712	1	liu	liu	PROPN
bptjm-17	712	2	,	,	PUNCT
bptjm-17	712	3	heng	heng	PROPN
bptjm-17	712	4	-	-	PUNCT
bptjm-17	712	5	jia	jia	PROPN
bptjm-17	712	6	&	&	CCONJ
bptjm-17	712	7	lizotte	lizotte	PROPN
bptjm-17	712	8	,	,	PUNCT
bptjm-17	712	9	patrick	patrick	PROPN
bptjm-17	712	10	&	&	CCONJ
bptjm-17	712	11	du	du	PROPN
bptjm-17	712	12	,	,	PUNCT
bptjm-17	712	13	heng	heng	PROPN
bptjm-17	712	14	&	&	CCONJ
bptjm-17	712	15	speranza	speranza	PROPN
bptjm-17	712	16	,	,	PUNCT
bptjm-17	712	17	maria	maria	PROPN
bptjm-17	712	18	&	&	CCONJ
bptjm-17	712	19	vaughan	vaughan	PROPN
bptjm-17	712	20	,	,	PUNCT
bptjm-17	712	21	spencer	spencer	PROPN
bptjm-17	712	22	&	&	CCONJ
bptjm-17	712	23	alesi	alesi	PROPN
bptjm-17	712	24	,	,	PUNCT
bptjm-17	712	25	nicola	nicola	PROPN
bptjm-17	712	26	&	&	CCONJ
bptjm-17	712	27	wong	wong	PROPN
bptjm-17	712	28	,	,	PUNCT
bptjm-17	712	29	kwok	kwok	PROPN
bptjm-17	712	30	-	-	PUNCT
bptjm-17	712	31	kin	kin	PROPN
bptjm-17	712	32	&	&	CCONJ
bptjm-17	712	33	freeman	freeman	PROPN
bptjm-17	712	34	,	,	PUNCT
bptjm-17	712	35	gordon	gordon	PROPN
bptjm-17	712	36	&	&	CCONJ
bptjm-17	712	37	sharpe	sharpe	PROPN
bptjm-17	712	38	,	,	PUNCT
bptjm-17	712	39	arlene	arlene	PROPN
bptjm-17	712	40	&	&	CCONJ
bptjm-17	712	41	henske	henske	PROPN
bptjm-17	712	42	,	,	PUNCT
bptjm-17	712	43	elizabeth	elizabeth	PROPN
bptjm-17	712	44	.	.	PUNCT
bptjm-17	712	45	(	(	PUNCT
bptjm-17	712	46	2018	2018	NUM
bptjm-17	712	47	)	)	PUNCT
bptjm-17	712	48	.	.	PUNCT
bptjm-17	713	1	abstract	abstract	ADJ
bptjm-17	713	2	1686	1686	NUM
bptjm-17	713	3	:	:	PUNCT
bptjm-17	713	4	tsc2	tsc2	NOUN
bptjm-17	713	5	enhances	enhance	VERB
bptjm-17	713	6	antitumor	antitumor	PROPN
bptjm-17	713	7	immunity	immunity	NOUN
bptjm-17	713	8	and	and	CCONJ
bptjm-17	713	9	potentiates	potentiate	NOUN
bptjm-17	713	10	pd-1	pd-1	ADP
bptjm-17	713	11	and	and	CCONJ
bptjm-17	713	12	ctla-4	ctla-4	NOUN
bptjm-17	713	13	blockade	blockade	NOUN
bptjm-17	713	14	.	.	PUNCT
bptjm-17	714	1	cancer	cancer	NOUN
bptjm-17	714	2	research	research	NOUN
bptjm-17	714	3	.	.	PUNCT
bptjm-17	715	1	78	78	NUM
bptjm-17	715	2	,	,	PUNCT
bptjm-17	715	3	1686	1686	NUM
bptjm-17	715	4	-	-	SYM
bptjm-17	715	5	1686	1686	NUM
bptjm-17	715	6	.	.	PUNCT
bptjm-17	716	1	55	55	NUM
bptjm-17	716	2	.	.	PUNCT
bptjm-17	717	1	liu	liu	PROPN
bptjm-17	717	2	,	,	PUNCT
bptjm-17	717	3	k.	k.	PROPN
bptjm-17	717	4	,	,	PUNCT
bptjm-17	717	5	chen	chen	PROPN
bptjm-17	717	6	,	,	PUNCT
bptjm-17	717	7	h.	h.	PROPN
bptjm-17	717	8	,	,	PUNCT
bptjm-17	717	9	you	you	PRON
bptjm-17	717	10	,	,	PUNCT
bptjm-17	717	11	q.	q.	PROPN
bptjm-17	717	12	,	,	PUNCT
bptjm-17	717	13	ye	ye	PROPN
bptjm-17	717	14	,	,	PUNCT
bptjm-17	717	15	q.	q.	PROPN
bptjm-17	717	16	,	,	PUNCT
bptjm-17	717	17	wang	wang	PROPN
bptjm-17	717	18	,	,	PUNCT
bptjm-17	717	19	f.	f.	PROPN
bptjm-17	717	20	,	,	PUNCT
bptjm-17	717	21	wang	wang	PROPN
bptjm-17	717	22	,	,	PUNCT
bptjm-17	717	23	s.	s.	PROPN
bptjm-17	717	24	,	,	PUNCT
bptjm-17	717	25	zhang	zhang	PROPN
bptjm-17	717	26	,	,	PUNCT
bptjm-17	717	27	s.	s.	PROPN
bptjm-17	717	28	,	,	PUNCT
bptjm-17	717	29	yu	yu	PROPN
bptjm-17	717	30	,	,	PUNCT
bptjm-17	717	31	k.	k.	PROPN
bptjm-17	717	32	,	,	PUNCT
bptjm-17	717	33	li	li	PROPN
bptjm-17	717	34	,	,	PUNCT
bptjm-17	717	35	w.	w.	PROPN
bptjm-17	717	36	,	,	PUNCT
bptjm-17	717	37	gu	gu	PROPN
bptjm-17	717	38	,	,	PUNCT
bptjm-17	717	39	m.	m.	NOUN
bptjm-17	717	40	(	(	PUNCT
bptjm-17	717	41	2018	2018	NUM
bptjm-17	717	42	)	)	PUNCT
bptjm-17	717	43	.	.	PUNCT
bptjm-17	718	1	mir-145	mir-145	PROPN
bptjm-17	718	2	inhibits	inhibit	VERB
bptjm-17	718	3	human	human	ADJ
bptjm-17	718	4	non	non	ADJ
bptjm-17	718	5	-	-	ADJ
bptjm-17	718	6	small	small	ADJ
bptjm-17	718	7	-	-	PUNCT
bptjm-17	718	8	cell	cell	NOUN
bptjm-17	718	9	lung	lung	NOUN
bptjm-17	718	10	cancer	cancer	NOUN
bptjm-17	718	11	growth	growth	NOUN
bptjm-17	718	12	by	by	ADP
bptjm-17	718	13	dual	dual	ADV
bptjm-17	718	14	-	-	PUNCT
bptjm-17	718	15	targeting	target	VERB
bptjm-17	718	16	riok2	riok2	NOUN
bptjm-17	718	17	and	and	CCONJ
bptjm-17	718	18	nob1	nob1	PROPN
bptjm-17	718	19	.	.	PUNCT
bptjm-17	719	1	international	international	ADJ
bptjm-17	719	2	journal	journal	PROPN
bptjm-17	719	3	of	of	ADP
bptjm-17	719	4	oncology	oncology	NOUN
bptjm-17	719	5	,	,	PUNCT
bptjm-17	719	6	53(1	53(1	NUM
bptjm-17	719	7	)	)	PUNCT
bptjm-17	719	8	,	,	PUNCT
bptjm-17	719	9	257	257	NUM
bptjm-17	719	10	-	-	SYM
bptjm-17	719	11	265	265	NUM
bptjm-17	719	12	.	.	PUNCT
bptjm-17	720	1	56	56	NUM
bptjm-17	720	2	.	.	PUNCT
bptjm-17	721	1	liu	liu	PROPN
bptjm-17	721	2	xg	xg	PROPN
bptjm-17	721	3	,	,	PUNCT
bptjm-17	721	4	zhu	zhu	PROPN
bptjm-17	721	5	wy	wy	PROPN
bptjm-17	721	6	,	,	PUNCT
bptjm-17	721	7	huang	huang	PROPN
bptjm-17	721	8	yy	yy	PROPN
bptjm-17	721	9	,	,	PUNCT
bptjm-17	721	10	ma	ma	PROPN
bptjm-17	721	11	ln	ln	PROPN
bptjm-17	721	12	,	,	PUNCT
bptjm-17	721	13	zhou	zhou	PROPN
bptjm-17	721	14	sq	sq	PROPN
bptjm-17	721	15	,	,	PUNCT
bptjm-17	721	16	et	et	PROPN
bptjm-17	721	17	al	al	PROPN
bptjm-17	721	18	.	.	PROPN
bptjm-17	721	19	high	high	ADJ
bptjm-17	721	20	expression	expression	NOUN
bptjm-17	721	21	of	of	ADP
bptjm-17	721	22	serum	serum	PROPN
bptjm-17	721	23	mir-21	mir-21	PROPN
bptjm-17	721	24	and	and	CCONJ
bptjm-17	721	25	tumor	tumor	NOUN
bptjm-17	721	26	mir-200c	mir-200c	NOUN
bptjm-17	721	27	associated	associate	VERB
bptjm-17	721	28	with	with	ADP
bptjm-17	721	29	poor	poor	ADJ
bptjm-17	721	30	prognosis	prognosis	NOUN
bptjm-17	721	31	in	in	ADP
bptjm-17	721	32	patients	patient	NOUN
bptjm-17	721	33	with	with	ADP
bptjm-17	721	34	lung	lung	NOUN
bptjm-17	721	35	cancer	cancer	NOUN
bptjm-17	721	36	,	,	PUNCT
bptjm-17	721	37	med	med	PROPN
bptjm-17	721	38	oncol	oncol	ADJ
bptjm-17	721	39	,	,	PUNCT
bptjm-17	721	40	2012	2012	NUM
bptjm-17	721	41	,	,	PUNCT
bptjm-17	721	42	vol	vol	NOUN
bptjm-17	721	43	.	.	PROPN
bptjm-17	721	44	29	29	NUM
bptjm-17	721	45	(	(	PUNCT
bptjm-17	721	46	pg	pg	INTJ
bptjm-17	721	47	.	.	PUNCT
bptjm-17	721	48	618	618	NUM
bptjm-17	721	49	-	-	SYM
bptjm-17	721	50	26	26	NUM
bptjm-17	721	51	)	)	PUNCT
bptjm-17	721	52	57	57	NUM
bptjm-17	721	53	.	.	PUNCT
bptjm-17	722	1	luk	luk	PROPN
bptjm-17	722	2	,	,	PUNCT
bptjm-17	722	3	p.	p.	PROPN
bptjm-17	722	4	p.	p.	PROPN
bptjm-17	722	5	,	,	PUNCT
bptjm-17	722	6	selinger	selinger	NOUN
bptjm-17	722	7	,	,	PUNCT
bptjm-17	722	8	c.	c.	PROPN
bptjm-17	722	9	i.	i.	PROPN
bptjm-17	722	10	,	,	PUNCT
bptjm-17	722	11	mahar	mahar	PROPN
bptjm-17	722	12	,	,	PUNCT
bptjm-17	722	13	a.	a.	PROPN
bptjm-17	722	14	,	,	PUNCT
bptjm-17	722	15	&	&	CCONJ
bptjm-17	722	16	cooper	cooper	PROPN
bptjm-17	722	17	,	,	PUNCT
bptjm-17	722	18	w.	w.	PROPN
bptjm-17	722	19	a.	a.	PROPN
bptjm-17	722	20	(	(	PUNCT
bptjm-17	722	21	2018	2018	NUM
bptjm-17	722	22	)	)	PUNCT
bptjm-17	722	23	.	.	PUNCT
bptjm-17	723	1	biomarkers	biomarker	NOUN
bptjm-17	723	2	for	for	ADP
bptjm-17	723	3	alk	alk	PROPN
bptjm-17	723	4	and	and	CCONJ
bptjm-17	723	5	ros1	ros1	VERB
bptjm-17	723	6	in	in	ADP
bptjm-17	723	7	lung	lung	NOUN
bptjm-17	723	8	cancer	cancer	NOUN
bptjm-17	723	9	:	:	PUNCT
bptjm-17	723	10	immunohistochemistry	immunohistochemistry	NOUN
bptjm-17	723	11	and	and	CCONJ
bptjm-17	723	12	fluorescent	fluorescent	NOUN
bptjm-17	723	13	in	in	ADP
bptjm-17	723	14	situ	situ	ADJ
bptjm-17	723	15	hybridization	hybridization	NOUN
bptjm-17	723	16	.	.	PUNCT
bptjm-17	724	1	archives	archive	NOUN
bptjm-17	724	2	of	of	ADP
bptjm-17	724	3	pathology	pathology	PROPN
bptjm-17	724	4	&	&	CCONJ
bptjm-17	724	5	laboratory	laboratory	PROPN
bptjm-17	724	6	medicine	medicine	NOUN
bptjm-17	724	7	,	,	PUNCT
bptjm-17	724	8	142(8	142(8	NUM
bptjm-17	724	9	)	)	PUNCT
bptjm-17	724	10	,	,	PUNCT
bptjm-17	724	11	922–928	922–928	NUM
bptjm-17	724	12	.	.	PUNCT
bptjm-17	725	1	https://doi.org/10.5858/	https://doi.org/10.5858/	PROPN
bptjm-17	725	2	arpa.2017	arpa.2017	PROPN
bptjm-17	725	3	-	-	PUNCT
bptjm-17	725	4	0502	0502	NUM
bptjm-17	725	5	-	-	PUNCT
bptjm-17	725	6	ra	ra	NOUN
bptjm-17	725	7	mader	mader	NOUN
bptjm-17	725	8	,	,	PUNCT
bptjm-17	725	9	s.	s.	PROPN
bptjm-17	725	10	,	,	PUNCT
bptjm-17	725	11	&	&	CCONJ
bptjm-17	725	12	pantel	pantel	PROPN
bptjm-17	725	13	,	,	PUNCT
bptjm-17	725	14	k.	k.	PROPN
bptjm-17	725	15	(	(	PUNCT
bptjm-17	725	16	2017	2017	NUM
bptjm-17	725	17	)	)	PUNCT
bptjm-17	725	18	.	.	PUNCT
bptjm-17	726	1	liquid	liquid	ADJ
bptjm-17	726	2	biopsy	biopsy	NOUN
bptjm-17	726	3	:	:	PUNCT
bptjm-17	726	4	current	current	ADJ
bptjm-17	726	5	berkeley	berkeley	PROPN
bptjm-17	726	6	pharma	pharma	PROPN
bptjm-17	726	7	tech	tech	NOUN
bptjm-17	726	8	journal	journal	NOUN
bptjm-17	726	9	of	of	ADP
bptjm-17	726	10	medicine	medicine	NOUN
bptjm-17	726	11	|	|	ADV
bptjm-17	726	12	150	150	NUM
bptjm-17	726	13	status	status	NOUN
bptjm-17	726	14	and	and	CCONJ
bptjm-17	726	15	future	future	ADJ
bptjm-17	726	16	perspectives.oncology	perspectives.oncology	NOUN
bptjm-17	726	17	research	research	NOUN
bptjm-17	726	18	and	and	CCONJ
bptjm-17	726	19	treatment	treatment	NOUN
bptjm-17	726	20	,	,	PUNCT
bptjm-17	726	21	40(7	40(7	NOUN
bptjm-17	726	22	-	-	SYM
bptjm-17	726	23	8)	8)	NUM
bptjm-17	726	24	,	,	PUNCT
bptjm-17	726	25	404–408	404–408	NUM
bptjm-17	726	26	.	.	PUNCT
bptjm-17	727	1	https://doi.org/10.1159/000478018	https://doi.org/10.1159/000478018	ADP
bptjm-17	727	2	58	58	NUM
bptjm-17	727	3	.	.	PUNCT
bptjm-17	728	1	madsen	madsen	PROPN
bptjm-17	728	2	,	,	PUNCT
bptjm-17	728	3	a.	a.	NOUN
bptjm-17	728	4	t.	t.	PROPN
bptjm-17	728	5	,	,	PUNCT
bptjm-17	728	6	winther	winther	PROPN
bptjm-17	728	7	-	-	PUNCT
bptjm-17	728	8	larsen	larsen	PROPN
bptjm-17	728	9	,	,	PUNCT
bptjm-17	728	10	a.	a.	PROPN
bptjm-17	728	11	,	,	PUNCT
bptjm-17	728	12	mcculloch	mcculloch	PROPN
bptjm-17	728	13	,	,	PUNCT
bptjm-17	728	14	t.	t.	PROPN
bptjm-17	728	15	,	,	PUNCT
bptjm-17	728	16	meldgaard	meldgaard	NOUN
bptjm-17	728	17	,	,	PUNCT
bptjm-17	728	18	p.	p.	PROPN
bptjm-17	728	19	,	,	PUNCT
bptjm-17	728	20	&	&	CCONJ
bptjm-17	728	21	sorensen	sorensen	PROPN
bptjm-17	728	22	,	,	PUNCT
bptjm-17	728	23	b.	b.	PROPN
bptjm-17	728	24	s.	s.	PROPN
bptjm-17	728	25	(	(	PUNCT
bptjm-17	728	26	2020	2020	NUM
bptjm-17	728	27	)	)	PUNCT
bptjm-17	728	28	.	.	PUNCT
bptjm-17	729	1	genomic	genomic	ADJ
bptjm-17	729	2	pro	pro	ADJ
bptjm-17	729	3	�	�	PROPN
bptjm-17	729	4	ling	ling	NOUN
bptjm-17	729	5	of	of	ADP
bptjm-17	729	6	circulating	circulate	VERB
bptjm-17	729	7	tumor	tumor	NOUN
bptjm-17	729	8	dna	dna	PROPN
bptjm-17	729	9	predicts	predict	NOUN
bptjm-17	729	10	outcome	outcome	VERB
bptjm-17	729	11	and	and	CCONJ
bptjm-17	729	12	demonstrates	demonstrate	VERB
bptjm-17	729	13	tumor	tumor	NOUN
bptjm-17	729	14	evolution	evolution	NOUN
bptjm-17	729	15	in	in	ADP
bptjm-17	729	16	alk	alk	NOUN
bptjm-17	729	17	-	-	PUNCT
bptjm-17	729	18	positive	positive	ADJ
bptjm-17	729	19	non	non	ADJ
bptjm-17	729	20	-	-	ADJ
bptjm-17	729	21	small	small	ADJ
bptjm-17	729	22	cell	cell	NOUN
bptjm-17	729	23	lung	lung	NOUN
bptjm-17	729	24	cancer	cancer	NOUN
bptjm-17	729	25	patients	patient	NOUN
bptjm-17	729	26	.	.	PUNCT
bptjm-17	730	1	cancers	cancer	NOUN
bptjm-17	730	2	,	,	PUNCT
bptjm-17	730	3	12(4	12(4	NUM
bptjm-17	730	4	)	)	PUNCT
bptjm-17	730	5	,	,	PUNCT
bptjm-17	730	6	947	947	NUM
bptjm-17	730	7	.	.	PUNCT
bptjm-17	731	1	https://doi.org/10.3390/cancers12040947	https://doi.org/10.3390/cancers12040947	PROPN
bptjm-17	731	2	59	59	NUM
bptjm-17	731	3	.	.	PUNCT
bptjm-17	731	4	mao	mao	PROPN
bptjm-17	731	5	,	,	PUNCT
bptjm-17	731	6	l.	l.	PROPN
bptjm-17	731	7	,	,	PUNCT
bptjm-17	731	8	liu	liu	PROPN
bptjm-17	731	9	,	,	PUNCT
bptjm-17	731	10	s.	s.	PROPN
bptjm-17	731	11	,	,	PUNCT
bptjm-17	731	12	hu	hu	PROPN
bptjm-17	731	13	,	,	PUNCT
bptjm-17	731	14	l.	l.	PROPN
bptjm-17	731	15	,	,	PUNCT
bptjm-17	731	16	jia	jia	PROPN
bptjm-17	731	17	,	,	PUNCT
bptjm-17	731	18	l.	l.	PROPN
bptjm-17	731	19	,	,	PUNCT
bptjm-17	731	20	wang	wang	PROPN
bptjm-17	731	21	,	,	PUNCT
bptjm-17	731	22	h.	h.	PROPN
bptjm-17	731	23	,	,	PUNCT
bptjm-17	731	24	guo	guo	PROPN
bptjm-17	731	25	,	,	PUNCT
bptjm-17	731	26	m.	m.	NOUN
bptjm-17	731	27	,	,	PUNCT
bptjm-17	731	28	…	…	PUNCT
bptjm-17	731	29	xu	xu	INTJ
bptjm-17	731	30	,	,	PUNCT
bptjm-17	731	31	l.	l.	PROPN
bptjm-17	731	32	(	(	PUNCT
bptjm-17	731	33	2018	2018	NUM
bptjm-17	731	34	)	)	PUNCT
bptjm-17	731	35	.	.	PUNCT
bptjm-17	732	1	mir-30	mir-30	NUM
bptjm-17	732	2	family	family	NOUN
bptjm-17	732	3	:	:	PUNCT
bptjm-17	732	4	a	a	DET
bptjm-17	732	5	promising	promising	ADJ
bptjm-17	732	6	regulator	regulator	NOUN
bptjm-17	732	7	in	in	ADP
bptjm-17	732	8	development	development	NOUN
bptjm-17	732	9	and	and	CCONJ
bptjm-17	732	10	disease	disease	NOUN
bptjm-17	732	11	.	.	PUNCT
bptjm-17	732	12	biomed	biome	VERB
bptjm-17	732	13	research	research	NOUN
bptjm-17	732	14	international	international	PROPN
bptjm-17	732	15	,	,	PUNCT
bptjm-17	732	16	2018	2018	NUM
bptjm-17	732	17	,	,	PUNCT
bptjm-17	732	18	1–8	1–8	X
bptjm-17	732	19	.	.	PUNCT
bptjm-17	733	1	https://doi.org/10.1155/2018/9623412	https://doi.org/10.1155/2018/9623412	PROPN
bptjm-17	733	2	60	60	NUM
bptjm-17	733	3	.	.	PUNCT
bptjm-17	733	4	mao	mao	PROPN
bptjm-17	733	5	,	,	PUNCT
bptjm-17	733	6	xiaowei	xiaowei	PROPN
bptjm-17	733	7	,	,	PUNCT
bptjm-17	733	8	zhou	zhou	PROPN
bptjm-17	733	9	zhang	zhang	PROPN
bptjm-17	733	10	,	,	PUNCT
bptjm-17	733	11	xiaoxuan	xiaoxuan	PROPN
bptjm-17	733	12	zheng	zheng	PROPN
bptjm-17	733	13	,	,	PUNCT
bptjm-17	733	14	fangfang	fangfang	PROPN
bptjm-17	733	15	xie	xie	PROPN
bptjm-17	733	16	,	,	PUNCT
bptjm-17	733	17	feidie	feidie	PROPN
bptjm-17	733	18	duan	duan	PROPN
bptjm-17	733	19	,	,	PUNCT
bptjm-17	733	20	liyan	liyan	VERB
bptjm-17	733	21	jiang	jiang	PROPN
bptjm-17	733	22	,	,	PUNCT
bptjm-17	733	23	shannon	shannon	PROPN
bptjm-17	733	24	chuai	chuai	PROPN
bptjm-17	733	25	,	,	PUNCT
bptjm-17	733	26	han	han	PROPN
bptjm-17	733	27	han	han	PROPN
bptjm-17	733	28	-	-	PUNCT
bptjm-17	733	29	zhang	zhang	PROPN
bptjm-17	733	30	,	,	PUNCT
bptjm-17	733	31	baohui	baohui	PROPN
bptjm-17	733	32	han	han	PROPN
bptjm-17	733	33	,	,	PUNCT
bptjm-17	733	34	and	and	CCONJ
bptjm-17	733	35	jiayuan	jiayuan	PROPN
bptjm-17	733	36	sun	sun	PROPN
bptjm-17	733	37	.	.	PUNCT
bptjm-17	734	1	(	(	PUNCT
bptjm-17	734	2	april	april	PROPN
bptjm-17	734	3	1	1	NUM
bptjm-17	734	4	,	,	PUNCT
bptjm-17	734	5	2017	2017	NUM
bptjm-17	734	6	)	)	PUNCT
bptjm-17	734	7	.	.	PUNCT
bptjm-17	735	1	capture	capture	NOUN
bptjm-17	735	2	-	-	PUNCT
bptjm-17	735	3	based	base	VERB
bptjm-17	735	4	targeted	target	VERB
bptjm-17	735	5	ultradeep	ultradeep	ADJ
bptjm-17	735	6	sequencing	sequence	VERB
bptjm-17	735	7	in	in	ADP
bptjm-17	735	8	paired	pair	VERB
bptjm-17	735	9	tissue	tissue	NOUN
bptjm-17	735	10	and	and	CCONJ
bptjm-17	735	11	plasma	plasma	NOUN
bptjm-17	735	12	samples	sample	NOUN
bptjm-17	735	13	demonstrates	demonstrate	VERB
bptjm-17	735	14	di	di	PROPN
bptjm-17	735	15	�	�	PROPN
bptjm-17	735	16	erential	erential	ADJ
bptjm-17	735	17	subclonal	subclonal	ADJ
bptjm-17	735	18	ctdna	ctdna	NOUN
bptjm-17	735	19	-	-	PUNCT
bptjm-17	735	20	releasing	release	VERB
bptjm-17	735	21	capability	capability	NOUN
bptjm-17	735	22	in	in	ADP
bptjm-17	735	23	advanced	advanced	ADJ
bptjm-17	735	24	lung	lung	NOUN
bptjm-17	735	25	cancer	cancer	NOUN
bptjm-17	735	26	.	.	PUNCT
bptjm-17	736	1	journal	journal	PROPN
bptjm-17	736	2	of	of	ADP
bptjm-17	736	3	thoracic	thoracic	NOUN
bptjm-17	736	4	oncology	oncology	NOUN
bptjm-17	736	5	,	,	PUNCT
bptjm-17	736	6	12(4	12(4	NUM
bptjm-17	736	7	)	)	PUNCT
bptjm-17	736	8	,	,	PUNCT
bptjm-17	736	9	663–72	663–72	NUM
bptjm-17	736	10	.	.	PUNCT
bptjm-17	737	1	https://doi.org/10.1016/j.jtho	https://doi.org/10.1016/j.jtho	NOUN
bptjm-17	737	2	.	.	PUNCT
bptjm-17	738	1	2016.11.2235	2016.11.2235	NUM
bptjm-17	738	2	.	.	NOUN
bptjm-17	738	3	61	61	NUM
bptjm-17	738	4	.	.	PUNCT
bptjm-17	739	1	mlak	mlak	PROPN
bptjm-17	739	2	,	,	PUNCT
bptjm-17	739	3	r.	r.	PROPN
bptjm-17	739	4	,	,	PUNCT
bptjm-17	739	5	powrózek	powrózek	NOUN
bptjm-17	739	6	,	,	PUNCT
bptjm-17	739	7	t.	t.	PROPN
bptjm-17	739	8	,	,	PUNCT
bptjm-17	739	9	brzozowska	brzozowska	PROPN
bptjm-17	739	10	,	,	PUNCT
bptjm-17	739	11	a.	a.	NOUN
bptjm-17	739	12	,	,	PUNCT
bptjm-17	739	13	homa	homa	NOUN
bptjm-17	739	14	-	-	PUNCT
bptjm-17	739	15	mlak	mlak	ADJ
bptjm-17	739	16	,	,	PUNCT
bptjm-17	739	17	i.	i.	NOUN
bptjm-17	739	18	,	,	PUNCT
bptjm-17	739	19	mazurek	mazurek	PROPN
bptjm-17	739	20	,	,	PUNCT
bptjm-17	739	21	m.	m.	NOUN
bptjm-17	739	22	,	,	PUNCT
bptjm-17	739	23	&	&	CCONJ
bptjm-17	739	24	małecka	małecka	PROPN
bptjm-17	739	25	massalska	massalska	PROPN
bptjm-17	739	26	,	,	PUNCT
bptjm-17	739	27	t.	t.	PROPN
bptjm-17	739	28	(	(	PUNCT
bptjm-17	739	29	2018	2018	NUM
bptjm-17	739	30	)	)	PUNCT
bptjm-17	739	31	.	.	PUNCT
bptjm-17	740	1	rrm1	rrm1	NOUN
bptjm-17	740	2	gene	gene	NOUN
bptjm-17	740	3	expression	expression	NOUN
bptjm-17	740	4	evaluated	evaluate	VERB
bptjm-17	740	5	in	in	ADP
bptjm-17	740	6	the	the	DET
bptjm-17	740	7	liquid	liquid	ADJ
bptjm-17	740	8	biopsy	biopsy	NOUN
bptjm-17	740	9	(	(	PUNCT
bptjm-17	740	10	blood	blood	NOUN
bptjm-17	740	11	cfrna	cfrna	NOUN
bptjm-17	740	12	)	)	PUNCT
bptjm-17	740	13	as	as	ADP
bptjm-17	740	14	a	a	DET
bptjm-17	740	15	non	non	ADJ
bptjm-17	740	16	-	-	ADJ
bptjm-17	740	17	invasive	invasive	ADJ
bptjm-17	740	18	,	,	PUNCT
bptjm-17	740	19	predictive	predictive	ADJ
bptjm-17	740	20	factor	factor	NOUN
bptjm-17	740	21	for	for	ADP
bptjm-17	740	22	radiotherapy	radiotherapy	NOUN
bptjm-17	740	23	-	-	PUNCT
bptjm-17	740	24	induced	induce	VERB
bptjm-17	740	25	oral	oral	ADJ
bptjm-17	740	26	mucositis	mucositis	NOUN
bptjm-17	740	27	and	and	CCONJ
bptjm-17	740	28	potential	potential	ADJ
bptjm-17	740	29	prognostic	prognostic	ADJ
bptjm-17	740	30	biomarker	biomarker	NOUN
bptjm-17	740	31	in	in	ADP
bptjm-17	740	32	head	head	NOUN
bptjm-17	740	33	and	and	CCONJ
bptjm-17	740	34	neck	neck	NOUN
bptjm-17	740	35	cancer	cancer	NOUN
bptjm-17	740	36	patients	patient	NOUN
bptjm-17	740	37	.	.	PUNCT
bptjm-17	741	1	cancer	cancer	NOUN
bptjm-17	741	2	biomarkers	biomarker	NOUN
bptjm-17	741	3	:	:	PUNCT
bptjm-17	741	4	section	section	NOUN
bptjm-17	741	5	a	a	PRON
bptjm-17	741	6	of	of	ADP
bptjm-17	741	7	disease	disease	NOUN
bptjm-17	741	8	markers	marker	NOUN
bptjm-17	741	9	,	,	PUNCT
bptjm-17	741	10	22(4	22(4	NUM
bptjm-17	741	11	)	)	PUNCT
bptjm-17	741	12	,	,	PUNCT
bptjm-17	741	13	657–667	657–667	NUM
bptjm-17	741	14	.	.	PUNCT
bptjm-17	741	15	https://doi.org/10.3233/cbm-171082	https://doi.org/10.3233/cbm-171082	ADP
bptjm-17	741	16	62	62	NUM
bptjm-17	741	17	.	.	PUNCT
bptjm-17	742	1	mo	mo	PROPN
bptjm-17	742	2	,	,	PUNCT
bptjm-17	742	3	h.	h.	PROPN
bptjm-17	742	4	n.	n.	PROPN
bptjm-17	742	5	,	,	PUNCT
bptjm-17	742	6	&	&	CCONJ
bptjm-17	742	7	liu	liu	PROPN
bptjm-17	742	8	,	,	PUNCT
bptjm-17	742	9	p.	p.	NOUN
bptjm-17	742	10	(	(	PUNCT
bptjm-17	742	11	2017	2017	NUM
bptjm-17	742	12	)	)	PUNCT
bptjm-17	742	13	.	.	PUNCT
bptjm-17	743	1	targeting	target	VERB
bptjm-17	743	2	met	meet	VERB
bptjm-17	743	3	in	in	ADP
bptjm-17	743	4	cancer	cancer	NOUN
bptjm-17	743	5	therapy	therapy	NOUN
bptjm-17	743	6	.	.	PUNCT
bptjm-17	744	1	chronic	chronic	ADJ
bptjm-17	744	2	diseases	disease	NOUN
bptjm-17	744	3	and	and	CCONJ
bptjm-17	744	4	translational	translational	ADJ
bptjm-17	744	5	medicine	medicine	NOUN
bptjm-17	744	6	,	,	PUNCT
bptjm-17	744	7	3(3	3(3	NUM
bptjm-17	744	8	)	)	PUNCT
bptjm-17	744	9	,	,	PUNCT
bptjm-17	744	10	148–153	148–153	NUM
bptjm-17	744	11	.	.	PUNCT
bptjm-17	745	1	https://doi.org/10.1016/j.cdtm.2017.06.002	https://doi.org/10.1016/j.cdtm.2017.06.002	NUM
bptjm-17	745	2	63	63	NUM
bptjm-17	745	3	.	.	PUNCT
bptjm-17	745	4	munagala	munagala	PROPN
bptjm-17	745	5	r	r	PROPN
bptjm-17	745	6	,	,	PUNCT
bptjm-17	745	7	aqil	aqil	PROPN
bptjm-17	745	8	f	f	PROPN
bptjm-17	745	9	,	,	PUNCT
bptjm-17	745	10	gupta	gupta	PROPN
bptjm-17	745	11	rc	rc	PROPN
bptjm-17	745	12	.	.	PUNCT
bptjm-17	745	13	(	(	PUNCT
bptjm-17	745	14	august	august	PROPN
bptjm-17	745	15	2016	2016	NUM
bptjm-17	745	16	)	)	PUNCT
bptjm-17	745	17	.	.	PUNCT
bptjm-17	746	1	exosomal	exosomal	ADJ
bptjm-17	746	2	mirnas	mirna	NOUN
bptjm-17	746	3	as	as	ADP
bptjm-17	746	4	biomarkers	biomarker	NOUN
bptjm-17	746	5	of	of	ADP
bptjm-17	746	6	recurrent	recurrent	ADJ
bptjm-17	746	7	lung	lung	NOUN
bptjm-17	746	8	cancer	cancer	NOUN
bptjm-17	746	9	.	.	PUNCT
bptjm-17	747	1	tumour	tumour	PROPN
bptjm-17	747	2	biol	biol	PROPN
bptjm-17	747	3	.	.	PUNCT
bptjm-17	747	4	,	,	PUNCT
bptjm-17	747	5	37(8	37(8	NUM
bptjm-17	747	6	)	)	PUNCT
bptjm-17	747	7	,	,	PUNCT
bptjm-17	747	8	10703	10703	NUM
bptjm-17	747	9	-	-	SYM
bptjm-17	747	10	14	14	NUM
bptjm-17	747	11	.	.	PUNCT
bptjm-17	748	1	doi	doi	NOUN
bptjm-17	748	2	:	:	PUNCT
bptjm-17	748	3	10.1007	10.1007	NUM
bptjm-17	748	4	/	/	SYM
bptjm-17	748	5	s13277	s13277	NOUN
bptjm-17	748	6	-	-	PUNCT
bptjm-17	748	7	016	016	NUM
bptjm-17	748	8	-	-	PUNCT
bptjm-17	748	9	4939	4939	NUM
bptjm-17	748	10	-	-	SYM
bptjm-17	748	11	8	8	NUM
bptjm-17	748	12	.	.	PUNCT
bptjm-17	749	1	epub	epub	PROPN
bptjm-17	749	2	2016	2016	NUM
bptjm-17	749	3	feb	feb	PROPN
bptjm-17	749	4	11	11	NUM
bptjm-17	749	5	.	.	PUNCT
bptjm-17	750	1	pmid	pmid	NOUN
bptjm-17	750	2	:	:	PUNCT
bptjm-17	750	3	26867772	26867772	NUM
bptjm-17	750	4	.	.	PUNCT
bptjm-17	751	1	64	64	NUM
bptjm-17	751	2	.	.	PUNCT
bptjm-17	751	3	reis	reis	NOUN
bptjm-17	751	4	,	,	PUNCT
bptjm-17	751	5	gerald	gerald	PROPN
bptjm-17	751	6	f.	f.	PROPN
bptjm-17	751	7	,	,	PUNCT
bptjm-17	751	8	melike	melike	ADJ
bptjm-17	751	9	pekmezci	pekmezci	NOUN
bptjm-17	751	10	,	,	PUNCT
bptjm-17	751	11	helen	helen	PROPN
bptjm-17	751	12	m.	m.	PROPN
bptjm-17	751	13	hansen	hansen	PROPN
bptjm-17	751	14	,	,	PUNCT
bptjm-17	751	15	terri	terri	PROPN
bptjm-17	751	16	rice	rice	PROPN
bptjm-17	751	17	,	,	PUNCT
bptjm-17	751	18	roxanne	roxanne	PROPN
bptjm-17	751	19	e.	e.	PROPN
bptjm-17	751	20	marshall	marshall	PROPN
bptjm-17	751	21	,	,	PUNCT
bptjm-17	751	22	annette	annette	PROPN
bptjm-17	751	23	m.	m.	PROPN
bptjm-17	751	24	molinaro	molinaro	PROPN
bptjm-17	751	25	,	,	PUNCT
bptjm-17	751	26	joanna	joanna	PROPN
bptjm-17	751	27	j.	j.	PROPN
bptjm-17	751	28	phillips	phillips	PROPN
bptjm-17	751	29	,	,	PUNCT
bptjm-17	751	30	et	et	PROPN
bptjm-17	751	31	al	al	PROPN
bptjm-17	751	32	.	.	PUNCT
bptjm-17	752	1	(	(	PUNCT
bptjm-17	752	2	may	may	PROPN
bptjm-17	752	3	1	1	NUM
bptjm-17	752	4	,	,	PUNCT
bptjm-17	752	5	2015	2015	NUM
bptjm-17	752	6	)	)	PUNCT
bptjm-17	752	7	.	.	PUNCT
bptjm-17	753	1	cdkn2a	cdkn2a	PROPN
bptjm-17	753	2	loss	loss	NOUN
bptjm-17	753	3	is	be	AUX
bptjm-17	753	4	associated	associate	VERB
bptjm-17	753	5	with	with	ADP
bptjm-17	753	6	shortened	shorten	VERB
bptjm-17	753	7	overall	overall	ADJ
bptjm-17	753	8	survival	survival	NOUN
bptjm-17	753	9	in	in	ADP
bptjm-17	753	10	lower	low	ADJ
bptjm-17	753	11	-	-	PUNCT
bptjm-17	753	12	grade	grade	NOUN
bptjm-17	753	13	(	(	PUNCT
bptjm-17	753	14	world	world	NOUN
bptjm-17	753	15	health	health	NOUN
bptjm-17	753	16	organization	organization	PROPN
bptjm-17	753	17	grades	grades	PROPN
bptjm-17	753	18	ii	ii	PROPN
bptjm-17	753	19	–	–	PUNCT
bptjm-17	753	20	iii	iii	NOUN
bptjm-17	753	21	)	)	PUNCT
bptjm-17	753	22	astrocytomas	astrocytoma	NOUN
bptjm-17	753	23	.	.	PUNCT
bptjm-17	754	1	journal	journal	PROPN
bptjm-17	754	2	of	of	ADP
bptjm-17	754	3	neuropathology	neuropathology	NOUN
bptjm-17	754	4	&	&	CCONJ
bptjm-17	754	5	experimental	experimental	ADJ
bptjm-17	754	6	neurology	neurology	NOUN
bptjm-17	754	7	,	,	PUNCT
bptjm-17	754	8	74(5	74(5	NOUN
bptjm-17	754	9	)	)	PUNCT
bptjm-17	754	10	,	,	PUNCT
bptjm-17	754	11	442–52	442–52	PROPN
bptjm-17	754	12	.	.	PUNCT
bptjm-17	755	1	https://doi.org/10.1097/nen.0000000000000188	https://doi.org/10.1097/nen.0000000000000188	PROPN
bptjm-17	755	2	.	.	PUNCT
bptjm-17	756	1	65	65	NUM
bptjm-17	756	2	.	.	PUNCT
bptjm-17	757	1	remon	remon	PROPN
bptjm-17	757	2	,	,	PUNCT
bptjm-17	757	3	jordi	jordi	PROPN
bptjm-17	757	4	,	,	PUNCT
bptjm-17	757	5	benjamin	benjamin	PROPN
bptjm-17	757	6	besse	besse	PROPN
bptjm-17	757	7	,	,	PUNCT
bptjm-17	757	8	alexandra	alexandra	PROPN
bptjm-17	757	9	leary	leary	PROPN
bptjm-17	757	10	,	,	PUNCT
bptjm-17	757	11	ivan	ivan	PROPN
bptjm-17	757	12	bièche	bièche	PROPN
bptjm-17	757	13	,	,	PUNCT
bptjm-17	757	14	bastien	bastien	PROPN
bptjm-17	757	15	job	job	PROPN
bptjm-17	757	16	,	,	PUNCT
bptjm-17	757	17	ludovic	ludovic	PROPN
bptjm-17	757	18	lacroix	lacroix	PROPN
bptjm-17	757	19	,	,	PUNCT
bptjm-17	757	20	aurélie	aurélie	NOUN
bptjm-17	757	21	auguste	auguste	PROPN
bptjm-17	757	22	,	,	PUNCT
bptjm-17	757	23	et	et	PROPN
bptjm-17	757	24	al	al	PROPN
bptjm-17	757	25	.	.	PUNCT
bptjm-17	758	1	(	(	PUNCT
bptjm-17	758	2	september	september	PROPN
bptjm-17	758	3	1	1	NUM
bptjm-17	758	4	,	,	PUNCT
bptjm-17	758	5	2020	2020	NUM
bptjm-17	758	6	)	)	PUNCT
bptjm-17	758	7	.	.	PUNCT
bptjm-17	759	1	somatic	somatic	ADJ
bptjm-17	759	2	and	and	CCONJ
bptjm-17	759	3	germline	germline	NOUN
bptjm-17	759	4	brca	brca	PROPN
bptjm-17	759	5	1	1	NUM
bptjm-17	759	6	and	and	CCONJ
bptjm-17	759	7	2	2	NUM
bptjm-17	759	8	mutations	mutation	NOUN
bptjm-17	759	9	in	in	ADP
bptjm-17	759	10	advanced	advanced	ADJ
bptjm-17	759	11	nsclc	nsclc	NOUN
bptjm-17	759	12	from	from	ADP
bptjm-17	759	13	the	the	DET
bptjm-17	759	14	safir02	safir02	NOUN
bptjm-17	759	15	-	-	PUNCT
bptjm-17	759	16	lung	lung	NOUN
bptjm-17	759	17	trial	trial	NOUN
bptjm-17	759	18	.	.	PUNCT
bptjm-17	760	1	jto	jto	PROPN
bptjm-17	760	2	clinical	clinical	ADJ
bptjm-17	760	3	and	and	CCONJ
bptjm-17	760	4	research	research	NOUN
bptjm-17	760	5	reports	report	NOUN
bptjm-17	760	6	,	,	PUNCT
bptjm-17	760	7	1(3	1(3	NUM
bptjm-17	760	8	)	)	PUNCT
bptjm-17	760	9	,	,	PUNCT
bptjm-17	760	10	100068	100068	NUM
bptjm-17	760	11	.	.	PUNCT
bptjm-17	761	1	https://doi.org/10.1016/j.jtocrr.2020.100068	https://doi.org/10.1016/j.jtocrr.2020.100068	PROPN
bptjm-17	761	2	.	.	PUNCT
bptjm-17	762	1	66	66	NUM
bptjm-17	762	2	.	.	PUNCT
bptjm-17	763	1	ricciuti	ricciuti	PROPN
bptjm-17	763	2	,	,	PUNCT
bptjm-17	763	3	b.	b.	PROPN
bptjm-17	763	4	,	,	PUNCT
bptjm-17	763	5	brambilla	brambilla	NOUN
bptjm-17	763	6	,	,	PUNCT
bptjm-17	763	7	m.	m.	NOUN
bptjm-17	763	8	,	,	PUNCT
bptjm-17	763	9	metro	metro	PROPN
bptjm-17	763	10	,	,	PUNCT
bptjm-17	763	11	g.	g.	PROPN
bptjm-17	763	12	,	,	PUNCT
bptjm-17	763	13	baglivo	baglivo	PROPN
bptjm-17	763	14	,	,	PUNCT
bptjm-17	763	15	s.	s.	PROPN
bptjm-17	763	16	,	,	PUNCT
bptjm-17	763	17	matocci	matocci	PROPN
bptjm-17	763	18	,	,	PUNCT
bptjm-17	763	19	r.	r.	PROPN
bptjm-17	763	20	,	,	PUNCT
bptjm-17	763	21	pirro	pirro	NOUN
bptjm-17	763	22	,	,	PUNCT
bptjm-17	763	23	m.	m.	NOUN
bptjm-17	763	24	,	,	PUNCT
bptjm-17	763	25	&	&	CCONJ
bptjm-17	763	26	chiari	chiari	PROPN
bptjm-17	763	27	,	,	PUNCT
bptjm-17	763	28	r.	r.	PROPN
bptjm-17	763	29	(	(	PUNCT
bptjm-17	763	30	2017	2017	NUM
bptjm-17	763	31	)	)	PUNCT
bptjm-17	763	32	.	.	PUNCT
bptjm-17	764	1	targeting	target	VERB
bptjm-17	764	2	ntrk	ntrk	NOUN
bptjm-17	764	3	fusion	fusion	NOUN
bptjm-17	764	4	in	in	ADP
bptjm-17	764	5	non	non	ADJ
bptjm-17	764	6	-	-	ADJ
bptjm-17	764	7	small	small	ADJ
bptjm-17	764	8	cell	cell	NOUN
bptjm-17	764	9	lung	lung	NOUN
bptjm-17	764	10	cancer	cancer	NOUN
bptjm-17	764	11	:	:	PUNCT
bptjm-17	764	12	rationale	rationale	NOUN
bptjm-17	764	13	and	and	CCONJ
bptjm-17	764	14	clinical	clinical	ADJ
bptjm-17	764	15	evidence	evidence	NOUN
bptjm-17	764	16	.	.	PUNCT
bptjm-17	765	1	medical	medical	ADJ
bptjm-17	765	2	oncology	oncology	NOUN
bptjm-17	765	3	(	(	PUNCT
bptjm-17	765	4	northwood	northwood	PROPN
bptjm-17	765	5	,	,	PUNCT
bptjm-17	765	6	london	london	PROPN
bptjm-17	765	7	,	,	PUNCT
bptjm-17	765	8	england	england	PROPN
bptjm-17	765	9	)	)	PUNCT
bptjm-17	765	10	,	,	PUNCT
bptjm-17	765	11	34(6	34(6	NOUN
bptjm-17	765	12	)	)	PUNCT
bptjm-17	765	13	,	,	PUNCT
bptjm-17	765	14	105	105	NUM
bptjm-17	765	15	.	.	PUNCT
bptjm-17	765	16	https://doi.org/10.1007/s12032-017-0967-5	https://doi.org/10.1007/s12032-017-0967-5	PROPN
bptjm-17	765	17	.	.	PUNCT
bptjm-17	766	1	67	67	NUM
bptjm-17	766	2	.	.	PUNCT
bptjm-17	766	3	rijavec	rijavec	PROPN
bptjm-17	766	4	,	,	PUNCT
bptjm-17	766	5	e.	e.	PROPN
bptjm-17	766	6	,	,	PUNCT
bptjm-17	766	7	coco	coco	PROPN
bptjm-17	766	8	,	,	PUNCT
bptjm-17	766	9	s.	s.	PROPN
bptjm-17	766	10	,	,	PUNCT
bptjm-17	766	11	genova	genova	PROPN
bptjm-17	766	12	,	,	PUNCT
bptjm-17	766	13	c.	c.	PROPN
bptjm-17	766	14	,	,	PUNCT
bptjm-17	766	15	rossi	rossi	PROPN
bptjm-17	766	16	,	,	PUNCT
bptjm-17	766	17	g.	g.	PROPN
bptjm-17	766	18	,	,	PUNCT
bptjm-17	766	19	longo	longo	PROPN
bptjm-17	766	20	,	,	PUNCT
bptjm-17	766	21	l.	l.	PROPN
bptjm-17	766	22	,	,	PUNCT
bptjm-17	766	23	&	&	CCONJ
bptjm-17	766	24	grossi	grossi	PROPN
bptjm-17	766	25	,	,	PUNCT
bptjm-17	766	26	f.	f.	PROPN
bptjm-17	766	27	(	(	PUNCT
bptjm-17	766	28	2019	2019	NUM
bptjm-17	766	29	)	)	PUNCT
bptjm-17	766	30	.	.	PUNCT
bptjm-17	767	1	liquid	liquid	ADJ
bptjm-17	767	2	biopsy	biopsy	NOUN
bptjm-17	767	3	in	in	ADP
bptjm-17	767	4	non	non	ADJ
bptjm-17	767	5	-	-	ADJ
bptjm-17	767	6	small	small	ADJ
bptjm-17	767	7	cell	cell	NOUN
bptjm-17	767	8	lung	lung	NOUN
bptjm-17	767	9	cancer	cancer	NOUN
bptjm-17	767	10	:	:	PUNCT
bptjm-17	767	11	highlights	highlight	NOUN
bptjm-17	767	12	and	and	CCONJ
bptjm-17	767	13	challenges	challenge	NOUN
bptjm-17	767	14	.	.	PUNCT
bptjm-17	768	1	cancers	cancer	NOUN
bptjm-17	768	2	,	,	PUNCT
bptjm-17	768	3	12(1	12(1	NUM
bptjm-17	768	4	)	)	PUNCT
bptjm-17	768	5	,	,	PUNCT
bptjm-17	768	6	17	17	NUM
bptjm-17	768	7	.	.	PUNCT
bptjm-17	768	8	https://doi.org/10.3390/cancers12010017	https://doi.org/10.3390/cancers12010017	PROPN
bptjm-17	768	9	68	68	NUM
bptjm-17	768	10	.	.	PUNCT
bptjm-17	769	1	rinaldi	rinaldi	PROPN
bptjm-17	769	2	a.	a.	PROPN
bptjm-17	769	3	(	(	PUNCT
bptjm-17	769	4	2011	2011	NUM
bptjm-17	769	5	)	)	PUNCT
bptjm-17	769	6	.	.	PUNCT
bptjm-17	770	1	teaming	team	VERB
bptjm-17	770	2	up	up	ADP
bptjm-17	770	3	for	for	ADP
bptjm-17	770	4	biomarker	biomarker	NOUN
bptjm-17	770	5	future	future	NOUN
bptjm-17	770	6	.	.	PUNCT
bptjm-17	771	1	many	many	ADJ
bptjm-17	771	2	problems	problem	NOUN
bptjm-17	771	3	still	still	ADV
bptjm-17	771	4	hinder	hinder	VERB
bptjm-17	771	5	the	the	DET
bptjm-17	771	6	use	use	NOUN
bptjm-17	771	7	of	of	ADP
bptjm-17	771	8	biomarkers	biomarker	NOUN
bptjm-17	771	9	in	in	ADP
bptjm-17	771	10	clinical	clinical	ADJ
bptjm-17	771	11	practice	practice	NOUN
bptjm-17	771	12	,	,	PUNCT
bptjm-17	771	13	but	but	CCONJ
bptjm-17	771	14	new	new	ADJ
bptjm-17	771	15	public	public	ADJ
bptjm-17	771	16	-	-	PUNCT
bptjm-17	771	17	private	private	ADJ
bptjm-17	771	18	partnerships	partnership	NOUN
bptjm-17	771	19	could	could	AUX
bptjm-17	771	20	improve	improve	VERB
bptjm-17	771	21	the	the	DET
bptjm-17	771	22	situation	situation	NOUN
bptjm-17	771	23	.	.	PUNCT
bptjm-17	772	1	embo	embo	PROPN
bptjm-17	772	2	reports	report	NOUN
bptjm-17	772	3	,	,	PUNCT
bptjm-17	772	4	12(6	12(6	NUM
bptjm-17	772	5	)	)	PUNCT
bptjm-17	772	6	,	,	PUNCT
bptjm-17	772	7	500–504	500–504	NUM
bptjm-17	772	8	.	.	PUNCT
bptjm-17	773	1	https://doi.org/10.1038/embor.2011.90	https://doi.org/10.1038/embor.2011.90	PROPN
bptjm-17	773	2	berkeley	berkeley	PROPN
bptjm-17	773	3	pharma	pharma	PROPN
bptjm-17	773	4	tech	tech	NOUN
bptjm-17	773	5	journal	journal	NOUN
bptjm-17	773	6	of	of	ADP
bptjm-17	773	7	medicine	medicine	NOUN
bptjm-17	773	8	|	|	ADV
bptjm-17	773	9	151	151	NUM
bptjm-17	773	10	69	69	NUM
bptjm-17	773	11	.	.	PUNCT
bptjm-17	774	1	rulli	rulli	PROPN
bptjm-17	774	2	,	,	PUNCT
bptjm-17	774	3	antonio	antonio	PROPN
bptjm-17	774	4	&	&	CCONJ
bptjm-17	774	5	antognelli	antognelli	PROPN
bptjm-17	774	6	,	,	PUNCT
bptjm-17	774	7	cinzia	cinzia	PROPN
bptjm-17	774	8	&	&	CCONJ
bptjm-17	774	9	covarelli	covarelli	PROPN
bptjm-17	774	10	,	,	PUNCT
bptjm-17	774	11	piero	piero	PROPN
bptjm-17	774	12	&	&	CCONJ
bptjm-17	774	13	izzo	izzo	PROPN
bptjm-17	774	14	,	,	PUNCT
bptjm-17	774	15	luciano	luciano	PROPN
bptjm-17	774	16	&	&	CCONJ
bptjm-17	774	17	vienna	vienna	PROPN
bptjm-17	774	18	,	,	PUNCT
bptjm-17	774	19	ludovini	ludovini	PROPN
bptjm-17	774	20	&	&	CCONJ
bptjm-17	774	21	annamaria	annamaria	PROPN
bptjm-17	774	22	,	,	PUNCT
bptjm-17	774	23	siggillino	siggillino	PROPN
bptjm-17	774	24	&	&	CCONJ
bptjm-17	774	25	nicola	nicola	PROPN
bptjm-17	774	26	,	,	PUNCT
bptjm-17	774	27	talesa	talesa	PROPN
bptjm-17	774	28	&	&	CCONJ
bptjm-17	774	29	svitlana	svitlana	PROPN
bptjm-17	774	30	,	,	PUNCT
bptjm-17	774	31	zayik	zayik	PROPN
bptjm-17	774	32	.	.	PUNCT
bptjm-17	774	33	(	(	PUNCT
bptjm-17	774	34	2020	2020	NUM
bptjm-17	774	35	)	)	PUNCT
bptjm-17	774	36	.	.	PUNCT
bptjm-17	775	1	liquid	liquid	ADJ
bptjm-17	775	2	biopsy	biopsy	NOUN
bptjm-17	775	3	in	in	ADP
bptjm-17	775	4	early	early	ADJ
bptjm-17	775	5	breast	breast	NOUN
bptjm-17	775	6	cancer	cancer	NOUN
bptjm-17	775	7	:	:	PUNCT
bptjm-17	775	8	a	a	DET
bptjm-17	775	9	preliminary	preliminary	ADJ
bptjm-17	775	10	report	report	NOUN
bptjm-17	775	11	.	.	PUNCT
bptjm-17	776	1	annals	annal	NOUN
bptjm-17	776	2	of	of	ADP
bptjm-17	776	3	clinical	clinical	ADJ
bptjm-17	776	4	oncology	oncology	NOUN
bptjm-17	776	5	.	.	PUNCT
bptjm-17	777	1	1	1	NUM
bptjm-17	777	2	-	-	SYM
bptjm-17	777	3	8	8	NUM
bptjm-17	777	4	.	.	NOUN
bptjm-17	777	5	10.31487	10.31487	NUM
bptjm-17	777	6	/	/	SYM
bptjm-17	777	7	j.aco.2020.01.01	j.aco.2020.01.01	PROPN
bptjm-17	777	8	.	.	PUNCT
bptjm-17	778	1	70	70	NUM
bptjm-17	778	2	.	.	PUNCT
bptjm-17	779	1	saito	saito	PROPN
bptjm-17	779	2	,	,	PUNCT
bptjm-17	779	3	m.	m.	NOUN
bptjm-17	779	4	,	,	PUNCT
bptjm-17	779	5	schetter	schetter	NOUN
bptjm-17	779	6	,	,	PUNCT
bptjm-17	779	7	a.	a.	PROPN
bptjm-17	779	8	j.	j.	PROPN
bptjm-17	779	9	,	,	PUNCT
bptjm-17	779	10	mollerup	mollerup	NOUN
bptjm-17	779	11	,	,	PUNCT
bptjm-17	779	12	s.	s.	PROPN
bptjm-17	779	13	,	,	PUNCT
bptjm-17	779	14	kohno	kohno	NOUN
bptjm-17	779	15	,	,	PUNCT
bptjm-17	779	16	t.	t.	PROPN
bptjm-17	779	17	,	,	PUNCT
bptjm-17	779	18	skaug	skaug	PROPN
bptjm-17	779	19	,	,	PUNCT
bptjm-17	779	20	v.	v.	PROPN
bptjm-17	779	21	,	,	PUNCT
bptjm-17	779	22	bowman	bowman	PROPN
bptjm-17	779	23	,	,	PUNCT
bptjm-17	779	24	e.	e.	PROPN
bptjm-17	779	25	d.	d.	PROPN
bptjm-17	779	26	,	,	PUNCT
bptjm-17	779	27	mathé	mathé	PROPN
bptjm-17	779	28	,	,	PUNCT
bptjm-17	779	29	e.	e.	PROPN
bptjm-17	779	30	a.	a.	PROPN
bptjm-17	779	31	,	,	PUNCT
bptjm-17	779	32	takenoshita	takenoshita	PROPN
bptjm-17	779	33	,	,	PUNCT
bptjm-17	779	34	s.	s.	PROPN
bptjm-17	779	35	,	,	PUNCT
bptjm-17	779	36	yokota	yokota	PROPN
bptjm-17	779	37	,	,	PUNCT
bptjm-17	779	38	j.	j.	PROPN
bptjm-17	779	39	,	,	PUNCT
bptjm-17	779	40	haugen	haugen	PROPN
bptjm-17	779	41	,	,	PUNCT
bptjm-17	779	42	a.	a.	PROPN
bptjm-17	779	43	,	,	PUNCT
bptjm-17	779	44	&	&	CCONJ
bptjm-17	779	45	harris	harris	PROPN
bptjm-17	779	46	,	,	PUNCT
bptjm-17	779	47	c.	c.	PROPN
bptjm-17	779	48	c.	c.	PROPN
bptjm-17	779	49	(	(	PUNCT
bptjm-17	779	50	2011	2011	NUM
bptjm-17	779	51	)	)	PUNCT
bptjm-17	779	52	.	.	PUNCT
bptjm-17	780	1	the	the	DET
bptjm-17	780	2	association	association	PROPN
bptjm-17	780	3	of	of	ADP
bptjm-17	780	4	microrna	microrna	PROPN
bptjm-17	780	5	expression	expression	NOUN
bptjm-17	780	6	with	with	ADP
bptjm-17	780	7	prognosis	prognosis	NOUN
bptjm-17	780	8	and	and	CCONJ
bptjm-17	780	9	progression	progression	NOUN
bptjm-17	780	10	in	in	ADP
bptjm-17	780	11	early	early	ADJ
bptjm-17	780	12	-	-	PUNCT
bptjm-17	780	13	stage	stage	NOUN
bptjm-17	780	14	,	,	PUNCT
bptjm-17	780	15	non	non	ADJ
bptjm-17	780	16	-	-	ADJ
bptjm-17	780	17	small	small	ADJ
bptjm-17	780	18	cell	cell	NOUN
bptjm-17	780	19	lung	lung	NOUN
bptjm-17	780	20	adenocarcinoma	adenocarcinoma	NOUN
bptjm-17	780	21	:	:	PUNCT
bptjm-17	780	22	a	a	DET
bptjm-17	780	23	retrospective	retrospective	ADJ
bptjm-17	780	24	analysis	analysis	NOUN
bptjm-17	780	25	of	of	ADP
bptjm-17	780	26	three	three	NUM
bptjm-17	780	27	cohorts	cohort	NOUN
bptjm-17	780	28	.	.	PUNCT
bptjm-17	781	1	clinical	clinical	ADJ
bptjm-17	781	2	cancer	cancer	NOUN
bptjm-17	781	3	research	research	NOUN
bptjm-17	781	4	:	:	PUNCT
bptjm-17	781	5	an	an	DET
bptjm-17	781	6	official	official	ADJ
bptjm-17	781	7	journal	journal	NOUN
bptjm-17	781	8	of	of	ADP
bptjm-17	781	9	the	the	DET
bptjm-17	781	10	american	american	PROPN
bptjm-17	781	11	association	association	PROPN
bptjm-17	781	12	for	for	ADP
bptjm-17	781	13	cancer	cancer	NOUN
bptjm-17	781	14	research	research	NOUN
bptjm-17	781	15	,	,	PUNCT
bptjm-17	781	16	17(7	17(7	NUM
bptjm-17	781	17	)	)	PUNCT
bptjm-17	781	18	,	,	PUNCT
bptjm-17	781	19	1875–1882	1875–1882	NUM
bptjm-17	781	20	.	.	PUNCT
bptjm-17	782	1	https://doi.org/10.1158/1078-0432.ccr-10-2961	https://doi.org/10.1158/1078-0432.ccr-10-2961	PROPN
bptjm-17	782	2	71	71	NUM
bptjm-17	782	3	.	.	PUNCT
bptjm-17	783	1	san	san	PROPN
bptjm-17	783	2	�	�	PROPN
bptjm-17	783	3	orenzo	orenzo	PROPN
bptjm-17	783	4	,	,	PUNCT
bptjm-17	783	5	c.	c.	PROPN
bptjm-17	783	6	,	,	PUNCT
bptjm-17	783	7	ilie	ilie	PROPN
bptjm-17	783	8	,	,	PUNCT
bptjm-17	783	9	m.	m.	NOUN
bptjm-17	783	10	i.	i.	PROPN
bptjm-17	783	11	,	,	PUNCT
bptjm-17	783	12	belaid	belaid	PROPN
bptjm-17	783	13	,	,	PUNCT
bptjm-17	783	14	a.	a.	PROPN
bptjm-17	783	15	,	,	PUNCT
bptjm-17	783	16	barlési	barlési	PROPN
bptjm-17	783	17	,	,	PUNCT
bptjm-17	783	18	f.	f.	PROPN
bptjm-17	783	19	,	,	PUNCT
bptjm-17	783	20	mouroux	mouroux	NOUN
bptjm-17	783	21	,	,	PUNCT
bptjm-17	783	22	j.	j.	PROPN
bptjm-17	783	23	,	,	PUNCT
bptjm-17	783	24	marquette	marquette	PROPN
bptjm-17	783	25	,	,	PUNCT
bptjm-17	783	26	c.	c.	PROPN
bptjm-17	783	27	h.	h.	PROPN
bptjm-17	783	28	,	,	PUNCT
bptjm-17	783	29	brest	brest	NOUN
bptjm-17	783	30	,	,	PUNCT
bptjm-17	783	31	p.	p.	NOUN
bptjm-17	783	32	,	,	PUNCT
bptjm-17	783	33	&	&	CCONJ
bptjm-17	783	34	hofman	hofman	PROPN
bptjm-17	783	35	,	,	PUNCT
bptjm-17	783	36	p.	p.	NOUN
bptjm-17	783	37	(	(	PUNCT
bptjm-17	783	38	2013	2013	NUM
bptjm-17	783	39	)	)	PUNCT
bptjm-17	783	40	.	.	PUNCT
bptjm-17	784	1	two	two	NUM
bptjm-17	784	2	panels	panel	NOUN
bptjm-17	784	3	of	of	ADP
bptjm-17	784	4	plasma	plasma	NOUN
bptjm-17	784	5	micrornas	microrna	NOUN
bptjm-17	784	6	as	as	ADP
bptjm-17	784	7	non	non	ADJ
bptjm-17	784	8	-	-	ADJ
bptjm-17	784	9	invasive	invasive	ADJ
bptjm-17	784	10	biomarkers	biomarker	NOUN
bptjm-17	784	11	for	for	ADP
bptjm-17	784	12	prediction	prediction	NOUN
bptjm-17	784	13	of	of	ADP
bptjm-17	784	14	recurrence	recurrence	NOUN
bptjm-17	784	15	in	in	ADP
bptjm-17	784	16	resectable	resectable	ADJ
bptjm-17	784	17	nsclc	nsclc	NOUN
bptjm-17	784	18	.	.	PUNCT
bptjm-17	785	1	plos	plos	PROPN
bptjm-17	785	2	one	one	NUM
bptjm-17	785	3	,	,	PUNCT
bptjm-17	785	4	8(1	8(1	NOUN
bptjm-17	785	5	)	)	PUNCT
bptjm-17	785	6	,	,	PUNCT
bptjm-17	785	7	e54596	e54596	NOUN
bptjm-17	785	8	.	.	PUNCT
bptjm-17	786	1	https://doi.org/	https://doi.org/	PROPN
bptjm-17	786	2	10.1371	10.1371	NUM
bptjm-17	786	3	/	/	SYM
bptjm-17	786	4	journal.pone.0054596	journal.pone.0054596	PROPN
bptjm-17	786	5	72	72	NUM
bptjm-17	786	6	.	.	PUNCT
bptjm-17	787	1	santiago	santiago	PROPN
bptjm-17	787	2	-	-	PUNCT
bptjm-17	787	3	walker	walker	PROPN
bptjm-17	787	4	,	,	PUNCT
bptjm-17	787	5	ademi	ademi	PROPN
bptjm-17	787	6	&	&	CCONJ
bptjm-17	787	7	moy	moy	PROPN
bptjm-17	787	8	,	,	PUNCT
bptjm-17	787	9	christopher	christopher	PROPN
bptjm-17	787	10	&	&	CCONJ
bptjm-17	787	11	cherkas	cherkas	PROPN
bptjm-17	787	12	,	,	PUNCT
bptjm-17	787	13	yauheniya	yauheniya	NOUN
bptjm-17	787	14	&	&	CCONJ
bptjm-17	787	15	loriot	loriot	PROPN
bptjm-17	787	16	,	,	PUNCT
bptjm-17	787	17	yohann	yohann	PROPN
bptjm-17	787	18	&	&	CCONJ
bptjm-17	787	19	siefker	siefker	NOUN
bptjm-17	787	20	-	-	PUNCT
bptjm-17	787	21	radtke	radtke	NOUN
bptjm-17	787	22	,	,	PUNCT
bptjm-17	787	23	arlene	arlene	PROPN
bptjm-17	787	24	&	&	CCONJ
bptjm-17	787	25	motley	motley	PROPN
bptjm-17	787	26	,	,	PUNCT
bptjm-17	787	27	cli	cli	PROPN
bptjm-17	787	28	�	�	PROPN
bptjm-17	787	29	ord	ord	PROPN
bptjm-17	787	30	&	&	CCONJ
bptjm-17	787	31	avadhani	avadhani	PROPN
bptjm-17	787	32	,	,	PUNCT
bptjm-17	787	33	anjali	anjali	PROPN
bptjm-17	787	34	&	&	CCONJ
bptjm-17	787	35	ohagan	ohagan	PROPN
bptjm-17	787	36	,	,	PUNCT
bptjm-17	787	37	anne	anne	PROPN
bptjm-17	787	38	&	&	CCONJ
bptjm-17	787	39	porre	porre	PROPN
bptjm-17	787	40	,	,	PUNCT
bptjm-17	787	41	peter	peter	PROPN
bptjm-17	787	42	&	&	CCONJ
bptjm-17	787	43	lorenzi	lorenzi	PROPN
bptjm-17	787	44	,	,	PUNCT
bptjm-17	787	45	matthew	matthew	PROPN
bptjm-17	787	46	&	&	CCONJ
bptjm-17	787	47	mcca	mcca	PROPN
bptjm-17	787	48	�	�	PROPN
bptjm-17	787	49	ery	ery	PROPN
bptjm-17	787	50	,	,	PUNCT
bptjm-17	787	51	ian	ian	PROPN
bptjm-17	787	52	.	.	PUNCT
bptjm-17	787	53	(	(	PUNCT
bptjm-17	787	54	2019	2019	NUM
bptjm-17	787	55	)	)	PUNCT
bptjm-17	787	56	.	.	PUNCT
bptjm-17	788	1	analysis	analysis	NOUN
bptjm-17	788	2	of	of	ADP
bptjm-17	788	3	fgfr	fgfr	ADJ
bptjm-17	788	4	alterations	alteration	NOUN
bptjm-17	788	5	from	from	ADP
bptjm-17	788	6	circulating	circulate	VERB
bptjm-17	788	7	tumor	tumor	NOUN
bptjm-17	788	8	dna	dna	NOUN
bptjm-17	788	9	(	(	PUNCT
bptjm-17	788	10	ctdna	ctdna	NOUN
bptjm-17	788	11	)	)	PUNCT
bptjm-17	788	12	and	and	CCONJ
bptjm-17	788	13	tissue	tissue	NOUN
bptjm-17	788	14	in	in	ADP
bptjm-17	788	15	a	a	DET
bptjm-17	788	16	phase	phase	NOUN
bptjm-17	788	17	ii	ii	NOUN
bptjm-17	788	18	trial	trial	NOUN
bptjm-17	788	19	of	of	ADP
bptjm-17	788	20	erda	erda	PROPN
bptjm-17	788	21	�	�	NOUN
bptjm-17	788	22	tinib	tinib	NOUN
bptjm-17	788	23	in	in	ADP
bptjm-17	788	24	urothelial	urothelial	ADJ
bptjm-17	788	25	carcinoma	carcinoma	NOUN
bptjm-17	788	26	(	(	PUNCT
bptjm-17	788	27	uc	uc	PROPN
bptjm-17	788	28	)	)	PUNCT
bptjm-17	788	29	..	..	PUNCT
bptjm-17	788	30	journal	journal	NOUN
bptjm-17	788	31	of	of	ADP
bptjm-17	788	32	clinical	clinical	ADJ
bptjm-17	788	33	oncology	oncology	NOUN
bptjm-17	788	34	.	.	PUNCT
bptjm-17	789	1	37	37	NUM
bptjm-17	789	2	.	.	X
bptjm-17	789	3	420	420	NUM
bptjm-17	789	4	-	-	SYM
bptjm-17	789	5	420	420	NUM
bptjm-17	789	6	.	.	PUNCT
bptjm-17	790	1	10.1200	10.1200	NUM
bptjm-17	790	2	/	/	SYM
bptjm-17	790	3	jco	jco	PROPN
bptjm-17	790	4	.	.	PUNCT
bptjm-17	791	1	2019.37.7_suppl.420	2019.37.7_suppl.420	NUM
bptjm-17	791	2	.	.	PUNCT
bptjm-17	792	1	73	73	NUM
bptjm-17	792	2	.	.	PUNCT
bptjm-17	793	1	satoh	satoh	NOUN
bptjm-17	793	2	,	,	PUNCT
bptjm-17	793	3	n.	n.	NOUN
bptjm-17	793	4	,	,	PUNCT
bptjm-17	793	5	maniwa	maniwa	PROPN
bptjm-17	793	6	,	,	PUNCT
bptjm-17	793	7	y.	y.	PROPN
bptjm-17	793	8	,	,	PUNCT
bptjm-17	793	9	bermudez	bermudez	PROPN
bptjm-17	793	10	,	,	PUNCT
bptjm-17	793	11	v.	v.	PROPN
bptjm-17	793	12	p.	p.	PROPN
bptjm-17	793	13	,	,	PUNCT
bptjm-17	793	14	nishimura	nishimura	PROPN
bptjm-17	793	15	,	,	PUNCT
bptjm-17	793	16	k.	k.	PROPN
bptjm-17	793	17	,	,	PUNCT
bptjm-17	793	18	nishio	nishio	PROPN
bptjm-17	793	19	,	,	PUNCT
bptjm-17	793	20	w.	w.	PROPN
bptjm-17	793	21	,	,	PUNCT
bptjm-17	793	22	yoshimura	yoshimura	NOUN
bptjm-17	793	23	,	,	PUNCT
bptjm-17	793	24	m.	m.	NOUN
bptjm-17	793	25	,	,	PUNCT
bptjm-17	793	26	okita	okita	PROPN
bptjm-17	793	27	,	,	PUNCT
bptjm-17	793	28	y.	y.	PROPN
bptjm-17	793	29	,	,	PUNCT
bptjm-17	793	30	ohbayashi	ohbayashi	ADJ
bptjm-17	793	31	,	,	PUNCT
bptjm-17	793	32	c.	c.	PROPN
bptjm-17	793	33	,	,	PUNCT
bptjm-17	793	34	hurwitz	hurwitz	PROPN
bptjm-17	793	35	,	,	PUNCT
bptjm-17	793	36	j.	j.	PROPN
bptjm-17	793	37	,	,	PUNCT
bptjm-17	793	38	&	&	CCONJ
bptjm-17	793	39	hayashi	hayashi	PROPN
bptjm-17	793	40	,	,	PUNCT
bptjm-17	793	41	y.	y.	PROPN
bptjm-17	793	42	(	(	PUNCT
bptjm-17	793	43	2011	2011	NUM
bptjm-17	793	44	)	)	PUNCT
bptjm-17	793	45	.	.	PUNCT
bptjm-17	794	1	oncogenic	oncogenic	ADJ
bptjm-17	794	2	phosphatase	phosphatase	NOUN
bptjm-17	794	3	wip1	wip1	PROPN
bptjm-17	794	4	is	be	AUX
bptjm-17	794	5	a	a	DET
bptjm-17	794	6	novel	novel	ADJ
bptjm-17	794	7	prognostic	prognostic	ADJ
bptjm-17	794	8	marker	marker	NOUN
bptjm-17	794	9	for	for	ADP
bptjm-17	794	10	lung	lung	NOUN
bptjm-17	794	11	adenocarcinoma	adenocarcinoma	PROPN
bptjm-17	794	12	patient	patient	NOUN
bptjm-17	794	13	survival	survival	NOUN
bptjm-17	794	14	.	.	PUNCT
bptjm-17	795	1	cancer	cancer	NOUN
bptjm-17	795	2	science	science	NOUN
bptjm-17	795	3	,	,	PUNCT
bptjm-17	795	4	102(5	102(5	NUM
bptjm-17	795	5	)	)	PUNCT
bptjm-17	795	6	,	,	PUNCT
bptjm-17	795	7	1101–1106	1101–1106	NUM
bptjm-17	795	8	.	.	PUNCT
bptjm-17	796	1	https://doi.org/10.1111/j.1349-7006.2011.01898.x	https://doi.org/10.1111/j.1349-7006.2011.01898.x	ADJ
bptjm-17	796	2	.	.	PUNCT
bptjm-17	797	1	74	74	NUM
bptjm-17	797	2	.	.	PUNCT
bptjm-17	797	3	sequist	sequist	PROPN
bptjm-17	797	4	,	,	PUNCT
bptjm-17	797	5	l.	l.	PROPN
bptjm-17	797	6	v.	v.	PROPN
bptjm-17	797	7	,	,	PUNCT
bptjm-17	797	8	von	von	PROPN
bptjm-17	797	9	pawel	pawel	PROPN
bptjm-17	797	10	,	,	PUNCT
bptjm-17	797	11	j.	j.	PROPN
bptjm-17	797	12	,	,	PUNCT
bptjm-17	797	13	garmey	garmey	NOUN
bptjm-17	797	14	,	,	PUNCT
bptjm-17	797	15	e.	e.	PROPN
bptjm-17	797	16	g.	g.	PROPN
bptjm-17	797	17	,	,	PUNCT
bptjm-17	797	18	akerley	akerley	PROPN
bptjm-17	797	19	,	,	PUNCT
bptjm-17	797	20	w.	w.	PROPN
bptjm-17	797	21	l.	l.	PROPN
bptjm-17	797	22	,	,	PUNCT
bptjm-17	797	23	brugger	brugger	PROPN
bptjm-17	797	24	,	,	PUNCT
bptjm-17	797	25	w.	w.	PROPN
bptjm-17	797	26	,	,	PUNCT
bptjm-17	797	27	ferrari	ferrari	PROPN
bptjm-17	797	28	,	,	PUNCT
bptjm-17	797	29	d.	d.	PROPN
bptjm-17	797	30	,	,	PUNCT
bptjm-17	797	31	chen	chen	PROPN
bptjm-17	797	32	,	,	PUNCT
bptjm-17	797	33	y.	y.	PROPN
bptjm-17	797	34	,	,	PUNCT
bptjm-17	797	35	costa	costa	PROPN
bptjm-17	797	36	,	,	PUNCT
bptjm-17	797	37	d.	d.	PROPN
bptjm-17	797	38	b.	b.	PROPN
bptjm-17	797	39	,	,	PUNCT
bptjm-17	797	40	gerber	gerber	PROPN
bptjm-17	797	41	,	,	PUNCT
bptjm-17	797	42	d.	d.	PROPN
bptjm-17	797	43	e.	e.	PROPN
bptjm-17	797	44	,	,	PUNCT
bptjm-17	797	45	orlov	orlov	PROPN
bptjm-17	797	46	,	,	PUNCT
bptjm-17	797	47	s.	s.	PROPN
bptjm-17	797	48	,	,	PUNCT
bptjm-17	797	49	ramlau	ramlau	PROPN
bptjm-17	797	50	,	,	PUNCT
bptjm-17	797	51	r.	r.	PROPN
bptjm-17	797	52	,	,	PUNCT
bptjm-17	797	53	arthur	arthur	PROPN
bptjm-17	797	54	,	,	PUNCT
bptjm-17	797	55	s.	s.	PROPN
bptjm-17	797	56	,	,	PUNCT
bptjm-17	797	57	gorbachevsky	gorbachevsky	PROPN
bptjm-17	797	58	,	,	PUNCT
bptjm-17	797	59	i.	i.	PROPN
bptjm-17	797	60	,	,	PUNCT
bptjm-17	797	61	schwartz	schwartz	PROPN
bptjm-17	797	62	,	,	PUNCT
bptjm-17	797	63	b.	b.	PROPN
bptjm-17	797	64	,	,	PUNCT
bptjm-17	797	65	&	&	CCONJ
bptjm-17	797	66	schiller	schiller	PROPN
bptjm-17	797	67	,	,	PUNCT
bptjm-17	797	68	j.	j.	PROPN
bptjm-17	797	69	h.	h.	PROPN
bptjm-17	797	70	(	(	PUNCT
bptjm-17	797	71	2011	2011	NUM
bptjm-17	797	72	)	)	PUNCT
bptjm-17	797	73	.	.	PUNCT
bptjm-17	798	1	randomized	randomize	VERB
bptjm-17	798	2	phase	phase	NOUN
bptjm-17	798	3	ii	ii	PROPN
bptjm-17	798	4	study	study	NOUN
bptjm-17	798	5	of	of	ADP
bptjm-17	798	6	erlotinib	erlotinib	NOUN
bptjm-17	798	7	plus	plus	CCONJ
bptjm-17	798	8	tivantinib	tivantinib	NOUN
bptjm-17	798	9	versus	versus	ADP
bptjm-17	798	10	erlotinib	erlotinib	NOUN
bptjm-17	798	11	plus	plus	CCONJ
bptjm-17	798	12	placebo	placebo	NOUN
bptjm-17	798	13	in	in	ADP
bptjm-17	798	14	previously	previously	ADV
bptjm-17	798	15	treated	treat	VERB
bptjm-17	798	16	non	non	ADJ
bptjm-17	798	17	-	-	ADJ
bptjm-17	798	18	small	small	ADJ
bptjm-17	798	19	-	-	PUNCT
bptjm-17	798	20	cell	cell	NOUN
bptjm-17	798	21	lung	lung	NOUN
bptjm-17	798	22	cancer	cancer	NOUN
bptjm-17	798	23	.	.	PUNCT
bptjm-17	799	1	journal	journal	NOUN
bptjm-17	799	2	of	of	ADP
bptjm-17	799	3	clinical	clinical	ADJ
bptjm-17	799	4	oncology	oncology	NOUN
bptjm-17	799	5	:	:	PUNCT
bptjm-17	799	6	official	official	ADJ
bptjm-17	799	7	journal	journal	NOUN
bptjm-17	799	8	of	of	ADP
bptjm-17	799	9	the	the	DET
bptjm-17	799	10	american	american	ADJ
bptjm-17	799	11	society	society	NOUN
bptjm-17	799	12	of	of	ADP
bptjm-17	799	13	clinical	clinical	ADJ
bptjm-17	799	14	oncology	oncology	NOUN
bptjm-17	799	15	,	,	PUNCT
bptjm-17	799	16	29(24	29(24	NUM
bptjm-17	799	17	)	)	PUNCT
bptjm-17	799	18	,	,	PUNCT
bptjm-17	799	19	3307–3315	3307–3315	NUM
bptjm-17	799	20	.	.	PUNCT
bptjm-17	800	1	https://doi.org/10.1200/jco.2010.34.0570	https://doi.org/10.1200/jco.2010.34.0570	NOUN
bptjm-17	800	2	.	.	PUNCT
bptjm-17	801	1	75	75	NUM
bptjm-17	801	2	.	.	PUNCT
bptjm-17	802	1	schildhaus	schildhaus	PROPN
bptjm-17	802	2	h.	h.	PROPN
bptjm-17	802	3	u.	u.	PROPN
bptjm-17	802	4	(	(	PUNCT
bptjm-17	802	5	2020	2020	NUM
bptjm-17	802	6	)	)	PUNCT
bptjm-17	802	7	.	.	PUNCT
bptjm-17	803	1	immunhistochemiebasierte	immunhistochemiebasierte	PROPN
bptjm-17	803	2	prädiktive	prädiktive	ADJ
bptjm-17	803	3	biomarker	biomarker	NOUN
bptjm-17	803	4	bei	bei	VERB
bptjm-17	803	5	lungenkarzinomen	lungenkarzinoman	NOUN
bptjm-17	803	6	[	[	X
bptjm-17	803	7	immunohistochemistry	immunohistochemistry	NOUN
bptjm-17	803	8	-	-	PUNCT
bptjm-17	803	9	based	base	VERB
bptjm-17	803	10	predictive	predictive	ADJ
bptjm-17	803	11	biomarkers	biomarker	NOUN
bptjm-17	803	12	for	for	ADP
bptjm-17	803	13	lung	lung	NOUN
bptjm-17	803	14	cancer	cancer	NOUN
bptjm-17	803	15	]	]	PUNCT
bptjm-17	803	16	.	.	PUNCT
bptjm-17	804	1	der	der	ADJ
bptjm-17	804	2	pathologe	pathologe	NOUN
bptjm-17	804	3	,	,	PUNCT
bptjm-17	804	4	41(1	41(1	NUM
bptjm-17	804	5	)	)	PUNCT
bptjm-17	804	6	,	,	PUNCT
bptjm-17	804	7	21–31	21–31	NUM
bptjm-17	804	8	.	.	PUNCT
bptjm-17	805	1	https://doi.org/10.1007/s00292-020-00750-7	https://doi.org/10.1007/s00292-020-00750-7	NUM
bptjm-17	805	2	76	76	NUM
bptjm-17	805	3	.	.	PUNCT
bptjm-17	806	1	shaw	shaw	PROPN
bptjm-17	806	2	,	,	PUNCT
bptjm-17	806	3	a.	a.	NOUN
bptjm-17	806	4	t.	t.	PROPN
bptjm-17	806	5	,	,	PUNCT
bptjm-17	806	6	yeap	yeap	PROPN
bptjm-17	806	7	,	,	PUNCT
bptjm-17	806	8	b.	b.	PROPN
bptjm-17	806	9	y.	y.	PROPN
bptjm-17	806	10	,	,	PUNCT
bptjm-17	806	11	solomon	solomon	PROPN
bptjm-17	806	12	,	,	PUNCT
bptjm-17	806	13	b.	b.	PROPN
bptjm-17	806	14	j.	j.	PROPN
bptjm-17	806	15	,	,	PUNCT
bptjm-17	806	16	riely	riely	PROPN
bptjm-17	806	17	,	,	PUNCT
bptjm-17	806	18	g.	g.	PROPN
bptjm-17	806	19	j.	j.	PROPN
bptjm-17	806	20	,	,	PUNCT
bptjm-17	806	21	gainor	gainor	PROPN
bptjm-17	806	22	,	,	PUNCT
bptjm-17	806	23	j.	j.	PROPN
bptjm-17	806	24	,	,	PUNCT
bptjm-17	806	25	engelman	engelman	PROPN
bptjm-17	806	26	,	,	PUNCT
bptjm-17	806	27	j.	j.	PROPN
bptjm-17	806	28	a.	a.	PROPN
bptjm-17	806	29	,	,	PUNCT
bptjm-17	806	30	shapiro	shapiro	PROPN
bptjm-17	806	31	,	,	PUNCT
bptjm-17	806	32	g.	g.	PROPN
bptjm-17	806	33	i.	i.	PROPN
bptjm-17	806	34	,	,	PUNCT
bptjm-17	806	35	costa	costa	PROPN
bptjm-17	806	36	,	,	PUNCT
bptjm-17	806	37	d.	d.	PROPN
bptjm-17	806	38	b.	b.	PROPN
bptjm-17	806	39	,	,	PUNCT
bptjm-17	806	40	ou	ou	PROPN
bptjm-17	806	41	,	,	PUNCT
bptjm-17	806	42	s.	s.	PROPN
bptjm-17	806	43	h.	h.	PROPN
bptjm-17	806	44	,	,	PUNCT
bptjm-17	806	45	butaney	butaney	NOUN
bptjm-17	806	46	,	,	PUNCT
bptjm-17	806	47	m.	m.	NOUN
bptjm-17	806	48	,	,	PUNCT
bptjm-17	806	49	salgia	salgia	NOUN
bptjm-17	806	50	,	,	PUNCT
bptjm-17	806	51	r.	r.	PROPN
bptjm-17	806	52	,	,	PUNCT
bptjm-17	806	53	maki	maki	PROPN
bptjm-17	806	54	,	,	PUNCT
bptjm-17	806	55	r.	r.	PROPN
bptjm-17	806	56	g.	g.	PROPN
bptjm-17	806	57	,	,	PUNCT
bptjm-17	806	58	varella	varella	NOUN
bptjm-17	806	59	garcia	garcia	PROPN
bptjm-17	806	60	,	,	PUNCT
bptjm-17	806	61	m.	m.	NOUN
bptjm-17	806	62	,	,	PUNCT
bptjm-17	806	63	doebele	doebele	PROPN
bptjm-17	806	64	,	,	PUNCT
bptjm-17	806	65	r.	r.	PROPN
bptjm-17	806	66	c.	c.	PROPN
bptjm-17	806	67	,	,	PUNCT
bptjm-17	806	68	bang	bang	PROPN
bptjm-17	806	69	,	,	PUNCT
bptjm-17	806	70	y.	y.	PROPN
bptjm-17	806	71	j.	j.	PROPN
bptjm-17	806	72	,	,	PUNCT
bptjm-17	806	73	kulig	kulig	PROPN
bptjm-17	806	74	,	,	PUNCT
bptjm-17	806	75	k.	k.	PROPN
bptjm-17	806	76	,	,	PUNCT
bptjm-17	806	77	selaru	selaru	PROPN
bptjm-17	806	78	,	,	PUNCT
bptjm-17	806	79	p.	p.	PROPN
bptjm-17	806	80	,	,	PUNCT
bptjm-17	806	81	tang	tang	PROPN
bptjm-17	806	82	,	,	PUNCT
bptjm-17	806	83	y.	y.	PROPN
bptjm-17	806	84	,	,	PUNCT
bptjm-17	806	85	wilner	wilner	PROPN
bptjm-17	806	86	,	,	PUNCT
bptjm-17	806	87	k.	k.	PROPN
bptjm-17	806	88	d.	d.	PROPN
bptjm-17	806	89	,	,	PUNCT
bptjm-17	806	90	kwak	kwak	PROPN
bptjm-17	806	91	,	,	PUNCT
bptjm-17	806	92	e.	e.	PROPN
bptjm-17	806	93	l.	l.	PROPN
bptjm-17	806	94	,	,	PUNCT
bptjm-17	806	95	…	…	PUNCT
bptjm-17	806	96	camidge	camidge	NOUN
bptjm-17	806	97	,	,	PUNCT
bptjm-17	806	98	d.	d.	PROPN
bptjm-17	806	99	r.	r.	PROPN
bptjm-17	806	100	(	(	PUNCT
bptjm-17	806	101	2011	2011	NUM
bptjm-17	806	102	)	)	PUNCT
bptjm-17	806	103	.	.	PUNCT
bptjm-17	807	1	e	e	X
bptjm-17	807	2	�	�	NOUN
bptjm-17	807	3	ect	ect	VERB
bptjm-17	807	4	of	of	ADP
bptjm-17	807	5	crizotinib	crizotinib	NOUN
bptjm-17	807	6	on	on	ADP
bptjm-17	807	7	overall	overall	ADJ
bptjm-17	807	8	survival	survival	NOUN
bptjm-17	807	9	in	in	ADP
bptjm-17	807	10	patients	patient	NOUN
bptjm-17	807	11	with	with	ADP
bptjm-17	807	12	advanced	advanced	ADJ
bptjm-17	807	13	non	non	ADJ
bptjm-17	807	14	-	-	ADJ
bptjm-17	807	15	small	small	ADJ
bptjm-17	807	16	-	-	PUNCT
bptjm-17	807	17	cell	cell	NOUN
bptjm-17	807	18	lung	lung	NOUN
bptjm-17	807	19	cancer	cancer	NOUN
bptjm-17	807	20	harbouring	harbouring	NOUN
bptjm-17	807	21	alk	alk	PROPN
bptjm-17	807	22	gene	gene	NOUN
bptjm-17	807	23	rearrangement	rearrangement	NOUN
bptjm-17	807	24	:	:	PUNCT
bptjm-17	807	25	a	a	DET
bptjm-17	807	26	retrospective	retrospective	ADJ
bptjm-17	807	27	analysis	analysis	NOUN
bptjm-17	807	28	.	.	PUNCT
bptjm-17	808	1	the	the	DET
bptjm-17	808	2	lancet	lancet	PROPN
bptjm-17	808	3	.	.	PUNCT
bptjm-17	809	1	oncology	oncology	NOUN
bptjm-17	809	2	,	,	PUNCT
bptjm-17	809	3	12(11	12(11	NUM
bptjm-17	809	4	)	)	PUNCT
bptjm-17	809	5	,	,	PUNCT
bptjm-17	809	6	1004–1012	1004–1012	NUM
bptjm-17	809	7	.	.	PUNCT
bptjm-17	809	8	https://doi.org/	https://doi.org/	VERB
bptjm-17	809	9	10.1016	10.1016	NUM
bptjm-17	809	10	/	/	SYM
bptjm-17	809	11	s1470	s1470	PROPN
bptjm-17	809	12	-	-	PUNCT
bptjm-17	809	13	2045(11)70232	2045(11)70232	NOUN
bptjm-17	809	14	-	-	PUNCT
bptjm-17	809	15	7	7	NUM
bptjm-17	809	16	77	77	NUM
bptjm-17	809	17	.	.	PUNCT
bptjm-17	810	1	shi	shi	PROPN
bptjm-17	810	2	gl	gl	PROPN
bptjm-17	810	3	,	,	PUNCT
bptjm-17	810	4	zhang	zhang	PROPN
bptjm-17	810	5	xy	xy	PROPN
bptjm-17	810	6	,	,	PUNCT
bptjm-17	810	7	chen	chen	PROPN
bptjm-17	810	8	y	y	PROPN
bptjm-17	810	9	,	,	PUNCT
bptjm-17	810	10	ma	ma	PROPN
bptjm-17	810	11	s	s	PROPN
bptjm-17	810	12	,	,	PUNCT
bptjm-17	810	13	bai	bai	PROPN
bptjm-17	810	14	wq	wq	PROPN
bptjm-17	810	15	,	,	PUNCT
bptjm-17	810	16	yin	yin	PROPN
bptjm-17	810	17	yj	yj	PROPN
bptjm-17	810	18	.	.	PROPN
bptjm-17	810	19	(	(	PUNCT
bptjm-17	810	20	june	june	PROPN
bptjm-17	810	21	1	1	NUM
bptjm-17	810	22	,	,	PUNCT
bptjm-17	810	23	2020	2020	NUM
bptjm-17	810	24	)	)	PUNCT
bptjm-17	810	25	.	.	PUNCT
bptjm-17	811	1	prognostic	prognostic	ADJ
bptjm-17	811	2	signi	signi	PROPN
bptjm-17	811	3	�	�	PROPN
bptjm-17	811	4	cance	cance	NOUN
bptjm-17	811	5	of	of	ADP
bptjm-17	811	6	serum	serum	NOUN
bptjm-17	811	7	mir-22	mir-22	NOUN
bptjm-17	811	8	,	,	PUNCT
bptjm-17	811	9	mir-125b	mir-125b	NOUN
bptjm-17	811	10	,	,	PUNCT
bptjm-17	811	11	and	and	CCONJ
bptjm-17	811	12	mir-15b	mir-15b	NOUN
bptjm-17	811	13	in	in	ADP
bptjm-17	811	14	non	non	ADJ
bptjm-17	811	15	-	-	ADJ
bptjm-17	811	16	small	small	ADJ
bptjm-17	811	17	cell	cell	NOUN
bptjm-17	811	18	lung	lung	NOUN
bptjm-17	811	19	cancer	cancer	NOUN
bptjm-17	811	20	patients	patient	NOUN
bptjm-17	811	21	.	.	PUNCT
bptjm-17	812	1	clin	clin	PROPN
bptjm-17	812	2	lab	lab	PROPN
bptjm-17	812	3	.	.	PUNCT
bptjm-17	812	4	,	,	PUNCT
bptjm-17	812	5	66(6	66(6	NUM
bptjm-17	812	6	)	)	PUNCT
bptjm-17	812	7	.	.	PUNCT
bptjm-17	813	1	doi	doi	NOUN
bptjm-17	813	2	:	:	PUNCT
bptjm-17	813	3	10.7754	10.7754	NUM
bptjm-17	813	4	/	/	SYM
bptjm-17	813	5	clin.lab.2019.191129	clin.lab.2019.191129	PROPN
bptjm-17	813	6	.	.	PUNCT
bptjm-17	814	1	pmid	pmid	NOUN
bptjm-17	814	2	:	:	PUNCT
bptjm-17	814	3	32538046	32538046	NUM
bptjm-17	814	4	.	.	PUNCT
bptjm-17	815	1	78	78	NUM
bptjm-17	815	2	.	.	PUNCT
bptjm-17	816	1	siravegna	siravegna	PROPN
bptjm-17	816	2	,	,	PUNCT
bptjm-17	816	3	giulia	giulia	PROPN
bptjm-17	816	4	,	,	PUNCT
bptjm-17	816	5	andrea	andrea	PROPN
bptjm-17	816	6	sartore	sartore	NOUN
bptjm-17	816	7	-	-	PUNCT
bptjm-17	816	8	bianchi	bianchi	NOUN
bptjm-17	816	9	,	,	PUNCT
bptjm-17	816	10	rebecca	rebecca	PROPN
bptjm-17	816	11	j.	j.	PROPN
bptjm-17	816	12	nagy	nagy	PROPN
bptjm-17	816	13	,	,	PUNCT
bptjm-17	816	14	kanwal	kanwal	PROPN
bptjm-17	816	15	raghav	raghav	PROPN
bptjm-17	816	16	,	,	PUNCT
bptjm-17	816	17	justin	justin	PROPN
bptjm-17	816	18	i.	i.	PROPN
bptjm-17	816	19	odegaard	odegaard	PROPN
bptjm-17	816	20	,	,	PUNCT
bptjm-17	816	21	richard	richard	PROPN
bptjm-17	816	22	b.	b.	PROPN
bptjm-17	816	23	lanman	lanman	PROPN
bptjm-17	816	24	,	,	PUNCT
bptjm-17	816	25	livio	livio	PROPN
bptjm-17	816	26	trusolino	trusolino	PROPN
bptjm-17	816	27	,	,	PUNCT
bptjm-17	816	28	silvia	silvia	PROPN
bptjm-17	816	29	marsoni	marsoni	PROPN
bptjm-17	816	30	,	,	PUNCT
bptjm-17	816	31	salvatore	salvatore	PROPN
bptjm-17	816	32	siena	siena	PROPN
bptjm-17	816	33	,	,	PUNCT
bptjm-17	816	34	and	and	CCONJ
bptjm-17	816	35	alberto	alberto	PROPN
bptjm-17	816	36	bardelli	bardelli	NOUN
bptjm-17	816	37	.	.	PUNCT
bptjm-17	817	1	(	(	PUNCT
bptjm-17	817	2	may	may	PROPN
bptjm-17	817	3	15	15	NUM
bptjm-17	817	4	,	,	PUNCT
bptjm-17	817	5	2019	2019	NUM
bptjm-17	817	6	)	)	PUNCT
bptjm-17	817	7	.	.	PUNCT
bptjm-17	818	1	plasma	plasma	NOUN
bptjm-17	818	2	her2	her2	PROPN
bptjm-17	818	3	(	(	PUNCT
bptjm-17	818	4	erbb2	erbb2	ADJ
bptjm-17	818	5	)	)	PUNCT
bptjm-17	818	6	copy	copy	NOUN
bptjm-17	818	7	number	number	NOUN
bptjm-17	818	8	predicts	predict	VERB
bptjm-17	818	9	response	response	NOUN
bptjm-17	818	10	to	to	ADP
bptjm-17	818	11	her2	her2	VERB
bptjm-17	818	12	-	-	PUNCT
bptjm-17	818	13	targeted	target	VERB
bptjm-17	818	14	therapy	therapy	NOUN
bptjm-17	818	15	in	in	ADP
bptjm-17	818	16	metastatic	metastatic	ADJ
bptjm-17	818	17	colorectal	colorectal	ADJ
bptjm-17	818	18	cancer	cancer	NOUN
bptjm-17	818	19	.	.	PUNCT
bptjm-17	819	1	clinical	clinical	ADJ
bptjm-17	819	2	cancer	cancer	NOUN
bptjm-17	819	3	research	research	NOUN
bptjm-17	819	4	,	,	PUNCT
bptjm-17	819	5	25(10	25(10	NOUN
bptjm-17	819	6	)	)	PUNCT
bptjm-17	819	7	,	,	PUNCT
bptjm-17	819	8	3046–53	3046–53	NOUN
bptjm-17	819	9	.	.	PUNCT
bptjm-17	820	1	https://doi.org/10.1158/1078-0432.ccr-18-3389	https://doi.org/10.1158/1078-0432.ccr-18-3389	PROPN
bptjm-17	820	2	.	.	PUNCT
bptjm-17	821	1	berkeley	berkeley	PROPN
bptjm-17	821	2	pharma	pharma	PROPN
bptjm-17	821	3	tech	tech	PROPN
bptjm-17	821	4	journal	journal	NOUN
bptjm-17	821	5	of	of	ADP
bptjm-17	821	6	medicine	medicine	NOUN
bptjm-17	821	7	|	|	ADV
bptjm-17	821	8	152	152	NUM
bptjm-17	821	9	79	79	NUM
bptjm-17	821	10	.	.	PUNCT
bptjm-17	822	1	sromek	sromek	PROPN
bptjm-17	822	2	m	m	PROPN
bptjm-17	822	3	,	,	PUNCT
bptjm-17	822	4	glogowski	glogowski	PROPN
bptjm-17	822	5	m	m	PROPN
bptjm-17	822	6	,	,	PUNCT
bptjm-17	822	7	chechlinska	chechlinska	PROPN
bptjm-17	822	8	m	m	PROPN
bptjm-17	822	9	,	,	PUNCT
bptjm-17	822	10	kulinczak	kulinczak	PROPN
bptjm-17	822	11	m	m	PROPN
bptjm-17	822	12	,	,	PUNCT
bptjm-17	822	13	szafron	szafron	NOUN
bptjm-17	822	14	l	l	NOUN
bptjm-17	822	15	,	,	PUNCT
bptjm-17	822	16	zakrzewska	zakrzewska	PROPN
bptjm-17	822	17	k	k	PROPN
bptjm-17	822	18	,	,	PUNCT
bptjm-17	822	19	owczarek	owczarek	PROPN
bptjm-17	822	20	j	j	PROPN
bptjm-17	822	21	,	,	PUNCT
bptjm-17	822	22	wisniewski	wisniewski	PROPN
bptjm-17	822	23	p	p	PROPN
bptjm-17	822	24	,	,	PUNCT
bptjm-17	822	25	wlodarczyk	wlodarczyk	VERB
bptjm-17	822	26	r	r	NOUN
bptjm-17	822	27	,	,	PUNCT
bptjm-17	822	28	talarek	talarek	NOUN
bptjm-17	822	29	l	l	NOUN
bptjm-17	822	30	,	,	PUNCT
bptjm-17	822	31	turski	turski	PROPN
bptjm-17	822	32	m	m	PROPN
bptjm-17	822	33	,	,	PUNCT
bptjm-17	822	34	siwicki	siwicki	PROPN
bptjm-17	822	35	jk	jk	PROPN
bptjm-17	822	36	.	.	PUNCT
bptjm-17	823	1	(	(	PUNCT
bptjm-17	823	2	october	october	PROPN
bptjm-17	823	3	2017	2017	NUM
bptjm-17	823	4	)	)	PUNCT
bptjm-17	823	5	.	.	PUNCT
bptjm-17	824	1	changes	change	NOUN
bptjm-17	824	2	in	in	ADP
bptjm-17	824	3	plasma	plasma	NOUN
bptjm-17	824	4	mir-9	mir-9	NOUN
bptjm-17	824	5	,	,	PUNCT
bptjm-17	824	6	mir-16	mir-16	NOUN
bptjm-17	824	7	,	,	PUNCT
bptjm-17	824	8	mir-205	mir-205	NOUN
bptjm-17	824	9	and	and	CCONJ
bptjm-17	824	10	mir-486	mir-486	ADJ
bptjm-17	824	11	levels	level	NOUN
bptjm-17	824	12	after	after	ADP
bptjm-17	824	13	non	non	ADJ
bptjm-17	824	14	-	-	ADJ
bptjm-17	824	15	small	small	ADJ
bptjm-17	824	16	cell	cell	NOUN
bptjm-17	824	17	lung	lung	NOUN
bptjm-17	824	18	cancer	cancer	NOUN
bptjm-17	824	19	resection	resection	NOUN
bptjm-17	824	20	.	.	PUNCT
bptjm-17	825	1	cell	cell	NOUN
bptjm-17	825	2	oncol	oncol	ADJ
bptjm-17	825	3	(	(	PUNCT
bptjm-17	825	4	dordr).;40(5):529	dordr).;40(5):529	NOUN
bptjm-17	825	5	-	-	PUNCT
bptjm-17	825	6	536	536	NUM
bptjm-17	825	7	.	.	PUNCT
bptjm-17	826	1	doi	doi	NOUN
bptjm-17	826	2	:	:	PUNCT
bptjm-17	826	3	10.1007	10.1007	NUM
bptjm-17	826	4	/	/	SYM
bptjm-17	826	5	s13402	s13402	PROPN
bptjm-17	826	6	-	-	PUNCT
bptjm-17	826	7	017	017	NUM
bptjm-17	826	8	-	-	PUNCT
bptjm-17	826	9	0334	0334	NUM
bptjm-17	826	10	-	-	PUNCT
bptjm-17	826	11	8	8	NUM
bptjm-17	826	12	.	.	PUNCT
bptjm-17	827	1	epub	epub	PROPN
bptjm-17	827	2	2017	2017	NUM
bptjm-17	827	3	jun	jun	PROPN
bptjm-17	827	4	20	20	NUM
bptjm-17	827	5	.	.	PUNCT
bptjm-17	828	1	pmid	pmid	NOUN
bptjm-17	828	2	:	:	PUNCT
bptjm-17	828	3	28634901	28634901	NUM
bptjm-17	828	4	.	.	PUNCT
bptjm-17	829	1	80	80	NUM
bptjm-17	829	2	.	.	PUNCT
bptjm-17	829	3	subbiah	subbiah	PROPN
bptjm-17	829	4	,	,	PUNCT
bptjm-17	829	5	vivek	vivek	PROPN
bptjm-17	829	6	,	,	PUNCT
bptjm-17	829	7	jenny	jenny	PROPN
bptjm-17	829	8	berry	berry	PROPN
bptjm-17	829	9	,	,	PUNCT
bptjm-17	829	10	michael	michael	PROPN
bptjm-17	829	11	roxas	roxas	PROPN
bptjm-17	829	12	,	,	PUNCT
bptjm-17	829	13	nandita	nandita	PROPN
bptjm-17	829	14	guha	guha	PROPN
bptjm-17	829	15	-	-	PUNCT
bptjm-17	829	16	thakurta	thakurta	PROPN
bptjm-17	829	17	,	,	PUNCT
bptjm-17	829	18	ishwaria	ishwaria	PROPN
bptjm-17	829	19	mohan	mohan	PROPN
bptjm-17	829	20	subbiah	subbiah	PROPN
bptjm-17	829	21	,	,	PUNCT
bptjm-17	829	22	siraj	siraj	PROPN
bptjm-17	829	23	m.	m.	PROPN
bptjm-17	829	24	ali	ali	PROPN
bptjm-17	829	25	,	,	PUNCT
bptjm-17	829	26	caitlin	caitlin	PROPN
bptjm-17	829	27	mcmahon	mcmahon	PROPN
bptjm-17	829	28	,	,	PUNCT
bptjm-17	829	29	et	et	PROPN
bptjm-17	829	30	al	al	PROPN
bptjm-17	829	31	.	.	PUNCT
bptjm-17	829	32	(	(	PUNCT
bptjm-17	829	33	july	july	PROPN
bptjm-17	829	34	1	1	NUM
bptjm-17	829	35	,	,	PUNCT
bptjm-17	829	36	2015	2015	NUM
bptjm-17	829	37	)	)	PUNCT
bptjm-17	829	38	.	.	PUNCT
bptjm-17	830	1	systemic	systemic	ADJ
bptjm-17	830	2	and	and	CCONJ
bptjm-17	830	3	cns	cns	NOUN
bptjm-17	830	4	activity	activity	NOUN
bptjm-17	830	5	of	of	ADP
bptjm-17	830	6	the	the	DET
bptjm-17	830	7	ret	ret	PROPN
bptjm-17	830	8	inhibitor	inhibitor	NOUN
bptjm-17	830	9	vandetanib	vandetanib	NOUN
bptjm-17	830	10	combined	combine	VERB
bptjm-17	830	11	with	with	ADP
bptjm-17	830	12	the	the	DET
bptjm-17	830	13	mtor	mtor	PROPN
bptjm-17	830	14	inhibitor	inhibitor	NOUN
bptjm-17	830	15	everolimus	everolimus	NOUN
bptjm-17	830	16	in	in	ADP
bptjm-17	830	17	kif5b	kif5b	PROPN
bptjm-17	830	18	-	-	PUNCT
bptjm-17	830	19	ret	ret	PROPN
bptjm-17	830	20	re	re	PROPN
bptjm-17	830	21	arranged	arrange	VERB
bptjm-17	830	22	non	non	ADJ
bptjm-17	830	23	-	-	ADJ
bptjm-17	830	24	small	small	ADJ
bptjm-17	830	25	cell	cell	NOUN
bptjm-17	830	26	lung	lung	NOUN
bptjm-17	830	27	cancer	cancer	NOUN
bptjm-17	830	28	with	with	ADP
bptjm-17	830	29	brain	brain	NOUN
bptjm-17	830	30	metastases	metastasis	NOUN
bptjm-17	830	31	.	.	PUNCT
bptjm-17	831	1	lung	lung	NOUN
bptjm-17	831	2	cancer	cancer	NOUN
bptjm-17	831	3	,	,	PUNCT
bptjm-17	831	4	89(1	89(1	NOUN
bptjm-17	831	5	)	)	PUNCT
bptjm-17	831	6	,	,	PUNCT
bptjm-17	831	7	76–79	76–79	ADV
bptjm-17	831	8	.	.	PUNCT
bptjm-17	832	1	https://doi.org/10.1016/j.lungcan.2015.04.004	https://doi.org/10.1016/j.lungcan.2015.04.004	PROPN
bptjm-17	832	2	.	.	PUNCT
bptjm-17	833	1	81	81	NUM
bptjm-17	833	2	.	.	PUNCT
bptjm-17	834	1	peter	peter	PROPN
bptjm-17	834	2	stein	stein	PROPN
bptjm-17	834	3	.	.	PUNCT
bptjm-17	835	1	(	(	PUNCT
bptjm-17	835	2	n.d	n.d	PROPN
bptjm-17	835	3	.	.	PROPN
bptjm-17	835	4	)	)	PUNCT
bptjm-17	835	5	.	.	PUNCT
bptjm-17	836	1	brief	brief	ADJ
bptjm-17	836	2	overview	overview	NOUN
bptjm-17	836	3	of	of	ADP
bptjm-17	836	4	biomarkers	biomarker	NOUN
bptjm-17	836	5	:	:	PUNCT
bptjm-17	836	6	value	value	NOUN
bptjm-17	836	7	,	,	PUNCT
bptjm-17	836	8	limitations	limitation	NOUN
bptjm-17	836	9	,	,	PUNCT
bptjm-17	836	10	and	and	CCONJ
bptjm-17	836	11	the	the	DET
bptjm-17	836	12	biomarker	biomarker	NOUN
bptjm-17	836	13	quali	quali	PROPN
bptjm-17	836	14	�	�	PROPN
bptjm-17	836	15	cation	cation	NOUN
bptjm-17	836	16	program	program	NOUN
bptjm-17	836	17	(	(	PUNCT
bptjm-17	836	18	bqp	bqp	PROPN
bptjm-17	836	19	)	)	PUNCT
bptjm-17	837	1	[	[	X
bptjm-17	837	2	brochure	brochure	NOUN
bptjm-17	837	3	]	]	X
bptjm-17	837	4	.	.	PUNCT
bptjm-17	838	1	u.s	u.s	PROPN
bptjm-17	838	2	.	.	PROPN
bptjm-17	838	3	food	food	PROPN
bptjm-17	838	4	and	and	CCONJ
bptjm-17	838	5	drug	drug	NOUN
bptjm-17	838	6	administration	administration	NOUN
bptjm-17	838	7	:	:	PUNCT
bptjm-17	838	8	author	author	NOUN
bptjm-17	838	9	.	.	PUNCT
bptjm-17	839	1	retrieved	retrieve	VERB
bptjm-17	839	2	from	from	ADP
bptjm-17	839	3	https://fnih.org/sites/default/�les/�nal/pdf/2-stein-bio	https://fnih.org/sites/default/�les/�nal/pdf/2-stein-bio	PROPN
bptjm-17	839	4	markers%20introduction.pdf	markers%20introduction.pdf	X
bptjm-17	839	5	82	82	NUM
bptjm-17	839	6	.	.	PUNCT
bptjm-17	840	1	tao	tao	PROPN
bptjm-17	840	2	,	,	PUNCT
bptjm-17	840	3	j.	j.	PROPN
bptjm-17	840	4	,	,	PUNCT
bptjm-17	840	5	sun	sun	PROPN
bptjm-17	840	6	,	,	PUNCT
bptjm-17	840	7	d.	d.	PROPN
bptjm-17	840	8	,	,	PUNCT
bptjm-17	840	9	dong	dong	PROPN
bptjm-17	840	10	,	,	PUNCT
bptjm-17	840	11	l.	l.	PROPN
bptjm-17	840	12	,	,	PUNCT
bptjm-17	840	13	zhu	zhu	PROPN
bptjm-17	840	14	,	,	PUNCT
bptjm-17	840	15	h.	h.	PROPN
bptjm-17	840	16	,	,	PUNCT
bptjm-17	840	17	&	&	CCONJ
bptjm-17	840	18	hou	hou	PROPN
bptjm-17	840	19	,	,	PUNCT
bptjm-17	840	20	h.	h.	PROPN
bptjm-17	840	21	(	(	PUNCT
bptjm-17	840	22	2020	2020	NUM
bptjm-17	840	23	)	)	PUNCT
bptjm-17	840	24	.	.	PUNCT
bptjm-17	841	1	advancement	advancement	NOUN
bptjm-17	841	2	in	in	ADP
bptjm-17	841	3	research	research	NOUN
bptjm-17	841	4	and	and	CCONJ
bptjm-17	841	5	therapy	therapy	NOUN
bptjm-17	841	6	of	of	ADP
bptjm-17	841	7	nf1	nf1	NOUN
bptjm-17	841	8	mutant	mutant	ADJ
bptjm-17	841	9	malignant	malignant	ADJ
bptjm-17	841	10	tumors	tumor	NOUN
bptjm-17	841	11	.	.	PUNCT
bptjm-17	842	1	cancer	cancer	NOUN
bptjm-17	842	2	cell	cell	NOUN
bptjm-17	842	3	international	international	NOUN
bptjm-17	842	4	,	,	PUNCT
bptjm-17	842	5	20	20	NUM
bptjm-17	842	6	,	,	PUNCT
bptjm-17	842	7	492	492	NUM
bptjm-17	842	8	.	.	PUNCT
bptjm-17	843	1	https://	https://	PROPN
bptjm-17	843	2	doi.org/10.1186/s12935-020-01570-8	doi.org/10.1186/s12935-020-01570-8	VERB
bptjm-17	843	3	83	83	NUM
bptjm-17	843	4	.	.	PUNCT
bptjm-17	844	1	teresi	teresi	PROPN
bptjm-17	844	2	,	,	PUNCT
bptjm-17	844	3	rosemary	rosemary	PROPN
bptjm-17	844	4	e.	e.	PROPN
bptjm-17	844	5	,	,	PUNCT
bptjm-17	844	6	chung	chung	PROPN
bptjm-17	844	7	-	-	PUNCT
bptjm-17	844	8	wai	wai	PROPN
bptjm-17	844	9	shaiu	shaiu	PROPN
bptjm-17	844	10	,	,	PUNCT
bptjm-17	844	11	ching	ching	PROPN
bptjm-17	844	12	-	-	PUNCT
bptjm-17	844	13	shih	shih	PROPN
bptjm-17	844	14	chen	chen	PROPN
bptjm-17	844	15	,	,	PUNCT
bptjm-17	844	16	v.	v.	ADP
bptjm-17	844	17	krishna	krishna	PROPN
bptjm-17	844	18	chatterjee	chatterjee	PROPN
bptjm-17	844	19	,	,	PUNCT
bptjm-17	844	20	kristin	kristin	PROPN
bptjm-17	844	21	a.	a.	PROPN
bptjm-17	844	22	waite	waite	PROPN
bptjm-17	844	23	,	,	PUNCT
bptjm-17	844	24	and	and	CCONJ
bptjm-17	844	25	charis	charis	PROPN
bptjm-17	844	26	eng	eng	PROPN
bptjm-17	844	27	.	.	PUNCT
bptjm-17	845	1	(	(	PUNCT
bptjm-17	845	2	2006	2006	NUM
bptjm-17	845	3	)	)	PUNCT
bptjm-17	845	4	.	.	PUNCT
bptjm-17	846	1	increased	increase	VERB
bptjm-17	846	2	pten	pten	NOUN
bptjm-17	846	3	expression	expression	NOUN
bptjm-17	846	4	due	due	ADP
bptjm-17	846	5	to	to	ADP
bptjm-17	846	6	transcriptional	transcriptional	ADJ
bptjm-17	846	7	activation	activation	NOUN
bptjm-17	846	8	of	of	ADP
bptjm-17	846	9	pparγ	pparγ	NOUN
bptjm-17	846	10	by	by	ADP
bptjm-17	846	11	lovastatin	lovastatin	NOUN
bptjm-17	846	12	and	and	CCONJ
bptjm-17	846	13	rosiglitazone	rosiglitazone	NOUN
bptjm-17	846	14	.	.	PUNCT
bptjm-17	847	1	international	international	ADJ
bptjm-17	847	2	journal	journal	PROPN
bptjm-17	847	3	of	of	ADP
bptjm-17	847	4	cancer	cancer	NOUN
bptjm-17	847	5	,	,	PUNCT
bptjm-17	847	6	118(10	118(10	NUM
bptjm-17	847	7	)	)	PUNCT
bptjm-17	847	8	,	,	PUNCT
bptjm-17	847	9	2390–98	2390–98	NUM
bptjm-17	847	10	.	.	PUNCT
bptjm-17	848	1	https://doi.org/10.1002/ijc.21799	https://doi.org/10.1002/ijc.21799	NOUN
bptjm-17	848	2	.	.	PUNCT
bptjm-17	849	1	84	84	NUM
bptjm-17	849	2	.	.	PUNCT
bptjm-17	850	1	thompson	thompson	PROPN
bptjm-17	850	2	,	,	PUNCT
bptjm-17	850	3	je	je	PROPN
bptjm-17	850	4	�	�	PROPN
bptjm-17	850	5	rey	rey	PROPN
bptjm-17	850	6	c.	c.	PROPN
bptjm-17	850	7	,	,	PUNCT
bptjm-17	850	8	stephanie	stephanie	PROPN
bptjm-17	850	9	s.	s.	PROPN
bptjm-17	850	10	yee	yee	PROPN
bptjm-17	850	11	,	,	PUNCT
bptjm-17	850	12	andrea	andrea	PROPN
bptjm-17	850	13	b.	b.	PROPN
bptjm-17	850	14	troxel	troxel	PROPN
bptjm-17	850	15	,	,	PUNCT
bptjm-17	850	16	samantha	samantha	PROPN
bptjm-17	850	17	l.	l.	PROPN
bptjm-17	850	18	savitch	savitch	PROPN
bptjm-17	850	19	,	,	PUNCT
bptjm-17	850	20	ryan	ryan	PROPN
bptjm-17	850	21	fan	fan	PROPN
bptjm-17	850	22	,	,	PUNCT
bptjm-17	850	23	david	david	PROPN
bptjm-17	850	24	balli	balli	PROPN
bptjm-17	850	25	,	,	PUNCT
bptjm-17	850	26	david	david	PROPN
bptjm-17	850	27	b.	b.	PROPN
bptjm-17	850	28	lieberman	lieberman	PROPN
bptjm-17	850	29	,	,	PUNCT
bptjm-17	850	30	et	et	PROPN
bptjm-17	850	31	al	al	PROPN
bptjm-17	850	32	.	.	PUNCT
bptjm-17	851	1	(	(	PUNCT
bptjm-17	851	2	december	december	PROPN
bptjm-17	851	3	1	1	NUM
bptjm-17	851	4	,	,	PUNCT
bptjm-17	851	5	2016	2016	NUM
bptjm-17	851	6	)	)	PUNCT
bptjm-17	851	7	.	.	PUNCT
bptjm-17	852	1	detection	detection	NOUN
bptjm-17	852	2	of	of	ADP
bptjm-17	852	3	therapeutically	therapeutically	ADV
bptjm-17	852	4	targetable	targetable	ADJ
bptjm-17	852	5	driver	driver	NOUN
bptjm-17	852	6	and	and	CCONJ
bptjm-17	852	7	resistance	resistance	NOUN
bptjm-17	852	8	mutations	mutation	NOUN
bptjm-17	852	9	in	in	ADP
bptjm-17	852	10	lung	lung	NOUN
bptjm-17	852	11	cancer	cancer	NOUN
bptjm-17	852	12	patients	patient	NOUN
bptjm-17	852	13	by	by	ADP
bptjm-17	852	14	next	next	ADJ
bptjm-17	852	15	-	-	PUNCT
bptjm-17	852	16	generation	generation	NOUN
bptjm-17	852	17	sequencing	sequencing	NOUN
bptjm-17	852	18	of	of	ADP
bptjm-17	852	19	cell	cell	NOUN
bptjm-17	852	20	-	-	PUNCT
bptjm-17	852	21	free	free	ADJ
bptjm-17	852	22	circulating	circulate	VERB
bptjm-17	852	23	tumor	tumor	NOUN
bptjm-17	852	24	dna	dna	PROPN
bptjm-17	852	25	.	.	PUNCT
bptjm-17	853	1	clinical	clinical	ADJ
bptjm-17	853	2	cancer	cancer	NOUN
bptjm-17	853	3	research	research	NOUN
bptjm-17	853	4	:	:	PUNCT
bptjm-17	853	5	an	an	DET
bptjm-17	853	6	official	official	ADJ
bptjm-17	853	7	journal	journal	NOUN
bptjm-17	853	8	of	of	ADP
bptjm-17	853	9	the	the	DET
bptjm-17	853	10	american	american	PROPN
bptjm-17	853	11	association	association	PROPN
bptjm-17	853	12	for	for	ADP
bptjm-17	853	13	cancer	cancer	NOUN
bptjm-17	853	14	research	research	NOUN
bptjm-17	853	15	,	,	PUNCT
bptjm-17	853	16	22(23	22(23	NOUN
bptjm-17	853	17	)	)	PUNCT
bptjm-17	853	18	,	,	PUNCT
bptjm-17	853	19	:	:	PUNCT
bptjm-17	853	20	5772–82	5772–82	NUM
bptjm-17	853	21	.	.	PUNCT
bptjm-17	854	1	https://doi.org/10.1158/1078-0432.ccr-16-1231	https://doi.org/10.1158/1078-0432.ccr-16-1231	X
bptjm-17	854	2	.	.	PUNCT
bptjm-17	854	3	85	85	NUM
bptjm-17	854	4	.	.	PUNCT
bptjm-17	855	1	tian	tian	PROPN
bptjm-17	855	2	f	f	PROPN
bptjm-17	855	3	,	,	PUNCT
bptjm-17	855	4	wang	wang	PROPN
bptjm-17	855	5	j	j	PROPN
bptjm-17	855	6	,	,	PUNCT
bptjm-17	855	7	ouyang	ouyang	PROPN
bptjm-17	855	8	t	t	PROPN
bptjm-17	855	9	,	,	PUNCT
bptjm-17	855	10	et	et	PROPN
bptjm-17	855	11	al	al	PROPN
bptjm-17	855	12	.	.	PROPN
bptjm-17	855	13	(	(	PUNCT
bptjm-17	855	14	2019	2019	NUM
bptjm-17	855	15	)	)	PUNCT
bptjm-17	855	16	.	.	PUNCT
bptjm-17	856	1	mir-486	mir-486	VERB
bptjm-17	856	2	-	-	PUNCT
bptjm-17	856	3	5p	5p	PROPN
bptjm-17	856	4	serves	serve	VERB
bptjm-17	856	5	as	as	ADP
bptjm-17	856	6	a	a	DET
bptjm-17	856	7	good	good	ADJ
bptjm-17	856	8	biomarker	biomarker	NOUN
bptjm-17	856	9	in	in	ADP
bptjm-17	856	10	non	non	ADJ
bptjm-17	856	11	small	small	ADJ
bptjm-17	856	12	cell	cell	NOUN
bptjm-17	856	13	lung	lung	NOUN
bptjm-17	856	14	cancer	cancer	NOUN
bptjm-17	856	15	and	and	CCONJ
bptjm-17	856	16	suppresses	suppress	VERB
bptjm-17	856	17	cell	cell	NOUN
bptjm-17	856	18	growth	growth	NOUN
bptjm-17	856	19	with	with	ADP
bptjm-17	856	20	the	the	DET
bptjm-17	856	21	involvement	involvement	NOUN
bptjm-17	856	22	of	of	ADP
bptjm-17	856	23	a	a	DET
bptjm-17	856	24	target	target	NOUN
bptjm-17	856	25	pik3r1	pik3r1	NOUN
bptjm-17	856	26	.	.	PUNCT
bptjm-17	857	1	front	front	ADJ
bptjm-17	857	2	genet	genet	PROPN
bptjm-17	857	3	.	.	PUNCT
bptjm-17	857	4	,	,	PUNCT
bptjm-17	857	5	10(688	10(688	NUM
bptjm-17	857	6	)	)	PUNCT
bptjm-17	857	7	.	.	PUNCT
bptjm-17	858	1	published	publish	VERB
bptjm-17	858	2	2019	2019	NUM
bptjm-17	858	3	jul	jul	PROPN
bptjm-17	858	4	26	26	NUM
bptjm-17	858	5	.	.	PUNCT
bptjm-17	859	1	doi:10.3389	doi:10.3389	PROPN
bptjm-17	859	2	/	/	SYM
bptjm-17	859	3	fgene.2019.00688	fgene.2019.00688	PROPN
bptjm-17	859	4	86	86	NUM
bptjm-17	859	5	.	.	PUNCT
bptjm-17	860	1	to	to	ADP
bptjm-17	860	2	,	,	PUNCT
bptjm-17	860	3	kenneth	kenneth	PROPN
bptjm-17	860	4	k.	k.	PROPN
bptjm-17	860	5	w.	w.	PROPN
bptjm-17	860	6	,	,	PUNCT
bptjm-17	860	7	william	william	PROPN
bptjm-17	860	8	k.	k.	PROPN
bptjm-17	860	9	k.	k.	PROPN
bptjm-17	860	10	wu	wu	PROPN
bptjm-17	860	11	,	,	PUNCT
bptjm-17	860	12	and	and	CCONJ
bptjm-17	860	13	herbert	herbert	PROPN
bptjm-17	860	14	h.	h.	PROPN
bptjm-17	860	15	f.	f.	PROPN
bptjm-17	860	16	loong	loong	PROPN
bptjm-17	860	17	.	.	PUNCT
bptjm-17	861	1	(	(	PUNCT
bptjm-17	861	2	march	march	PROPN
bptjm-17	861	3	15	15	NUM
bptjm-17	861	4	,	,	PUNCT
bptjm-17	861	5	2018	2018	NUM
bptjm-17	861	6	)	)	PUNCT
bptjm-17	861	7	.	.	PUNCT
bptjm-17	862	1	ppargamma	ppargamma	PROPN
bptjm-17	862	2	agonists	agonist	NOUN
bptjm-17	862	3	sensitize	sensitize	VERB
bptjm-17	862	4	pten	pten	NOUN
bptjm-17	862	5	-	-	PUNCT
bptjm-17	862	6	de	de	X
bptjm-17	862	7	�	�	NOUN
bptjm-17	862	8	cient	cient	NOUN
bptjm-17	862	9	resistant	resistant	ADJ
bptjm-17	862	10	lung	lung	NOUN
bptjm-17	862	11	cancer	cancer	NOUN
bptjm-17	862	12	cells	cell	NOUN
bptjm-17	862	13	to	to	PART
bptjm-17	862	14	egfr	egfr	VERB
bptjm-17	862	15	tyrosine	tyrosine	PROPN
bptjm-17	862	16	kinase	kinase	PROPN
bptjm-17	862	17	inhibitors	inhibitor	NOUN
bptjm-17	862	18	by	by	ADP
bptjm-17	862	19	inducing	induce	VERB
bptjm-17	862	20	autophagy	autophagy	NOUN
bptjm-17	862	21	.	.	PUNCT
bptjm-17	863	1	european	european	ADJ
bptjm-17	863	2	journal	journal	PROPN
bptjm-17	863	3	of	of	ADP
bptjm-17	863	4	pharmacology	pharmacology	NOUN
bptjm-17	863	5	,	,	PUNCT
bptjm-17	863	6	823	823	NUM
bptjm-17	863	7	,	,	PUNCT
bptjm-17	863	8	19–26	19–26	NUM
bptjm-17	863	9	.	.	PUNCT
bptjm-17	864	1	https://doi.org/10.1016/j.ejphar.2018.01.036	https://doi.org/10.1016/j.ejphar.2018.01.036	PROPN
bptjm-17	864	2	.	.	PROPN
bptjm-17	865	1	87	87	NUM
bptjm-17	865	2	.	.	PUNCT
bptjm-17	866	1	veldore	veldore	PROPN
bptjm-17	866	2	,	,	PUNCT
bptjm-17	866	3	vidya	vidya	PROPN
bptjm-17	866	4	h	h	PROPN
bptjm-17	866	5	,	,	PUNCT
bptjm-17	866	6	anuradha	anuradha	PROPN
bptjm-17	866	7	choughule	choughule	NOUN
bptjm-17	866	8	,	,	PUNCT
bptjm-17	866	9	tejaswi	tejaswi	PROPN
bptjm-17	866	10	routhu	routhu	PROPN
bptjm-17	866	11	,	,	PUNCT
bptjm-17	866	12	nitin	nitin	PROPN
bptjm-17	866	13	mandloi	mandloi	PROPN
bptjm-17	866	14	,	,	PUNCT
bptjm-17	866	15	vanita	vanita	PROPN
bptjm-17	866	16	noronha	noronha	NOUN
bptjm-17	866	17	,	,	PUNCT
bptjm-17	866	18	amit	amit	PROPN
bptjm-17	866	19	joshi	joshi	PROPN
bptjm-17	866	20	,	,	PUNCT
bptjm-17	866	21	amit	amit	PROPN
bptjm-17	866	22	dutt	dutt	PROPN
bptjm-17	866	23	,	,	PUNCT
bptjm-17	866	24	ravi	ravi	NOUN
bptjm-17	866	25	gupta	gupta	PROPN
bptjm-17	866	26	,	,	PUNCT
bptjm-17	866	27	ramprasad	ramprasad	ADJ
bptjm-17	866	28	vedam	vedam	NOUN
bptjm-17	866	29	,	,	PUNCT
bptjm-17	866	30	and	and	CCONJ
bptjm-17	866	31	kumar	kumar	PROPN
bptjm-17	866	32	prabhash	prabhash	PROPN
bptjm-17	866	33	.	.	PUNCT
bptjm-17	867	1	(	(	PUNCT
bptjm-17	867	2	january	january	PROPN
bptjm-17	867	3	3	3	NUM
bptjm-17	867	4	,	,	PUNCT
bptjm-17	867	5	2018	2018	NUM
bptjm-17	867	6	)	)	PUNCT
bptjm-17	867	7	.	.	PUNCT
bptjm-17	868	1	validation	validation	NOUN
bptjm-17	868	2	of	of	ADP
bptjm-17	868	3	liquid	liquid	ADJ
bptjm-17	868	4	biopsy	biopsy	NOUN
bptjm-17	868	5	:	:	PUNCT
bptjm-17	868	6	plasma	plasma	NOUN
bptjm-17	868	7	cell	cell	NOUN
bptjm-17	868	8	-	-	PUNCT
bptjm-17	868	9	free	free	ADJ
bptjm-17	868	10	dna	dna	NOUN
bptjm-17	868	11	testing	testing	NOUN
bptjm-17	868	12	in	in	ADP
bptjm-17	868	13	clinical	clinical	ADJ
bptjm-17	868	14	management	management	NOUN
bptjm-17	868	15	of	of	ADP
bptjm-17	868	16	advanced	advanced	ADJ
bptjm-17	868	17	non	non	ADJ
bptjm-17	868	18	-	-	ADJ
bptjm-17	868	19	small	small	ADJ
bptjm-17	868	20	cell	cell	NOUN
bptjm-17	868	21	lung	lung	NOUN
bptjm-17	868	22	cancer	cancer	NOUN
bptjm-17	868	23	.	.	PUNCT
bptjm-17	869	1	lung	lung	NOUN
bptjm-17	869	2	cancer	cancer	NOUN
bptjm-17	869	3	:	:	PUNCT
bptjm-17	869	4	targets	target	NOUN
bptjm-17	869	5	and	and	CCONJ
bptjm-17	869	6	therapy	therapy	NOUN
bptjm-17	869	7	,	,	PUNCT
bptjm-17	869	8	9	9	NUM
bptjm-17	869	9	,	,	PUNCT
bptjm-17	869	10	1–11	1–11	PROPN
bptjm-17	869	11	.	.	PUNCT
bptjm-17	870	1	https://doi.org/10.2147/lctt.s147841	https://doi.org/10.2147/lctt.s147841	PROPN
bptjm-17	870	2	.	.	PUNCT
bptjm-17	871	1	88	88	NUM
bptjm-17	871	2	.	.	PUNCT
bptjm-17	872	1	vincent	vincent	PROPN
bptjm-17	872	2	,	,	PUNCT
bptjm-17	872	3	m.	m.	PROPN
bptjm-17	872	4	d.	d.	PROPN
bptjm-17	872	5	,	,	PUNCT
bptjm-17	872	6	kuruvilla	kuruvilla	PROPN
bptjm-17	872	7	,	,	PUNCT
bptjm-17	872	8	m.	m.	NOUN
bptjm-17	872	9	s.	s.	PROPN
bptjm-17	872	10	,	,	PUNCT
bptjm-17	872	11	leighl	leighl	NOUN
bptjm-17	872	12	,	,	PUNCT
bptjm-17	872	13	n.	n.	PROPN
bptjm-17	872	14	b.	b.	PROPN
bptjm-17	872	15	,	,	PUNCT
bptjm-17	872	16	&	&	CCONJ
bptjm-17	872	17	kamel	kamel	PROPN
bptjm-17	872	18	-	-	PUNCT
bptjm-17	872	19	reid	reid	PROPN
bptjm-17	872	20	,	,	PUNCT
bptjm-17	872	21	s.	s.	PROPN
bptjm-17	872	22	(	(	PUNCT
bptjm-17	872	23	2012	2012	NUM
bptjm-17	872	24	)	)	PUNCT
bptjm-17	872	25	.	.	PUNCT
bptjm-17	873	1	biomarkers	biomarker	NOUN
bptjm-17	873	2	that	that	SCONJ
bptjm-17	873	3	currently	currently	ADV
bptjm-17	873	4	a	a	DET
bptjm-17	873	5	�	�	NOUN
bptjm-17	873	6	ect	ect	VERB
bptjm-17	873	7	clinical	clinical	ADJ
bptjm-17	873	8	practice	practice	NOUN
bptjm-17	873	9	:	:	PUNCT
bptjm-17	873	10	egfr	egfr	X
bptjm-17	873	11	,	,	PUNCT
bptjm-17	873	12	alk	alk	PROPN
bptjm-17	873	13	,	,	PUNCT
bptjm-17	873	14	met	meet	VERB
bptjm-17	873	15	,	,	PUNCT
bptjm-17	873	16	kras	kras	PROPN
bptjm-17	873	17	.	.	PUNCT
bptjm-17	874	1	current	current	ADJ
bptjm-17	874	2	oncology	oncology	NOUN
bptjm-17	874	3	(	(	PUNCT
bptjm-17	874	4	toronto	toronto	PROPN
bptjm-17	874	5	,	,	PUNCT
bptjm-17	874	6	ont	ont	PROPN
bptjm-17	874	7	.	.	PUNCT
bptjm-17	874	8	)	)	PUNCT
bptjm-17	874	9	,	,	PUNCT
bptjm-17	874	10	19(suppl	19(suppl	NUM
bptjm-17	874	11	1	1	NUM
bptjm-17	874	12	)	)	PUNCT
bptjm-17	874	13	,	,	PUNCT
bptjm-17	874	14	s33	s33	NOUN
bptjm-17	874	15	–	–	PUNCT
bptjm-17	874	16	s44	s44	ADJ
bptjm-17	874	17	.	.	PUNCT
bptjm-17	875	1	https://doi.org/10.3747/co.19.1149	https://doi.org/10.3747/co.19.1149	X
bptjm-17	876	1	89	89	NUM
bptjm-17	876	2	.	.	PUNCT
bptjm-17	877	1	wang	wang	PROPN
bptjm-17	877	2	,	,	PUNCT
bptjm-17	877	3	l.	l.	PROPN
bptjm-17	877	4	,	,	PUNCT
bptjm-17	877	5	hu	hu	PROPN
bptjm-17	877	6	,	,	PUNCT
bptjm-17	877	7	y.	y.	PROPN
bptjm-17	877	8	,	,	PUNCT
bptjm-17	877	9	wang	wang	PROPN
bptjm-17	877	10	,	,	PUNCT
bptjm-17	877	11	s.	s.	PROPN
bptjm-17	877	12	,	,	PUNCT
bptjm-17	877	13	shen	shen	PROPN
bptjm-17	877	14	,	,	PUNCT
bptjm-17	877	15	j.	j.	PROPN
bptjm-17	877	16	,	,	PUNCT
bptjm-17	877	17	&	&	CCONJ
bptjm-17	877	18	wang	wang	PROPN
bptjm-17	877	19	,	,	PUNCT
bptjm-17	877	20	x.	x.	NOUN
bptjm-17	877	21	(	(	PUNCT
bptjm-17	877	22	2020	2020	NUM
bptjm-17	877	23	)	)	PUNCT
bptjm-17	877	24	.	.	PUNCT
bptjm-17	878	1	biomarkers	biomarker	NOUN
bptjm-17	878	2	of	of	ADP
bptjm-17	878	3	immunotherapy	immunotherapy	NOUN
bptjm-17	878	4	in	in	ADP
bptjm-17	878	5	non	non	ADJ
bptjm-17	878	6	-	-	ADJ
bptjm-17	878	7	small	small	ADJ
bptjm-17	878	8	cell	cell	NOUN
bptjm-17	878	9	lung	lung	NOUN
bptjm-17	878	10	cancer	cancer	NOUN
bptjm-17	878	11	.	.	PUNCT
bptjm-17	879	1	oncology	oncology	NOUN
bptjm-17	879	2	letters	letter	NOUN
bptjm-17	879	3	,	,	PUNCT
bptjm-17	879	4	20(5	20(5	NUM
bptjm-17	879	5	)	)	PUNCT
bptjm-17	879	6	,	,	PUNCT
bptjm-17	879	7	139	139	NUM
bptjm-17	879	8	.	.	PUNCT
bptjm-17	880	1	https://doi.org/10.3892/ol	https://doi.org/10.3892/ol	NOUN
bptjm-17	880	2	.	.	PUNCT
bptjm-17	881	1	2020.11999	2020.11999	NUM
bptjm-17	881	2	90	90	NUM
bptjm-17	881	3	.	.	PUNCT
bptjm-17	882	1	wang	wang	PROPN
bptjm-17	882	2	,	,	PUNCT
bptjm-17	882	3	h.	h.	PROPN
bptjm-17	882	4	,	,	PUNCT
bptjm-17	882	5	peng	peng	PROPN
bptjm-17	882	6	,	,	PUNCT
bptjm-17	882	7	r.	r.	PROPN
bptjm-17	882	8	,	,	PUNCT
bptjm-17	882	9	wang	wang	PROPN
bptjm-17	882	10	,	,	PUNCT
bptjm-17	882	11	j.	j.	PROPN
bptjm-17	882	12	,	,	PUNCT
bptjm-17	882	13	qin	qin	PROPN
bptjm-17	882	14	,	,	PUNCT
bptjm-17	882	15	z.	z.	PROPN
bptjm-17	882	16	,	,	PUNCT
bptjm-17	882	17	&	&	CCONJ
bptjm-17	882	18	xue	xue	PROPN
bptjm-17	882	19	,	,	PUNCT
bptjm-17	882	20	l.	l.	PROPN
bptjm-17	882	21	(	(	PUNCT
bptjm-17	882	22	2018	2018	NUM
bptjm-17	882	23	)	)	PUNCT
bptjm-17	882	24	.	.	PUNCT
bptjm-17	883	1	circulating	circulate	VERB
bptjm-17	883	2	micrornas	microrna	NOUN
bptjm-17	883	3	as	as	ADP
bptjm-17	883	4	potential	potential	ADJ
bptjm-17	883	5	cancer	cancer	NOUN
bptjm-17	883	6	biomarkers	biomarker	NOUN
bptjm-17	883	7	:	:	PUNCT
bptjm-17	883	8	the	the	DET
bptjm-17	883	9	advantage	advantage	NOUN
bptjm-17	883	10	and	and	CCONJ
bptjm-17	883	11	disadvantage	disadvantage	NOUN
bptjm-17	883	12	.	.	PUNCT
bptjm-17	884	1	clinical	clinical	ADJ
bptjm-17	884	2	berkeley	berkeley	PROPN
bptjm-17	884	3	pharma	pharma	PROPN
bptjm-17	884	4	tech	tech	NOUN
bptjm-17	884	5	journal	journal	NOUN
bptjm-17	884	6	of	of	ADP
bptjm-17	884	7	medicine	medicine	NOUN
bptjm-17	884	8	|	|	ADV
bptjm-17	884	9	153	153	NUM
bptjm-17	884	10	epigenetics	epigenetic	NOUN
bptjm-17	884	11	,	,	PUNCT
bptjm-17	884	12	10	10	NUM
bptjm-17	884	13	,	,	PUNCT
bptjm-17	884	14	59	59	NUM
bptjm-17	884	15	.	.	PUNCT
bptjm-17	885	1	https://doi.org/10.1186/s13148-018-0492-1	https://doi.org/10.1186/s13148-018-0492-1	PROPN
bptjm-17	885	2	91	91	NUM
bptjm-17	885	3	.	.	PUNCT
bptjm-17	886	1	wang	wang	PROPN
bptjm-17	886	2	,	,	PUNCT
bptjm-17	886	3	j.	j.	PROPN
bptjm-17	886	4	,	,	PUNCT
bptjm-17	886	5	tian	tian	PROPN
bptjm-17	886	6	,	,	PUNCT
bptjm-17	886	7	x.	x.	PROPN
bptjm-17	886	8	,	,	PUNCT
bptjm-17	886	9	han	han	PROPN
bptjm-17	886	10	,	,	PUNCT
bptjm-17	886	11	r.	r.	PROPN
bptjm-17	886	12	et	et	PROPN
bptjm-17	886	13	al	al	PROPN
bptjm-17	886	14	.	.	PROPN
bptjm-17	886	15	(	(	PUNCT
bptjm-17	886	16	2014	2014	NUM
bptjm-17	886	17	)	)	PUNCT
bptjm-17	886	18	.	.	PUNCT
bptjm-17	887	1	downregulation	downregulation	NOUN
bptjm-17	887	2	of	of	ADP
bptjm-17	887	3	mir-486	mir-486	ADJ
bptjm-17	887	4	-	-	PUNCT
bptjm-17	887	5	5p	5p	NUM
bptjm-17	887	6	contributes	contribute	VERB
bptjm-17	887	7	to	to	ADP
bptjm-17	887	8	tumor	tumor	NOUN
bptjm-17	887	9	progression	progression	NOUN
bptjm-17	887	10	and	and	CCONJ
bptjm-17	887	11	metastasis	metastasis	NOUN
bptjm-17	887	12	by	by	ADP
bptjm-17	887	13	targeting	target	VERB
bptjm-17	887	14	protumorigenic	protumorigenic	NOUN
bptjm-17	887	15	arhgap5	arhgap5	VERB
bptjm-17	887	16	in	in	ADP
bptjm-17	887	17	lung	lung	NOUN
bptjm-17	887	18	cancer	cancer	NOUN
bptjm-17	887	19	.	.	PUNCT
bptjm-17	888	1	oncogene	oncogene	NOUN
bptjm-17	888	2	,	,	PUNCT
bptjm-17	888	3	33	33	NUM
bptjm-17	888	4	,	,	PUNCT
bptjm-17	888	5	1181–1189	1181–1189	NUM
bptjm-17	888	6	.	.	PUNCT
bptjm-17	889	1	https://doi.org/10.1038/onc.2013.42	https://doi.org/10.1038/onc.2013.42	NOUN
bptjm-17	889	2	92	92	NUM
bptjm-17	889	3	.	.	PUNCT
bptjm-17	890	1	wang	wang	PROPN
bptjm-17	890	2	y	y	PROPN
bptjm-17	890	3	,	,	PUNCT
bptjm-17	890	4	zeng	zeng	PROPN
bptjm-17	890	5	g	g	PROPN
bptjm-17	890	6	,	,	PUNCT
bptjm-17	890	7	jiang	jiang	PROPN
bptjm-17	890	8	y.	y.	PROPN
bptjm-17	890	9	(	(	PUNCT
bptjm-17	890	10	2020	2020	NUM
bptjm-17	890	11	)	)	PUNCT
bptjm-17	890	12	.	.	PUNCT
bptjm-17	891	1	the	the	DET
bptjm-17	891	2	emerging	emerge	VERB
bptjm-17	891	3	roles	role	NOUN
bptjm-17	891	4	of	of	ADP
bptjm-17	891	5	mir-125b	mir-125b	NOUN
bptjm-17	891	6	in	in	ADP
bptjm-17	891	7	cancers	cancer	NOUN
bptjm-17	891	8	.	.	PUNCT
bptjm-17	892	1	cancer	cancer	NOUN
bptjm-17	892	2	manag	manag	PROPN
bptjm-17	892	3	res	re	NOUN
bptjm-17	892	4	.	.	PROPN
bptjm-17	892	5	,	,	PUNCT
bptjm-17	892	6	12	12	NUM
bptjm-17	892	7	,	,	PUNCT
bptjm-17	892	8	1079	1079	NUM
bptjm-17	892	9	-	-	SYM
bptjm-17	892	10	1088	1088	NUM
bptjm-17	892	11	.	.	PUNCT
bptjm-17	893	1	published	publish	VERB
bptjm-17	893	2	2020	2020	NUM
bptjm-17	893	3	feb	feb	PROPN
bptjm-17	893	4	12	12	NUM
bptjm-17	893	5	.	.	PUNCT
bptjm-17	894	1	doi:10.2147	doi:10.2147	NOUN
bptjm-17	894	2	/	/	SYM
bptjm-17	894	3	cmar.s232388	cmar.s232388	X
bptjm-17	894	4	93	93	NUM
bptjm-17	894	5	.	.	PUNCT
bptjm-17	895	1	wang	wang	PROPN
bptjm-17	895	2	,	,	PUNCT
bptjm-17	895	3	y.	y.	PROPN
bptjm-17	895	4	,	,	PUNCT
bptjm-17	895	5	wang	wang	PROPN
bptjm-17	895	6	,	,	PUNCT
bptjm-17	895	7	y.	y.	PROPN
bptjm-17	895	8	,	,	PUNCT
bptjm-17	895	9	li	li	PROPN
bptjm-17	895	10	,	,	PUNCT
bptjm-17	895	11	j.	j.	PROPN
bptjm-17	895	12	,	,	PUNCT
bptjm-17	895	13	li	li	PROPN
bptjm-17	895	14	,	,	PUNCT
bptjm-17	895	15	j.	j.	PROPN
bptjm-17	895	16	,	,	PUNCT
bptjm-17	895	17	&	&	CCONJ
bptjm-17	895	18	che	che	PROPN
bptjm-17	895	19	,	,	PUNCT
bptjm-17	895	20	g.	g.	PROPN
bptjm-17	895	21	(	(	PUNCT
bptjm-17	895	22	2020	2020	NUM
bptjm-17	895	23	)	)	PUNCT
bptjm-17	895	24	.	.	PUNCT
bptjm-17	896	1	clinical	clinical	ADJ
bptjm-17	896	2	signi	signi	PROPN
bptjm-17	896	3	�	�	PROPN
bptjm-17	896	4	cance	cance	NOUN
bptjm-17	896	5	of	of	ADP
bptjm-17	896	6	pik3ca	pik3ca	PROPN
bptjm-17	896	7	gene	gene	NOUN
bptjm-17	896	8	in	in	ADP
bptjm-17	896	9	non	non	ADJ
bptjm-17	896	10	-	-	ADJ
bptjm-17	896	11	small	small	ADJ
bptjm-17	896	12	-	-	PUNCT
bptjm-17	896	13	cell	cell	NOUN
bptjm-17	896	14	lung	lung	NOUN
bptjm-17	896	15	cancer	cancer	NOUN
bptjm-17	896	16	:	:	PUNCT
bptjm-17	896	17	a	a	DET
bptjm-17	896	18	systematic	systematic	ADJ
bptjm-17	896	19	review	review	NOUN
bptjm-17	896	20	and	and	CCONJ
bptjm-17	896	21	meta	meta	ADJ
bptjm-17	896	22	-	-	PUNCT
bptjm-17	896	23	analysis	analysis	NOUN
bptjm-17	896	24	.	.	PUNCT
bptjm-17	896	25	biomed	biome	VERB
bptjm-17	896	26	research	research	NOUN
bptjm-17	896	27	international	international	PROPN
bptjm-17	896	28	,	,	PUNCT
bptjm-17	896	29	2020	2020	NUM
bptjm-17	896	30	,	,	PUNCT
bptjm-17	896	31	3608241	3608241	NUM
bptjm-17	896	32	.	.	PUNCT
bptjm-17	897	1	https://doi.org/10.1155/2020/3608241	https://doi.org/10.1155/2020/3608241	VERB
bptjm-17	897	2	94	94	NUM
bptjm-17	897	3	.	.	PUNCT
bptjm-17	898	1	wang	wang	PROPN
bptjm-17	898	2	zx	zx	PROPN
bptjm-17	898	3	,	,	PUNCT
bptjm-17	898	4	bian	bian	PROPN
bptjm-17	898	5	hb	hb	PROPN
bptjm-17	898	6	,	,	PUNCT
bptjm-17	898	7	wang	wang	PROPN
bptjm-17	898	8	jr	jr	PROPN
bptjm-17	898	9	,	,	PUNCT
bptjm-17	898	10	cheng	cheng	PROPN
bptjm-17	898	11	zx	zx	PROPN
bptjm-17	898	12	,	,	PUNCT
bptjm-17	898	13	wang	wang	PROPN
bptjm-17	898	14	km	km	PROPN
bptjm-17	898	15	,	,	PUNCT
bptjm-17	898	16	de	de	PROPN
bptjm-17	898	17	w.	w.	PROPN
bptjm-17	898	18	(	(	PUNCT
bptjm-17	898	19	december	december	PROPN
bptjm-17	898	20	2011	2011	NUM
bptjm-17	898	21	)	)	PUNCT
bptjm-17	898	22	.	.	PUNCT
bptjm-17	899	1	prognostic	prognostic	ADJ
bptjm-17	899	2	signi	signi	PROPN
bptjm-17	899	3	�	�	PROPN
bptjm-17	899	4	cance	cance	NOUN
bptjm-17	899	5	of	of	ADP
bptjm-17	899	6	serum	serum	NOUN
bptjm-17	899	7	mirna-21	mirna-21	ADJ
bptjm-17	899	8	expression	expression	NOUN
bptjm-17	899	9	in	in	ADP
bptjm-17	899	10	human	human	ADJ
bptjm-17	899	11	non	non	ADJ
bptjm-17	899	12	-	-	ADJ
bptjm-17	899	13	small	small	ADJ
bptjm-17	899	14	cell	cell	NOUN
bptjm-17	899	15	lung	lung	NOUN
bptjm-17	899	16	cancer	cancer	NOUN
bptjm-17	899	17	.	.	PUNCT
bptjm-17	900	1	j	j	PROPN
bptjm-17	900	2	surg	surg	PROPN
bptjm-17	900	3	oncol	oncol	PROPN
bptjm-17	900	4	.	.	PUNCT
bptjm-17	900	5	,	,	PUNCT
bptjm-17	900	6	104(7):847	104(7):847	NUM
bptjm-17	900	7	-	-	SYM
bptjm-17	900	8	51	51	NUM
bptjm-17	900	9	.	.	PUNCT
bptjm-17	901	1	doi	doi	NOUN
bptjm-17	901	2	:	:	PUNCT
bptjm-17	901	3	10.1002	10.1002	NUM
bptjm-17	901	4	/	/	SYM
bptjm-17	901	5	jso.22008	jso.22008	NOUN
bptjm-17	901	6	.	.	PUNCT
bptjm-17	902	1	epub	epub	PROPN
bptjm-17	902	2	2011	2011	NUM
bptjm-17	902	3	jun	jun	PROPN
bptjm-17	902	4	30	30	NUM
bptjm-17	902	5	.	.	PUNCT
bptjm-17	903	1	pmid	pmid	NOUN
bptjm-17	903	2	:	:	PUNCT
bptjm-17	903	3	2172101	2172101	NUM
bptjm-17	903	4	95	95	NUM
bptjm-17	903	5	.	.	PUNCT
bptjm-17	904	1	wang	wang	PROPN
bptjm-17	904	2	,	,	PUNCT
bptjm-17	904	3	yanye	yanye	PROPN
bptjm-17	904	4	et	et	PROPN
bptjm-17	904	5	al	al	PROPN
bptjm-17	904	6	.	.	PROPN
bptjm-17	904	7	(	(	PUNCT
bptjm-17	904	8	2020	2020	NUM
bptjm-17	904	9	)	)	PUNCT
bptjm-17	904	10	.	.	PUNCT
bptjm-17	905	1	clinical	clinical	ADJ
bptjm-17	905	2	and	and	CCONJ
bptjm-17	905	3	molecular	molecular	ADJ
bptjm-17	905	4	characteristics	characteristic	NOUN
bptjm-17	905	5	of	of	ADP
bptjm-17	905	6	tsc1/2	tsc1/2	PROPN
bptjm-17	905	7	mutant	mutant	ADJ
bptjm-17	905	8	lung	lung	NOUN
bptjm-17	905	9	cancer	cancer	NOUN
bptjm-17	905	10	.	.	PUNCT
bptjm-17	906	1	journal	journal	NOUN
bptjm-17	906	2	of	of	ADP
bptjm-17	906	3	clinical	clinical	ADJ
bptjm-17	906	4	oncology	oncology	NOUN
bptjm-17	906	5	,	,	PUNCT
bptjm-17	906	6	38(15	38(15	NUM
bptjm-17	906	7	)	)	PUNCT
bptjm-17	906	8	.	.	PUNCT
bptjm-17	907	1	doi:10.1200	doi:10.1200	PROPN
bptjm-17	907	2	/	/	SYM
bptjm-17	907	3	jco.2020.38.15_suppl.e21647	jco.2020.38.15_suppl.e21647	PROPN
bptjm-17	907	4	.	.	PROPN
bptjm-17	908	1	96	96	NUM
bptjm-17	908	2	.	.	PUNCT
bptjm-17	909	1	wachters	wachter	NOUN
bptjm-17	909	2	,	,	PUNCT
bptjm-17	909	3	f.	f.	PROPN
bptjm-17	909	4	m.	m.	PROPN
bptjm-17	909	5	,	,	PUNCT
bptjm-17	909	6	l.	l.	PROPN
bptjm-17	909	7	s.	s.	PROPN
bptjm-17	909	8	m.	m.	PROPN
bptjm-17	909	9	wong	wong	PROPN
bptjm-17	909	10	,	,	PUNCT
bptjm-17	909	11	w.	w.	PROPN
bptjm-17	909	12	timens	timens	PROPN
bptjm-17	909	13	,	,	PUNCT
bptjm-17	909	14	h.	h.	PROPN
bptjm-17	909	15	h.	h.	PROPN
bptjm-17	909	16	kampinga	kampinga	PROPN
bptjm-17	909	17	,	,	PUNCT
bptjm-17	909	18	and	and	CCONJ
bptjm-17	909	19	h.	h.	PROPN
bptjm-17	909	20	j.	j.	PROPN
bptjm-17	909	21	m.	m.	PROPN
bptjm-17	909	22	groen	groen	PROPN
bptjm-17	909	23	.	.	PUNCT
bptjm-17	910	1	(	(	PUNCT
bptjm-17	910	2	november	november	PROPN
bptjm-17	910	3	2005	2005	NUM
bptjm-17	910	4	)	)	PUNCT
bptjm-17	910	5	.	.	PUNCT
bptjm-17	911	1	ercc1	ercc1	PROPN
bptjm-17	911	2	,	,	PUNCT
bptjm-17	911	3	hrad51	hrad51	NOUN
bptjm-17	911	4	,	,	PUNCT
bptjm-17	911	5	and	and	CCONJ
bptjm-17	911	6	brca1	brca1	NOUN
bptjm-17	911	7	protein	protein	NOUN
bptjm-17	911	8	expression	expression	NOUN
bptjm-17	911	9	in	in	ADP
bptjm-17	911	10	relation	relation	NOUN
bptjm-17	911	11	to	to	ADP
bptjm-17	911	12	tumour	tumour	NOUN
bptjm-17	911	13	response	response	NOUN
bptjm-17	911	14	and	and	CCONJ
bptjm-17	911	15	survival	survival	NOUN
bptjm-17	911	16	of	of	ADP
bptjm-17	911	17	stage	stage	NOUN
bptjm-17	911	18	iii	iii	SYM
bptjm-17	911	19	/	/	SYM
bptjm-17	911	20	iv	iv	NUM
bptjm-17	911	21	nsclc	nsclc	NOUN
bptjm-17	911	22	patients	patient	NOUN
bptjm-17	911	23	treated	treat	VERB
bptjm-17	911	24	with	with	ADP
bptjm-17	911	25	chemotherapy	chemotherapy	NOUN
bptjm-17	911	26	.	.	PUNCT
bptjm-17	912	1	lung	lung	NOUN
bptjm-17	912	2	cancer	cancer	NOUN
bptjm-17	912	3	(	(	PUNCT
bptjm-17	912	4	amsterdam	amsterdam	PROPN
bptjm-17	912	5	,	,	PUNCT
bptjm-17	912	6	netherlands	netherlands	PROPN
bptjm-17	912	7	)	)	PUNCT
bptjm-17	912	8	50(2	50(2	NUM
bptjm-17	912	9	)	)	PUNCT
bptjm-17	912	10	,	,	PUNCT
bptjm-17	912	11	211–19	211–19	NUM
bptjm-17	912	12	.	.	PUNCT
bptjm-17	913	1	https://doi.org/10.1016/	https://doi.org/10.1016/	PROPN
bptjm-17	913	2	j.lungcan.2005.06.013	j.lungcan.2005.06.013	PROPN
bptjm-17	913	3	.	.	PROPN
bptjm-17	914	1	97	97	NUM
bptjm-17	914	2	.	.	PUNCT
bptjm-17	915	1	waters	water	NOUN
bptjm-17	915	2	,	,	PUNCT
bptjm-17	915	3	d.	d.	PROPN
bptjm-17	915	4	l.	l.	PROPN
bptjm-17	915	5	,	,	PUNCT
bptjm-17	915	6	&	&	CCONJ
bptjm-17	915	7	shapter	shapter	PROPN
bptjm-17	915	8	,	,	PUNCT
bptjm-17	915	9	f.	f.	PROPN
bptjm-17	915	10	m.	m.	PROPN
bptjm-17	915	11	(	(	PUNCT
bptjm-17	915	12	2014	2014	NUM
bptjm-17	915	13	)	)	PUNCT
bptjm-17	915	14	.	.	PUNCT
bptjm-17	916	1	the	the	DET
bptjm-17	916	2	polymerase	polymerase	NOUN
bptjm-17	916	3	chain	chain	NOUN
bptjm-17	916	4	reaction	reaction	NOUN
bptjm-17	916	5	(	(	PUNCT
bptjm-17	916	6	pcr	pcr	PROPN
bptjm-17	916	7	):	):	PUNCT
bptjm-17	916	8	general	general	ADJ
bptjm-17	916	9	methods	method	NOUN
bptjm-17	916	10	.	.	PUNCT
bptjm-17	917	1	methods	method	NOUN
bptjm-17	917	2	in	in	ADP
bptjm-17	917	3	molecular	molecular	ADJ
bptjm-17	917	4	biology	biology	NOUN
bptjm-17	917	5	(	(	PUNCT
bptjm-17	917	6	clifton	clifton	PROPN
bptjm-17	917	7	,	,	PUNCT
bptjm-17	917	8	n.j	n.j	PROPN
bptjm-17	917	9	.	.	PROPN
bptjm-17	917	10	)	)	PUNCT
bptjm-17	917	11	,	,	PUNCT
bptjm-17	917	12	1099	1099	NUM
bptjm-17	917	13	,	,	PUNCT
bptjm-17	917	14	65–75	65–75	NUM
bptjm-17	917	15	.	.	PUNCT
bptjm-17	917	16	https://doi.org/	https://doi.org/	VERB
bptjm-17	917	17	10.1007/978	10.1007/978	NUM
bptjm-17	917	18	-	-	SYM
bptjm-17	917	19	1	1	NUM
bptjm-17	917	20	-	-	PUNCT
bptjm-17	917	21	62703	62703	NUM
bptjm-17	917	22	-	-	PUNCT
bptjm-17	917	23	715	715	NUM
bptjm-17	917	24	-	-	PUNCT
bptjm-17	917	25	0_7	0_7	NUM
bptjm-17	917	26	wei	wei	PROPN
bptjm-17	917	27	j	j	PROPN
bptjm-17	917	28	,	,	PUNCT
bptjm-17	917	29	gao	gao	PROPN
bptjm-17	917	30	w	w	PROPN
bptjm-17	917	31	,	,	PUNCT
bptjm-17	917	32	zhu	zhu	PROPN
bptjm-17	917	33	cj	cj	PROPN
bptjm-17	917	34	,	,	PUNCT
bptjm-17	917	35	liu	liu	PROPN
bptjm-17	917	36	yq	yq	PROPN
bptjm-17	917	37	,	,	PUNCT
bptjm-17	917	38	mei	mei	PROPN
bptjm-17	917	39	z	z	PROPN
bptjm-17	917	40	,	,	PUNCT
bptjm-17	917	41	cheng	cheng	PROPN
bptjm-17	917	42	t	t	PROPN
bptjm-17	917	43	,	,	PUNCT
bptjm-17	917	44	shu	shu	PROPN
bptjm-17	917	45	yq	yq	PROPN
bptjm-17	917	46	.	.	PUNCT
bptjm-17	918	1	(	(	PUNCT
bptjm-17	918	2	june	june	PROPN
bptjm-17	918	3	2011	2011	NUM
bptjm-17	918	4	)	)	PUNCT
bptjm-17	918	5	.	.	PUNCT
bptjm-17	919	1	identi	identi	PROPN
bptjm-17	919	2	�	�	PROPN
bptjm-17	919	3	cation	cation	NOUN
bptjm-17	919	4	of	of	ADP
bptjm-17	919	5	plasma	plasma	NOUN
bptjm-17	919	6	microrna-21	microrna-21	PROPN
bptjm-17	919	7	as	as	ADP
bptjm-17	919	8	a	a	DET
bptjm-17	919	9	biomarker	biomarker	NOUN
bptjm-17	919	10	for	for	ADP
bptjm-17	919	11	early	early	ADJ
bptjm-17	919	12	detection	detection	NOUN
bptjm-17	919	13	and	and	CCONJ
bptjm-17	919	14	chemosensitivity	chemosensitivity	NOUN
bptjm-17	919	15	of	of	ADP
bptjm-17	919	16	non	non	ADJ
bptjm-17	919	17	-	-	ADJ
bptjm-17	919	18	small	small	ADJ
bptjm-17	919	19	cell	cell	NOUN
bptjm-17	919	20	lung	lung	NOUN
bptjm-17	919	21	cancer	cancer	NOUN
bptjm-17	919	22	.	.	PUNCT
bptjm-17	920	1	chin	chin	PROPN
bptjm-17	920	2	j	j	PROPN
bptjm-17	920	3	cancer	cancer	PROPN
bptjm-17	920	4	,	,	PUNCT
bptjm-17	920	5	30(6	30(6	NUM
bptjm-17	920	6	)	)	PUNCT
bptjm-17	920	7	,	,	PUNCT
bptjm-17	920	8	407	407	NUM
bptjm-17	920	9	-	-	SYM
bptjm-17	920	10	14	14	NUM
bptjm-17	920	11	.	.	PUNCT
bptjm-17	921	1	doi	doi	NOUN
bptjm-17	921	2	:	:	PUNCT
bptjm-17	921	3	10.5732	10.5732	NUM
bptjm-17	921	4	/	/	SYM
bptjm-17	922	1	cjc.010.10522	cjc.010.10522	NOUN
bptjm-17	922	2	.	.	PUNCT
bptjm-17	923	1	pmid	pmid	NOUN
bptjm-17	923	2	:	:	PUNCT
bptjm-17	923	3	21627863	21627863	NUM
bptjm-17	923	4	;	;	PUNCT
bptjm-17	923	5	pmcid	pmcid	ADJ
bptjm-17	923	6	:	:	PUNCT
bptjm-17	923	7	pmc4013415	pmc4013415	NOUN
bptjm-17	923	8	.	.	PUNCT
bptjm-17	924	1	98	98	NUM
bptjm-17	924	2	.	.	X
bptjm-17	925	1	wen	wen	PROPN
bptjm-17	925	2	,	,	PUNCT
bptjm-17	925	3	shiwang	shiwang	PROPN
bptjm-17	925	4	,	,	PUNCT
bptjm-17	925	5	lei	lei	PROPN
bptjm-17	925	6	dai	dai	PROPN
bptjm-17	925	7	,	,	PUNCT
bptjm-17	925	8	lei	lei	PROPN
bptjm-17	925	9	wang	wang	PROPN
bptjm-17	925	10	,	,	PUNCT
bptjm-17	925	11	wenjian	wenjian	PROPN
bptjm-17	925	12	wang	wang	PROPN
bptjm-17	925	13	,	,	PUNCT
bptjm-17	925	14	duoguang	duoguang	PROPN
bptjm-17	925	15	wu	wu	PROPN
bptjm-17	925	16	,	,	PUNCT
bptjm-17	925	17	kefeng	kefeng	PROPN
bptjm-17	925	18	wang	wang	PROPN
bptjm-17	925	19	,	,	PUNCT
bptjm-17	925	20	zhanghai	zhanghai	VERB
bptjm-17	926	1	he	he	PRON
bptjm-17	926	2	,	,	PUNCT
bptjm-17	926	3	et	et	PROPN
bptjm-17	926	4	al	al	PROPN
bptjm-17	926	5	.	.	PUNCT
bptjm-17	926	6	(	(	PUNCT
bptjm-17	926	7	november	november	PROPN
bptjm-17	926	8	2019	2019	NUM
bptjm-17	926	9	)	)	PUNCT
bptjm-17	926	10	.	.	PUNCT
bptjm-17	927	1	genomic	genomic	ADJ
bptjm-17	927	2	signature	signature	NOUN
bptjm-17	927	3	of	of	ADP
bptjm-17	927	4	driver	driver	NOUN
bptjm-17	927	5	genes	gene	NOUN
bptjm-17	927	6	identi	identi	NOUN
bptjm-17	927	7	�	�	PROPN
bptjm-17	927	8	ed	ed	NOUN
bptjm-17	927	9	by	by	ADP
bptjm-17	927	10	target	target	NOUN
bptjm-17	927	11	next	next	ADJ
bptjm-17	927	12	generation	generation	NOUN
bptjm-17	927	13	sequencing	sequence	VERB
bptjm-17	927	14	in	in	ADP
bptjm-17	927	15	chinese	chinese	ADJ
bptjm-17	927	16	non	non	ADJ
bptjm-17	927	17	-	-	ADJ
bptjm-17	927	18	small	small	ADJ
bptjm-17	927	19	cell	cell	NOUN
bptjm-17	927	20	lung	lung	NOUN
bptjm-17	927	21	cancer	cancer	NOUN
bptjm-17	927	22	.	.	PUNCT
bptjm-17	928	1	the	the	DET
bptjm-17	928	2	oncologist	oncologist	NOUN
bptjm-17	928	3	,	,	PUNCT
bptjm-17	928	4	24(11	24(11	NUM
bptjm-17	928	5	)	)	PUNCT
bptjm-17	928	6	,	,	PUNCT
bptjm-17	928	7	e1070–81	e1070–81	NUM
bptjm-17	928	8	.	.	PUNCT
bptjm-17	928	9	https://doi.org/10.1634/theoncologist.2018-0572	https://doi.org/10.1634/theoncologist.2018-0572	NOUN
bptjm-17	928	10	.	.	PUNCT
bptjm-17	929	1	99	99	NUM
bptjm-17	929	2	.	.	PUNCT
bptjm-17	930	1	xie	xie	PROPN
bptjm-17	930	2	,	,	PUNCT
bptjm-17	930	3	p.	p.	PROPN
bptjm-17	930	4	,	,	PUNCT
bptjm-17	930	5	li	li	PROPN
bptjm-17	930	6	,	,	PUNCT
bptjm-17	930	7	x.	x.	PROPN
bptjm-17	930	8	,	,	PUNCT
bptjm-17	930	9	tan	tan	PROPN
bptjm-17	930	10	,	,	PUNCT
bptjm-17	930	11	x.	x.	NOUN
bptjm-17	930	12	,	,	PUNCT
bptjm-17	930	13	sun	sun	PROPN
bptjm-17	930	14	,	,	PUNCT
bptjm-17	930	15	x.	x.	PROPN
bptjm-17	930	16	,	,	PUNCT
bptjm-17	930	17	wang	wang	PROPN
bptjm-17	930	18	,	,	PUNCT
bptjm-17	930	19	c.	c.	PROPN
bptjm-17	930	20	,	,	PUNCT
bptjm-17	930	21	yu	yu	PROPN
bptjm-17	930	22	,	,	PUNCT
bptjm-17	930	23	j.	j.	PROPN
bptjm-17	930	24	(	(	PUNCT
bptjm-17	930	25	2016	2016	NUM
bptjm-17	930	26	)	)	PUNCT
bptjm-17	930	27	.	.	PUNCT
bptjm-17	931	1	sequential	sequential	ADJ
bptjm-17	931	2	serum	serum	NOUN
bptjm-17	931	3	let-7	let-7	PUNCT
bptjm-17	931	4	is	be	AUX
bptjm-17	931	5	a	a	DET
bptjm-17	931	6	novel	novel	ADJ
bptjm-17	931	7	biomarker	biomarker	NOUN
bptjm-17	931	8	to	to	PART
bptjm-17	931	9	predict	predict	VERB
bptjm-17	931	10	accelerated	accelerate	VERB
bptjm-17	931	11	reproliferation	reproliferation	NOUN
bptjm-17	931	12	during	during	ADP
bptjm-17	931	13	fractional	fractional	ADJ
bptjm-17	931	14	radiotherapy	radiotherapy	NOUN
bptjm-17	931	15	in	in	ADP
bptjm-17	931	16	lung	lung	NOUN
bptjm-17	931	17	cancer	cancer	NOUN
bptjm-17	931	18	.	.	PUNCT
bptjm-17	932	1	clinical	clinical	ADJ
bptjm-17	932	2	lung	lung	NOUN
bptjm-17	932	3	cancer	cancer	NOUN
bptjm-17	932	4	,	,	PUNCT
bptjm-17	932	5	17(5	17(5	NUM
bptjm-17	932	6	)	)	PUNCT
bptjm-17	932	7	.	.	PUNCT
bptjm-17	933	1	https://doi.org/10.1016/j.cllc	https://doi.org/10.1016/j.cllc	NOUN
bptjm-17	933	2	.	.	PUNCT
bptjm-17	934	1	2016.03.010	2016.03.010	NUM
bptjm-17	934	2	100	100	NUM
bptjm-17	934	3	.	.	PUNCT
bptjm-17	935	1	xu	xu	INTJ
bptjm-17	935	2	,	,	PUNCT
bptjm-17	935	3	s.	s.	PROPN
bptjm-17	935	4	,	,	PUNCT
bptjm-17	935	5	&	&	CCONJ
bptjm-17	935	6	xu	xu	PROPN
bptjm-17	935	7	,	,	PUNCT
bptjm-17	935	8	s.	s.	PROPN
bptjm-17	935	9	(	(	PUNCT
bptjm-17	935	10	2019	2019	NUM
bptjm-17	935	11	)	)	PUNCT
bptjm-17	935	12	.	.	PUNCT
bptjm-17	936	1	high	high	ADJ
bptjm-17	936	2	expression	expression	NOUN
bptjm-17	936	3	of	of	ADP
bptjm-17	936	4	mir-155	mir-155	NOUN
bptjm-17	936	5	and	and	CCONJ
bptjm-17	936	6	mir-21	mir-21	PROPN
bptjm-17	936	7	in	in	ADP
bptjm-17	936	8	the	the	DET
bptjm-17	936	9	recurrence	recurrence	NOUN
bptjm-17	936	10	or	or	CCONJ
bptjm-17	936	11	metastasis	metastasis	NOUN
bptjm-17	936	12	of	of	ADP
bptjm-17	936	13	non	non	ADJ
bptjm-17	936	14	-	-	ADJ
bptjm-17	936	15	small	small	ADJ
bptjm-17	936	16	cell	cell	NOUN
bptjm-17	936	17	lung	lung	NOUN
bptjm-17	936	18	cancer	cancer	NOUN
bptjm-17	936	19	.	.	PUNCT
bptjm-17	937	1	oncology	oncology	NOUN
bptjm-17	937	2	letters	letter	NOUN
bptjm-17	937	3	,	,	PUNCT
bptjm-17	937	4	18	18	NUM
bptjm-17	937	5	,	,	PUNCT
bptjm-17	937	6	758	758	NUM
bptjm-17	937	7	-	-	SYM
bptjm-17	937	8	763	763	NUM
bptjm-17	937	9	.	.	PUNCT
bptjm-17	938	1	https://doi.org/	https://doi.org/	VERB
bptjm-17	938	2	10.3892	10.3892	NUM
bptjm-17	938	3	/	/	SYM
bptjm-17	938	4	ol.2019.10337	ol.2019.10337	NOUN
bptjm-17	938	5	.	.	PUNCT
bptjm-17	939	1	101	101	NUM
bptjm-17	939	2	.	.	PUNCT
bptjm-17	940	1	yang	yang	PROPN
bptjm-17	940	2	,	,	PUNCT
bptjm-17	940	3	nong	nong	PROPN
bptjm-17	940	4	,	,	PUNCT
bptjm-17	940	5	yi	yi	PROPN
bptjm-17	940	6	li	li	PROPN
bptjm-17	940	7	,	,	PUNCT
bptjm-17	940	8	zhidong	zhidong	PROPN
bptjm-17	940	9	liu	liu	PROPN
bptjm-17	940	10	,	,	PUNCT
bptjm-17	940	11	hao	hao	PROPN
bptjm-17	940	12	qin	qin	PROPN
bptjm-17	940	13	,	,	PUNCT
bptjm-17	940	14	duanming	duanme	VERB
bptjm-17	940	15	du	du	PROPN
bptjm-17	940	16	,	,	PUNCT
bptjm-17	940	17	xinkai	xinkai	PROPN
bptjm-17	940	18	cao	cao	PROPN
bptjm-17	940	19	,	,	PUNCT
bptjm-17	940	20	xiaoqing	xiaoqing	PROPN
bptjm-17	940	21	cao	cao	PROPN
bptjm-17	940	22	,	,	PUNCT
bptjm-17	940	23	et	et	PROPN
bptjm-17	940	24	al	al	PROPN
bptjm-17	940	25	.	.	PUNCT
bptjm-17	941	1	(	(	PUNCT
bptjm-17	941	2	march	march	PROPN
bptjm-17	941	3	23	23	NUM
bptjm-17	941	4	,	,	PUNCT
bptjm-17	941	5	2018	2018	NUM
bptjm-17	941	6	)	)	PUNCT
bptjm-17	941	7	.	.	PUNCT
bptjm-17	942	1	the	the	DET
bptjm-17	942	2	characteristics	characteristic	NOUN
bptjm-17	942	3	of	of	ADP
bptjm-17	942	4	ctdna	ctdna	NOUN
bptjm-17	942	5	reveal	reveal	VERB
bptjm-17	942	6	the	the	DET
bptjm-17	942	7	high	high	ADJ
bptjm-17	942	8	complexity	complexity	NOUN
bptjm-17	942	9	in	in	ADP
bptjm-17	942	10	matching	match	VERB
bptjm-17	942	11	the	the	DET
bptjm-17	942	12	corresponding	correspond	VERB
bptjm-17	942	13	tumor	tumor	NOUN
bptjm-17	942	14	tissues	tissue	NOUN
bptjm-17	942	15	.	.	PUNCT
bptjm-17	943	1	bmc	bmc	ADJ
bptjm-17	943	2	cancer	cancer	NOUN
bptjm-17	943	3	18(1	18(1	NOUN
bptjm-17	943	4	)	)	PUNCT
bptjm-17	943	5	,	,	PUNCT
bptjm-17	943	6	319	319	NUM
bptjm-17	943	7	.	.	PUNCT
bptjm-17	943	8	https://doi.org/10.1186/s12885-018-4199-7	https://doi.org/10.1186/s12885-018-4199-7	NUM
bptjm-17	943	9	.	.	PUNCT
bptjm-17	944	1	102	102	NUM
bptjm-17	944	2	.	.	X
bptjm-17	945	1	yarlagadda	yarlagadda	NOUN
bptjm-17	945	2	,	,	PUNCT
bptjm-17	945	3	bhavya	bhavya	NOUN
bptjm-17	945	4	,	,	PUNCT
bptjm-17	945	5	vaishnavi	vaishnavi	PROPN
bptjm-17	945	6	kamatham	kamatham	PROPN
bptjm-17	945	7	,	,	PUNCT
bptjm-17	945	8	ashton	ashton	PROPN
bptjm-17	945	9	ritter	ritter	PROPN
bptjm-17	945	10	,	,	PUNCT
bptjm-17	945	11	faisal	faisal	ADJ
bptjm-17	945	12	shahjehan	shahjehan	PROPN
bptjm-17	945	13	,	,	PUNCT
bptjm-17	945	14	and	and	CCONJ
bptjm-17	945	15	pashtoon	pashtoon	PROPN
bptjm-17	945	16	m.	m.	PROPN
bptjm-17	945	17	kasi	kasi	PROPN
bptjm-17	945	18	.	.	PUNCT
bptjm-17	946	1	(	(	PUNCT
bptjm-17	946	2	august	august	PROPN
bptjm-17	946	3	19	19	NUM
bptjm-17	946	4	,	,	PUNCT
bptjm-17	946	5	2019	2019	NUM
bptjm-17	946	6	)	)	PUNCT
bptjm-17	946	7	.	.	PUNCT
bptjm-17	947	1	trastuzumab	trastuzumab	NOUN
bptjm-17	947	2	and	and	CCONJ
bptjm-17	947	3	pertuzumab	pertuzumab	NOUN
bptjm-17	947	4	in	in	ADP
bptjm-17	947	5	circulating	circulate	VERB
bptjm-17	947	6	tumor	tumor	NOUN
bptjm-17	947	7	dna	dna	PROPN
bptjm-17	947	8	erbb2ampli	erbb2ampli	PROPN
bptjm-17	947	9	�	�	PROPN
bptjm-17	947	10	ed	ed	PROPN
bptjm-17	947	11	her2	her2	PROPN
bptjm-17	947	12	-	-	PUNCT
bptjm-17	947	13	positive	positive	ADJ
bptjm-17	947	14	refractory	refractory	NOUN
bptjm-17	947	15	cholangiocarcinoma	cholangiocarcinoma	NOUN
bptjm-17	947	16	.	.	PUNCT
bptjm-17	948	1	npj	npj	PROPN
bptjm-17	948	2	precision	precision	PROPN
bptjm-17	948	3	oncology	oncology	NOUN
bptjm-17	948	4	,	,	PUNCT
bptjm-17	948	5	3(1	3(1	NUM
bptjm-17	948	6	)	)	PUNCT
bptjm-17	948	7	,	,	PUNCT
bptjm-17	948	8	1–5	1–5	PROPN
bptjm-17	948	9	.	.	NOUN
bptjm-17	948	10	https://doi.org/10.1038/s41698-019-0091-4	https://doi.org/10.1038/s41698-019-0091-4	NUM
bptjm-17	948	11	.	.	PUNCT
bptjm-17	949	1	103	103	NUM
bptjm-17	949	2	.	.	PUNCT
bptjm-17	950	1	yuxia	yuxia	PROPN
bptjm-17	950	2	m	m	PROPN
bptjm-17	950	3	,	,	PUNCT
bptjm-17	950	4	zhennan	zhennan	PROPN
bptjm-17	950	5	t	t	PROPN
bptjm-17	950	6	,	,	PUNCT
bptjm-17	950	7	wei	wei	PROPN
bptjm-17	950	8	z.	z.	PROPN
bptjm-17	950	9	(	(	PUNCT
bptjm-17	950	10	december	december	PROPN
bptjm-17	950	11	2012	2012	NUM
bptjm-17	950	12	)	)	PUNCT
bptjm-17	950	13	.	.	PUNCT
bptjm-17	951	1	circulating	circulate	VERB
bptjm-17	951	2	mir-125b	mir-125b	PROPN
bptjm-17	951	3	is	be	AUX
bptjm-17	951	4	a	a	DET
bptjm-17	951	5	novel	novel	ADJ
bptjm-17	951	6	biomarker	biomarker	NOUN
bptjm-17	951	7	for	for	ADP
bptjm-17	951	8	screening	screen	VERB
bptjm-17	951	9	berkeley	berkeley	PROPN
bptjm-17	951	10	pharma	pharma	PROPN
bptjm-17	951	11	tech	tech	NOUN
bptjm-17	951	12	journal	journal	NOUN
bptjm-17	951	13	of	of	ADP
bptjm-17	951	14	medicine	medicine	NOUN
bptjm-17	951	15	|	|	ADV
bptjm-17	951	16	154	154	NUM
bptjm-17	951	17	non	non	ADJ
bptjm-17	951	18	-	-	ADJ
bptjm-17	951	19	small	small	ADJ
bptjm-17	951	20	-	-	PUNCT
bptjm-17	951	21	cell	cell	NOUN
bptjm-17	951	22	lung	lung	NOUN
bptjm-17	951	23	cancer	cancer	NOUN
bptjm-17	951	24	and	and	CCONJ
bptjm-17	951	25	predicts	predict	VERB
bptjm-17	951	26	poor	poor	ADJ
bptjm-17	951	27	prognosis	prognosis	NOUN
bptjm-17	951	28	.	.	PUNCT
bptjm-17	952	1	j	j	PROPN
bptjm-17	952	2	cancer	cancer	NOUN
bptjm-17	952	3	res	re	VERB
bptjm-17	952	4	clin	clin	PROPN
bptjm-17	952	5	oncol	oncol	PROPN
bptjm-17	952	6	.	.	PUNCT
bptjm-17	952	7	,	,	PUNCT
bptjm-17	952	8	138(12):2045	138(12):2045	NUM
bptjm-17	952	9	-	-	SYM
bptjm-17	952	10	50	50	NUM
bptjm-17	952	11	.	.	PUNCT
bptjm-17	953	1	doi:10.1007	doi:10.1007	VERB
bptjm-17	953	2	/	/	SYM
bptjm-17	953	3	s00432	s00432	PROPN
bptjm-17	953	4	-	-	PUNCT
bptjm-17	953	5	012	012	NUM
bptjm-17	953	6	-	-	PUNCT
bptjm-17	953	7	1285	1285	NUM
bptjm-17	953	8	-	-	SYM
bptjm-17	953	9	0	0	NUM
bptjm-17	953	10	.	.	PUNCT
bptjm-17	954	1	epub	epub	PROPN
bptjm-17	954	2	2012	2012	NUM
bptjm-17	954	3	jul	jul	PROPN
bptjm-17	954	4	18	18	NUM
bptjm-17	954	5	.	.	PUNCT
bptjm-17	955	1	pmid	pmid	NOUN
bptjm-17	955	2	:	:	PUNCT
bptjm-17	955	3	22806310	22806310	NUM
bptjm-17	955	4	.	.	PUNCT
bptjm-17	956	1	104	104	NUM
bptjm-17	956	2	.	.	PUNCT
bptjm-17	957	1	zeng	zeng	PROPN
bptjm-17	957	2	,	,	PUNCT
bptjm-17	957	3	hanlin	hanlin	PROPN
bptjm-17	957	4	,	,	PUNCT
bptjm-17	957	5	aparna	aparna	PROPN
bptjm-17	957	6	jorapur	jorapur	PROPN
bptjm-17	957	7	,	,	PUNCT
bptjm-17	957	8	a.	a.	NOUN
bptjm-17	957	9	hunter	hunter	PROPN
bptjm-17	957	10	shain	shain	PROPN
bptjm-17	957	11	,	,	PUNCT
bptjm-17	957	12	ursula	ursula	PROPN
bptjm-17	957	13	e.	e.	PROPN
bptjm-17	957	14	lang	lang	PROPN
bptjm-17	957	15	,	,	PUNCT
bptjm-17	957	16	rodrigo	rodrigo	PROPN
bptjm-17	957	17	torres	torres	PROPN
bptjm-17	957	18	,	,	PUNCT
bptjm-17	957	19	yuntian	yuntian	PROPN
bptjm-17	957	20	zhang	zhang	PROPN
bptjm-17	957	21	,	,	PUNCT
bptjm-17	957	22	andrew	andrew	PROPN
bptjm-17	957	23	s.	s.	PROPN
bptjm-17	957	24	mcneal	mcneal	PROPN
bptjm-17	957	25	,	,	PUNCT
bptjm-17	957	26	et	et	PROPN
bptjm-17	957	27	al	al	PROPN
bptjm-17	957	28	.	.	PUNCT
bptjm-17	957	29	(	(	PUNCT
bptjm-17	957	30	july	july	PROPN
bptjm-17	957	31	9	9	NUM
bptjm-17	957	32	,	,	PUNCT
bptjm-17	957	33	2018	2018	NUM
bptjm-17	957	34	)	)	PUNCT
bptjm-17	957	35	.	.	PUNCT
bptjm-17	958	1	bi	bi	ADJ
bptjm-17	958	2	-	-	ADJ
bptjm-17	958	3	allelic	allelic	ADJ
bptjm-17	958	4	loss	loss	NOUN
bptjm-17	958	5	of	of	ADP
bptjm-17	958	6	cdkn2a	cdkn2a	PROPN
bptjm-17	958	7	initiates	initiate	VERB
bptjm-17	958	8	melanoma	melanoma	NOUN
bptjm-17	958	9	invasion	invasion	NOUN
bptjm-17	958	10	via	via	ADP
bptjm-17	958	11	brn2	brn2	NOUN
bptjm-17	958	12	activation	activation	NOUN
bptjm-17	958	13	.	.	PUNCT
bptjm-17	959	1	cancer	cancer	NOUN
bptjm-17	959	2	cell	cell	NOUN
bptjm-17	959	3	,	,	PUNCT
bptjm-17	959	4	34(1	34(1	NUM
bptjm-17	959	5	)	)	PUNCT
bptjm-17	959	6	:	:	PUNCT
bptjm-17	959	7	56	56	NUM
bptjm-17	959	8	-	-	SYM
bptjm-17	959	9	68.e9	68.e9	NOUN
bptjm-17	959	10	.	.	PUNCT
bptjm-17	960	1	https://doi.org/10.1016/j.ccell.2018.05.014	https://doi.org/10.1016/j.ccell.2018.05.014	PROPN
bptjm-17	960	2	.	.	PUNCT
bptjm-17	961	1	105	105	NUM
bptjm-17	961	2	.	.	PUNCT
bptjm-17	962	1	zhang	zhang	PROPN
bptjm-17	962	2	,	,	PUNCT
bptjm-17	962	3	g.	g.	PROPN
bptjm-17	962	4	b.	b.	PROPN
bptjm-17	962	5	,	,	PUNCT
bptjm-17	962	6	chen	chen	PROPN
bptjm-17	962	7	,	,	PUNCT
bptjm-17	962	8	j.	j.	PROPN
bptjm-17	962	9	,	,	PUNCT
bptjm-17	962	10	wang	wang	PROPN
bptjm-17	962	11	,	,	PUNCT
bptjm-17	962	12	l.	l.	PROPN
bptjm-17	962	13	r.	r.	PROPN
bptjm-17	962	14	,	,	PUNCT
bptjm-17	962	15	li	li	PROPN
bptjm-17	962	16	,	,	PUNCT
bptjm-17	962	17	j.	j.	PROPN
bptjm-17	962	18	,	,	PUNCT
bptjm-17	962	19	li	li	PROPN
bptjm-17	962	20	,	,	PUNCT
bptjm-17	962	21	m.	m.	PROPN
bptjm-17	962	22	w.	w.	PROPN
bptjm-17	962	23	,	,	PUNCT
bptjm-17	962	24	xu	xu	PROPN
bptjm-17	962	25	,	,	PUNCT
bptjm-17	962	26	n.	n.	PROPN
bptjm-17	962	27	,	,	PUNCT
bptjm-17	962	28	wang	wang	PROPN
bptjm-17	962	29	,	,	PUNCT
bptjm-17	962	30	y.	y.	PROPN
bptjm-17	962	31	,	,	PUNCT
bptjm-17	962	32	&	&	CCONJ
bptjm-17	962	33	shentu	shentu	PROPN
bptjm-17	962	34	,	,	PUNCT
bptjm-17	962	35	j.	j.	PROPN
bptjm-17	962	36	z.	z.	PROPN
bptjm-17	962	37	(	(	PUNCT
bptjm-17	962	38	2012	2012	NUM
bptjm-17	962	39	)	)	PUNCT
bptjm-17	962	40	.	.	PUNCT
bptjm-17	963	1	rrm1	rrm1	NOUN
bptjm-17	963	2	and	and	CCONJ
bptjm-17	963	3	ercc1	ercc1	NOUN
bptjm-17	963	4	expression	expression	NOUN
bptjm-17	963	5	in	in	ADP
bptjm-17	963	6	peripheral	peripheral	ADJ
bptjm-17	963	7	blood	blood	NOUN
bptjm-17	963	8	versus	versus	ADP
bptjm-17	963	9	tumor	tumor	NOUN
bptjm-17	963	10	tissue	tissue	NOUN
bptjm-17	963	11	in	in	ADP
bptjm-17	963	12	gemcitabine	gemcitabine	NOUN
bptjm-17	963	13	/	/	SYM
bptjm-17	963	14	carboplatin	carboplatin	NOUN
bptjm-17	963	15	-	-	PUNCT
bptjm-17	963	16	treated	treat	VERB
bptjm-17	963	17	advanced	advanced	ADJ
bptjm-17	963	18	non	non	ADJ
bptjm-17	963	19	-	-	ADJ
bptjm-17	963	20	small	small	ADJ
bptjm-17	963	21	cell	cell	NOUN
bptjm-17	963	22	lung	lung	NOUN
bptjm-17	963	23	cancer	cancer	NOUN
bptjm-17	963	24	.	.	PUNCT
bptjm-17	964	1	cancer	cancer	NOUN
bptjm-17	964	2	chemotherapy	chemotherapy	NOUN
bptjm-17	964	3	and	and	CCONJ
bptjm-17	964	4	pharmacology	pharmacology	NOUN
bptjm-17	964	5	,	,	PUNCT
bptjm-17	964	6	69(5	69(5	NUM
bptjm-17	964	7	)	)	PUNCT
bptjm-17	964	8	,	,	PUNCT
bptjm-17	964	9	1277–1287	1277–1287	NUM
bptjm-17	964	10	.	.	PUNCT
bptjm-17	965	1	https://doi.org/10.1007/	https://doi.org/10.1007/	PROPN
bptjm-17	965	2	s00280	s00280	PROPN
bptjm-17	965	3	-	-	PUNCT
bptjm-17	965	4	012	012	NUM
bptjm-17	965	5	-	-	PUNCT
bptjm-17	965	6	1834	1834	NUM
bptjm-17	965	7	-	-	PUNCT
bptjm-17	965	8	x	x	SYM
bptjm-17	965	9	106	106	NUM
bptjm-17	965	10	.	.	PUNCT
bptjm-17	966	1	zhang	zhang	PROPN
bptjm-17	966	2	,	,	PUNCT
bptjm-17	966	3	y.	y.	PROPN
bptjm-17	966	4	,	,	PUNCT
bptjm-17	966	5	roth	roth	PROPN
bptjm-17	966	6	,	,	PUNCT
bptjm-17	966	7	j.	j.	PROPN
bptjm-17	966	8	a.	a.	PROPN
bptjm-17	966	9	,	,	PUNCT
bptjm-17	966	10	yu	yu	PROPN
bptjm-17	966	11	,	,	PUNCT
bptjm-17	966	12	h.	h.	PROPN
bptjm-17	966	13	,	,	PUNCT
bptjm-17	966	14	ye	ye	PROPN
bptjm-17	966	15	,	,	PUNCT
bptjm-17	966	16	y.	y.	PROPN
bptjm-17	966	17	,	,	PUNCT
bptjm-17	966	18	xie	xie	PROPN
bptjm-17	966	19	,	,	PUNCT
bptjm-17	966	20	k.	k.	PROPN
bptjm-17	966	21	,	,	PUNCT
bptjm-17	966	22	zhao	zhao	PROPN
bptjm-17	966	23	,	,	PUNCT
bptjm-17	966	24	h.	h.	PROPN
bptjm-17	966	25	,	,	PUNCT
bptjm-17	966	26	chang	chang	PROPN
bptjm-17	966	27	,	,	PUNCT
bptjm-17	966	28	d.	d.	PROPN
bptjm-17	966	29	w.	w.	PROPN
bptjm-17	966	30	,	,	PUNCT
bptjm-17	966	31	huang	huang	PROPN
bptjm-17	966	32	,	,	PUNCT
bptjm-17	966	33	m.	m.	NOUN
bptjm-17	966	34	,	,	PUNCT
bptjm-17	966	35	li	li	PROPN
bptjm-17	966	36	,	,	PUNCT
bptjm-17	966	37	h.	h.	PROPN
bptjm-17	966	38	,	,	PUNCT
bptjm-17	966	39	qu	qu	PROPN
bptjm-17	966	40	,	,	PUNCT
bptjm-17	966	41	j.	j.	PROPN
bptjm-17	966	42	,	,	PUNCT
bptjm-17	966	43	&	&	CCONJ
bptjm-17	966	44	wu	wu	PROPN
bptjm-17	966	45	,	,	PUNCT
bptjm-17	966	46	x.	x.	NOUN
bptjm-17	966	47	(	(	PUNCT
bptjm-17	966	48	2019	2019	NUM
bptjm-17	966	49	)	)	PUNCT
bptjm-17	966	50	.	.	PUNCT
bptjm-17	967	1	a	a	DET
bptjm-17	967	2	5	5	NUM
bptjm-17	967	3	-	-	PUNCT
bptjm-17	967	4	microrna	microrna	PROPN
bptjm-17	967	5	signature	signature	NOUN
bptjm-17	967	6	identi	identi	PROPN
bptjm-17	967	7	�	�	PROPN
bptjm-17	967	8	ed	ed	PROPN
bptjm-17	967	9	from	from	ADP
bptjm-17	967	10	serum	serum	PROPN
bptjm-17	967	11	microrna	microrna	PROPN
bptjm-17	967	12	pro	pro	PROPN
bptjm-17	967	13	�	�	PROPN
bptjm-17	967	14	ling	ling	NOUN
bptjm-17	967	15	predicts	predict	NOUN
bptjm-17	967	16	survival	survival	NOUN
bptjm-17	967	17	in	in	ADP
bptjm-17	967	18	patients	patient	NOUN
bptjm-17	967	19	with	with	ADP
bptjm-17	967	20	advanced	advanced	ADJ
bptjm-17	967	21	stage	stage	NOUN
bptjm-17	967	22	non	non	ADJ
bptjm-17	967	23	-	-	ADJ
bptjm-17	967	24	small	small	ADJ
bptjm-17	967	25	cell	cell	NOUN
bptjm-17	967	26	lung	lung	NOUN
bptjm-17	967	27	cancer	cancer	NOUN
bptjm-17	967	28	.	.	PUNCT
bptjm-17	968	1	carcinogenesis	carcinogenesis	NOUN
bptjm-17	968	2	,	,	PUNCT
bptjm-17	968	3	40(5	40(5	NOUN
bptjm-17	968	4	)	)	PUNCT
bptjm-17	968	5	,	,	PUNCT
bptjm-17	968	6	643–650	643–650	NUM
bptjm-17	968	7	.	.	PUNCT
bptjm-17	969	1	https://doi.org/10.1093/carcin/bgy132	https://doi.org/10.1093/carcin/bgy132	PROPN
bptjm-17	969	2	107	107	NUM
bptjm-17	969	3	.	.	PUNCT
bptjm-17	970	1	zhao	zhao	NOUN
bptjm-17	970	2	,	,	PUNCT
bptjm-17	970	3	m.	m.	NOUN
bptjm-17	970	4	,	,	PUNCT
bptjm-17	970	5	zhang	zhang	PROPN
bptjm-17	970	6	,	,	PUNCT
bptjm-17	970	7	h.	h.	PROPN
bptjm-17	970	8	,	,	PUNCT
bptjm-17	970	9	zhu	zhu	PROPN
bptjm-17	970	10	,	,	PUNCT
bptjm-17	970	11	g.	g.	PROPN
bptjm-17	970	12	,	,	PUNCT
bptjm-17	970	13	liang	liang	PROPN
bptjm-17	970	14	,	,	PUNCT
bptjm-17	970	15	j.	j.	PROPN
bptjm-17	970	16	,	,	PUNCT
bptjm-17	970	17	chen	chen	PROPN
bptjm-17	970	18	,	,	PUNCT
bptjm-17	970	19	n.	n.	PROPN
bptjm-17	970	20	,	,	PUNCT
bptjm-17	970	21	yang	yang	PROPN
bptjm-17	970	22	,	,	PUNCT
bptjm-17	970	23	y.	y.	PROPN
bptjm-17	970	24	,	,	PUNCT
bptjm-17	970	25	liang	liang	PROPN
bptjm-17	970	26	,	,	PUNCT
bptjm-17	970	27	x.	x.	PROPN
bptjm-17	970	28	,	,	PUNCT
bptjm-17	970	29	cai	cai	PROPN
bptjm-17	970	30	,	,	PUNCT
bptjm-17	970	31	h.	h.	PROPN
bptjm-17	970	32	,	,	PUNCT
bptjm-17	970	33	&	&	CCONJ
bptjm-17	970	34	liu	liu	PROPN
bptjm-17	970	35	,	,	PUNCT
bptjm-17	970	36	w.	w.	PROPN
bptjm-17	970	37	(	(	PUNCT
bptjm-17	970	38	2016	2016	NUM
bptjm-17	970	39	)	)	PUNCT
bptjm-17	970	40	.	.	PUNCT
bptjm-17	971	1	association	association	NOUN
bptjm-17	971	2	between	between	ADP
bptjm-17	971	3	overexpression	overexpression	NOUN
bptjm-17	971	4	of	of	ADP
bptjm-17	971	5	wip1	wip1	NOUN
bptjm-17	971	6	and	and	CCONJ
bptjm-17	971	7	prognosis	prognosis	NOUN
bptjm-17	971	8	of	of	ADP
bptjm-17	971	9	patients	patient	NOUN
bptjm-17	971	10	with	with	ADP
bptjm-17	971	11	non	non	PRON
bptjm-17	971	12	small	small	ADJ
bptjm-17	971	13	cell	cell	NOUN
bptjm-17	971	14	lung	lung	NOUN
bptjm-17	971	15	cancer	cancer	NOUN
bptjm-17	971	16	.	.	PUNCT
bptjm-17	972	1	oncology	oncology	NOUN
bptjm-17	972	2	letters	letter	NOUN
bptjm-17	972	3	,	,	PUNCT
bptjm-17	972	4	11(4	11(4	NUM
bptjm-17	972	5	)	)	PUNCT
bptjm-17	972	6	,	,	PUNCT
bptjm-17	972	7	2365–2370	2365–2370	NUM
bptjm-17	972	8	.	.	PUNCT
bptjm-17	973	1	https://doi.org/10.3892/ol	https://doi.org/10.3892/ol	NOUN
bptjm-17	973	2	.	.	PUNCT
bptjm-17	974	1	2016.4245	2016.4245	NUM
bptjm-17	974	2	.	.	NOUN
bptjm-17	975	1	108	108	NUM
bptjm-17	975	2	.	.	PUNCT
bptjm-17	976	1	zhao	zhao	PROPN
bptjm-17	976	2	w	w	PROPN
bptjm-17	976	3	,	,	PUNCT
bptjm-17	976	4	zhao	zhao	PROPN
bptjm-17	976	5	jj	jj	PROPN
bptjm-17	976	6	,	,	PUNCT
bptjm-17	976	7	zhang	zhang	PROPN
bptjm-17	976	8	l	l	PROPN
bptjm-17	976	9	,	,	PUNCT
bptjm-17	976	10	xu	xu	PROPN
bptjm-17	976	11	qf	qf	PROPN
bptjm-17	976	12	,	,	PUNCT
bptjm-17	976	13	zhao	zhao	PROPN
bptjm-17	976	14	ym	ym	PROPN
bptjm-17	976	15	,	,	PUNCT
bptjm-17	976	16	shi	shi	PROPN
bptjm-17	976	17	xy	xy	PROPN
bptjm-17	976	18	and	and	CCONJ
bptjm-17	976	19	xu	xu	PROPN
bptjm-17	976	20	ag	ag	PROPN
bptjm-17	976	21	.	.	PUNCT
bptjm-17	976	22	(	(	PUNCT
bptjm-17	976	23	2015	2015	NUM
bptjm-17	976	24	)	)	PUNCT
bptjm-17	976	25	.	.	PUNCT
bptjm-17	977	1	serum	serum	PROPN
bptjm-17	977	2	mir-21	mir-21	PROPN
bptjm-17	977	3	level	level	NOUN
bptjm-17	977	4	:	:	PUNCT
bptjm-17	977	5	a	a	DET
bptjm-17	977	6	potential	potential	ADJ
bptjm-17	977	7	diagnostic	diagnostic	ADJ
bptjm-17	977	8	and	and	CCONJ
bptjm-17	977	9	prognostic	prognostic	ADJ
bptjm-17	977	10	biomarker	biomarker	NOUN
bptjm-17	977	11	for	for	ADP
bptjm-17	977	12	non	non	ADJ
bptjm-17	977	13	-	-	ADJ
bptjm-17	977	14	small	small	ADJ
bptjm-17	977	15	cell	cell	NOUN
bptjm-17	977	16	lung	lung	NOUN
bptjm-17	977	17	cancer	cancer	NOUN
bptjm-17	977	18	.	.	PUNCT
bptjm-17	978	1	int	int	PROPN
bptjm-17	979	1	j	j	PROPN
bptjm-17	979	2	clin	clin	PROPN
bptjm-17	979	3	exp	exp	PROPN
bptjm-17	979	4	med	med	PROPN
bptjm-17	979	5	.	.	PROPN
bptjm-17	979	6	,	,	PUNCT
bptjm-17	979	7	8:14759–14763	8:14759–14763	NUM
bptjm-17	979	8	.	.	PUNCT
bptjm-17	979	9	2015	2015	NUM
bptjm-17	979	10	109	109	NUM
bptjm-17	979	11	.	.	PUNCT
bptjm-17	980	1	zhu	zhu	PROPN
bptjm-17	980	2	,	,	PUNCT
bptjm-17	980	3	w.	w.	PROPN
bptjm-17	980	4	,	,	PUNCT
bptjm-17	980	5	luo	luo	PROPN
bptjm-17	980	6	,	,	PUNCT
bptjm-17	980	7	b.	b.	PROPN
bptjm-17	980	8	,	,	PUNCT
bptjm-17	980	9	an	an	PRON
bptjm-17	980	10	,	,	PUNCT
bptjm-17	980	11	j.	j.	PROPN
bptjm-17	980	12	,	,	PUNCT
bptjm-17	980	13	he	he	PRON
bptjm-17	980	14	,	,	PUNCT
bptjm-17	980	15	j.	j.	PROPN
bptjm-17	980	16	,	,	PUNCT
bptjm-17	980	17	chen	chen	PROPN
bptjm-17	980	18	,	,	PUNCT
bptjm-17	980	19	d.	d.	PROPN
bptjm-17	980	20	,	,	PUNCT
bptjm-17	980	21	xu	xu	PROPN
bptjm-17	980	22	,	,	PUNCT
bptjm-17	980	23	l.	l.	PROPN
bptjm-17	980	24	,	,	PUNCT
bptjm-17	980	25	.	.	PUNCT
bptjm-17	980	26	.	.	PUNCT
bptjm-17	980	27	.	.	PUNCT
bptjm-17	981	1	zhang	zhang	PROPN
bptjm-17	981	2	,	,	PUNCT
bptjm-17	981	3	y.	y.	PROPN
bptjm-17	981	4	(	(	PUNCT
bptjm-17	981	5	2014	2014	NUM
bptjm-17	981	6	)	)	PUNCT
bptjm-17	981	7	.	.	PUNCT
bptjm-17	982	1	di	di	PROPN
bptjm-17	982	2	�	�	PROPN
bptjm-17	982	3	erential	erential	ADJ
bptjm-17	982	4	expression	expression	NOUN
bptjm-17	982	5	of	of	ADP
bptjm-17	982	6	mir-125a-5p	mir-125a-5p	PROPN
bptjm-17	982	7	and	and	CCONJ
bptjm-17	982	8	let-7e	let-7e	PROPN
bptjm-17	982	9	predicts	predict	VERB
bptjm-17	982	10	the	the	DET
bptjm-17	982	11	progression	progression	NOUN
bptjm-17	982	12	and	and	CCONJ
bptjm-17	982	13	prognosis	prognosis	NOUN
bptjm-17	982	14	of	of	ADP
bptjm-17	982	15	non	non	ADJ
bptjm-17	982	16	small	small	ADJ
bptjm-17	982	17	cell	cell	NOUN
bptjm-17	982	18	lung	lung	NOUN
bptjm-17	982	19	cancer	cancer	NOUN
bptjm-17	982	20	.	.	PUNCT
bptjm-17	983	1	cancer	cancer	NOUN
bptjm-17	983	2	investigation	investigation	NOUN
bptjm-17	983	3	,	,	PUNCT
bptjm-17	983	4	32(8	32(8	NUM
bptjm-17	983	5	)	)	PUNCT
bptjm-17	983	6	,	,	PUNCT
bptjm-17	983	7	394	394	NUM
bptjm-17	983	8	-	-	SYM
bptjm-17	983	9	401	401	NUM
bptjm-17	983	10	.	.	PUNCT
bptjm-17	984	1	doi:10.3109/07357907.2014.922569	doi:10.3109/07357907.2014.922569	PROPN
bptjm-17	984	2	berkeley	berkeley	PROPN
bptjm-17	984	3	pharma	pharma	PROPN
bptjm-17	984	4	tech	tech	NOUN
bptjm-17	984	5	journal	journal	NOUN
bptjm-17	984	6	of	of	ADP
bptjm-17	984	7	medicine	medicine	NOUN
bptjm-17	984	8	|	|	ADV
bptjm-17	984	9	155	155	NUM
bptjm-17	984	10	2	2	NUM
bptjm-17	984	11	.	.	PUNCT
bptjm-17	984	12	front	front	ADJ
bptjm-17	984	13	page	page	NOUN
bptjm-17	984	14	circulating	circulate	VERB
bptjm-17	984	15	nucleic	nucleic	ADJ
bptjm-17	984	16	acids	acid	NOUN
bptjm-17	984	17	as	as	ADP
bptjm-17	984	18	promising	promise	VERB
bptjm-17	984	19	biomarkersa	biomarkersa	ADJ
bptjm-17	984	20	new	new	ADJ
bptjm-17	984	21	frontier	frontier	NOUN
bptjm-17	984	22	of	of	ADP
bptjm-17	984	23	personalized	personalized	ADJ
bptjm-17	984	24	medicine	medicine	NOUN
bptjm-17	984	25	(	(	PUNCT
bptjm-17	984	26	2).pdf	2).pdf	NUM
bptjm-17	984	27	3	3	X
bptjm-17	984	28	.	.	PUNCT
bptjm-17	984	29	body	body	NOUN
bptjm-17	984	30	pages	page	NOUN
bptjm-17	984	31	circulating	circulate	VERB
bptjm-17	984	32	nucleic	nucleic	ADJ
bptjm-17	984	33	acids	acid	NOUN
bptjm-17	984	34	paper	paper	NOUN
bptjm-17	984	35	(	(	PUNCT
bptjm-17	984	36	body	body	NOUN
bptjm-17	984	37	template).docx	template).docx	NOUN
bptjm-17	984	38	(	(	PUNCT
bptjm-17	984	39	1).pdf	1).pdf	NUM
bptjm-17	984	40	circulating	circulate	VERB
bptjm-17	984	41	nucleic	nucleic	ADJ
bptjm-17	984	42	acids	acid	NOUN
bptjm-17	984	43	paper	paper	NOUN
bptjm-17	984	44	(	(	PUNCT
bptjm-17	984	45	reference	reference	NOUN
bptjm-17	984	46	page	page	NOUN
bptjm-17	984	47	template	template	NOUN
bptjm-17	984	48	)	)	PUNCT
bptjm-17	984	49	(	(	PUNCT
bptjm-17	984	50	1).pdf	1).pdf	NUM